188339
D003276_D008113 CID contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tumors/NNS -PUNC- contraceptive/JJ (r_amod) steroids/NNS (r_dobj) using/VBG (r_advcl) seen/VBN (l_nsubjpass) tumors/NNS
D013256_D008113 NONE steroids/NNS (r_dobj) using/VBG (r_advcl) seen/VBN (l_nsubjpass) tumors/NNS
6153967
D004737_D012640 CID enflurane/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- enflurane/NN (r_pobj) by/IN (r_agent) activated/VBN (r_conj) delineated/VBN (l_conj) are/VBP (l_acomp) free/JJ (l_npadvmod) seizure/NN
D004737_D004827 NONE enflurane/NN (r_pobj) by/IN (r_agent) activated/VBN (r_conj) delineated/VBN (l_nsubj) foci/NN (l_amod) Epileptic/JJ -PUNC- enflurane/NN (r_nsubj) prove/VB (l_xcomp) be/VB (l_attr) activator/NN (l_prep) of/IN (l_pobj) foci/VBD (l_amod) epileptic/JJ
8677458
D007069_D064420 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) toxicity/NN
D007069_D003556 CID ifosfamide/RB (r_advmod) induced/VBN (r_amod) cystitis/NN -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_attr) is/VBZ (l_nsubj) cystitis/NN
D007069_D006470 CID ifosfamide/RB (r_advmod) induced/VBN (r_amod) cystitis/NN -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_attr) is/VBZ (l_nsubj) cystitis/NN
D007069_D014839 NONE ifosfamide/RB (r_advmod) induced/VBN (r_amod) emesis/NN
D015080_D014839 NONE mesna/NN (r_compound) concentrations/NNS (l_prep) as/IN (l_prep) in/IN (l_pobj) patient/NN (l_relcl) experiences/VBZ (l_dobj) emesis/NN -PUNC- mesna/NN (r_dobj) taking/VBG (r_acl) patient/NN (l_relcl) experiences/VBZ (l_dobj) emesis/NN
D015080_D006470 CID mesna/NN (r_pobj) of/IN (r_prep) administration/NN (l_relcl) prevent/VB (l_dobj) cystitis/NN -PUNC- mesna/NN (r_dobj) administering/VBG (r_pcomp) by/IN (r_agent) prevented/VBN (r_relcl) toxicity/NN (r_attr) is/VBZ (l_nsubj) cystitis/NN
D015080_D003556 CID mesna/NN (r_pobj) of/IN (r_prep) administration/NN (l_relcl) prevent/VB (l_dobj) cystitis/NN -PUNC- mesna/NN (r_dobj) administering/VBG (r_pcomp) by/IN (r_agent) prevented/VBN (r_relcl) toxicity/NN (r_attr) is/VBZ (l_nsubj) cystitis/NN
D015080_D064420 NONE mesna/NN (r_dobj) administering/VBG (r_pcomp) by/IN (r_agent) prevented/VBN (r_relcl) toxicity/NN
1835291
D013806_D029424 NONE theophylline/NN (r_conj) bromide/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) disease/NN -PUNC- theophylline/NN (r_amod) tablets/NNS (r_conj) aerosol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) study/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- theophylline/NN (r_pobj) than/IN (r_prep) bronchodilator/NN (r_attr) is/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) obstruction/NN
D013806_D002318 CID theophylline/JJ (r_amod) use/NN (r_pobj) after/IN (r_prep) experienced/VBN (r_acl) those/DT (r_nsubj) involve/VB (l_dobj) systems/NNS
D009241_D029424 NONE bromide/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) disease/NN -PUNC- bromide/NN (r_compound) aerosol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) study/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- ipratropium/NN (r_nsubj) is/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) obstruction/NN
D013806_D005767 CID theophylline/JJ (r_amod) use/NN (r_pobj) after/IN (r_prep) experienced/VBN (r_acl) those/DT (r_nsubj) involve/VB (l_dobj) systems/NNS
871943
D013390_D001049 CID succinylcholine/NN (r_compound) apnoea/NN -PUNC- succinylcholine/NN (r_nsubjpass) treated/VBN (r_advcl) demonstrating/VBG (l_dobj) apnoea/NN -PUNC- succinylcholine/NN (r_compound) apnoea/NN
3686155
D001971_D007775 NONE bromocriptine/NN (r_dobj) received/VBN (l_prep) for/IN (l_pobj) inhibition/NN (l_prep) of/IN (l_pobj) lactation/NN
D001971_D010300 NONE Bromocriptine/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) psychosis/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) receiving/VBG (l_dobj) drug/NN (l_prep) for/IN (l_pobj) disease/NN
D001971_D011605 CID bromocriptine/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) psychosis/NN -PUNC- bromocriptine/NN (r_dobj) received/VBN (r_advcl) seen/VBN (l_prep) with/IN (l_pobj) psychosis/NN -PUNC- Bromocriptine/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) psychosis/NN -PUNC- bromocriptine/NN (r_nsubj) cause/VB (l_dobj) psychosis/NN
D001971_D001523 NONE bromocriptine/NN (r_dobj) received/VBN (r_advcl) seen/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_amod) psychiatric/JJ
8854309
D016578_D010259 NONE cocaine/NN (r_compound) abusers/NNS (l_acl) endorsing/VBG (l_prep) past/IN (l_pobj) CIP/NNP -PUNC- cocaine/NN (r_compound) abusers/NNS (l_acl) endorsing/VBG (l_prep) from/IN (l_pobj) group/NN (l_relcl) denied/VBD (l_prep) past/IN (l_pobj) CIP/NNP -PUNC- crack/NN (r_compound) addicts/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) from/IN (r_prep) endorsing/VBG (l_prep) past/IN (l_pobj) CIP/NNP -PUNC- crack/NN (r_compound) addicts/NNS (r_pobj) of/IN (r_prep) group/NN (l_relcl) denied/VBD (l_prep) past/IN (l_pobj) CIP/NNP
D016578_D011681 NONE cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) group/NN (r_dobj) distinguish/VB (r_xcomp) able/JJ (r_acomp) were/VBD (l_nsubj) Measures/NNS (l_prep) of/IN (l_pobj) oscillation/NN -PUNC- crack/NN (r_compound) addicts/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) from/IN (r_prep) endorsing/VBG (r_acl) abusers/NNS (r_pobj) of/IN (r_prep) group/NN (r_dobj) distinguish/VB (r_xcomp) able/JJ (r_acomp) were/VBD (l_nsubj) Measures/NNS (l_prep) of/IN (l_pobj) oscillation/NN
D003042_D011681 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) paranoia/NN (r_pobj) of/IN (r_prep) marker/NN (r_pobj) as/IN (r_prep) measure/NN (l_prep) of/IN (l_pobj) oscillation/NN
D003042_D010259 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) paranoia/NN -PUNC- Cocaine/NN (r_npadvmod) induced/VBN (r_amod) paranoia/NN -PUNC- Cocaine/NN (r_npadvmod) induced/VBN (r_amod) paranoia/NN (l_appos) CIP/NNP -PUNC- Cocaine/NN (r_npadvmod) induced/VBN (r_amod) paranoia/NN (r_nsubj) remains/VBZ (l_attr) model/NN (l_prep) of/IN (l_pobj) paranoia/NN
11250767
D011441_D010493 CID Propylthiouracil/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN (l_prep) in/IN (l_pobj) conjunction/NN (l_prep) with/IN (l_pobj) pericarditis/NN -PUNC- propylthiouracil/NN (r_npadvmod) induced/VBN (r_amod) vasculitis/NN (l_acl) manifesting/VBG (l_prep) with/IN (l_pobj) pericarditis/NN -PUNC- propylthiouracil/NN (l_relcl) developed/VBD (l_nsubj) syndrome/NN (l_prep) of/IN (l_pobj) pericarditis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) vasculitis/NN (r_pobj) in/IN (r_prep) reports/NNS (l_prep) of/IN (l_pobj) pericarditis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_appos) propylthio-/VB (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) manifestation/NN (r_attr) be/VB (l_nsubj) Pericarditis/NNP
D011441_D005334 CID propylthiouracil/NN (l_relcl) developed/VBD (l_nsubj) syndrome/NN (l_prep) of/IN (l_pobj) pericarditis/NN (l_conj) fever/NN
D011441_D014657 NONE Propylthiouracil/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN -PUNC- propylthiouracil/NN (r_npadvmod) induced/VBN (r_amod) vasculitis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) vasculitis/NN -PUNC- uracil/NN (r_compound) therapy/NN (r_appos) propylthio-/VB (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) manifestation/NN (l_prep) of/IN (l_pobj) vasculitis/NN
D011441_D005921 CID propylthiouracil/NN (l_relcl) developed/VBD (l_nsubj) syndrome/NN (l_prep) of/IN (l_pobj) pericarditis/NN (l_conj) fever/NN (l_conj) glomerulonephritis/NN
D011441_D006980 NONE propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) report/NN (l_prep) of/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) hyperthyroidism/NN
14982270
D008713_D011537 CID methimazole/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) itching/NN
D008713_D006980 NONE methimazole/NN (r_dobj) receiving/VBG (l_conj) propranolol/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
D011433_D002779 NONE propranolol/NN (r_conj) diagnosed/VBN (l_nsubjpass) cholestasis/NN
D011433_D006980 NONE propranolol/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
D011433_D007565 NONE propranolol/NN (r_conj) receiving/VBG (r_pcomp) after/IN (r_prep) itching/NN (r_conj) had/VBD (l_dobj) jaundice/NN
D008713_D002779 NONE Methimazole/NN (r_npadvmod) induced/VBN (r_amod) cholestasis/NN
D011433_D011537 NONE propranolol/NN (r_conj) receiving/VBG (r_pcomp) after/IN (r_prep) itching/NN
D008713_D041781 CID Methimazole/NN (r_npadvmod) induced/VBN (r_amod) jaundice/NN
D008713_D007565 NONE methimazole/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) itching/NN (r_conj) had/VBD (l_dobj) jaundice/NN
10533019
D002122_D013746 NONE chloride/NN (r_pobj) with/IN (r_prep) tetany/NN -PUNC- chloride/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resolved/VBD (l_dobj) tetany/NN -PUNC- chloride/NN (r_nsubj) be/VB (r_conj) accompany/VB (l_nsubj) tetany/NN
D004110_D012131 NONE diltiazem/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) after/IN (r_prep) developed/VBD (l_prep) with/IN (l_pobj) arrest/NN
D004110_D013746 CID diltiazem/NN (r_npadvmod) induced/VBN (r_amod) tetany/NN -PUNC- diltiazem/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) tetany/NN -PUNC- diltiazem/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) accompany/VB (l_nsubj) tetany/NN
12464714
D004878_D006261 NONE ergotamine/NN (r_nmod) caffeine/NN (r_dobj) preferred/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_conj) rizatriptan/JJ (r_dobj) preferring/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) cited/VBN (r_acl) reason/NN (r_attr) was/VBD (l_nsubj) relief/NN (l_prep) of/IN (l_pobj) headache/NN
C093622_D009325 CID Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN -PUNC- rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN
D004878_D014839 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG
C093622_D004244 CID rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (r_nsubj) were/VBD (l_attr) dizziness/NN
D004878_D012001 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS
D002110_D010146 NONE caffeine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) %/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- caffeine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN
D004878_D006970 NONE ergotamine/NNP (r_nmod) caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN (l_conj) somnolence/NN
C093622_D008881 NONE rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_conj) efficacy/NN (r_pobj) of/IN (r_prep) comparison/NN (l_conj) caffeine/NN (l_prep) in/IN (l_pobj) migraine/NN -PUNC- Rizatriptan/NNP (r_nsubj) is/VBZ (l_attr) agonist/NN (l_prep) with/IN (l_pobj) absorption/NN (l_conj) onset/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) migraine/NN -PUNC- rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_dobj) assessed/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treating/VBG (l_dobj) attack/NN (l_compound) migraine/JJ
C093622_D014839 NONE Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG
C093622_D012001 NONE Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS
C093622_D006261 NONE rizatriptan/JJ (r_dobj) preferring/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) cited/VBN (r_acl) reason/NN (r_attr) was/VBD (l_nsubj) relief/NN (l_prep) of/IN (l_pobj) headache/NN
D012701_D008881 NONE 5-HT(1B/1D/CD (r_nummod) receptor/NN (r_compound) agonist/NN (l_prep) with/IN (l_pobj) absorption/NN (l_conj) onset/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) migraine/NN
C093622_D010146 NONE rizatriptan/NN (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- rizatriptan/JJ (r_nsubj) being/VBG (r_advcl) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- rizatriptan/NN (r_dobj) taking/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN
D004878_D004244 NONE ergotamine/NNP (r_nmod) caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (r_nsubj) were/VBD (l_attr) dizziness/NN
D004878_D020795 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS (l_conj) photophobia/NNS
C093622_D006970 NONE rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN (l_conj) somnolence/NN
C093622_D020795 NONE Rizatriptan/NNP (r_nsubj) was/VBD (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS (l_conj) photophobia/NNS
D004878_D008881 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) migraine/NN -PUNC- ergotamine/NN (r_pobj) to/IN (r_prep) tablet/NN (r_amod) rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_dobj) assessed/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treating/VBG (l_dobj) attack/NN (l_compound) migraine/JJ
D002110_D006261 NONE caffeine/NN (r_dobj) preferred/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_conj) rizatriptan/JJ (r_dobj) preferring/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) cited/VBN (r_acl) reason/NN (r_attr) was/VBD (l_nsubj) relief/NN (l_prep) of/IN (l_pobj) headache/NN
D002110_D008881 NONE caffeine/NN (l_prep) in/IN (l_pobj) migraine/NN -PUNC- caffeine/NN (r_appos) ergotamine/NN (r_pobj) to/IN (r_prep) tablet/NN (r_amod) rizatriptan/JJ (r_pobj) for/IN (r_prep) preference/NN (r_dobj) assessed/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treating/VBG (l_dobj) attack/NN (l_compound) migraine/JJ
D004878_D010146 NONE ergotamine/NN (r_nmod) caffeine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) %/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN -PUNC- ergotamine/NNP (r_nmod) caffeine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) free/JJ (l_npadvmod) pain/NN
D004878_D009325 NONE ergotamine/NN (r_nmod) caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN -PUNC- ergotamine/NNP (r_nmod) caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN
D002110_D020795 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS (l_conj) photophobia/NNS
D002110_D004244 NONE caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (r_nsubj) were/VBD (l_attr) dizziness/NN
D002110_D009325 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN -PUNC- caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN
D002110_D012001 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG (l_conj) phonophobia/NNS
D002110_D006970 NONE caffeine/NN (r_conj) rizatriptan/NN (r_pobj) after/IN (r_prep) >/XX (r_appos) events/NNS (l_appos) nausea/NN (l_conj) somnolence/NN
D002110_D014839 NONE caffeine/NN (l_prep) in/IN (l_pobj) proportions/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nausea/NN (l_conj) vomiting/VBG
11900788
D001285_D002375 NONE atropine/NN (r_pobj) of/IN (r_prep) administration/NN (l_appos) catalepsy/NN -PUNC- atropine/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) decreased/VBD (l_dobj) catalepsy/NN
D008464_D002375 NONE mecamylamine/NN (r_conj) naloxone/NN (r_appos) administration/NN (l_appos) catalepsy/NN
D009020_D002375 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- Morphine/NNP (r_nsubj) induced/VBD (l_dobj) catalepsy/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- morphine/NN (r_compound) catalepsy/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) potentiation/NN (r_nsubjpass) mediated/VBN (r_conj) elicited/VBN (l_nsubjpass) catalepsy/NN
D018738_D002375 NONE hexamethonium/NN (r_conj) mecamylamine/NN (r_conj) naloxone/NN (r_appos) administration/NN (l_appos) catalepsy/NN -PUNC- hexamethonium/NN (r_conj) atropine/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) decreased/VBD (l_dobj) catalepsy/NN
D009270_D002375 NONE naloxone/NN (r_appos) administration/NN (l_appos) catalepsy/NN -PUNC- naloxone/NN (r_conj) hexamethonium/NN (r_conj) atropine/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) decreased/VBD (l_dobj) catalepsy/NN
D009538_D002375 CID Nicotine/NN (r_compound) potentiation/NN (l_prep) of/IN (l_pobj) catalepsy/NN -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- nicotine/NN (r_conj) Morphine/NNP (r_nsubj) induced/VBD (l_dobj) catalepsy/NN -PUNC- nicotine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- nicotine/NN (r_conj) morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- nicotine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) potentiation/NN (r_nsubjpass) mediated/VBN (r_conj) elicited/VBN (l_nsubjpass) catalepsy/NN
12589964
D004317_D006331 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) damage/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) for/IN (r_prep) investigated/VBD (l_conj) examined/VBD (l_dobj) relationship/NN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) disorders/NNS -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN (r_appos) model/NN (r_pobj) in/IN (r_prep) damage/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) for/IN (r_prep) investigated/VBD (l_conj) examined/VBD (l_dobj) relationship/NN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) disorders/NNS
D004317_D005355 NONE DOX/NNP (r_pobj) given/VBN (r_prep) rats/NNS (r_pobj) from/IN (r_prep) hearts/NNS (r_pobj) of/IN (r_prep) evaluation/NN (r_nsubj) revealed/VBD (l_dobj) degrees/NNS (l_prep) of/IN (l_pobj) fibrosis/NN
D004317_D064420 NONE DOX/NNP (r_compound) rats/NNS (r_pobj) of/IN (r_prep) Eighteen/CD (r_nsubj) died/VBD (l_prep) of/IN (l_pobj) toxicity/NN
D004317_D066126 NONE DOX/NNP (r_pobj) after/IN (r_prep) amount/NN (r_pobj) between/IN (r_prep) discrepancy/NN (r_attr) was/VBD (r_advcl) is/VBZ (l_acomp) likely/JJ (l_ccomp) indicates/VBZ (l_conj) be/VB (l_attr) marker/NN (l_prep) for/IN (l_pobj) prediction/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_nsubj) indicates/VBZ (l_conj) be/VB (l_attr) marker/NN (l_prep) for/IN (l_pobj) prediction/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN
D004317_D009202 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) damage/NN -PUNC- doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) rats/NNS (l_amod) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) damage/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (l_appos) cardiomyopathy/NN -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN (r_appos) model/NN (r_pobj) in/IN (r_prep) damage/NN -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN -PUNC- DOX/NNP (r_pobj) after/IN (r_prep) markers/NNS (r_pobj) Among/IN (r_prep) showed/VBD (l_dobj) ability/NN (l_acl) detect/VB (l_dobj) damage/NN
D004317_D017202 NONE DOX/NNP (r_pobj) after/IN (r_prep) markers/NNS (l_prep) of/IN (l_pobj) injury/NN
17366349
C092292_D009459 CID ziprasidone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) syndrome/NN -PUNC- ziprasidone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) syndrome/NN -PUNC- ziprasidone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) syndrome/NN (l_appos) NMS/NNP -PUNC- ziprasidone/NN (r_pobj) like/IN (r_prep) drugs/NNS (l_nmod) NMS/NNP -PUNC- ziprasidone/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) NMS/NNP -PUNC- ziprasidone/NNP (r_xcomp) due/IN (r_amod) NMS/NNP
C092292_D012559 NONE ziprasidone/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) schizophrenia/NN
11860278
D000109_D012640 NONE acetylcholine/NN (r_conj) glutamate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) mice/NNS (r_pobj) in/IN (r_prep) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D004298_D004827 NONE Dopamine/NNP (r_nsubj) plays/VBZ (l_prep) in/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- DA/NNP (r_appos) Dopamine/NNP (r_nsubj) plays/VBZ (l_prep) in/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- DA/NNP (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) occurrence/NN (l_prep) of/IN (l_pobj) death/NN (l_amod) induced/VBN (l_npadvmod) epilepsy/NN
D010862_D020258 NONE pilocarpine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) mice/NNS (r_pobj) in/IN (r_prep) seizures/NNS (l_conj) neurotoxicity/NN
D018698_D012640 NONE glutamate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D007608_D012640 CID KA/NNP (r_pobj) to/IN (r_prep) comparison/NN (r_pobj) in/IN (r_prep) death/NN (r_pobj) in/IN (r_prep) result/VBP (l_nsubj) seizures/NNS
8841157
C081489_D004487 CID valsartan/NN (r_pobj) for/IN (r_prep) %/NN (r_appos) dose/NN (r_pobj) at/IN (r_prep) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) edema/NN -PUNC- valsartan/NN (r_pobj) for/IN (r_prep) %/NN (r_conj) %/NN (r_npadvmod) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) edema/NN
C081489_D006973 NONE Valsartan/NNP (l_appos) antagonist/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- valsartan/NN (r_dobj) receive/VB (r_advcl) allocated/VBN (l_nsubjpass) outpatients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- valsartan/NN (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_prep) as/IN (l_pobj) amlodipine/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN
D017311_D004487 CID amlodipine/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) edema/NN -PUNC- amlodipine/NN (r_pobj) for/IN (r_prep) %/NN (r_npadvmod) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) edema/NN -PUNC- amlodipine/NN (r_conj) %/NN (r_conj) %/NN (r_npadvmod) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) edema/NN -PUNC- amlodipine/NN (r_pobj) for/IN (r_prep) %/NN (r_appos) %/NN (r_npadvmod) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) edema/NN
D000804_D006973 NONE II/CD (r_compound) antagonist/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN
D017311_D006973 NONE amlodipine/NN (r_pobj) against/IN (r_prep) safety/NN (r_conj) efficacy/NN (r_pobj) of/IN (r_prep) study/NN (r_appos) Valsartan/NNP (l_appos) antagonist/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- amlodipine/NN (r_conj) valsartan/NN (r_dobj) receive/VB (r_advcl) allocated/VBN (l_nsubjpass) outpatients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- amlodipine/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN
7843916
D003907_D009798 CID Dexamethasone/NN (r_npadvmod) induced/VBN (l_dobj) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) treated/VBN (r_amod) eyes/NNS -PUNC- Dexamethasone/NN (r_compound) treatment/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) generation/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) treated/VBN (r_amod) eyes/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) generation/NN (l_prep) of/IN (l_pobj) hypertension/NN
D013256_D005901 NONE Steroid/NN (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) meshwork/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) reported/VBN (l_prep) for/IN (l_pobj) glaucoma/NN
D013256_D005902 NONE Steroid/NN (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) meshwork/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) reported/VBN (l_prep) for/IN (l_pobj) glaucoma/NN (l_conj) glaucoma/NN
7905523
C059896_D007153 NONE SC-48334/VBP (r_nmod) level/NN (r_nsubj) was/VBD (l_prep) below/IN (l_pobj) concentration/NN (l_prep) for/IN (l_pobj) virus/NN (l_compound) immunodeficiency/NN
C059896_D015658 NONE deoxynojirimycin/NNP (l_conj) zidovudine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infection/NN -PUNC- SC-48334/NNP (r_appos) deoxynojirimycin/NNP (l_conj) zidovudine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infection/NN
D015215_D015658 NONE zidovudine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infection/NN
9812111
D006220_D019958 NONE haloperidol/NN (l_prep) for/IN (l_pobj) psychosis/NN (l_conj) behaviors/NNS -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) psychosis/NN (l_conj) behaviors/NNS -PUNC- haloperidol/NN (r_pobj) with/IN (r_prep) observed/VBN (r_nsubj) apply/VB (l_prep) to/IN (l_pobj) neuroleptics/NNS (l_acl) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psychosis/NN (l_conj) behaviors/NNS
D006220_D011595 NONE haloperidol/NN (r_appos) A/NNP (r_dobj) completed/VBD (r_relcl) patients/NNS (r_pobj) For/IN (r_prep) was/VBD (l_acomp) efficacious/JJ (l_prep) to/IN (l_pobj) haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_conj) on/IN (l_pobj) agitation/NN -PUNC- haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_conj) on/IN (l_pobj) agitation/NN
D006220_D000544 NONE haloperidol/NN (l_prep) for/IN (l_pobj) psychosis/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_appos) phase/NN (r_preconj) In/IN (r_prep) compared/VBN (l_prep) in/IN (l_pobj) outpatients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_conj) phase/NN (r_preconj) In/IN (r_prep) compared/VBN (l_prep) in/IN (l_pobj) outpatients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- haloperidol/NN (r_pobj) with/IN (r_prep) observed/VBN (r_nsubj) apply/VB (l_prep) to/IN (l_pobj) neuroleptics/NNS (l_acl) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
D006220_D001480 CID haloperidol/NN (r_pobj) for/IN (r_prep) profile/NN (r_dobj) indicated/VBD (l_advcl) developed/VBD (l_acomp) moderate/JJ (l_prep) to/TO (l_pobj) signs/NNS
D006220_D011618 NONE haloperidol/NN (l_prep) for/IN (l_pobj) psychosis/NN -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) psychosis/NN -PUNC- haloperidol/NN (r_appos) A/NNP (r_dobj) completed/VBD (r_relcl) patients/NNS (r_pobj) For/IN (r_prep) was/VBD (l_acomp) efficacious/JJ (l_prep) to/IN (l_pobj) haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_pobj) factor/NN (l_compound) psychosis/NN -PUNC- haloperidol/NN (l_prep) for/IN (l_pobj) scores/NNS (l_prep) on/IN (l_pobj) factor/NN (l_compound) psychosis/NN -PUNC- haloperidol/NN (r_pobj) with/IN (r_prep) observed/VBN (r_nsubj) apply/VB (l_prep) to/IN (l_pobj) neuroleptics/NNS (l_acl) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psychosis/NN
8829025
D009543_D006973 NONE nifedipine/NN (r_dobj) receiving/VBG (r_relcl) patients/NNS (l_amod) hypertensive/JJ -PUNC- nifedipine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_dobj) comprising/VBG (r_acl) other/JJ (r_conj) group/NN (l_acl) comprising/VBG (l_dobj) patients/NNS (l_amod) hypertensive/JJ -PUNC- nifedipine/NN (r_pobj) of/IN (r_prep) impact/NN (r_nsubj) be/VB (l_attr) factor/NN (l_prep) in/IN (l_pcomp) selecting/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN
D009543_D007674 NONE nifedipine/NN (r_pobj) of/IN (r_prep) impact/NN (l_prep) on/IN (l_pcomp) reducing/VBG (l_dobj) nephrotoxicity/NN
D016559_D006973 CID tacrolimus/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) groups/NNS (r_nsubjpass) compared/VBN (l_appos) group/NN (l_acl) comprising/VBG (l_dobj) patients/NNS (l_amod) hypertensive/JJ -PUNC- tacrolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) nephrotoxicity/NN (r_dobj) reducing/VBG (r_pcomp) on/IN (r_prep) impact/NN (r_nsubj) be/VB (l_attr) factor/NN (l_prep) in/IN (l_pcomp) selecting/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN
D016559_D007674 NONE tacrolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) nephrotoxicity/NN
9514561
D002211_D010146 CID capsaicin/NN (r_pobj) by/IN (r_agent) elicited/VBN (r_acl) pain/NN -PUNC- capsaicin/NN (r_pobj) of/IN (r_prep) amount/NN (r_nsubjpass) administered/VBN (l_advcl) evoke/VB (l_dobj) sensation/NN (l_amod) painful/JJ
8494478
D002939_D009369 NONE Ciprofloxacin/NNP (r_npadvmod) induced/VBN (l_dobj) nephrotoxicity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- ciprofloxacin/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) followed/VBD (r_relcl) failure/NN (r_dobj) developed/VBD (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D002939_D058186 CID ciprofloxacin/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) followed/VBD (r_relcl) failure/NN -PUNC- ciprofloxacin/NNS (r_npadvmod) induced/VBN (r_amod) failure/NN
D002939_D007674 NONE Ciprofloxacin/NNP (r_npadvmod) induced/VBN (l_dobj) nephrotoxicity/NN -PUNC- ciprofloxacin/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Nephrotoxicity/NN
1728522
D019980_D056486 CID acid/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) due/JJ (r_prep) hepatitis/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN
D019980_D006099 CID acid/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) due/JJ (r_prep) hepatitis/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) of/IN (r_prep) case/NN (l_prep) with/IN (l_pobj) granulomas/NNS
10457883
14568327
D015632_D004409 NONE MPTP/NNP (r_npadvmod) induced/VBN (r_amod) parkinsonism/NN (r_pobj) of/IN (r_prep) types/NNS (r_pobj) with/IN (r_prep) Using/VBG (r_advcl) evaluated/VBD (l_dobj) degree/NN (l_relcl) involved/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) LIDs/NNS -PUNC- MPTP/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) Monkeys/NNS (r_nsubj) developed/VBD (l_dobj) dyskinesia/RB -PUNC- MPTP/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) monkeys/NNS (r_nsubj) progression/NN (r_nsubj) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pcomp) developing/VBG (l_dobj) LIDs/NNS -PUNC- MPTP/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) monkeys/NNS (r_nsubj) progression/NN (r_nsubj) were/VBD (l_parataxis) developed/VBD (l_nsubj) dyskinesia/NN
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LIDs/NNPS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) response/NN (r_conj) severity/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) LIDs/NNS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) developed/VBD (l_dobj) dyskinesia/RB -PUNC- levodopa/JJ (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_npadvmod) developed/VBD (l_dobj) dyskinesia/RB -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) progression/NN (r_nsubj) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pcomp) developing/VBG (l_dobj) LIDs/NNS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) progression/NN (r_nsubj) were/VBD (l_parataxis) developed/VBD (l_nsubj) dyskinesia/NN -PUNC- levodopa/JJ (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) than/IN (r_prep) sooner/RBR (r_advmod) developed/VBD (r_parataxis) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pcomp) developing/VBG (l_dobj) LIDs/NNS -PUNC- levodopa/JJ (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) than/IN (r_prep) sooner/RBR (r_advmod) developed/VBD (l_nsubj) dyskinesia/NN -PUNC- levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) develop/VB (l_dobj) LIDs/NNS -PUNC- levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) develop/VB (r_acl) propensity/NN (r_pobj) in/IN (r_prep) differences/NNS (r_dobj) suggest/VBP (l_conj) demonstrate/VB (l_dobj) value/NN (l_prep) for/IN (l_pcomp) studying/VBG (l_dobj) pathophysiology/NN (l_prep) of/IN (l_pobj) LIDs/NNS
D015632_D010302 CID MPTP/NNP (r_npadvmod) induced/VBN (r_amod) parkinsonism/NN
D007980_D010302 NONE levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) response/NN (r_conj) severity/NN (r_nsubjpass) involved/VBN (r_relcl) degree/NN (r_dobj) evaluated/VBD (l_advcl) Using/VBG (l_prep) with/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) parkinsonism/NN
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_prep) in/IN (l_pobj) monkeys/NNS (l_amod) parkinsonian/JJ -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_nsubj) present/VBP (l_dobj) problem/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_nmod) disease/NN -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_nsubj) present/VBP (l_dobj) problem/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_nmod) PD/NNP
7468724
D013726_D007752 NONE terbutaline/JJ (r_compound) treatment/NN (l_prep) for/IN (l_pobj) labor/NN -PUNC- terbutaline/NN (l_prep) for/IN (l_pobj) labor/NN
D013726_D002318 CID terbutaline/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complications/NNS -PUNC- terbutaline/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) complications/NNS
9630698
D006220_D009127 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) rigidity/NN -PUNC- haloperidol/NN (r_advmod) induced/VBN (r_amod) rigidity/NN
C066192_D009127 NONE acid/NN (r_nsubj) injected/VBN (l_conj) decreased/VBD (l_dobj) rigidity/NN -PUNC- 5,7-DCKA/CD (r_appos) acid/NN (r_nsubj) injected/VBN (l_conj) decreased/VBD (l_dobj) rigidity/NN
D005998_D009127 NONE glycine/NN (r_compound) site/NN (r_compound) antagonist/NN (r_appos) acid/NN (r_nsubj) injected/VBN (l_conj) decreased/VBD (l_dobj) rigidity/NN
16787750
D014635_D056486 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN (r_conj) hepatotoxicity/NN
D014635_D022124 NONE VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) of/IN (r_prep) signs/NNS (r_nsubj) are/VBP (l_advcl) marked/VBD (l_ccomp) slowing/VBG (l_dobj) frequency/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) hyperammonemia/NN
D014635_D001855 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN (l_conj) suppression/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN (r_conj) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN (l_conj) suppression/NN
D014635_D012640 NONE VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) of/IN (r_prep) signs/NNS (r_nsubj) are/VBP (l_advcl) marked/VBD (l_ccomp) slowing/VBG (l_dobj) frequency/NN (l_compound) seizure/NN
D014635_D001927 CID acid/NN (r_nsubj) induced/VBD (l_advmod) encephalopathy--19/NNP -PUNC- VPA/NNP (r_compound) therapy/NN (r_pobj) to/IN (r_prep) associated/VBN (r_acl) effect/NN (r_pobj) to/IN (r_prep) induced/VBD (l_advmod) encephalopathy--19/NNP -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (l_conj) encephalopathy/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- VPA/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) encephalopathy/JJ -PUNC- VPA/NNP (r_npadvmod) associated/VBN (r_amod) encephalopathy/NN
D014635_D010195 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN -PUNC- VPA/NNP (r_npadvmod) induced/VBN (r_compound) encephalopathy/NN (r_conj) hepatotoxicity/NN (r_npadvmod) occur/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) including/VBG (l_pobj) pancreatitis/NN
D014635_D003244 CID VPA/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) of/IN (r_prep) signs/NNS (r_nsubj) are/VBP (l_attr) consciousness/NN
18020536
D001569_D007319 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_npadvmod) inability/NN (l_acl) sleep/VB
D001569_D004244 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) dizziness/NN
D001569_D005221 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_npadvmod) inability/NN (l_acl) sleep/VB (l_prep) after/IN (l_pcomp) awaking/VBG (l_prep) at/IN (l_pobj) night/NN (l_conj) tiredness/NN
D001569_D003866 CID BZDs/NNP (r_nmod) RDs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_npadvmod) inability/NN (l_acl) sleep/VB (l_prep) after/IN (l_conj) with/IN (l_pobj) symptoms/NNS
16720068
D000525_D009127 NONE alprazolam/NN (r_compound) treatment/NN (r_conj) paroxetine/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) exhibited/VBD (l_dobj) retardation/NN (l_conj) disorientation/NN (l_conj) rigidity/NN
D017374_D009127 NONE paroxetine/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) exhibited/VBD (l_dobj) retardation/NN (l_conj) disorientation/NN (l_conj) rigidity/NN
D017374_D014202 NONE paroxetine/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) exhibited/VBD (l_dobj) retardation/NN (l_conj) disorientation/NN (l_conj) rigidity/NN (l_prep) with/IN (l_pobj) tremors/NNS
D017374_D011596 NONE paroxetine/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) exhibited/VBD (l_dobj) retardation/NN
D000525_D014202 NONE alprazolam/NN (r_compound) treatment/NN (r_conj) paroxetine/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) exhibited/VBD (l_dobj) retardation/NN (l_conj) disorientation/NN (l_conj) rigidity/NN (l_prep) with/IN (l_pobj) tremors/NNS
D017374_D009459 CID paroxetine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) syndrome/NN -PUNC- paroxetine/NN (r_pobj) after/IN (r_prep) occur/VB (r_ccomp) demonstrating/VBG (r_advcl) presented/VBN (l_prep) with/IN (l_pobj) symptoms/NNS (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- paroxetine/NN (r_pobj) after/IN (r_prep) occur/VB (r_ccomp) demonstrating/VBG (r_advcl) presented/VBN (l_prep) with/IN (l_pobj) symptoms/NNS (l_prep) of/IN (l_pobj) syndrome/NN (l_appos) NMS/NNP -PUNC- paroxetine/NN (r_pobj) after/IN (r_prep) occur/VB (l_nsubj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) NMS/NNP
D000525_D011596 NONE alprazolam/NN (r_compound) treatment/NN (r_conj) paroxetine/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) exhibited/VBD (l_dobj) retardation/NN
D000525_D009459 CID alprazolam/NN (r_conj) paroxetine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) syndrome/NN -PUNC- alprazolam/NN (r_compound) treatment/NN (r_conj) paroxetine/NN (r_pobj) after/IN (r_prep) occur/VB (r_ccomp) demonstrating/VBG (r_advcl) presented/VBN (l_prep) with/IN (l_pobj) symptoms/NNS (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- alprazolam/NN (r_compound) treatment/NN (r_conj) paroxetine/NN (r_pobj) after/IN (r_prep) occur/VB (r_ccomp) demonstrating/VBG (r_advcl) presented/VBN (l_prep) with/IN (l_pobj) symptoms/NNS (l_prep) of/IN (l_pobj) syndrome/NN (l_appos) NMS/NNP -PUNC- alprazolam/NN (r_compound) treatment/NN (r_conj) paroxetine/NN (r_pobj) after/IN (r_prep) occur/VB (l_nsubj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) NMS/NNP
9862868
D004997_D002780 CID estradiol/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN (r_dobj) used/VBD (l_dobj) models/NNS (l_prep) of/IN (l_pobj) cholestasis/NN -PUNC- EE/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN (r_dobj) used/VBD (l_dobj) models/NNS (l_prep) of/IN (l_pobj) cholestasis/NN
D004997_D001651 NONE estradiol/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN -PUNC- EE/NNP (r_nmod) treatment/NN (r_nmod) cholestasis/NN
10091616
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D001058_D004409 CID apomorphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) worsening/VBG (r_pobj) on/IN (r_prep) tasks/NNS (r_dobj) speaking/VBG (r_dep) evaluate/VB (r_advcl) included/VBN (l_nsubjpass) patients/NNS (l_relcl) had/VBD (l_prep) with/IN (l_pcomp) disabling/VBG (l_dobj) dyskinesia/NN -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) worsening/VBG (l_prep) of/IN (l_pobj) dyskinesia/JJ
D001058_D010300 NONE apomorphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) worsening/VBG (r_pobj) on/IN (r_prep) tasks/NNS (r_dobj) speaking/VBG (r_dep) evaluate/VB (r_advcl) included/VBN (l_nsubjpass) patients/NNS (l_relcl) had/VBD (l_dobj) disease/NN
17344566
D013974_D007037 NONE thyroxine/NN (l_compound) taking/VBG (l_nsubj) male/NN (l_amod) hypothyroid/JJ
D013974_D003161 NONE thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN
D019821_D009135 NONE Simvastatin/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN (l_conj) myonecrosis/NN -PUNC- simvastatin/NN (r_conj) thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN (l_conj) myonecrosis/NN
D013974_D009135 NONE thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN (l_conj) myonecrosis/NN
D019821_D003161 CID Simvastatin/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- simvastatin/NN (r_conj) thyroxine/NN (r_nsubj) presented/VBD (l_prep) with/IN (l_pobj) syndrome/NN
D019821_D007037 NONE Simvastatin/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hypothyroidism/NN -PUNC- simvastatin/NN (r_conj) thyroxine/NN (l_compound) taking/VBG (l_nsubj) male/NN (l_amod) hypothyroid/JJ
6732043
D000728_D012891 NONE androgens/NNS (r_pobj) of/IN (r_prep) role/NN (r_dobj) favored/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) apnea/NN
D000728_D020181 CID androgen/JJ (r_compound) administration/NN (r_pobj) by/IN (r_prep) woman/NN (r_pobj) in/IN (r_prep) syndrome/NN -PUNC- androgens/NNS (r_dobj) administered/VBN (r_advcl) developed/VBN (l_dobj) changes/NNS (l_conj) syndrome/NN (l_prep) of/IN (l_pobj) apnea/NN -PUNC- androgen/NN (r_nmod) symptoms/NNS (l_prep) of/IN (l_pobj) apnea/NN -PUNC- androgen/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effect/NN (r_oprd) considered/VBN (l_nsubjpass) Development/NN (l_prep) of/IN (l_pobj) syndrome/NN
2312209
D007548_D009203 CID dinitrate/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) infarction/NN -PUNC- dinitrate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) suffered/VBD (l_dobj) infarction/NN
D007548_D009336 NONE dinitrate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) suffered/VBD (l_nsubj) necrosis/NN
8988571
D003042_D003645 CID cocaine/NN (r_compound) use/NN (r_nsubj) disrupts/VBZ (r_acl) hypothesis/NN (r_pobj) with/IN (r_prep) consistent/JJ (r_acomp) are/VBP (l_advcl) precipitate/VB (l_dobj) agitation/NN (l_conj) delirium/NN (l_conj) thermoregulation/NN (l_conj) rhabdomyolysis/NN (l_conj) death/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) coupled/VBN (r_advcl) precipitate/VB (l_dobj) agitation/NN (l_conj) delirium/NN (l_conj) thermoregulation/NN (l_conj) rhabdomyolysis/NN (l_conj) death/NN
D003042_D064420 NONE cocaine/NN (r_compound) use/NN (r_dobj) following/VBG (r_acl) delirium/NN (r_dep) provide/VBP (l_dobj) evidence/NN (l_prep) for/IN (l_pobj) mechanisms/NNS (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- cocaine/NN (r_compound) toxicity/NN
D003042_D062787 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) deaths/NNS (r_pobj) of/IN (r_prep) registry/NN (r_pobj) From/IN (r_prep) compared/VBN (l_prep) with/IN (l_pobj) victims/NNS (l_prep) of/IN (l_pobj) overdose/NN -PUNC- cocaine/NN (r_compound) overdose/NN
C005618_D003693 NONE benzoylecgonine/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) had/VBD (l_nsubj) EDDs/NNS
D003042_D011595 NONE cocaine/NN (r_compound) use/NN (r_nsubj) disrupts/VBZ (r_acl) hypothesis/NN (r_pobj) with/IN (r_prep) consistent/JJ (r_acomp) are/VBP (l_advcl) precipitate/VB (l_dobj) agitation/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) coupled/VBN (r_advcl) precipitate/VB (l_dobj) agitation/NN
D003042_D003693 CID cocaine/NN (r_compound) use/NN (r_dobj) following/VBG (r_acl) delirium/NN -PUNC- cocaine/NN (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) mechanisms/NNS (r_pobj) for/IN (r_prep) evidence/NN (r_dobj) provide/VBP (l_dep) delirium/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) delirium/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) delirium/NN (l_appos) EDDs/NNP -PUNC- cocaine/NN (r_npadvmod) related/VBN (r_amod) deaths/NNS (r_pobj) of/IN (r_prep) registry/NN (r_pobj) From/IN (r_prep) compared/VBN (l_nsubjpass) EDDs/NNS -PUNC- cocaine/NN (r_npadvmod) related/VBN (r_amod) deaths/NNS (r_pobj) of/IN (r_prep) registry/NN (r_pobj) From/IN (r_prep) compared/VBN (l_prep) with/IN (l_pobj) victims/NNS (l_prep) without/IN (l_pobj) delirium/NN -PUNC- cocaine/NN (r_compound) overdose/NN (r_pobj) of/IN (r_prep) victims/NNS (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) EDDs/NNS -PUNC- cocaine/NN (r_compound) overdose/NN (r_pobj) of/IN (r_prep) victims/NNS (l_prep) without/IN (l_pobj) delirium/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) had/VBD (l_nsubj) EDDs/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_nsubj) disrupts/VBZ (r_acl) hypothesis/NN (r_pobj) with/IN (r_prep) consistent/JJ (r_acomp) are/VBP (l_advcl) precipitate/VB (l_dobj) agitation/NN (l_conj) delirium/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) coupled/VBN (r_advcl) precipitate/VB (l_dobj) agitation/NN (l_conj) delirium/NN
D003042_D012206 CID cocaine/NN (r_compound) use/NN (r_nsubj) disrupts/VBZ (r_acl) hypothesis/NN (r_pobj) with/IN (r_prep) consistent/JJ (r_acomp) are/VBP (l_advcl) precipitate/VB (l_dobj) agitation/NN (l_conj) delirium/NN (l_conj) thermoregulation/NN (l_conj) rhabdomyolysis/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) coupled/VBN (r_advcl) precipitate/VB (l_dobj) agitation/NN (l_conj) delirium/NN (l_conj) thermoregulation/NN (l_conj) rhabdomyolysis/NN
1928887
D002216_D007022 NONE captopril/NN (r_compound) overdose/NN (r_pobj) due/IN (r_prep) reversal/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- captopril/NN (r_pobj) of/IN (r_prep) actions/NNS (l_amod) hypotensive/JJ -PUNC- captopril/NN (r_compound) overdose/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) report/VBP (l_advcl) manifested/VBN (l_agent) by/IN (l_pobj) hypotension/NN -PUNC- captopril/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- captopril/NN (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) hypotension/NN
D009270_D007022 NONE Naloxone/NN (r_compound) reversal/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- naloxone/NN (r_appos) antagonist/NN (r_nsubjpass) shown/VBN (l_xcomp) block/VB (l_conj) reverse/VB (l_dobj) actions/NNS (l_amod) hypotensive/JJ -PUNC- naloxone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) resolved/VBD (r_ccomp) report/VBP (l_advcl) manifested/VBN (l_agent) by/IN (l_pobj) hypotension/NN -PUNC- naloxone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) hypotension/NN -PUNC- naloxone/NN (l_prep) in/IN (l_pobj) reversal/NN (l_prep) of/IN (l_pobj) hypotension/NN
D009270_D062787 NONE Naloxone/NN (r_compound) reversal/NN (l_prep) due/IN (l_pobj) overdose/NN -PUNC- naloxone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) resolved/VBD (r_ccomp) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) overdose/NN
D002216_D062787 NONE captopril/NN (r_compound) overdose/NN -PUNC- captopril/NN (r_compound) overdose/NN
12452237
D013390_D063806 NONE succinylcholine/NN (r_npadvmod) induced/VBN (r_amod) myalgia/NN
D008012_D063806 NONE lidocaine/JJ (r_compound) pretreatment/NN (l_prep) on/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) myalgia/NN
D008012_D010149 NONE lidocaine/RB (r_nsubj) reduce/VB (l_conj) induced/VBD (l_dobj) myalgia/NN -PUNC- lidocaine/NN (r_nsubjpass) proven/VBN (l_xcomp) be/VB (l_attr) agent/NN (l_prep) for/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) myalgia/NN
D013390_D010149 CID succinylcholine/NN (r_dobj) reduce/VB (l_conj) induced/VBD (l_dobj) myalgia/NN -PUNC- succinylcholine/NN (r_nsubjpass) used/VBN (r_advcl) proven/VBN (l_xcomp) be/VB (l_attr) agent/NN (l_prep) for/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) myalgia/NN
10579464
D008694_D006948 CID methamphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN -PUNC- MAP/NNP (r_appos) methamphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D003024_D006948 NONE clozapine/NN (r_conj) NRA0160/NNP (r_nsubj) antagonized/VBN (l_dobj) hyperactivity/NN
C121249_D006948 NONE NRA0160/NNP (r_nsubj) antagonized/VBN (l_dobj) hyperactivity/NN
D003024_D002375 CID clozapine/NN (r_conj) NRA0160/NNP (r_nsubj) induced/VBN (l_dobj) catalepsy/NN
C121249_D002375 CID NRA0160/NNP (r_nsubj) induced/VBN (l_dobj) catalepsy/NN
3341566
D009599_D007022 CID nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN -PUNC- SNP/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) that/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) higher/RBR (r_acomp) was/VBD (l_prep) During/IN (l_pobj) hypotension/NN -PUNC- SNP/NNP (r_compound) groups/NNS (r_pobj) in/IN (r_prep) Hg/NNP (l_prep) during/IN (l_pobj) hypotension/NN
D009599_D006470 NONE nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN (r_pobj) during/IN (r_prep) than/IN (r_prep) is/VBZ (l_prep) during/IN (l_pobj) hemorrhage/NN -PUNC- nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN -PUNC- nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN (l_appos) HEM/NNP -PUNC- SNP/NNP (r_dep) n/CC (r_npadvmod) nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN -PUNC- SNP/NNP (r_dep) n/CC (r_npadvmod) nitroprusside/NN (r_advcl) decreased/VBN (l_prep) for/IN (l_pobj) minutes/NNS (l_prep) by/IN (l_pobj) hemorrhage/NN (l_appos) HEM/NNP -PUNC- SNP/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) that/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) higher/RBR (r_acomp) was/VBD (l_prep) During/IN (l_pobj) hypotension/NN (l_amod) induced/VBN (l_npadvmod) HEM/NNP -PUNC- SNP/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) Hg/NNP (r_appos) mm/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) Hg/NNP (l_prep) in/IN (l_pobj) group/NN (l_compound) HEM/NNP -PUNC- SNP/NNP (r_compound) groups/NNS (l_nmod) HEM/NNP
3560095
D005480_D001168 NONE flurbiprofen/JJ (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) arthritis/NN (r_pobj) with/IN (r_prep) patients/NNS (r_nsubj) had/VBD (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) indices/NNS (l_compound) arthritis/NN
D005480_D001171 NONE Flurbiprofen/NNP (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) arthritis/NN -PUNC- flurbiprofen/JJ (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) arthritis/NN
11583940
D020123_D007674 NONE sirolimus/NN (r_conj) mofetil/NNS (r_dobj) mycophenolate/VB (l_dep) have/VBP (l_dobj) nephrotoxicity/NN -PUNC- rapamycin/NNS (r_appos) mofetil/NNS (r_dobj) mycophenolate/VB (l_dep) have/VBP (l_dobj) nephrotoxicity/NN
C063008_D007674 NONE mofetil/NNS (r_dobj) mycophenolate/VB (l_dep) have/VBP (l_dobj) nephrotoxicity/NN
982002
D012293_D051437 NONE rifampicin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBN (l_dobj) failure/NN
D012293_D058186 CID rifampicin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) subsequent/JJ (r_amod) failure/NN
15737522
D002443_D001660 CID Ceftriaxone/NN (r_npadvmod) associated/VBN (r_amod) pseudolithiasis/NN -PUNC- ceftriaxone/NN (r_nsubj) leads/VBZ (l_xcomp) pseudolithiasis/NN -PUNC- ceftriaxone/CD (r_compound) treatment/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) pseudolithiasis/NN
18809400
D008063_D020258 NONE acid/NN (r_nsubj) prevents/VBZ (l_dobj) damage/NN (l_conj) neurotoxicity/NN -PUNC- acid/NN (r_nsubj) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) depend/VBP (r_conj) plays/VBZ (r_advcl) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- acid/NN (r_nsubj) exerts/VBZ (l_conj) induced/VBN (l_dobj) neurotoxicity/NN
D002945_D010523 CID cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) to/IN (r_prep) neurons/NNS (r_appos) ganglion/NN (r_pobj) of/IN (r_prep) cultures/NNS (r_dobj) exposing/VBG (r_pcomp) by/IN (r_prep) mimic/VBP (r_relcl) model/NN (r_dobj) used/VBD (l_xcomp) induced/VBD (l_dobj) neuropathy/NN
D002945_D020258 NONE cisplatin/NN (r_conj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN
D017239_D028361 NONE paclitaxel/NN (r_conj) cisplatin/NN (r_nsubj) cause/VBP (l_dobj) impairment/NN -PUNC- paclitaxel/NN (r_pobj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D002945_D028361 NONE cisplatin/NN (r_nsubj) cause/VBP (l_dobj) impairment/NN -PUNC- cisplatin/NN (r_conj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D008063_D009410 NONE acid/NN (r_nsubj) is/VBZ (l_advcl) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) cascade/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) depend/VBP (r_conj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) cascade/NN
D017239_D010523 CID paclitaxel/NN (r_pobj) to/IN (r_prep) neurons/NNS (r_appos) ganglion/NN (r_pobj) of/IN (r_prep) cultures/NNS (r_dobj) exposing/VBG (r_pcomp) by/IN (r_prep) mimic/VBP (r_relcl) model/NN (r_dobj) used/VBD (l_xcomp) induced/VBD (l_dobj) neuropathy/NN
D008063_D010523 NONE acid/NN (r_nsubj) reduce/VB (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) toxicity/NN
D008063_D028361 NONE acid/NN (r_nsubj) prevents/VBZ (l_dobj) damage/NN -PUNC- acid/NN (r_nsubj) is/VBZ (l_advcl) plays/VBZ (l_nsubj) damage/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) depend/VBP (r_conj) plays/VBZ (l_nsubj) damage/NN -PUNC- acid/NN (r_nsubj) exerts/VBZ (r_ccomp) rescues/VBZ (l_dobj) toxicity/NN
D008063_D001480 NONE acid/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) damage/NN -PUNC- acid/NN (r_conj) agents/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) function/NN (r_conj) apoptosis/NN (r_conj) investigating/VBG (l_dobj) efficacy/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) damage/NN
D017239_D020258 NONE paclitaxel/NN (r_pobj) in/IN (r_prep) event/NN (r_attr) is/VBZ (l_advcl) induced/VBN (l_dobj) neurotoxicity/NN
D008063_D009422 NONE acid/NN (r_nsubj) prevents/VBZ (l_dobj) damage/NN (l_prep) in/IN (l_pobj) neuropathy/NN
11431197
D011899_D009395 CID Ranitidine/NNP (r_npadvmod) induced/VBN (r_amod) nephritis/NN -PUNC- ranitidine/NN (r_npadvmod) induced/VBN (r_amod) nephritis/NN
12571256
D007472_D007674 CID iohexol/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) effects/NNS (l_amod) nephrotoxic/JJ
C044834_D007674 NONE iodixanol/NN (r_appos) medium/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- iodixanol/NN (r_nsubjpass) used/VBN (r_advcl) develop/VB (r_xcomp) likely/JJ (r_acomp) be/VB (l_csubj) induced/VBN (l_nsubj) Nephropathy/NNP
D003404_D003920 NONE creatinine/JJ (r_compound) concentrations/NNS (r_pobj) with/IN (r_prep) diabetes/NNS
18004067
D000431_D017093 NONE alcohol/NN (r_pobj) of/IN (r_prep) consumers/NNS (r_attr) were/VBD (l_conj) developed/VBD (l_dobj) failure/NN -PUNC- alcohol/NN (r_compound) consumption/NN (r_dobj) stopping/VBG (r_conj) developed/VBD (l_dobj) failure/NN -PUNC- alcohol/NN (r_pobj) of/IN (r_prep) consumption/NN (r_appos) factors/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) In/IN (r_prep) is/VBZ (l_nsubj) failure/NN
D000431_D056486 NONE alcohol/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D000082_D017114 NONE paracetamol/NN (r_dobj) ingesting/VBG (r_acl) consumption/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) failure/NN
D000082_D017093 CID paracetamol/JJ (r_advmod) 4/CD (r_nummod) day/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) stopping/VBG (r_conj) developed/VBD (l_dobj) failure/NN
D000431_D017114 NONE alcohol/NN (r_compound) consumption/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) failure/NN
D000082_D056486 CID paracetamol/JJ (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatotoxicity/NN -PUNC- acetaminophen/NN (r_appos) paracetamol/JJ (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatotoxicity/NN -PUNC- paracetamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
3828020
D010665_D002544 CID phenylpropanolamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) infarction/NN -PUNC- PPA/NNP (r_pobj) of/IN (r_prep) dose/NN (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) suffered/VBD (l_dobj) infarction/NN
9915601
D001262_D001919 NONE atenolol/NN (r_conj) labetalol/JJ (r_conj) pindolol/NN (r_conj) propranolol/NN (r_advcl) increased/VBD (l_acomp) bradycardia/NNP
D007538_D013610 NONE isoniazid/NN (r_pobj) of/IN (r_prep) doses/NNS (l_appos) hypotension/NN (l_conj) change/VB (l_dobj) tachycardia/NN
D002698_D001919 NONE chloralose/NN (r_compound) urethane/NN (r_pobj) with/IN (r_prep) anaesthetised/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) determined/VBN (l_nsubjpass) enhancement/NN (l_prep) by/IN (l_pobj) isoniazid/NN (l_prep) of/IN (l_pobj) bradycardia/NN
D005680_D013610 NONE acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) interaction/NN (r_appos) doses/NNS (l_appos) hypotension/NN (l_conj) change/VB (l_dobj) tachycardia/NN -PUNC- GABA/NNP (r_appos) acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) interaction/NN (r_appos) doses/NNS (l_appos) hypotension/NN (l_conj) change/VB (l_dobj) tachycardia/NN
D014520_D001919 NONE urethane/NN (r_pobj) with/IN (r_prep) anaesthetised/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) determined/VBN (l_nsubjpass) enhancement/NN (l_prep) by/IN (l_pobj) isoniazid/NN (l_prep) of/IN (l_pobj) bradycardia/NN
D018738_D001919 NONE hexamethonium/NN (r_pobj) after/IN (r_conj) increased/VBD (l_acomp) bradycardia/NNP
D005680_D001919 NONE acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) interaction/NN (r_appos) doses/NNS (l_appos) hypotension/NN (l_conj) change/VB (l_prep) to/IN (l_pobj) bradycardia/NNP -PUNC- GABA/NNP (r_appos) acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) interaction/NN (r_appos) doses/NNS (l_appos) hypotension/NN (l_conj) change/VB (l_prep) to/IN (l_pobj) bradycardia/NNP
D010869_D001919 NONE pindolol/NN (r_conj) propranolol/NN (r_advcl) increased/VBD (l_acomp) bradycardia/NNP
D005680_D007022 NONE acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) interaction/NN (r_appos) doses/NNS (l_appos) hypotension/NN -PUNC- GABA/NNP (r_appos) acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) interaction/NN (r_appos) doses/NNS (l_appos) hypotension/NN
D003000_D001919 NONE clonidine/NN (r_pobj) after/IN (r_prep) as/IN (r_cc) increased/VBD (l_acomp) bradycardia/NNP
D011433_D001919 NONE propranolol/NN (r_advcl) increased/VBD (l_acomp) bradycardia/NNP
D002217_D001919 NONE carbachol/NN (r_conj) hexamethonium/NN (r_pobj) after/IN (r_conj) increased/VBD (l_acomp) bradycardia/NNP
D007741_D001919 NONE labetalol/JJ (r_conj) pindolol/NN (r_conj) propranolol/NN (r_advcl) increased/VBD (l_acomp) bradycardia/NNP
D007538_D007022 CID isoniazid/NN (r_pobj) of/IN (r_prep) doses/NNS (l_appos) hypotension/NN
D007538_D001919 CID isoniazid/NN (r_pobj) with/IN (r_prep) pretreated/VBD (r_acl) rats/NNS (r_pobj) in/IN (r_prep) antagonists/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) bradycardia/NNS -PUNC- isoniazid/NN (r_pobj) of/IN (r_prep) doses/NNS (l_appos) hypotension/NN (l_conj) change/VB (l_prep) to/IN (l_pobj) bradycardia/NNP -PUNC- isoniazid/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- Isoniazid/NNP (r_nsubj) increased/VBD (l_acomp) bradycardia/NNP
8766220
D017374_-1 NONE paroxetine/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) initiated/VBN (l_conj) dosulepine/JJ (l_prep) in/IN (l_pobj) patient/NN (l_amod) tetraparetic/JJ
D014147_D010146 NONE Tramadol/NNP (r_nsubj) is/VBZ (l_attr) opioid/NN (l_prep) with/IN (l_pobj) effects/NNS (l_relcl) used/VBN (l_xcomp) treat/VB (l_dobj) pain/NN -PUNC- Tramadol/NNP (r_nsubj) is/VBZ (l_attr) opioid/NN (l_prep) with/IN (l_pobj) effects/NNS (l_relcl) used/VBN (l_xcomp) treat/VB (l_dobj) pain/NN (l_conj) pain/NN
D014147_D009369 NONE Tramadol/NNP (r_nsubj) is/VBZ (l_attr) opioid/NN (l_prep) with/IN (l_pobj) effects/NNS (l_relcl) used/VBN (l_xcomp) treat/VB (l_dobj) pain/NN (l_compound) cancer/NN
D004308_-1 NONE hydrochloride/NN (r_dobj) dosulepine/JJ (l_prep) in/IN (l_pobj) patient/NN (l_amod) tetraparetic/JJ
D004308_D059350 NONE hydrochloride/NN (r_dobj) dosulepine/JJ (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) pain/NN
D017374_D059350 NONE paroxetine/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) initiated/VBN (l_conj) dosulepine/JJ (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) pain/NN
D014147_D006212 CID tramadol/NN (r_pobj) of/IN (r_prep) intake/NN (r_pobj) after/IN (r_prep) Nightmares/NNS (l_conj) hallucinations/NNS -PUNC- tramadol/NN (r_conj) drugs/NNS (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) after/IN (r_prep) stopped/VBD (r_relcl) hallucinations/NNS
3371379
D002118_D020258 NONE calcium/NN (r_compound) entry/NN (r_compound) blocker/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) recovery/NN (r_dobj) showed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN
D014700_D020258 CID Verapamil/NNP (r_npadvmod) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- verapamil/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) signs/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN
D002220_D020258 CID carbamazepine/NN (r_compound) neurotoxicity/NN -PUNC- carbamazepine/JJ (r_compound) neurotoxicity/NN
12739036
D001379_D008180 NONE azathioprine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) periods/NNS (r_dobj) undergone/JJ (r_conj) suffering/VBG (l_prep) from/IN (l_pobj) erythematosus/NN -PUNC- azathioprine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) periods/NNS (r_dobj) undergone/JJ (r_conj) suffering/VBG (l_prep) from/IN (l_pobj) erythematosus/NN (l_appos) SLE/NNP
D003520_D007674 NONE cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) periods/NNS (r_dobj) undergone/JJ (r_conj) suffering/VBG (l_prep) with/IN (l_pobj) involvement/NN
D013256_D009220 NONE steroids/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) suspected/VBN (l_nsubjpass) Myositis/NNP
D002738_D009135 NONE chloroquine/NN (r_advmod) induced/VBN (r_amod) myopathy/NN -PUNC- chloroquine/NN (r_npadvmod) induced/VBN (r_compound) myopathy/NN
D001379_D007674 NONE azathioprine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) periods/NNS (r_dobj) undergone/JJ (r_conj) suffering/VBG (l_prep) with/IN (l_pobj) involvement/NN
D003401_D008180 NONE creatine/NN (r_compound) levels/NNS (l_prep) in/IN (l_pobj) erythematosus/NN
D002738_D018771 NONE chloroquine/NN (r_amod) CQ/NNP (r_pobj) with/IN (r_prep) therapy/NN (r_nsubjpass) started/VBN (l_prep) because/IN (l_pobj) arthralgia/NN -PUNC- CQ/NNP (r_pobj) with/IN (r_prep) therapy/NN (r_nsubjpass) started/VBN (l_prep) because/IN (l_pobj) arthralgia/NN
D003520_D008180 NONE cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) periods/NNS (r_dobj) undergone/JJ (r_conj) suffering/VBG (l_prep) from/IN (l_pobj) erythematosus/NN -PUNC- cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) periods/NNS (r_dobj) undergone/JJ (r_conj) suffering/VBG (l_prep) from/IN (l_pobj) erythematosus/NN (l_appos) SLE/NNP
11868798
D000666_D006402 NONE AmB/VB (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS -PUNC- AmB/JJ (r_conj) AmB/VB (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
D011188_D007008 NONE potassium/NN (r_compound) requirements/NNS (r_dobj) reduce/VB (l_conj) prevent/VB (l_dobj) hypokalemia/NN -PUNC- potassium/NN (r_compound) requirements/NNS (r_dobj) reduce/VB (l_conj) prevent/VBP (l_dobj) hypokalemia/NN -PUNC- potassium/NN (r_compound) loss/NN (r_dobj) reducing/VBG (r_pcomp) by/IN (r_prep) prevent/VBP (l_dobj) hypokalemia/NN
D011188_D009503 NONE potassium/NN (r_compound) requirements/NNS (r_dobj) reduce/VB (l_conj) prevent/VB (l_dobj) hypokalemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) neutropenic/JJ -PUNC- potassium/NN (r_compound) requirements/NNS (r_dobj) reduce/VB (l_conj) prevent/VBP (l_prep) by/IN (l_pcomp) reducing/VBG (l_dobj) loss/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) neutropenic/JJ -PUNC- potassium/NN (r_compound) loss/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) neutropenic/JJ
D000666_D007008 CID B/NN (r_npadvmod) related/VBN (r_amod) hypokalemia/NN -PUNC- AmB/JJ (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) hypokalemia/NN -PUNC- AmB/JJ (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) loss/NN (r_dobj) reducing/VBG (r_pcomp) by/IN (r_prep) prevent/VBP (l_dobj) hypokalemia/NN
D013148_D006402 NONE spironolactone/NN (r_conj) AmB/VB (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
D013148_D009181 NONE spironolactone/NN (r_conj) AmB/VB (r_dobj) receive/VB (l_advcl) developing/VBG (l_dobj) infection/NN
D000666_D009503 NONE AmB/JJ (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (l_amod) neutropenic/JJ -PUNC- AmB/JJ (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (l_amod) neutropenic/JJ
D013148_D007008 NONE Spironolactone/NNP (r_npadvmod) is/VBZ (l_attr) drug/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) hypokalemia/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) reduce/VB (l_conj) prevent/VB (l_dobj) hypokalemia/NN -PUNC- spironolactone/NN (r_nsubj) reduce/VB (l_conj) prevent/VBP (l_dobj) hypokalemia/NN
D000666_D064420 NONE AmB./NNP (r_compound) Potassium/NN (r_compound) depletion/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) wasting/VBG (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_nsubj) toxicity/NN -PUNC- AmB./NNP (r_compound) Potassium/NN (r_compound) depletion/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) wasting/VBG (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_conj) potentiates/VBZ (l_dobj) toxicity/NN -PUNC- AmB./NN (r_pobj) of/IN (r_prep) toxicity/NN (r_dobj) potentiates/VBZ (r_conj) seems/VBZ (l_nsubj) toxicity/NN -PUNC- AmB./NN (r_pobj) of/IN (r_prep) toxicity/NN
D000666_D009369 NONE B/NN (r_npadvmod) related/VBN (r_amod) hypokalemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D011188_D064420 NONE potassium/NN (r_compound) wasting/VBG (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_nsubj) toxicity/NN -PUNC- potassium/NN (r_compound) wasting/VBG (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_conj) potentiates/VBZ (l_dobj) toxicity/NN -PUNC- Potassium/NN (r_compound) depletion/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) wasting/VBG (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_nsubj) toxicity/NN -PUNC- Potassium/NN (r_compound) depletion/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) wasting/VBG (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_conj) potentiates/VBZ (l_dobj) toxicity/NN
D000666_D009181 NONE AmB/VB (r_dobj) receive/VB (l_advcl) developing/VBG (l_dobj) infection/NN -PUNC- AmB/JJ (r_conj) AmB/VB (r_dobj) receive/VB (l_advcl) developing/VBG (l_dobj) infection/NN
D013148_D009369 NONE Spironolactone/NNP (r_npadvmod) is/VBZ (l_attr) drug/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) hypokalemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D013148_D009503 NONE spironolactone/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) reduce/VB (l_conj) prevent/VB (l_dobj) hypokalemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) neutropenic/JJ -PUNC- spironolactone/NN (r_nsubj) reduce/VB (l_conj) prevent/VBP (l_prep) by/IN (l_pcomp) reducing/VBG (l_dobj) loss/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) neutropenic/JJ
D000666_D007674 NONE B/NNP (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Nephrotoxicity/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Nephrotoxicity/NN
17702969
D005473_D006976 CID fluoxetine/NN (r_advmod) induces/VBZ (l_dobj) hypertension/NN -PUNC- fluoxetine/NN (r_amod) exposure/NN (r_nsubj) increases/VBZ (l_dobj) prevalence/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- fluoxetine/NN (r_amod) effect/NN (r_appos) evidence/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- fluoxetine/NN (r_amod) exposure/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- fluoxetine/NN (r_amod) exposure/NN (r_nsubj) induces/VBZ (l_dobj) hypertension/NN
D005473_D005315 CID fluoxetine/NN (r_advmod) induces/VBZ (l_dobj) hypertension/NN -PUNC- fluoxetine/NN (r_amod) exposure/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) hypertension/NN
11679859
D011346_D014839 NONE prochlorperazine/NN (l_prep) for/IN (l_pobj) headache/NN (l_conj) nausea/NN (l_conj) vomiting/NN
D011346_D009325 NONE prochlorperazine/NN (l_prep) for/IN (l_pobj) headache/NN (l_conj) nausea/NN -PUNC- prochlorperazine/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) headache/NN (l_conj) nausea/NN
D011346_D017109 CID prochlorperazine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) affect/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- prochlorperazine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) akathisia/NN -PUNC- prochlorperazine/NN (r_nsubjpass) administered/VBN (r_advcl) reduction/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN
D011346_D006261 NONE prochlorperazine/NN (l_prep) for/IN (l_pobj) headache/NN -PUNC- prochlorperazine/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) headache/NN
7881871
D010100_D007674 NONE oxygen/NN (r_compound) species/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D011692_D007674 CID aminonucleoside/NN (r_advmod) induced/VBN (r_amod) nephropathy/NN -PUNC- aminonucleoside/NN (r_nmod) nephropathy/NN -PUNC- PAN)-induced/JJ (r_amod) nephropathy/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN
D011692_D011507 CID aminonucleoside/NN (r_nmod) nephropathy/NN (r_pobj) of/IN (r_prep) pathogenesis/NN (r_pobj) in/IN (r_prep) implicated/VBN (l_prep) with/IN (l_pcomp) reducing/VBG (l_dobj) proteinuria/NN -PUNC- PAN)-induced/JJ (r_amod) nephropathy/NN (r_pobj) of/IN (r_prep) pathogenesis/NN (r_pobj) in/IN (r_prep) implicated/VBN (l_prep) with/IN (l_pcomp) reducing/VBG (l_dobj) proteinuria/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN (r_pobj) in/IN (r_prep) injury/NN
D010100_D011507 NONE oxygen/NN (r_compound) species/NNS (r_nsubjpass) implicated/VBN (l_prep) with/IN (l_pcomp) reducing/VBG (l_dobj) proteinuria/NN
9321531
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D007980_D010300 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_dobj) reduces/VBZ (l_prep) In/IN (l_pobj) disease/NN
9121607
D013256_D013226 NONE steroids/NNS (r_nsubj) protect/VBP (l_advcl) epilepticus/NN -PUNC- Steroids/NNS (r_nsubj) were/VBD (l_npadvmod) values/NNS (l_amod) epilepticus/NN -PUNC- steroid/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubjpass) administered/VBN (r_advcl) hr/NN (r_nmod) protection/NN (l_prep) from/IN (l_pobj) seizures/NNS (l_conj) epilepticus/NN -PUNC- steroids/NNS (r_nsubj) are/VBP (l_advcl) epilepticus/NN -PUNC- steroids/NNS (r_nsubj) are/VBP (l_conj) be/VB (l_advmod) epilepticus/NN
D001569_D012640 NONE benzodiazepine/JJ (r_amod) clonazepam/NN (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- benzodiazepine/JJ (r_amod) clonazepam/NN (r_advcl) potent/JJ (r_acomp) were/VBD (r_advcl) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN
D016202_D012640 NONE aspartate/NNP (l_appos) seizures/NNS -PUNC- NMDA)-induced/JJ (r_amod) seizures/NNS -PUNC- NMDA/NNP (r_pobj) in/IN (r_prep) delay/NN (r_dobj) caused/VBD (l_conj) protect/VB (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- NMDA/NNP (r_compound) seizures/NNS
D010862_D064420 NONE pilocarpine/NN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) clonazepam/NN (r_advcl) potent/JJ (r_acomp) were/VBD (r_advcl) had/VBD (l_advcl) indicating/VBG (l_ccomp) have/VB (l_dobj) toxicity/NN
D002998_D064420 NONE clonazepam/NN (r_advcl) potent/JJ (r_acomp) were/VBD (r_advcl) had/VBD (l_advcl) indicating/VBG (l_ccomp) have/VB (l_dobj) toxicity/NN -PUNC- clonazepam/NN (r_advcl) had/VBD (l_advcl) indicating/VBG (l_ccomp) have/VB (l_dobj) toxicity/NN
D002998_D012640 NONE clonazepam/NN (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- clonazepam/NN (r_advcl) potent/JJ (r_acomp) were/VBD (r_advcl) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN -PUNC- clonazepam/NN (r_advcl) had/VBD (l_advcl) were/VBD (l_acomp) potent/JJ (l_advcl) clonazepam/NN (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- clonazepam/NN (r_advcl) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN
D013256_D064420 NONE steroids/NNS (r_nsubj) were/VBD (r_advcl) had/VBD (l_advcl) indicating/VBG (l_ccomp) have/VB (l_dobj) toxicity/NN -PUNC- steroids/NNS (r_nsubj) had/VBD (l_advcl) indicating/VBG (l_ccomp) have/VB (l_dobj) toxicity/NN -PUNC- steroids/NNS (r_nsubj) have/VB (l_dobj) toxicity/NN
D010862_D013226 CID pilocarpine-/NN (r_nmod) seizures/NNS (r_pobj) against/IN (r_prep) protect/VBP (l_advcl) epilepticus/NN -PUNC- pilocarpine/NN (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) effective/JJ (r_acomp) were/VBD (l_npadvmod) values/NNS (l_amod) epilepticus/NN -PUNC- pilocarpine-/NN (r_nmod) seizures/NNS (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) effective/JJ (r_acomp) are/VBP (l_advcl) epilepticus/NN -PUNC- pilocarpine-/NN (r_nmod) seizures/NNS (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) effective/JJ (r_acomp) are/VBP (l_conj) be/VB (l_advmod) epilepticus/NN
D007608_D013226 CID acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protect/VBP (l_advcl) epilepticus/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_conj) epilepticus/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) effective/JJ (r_acomp) are/VBP (l_advcl) epilepticus/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) effective/JJ (r_acomp) are/VBP (l_conj) be/VB (l_advmod) epilepticus/NN
D001569_D064420 NONE benzodiazepine/JJ (r_amod) clonazepam/NN (r_advcl) potent/JJ (r_acomp) were/VBD (r_advcl) had/VBD (l_advcl) indicating/VBG (l_ccomp) have/VB (l_dobj) toxicity/NN
D013256_D012640 NONE steroids/NNS (r_nsubj) protect/VBP (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- Steroids/NNS (r_nsubj) were/VBD (l_parataxis) mg/kg/NNS (l_conj) s.c.)-induced/VBN (l_dobj) seizures/NNS -PUNC- steroids/NNS (r_nsubj) were/VBD (l_acomp) potent/JJ (l_advcl) clonazepam/NN (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroids/NNS (r_nsubj) were/VBD (r_advcl) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN -PUNC- steroids/NNS (r_nsubj) had/VBD (l_advcl) were/VBD (l_acomp) potent/JJ (l_advcl) clonazepam/NN (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroids/NNS (r_nsubj) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN -PUNC- steroids/NNS (r_nsubj) have/VB (r_ccomp) indicating/VBG (r_advcl) had/VBD (l_advcl) were/VBD (l_acomp) potent/JJ (l_advcl) clonazepam/NN (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroids/NNS (r_nsubj) have/VB (r_ccomp) indicating/VBG (r_advcl) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN -PUNC- Steroids/NNS (r_nsubj) produced/VBD (l_dobj) delay/NN (l_prep) in/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- Steroids/NNS (r_nsubj) produced/VBD (l_conj) protect/VB (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroid/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubjpass) administered/VBN (r_advcl) hr/NN (r_nmod) protection/NN (l_prep) from/IN (l_pobj) seizures/NNS -PUNC- steroids/NNS (r_nsubj) caused/VBD (l_conj) protect/VB (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroids/NNS (r_nsubj) are/VBP (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizures/NNS
D007608_D012640 CID acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- acid/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) delay/NN (l_prep) in/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acid/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) delay/NN (r_dobj) produced/VBD (l_conj) protect/VB (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D010862_D012640 CID pilocarpine-/NN (r_nmod) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) effective/JJ (r_acomp) were/VBD (l_parataxis) mg/kg/NNS (l_conj) s.c.)-induced/VBN (l_dobj) seizures/NNS -PUNC- pilocarpine/NN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protecting/VBG (r_pcomp) in/IN (r_prep) clonazepam/NN (r_advcl) potent/JJ (r_acomp) were/VBD (r_advcl) had/VBD (l_dobj) values/NNS (l_appos) TD50/NNP (l_acl) divided/VBN (l_prep) for/IN (l_pobj) protection/NN (l_compound) seizure/NN -PUNC- pilocarpine-/NN (r_nmod) seizures/NNS
8741744
D009538_D006948 CID nicotine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoactivity/NN (r_dobj) blunted/VBD (l_advcl) enhanced/VBD (l_dobj) hyperactivity/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D009538_D009069 NONE nicotine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoactivity/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_dobj) enhanced/VBD (r_advcl) blunted/VBD (l_dobj) hypoactivity/NN
3564823
D013874_D002545 NONE pentothal/NNS (r_nsubjpass) infused/VBN (l_advcl) minimize/VB (l_dobj) ischaemia/NN
D008012_D013035 NONE lidocaine/NN (r_pobj) by/IN (r_prep) relieved/VBN (l_nsubj) spasm/NN
D008012_D020301 NONE lidocaine/NN (r_nsubjpass) given/VBN (l_advcl) counteract/VB (l_dobj) vasospasm/NN
19300240
D002395_D054549 NONE catecholamines/NNS (r_pobj) of/IN (r_prep) levels/NNS (r_nsubj) contributed/VBN (l_dobj) development/NN (l_prep) of/IN (l_pobj) ABS/NN
D005472_D054549 CID flourouracil/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN
D002395_D009369 NONE catecholamines/NNS (r_pobj) of/IN (r_prep) levels/NNS (l_acl) caused/VBN (l_agent) by/IN (l_pobj) diagnosis/NN (l_compound) cancer/NN
D005472_D015179 NONE fluorouracil/NN (r_pobj) with/IN (r_prep) underwent/VBD (l_prep) for/IN (l_pobj) cancer/NN
6773726
D005996_D007022 CID nitroglycerin/NN (r_pobj) by/IN (r_prep) hypotension/NN
D005996_D003929 NONE nitroglycerin/NN (l_prep) in/IN (l_pobj) neuropathy/NN
D005996_D009422 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_prep) without/IN (l_pobj) neuropathy/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_conj) subjects/NNS (l_prep) with/IN (l_pobj) neuropathy/NN -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_acomp) similar/JJ (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) without/IN (l_pobj) neuropathy/NN -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_advcl) occurred/VBD (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) neuropathy/NN
D005996_D003920 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_amod) diabetic/JJ -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) compared/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_appos) subjects/NNS (l_conj) subjects/NNS (l_amod) diabetic/JJ -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_acomp) similar/JJ (l_prep) in/IN (l_pobj) subjects/NNS (l_amod) normal/JJ (l_conj) diabetic/JJ -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) were/VBD (l_advcl) occurred/VBD (l_prep) in/IN (l_pobj) subjects/NNS (l_amod) diabetic/JJ
18808529
D010100_D007022 NONE oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) mismatch/NN (l_prep) vs./IN (l_pobj) demand/NN (l_prep) following/VBG (l_pobj) hyperactivity/NN (l_nmod) hypotension/NN
D007545_D007022 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) damage/NN (r_pobj) of/IN (r_prep) mechanism/NN (r_nsubj) is/VBZ (l_conj) is/VBZ (l_nsubj) mismatch/NN (l_prep) vs./IN (l_pobj) demand/NN (l_prep) following/VBG (l_pobj) hyperactivity/NN (l_nmod) hypotension/NN
D007545_D007511 CID isoproterenol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) alterations/NNS (r_dobj) explain/VBP (l_nsubj) changes/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) injury/NN
D010100_D009202 NONE oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) mismatch/NN (r_nsubj) is/VBZ (r_conj) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) damage/NN -PUNC- oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) mismatch/NN (l_prep) vs./IN (l_pobj) demand/NN (l_prep) following/VBG (l_pobj) hyperactivity/NN
D007545_D009202 CID Isoproterenol/NN (r_nsubj) induces/VBZ (l_dobj) correlation/NN (l_prep) with/IN (l_pobj) injury/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) damage/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) damage/NN (r_pobj) of/IN (r_prep) mechanism/NN (r_nsubj) is/VBZ (l_conj) is/VBZ (l_nsubj) mismatch/NN (l_prep) vs./IN (l_pobj) demand/NN (l_prep) following/VBG (l_pobj) hyperactivity/NN
19234905
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D014635_D006423 NONE Valproate/NNP (r_pobj) with/IN (r_prep) improved/VBD (r_advcl) developed/VBN (r_conj) had/VBD (l_dobj) hemianopsia/NN
19370593
D004967_D001943 NONE oestrogen/NN (r_nmod) HT/NNP (r_nsubj) increased/VBD (l_conj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN
D004967_D005705 CID oestrogen/NN (r_nmod) HT/NNP (r_nsubj) increased/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) embolism/NN (l_appos) disease/NN
D004967_D054556 CID oestrogen/NN (r_nmod) HT/NNP (r_nsubj) increased/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) embolism/NN
D004967_D020521 CID oestrogen/NN (r_nmod) HT/NNP (r_nsubj) increased/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) embolism/NN (l_appos) disease/NN (l_nmod) stroke/NN
11077455
D020888_D014786 CID vigabatrin/NN (r_npadvmod) attributed/VBN (r_amod) constriction/NN -PUNC- vigabatrin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_xcomp) thought/NN (l_nsubj) constriction/NN -PUNC- vigabatrin/NN (r_npadvmod) attributed/VBN (r_amod) loss/NN -PUNC- vigabatrin/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_xcomp) appears/VBZ (l_nsubj) constriction/NN
16364460
D012601_D000647 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_nmod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN
D016713_D000647 NONE ritanserin/NN (r_pobj) of/IN (r_prep) Microinjection/NN (r_nsubj) improves/VBZ (l_dobj) amnesia/NN -PUNC- ritanserin/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) amnesia/NN -PUNC- ritanserin/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_nsubj) improves/VBZ (l_dobj) amnesia/NN
18768591
D012964_D005355 NONE sodium/NN (r_compound) channel/NN (l_appos) retention/NN (l_conj) fibrosis/NN
D004317_D009404 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN
D014508_D009404 NONE urea/NN (r_compound) concentrations/NNS (r_nsubj) increased/VBD (l_prep) During/IN (l_pobj) course/NN (l_prep) of/IN (l_pobj) syndrome/NN
D012964_D016055 NONE sodium/NN (r_compound) channel/NN (l_appos) retention/NN
D004317_D034141 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) with/IN (l_pobj) ascites/NNS (l_conj) lipidemia/NN (l_conj) hypoalbuminemia/VB
D000450_D005355 NONE aldosterone/NN (r_npadvmod) sensitive/JJ (r_amod) SGK1/NNP (r_nsubjpass) shown/VBN (l_xcomp) participate/VB (l_conj) mediate/VB (l_dobj) fibrosis/NN
D000450_D009404 NONE aldosterone/NN (r_compound) levels/NNS (r_nsubj) increased/VBD (l_prep) in/IN (l_pobj) mice/NNS (l_amod) nephrotic/JJ
D004317_D011507 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) proteinuria/NN
D012964_D007674 NONE sodium/NN (r_compound) channel/NN (r_pobj) to/IN (r_prep) leads/VBZ (l_nsubj) nephropathy/NN
D004317_D007674 NONE Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D004317_D016055 NONE Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) channel/NN (l_appos) retention/NN
D004317_D005355 NONE Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) channel/NN (l_appos) retention/NN (l_conj) fibrosis/NN
D004317_D001201 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) with/IN (l_pobj) ascites/NNS
D004317_D006949 CID Doxorubicin/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) 15/44/CD (l_prep) of/IN (l_pobj) mice/NNS (l_acl) leading/VBG (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) with/IN (l_pobj) ascites/NNS (l_conj) lipidemia/NN
15565293
D004977_D051437 NONE EMB/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) management/NN (r_pobj) of/IN (r_prep) terms/NNS (r_pobj) in/IN (r_prep) is/VBZ (l_acomp) important/JJ (l_xcomp) manage/VB (l_dobj) dosing/VBG (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) impairment/NN -PUNC- ethambutol/NN (r_amod) dosing/VBG (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) impairment/NN
D004977_D014786 CID ethambutol/NN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) subjects/NNS (r_nsubjpass) administered/VBN (l_nsubjpass) deficits/NNS -PUNC- EMB)-induced/VBN (r_amod) optic/JJ (r_compound) neuropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) subjects/NNS (r_nsubjpass) administered/VBN (l_nsubjpass) deficits/NNS -PUNC- EMB/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) subjects/NNS (r_pobj) In/IN (r_prep) was/VBD (l_attr) loss/NN (l_prep) with/IN (l_pobj) recovery/NN (l_prep) with/IN (l_pobj) deficits/NNS -PUNC- EMB/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) subjects/NNS (r_pobj) In/IN (r_prep) was/VBD (l_attr) loss/NN (l_conj) loss/NN (l_conj) C/NN (l_prep) with/IN (l_pobj) deficits/NNS
D004977_D014376 NONE Ethambutol/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_acl) used/VBD (l_xcomp) treat/VB (l_dobj) tuberculosis/NN
D004977_D009410 NONE ethambutol/NN (r_advmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) in/IN (r_prep) degeneration/NN
D004977_D009901 CID ethambutol/NN (r_advmod) induced/VBN (r_amod) neuropathy/NN -PUNC- ethambutol/NN (r_advmod) induced/VBN (r_amod) neuropathy/NN -PUNC- ethambutol/NN (r_pobj) of/IN (r_prep) complication/NN (r_nsubj) is/VBZ (l_attr) neuropathy/NN -PUNC- ethambutol/NN (r_amod) neuropathy/NN -PUNC- EMB)-induced/VBN (r_amod) optic/JJ (r_compound) neuropathy/NN -PUNC- EMB/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- EMB/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- EMB/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- ethambutol/NN (r_amod) dosing/VBG (r_dobj) manage/VB (r_xcomp) important/JJ (r_acomp) is/VBZ (l_prep) in/IN (l_pobj) terms/NNS (l_prep) of/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) neuropathy/NN
16181582
D014635_D001927 CID Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- valproate/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN
D014635_D004827 NONE Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_nsubj) is/VBZ (l_attr) syndrome/NN (l_relcl) manifest/VB (l_prep) in/RP (l_pobj) individuals/NNS (l_amod) epileptic/JJ
9495837
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
C087567_D000647 NONE /-)-PG-9/. (r_nsubj) was/VBD (l_acomp) able/JJ (l_xcomp) prevent/VB (l_dobj) amnesia/NN -PUNC- /-)-PG-9/NFP (r_conj) of/IN (r_prep) profiles/NNS (r_nsubj) shown/VBN (l_dobj) ratio/NN (l_relcl) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) antinociception/NN (l_conj) effect/NN (l_amod) amnesic/JJ -PUNC- /-)-PG-9/NFP (r_punct) shown/VBN (l_dobj) ratio/NN (l_relcl) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) antinociception/NN (l_conj) effect/NN (l_amod) amnesic/JJ
D004025_D000647 CID dicyclomine/NN (r_conj) kg-1/NNP (r_appos) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D000109_D000647 NONE acetylcholine/NN (r_amod) levels/NNS (r_pobj) in/IN (r_prep) increase/NN (r_pobj) through/IN (r_prep) /-)-PG-9/NFP (r_punct) shown/VBN (l_dobj) ratio/NN (l_relcl) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) antinociception/NN (l_conj) effect/NN (l_amod) amnesic/JJ
11426838
D009838_D012640 NONE oligodeoxynucleotide/NN (r_appos) receptors/NNS (r_pobj) of/IN (r_prep) antagonism/NN (r_dobj) involved/VBD (r_acl) ligands/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) shown/VBN (l_xcomp) attenuate/VB (l_dobj) effects/NNS (l_amod) convulsive/JJ
D003042_D064420 NONE cocaine/NN (r_pobj) of/IN (r_prep) toxicity/NN
C093337_D012640 NONE BD1063/NNP (r_conj) BD1018/NN (r_pobj) with/IN (r_punct) attenuated/VBD (r_amod) convulsions/NNS
C050232_D064420 NONE tolylguanidine/NN (r_nmod) DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN -PUNC- DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN
-1_D064420 NONE BD1031/NN (r_conj) DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN -PUNC- 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane/NN (r_appos) BD1031/NN (r_conj) DTG/NNP (r_appos) antagonists/NNS (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) worsened/VBD (l_dobj) toxicity/NN
D003042_D012640 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- cocaine/NN (r_compound) effects/NNS (r_nsubjpass) shown/VBN (l_xcomp) attenuate/VB (l_dobj) effects/NNS (l_amod) convulsive/JJ -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) convulsive/JJ
-1_D012640 NONE BD1018/NN (r_pobj) with/IN (r_punct) attenuated/VBD (r_amod) convulsions/NNS -PUNC- LR132/NNS (r_conj) BD1063/NNP (r_conj) BD1018/NN (r_pobj) with/IN (r_punct) attenuated/VBD (r_amod) convulsions/NNS
8170551
D000086_D009468 NONE Acetazolamide/RB (r_npadvmod) induced/VBN (r_amod) nephrolithiasis/NN (l_appos) implications/NNS (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorders/NNS
D000086_D007669 CID acetazolamide/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) developed/VBN (l_dobj) calculi/NNS
D000086_D053040 NONE Acetazolamide/RB (r_npadvmod) induced/VBN (r_amod) nephrolithiasis/NN -PUNC- acetazolamide/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) Nephrolithiasis/NNP
7234705
D011342_D008133 NONE procainamide/NN (r_nsubj) produce/VB (l_dobj) syndrome/NN
D011342_D001282 NONE procainamide/NN (r_nsubjpass) administered/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) contractions/NNS (l_conj) flutter/NN
D011342_D018879 NONE procainamide/NN (r_nsubjpass) administered/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) contractions/NNS
D011342_D017180 CID Procainamide/NNP (r_npadvmod) induced/VBN (l_dobj) tachycardia/NN -PUNC- procainamide/RB (r_advmod) induced/VBN (r_amod) tachycardia/NNS -PUNC- procainamide/NN (r_pobj) of/IN (r_prep) mg/IN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) appeared/VBD (l_nsubj) tachycardia/NN -PUNC- procainamide/NN (r_pobj) of/IN (r_prep) mg/IN (r_pobj) of/IN (r_prep) administration/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tachycardia/NN -PUNC- procainamide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) continuation/NN (r_pobj) despite/IN (r_prep) reoccur/VB (l_nsubj) tachycardia/NN -PUNC- procainamide/NN (r_nsubj) produce/VB (l_prep) with/IN (l_pobj) tachycardia/NN
9245658
D009538_D002318 CID nicotine/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- Nicotine/NNP (r_nsubj) activates/VBZ (l_conj) contribute/VB (l_prep) to/IN (l_pobj) disease/NN
D009538_D013927 NONE Nicotine/NN (r_nsubj) appear/VB (l_xcomp) enhance/VB (l_dobj) thrombosis/NN
D009538_D050197 CID nicotine/NN (r_nsubj) play/VB (l_dobj) role/NN (l_prep) in/IN (l_pcomp) accelerating/VBG (l_dobj) atherosclerosis/NN
11999899
D016202_D014202 NONE NMDA/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) blockage/NN (r_nsubj) restore/VB (l_dobj) signs/NNS (l_prep) as/IN (l_pobj) movements/NNS (l_conj) protrusions/NNS (l_conj) catalepsy/NN (l_conj) tremor/NN
D016291_D010300 NONE MK-801/NNP (r_punct) produced/VBD (l_dobj) tremor/NN (l_relcl) are/VBP (l_attr) signs/NNS (l_amod) suggestive/JJ (l_prep) of/IN (l_pobj) disease/NN
D016291_D002375 NONE MK-801/NNP (r_punct) produced/VBD (l_dobj) tremor/NN (l_conj) catalepsy/NN -PUNC- MK-801/NNP (r_punct) induced/VBN (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN (l_conj) catalepsy/NN -PUNC- MK-801/NNP (r_punct) injection/NN (r_nsubj) min/NN (r_nsubj) reversed/VBD (r_advcl) produced/VBD (l_conj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN (l_conj) catalepsy/NN
D012110_D014202 CID Reserpine/NN (r_nsubj) produced/VBD (l_dobj) tremor/NN -PUNC- reserpine/NN (r_npadvmod) treated/VBN (r_amod) mice/NNS (r_pobj) in/IN (r_prep) increase/NN (l_prep) of/IN (l_pobj) tremor/NN -PUNC- reserpine/NN (r_nsubj) induced/VBN (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN -PUNC- reserpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN (l_conj) tremor/NN -PUNC- reserpine/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (l_acl) produced/VBD (l_conj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN -PUNC- reserpine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) reversed/VBD (r_advcl) produced/VBD (l_conj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN
D016291_D014202 NONE MK-801/NNP (r_punct) produced/VBD (l_dobj) tremor/NN -PUNC- MK-801/NNP (r_punct) produced/VBD (l_dobj) increase/NN (l_prep) of/IN (l_pobj) tremor/NN -PUNC- MK-801/NNP (r_punct) induced/VBN (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN -PUNC- MK-801/NNP (r_punct) injection/NN (r_nsubj) min/NN (r_nsubj) reversed/VBD (r_advcl) produced/VBD (l_conj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN
D012110_D010300 NONE Reserpine/NN (r_nsubj) produced/VBD (l_dobj) tremor/NN (l_relcl) are/VBP (l_attr) signs/NNS (l_amod) suggestive/JJ (l_prep) of/IN (l_pobj) disease/NN -PUNC- reserpine/NN (r_nsubj) produces/VBZ (l_dobj) movements/NNS (l_relcl) related/VBN (l_conj) considered/VBN (l_prep) as/IN (l_pobj) signs/NNS (l_amod) parkinsonian/JJ
D012110_D009069 NONE Reserpine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) dyskinesia/NN -PUNC- Reserpine/NN (r_nsubj) administered/VBN (r_ccomp) produce/VB (l_dobj) dyskinesia/NN
D012110_D002375 CID Reserpine/NN (r_nsubj) produced/VBD (l_dobj) tremor/NN (l_conj) catalepsy/NN -PUNC- reserpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) movements/NNS (l_conj) protrusions/NNS (l_conj) catalepsy/NN -PUNC- reserpine/NN (r_nsubj) induced/VBN (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN (l_conj) catalepsy/NN -PUNC- reserpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- reserpine/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (l_acl) produced/VBD (l_conj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN (l_conj) catalepsy/NN -PUNC- reserpine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) reversed/VBD (r_advcl) produced/VBD (l_conj) increases/NNS (l_prep) in/IN (l_pobj) tremor/NN (l_conj) catalepsy/NN
D012110_D004409 CID Reserpine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) dyskinesia/NN (l_relcl) are/VBP (l_attr) signs/NNS (l_amod) indicative/JJ (l_prep) of/IN (l_pobj) dyskinesia/NN -PUNC- reserpine/NN (r_nsubj) produces/VBZ (l_dobj) movements/NNS -PUNC- reserpine/NN (r_nsubj) produces/VBZ (l_dobj) movements/NNS (l_relcl) related/VBN (l_conj) considered/VBN (l_prep) as/IN (l_pobj) signs/NNS (l_compound) dsykinesia/NN
D016202_D002375 NONE NMDA/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) blockage/NN (r_nsubj) restore/VB (l_dobj) signs/NNS (l_prep) as/IN (l_pobj) movements/NNS (l_conj) protrusions/NNS (l_conj) catalepsy/NN
D001058_D009069 NONE apomophine/JJ (r_amod) injection/NN (r_pobj) by/IN (r_agent) followed/VBN (r_conj) administered/VBN (r_ccomp) produce/VB (l_dobj) dyskinesia/NN
20196116
D001663_D001927 NONE bilirubin/NN (l_appos) time/NN (l_conj) encephalopathy/NN
D000995_D017114 CID Antituberculosis/NNP (r_nsubj) induced/VBN (l_dobj) failure/NN -PUNC- Antituberculosis/NN (r_compound) therapy/NN (l_appos) failure/NN -PUNC- Antituberculosis/NN (r_compound) therapy/NN (l_appos) failure/NN (l_appos) ALF/NNP -PUNC- Antituberculosis/NN (r_compound) therapy/NN (r_nsubj) is/VBZ (l_attr) ALF/NNP
12707296
D001120_D006973 NONE arginine/NN (r_compound) transport/NN (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- arginine/NN (r_compound) nitric/NN (r_compound) system/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- arginine/NN (r_compound) system/NN (r_pobj) in/IN (r_prep) abnormalities/NNS (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) increases/NNS (l_prep) in/IN (l_pobj) pressure/NN
D006854_D006973 NONE cortisol/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- cortisol/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- cortisol/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (l_prep) in/IN (l_pobj) pressure/NN
D009569_D006973 NONE oxide/NN (r_compound) system/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) hypertension/NN
1899352
D015080_D006417 NONE Mesna/NNP (r_dobj) adding/VBG (r_advcl) is/VBZ (r_conj) are/VBP (l_nsubj) frequency/NN (l_conj) predictability/NN (l_prep) of/IN (l_pobj) hematuria/NN -PUNC- Mesna/NNP (r_dobj) adding/VBG (l_prep) to/IN (l_pobj) infusate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hematuria/NN
15814210
D003907_D009422 CID dexamethasone/NN (r_compound) treatment/NN (r_pobj) after/IN (r_prep) dysfunction/NN -PUNC- dexamethasone/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) assess/VB (l_dobj) dysfunction/NN -PUNC- dexamethasone/NN (r_compound) treatment/NN (r_pobj) After/IN (r_prep) showed/VBD (l_dobj) rate/NN (l_prep) of/IN (l_pobj) dysfunctions/NNS
9022662
D010389_D009069 NONE Pemoline/NNP (r_nsubjpass) associated/VBN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) disorders/NNS -PUNC- Pemoline/NN (r_nmod) disorder/NN
D001569_D001264 NONE benzodiazepines/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_conj) decontamination/NN (r_dobj) received/VBD (l_prep) in/IN (l_pobj) attempt/NN (l_acl) control/VB (l_dobj) movements/NNS (l_compound) choreoathetoid/JJ
D010389_D062787 CID pemoline/NN (r_compound) overdose/NN
D008774_D001289 NONE methylphenidate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) disorder/NN
D010389_D002819 CID Pemoline/NNP (r_nsubj) induced/VBD (l_dobj) choreoathetosis/NN -PUNC- pemoline/NN (l_relcl) experienced/VBD (l_dobj) choreoathetosis/NN -PUNC- pemoline/NN (r_compound) overdose/NN (r_pobj) after/IN (r_prep) presenting/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) considered/VBN (l_nsubjpass) possibility/NN (l_prep) of/IN (l_pobj) movements/NNS (l_compound) choreoathetoid/JJ
D000662_D001289 NONE amphetamines/NNS (r_pobj) from/IN (r_prep) different/JJ (r_acomp) is/VBZ (l_conj) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN
D010389_D001264 CID Pemoline/NNP (r_nsubj) induced/VBD (l_dobj) choreoathetosis/NN -PUNC- pemoline/NN (l_relcl) experienced/VBD (l_dobj) choreoathetosis/NN -PUNC- pemoline/NN (r_compound) overdose/NN (r_pobj) after/IN (r_prep) presenting/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) considered/VBN (l_nsubjpass) possibility/NN (l_prep) of/IN (l_pobj) movements/NNS (l_compound) choreoathetoid/JJ
D010389_D001289 NONE Pemoline/NNP (r_nsubj) is/VBZ (l_attr) derivative/NN (l_relcl) is/VBZ (l_conj) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN
D001569_D002819 NONE benzodiazepines/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_conj) decontamination/NN (r_dobj) received/VBD (l_prep) in/IN (l_pobj) attempt/NN (l_acl) control/VB (l_dobj) movements/NNS (l_compound) choreoathetoid/JJ
C064210_D001289 NONE oxazolidine/JJ (r_compound) derivative/NN (l_relcl) is/VBZ (l_conj) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN
20735774
D000082_D017114 CID paracetamol/NN (r_npadvmod) induced/VBN (r_amod) failure/NN -PUNC- paracetamol/NN (r_npadvmod) induced/VBN (r_amod) failure/NN -PUNC- paracetamol/NN (r_advmod) induced/VBN (r_nmod) increases/VBZ (l_nsubj) failure/NN -PUNC- paracetamol/RB (r_npadvmod) induced/VBN (r_amod) injury/NN (r_nsubj) caused/VBN (l_dobj) failure/NN -PUNC- paracetamol/RB (r_npadvmod) induced/VBN (r_amod) injury/NN (r_nsubj) caused/VBN (r_relcl) patients/NNS (r_pobj) for/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_conj) was/VBD (l_conj) died/VBD (l_nsubj) survivors/NNS (l_prep) of/IN (l_pobj) failure/NN -PUNC- Paracetamol/NNP (r_npadvmod) induced/VBN (r_amod) failure/NN
D000082_D008107 NONE paracetamol/RB (r_npadvmod) induced/VBN (r_amod) injury/NN (r_nsubj) caused/VBN (r_relcl) patients/NNS (r_pobj) for/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_conj) was/VBD (l_conj) died/VBD (l_prep) of/IN (l_pobj) disease/NN
D000082_D056486 NONE paracetamol/NN (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- paracetamol/RB (r_npadvmod) induced/VBN (r_amod) injury/NN
12734532
D010665_D062787 NONE PPA/NNP (r_pobj) of/IN (r_prep) abuse/NN (r_dobj) linked/VBN (l_advcl) involved/VBN (l_nsubjpass) overdose/NN
D010665_D009203 CID Dexatrim/NNP (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- Phenylpropanolamine/NNP (r_appos) Dexatrim/NNP (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) infarction/NN
D010665_D009202 NONE PPA/NNP (r_pobj) of/IN (r_prep) abuse/NN (l_prep) with/IN (l_pobj) injury/NN -PUNC- Dexatrim/NNP (r_nmod) injury/NN -PUNC- PPA)-induced/VBN (r_amod) injury/NN -PUNC- PPA/NN (r_pobj) of/IN (r_prep) cases/NNS (l_acl) related/VBN (l_dobj) injury/NN
14698717
D010672_D014277 NONE phenytoin/JJ (r_compound) treatment/NN (l_prep) for/IN (l_pobj) neuralgia/NN
D010672_D011605 NONE phenytoin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) due/IN (r_amod) psychosis/NN -PUNC- phenytoin/JJ (r_compound) treatment/NN (r_dobj) following/VBG (r_acl) psychosis/NN -PUNC- phenytoin/JJ (r_compound) treatment/NN (r_pobj) following/VBG (r_prep) occur/VBP (r_relcl) symptoms/NNS
D010672_D012640 NONE phenytoin/JJ (r_compound) treatment/NN (r_pobj) following/VBG (r_prep) occur/VBP (r_relcl) symptoms/NNS (r_nsubj) be/VB (l_attr) result/NN (l_amod) unrelated/JJ (l_prep) to/IN (l_pobj) seizures/NNS
D010672_D004827 NONE phenytoin/JJ (r_compound) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) epileptic/JJ
17682013
D005472_D056784 CID 5-fluorouracil/CD (r_punct) identified/VBD (l_dobj) reports/NNS (l_prep) of/IN (l_pobj) leukoencephalopathy/JJ
C110904_D056784 CID capecitabine/NN (r_conj) carmofur/NN (r_conj) identified/VBD (l_dobj) reports/NNS (l_prep) of/IN (l_pobj) leukoencephalopathy/JJ
D008727_D002544 NONE methotrexate/NN (r_pobj) of/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) leukoencephalopathy/JJ (l_acl) mimicking/VBG (l_dobj) accident/NN
D008727_D007938 NONE methotrexate/NN (l_prep) for/IN (l_pobj) leukaemia/NN
D008727_D056784 CID methotrexate/NN (r_pobj) of/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) leukoencephalopathy/JJ -PUNC- methotrexate/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) leukoencephalopathy/JJ
C017367_D056784 CID carmofur/NN (r_conj) identified/VBD (l_dobj) reports/NNS (l_prep) of/IN (l_pobj) leukoencephalopathy/JJ
17931375
D006493_D010146 CID heparin/JJ (r_compound) injection/NN (l_prep) on/IN (l_pobj) bruising/VBG (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) bruising/VBG (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) bruising/NN (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (r_acl) methods/NNS (r_nsubjpass) studied/VBN (r_advcl) documented/JJ (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) occurrence/NN (l_prep) of/IN (l_pobj) bruising/VBG (l_conj) pain/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) bruising/VBG (l_conj) pain/NN
D006493_D003288 CID heparin/JJ (r_compound) injection/NN (l_prep) on/IN (l_pobj) bruising/VBG -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) bruising/VBG -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) bruising/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) prevent/VB (r_acl) methods/NNS (r_nsubjpass) studied/VBN (r_advcl) documented/JJ (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) on/IN (l_pobj) occurrence/NN (l_prep) of/IN (l_pobj) bruising/VBG -PUNC- heparin/NN (r_pobj) on/IN (r_prep) bruising/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) bruising/VBG
8739323
D008727_D007674 NONE methotrexate/NNP (r_conj) nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ -PUNC- MTX/NNP (r_appos) methotrexate/NNP (r_conj) nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ -PUNC- MTX/NNP (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- MTX/NNP (r_pobj) of/IN (r_prep) nephrotoxicity/NN
D003520_D007674 NONE cyclophosphamide/NN (r_conj) 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- CY/NNP (r_appos) cyclophosphamide/NN (r_conj) 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- CY/NNP (r_conj) 5-FU/CD (r_conj) MTX/NNP (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- CY/NNP (r_conj) 5-FU/CD (r_nsubj) is/VBZ (r_ccomp) indicate/VBP (l_dobj) nephrotoxicity/NN
D005472_D007674 NONE 5-fluorouracil/CD (r_punct) 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- 5-FU/CD (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- 5-FU/CD (r_conj) MTX/NNP (r_appos) action/NN (l_amod) nephrotoxic/JJ -PUNC- 5-FU/CD (r_nsubj) is/VBZ (r_ccomp) indicate/VBP (l_dobj) nephrotoxicity/NN
D008466_D007674 NONE nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ -PUNC- NG/NNP (r_appos) nitrogranulogen/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) action/NN (l_amod) nephrotoxic/JJ
D008727_D003556 NONE MTX/NNP (r_conj) 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D005472_D003556 NONE 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D008727_D006470 NONE MTX/NNP (r_conj) 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D003520_D006470 CID CY/NNP (r_nsubj) caused/VBD (l_dobj) cystitis/NN
D005472_D006470 NONE 5-FU/CD (r_pobj) with/IN (r_prep) combined/VBN (r_advcl) cause/VB (r_conj) caused/VBD (l_dobj) cystitis/NN
D003520_D003556 CID CY/NNP (r_nsubj) caused/VBD (l_dobj) cystitis/NN
3431591
C031662_D064420 NONE 3717/CD (r_nummod) CB/NN (r_nsubj) is/VBZ (l_attr) inhibitor/NN (l_relcl) mediated/VBN (l_nsubjpass) cytotoxicity/NN -PUNC- acid/NN (r_appos) CB/NN (r_nsubj) is/VBZ (l_attr) inhibitor/NN (l_relcl) mediated/VBN (l_nsubjpass) cytotoxicity/NN -PUNC- 3717/CD (r_nummod) CB/NNP (r_pobj) than/IN (r_prep) potent/JJ (r_amod) 26-/NNPS (r_attr) are/VBP (l_conj) be/VB (l_attr) determinant/NN (l_prep) of/IN (l_pobj) cytotoxicity/NN -PUNC- 3717/CD (r_nummod) cytotoxicity/NN
C031662_D008654 NONE 3717/CD (r_nummod) CB/NNP (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) In/IN (r_prep) seen/VBN (l_prep) in/IN (l_pobj) cancer/NN (l_conj) cancer/NN (l_conj) hepatoma/NN (l_conj) mesothelioma/NN
C031662_D001943 NONE 3717/CD (r_nummod) CB/NNP (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) In/IN (r_prep) seen/VBN (l_prep) in/IN (l_pobj) cancer/NN
C031662_D006528 NONE 3717/CD (r_nummod) CB/NNP (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) In/IN (r_prep) seen/VBN (l_prep) in/IN (l_pobj) cancer/NN (l_conj) cancer/NN (l_conj) hepatoma/NN
C031662_D010051 NONE 3717/CD (r_nummod) CB/NNP (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) In/IN (r_prep) seen/VBN (l_prep) in/IN (l_pobj) cancer/NN (l_conj) cancer/NN
17263743
C009250_D006323 NONE sevoflurane/NN (r_amod) induction/NN (r_dobj) undergoing/VBG (r_acl) arrest/NN
D003000_D006323 CID clonidine/NN (r_pobj) after/IN (r_prep) anesthesia/NN (r_pobj) of/IN (r_prep) induction/NN (r_dobj) undergoing/VBG (r_acl) arrest/NN -PUNC- clonidine/NN (r_npadvmod) associated/VBN (r_amod) arrest/NN
D003000_D002547 NONE clonidine/NN (r_pobj) after/IN (r_prep) anesthesia/NN (r_pobj) of/IN (r_prep) induction/NN (r_dobj) undergoing/VBG (r_acl) arrest/NN (l_prep) in/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) palsy/JJ -PUNC- clonidine/NN (r_dobj) receiving/VBG (r_advcl) present/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) disorder/NN (l_nmod) palsy/JJ
D001418_D002547 NONE baclofen/JJ (r_compound) pump/NN (r_pobj) of/IN (r_prep) placement/NN (r_pobj) for/IN (r_prep) presented/VBD (r_relcl) restlessness/NN (r_pobj) for/IN (r_prep) receiving/VBG (r_advcl) present/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) disorder/NN (l_nmod) palsy/JJ
C009250_D002547 NONE sevoflurane/NN (r_amod) induction/NN (r_dobj) undergoing/VBG (r_acl) arrest/NN (l_prep) in/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) palsy/JJ
D003000_D001008 NONE clonidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) administered/VBD (l_advcl) reduce/VB (l_dobj) anxiety/NN
D001418_D004827 NONE baclofen/JJ (r_compound) pump/NN (r_pobj) of/IN (r_prep) placement/NN (r_pobj) for/IN (r_prep) presented/VBD (r_relcl) restlessness/NN (r_pobj) for/IN (r_prep) receiving/VBG (r_advcl) present/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) disorder/NN
D003000_D004827 NONE clonidine/NN (r_dobj) receiving/VBG (r_advcl) present/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) disorder/NN
D003000_D011595 NONE clonidine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) restlessness/NN
D001418_D011595 NONE baclofen/JJ (r_compound) pump/NN (r_pobj) of/IN (r_prep) placement/NN (r_pobj) for/IN (r_prep) presented/VBD (r_relcl) restlessness/NN
230316
D007464_D009422 NONE clioquinol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN (r_pobj) of/IN (r_prep) consisted/VBD (l_nsubj) disturbance/NN
D006912_D020258 NONE hydroxyquinolines/NNS (r_pobj) of/IN (r_prep) Neurotoxicity/NN -PUNC- hydroxyquinolines/NNS (r_pobj) to/IN (r_prep) reactions/NNS (l_amod) neurotoxic/JJ
D007464_C538178 NONE clioquinol/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) enteropathica/NN
D007464_D001927 CID clioquinol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN
12852481
D001241_D000014 CID Aspirin/NNP (r_nsubj) acetylsalicylic/JJ (l_conj) induces/VBZ (l_dobj) anomalies/NNS -PUNC- acid/NN (r_npadvmod) acetylsalicylic/JJ (l_conj) induces/VBZ (l_dobj) anomalies/NNS -PUNC- ASA/NNP (r_appos) acid/NN (r_npadvmod) acetylsalicylic/JJ (l_conj) induces/VBZ (l_dobj) anomalies/NNS -PUNC- ASA/NNP (r_nsubjpass) administered/VBN (r_advcl) compare/VB (r_xcomp) were/VBD (l_nsubj) Objectives/NNS (l_acl) compare/VB (l_conj) test/VB (l_dobj) hypothesis/NN (l_acl) confounds/VBZ (l_dobj) detection/NN (l_prep) of/IN (l_pobj) malformations/NNS -PUNC- ASA/NNP (r_pobj) with/IN (r_prep) malformations/NNS -PUNC- ASA/NNP (r_nsubj) induces/VBZ (r_advcl) focused/VBD (l_prep) on/IN (l_pobj) malformations/NNS -PUNC- ASA/NNP (r_nsubj) induces/VBZ (l_dobj) malformations/NNS -PUNC- ASA/NNP (r_nsubjpass) administered/VBN (r_advcl) were/VBD (l_nsubj) Variations/NNS (l_conj) malformations/NNS -PUNC- ASA/NNP (r_pobj) with/IN (r_prep) induced/VBN (l_nsubjpass) malformations/NNS
D001241_D005767 NONE ASA/NNP (r_nsubjpass) administered/VBN (r_advcl) compare/VB (r_xcomp) were/VBD (l_nsubj) Objectives/NNS (l_acl) compare/VB (l_conj) test/VB (l_dobj) hypothesis/NN (l_acl) confounds/VBZ (l_nsubj) toxicity/NN -PUNC- ASA/NNP (r_pobj) with/IN (r_prep) malformations/NNS (r_pobj) of/IN (r_prep) detection/NN (r_dobj) confounds/VBZ (l_nsubj) toxicity/NN
8480959
D008148_D006937 NONE lovastatin/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) hypercholesterolemia/NN -PUNC- lovastatin/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) evaluate/VB (l_prep) with/IN (l_pobj) hypercholesterolemia/NN -PUNC- Lovastatin/NNP (r_nsubj) is/VBZ (l_conj) tolerated/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) hypercholesterolemia/NN
D003401_D009135 NONE creatine/NN (r_compound) kinase/NN (r_compound) elevations/NNS (r_pobj) with/IN (r_prep) symptoms/NNS (r_pobj) as/IN (r_prep) defined/VBN (r_acl) Myopathy/NNP
D008148_D009135 CID lovastatin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) associated/VBN (r_conj) was/VBD (l_nsubj) Myopathy/NNP
10791295
D001058_D010554 CID apomorphine/NN (r_pobj) of/IN (r_prep) Development/NN (r_nsubj) induced/VBN (l_dobj) behavior/NN -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) development/NN (r_nsubj) induced/VBN (l_dobj) behavior/NN -PUNC- apomorphine/NN (r_compound) treatment/NN (r_nsubj) induced/VBD (l_dobj) development/NN (l_prep) of/IN (l_pobj) behavior/NN -PUNC- apomorphine/NN (r_compound) treatment/NN (r_nsubj) induced/VBD (l_advcl) evidenced/VBN (l_agent) by/IN (l_pobj) intensity/NN (l_prep) of/IN (l_pobj) aggressiveness/NN -PUNC- apomorphine/NN (r_preconj) the/DT (r_det) behavior/NN
1786266
D000928_D001480 NONE antidepressant/NN (r_compound) use/NN (r_conj) syndrome/NN
20533999
D008694_D064420 NONE methamphetamine/NN (l_acl) METH)-induced/JJ (l_dobj) toxicity/NN -PUNC- methamphetamine/NN (r_dobj) mediates/VBZ (l_advcl) decrease/NN (l_dobj) toxicity/NN -PUNC- methamphetamine/NN (r_dobj) mediates/VBZ (l_advcl) decrease/NN (l_advcl) enhance/VB (l_dobj) toxicity/NN -PUNC- METH)-induced/JJ (l_dobj) toxicity/NN -PUNC- METH)-induced/JJ (r_acl) methamphetamine/NN (r_dobj) mediates/VBZ (l_advcl) decrease/NN (l_dobj) toxicity/NN -PUNC- METH)-induced/JJ (r_acl) methamphetamine/NN (r_dobj) mediates/VBZ (l_advcl) decrease/NN (l_advcl) enhance/VB (l_dobj) toxicity/NN
D019805_D020258 NONE tyrosine/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN
D004298_D009461 NONE DA/NNP (r_compound) deficits/NNS (r_dobj) have/VB (r_xcomp) engineered/VBN (l_conj) develop/VBP (l_dobj) deficits/NNS
D008694_D009461 NONE METH/NN (r_npadvmod) induced/VBN (r_amod) deficits/NNS
D004298_D064420 NONE dopamine/NN (r_nsubj) mediates/VBZ (l_dobj) methamphetamine/NN (l_acl) METH)-induced/JJ (l_dobj) toxicity/NN -PUNC- dopamine/NN (r_nsubj) mediates/VBZ (l_advcl) decrease/NN (l_dobj) toxicity/NN -PUNC- dopamine/NN (r_nsubj) mediates/VBZ (l_advcl) decrease/NN (l_advcl) enhance/VB (l_dobj) toxicity/NN -PUNC- DA/NNP (r_appos) dopamine/NN (r_nsubj) mediates/VBZ (l_dobj) methamphetamine/NN (l_acl) METH)-induced/JJ (l_dobj) toxicity/NN -PUNC- DA/NNP (r_appos) dopamine/NN (r_nsubj) mediates/VBZ (l_advcl) decrease/NN (l_dobj) toxicity/NN -PUNC- DA/NNP (r_appos) dopamine/NN (r_nsubj) mediates/VBZ (l_advcl) decrease/NN (l_advcl) enhance/VB (l_dobj) toxicity/NN -PUNC- DA/NNP (r_compound) neurotransmission/NN (r_pobj) with/IN (r_prep) interfere/VBP (r_relcl) drugs/NNS (r_nsubj) decrease/NN (r_advcl) mediates/VBZ (l_dobj) methamphetamine/NN (l_acl) METH)-induced/JJ (l_dobj) toxicity/NN -PUNC- DA/NNP (r_compound) neurotransmission/NN (r_pobj) with/IN (r_prep) interfere/VBP (r_relcl) drugs/NNS (r_nsubj) decrease/NN (l_dobj) toxicity/NN -PUNC- DA/NNP (r_compound) neurotransmission/NN (r_pobj) with/IN (r_prep) interfere/VBP (r_relcl) drugs/NNS (r_nsubj) decrease/NN (l_advcl) enhance/VB (l_dobj) toxicity/NN -PUNC- DA/NNP (r_compound) neurotransmission/NN (r_dobj) increase/VBP (r_relcl) drugs/NNS (r_nsubj) enhance/VB (r_advcl) decrease/NN (r_advcl) mediates/VBZ (l_dobj) methamphetamine/NN (l_acl) METH)-induced/JJ (l_dobj) toxicity/NN -PUNC- DA/NNP (r_compound) neurotransmission/NN (r_dobj) increase/VBP (r_relcl) drugs/NNS (r_nsubj) enhance/VB (r_advcl) decrease/NN (l_dobj) toxicity/NN -PUNC- DA/NNP (r_compound) neurotransmission/NN (r_dobj) increase/VBP (r_relcl) drugs/NNS (r_nsubj) enhance/VB (l_dobj) toxicity/NN
D007980_D020258 NONE dihydroxyphenylalanine/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) reverse/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) tyrosine/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN
D004298_D020258 NONE Dopamine/NN (r_nsubj) is/VBZ (l_acomp) essential/JJ (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- DA/NNP (r_compound) neurotoxicity/NN -PUNC- DA/NN (r_pobj) in/IN (r_prep) deficient/JJ (r_acomp) be/VB (r_xcomp) engineered/VBN (l_conj) develop/VBP (l_dobj) neurotoxicity/NN -PUNC- DA/NNP (r_nsubj) is/VBZ (l_acomp) essential/JJ (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- DA/JJ (r_pobj) of/IN (r_prep) independent/JJ (r_amod) mechanisms/NNS (r_nsubj) warrant/NN (r_ccomp) suggest/VBP (r_conj) is/VBZ (l_acomp) essential/JJ (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D008694_D020258 CID methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- METH/NNP (r_compound) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) preserved/VBN (r_advcl) long/RB (r_advmod) develop/VBP (l_dobj) neurotoxicity/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
9867728
D020372_D006349 NONE dexfenfluramine/NN (r_conj) fenfluramine/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) among/IN (r_prep) disease/NN -PUNC- dexfenfluramine/NN (r_conj) fenfluramine/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) had/VBD (l_dobj) disease/NN -PUNC- dexfenfluramine/NN (r_conj) fenfluramine/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) among/IN (r_prep) abnormalities/NNS
D005277_D006349 NONE fenfluramine/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) among/IN (r_prep) disease/NN -PUNC- fenfluramine/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) had/VBD (l_dobj) disease/NN -PUNC- fenfluramine/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) among/IN (r_prep) abnormalities/NNS -PUNC- fenfluramine/JJ (r_compound) phentermine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) developed/VBD (l_dobj) disease/NN
D010645_D006349 NONE phentermine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) developed/VBD (l_dobj) disease/NN
2348231
C008514_D007383 NONE methylxanthine/NN (r_compound) derivative/NN (l_relcl) improve/VB (l_dobj) claudication/NN
D004176_D006940 CID dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/JJ (r_npadvmod) thallium-201/NN (r_nmod) imaging/NN (r_pobj) for/IN (r_prep) implications/NNS (r_appos) hyperemia/NN -PUNC- dipyridamole/NN (r_dep) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/NN (r_compound) thallium-201/NN (r_compound) imaging/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) stopped/VBN (r_conj) inhibits/VBZ (l_dobj) hyperemia/NN -PUNC- dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN
D013793_D006940 NONE thallium-201/NN (r_nmod) imaging/NN (r_pobj) for/IN (r_prep) implications/NNS (r_appos) hyperemia/NN -PUNC- thallium-201/NN (r_compound) imaging/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) stopped/VBN (r_conj) inhibits/VBZ (l_dobj) hyperemia/NN
C008514_D006940 NONE methylxanthines/NNS (r_pobj) like/IN (r_prep) hyperemia/NN
D010431_D007383 CID pentoxifylline/NN (r_dobj) taking/VBG (l_conj) derivative/NN (l_relcl) improve/VB (l_dobj) claudication/NN -PUNC- Trental/NNP (r_npadvmod) taking/VBG (l_conj) derivative/NN (l_relcl) improve/VB (l_dobj) claudication/NN
D013806_D006940 NONE theophylline/NN (r_pobj) as/IN (r_prep) methylxanthines/NNS (r_pobj) like/IN (r_prep) hyperemia/NN -PUNC- theophylline/NN (r_pobj) after/IN (r_prep) was/VBD (r_ccomp) peak/JJ (r_advcl) decreased/VBD (l_dobj) hyperemia/NN
D010431_D006940 NONE Pentoxifylline/NNP (r_nsubj) inhibit/VB (l_dobj) hyperemia/NN -PUNC- Trental/NNP (r_appos) Pentoxifylline/NNP (r_nsubj) inhibit/VB (l_dobj) hyperemia/NN -PUNC- pentoxifylline/NN (r_nsubj) inhibits/VBZ (l_dobj) hyperemia/NN -PUNC- pentoxifylline/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) decreased/VBD (l_dobj) hyperemia/NN -PUNC- pentoxyifylline/NN (r_nsubj) inhibit/VB (l_dobj) hyperemia/NN
3997294
D000638_D013617 NONE amiodarone/NN (l_prep) for/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) tachyarrhythmias/NNS
D000638_D010490 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) effusion/NN
D013256_D011014 NONE steroid/NN (r_compound) therapy/NN (r_conj) prompt/JJ (r_conj) withdrawal/NN (r_dobj) indicates/VBZ (l_dobj) need/NN (l_prep) for/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) pneumonitis/NN
D000638_D002318 NONE amiodarone/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patient/NN (l_prep) with/IN (l_pobj) disease/NN
D000638_D011014 CID amiodarone/NN (r_compound) pneumonitis/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_dobj) indicates/VBZ (l_dobj) need/NN (l_prep) for/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) pneumonitis/NN
D000638_D009422 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) effusion/NN (l_conj) neuropathy/NN
D000638_D010996 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) effusion/NN
17608141
D008070_D020258 NONE lipopolysaccharide/NN (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) neurotoxicity/NN -PUNC- lipopolysaccharide/NN (r_pobj) of/IN (r_prep) roles/NNS (l_appos) factor/NN (l_conj) treatment/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) neurotoxicity/NN -PUNC- lipopolysaccharide/NN (r_compound) pretreatment/NN (l_prep) in/IN (l_pcomp) exerting/VBG (l_dobj) protection/NN (l_prep) against/IN (l_pobj) neurotoxicity/NN
D008694_D009422 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) damage/NN
D008694_D020258 NONE methamphetamine/NN (r_npadvmod) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
D008694_D005334 CID methamphetamine/NN (r_npadvmod) elicited/VBN (r_amod) hyperthermia/NN
D004298_D020258 NONE dopamine/NN (r_compound) neurotoxicity/NN -PUNC- dopamine/NN (r_compound) neurotoxicity/NN
D008070_D005334 NONE Lipopolysaccharide/JJ (r_compound) pretreatment/NN (r_nsubj) affect/VB (l_dobj) temperature/NN (l_conj) hyperthermia/NN
12231232
D006220_D009127 CID Haloperidol/NN (r_nsubj) induced/VBD (l_dobj) rigidity/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN
D006220_D010300 NONE Haloperidol/NN (r_nsubj) induced/VBD (l_dobj) rigidity/NN (l_amod) parkinsonian/JJ
C095756_D009127 NONE AIDA/NNP (r_nsubj) diminished/VBD (l_dobj) rigidity/NN
7007443
D000082_D006525 NONE paracetamol/JJ (r_compound) overdose/NN (r_pobj) after/IN (r_prep) survived/VBD (r_relcl) those/DT (r_pobj) in/IN (r_prep) fourfold/RB (r_conj) died/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) increased/VBN (l_advcl) increased/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_amod) due/IN (l_pcomp) to/IN (l_pobj) hepatitis/NN
D000082_D017114 CID paracetamol/JJ (r_compound) overdose/NN (r_pobj) after/IN (r_prep) survived/VBD (l_dobj) failure/NN -PUNC- paracetamol/JJ (r_compound) overdose/NN (r_pobj) after/IN (r_prep) survived/VBD (r_relcl) those/DT (r_pobj) in/IN (r_prep) fourfold/RB (r_conj) died/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) increased/VBN (l_advcl) increased/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D000082_D062787 NONE paracetamol/JJ (r_compound) overdose/NN
26094
D008750_D003866 CID dopa/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) depressions/NNS
D008750_D001523 NONE dopa/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) depressions/NNS (r_pobj) of/IN (r_prep) number/NN (l_acl) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) histories/NNS (l_amod) psychiatric/JJ
12523465
C022189_D012640 NONE Zonisamide/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_acl) used/VBN (l_xcomp) treat/VB (l_dobj) types/NNS (l_prep) of/IN (l_pobj) seizures/NNS
C022189_D006212 CID zonisamide/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hallucinations/NNS -PUNC- zonisamide/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) altered/VBD (r_conj) experienced/VBD (r_relcl) patients/NNS (r_dobj) describe/VBP (l_advcl) reported/VBN (l_nsubjpass) hallucinations/NNS -PUNC- zonisamide/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) altered/VBD (r_conj) experienced/VBD (l_dobj) hallucinations/NNS
3192036
1636026
D014527_D007674 NONE acid/NN (r_pobj) of/IN (r_prep) dL/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) buffer/NN (r_pobj) with/IN (r_prep) perfused/VBN (r_acl) kidney/NN (r_pobj) in/IN (r_prep) compared/VBN (l_nsubjpass) effects/NNS (l_amod) nephrotoxic/JJ
D014527_D058186 NONE acid/NN (r_pobj) of/IN (r_prep) distribution/NN (r_dobj) altering/VBG (r_pcomp) by/IN (r_prep) likely/JJ (r_advcl) causes/VBZ (l_dobj) declines/NNS (l_prep) in/IN (l_pobj) function/NN
D013496_D007674 NONE suprofen/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubjpass) compared/VBN (l_nsubjpass) effects/NNS (l_amod) nephrotoxic/JJ
D013496_D058186 CID suprofen/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- suprofen/VB (r_nsubj) causes/VBZ (l_dobj) declines/NNS (l_prep) in/IN (l_pobj) function/NN
10523326
D014810_D006973 NONE E/NN (r_compound) supplementation/NN (r_nsubj) ameliorated/VBD (l_dobj) hypertension/NN
D009569_D006973 NONE oxide/NN (r_compound) synthase/NN (r_compound) expression/NN (l_prep) in/IN (l_pobj) course/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- NO/DT (r_det) metabolites/NNS (r_pobj) of/IN (r_prep) excretion/NN (r_dobj) showed/VBD (l_conj) increased/VBD (l_dobj) sequestration/NN (l_prep) as/IN (l_pobj) nitrotyrosine/JJ (l_prep) in/IN (l_pobj) tissues/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- NO/DT (r_det) sequestration/NN (l_prep) as/IN (l_pobj) nitrotyrosine/JJ (l_prep) in/IN (l_pobj) tissues/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- NO/DT (r_det) synthase/NN (r_nmod) expression/NN (r_pobj) due/IN (r_prep) is/VBZ (l_nsubj) reduction/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- NO/DT (r_compound) inactivation/NN (l_appos) inhibition/NN (l_conj) actions/NNS (l_prep) of/IN (l_pobj) stress/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hypertension/NN
D010100_D006973 NONE oxygen/NN (r_compound) species/NNS (r_dobj) showed/VBD (l_conj) increased/VBD (l_dobj) sequestration/NN (l_prep) as/IN (l_pobj) nitrotyrosine/JJ (l_prep) in/IN (l_pobj) tissues/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D007854_D006973 CID lead/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- lead/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- lead/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- lead/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- lead/NN (r_npadvmod) associated/VBN (r_amod) inhibition/NN (l_conj) actions/NNS (l_prep) of/IN (l_pobj) stress/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hypertension/NN
D008315_D006973 NONE MDA/NNP (r_compound) concentration/NN (r_dobj) lowered/VBD (r_conj) ameliorated/VBD (l_dobj) hypertension/NN
C002744_D006973 NONE nitrotyrosine/JJ (l_prep) in/IN (l_pobj) tissues/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN
18329269
D006220_D010300 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_prep) for/IN (l_pobj) disease/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) catalepsy/NN
8590259
C016986_D015814 CID apraclonidine/NN (r_npadvmod) treated/VBN (r_amod) eyes/NNS (r_pobj) for/IN (r_prep) significant/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_amod) hypotensive/JJ -PUNC- apraclonidine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) hours/NNS (r_pobj) from/IN (r_prep) significant/JJ (r_conj) significant/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_amod) hypotensive/JJ
8410052
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) by/IN (r_agent) evoked/VBN (l_advmod) epilepticus/NN
D010862_D002544 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) by/IN (r_agent) evoked/VBN (l_nsubjpass) Infarcts/NNS (l_prep) in/IN (l_pobj) reticulata/NNS
D019344_D001480 NONE lactate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) injury/NN (l_prep) in/IN (l_pobj) cortex/NN
9746003
D002220_D009207 CID carbamazepine/NN (l_conj) two/CD (l_prep) of/IN (l_pobj) jerks/NNS -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) on/IN (r_prep) resolved/VBD (r_relcl) jerks/NNS
D002220_D004832 CID carbamazepine/NN (l_conj) vigabatrin/VBP (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- Carbamazepine/NNP (r_nsubjpass) contraindicated/VBN (l_prep) in/IN (l_pobj) seizures/NNS
D020888_D004832 CID vigabatrin/VBP (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- vigabatrin/NN (r_conj) Carbamazepine/NNP (r_nsubjpass) contraindicated/VBN (l_prep) in/IN (l_pobj) seizures/NNS
10835440
D009553_D020521 NONE nimodipine/NN (r_pobj) of/IN (r_prep) Effect/NN (l_prep) after/IN (l_pobj) stroke/NN -PUNC- Nimodipine/NNP (r_compound) Trial/NN (l_compound) Stroke/NNP -PUNC- Nimodipine/NNP (r_compound) Trial/NN (r_nsubj) found/VBD (l_dobj) correlation/NN (l_prep) between/IN (l_pobj) reduction/NN (l_conj) outcome/NN (l_prep) in/IN (l_pobj) stroke/NN -PUNC- nimodipine/NN (r_npadvmod) induced/VBN (r_amod) reduction/NN (r_pobj) between/IN (r_prep) correlation/NN (r_dobj) found/VBD (l_nsubj) Trial/NN (l_compound) Stroke/NNP -PUNC- nimodipine/NN (r_npadvmod) induced/VBN (r_amod) reduction/NN (l_conj) outcome/NN (l_prep) in/IN (l_pobj) stroke/NN -PUNC- nimodipine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) worsening/VBG (l_prep) after/IN (l_pobj) stroke/NN
D009553_D007022 CID Nimodipine/NNP (r_compound) Trial/NN (r_nsubj) found/VBD (l_dobj) correlation/NN (l_prep) between/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- nimodipine/NN (r_npadvmod) induced/VBN (r_amod) reduction/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- Nimodipine/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) BP/NNP
D009553_D002544 NONE nimodipine/NN (r_parataxis) h/NN (r_appos) receive/VB (r_advcl) allocated/VBN (l_nsubjpass) METHODS/NNS (l_appos) Patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- nimodipine/NN (r_conj) nimodipine/NN (r_parataxis) h/NN (r_appos) receive/VB (r_advcl) allocated/VBN (l_nsubjpass) METHODS/NNS (l_appos) Patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) stroke/NN
11302406
D015725_D006333 NONE fluconazole/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) between/IN (r_prep) association/NN (r_attr) was/VBD (r_relcl) factors/NNS (l_prep) including/VBG (l_pobj) disease/NN (l_amod) cardiomyopathy/NN (l_conj) failure/NN
D015725_D008133 NONE fluconazole/NN (r_ccomp) aware/JJ (r_acomp) be/VB (l_conj) cause/VB (l_dobj) prolongation/NN (l_prep) of/IN (l_pobj) interval/NN
D015725_D003324 NONE fluconazole/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) between/IN (r_prep) association/NN (r_attr) was/VBD (r_relcl) factors/NNS (l_prep) including/VBG (l_pobj) disease/NN
D015725_D009202 NONE fluconazole/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) between/IN (r_prep) association/NN (r_attr) was/VBD (r_relcl) factors/NNS (l_prep) including/VBG (l_pobj) disease/NN (l_amod) cardiomyopathy/NN
D015725_D017180 NONE fluconazole/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (r_ccomp) continued/VBD (l_conj) tachycardia/NN -PUNC- fluconazole/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (r_ccomp) continued/VBD (l_conj) tachycardia/NN (l_appos) NSVT/NNP -PUNC- fluconazole/NN (r_dobj) suggests/VBZ (l_csubj) followed/VBN (l_nsubj) disappearance/NN (l_prep) of/IN (l_pobj) NSVT/NNP
D015725_D016171 CID Fluconazole/NNP (r_npadvmod) induced/VBN (r_amod) torsade/NN (r_nmod) pointes/FW -PUNC- fluconazole/NN (r_advmod) associated/VBN (r_amod) pointes/FW -PUNC- fluconazole/NN (r_advmod) associated/VBN (r_amod) pointes/FW (l_appos) TDP/NNP -PUNC- fluconazole/NN (r_advmod) associated/VBN (r_amod) pointes/FW (r_pobj) of/IN (r_prep) case/NN (r_dobj) present/VB (l_conj) discuss/VB (l_dobj) role/NN (l_prep) in/IN (l_pcomp) causing/VBG (l_dobj) TDP/NNP -PUNC- fluconazole/NN (r_poss) role/NN (r_dobj) discuss/VB (r_conj) present/VB (l_dobj) case/NN (l_prep) of/IN (l_pobj) pointes/FW -PUNC- fluconazole/NN (r_poss) role/NN (r_dobj) discuss/VB (r_conj) present/VB (l_dobj) case/NN (l_prep) of/IN (l_pobj) pointes/FW (l_appos) TDP/NNP -PUNC- fluconazole/NN (r_poss) role/NN (l_prep) in/IN (l_pcomp) causing/VBG (l_dobj) TDP/NNP -PUNC- fluconazole/NN (r_dobj) commencing/VBG (r_pcomp) after/IN (r_prep) glabrata/NNS (l_xcomp) isolated/VBN (l_prep) from/IN (l_pobj) abscess/NN (l_acl) developed/VBD (l_dobj) TDP/NNP -PUNC- fluconazole/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) between/IN (r_prep) association/NN (r_attr) was/VBD (r_relcl) factors/NNS (l_prep) for/IN (l_pobj) TDP/NNP -PUNC- fluconazole/NN (l_conj) TDP/NNP -PUNC- fluconazole/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (l_nsubj) TDP/NNP -PUNC- fluconazole/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) TDP/NNP -PUNC- fluconazole/NN (r_ccomp) aware/JJ (r_acomp) be/VB (l_conj) cause/VB (l_advcl) leading/VBG (l_prep) to/IN (l_pobj) TDP/NNP
D015725_D018879 NONE fluconazole/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (r_ccomp) continued/VBD (l_xcomp) have/VB (l_dobj) contractions/NNS -PUNC- fluconazole/NN (r_dobj) suggests/VBZ (l_csubj) followed/VBN (l_nsubj) disappearance/NN (l_conj) contractions/NNS
D011188_D003866 NONE potassium/NN (r_compound) currents/NNS (r_dobj) activating/VBG (r_pcomp) of/IN (r_prep) depression/NN
D015725_D001145 NONE fluconazole/NN (r_nsubjpass) administered/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) are/VBP (l_prep) at/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) arrhythmias/NNS
6692345
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- FANFT/NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- FANFT/NNP (r_npadvmod) induced/VBN (r_amod) carcinomas/NNS (r_pobj) of/IN (r_prep) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) carcinomas/NNS -PUNC- FANFT/NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide/NNP (r_pobj) with/IN (r_prep) aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) carcinomas/NNS -PUNC- FANFT/NNP (r_npadvmod) induced/VBN (r_amod) carcinomas/NNS
D001241_D013274 NONE aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_conj) induction/NN (l_prep) of/IN (l_pobj) tumors/NNS
D001241_D063646 NONE aspirin/NN (r_poss) effect/NN (r_nsubj) is/VBZ (r_conj) involved/VBN (l_prep) in/IN (l_pobj) carcinogenesis/NN
D001241_D001749 NONE aspirin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) carcinomas/NNS
D005200_D063646 NONE FANFT/NNP (r_compound) carcinogenesis/NN -PUNC- FANFT/NNP (r_pobj) on/IN (r_prep) effect/NN (r_nsubj) is/VBZ (r_conj) involved/VBN (l_prep) in/IN (l_pobj) carcinogenesis/NN
6615052
D006493_D013923 CID heparin/VBN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) events/NNS (l_compound) thromboembolic/JJ
D006493_D001791 NONE heparin/NN (r_pobj) to/IN (r_prep) resistance/NN (r_dobj) increased/VBN (r_conj) revealed/VBN (l_dobj) count/NN -PUNC- heparin/NN (r_nsubjpass) added/VBN (r_conj) increased/VBN (r_conj) revealed/VBN (l_dobj) count/NN -PUNC- heparin/JJ (l_appos) testing/NN (l_compound) aggregation/NN
D006493_D013921 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN
D006493_D013927 NONE Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) thrombosis/NN
D006493_D006470 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) thrombosis/NN (l_conj) hemorrhage/NN -PUNC- heparin/VBN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) events/NNS (r_appos) hemorrhage/NN
8386779
D010208_D007172 NONE papaverine/NN (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) ml./NN (r_dobj) received/VBD (l_nsubj) total/NN (l_prep) of/IN (l_pobj) patients/NNS (l_relcl) presented/VBD (l_prep) with/IN (l_pobj) impotence/NN
D017693_D004414 NONE bicarbonate/NN (r_nsubj) alleviates/VBZ (l_dobj) pain/NN -PUNC- bicarbonate/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) injections/NNS (r_pobj) following/VBG (r_prep) comparing/VBG (r_acl) study/NN (r_dobj) performed/VBD (l_prep) In/IN (l_pobj) attempt/NN (l_acl) determine/VB (l_ccomp) be/VB (l_nsubj) pain/NN -PUNC- bicarbonate/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) injections/NNS (r_pobj) following/VBG (r_prep) comparing/VBG (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_pobj) without/IN (r_prep) patients/NNS (r_pobj) Of/IN (r_prep) complained/VBD (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_pobj) without/IN (r_prep) patients/NNS (r_pobj) Of/IN (r_prep) complained/VBD (l_advcl) complained/VBD (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_dobj) received/VBD (r_relcl) men/NNS (r_pobj) of/IN (r_prep) 1/CD (r_nsubj) complained/VBD (r_advcl) complained/VBD (l_prep) of/IN (l_pobj) pain/NN -PUNC- bicarbonate/NN (r_dobj) received/VBD (r_relcl) men/NNS (r_pobj) of/IN (r_prep) 1/CD (r_nsubj) complained/VBD (l_prep) of/IN (l_pobj) pain/NN
D017693_D007172 NONE bicarbonate/NN (r_nsubj) alleviates/VBZ (l_advcl) induced/VBN (l_agent) by/IN (l_pobj) injections/NNS (l_prep) for/IN (l_pobj) dysfunction/NN
8669433
D010615_D007676 CID phenacetin/NN (r_pobj) with/IN (r_prep) comparison/NN (r_appos) use/NN (l_prep) as/IN (l_pobj) factor/NN (l_prep) for/IN (l_pobj) failure/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN (l_conj) disease/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN (l_conj) disease/NN (l_appos) ESRD/NNP -PUNC- phenacetin/NN (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) burden/NN (l_prep) of/IN (l_pobj) ESRD/NNP
D000082_D007676 NONE acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) as/IN (l_pobj) factor/NN (l_prep) for/IN (l_pobj) failure/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN (l_conj) ESRD/NNP -PUNC- acetaminophen/RB (r_conj) phenacetin/NN (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) burden/NN (l_prep) of/IN (l_pobj) ESRD/NNP -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) ESRD/NNP
16725121
D009638_D012640 NONE norepinephrine/NN (r_amod) function/NN (r_pobj) of/IN (r_prep) regulation/NN (l_acl) induced/VBN (l_xcomp) linking/VBG (l_prep) to/IN (l_pobj) alteration/NN (l_prep) of/IN (l_pobj) sensitivity/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- norepinephrine/NN (r_compound) transporter/NN (r_nmod) function/NN (l_prep) by/IN (l_pobj) inhibition/NN (l_prep) in/IN (l_pobj) relation/NN (l_prep) to/IN (l_pobj) sensitization/NN (l_prep) to/IN (l_pobj) seizures/NNS
D003042_D012640 CID cocaine/NN (r_pobj) by/IN (r_agent) induce/VB (r_acl) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS (r_pobj) of/IN (r_prep) that/DT (r_dobj) decreased/VBD (r_conj) increased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) appearance/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- cocaine/NN (r_conj) lidocaine/NN (r_pobj) of/IN (r_prep) activity/NN (l_amod) convulsive/JJ -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) kindling/VBG (r_pobj) from/IN (r_prep) distinct/JJ (r_amod) mechanism/NN (r_dobj) have/VB (l_nsubj) sensitization/NN (l_prep) of/IN (l_pobj) seizures/NNS
D003891_D012640 NONE desipramine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_xcomp) linking/VBG (l_prep) to/IN (l_pobj) alteration/NN (l_prep) of/IN (l_pobj) sensitivity/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- desipramine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) increased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) appearance/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- desipramine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) increased/VBD (l_conj) decreased/VBD (l_dobj) that/DT (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- desipramine/NN (r_pobj) with/IN (r_prep) lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) changes/NNS (l_prep) of/IN (l_pobj) activity/NN (l_amod) convulsive/JJ -PUNC- desipramine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) changes/NNS (l_prep) of/IN (l_pobj) activity/NN (l_amod) convulsive/JJ -PUNC- desipramine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) regulation/NN (r_nsubj) be/VB (l_acomp) relevant/JJ (l_prep) to/IN (l_pobj) sensitization/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- desipramine/NN (r_advmod) induced/VBN (r_amod) sensitization/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- Desipramine/NN (r_nsubj) induced/VBN (r_amod) sensitization/NN (l_prep) of/IN (l_pobj) seizures/NNS
D008012_D012640 CID lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS (r_pobj) of/IN (r_prep) appearance/NN (r_pobj) of/IN (r_prep) incidence/NN (r_dobj) increased/VBD (l_conj) decreased/VBD (l_dobj) that/DT (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) changes/NNS (l_prep) of/IN (l_pobj) activity/NN (l_amod) convulsive/JJ -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) activity/NN (l_amod) convulsive/JJ -PUNC- lidocaine/NN (r_compound) convulsions/NNS -PUNC- lidocaine/NN (r_compound) seizures/NNS
322550
D009599_D002303 NONE nitroprusside/JJ (r_amod) infusion/NN (r_nsubj) produced/VBD (l_conj) increased/VBN (l_conj) decreased/VBD (l_dobj) output/NN -PUNC- nitroprusside/JJ (r_amod) levels/NNS (r_pobj) During/IN (r_prep) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
D014867_D002303 NONE H2O/NNP (r_punct) levels/NNS (r_conj) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
D014867_D007022 NONE H2O/NNP (r_punct) levels/NNS (r_conj) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
D009599_D007022 CID nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN -PUNC- nitroprusside/JJ (r_amod) infusion/NN (r_nsubj) produced/VBD (l_dobj) decrease/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- Nitroprusside/NNP (r_nsubj) caused/VBD (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN
D009599_D007022 NONE nitroprusside/JJ (r_amod) levels/NNS (r_pobj) During/IN (r_prep) alter/VB (l_conj) produce/VBP (l_dobj) decreases/NNS (l_prep) in/IN (l_pobj) pressure/NN (l_conj) output/NN
4071154
D007213_D005355 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN
D007213_D011660 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN (l_conj) ascites/NNS (l_conj) pulmonale/NN
D007213_D051437 NONE Indomethacin/NNP (r_npadvmod) induced/VBN (r_amod) insufficiency/NN -PUNC- indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) of/IN (l_pobj) failure/NN
D007213_D001201 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN (l_conj) ascites/NNS
D007213_D009846 CID indomethacin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_punct) caused/VBD (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) oliguria/NN
D007213_D006947 CID indomethacin/NN (r_advcl) reported/VBN (l_dobj) case/NN (l_prep) of/IN (l_pobj) failure/NN (l_prep) with/IN (l_pobj) hyperkalemia/NN
6534871
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
19692487
D008094_D011141 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN
D015232_D011141 NONE )/-RRB- (r_punct) PGE(2/NNP (r_appos) urine/NN (r_pobj) of/IN (r_prep) blockade/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_advcl) were/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pobj) polyuria/NN -PUNC- )/-RRB- (r_punct) PGE(2/NNP (r_nsubj) mediates/VBZ (l_dobj) polyuria/NN
D011458_D011141 NONE E/NN (r_appos) microsomal/JJ (r_pobj) in/IN (r_prep) deficient/JJ (r_pobj) in/IN (r_prep) polyuria/NN
2950248
D004176_D003324 NONE dipyridamole/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) as/IN (r_prep) reported/VBN (l_advcl) demonstrated/VBN (l_xcomp) occur/VB (l_prep) with/IN (l_pobj) disease/NN -PUNC- dipyridamole/NN (r_dep) induced/VBN (r_amod) ischemia/NN (r_nsubjpass) demonstrated/VBN (l_xcomp) occur/VB (l_prep) with/IN (l_pobj) disease/NN
D004176_D000787 CID dipyridamole/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) Angina/NNP
D004176_D017202 NONE Dipyridamole/NNP (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dipyridamole/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) as/IN (r_prep) reported/VBN (l_advcl) demonstrated/VBN (l_nsubjpass) ischemia/NN -PUNC- dipyridamole/NN (r_dep) induced/VBN (r_amod) ischemia/NN
D004176_D007511 NONE dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN
2021202
D007530_D007022 CID isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- isoflurane/NN (r_amod) concentration/NN (r_dobj) increasing/VBG (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubjpass) Hypotension/NNP -PUNC- isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN
9284778
-1_D008107 NONE hydrochlorofluorocarbons/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Epidemic/NN (l_prep) of/IN (l_pobj) disease/NN
D010126_D008107 NONE ozone/NN (r_npadvmod) sparing/VBG (r_amod) substitutes/NNS (r_pobj) as/IN (r_prep) used/VBN (r_acl) hydrochlorofluorocarbons/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Epidemic/NN (l_prep) of/IN (l_pobj) disease/NN
C072959_D056486 NONE 124/CD (r_conj) HCFCs/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) injury/NN
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane/CD (r_pobj) as/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) metabolised/VBN (l_advcl) form/VB (l_dobj) intermediates/NNS (l_relcl) implicated/VBN (l_prep) in/IN (l_pobj) hepatotoxicity/NN -PUNC- halothane/NN (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane/CD (r_pobj) as/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) metabolised/VBN (l_advcl) form/VB (l_dobj) intermediates/NNS (l_relcl) implicated/VBN (l_prep) in/IN (l_pobj) hepatotoxicity/NN -PUNC- halothane/NN (r_pobj) of/IN (r_prep) hepatotoxicity/NN
D014269_D056486 NONE trifluoroacetyl/NNS (r_compound) halide/NN (r_compound) intermediates/NNS (l_relcl) implicated/VBN (l_prep) in/IN (l_pobj) hepatotoxicity/NN -PUNC- trifluoroacetyl/NN (r_npadvmod) altered/VBN (r_amod) proteins/NNS (r_nsubjpass) involved/VBN (r_ccomp) suggest/VBP (l_advcl) known/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D017402_D008107 NONE chlorofluorocarbons/NNS (r_pobj) of/IN (r_prep) substitutes/NNS (r_pobj) as/IN (r_prep) used/VBN (r_acl) hydrochlorofluorocarbons/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Epidemic/NN (l_prep) of/IN (l_pobj) disease/NN
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 123/CD (r_nummod) HCFC/NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 124/CD (r_conj) HCFCs/NNS (r_nsubj) result/VB (l_prep) in/IN (l_pobj) disease/NN
C067411_D056486 NONE 124/CD (r_conj) HCFCs/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) injury/NN
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane/NN (r_conj) HCFC/NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 124/CD (r_nummod) HCFC/NNP (r_appos) HCFC/NNP (r_appos) 1,1-dichloro-2,2,2-trifluoroethane/CD (r_pobj) of/IN (r_prep) mixture/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) repeated/VBN (r_relcl) workers/NNS (r_pobj) in/IN (r_prep) epidemic/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- 124/CD (r_conj) HCFCs/NNS (r_nsubj) result/VB (l_prep) in/IN (l_pobj) disease/NN
12093990
D012254_D000740 NONE ribavirin/RB (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) is/VBZ (l_attr) anemia/NN
D012254_D000257 NONE ribavirin/JJ (r_compound) treatment/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- ribavirin/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) experience/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- ribavirin/RB (r_pobj) with/IN (r_prep) treated/VBN (l_prep) for/IN (l_pobj) disease/NN -PUNC- ribavirin/NN (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) for/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- ribavirin/RB (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) children/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- ribavirin/NN (r_pobj) as/IN (r_prep) therapies/NNS (r_pobj) of/IN (r_prep) trial/NN (r_conj) children/NNS (r_appos) hosts/NNS (r_pobj) in/IN (r_prep) prevalence/NN (l_prep) of/IN (l_pobj) disease/NN
D012254_D018357 NONE Ribavirin/NNP (r_nsubjpass) licensed/VBN (l_prep) in/IN (l_pobj) form/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) infection/NN -PUNC- ribavirin/RB (r_dobj) treat/VB (r_conj) licensed/VBN (l_prep) in/IN (l_pobj) form/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) infection/NN
C059262_D009503 CID cidofovir/NN (r_pobj) of/IN (r_prep) Use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN (l_conj) neutropenia/NN
C059262_D007674 NONE cidofovir/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) limited/VBN (r_ccomp) is/VBZ (l_attr) nephrotoxicity/NN
D012254_D006482 NONE Ribavirin/NNP (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) infection/NN (l_prep) with/IN (l_pobj) viruses/NNS -PUNC- ribavirin/RB (r_dobj) treat/VB (r_conj) licensed/VBN (l_conj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) infection/NN (l_prep) with/IN (l_pobj) viruses/NNS
C059262_D058186 CID cidofovir/NN (r_pobj) of/IN (r_prep) Use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN
D012254_D007239 NONE ribavirin/NN (r_nsubj) was/VBD (r_advcl) is/VBZ (l_advcl) begun/VBN (l_prep) in/IN (l_pobj) course/NN (l_prep) of/IN (l_pobj) infection/NN
D012254_D006526 NONE Ribavirin/NNP (r_nsubjpass) licensed/VBN (l_conj) treat/VB (l_dobj) ribavirin/RB (l_compound) Intravenous/NNP (l_compound) C./NNP -PUNC- ribavirin/RB (l_compound) Intravenous/NNP (l_compound) C./NNP
C059262_D000257 NONE cidofovir/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) infection/NN
3985451
D014859_D020428 CID Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) hemorrhage/NN (l_prep) with/IN (l_pobj) palsy/JJ -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (l_nsubj) palsy/JJ
D014859_D003286 NONE warfarin/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) man/NN (l_relcl) sustained/VBD (l_conj) developed/VBD (l_dobj) pain/NN (l_conj) contracture/NN -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (r_ccomp) characterized/VBN (l_agent) by/IN (l_pobj) pain/NN (l_conj) degrees/NNS (l_conj) contracture/NN
D014859_D009135 CID warfarin/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) man/NN (l_relcl) sustained/VBD (l_dobj) tear/NN
D014859_D015417 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (r_ccomp) characterized/VBN (l_agent) by/IN (l_pobj) pain/NN (l_conj) degrees/NNS (l_prep) of/IN (l_pobj) impairment/NN
D014859_D010146 NONE warfarin/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) man/NN (l_relcl) sustained/VBD (l_conj) developed/VBD (l_dobj) pain/NN -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN (r_pobj) of/IN (r_prep) form/NN (r_dobj) represents/VBZ (r_ccomp) characterized/VBN (l_agent) by/IN (l_pobj) pain/NN
D014859_D006470 NONE Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) hemorrhage/NN
D014859_D010523 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) neuropathy/NN
1468485
D003520_D014890 NONE cyclophosphamide/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) granulomatosis/NN
D015237_D006470 NONE alpha/NN (r_pobj) of/IN (r_prep) saline/NN (r_pobj) with/IN (r_prep) irrigation/NN (r_pobj) including/VBG (r_prep) treatment/NN (r_nsubj) failed/VBD (l_xcomp) control/VB (l_dobj) hemorrhage/NN
D010100_D003556 NONE oxygen/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) cystitis/NN
D010100_D006470 NONE oxygen/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) control/NN (l_prep) of/IN (l_pobj) cystitis/NN
D003520_D006470 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) in/IN (r_prep) alternative/NN (r_dobj) offer/VB (l_dobj) cystitis/NN
D003520_D003556 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) in/IN (r_prep) alternative/NN (r_dobj) offer/VB (l_dobj) cystitis/NN
17244258
D003520_D003556 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN
1355091
C014282_D001919 CID cirazoline/NN (r_pobj) to/IN (r_prep) bradycardia/NNS -PUNC- cirazoline/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) bradycardia/NN
D011224_D001919 NONE prazosin/NN (r_compound) pretreatment/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) determined/VBN (l_nsubjpass) responses/NNS (l_conj) bradycardia/NNS -PUNC- prazosin/NN (r_pobj) in/IN (r_prep) abolished/VBN (l_nsubjpass) pressor/NN (l_conj) effects/NNS (l_amod) bradycardia/NN -PUNC- prazosin/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) SHR/NNP (r_pobj) in/IN (r_prep) greater/JJR (r_acomp) was/VBD (l_nsubj) bradycardia/NN -PUNC- prazosin/NN (r_compound) treatment/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) bradycardia/NN
C056299_D001919 CID Abbott-53693/NNP (r_appos) responses/NNS (l_conj) bradycardia/NNS -PUNC- Abbott-53693/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) were/VBD (l_conj) was/VBD (l_nsubj) bradycardia/NN
D011224_D007024 CID prazosin/NN (r_npadvmod) pretreated/VBN (r_amod) conscious/JJ (r_amod) rats/NNS (r_pobj) in/IN (r_prep) blockade/NN (r_pobj) following/VBG (r_prep) occurs/VBZ (l_nsubj) hypotension/NN -PUNC- prazosin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) hypotension/NN -PUNC- prazosin/NN (r_pobj) of/IN (r_prep) dosing/NN (r_pobj) after/IN (r_conj) to/IN (r_prep) prior/RB (r_advmod) performed/VBN (r_advcl) produce/VB (l_dobj) hypotension/NN
D009638_D001919 CID noradrenaline/NN (r_conj) responses/NNS (l_conj) bradycardia/NNS -PUNC- noradrenaline/NN (r_npadvmod) induced/VBN (r_amod) effect/NN (r_dobj) accompanied/VBD (r_relcl) bradycardia/NN
D015016_D007024 NONE rauwolscine/JJ (r_pobj) with/IN (r_prep) treated/VBN (r_acl) SHR/NN (r_pobj) in/IN (r_conj) induced/VBN (l_dobj) hypotension/NN
D011224_D006973 NONE prazosin/NN (r_npadvmod) pretreated/VBN (r_amod) conscious/JJ (r_amod) rats/NNS (l_amod) hypertensive/JJ -PUNC- prazosin/NN (r_compound) treatment/NN (r_nsubj) alters/VBZ (l_prep) for/IN (l_pobj) control/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
3769769
D014282_D001919 CID hydrochloride/NN (r_pobj) due/JJ (r_amod) Bradycardia/NNS
D014282_D012559 NONE hydrochloride/NN (r_dobj) trihexyphenidyl/JJ (r_conj) treated/VBN (l_nsubjpass) patient/NN (l_amod) schizophrenic/JJ
2722224
D006854_D006973 CID Hydrocortisone/NNP (r_npadvmod) induced/VBN (l_dobj) hypertension/NN -PUNC- hydrocortisone/NN (r_pobj) with/IN (r_prep) pressure/NN
D006854_D016534 NONE hydrocortisone/NN (r_pobj) with/IN (r_prep) pressure/NN (r_dobj) resting/VBG (r_pcomp) in/IN (r_prep) rise/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) output/NN
15867025
D006514_D012409 NONE antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_relcl) infants/NNS (r_pobj) to/IN (r_prep) administration/NN (r_conj) dose/NN (r_conj) screening/NN (l_prep) for/IN (l_pobj) B/NNP (l_conj) rubella/NN -PUNC- antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (l_conj) immunity/NN (l_compound) rubella/NN -PUNC- antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (l_conj) immunity/NN (l_conj) administration/NN (l_prep) of/IN (l_pobj) vaccine/NN (l_compound) rubella/NN -PUNC- antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (l_prep) to/TO (l_pobj) women/NNS (l_compound) rubella/VB
D006514_D006509 CID antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_relcl) infants/NNS (r_pobj) to/IN (r_prep) administration/NN (r_conj) dose/NN (r_conj) screening/NN (l_prep) for/IN (l_pobj) B/NNP -PUNC- antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_relcl) infants/NNS (r_pobj) to/IN (r_prep) administration/NN (r_conj) dose/NN (l_nsubj) administration/NN (l_prep) of/IN (l_pobj) birth/NN (l_compound) vaccine/NN (l_compound) B/NNP -PUNC- antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_relcl) infants/NNS (r_pobj) to/IN (r_prep) administration/NN (l_prep) of/IN (l_pobj) globulin/NN (l_compound) B/NNP -PUNC- antigen/NN (r_npadvmod) positive/JJ (r_amod) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_relcl) infants/NNS (r_nsubj) received/VBD (l_dobj) globulin/NN (l_compound) B/NN
18674790
D004317_D006331 CID doxorubicin/NN (r_nmod) kg/NNS (r_appos) dose/NN (l_acl) administered/VBN (l_prep) on/IN (l_pobj) day/NN (l_nummod) 43/CD (l_prep) of/IN (l_pobj) regimen/NN (l_acl) led/VBD (l_prep) to/IN (l_pobj) cardiotoxicity/NN (l_conj) dysfunction/NN
D004317_D009765 NONE doxorubicin/RB (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) are/VBP (l_nsubj) rats/NNS (l_amod) obese/JJ -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN (r_pobj) to/IN (r_prep) sensitizes/VBZ (l_nsubj) intervention/NN (l_prep) by/IN (l_pcomp) feeding/VBG (l_dobj) diet/NN (l_relcl) induces/VBZ (l_dobj) obesity/NN -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_appos) dose/NN (l_acl) administered/VBN (l_prep) on/IN (l_pobj) day/NN (l_nummod) 43/CD (l_prep) of/IN (l_pobj) regimen/NN (l_acl) led/VBD (l_prep) to/IN (l_pobj) cardiotoxicity/NN (l_conj) dysfunction/NN (l_conj) peroxidation/NN (l_conj) mortality/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) obese/JJ -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_appos) dose/NN (l_acl) administered/VBN (l_prep) on/IN (l_pobj) day/NN (l_nummod) 43/CD (l_prep) of/IN (l_pobj) regimen/NN (l_acl) led/VBD (l_prep) to/IN (l_pobj) cardiotoxicity/NN (l_conj) dysfunction/NN (l_conj) peroxidation/NN (l_conj) mortality/NN (l_prep) in/IN (l_pobj) rats/NNS (l_nmod) OB/NNP -PUNC- Doxorubicin/NNP (r_compound) toxicokinetics/NNS (r_compound) studies/NNS (r_nsubj) revealed/VBD (l_dobj) change/NN (l_conj) hearts/NNS (l_compound) OB/NNP -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) accumulation/NN (r_pobj) in/IN (r_prep) change/NN (l_conj) hearts/NNS (l_compound) OB/NNP -PUNC- doxorubicin/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) ratio/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) drop/NN (r_conj) decreased/VBD (r_ccomp) revealed/VBD (l_ccomp) sensitized/VBN (l_nsubjpass) rats/NNS (l_compound) OB/NNP -PUNC- doxorubicin/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) ratio/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) drop/NN (r_conj) decreased/VBD (l_nsubj) stress/NN (l_acl) activated/VBN (l_dobj) oxidation/NN (l_appos) heart/NN (l_prep) versus/IN (l_pobj) heart/NN (l_prep) in/IN (l_pobj) OB/NNP -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_pobj) to/IN (r_prep) sensitized/JJ (r_acomp) are/VBP (l_nsubj) rats/NNS (l_amod) obese/JJ
C010013_D009765 NONE doxorubicinol/NN (r_conj) doxorubicin/NN (r_pobj) of/IN (r_prep) accumulation/NN (r_pobj) in/IN (r_prep) change/NN (l_conj) hearts/NNS (l_compound) OB/NNP
D004317_D066126 NONE doxorubicin/RB (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) by/IN (r_prep) chemotherapy/NN (r_nsubjpass) limited/VBN (l_prep) due/IN (l_pobj) life/NN (l_acl) threatening/VBG (l_dobj) cardiotoxicity/NN -PUNC- Adriamycin/NNP (r_punct) )/-RRB- (r_punct) is/VBZ (r_auxpass) limited/VBN (l_prep) due/IN (l_pobj) life/NN (l_acl) threatening/VBG (l_dobj) cardiotoxicity/NN -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_appos) dose/NN (l_acl) administered/VBN (l_prep) on/IN (l_pobj) day/NN (l_nummod) 43/CD (l_prep) of/IN (l_pobj) regimen/NN (l_acl) led/VBD (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
D000255_D009765 NONE ATP/NNP (r_compound) levels/NNS (r_pobj) in/IN (r_prep) drop/NN (r_conj) decreased/VBD (r_ccomp) revealed/VBD (l_ccomp) sensitized/VBN (l_nsubjpass) rats/NNS (l_compound) OB/NNP -PUNC- ATP/NNP (r_compound) levels/NNS (r_pobj) in/IN (r_prep) drop/NN (r_conj) decreased/VBD (l_nsubj) stress/NN (l_acl) activated/VBN (l_dobj) oxidation/NN (l_appos) heart/NN (l_prep) versus/IN (l_pobj) heart/NN (l_prep) in/IN (l_pobj) OB/NNP -PUNC- ATP/NNP (r_nmod) ADP/NNP (r_compound) ratio/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) drop/NN (r_conj) decreased/VBD (r_ccomp) revealed/VBD (l_ccomp) sensitized/VBN (l_nsubjpass) rats/NNS (l_compound) OB/NNP -PUNC- ATP/NNP (r_nmod) ADP/NNP (r_compound) ratio/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) drop/NN (r_conj) decreased/VBD (l_nsubj) stress/NN (l_acl) activated/VBN (l_dobj) oxidation/NN (l_appos) heart/NN (l_prep) versus/IN (l_pobj) heart/NN (l_prep) in/IN (l_pobj) OB/NNP -PUNC- ATP/NNP (r_compound) generation/NN (r_dobj) downregulating/VBG (r_pcomp) by/IN (r_prep) sensitized/JJ (r_acomp) are/VBP (l_nsubj) rats/NNS (l_amod) obese/JJ
D004041_D009765 CID fat/JJ (r_amod) rats/NNS (l_amod) obese/JJ -PUNC- fat/JJ (r_amod) diet/NN (l_relcl) induces/VBZ (l_dobj) obesity/NN
D000255_D066126 NONE ATP/NNP (r_compound) generation/NN (r_dobj) downregulating/VBG (r_pcomp) by/IN (r_prep) sensitized/JJ (l_prep) to/IN (l_pobj) cardiotoxicity/NN
D004041_D066126 NONE fat/JJ (r_amod) rats/NNS (r_nsubj) are/VBP (l_acomp) sensitive/JJ (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- fat/JJ (r_amod) diet/NN (r_dobj) feeding/VBG (r_pcomp) by/IN (r_prep) intervention/NN (r_nsubj) sensitizes/VBZ (l_prep) to/IN (l_pobj) cardiotoxicity/NN
D000249_D009765 NONE AMP/NN (r_compound) alpha2/NN (r_compound) kinase/NN (r_dobj) decreased/VBD (r_ccomp) revealed/VBD (l_ccomp) sensitized/VBN (l_nsubjpass) rats/NNS (l_compound) OB/NNP -PUNC- AMP/NN (r_compound) alpha2/NN (r_compound) kinase/NN (r_dobj) decreased/VBD (l_nsubj) stress/NN (l_acl) activated/VBN (l_dobj) oxidation/NN (l_appos) heart/NN (l_prep) versus/IN (l_pobj) heart/NN (l_prep) in/IN (l_pobj) OB/NNP
D004317_D007674 NONE doxorubicin/NN (r_nmod) kg/NNS (r_appos) dose/NN (l_acl) administered/VBN (l_prep) on/IN (l_pobj) day/NN (l_nummod) 43/CD (l_prep) of/IN (l_pobj) regimen/NN (l_acl) led/VBD (l_prep) to/IN (l_pobj) cardiotoxicity/NN (l_conj) dysfunction/NN (l_conj) peroxidation/NN (l_conj) mortality/NN (l_prep) in/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) toxicity/NN
D004317_D056486 NONE doxorubicin/NN (r_nmod) kg/NNS (r_appos) dose/NN (l_acl) administered/VBN (l_prep) on/IN (l_pobj) day/NN (l_nummod) 43/CD (l_prep) of/IN (l_pobj) regimen/NN (l_acl) led/VBD (l_prep) to/IN (l_pobj) cardiotoxicity/NN (l_conj) dysfunction/NN (l_conj) peroxidation/NN (l_conj) mortality/NN (l_prep) in/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) toxicity/NN
D000244_D009765 NONE ADP/NNP (r_compound) ratio/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) drop/NN (r_conj) decreased/VBD (r_ccomp) revealed/VBD (l_ccomp) sensitized/VBN (l_nsubjpass) rats/NNS (l_compound) OB/NNP -PUNC- ADP/NNP (r_compound) ratio/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) drop/NN (r_conj) decreased/VBD (l_nsubj) stress/NN (l_acl) activated/VBN (l_dobj) oxidation/NN (l_appos) heart/NN (l_prep) versus/IN (l_pobj) heart/NN (l_prep) in/IN (l_pobj) OB/NNP
18083142
D003042_D001008 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- cocaine/NN (r_poss) effects/NNS (r_nsubjpass) studied/VBN (r_advcl) paid/VBN (l_dative) to/IN (l_pobj) states/NNS (l_acl) induced/VBN (l_agent) by/IN (l_pobj) cocaine/NN (l_prep) as/IN (l_pobj) anxiety/NN -PUNC- cocaine/NN (l_prep) as/IN (l_pobj) anxiety/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- cocaine/NN (r_nsubj) increased/VBN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN -PUNC- Cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN
D009638_D001008 NONE Norepinephrine/NN (r_compound) signaling/VBG (r_nsubj) is/VBZ (l_acomp) critical/JJ (l_prep) for/IN (l_pobj) expression/NN (l_prep) of/IN (l_pobj) anxiety/NN -PUNC- norepinephrine/NN (r_dobj) lack/VBP (r_relcl) mice/NNS (r_appos) knockout/NN (r_pobj) of/IN (r_prep) performance/NN (r_dobj) evaluated/VBD (l_advcl) examine/VB (l_dobj) contribution/NN (l_prep) of/IN (l_pobj) signaling/NN (l_prep) to/IN (l_pobj) anxiety/NN -PUNC- NE/NNP (r_appos) norepinephrine/NN (r_dobj) lack/VBP (r_relcl) mice/NNS (r_appos) knockout/NN (r_pobj) of/IN (r_prep) performance/NN (r_dobj) evaluated/VBD (l_advcl) examine/VB (l_dobj) contribution/NN (l_prep) of/IN (l_pobj) signaling/NN (l_prep) to/IN (l_pobj) anxiety/NN
D011224_D001008 NONE prazosin/NN (r_nsubj) had/VBD (r_advcl) pretreatment/NN (l_prep) with/IN (l_pobj) antagonist/NN (l_acl) propranolol/NN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
D015016_D001008 NONE yohimbine/NN (r_appos) antagonist/NN (r_conj) prazosin/NN (r_nsubj) had/VBD (r_advcl) pretreatment/NN (l_prep) with/IN (l_pobj) antagonist/NN (l_acl) propranolol/NN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
D011433_D001008 NONE propranolol/NN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
D004298_D001008 NONE dopamine/NN (r_compound) knockout/NN (r_pobj) of/IN (r_prep) performance/NN (r_dobj) evaluated/VBD (l_advcl) examine/VB (l_dobj) contribution/NN (l_prep) of/IN (l_pobj) signaling/NN (l_prep) to/IN (l_pobj) anxiety/NN -PUNC- dopamine/NN (r_nmod) hydroxylase/NN (r_nmod) inhibitor/NN (r_appos) administration/NN (r_pobj) following/VBG (r_prep) attenuated/VBN (l_nsubjpass) anxiety/NN
D004221_D001008 NONE disulfiram/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) attenuated/VBN (l_nsubjpass) anxiety/NN
11752354
D017135_D009203 NONE desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
D003276_D009203 CID contraceptives/NNS (l_conj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_pobj) of/IN (r_prep) use/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- contraceptive/NN (r_pobj) of/IN (r_prep) type/NN (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) among/IN (r_prep) infarction/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) Among/IN (r_prep) was/VBD (r_ccomp) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) among/IN (r_prep) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) among/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN
D016912_D009203 NONE levonorgestrel/JJ (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- levonorgestrel/JJ (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
D011372_D009203 NONE progestagen/NN (r_pobj) of/IN (r_prep) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- progestagen/NN (r_pobj) of/IN (r_prep) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
C033273_D009203 NONE gestodene/NN (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- gestodene/NN (r_conj) desogestrel/NN (r_appos) generation/NN (r_nmod) contraceptives/NNS (r_pobj) in/IN (r_prep) included/VBN (r_acl) type/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) investigated/VBD (l_conj) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
D004967_D009203 NONE estrogen/NN (r_pobj) of/IN (r_prep) dose/NN (r_dep) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN -PUNC- estrogen/NN (r_pobj) of/IN (r_prep) dose/NN (r_dep) identified/VBD (l_conj) enrolled/VBD (l_dobj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN (l_prep) between/IN (l_pobj) 1990/CD (l_conj) women/NNS (l_relcl) had/VBN (l_dobj) infarction/NN
3070035
D002216_D006978 NONE captopril/NN (r_npadvmod) induced/VBN (r_amod) insufficiency/NN (r_pobj) of/IN (r_prep) Reversibility/NN (l_prep) after/IN (l_pobj) use/NN (l_prep) in/IN (l_pobj) case/NN (l_prep) of/IN (l_pobj) hypertension/NN
D002216_D058186 CID captopril/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) deterioration/NN (l_prep) of/IN (l_pobj) function/NN
D002216_D051437 NONE captopril/NN (r_npadvmod) induced/VBN (r_amod) insufficiency/NN -PUNC- captopril/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
D002216_D006973 NONE captopril/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) deterioration/NN (r_dobj) developed/VBD (r_relcl) kidney/NN (r_pobj) to/IN (r_prep) artery/NN (r_pobj) with/IN (r_prep) hypertension/NN
1428568
D015784_D003866 NONE betaxolol/NN (r_nsubj) be/VB (l_attr) less/JJR (l_prep) of/IN (l_pobj) inducer/NN (l_compound) depression/NN
D013999_D003866 CID timolol/NN (r_compound) 0.5%/12h/CD (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) suffering/VBG (l_prep) from/IN (l_pobj) depression/NN -PUNC- timolol/NN (r_compound) treatment/NN (r_pobj) under/IN (r_prep) patients/NNS (r_nsubj) presented/VBD (l_dobj) values/NNS (l_compound) depression/NN -PUNC- timolol/NN (r_pobj) than/IN (r_prep) less/JJR (l_prep) of/IN (l_pobj) inducer/NN (l_compound) depression/NN
D013999_D005901 NONE timolol/NN (r_compound) 0.5%/12h/CD (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_amod) glaucomatous/JJ
17600377
D012601_D003072 CID scopolamine/NN (r_npadvmod) injected/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) decline/NN
C524754_D003704 NONE coumarate/NN (r_appos) compound/NN (r_nsubj) attenuates/VBZ (l_conj) shows/VBZ (l_dobj) effects/NNS (l_prep) in/IN (l_amod) vitro/FW (l_conj) in/IN (l_pobj) models/NNS (l_compound) dementia/NN
C524754_D000544 NONE coumarate/NN (r_nsubj) is/VBZ (l_attr) candidate/NN (l_prep) against/IN (l_pobj) disease/NN
C524754_D003072 NONE coumarate/NN (r_appos) compound/NN (r_nsubj) attenuates/VBZ (l_dobj) deficits/NNS -PUNC- coumarate/NN (r_nsubj) improve/VB (l_dobj) decline/NN -PUNC- coumarate/NN (r_nsubjpass) found/VBN (l_xcomp) attenuate/VB (l_dobj) deficits/NNS -PUNC- coumarate/NN (r_nsubj) is/VBZ (l_attr) candidate/NN (l_relcl) characterized/VBN (l_agent) by/IN (l_pobj) death/NN (l_conj) decline/NN (l_prep) of/IN (l_pobj) function/NN
C524754_D009410 NONE coumarate/NN (r_nsubj) is/VBZ (l_attr) candidate/NN (l_relcl) characterized/VBN (l_agent) by/IN (l_pobj) death/NN
C544092_D003072 NONE beta/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) decline/NN -PUNC- 42)-infused/VBN (r_amod) rats/NNS (r_dobj) beta/NN (r_advcl) found/VBN (l_xcomp) attenuate/VB (l_dobj) deficits/NNS
20067456
D016642_D012735 NONE bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- bupropion/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) determine/VB (r_csubj) induced/VBN (l_advcl) is/VBZ (l_nsubj) SD/NN -PUNC- Bupropion/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) SD/NN
D017367_D012735 NONE inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) dysfunction/NN -PUNC- inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advcl) is/VBZ (l_nsubj) SD/NN -PUNC- SSRI/NNP (r_appos) inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- SSRI/NNP (r_appos) inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- SSRI/NNP (r_appos) inhibitor/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advcl) is/VBZ (l_nsubj) SD/NN -PUNC- SSRIs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_advcl) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- SSRIs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_advcl) induced/VBN (l_csubj) determine/VB (l_dobj) safety/NN (l_prep) of/IN (l_pobj) bupropion/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_appos) SD/NN -PUNC- SSRIs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) SD/NN -PUNC- SSRI/NNP (r_pobj) of/IN (r_prep) type/NN (r_appos) SD/NN -PUNC- SSRIs/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) treatment/NN (l_prep) for/IN (l_pobj) SD/NN
19674115
D011718_D056486 NONE Pyrazinamide/NNP (r_nsubj) have/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) toxicity/NN
D011718_D033461 NONE Pyrazinamide/NNP (r_nsubj) have/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) toxicity/NN (l_conj) disorders/NNS (l_nmod) hyperuricemia/NN
D011718_D000857 CID pyrazinamide/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) dysosmia/NN -PUNC- pyrazinamide/VB (r_xcomp) related/VBN (r_acl) disorder/NN -PUNC- pyrazinamide/JJ (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) disappeared/VBD (l_nsubj) Dysosmia/NNP
9326871
D004917_D066126 NONE erythromycin/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) demonstrated/VBN (l_nsubjpass) Cardiotoxicity/NN
D018942_D066126 NONE macrolides/NNS (r_pobj) with/IN (r_prep) reported/VBN (r_conj) demonstrated/VBN (l_nsubjpass) Cardiotoxicity/NN
D018942_D005759 NONE macrolides/NNS (r_pobj) with/IN (r_prep) experience/NN (l_prep) including/VBG (l_pobj) gastroenteritis/JJ
D017291_D017180 CID Clarithromycin/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN
D017291_D001145 NONE clarithromycin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) after/IN (r_prep) occurred/VBD (r_relcl) dysrhythmias/NNS
D004917_D005759 CID erythromycin/NNP (r_pobj) of/IN (r_prep) profile/NN (r_nsubjpass) established/VBN (r_advcl) recorded/VBN (l_nsubjpass) experience/NN (l_prep) including/VBG (l_pobj) gastroenteritis/JJ
9875685
D014031_D064420 NONE tobramicyn/NN (l_prep) on/IN (l_pobj) concentrations/NNS (l_conj) toxicity/NN
D003404_D007674 NONE creatinine/NN (r_nsubjpass) observed/VBN (l_prep) without/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
1628552
D002738_D012164 CID chloroquine/NN (r_amod) retinopathy/NN
D002738_D006327 NONE Chloroquine/NNP (r_nsubj) related/VBD (l_dobj) block/NN -PUNC- chloroquine/NN (r_amod) retinopathy/NN (r_pobj) of/IN (r_prep) features/NNS (r_dobj) revealed/VBD (r_ccomp) revealed/VBD (l_dobj) features/NNS (l_conj) block/NN -PUNC- chloroquine/NN (r_amod) discontinuation/NN (r_dobj) following/VBG (r_prep) resolved/VBD (r_conj) treated/VBN (l_nsubjpass) block/NN
D002738_D015354 NONE chloroquine/NN (r_amod) ingestion/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) vision/NN
D002738_D001766 CID Chloroquine/NNP (r_nsubj) related/VBD (l_dobj) block/NN (l_prep) with/IN (l_pobj) blindness/NN
D002738_D002037 CID chloroquine/NN (r_amod) retinopathy/NN (r_pobj) of/IN (r_prep) features/NNS (r_dobj) revealed/VBD (r_ccomp) revealed/VBD (l_dobj) features/NNS (l_conj) block/NN (l_prep) with/IN (l_pobj) pattern/NN (l_compound) block/NN
D002738_D004244 CID chloroquine/NN (r_amod) ingestion/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) deterioration/NN (l_conj) fatiguability/NN (l_conj) dyspnoea/NN (l_conj) dizziness/NN
D002738_D013575 CID chloroquine/NN (r_amod) ingestion/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) deterioration/NN (l_conj) fatiguability/NN (l_conj) dyspnoea/NN (l_conj) dizziness/NN (l_acl) progressing/VBG (l_prep) to/IN (l_pobj) attacks/NNS
D002738_D004417 CID chloroquine/NN (r_amod) ingestion/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) deterioration/NN (l_conj) fatiguability/NN (l_conj) dyspnoea/NN
D002738_D006333 CID chloroquine/NN (r_amod) retinopathy/NN (r_pobj) of/IN (r_prep) features/NNS (r_dobj) revealed/VBD (r_ccomp) revealed/VBD (l_dobj) features/NNS (l_prep) of/IN (l_pobj) failure/NN -PUNC- chloroquine/NN (r_amod) discontinuation/NN (r_dobj) following/VBG (r_prep) resolved/VBD (l_nsubj) failure/NN
D002738_D005221 CID chloroquine/NN (r_amod) ingestion/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) deterioration/NN (l_conj) fatiguability/NN
20195852
D007472_D007674 CID iohexol/NN (r_conj) iopromide/JJ (r_appos) media/NNS (r_pobj) for/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP
D003287_D007674 CID media/NNS (r_dobj) contrast/NN (l_nsubj) Risk/NN (l_prep) of/IN (l_pobj) nephropathy/NN -PUNC- media/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- media/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (l_appos) CIN/NNP -PUNC- media/NNS (r_pobj) for/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_appos) media/NNS (r_pobj) for/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_pobj) of/IN (r_prep) type/NN (r_pobj) to/IN (r_prep) relation/NN (r_pobj) in/IN (r_prep) complication/NN (r_pobj) for/IN (r_prep) rates/NNS (r_dobj) compared/VBD (r_conj) among/IN (r_prep) determined/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_pobj) of/IN (r_prep) dosage/NN (r_dobj) received/VBD (r_relcl) those/DT (r_pobj) among/IN (r_prep) were/VBD (l_nsubj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_pobj) of/IN (r_prep) dosage/NN (r_dobj) received/VBD (r_relcl) those/DT (r_pobj) among/IN (r_prep) were/VBD (r_advcl) increased/VBD (l_prep) with/IN (l_pobj) difference/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_pobj) of/IN (r_prep) dosages/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) incidence/NN (r_pobj) in/IN (r_prep) difference/NN (r_pobj) with/IN (r_prep) increased/VBD (l_advcl) were/VBD (l_nsubj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_pobj) of/IN (r_prep) dosages/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP -PUNC- CM/NNP (r_pobj) of/IN (r_prep) type/NN (r_pobj) on/IN (r_conj) on/IN (r_prep) depends/VBZ (l_conj) needed/VBN (l_advcl) is/VBZ (l_nsubj) CIN/NNP
C038192_D003490 NONE iopromide/JJ (r_appos) media/NNS (r_pobj) for/IN (r_prep) incidence/NN (r_dobj) determined/VBD (l_prep) among/IN (l_conj) compared/VBD (l_dobj) rates/NNS (l_prep) for/IN (l_pobj) complication/NN (l_prep) in/IN (l_pobj) relation/NN (l_prep) to/IN (l_pobj) type/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) cyanosis/NN
D003287_D003490 NONE media/NNS (r_pobj) for/IN (r_prep) incidence/NN (r_dobj) determined/VBD (l_prep) among/IN (l_conj) compared/VBD (l_dobj) rates/NNS (l_prep) for/IN (l_pobj) complication/NN (l_prep) in/IN (l_pobj) relation/NN (l_prep) to/IN (l_pobj) type/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) cyanosis/NN -PUNC- CM/NNP (r_appos) media/NNS (r_pobj) for/IN (r_prep) incidence/NN (r_dobj) determined/VBD (l_prep) among/IN (l_conj) compared/VBD (l_dobj) rates/NNS (l_prep) for/IN (l_pobj) complication/NN (l_prep) in/IN (l_pobj) relation/NN (l_prep) to/IN (l_pobj) type/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) cyanosis/NN -PUNC- CM/NNP (r_pobj) of/IN (r_prep) type/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) cyanosis/NN -PUNC- CM/NNP (r_pobj) of/IN (r_prep) type/NN (r_pobj) on/IN (l_conj) on/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) cyanosis/NN
D007472_D003490 NONE iohexol/NN (r_conj) iopromide/JJ (r_appos) media/NNS (r_pobj) for/IN (r_prep) incidence/NN (r_dobj) determined/VBD (l_prep) among/IN (l_conj) compared/VBD (l_dobj) rates/NNS (l_prep) for/IN (l_pobj) complication/NN (l_prep) in/IN (l_pobj) relation/NN (l_prep) to/IN (l_pobj) type/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) cyanosis/NN
C038192_D007674 CID iopromide/JJ (r_appos) media/NNS (r_pobj) for/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) CIN/NNP
3827439
D000666_D005355 NONE B/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_acl) failure/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN
D000666_D058186 CID amphotericin/JJ (r_pobj) from/IN (r_prep) failure/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_acl) failure/NN -PUNC- amphotericin/JJ (r_advmod) propose/VBP (l_conj) activate/VB (l_advcl) contributing/VBG (l_prep) to/IN (l_pobj) failure/NN
D000666_D013174 NONE B/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_acl) failure/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_conj) disseminated/VBN (l_dobj) sporotrichosis/NN
11226639
D003975_D053608 CID diazepam/NN (r_npadvmod) induced/VBN (r_conj) ketamine-/NNS (r_nmod) narcosis/NN
D008550_D053608 CID melatonin/NN (l_prep) on/IN (l_pobj) narcosis/NN -PUNC- Melatonin/NNP (r_nsubj) affects/VBZ (l_conj) is/VBZ (l_ccomp) influence/VB (l_dobj) narcosis/NN -PUNC- Melatonin/NNP (r_nsubjpass) found/VBN (l_punct) ,/, (l_punct) affected/VBN (l_prep) in/IN (l_pobj) narcosis/NN -PUNC- melatonin/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) caused/VBD (l_conj) produced/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) narcosis/NN -PUNC- Melatonin/NNP (r_nsubj) influenced/VBD (l_dobj) duration/NN (l_conj) latency/NN (l_prep) of/IN (l_pobj) narcosis/NN -PUNC- melatonin/NN (l_prep) on/IN (l_pobj) narcosis/NN
C032232_D053608 NONE barbiturate/NN (r_npadvmod) induced/VBN (r_amod) narcosis/NN -PUNC- barbiturate/NN (r_compound) narcosis/NN -PUNC- barbiturate/NN (r_compound) narcosis/NN -PUNC- barbiturate/JJ (r_compound) mechanism/NN (r_pobj) for/IN (r_prep) specific/JJ (r_acomp) be/VB (r_xcomp) seems/VBZ (l_nsubj) action/NN (l_prep) of/IN (l_pobj) melatonin/NN (l_prep) on/IN (l_pobj) narcosis/NN
D007649_D053608 CID ketamine-/NNS (r_nmod) narcosis/NN
11256525
D000804_D014652 NONE II/NNP (r_compound) antagonist/NN (r_compound) losartan/NN (r_nsubj) cause/VB (l_dobj) complications/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D000809_D006333 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) activation/NN (r_pobj) in/IN (r_prep) resulted/VBD (l_nsubj) stenosis/NN (l_acl) combined/VBN (l_prep) with/IN (l_pobj) failure/NN
D000809_D012078 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) activation/NN (r_pobj) in/IN (r_prep) resulted/VBD (l_nsubj) stenosis/NN
D019808_D001002 CID losartan/NN (r_amod) administration/NN (r_dobj) following/VBG (r_prep) anuria/NN -PUNC- losartan/NN (r_amod) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) anuria/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) mg/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) anuria/NN -PUNC- losartan/NN (r_nsubjpass) prescribed/VBN (l_conj) developed/VBD (l_dobj) episode/NN (l_prep) of/IN (l_pobj) anuria/NN
D000588_D001002 NONE amine/NN (r_conj) furosemide/NN (r_nmod) infusion/NN (r_pobj) despite/IN (r_prep) lasted/VBD (r_relcl) anuria/NN
D019808_D006973 NONE losartan/NN (r_amod) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) kidney/NN (r_pobj) with/IN (r_prep) man/NN (l_amod) hypertensive/JJ
D019808_D014652 NONE losartan/NN (r_nsubj) cause/VB (l_dobj) complications/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D005665_D001002 NONE furosemide/NN (r_nmod) infusion/NN (r_pobj) despite/IN (r_prep) lasted/VBD (r_relcl) anuria/NN
D019808_D006331 NONE losartan/NN (l_compound) dysfunction/NN
D019808_D051436 NONE losartan/NN (r_amod) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) kidney/NN (l_conj) insufficiency/NN
9034419
C047426_D062787 CID venlafaxine/NNP (r_amod) overdose/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN -PUNC- venlafaxine/NN (r_pobj) of/IN (r_prep) overdose/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN
C047426_D003865 NONE venlafaxine/NN (r_pobj) of/IN (r_prep) overdose/NN (r_dobj) took/VBD (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) depression/NN
C047426_D012640 CID venlafaxine/NNP (r_amod) overdose/NN (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) Seizure/NN -PUNC- venlafaxine/NNP (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) After/IN (r_prep) experienced/VBD (l_dobj) seizure/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN (r_pobj) of/IN (r_prep) case/NN (l_relcl) resulted/VBD (l_prep) in/IN (l_pobj) seizure/NN -PUNC- venlafaxine/NNP (r_amod) overdose/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) episode/NN (l_prep) of/IN (l_pobj) seizure/NN
8319760
D019808_D011507 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN
D000804_D006937 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN
D000804_D011507 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN
D011692_D009404 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D011692_D006937 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN
D019808_D009401 NONE 753/CD (r_nummod) Dup/NN (r_nsubj) prevents/VBZ (l_dobj) development/NN (l_prep) of/IN (l_pobj) nephrosis/NN
D001806_D009404 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN (r_conj) hypoalbuminemia/NN (r_conj) proteinuria/NN (r_pobj) as/IN (r_prep) syndromes/NNS
D001806_D034141 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN (r_conj) hypoalbuminemia/NN
D019808_D006937 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN (l_conj) hypercholesterolemia/NN
D000804_D009404 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D019808_D009404 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D019808_D034141 NONE 753/CD (r_nummod) Dup/NN (r_nmod) losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN -PUNC- losartan/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN
D001806_D011507 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN (r_conj) hypoalbuminemia/NN (r_conj) proteinuria/NN
D011692_D011507 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN
D011692_D034141 CID aminonucleoside/NN (r_advmod) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN
D011692_D009401 NONE aminonucleoside/NN (r_advmod) induced/VBN (r_amod) nephrosis/NN -PUNC- aminonucleoside/NN (r_advmod) induced/VBN (r_amod) nephrosis/NN
D000809_D009401 NONE angiotensin/NN (r_compound) system/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) nephrosis/NN
D001806_D006937 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_conj) hypercholesterolemia/NN
D000804_D034141 NONE II/NNP (r_compound) antagonist/NN (r_appos) inhibited/VBN (l_ccomp) induced/VBN (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) proteinuria/NN (l_conj) hypoalbuminemia/NN
10193204
C009438_D013927 NONE tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- TET/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C060802_D013927 NONE fangchinoline/NN (r_conj) tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C009438_D001778 NONE TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN
D001241_D013927 NONE acid/NN (r_dobj) acetylsalicylic/JJ (r_advcl) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN -PUNC- ASA/NNP (r_appos) acid/NN (r_dobj) acetylsalicylic/JJ (r_advcl) showed/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C060802_D001791 NONE fangchinoline/NN (r_conj) tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN (l_prep) in/IN (l_pobj) mice/NNS (l_conj) aggregation/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN -PUNC- FAN/NNP (r_conj) TET/NNP (r_nsubj) showed/VBD (l_prep) In/IN (l_pobj) aggregations/NNS
D004837_D001791 NONE epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN -PUNC- EP/NN (r_appos) epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN
C060802_D001778 NONE FAN/NNP (r_conj) TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN
C009438_D001791 NONE tetrandrine/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) thrombosis/NN (l_prep) in/IN (l_pobj) mice/NNS (l_conj) aggregation/NN -PUNC- TET/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN -PUNC- TET/NNP (r_nsubj) showed/VBD (l_prep) In/IN (l_pobj) aggregations/NNS
D004837_D001778 NONE epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN -PUNC- EP/NN (r_appos) epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) undertaken/VBN (l_conj) in/IN (l_nsubj) aggregation/NN (l_conj) coagulation/NN
D004837_D013927 CID epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN -PUNC- EP/NN (r_appos) epinephrine/NN (r_conj) collagen/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) thrombosis/NN
3714122
C005238_D013118 CID Mipafox/NNP (r_pobj) of/IN (r_prep) dosages/NNS (r_nsubj) produced/VBN (l_dobj) degree/NN (l_prep) of/IN (l_pobj) damage/NN
C005238_D020258 NONE mipafox/NN (r_npadvmod) induced/VBN (r_amod) damage/NN (r_conj) inhibition/NN (l_amod) neurotoxic/JJ -PUNC- Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_amod) neurotoxic/JJ -PUNC- Mipafox/NNP (l_appos) organophosphate/NN (l_amod) neurotoxic/JJ -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_amod) neurotoxic/JJ -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (l_appos) organophosphate/NN (l_amod) neurotoxic/JJ
D010755_D009422 NONE organophosphate/NN (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN -PUNC- organophosphate/NN (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_conj) enzyme/NN (l_compound) target/NN (l_compound) neuropathy/NN
C005238_D009422 NONE mipafox/NN (r_npadvmod) induced/VBN (r_amod) damage/NN -PUNC- Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN -PUNC- Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_conj) enzyme/NN (l_compound) target/NN (l_compound) neuropathy/NN -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN -PUNC- N'-diisopropylphosphorodiamidofluoridate/NNP (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_conj) enzyme/NN (l_compound) target/NN (l_compound) neuropathy/NN -PUNC- Mipafox/NNP (r_compound) exposure/NN (r_nsubj) predict/VB (l_dobj) damage/NN
D010755_D020258 NONE organophosphate/NN (r_appos) Mipafox/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) examined/VBN (l_nsubjpass) correlation/NN (l_prep) between/IN (l_pobj) damage/NN (l_prep) of/IN (l_pobj) esterase/NN (l_amod) neurotoxic/JJ -PUNC- organophosphate/NN (l_amod) neurotoxic/JJ
17241784
D019821_-1 NONE Statins/NNS (r_nsubj) cause/VB (l_ccomp) myopathy/NN (l_conj) hyperCKaemia/NN
D019821_D009135 CID statin/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) myopathy/NNS -PUNC- Statins/NNS (r_nsubj) cause/VB (l_ccomp) myopathy/NN -PUNC- statins/NNS (r_nsubj) induce/VB (l_dobj) myopathy/NN -PUNC- statins/NNS (r_nsubj) initiate/VB (l_dobj) myopathy/NN -PUNC- statins/NNS (r_pobj) by/IN (r_prep) induction/NN (r_dobj) involve/VB (r_conj) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) myopathy/NN
1616457
D010424_D000647 CID pentobarbital/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) amnesia/NN -PUNC- pentobarbital/NN (r_nmod) ip/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) amnesia/NN
435349
D013390_D013746 NONE Sch/NNP (r_nsubjpass) exceeded/VBN (r_advcl) was/VBD (l_attr) response/NN (l_prep) to/IN (l_pobj) stimulation/NN (l_compound) tetanic/JJ
D013390_D005207 CID Suxamethonium/JJ (r_compound) rate/NN (l_conj) observed/JJ (l_dobj) fasciculations/NNS
12596116
D015282_D006976 CID Octreotide/NNP (r_npadvmod) induced/VBN (l_dobj) hypoxemia/NN (l_conj) hypertension/NN -PUNC- octreotide/NN (r_advmod) developed/VBD (l_nsubj) hypertension/NN
D015282_D000860 NONE Octreotide/NNP (r_npadvmod) induced/VBN (l_dobj) hypoxemia/NN
D015282_D005402 NONE octreotide/NN (r_advmod) developed/VBD (l_advcl) enhance/VB (l_dobj) resolution/NN (l_prep) of/IN (l_pobj) fistula/NN
14704468
C066440_D012640 NONE Loreclezole/NNP (r_nsubj) exerted/VBD (l_advcl) reducing/VBG (l_dobj) seizure/NN
10901305
D007649_D050723 NONE Ketamine/NN (l_dobj) sedation/NN (l_prep) for/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) fractures/NNS -PUNC- ketamine/NN (l_prep) for/IN (l_pobj) sedation/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) fractures/NNS -PUNC- ketamine/NN (l_prep) to/IN (l_pobj) manipulation/NN (l_prep) of/IN (l_pobj) fracture/NN -PUNC- Ketamine/NNP (r_nsubj) provided/VBD (l_dobj) sedation/NN (l_acl) facilitate/VB (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) fractures/NNS
D007649_D004204 NONE ketamine/NN (l_prep) to/IN (l_pobj) manipulation/NN (l_prep) of/IN (l_pobj) fracture/NN (l_conj) dislocation/NN
7651879
D005442_D012640 CID flumazenil/JJ (r_compound) administration/NN (r_pobj) after/IN (r_prep) Seizure/NN -PUNC- flumazenil/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) seizure/NN
D005442_D012131 NONE Flumazenil/NNP (r_nsubj) is/VBZ (l_attr) antagonist/NN (l_acl) used/VBD (l_xcomp) reverse/VB (l_dobj) sedation/NN (l_conj) depression/NN
D001569_D012131 NONE benzodiazepine/JJ (r_amod) antagonist/NN (l_acl) used/VBD (l_xcomp) reverse/VB (l_dobj) sedation/NN (l_conj) depression/NN -PUNC- benzodiazepines/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) sedation/NN (l_conj) depression/NN
12760988
D003907_D063806 NONE dexamethasone/NN (r_conj) saline/NN (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- dexamethasone/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_nsubj) complained/VBD (r_acl) groups/NNS (r_pobj) between/IN (r_prep) differ/VB (l_nsubj) Incidence/NN (l_conj) severity/NN (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- dexamethasone/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_nsubj) complained/VBD (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- dexamethasone/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_nsubj) complained/VBD (l_conj) reported/VBN (l_nsubjpass) myalgia/NN
D013390_D063806 CID succinylcholine/NN (r_npadvmod) associated/VBN (r_amod) myalgia/NN -PUNC- succinylcholine/NN (r_pobj) before/IN (r_prep) pretreated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- succinylcholine/NN (r_npadvmod) associated/VBN (r_amod) myalgia/NN
D013390_D010149 CID succinylcholine/NN (r_pobj) after/IN (r_prep) myalgia/NN -PUNC- succinylcholine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) effect/NN (r_nsubj) is/VBZ (l_attr) myalgia/NN -PUNC- succinylcholine/NN (r_pobj) before/IN (r_punct) IMPLICATIONS/NNS (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) decreasing/VBG (l_dobj) incidence/NN (l_conj) severity/NN (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- succinylcholine/NN (r_npadvmod) induced/VBN (r_amod) myalgia/NN -PUNC- succinylcholine/NN (r_pobj) after/IN (r_prep) prevent/VB (l_dobj) myalgia/NN
D003907_D010149 NONE dexamethasone/NN (r_pobj) of/IN (r_prep) Administration/NN (r_appos) IMPLICATIONS/NNS (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) decreasing/VBG (l_dobj) incidence/NN (l_conj) severity/NN (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- dexamethasone/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) is/VBZ (l_acomp) justified/VBN (l_xcomp) prevent/VB (l_dobj) myalgia/NN
11079278
D004280_D017202 CID dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dobutamine/NN (r_pcomp) During/IN (r_prep) attenuates/VBZ (l_conj) eliminates/VBZ (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) ischemia/NN
D008790_D017202 NONE metoprolol/NN (l_conj) metoprolol/NN (l_conj) glucagon/NN (l_prep) on/IN (l_pobj) ischemia/NN -PUNC- metoprolol/NN (l_conj) glucagon/NN (l_prep) on/IN (l_pobj) ischemia/NN -PUNC- metoprolol/FW (r_nsubj) attenuates/VBZ (l_conj) eliminates/VBZ (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) ischemia/NN
3676049
D010100_D007022 NONE oxygen/NN (r_pobj) for/IN (r_prep) rate/NN (r_conj) flow/NN (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) hypotension/NN
D010100_D002532 NONE oxygen/NN (r_pobj) for/IN (r_prep) rate/NN (r_conj) flow/NN (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) hypotension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) subjected/VBN (l_prep) to/IN (l_pobj) craniotomy/NN (l_prep) for/IN (l_pobj) clipping/NN (l_prep) of/IN (l_pobj) aneurysm/NN
D008628_D007022 NONE Hg/NNP (r_pobj) of/IN (r_prep) MAP/NNP (r_pobj) to/IN (r_prep) hypotension/NN
D007530_D000783 NONE isoflurane/JJ (r_amod) concentration/NN (r_nsubjpass) reduced/VBN (l_prep) After/IN (l_pobj) clipping/NN (l_prep) of/IN (l_pobj) aneurysm/NN
D014978_D013345 NONE xenon-133/. (r_punct) measured/VBN (l_prep) after/IN (l_pobj) haemorrhage/NN
D007530_D007022 CID isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- isoflurane/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) increasing/VBG (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubjpass) hypotension/NN
D007530_D002532 NONE isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) subjected/VBN (l_prep) for/IN (l_pobj) aneurysms/NNS -PUNC- isoflurane/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) subjected/VBN (l_prep) to/IN (l_pobj) craniotomy/NN (l_prep) for/IN (l_pobj) clipping/NN (l_prep) of/IN (l_pobj) aneurysm/NN
18006530
C071741_D010146 NONE remifentanil/NN (r_conj) propofol/NN (r_pobj) with/IN (r_prep) induction/NN (r_pobj) during/IN (r_prep) Reduction/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- remifentanil/NN (r_dobj) infusing/VBG (r_pcomp) by/IN (r_prep) prevented/VBN (l_nsubjpass) pain/NN -PUNC- remifentanil/NN (r_pobj) of/IN (r_prep) Ce/NNP (r_appos) concentration/NN (l_relcl) prevent/VB (l_dobj) pain/NN -PUNC- Remifentanil/NN (r_npadvmod) related/VBN (r_amod) complications/NNS (r_nsubjpass) assessed/VBN (l_conj) evaluated/VBN (l_nsubjpass) pain/NN -PUNC- remifentanil/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) assessed/VBN (l_conj) evaluated/VBN (l_nsubjpass) pain/NN -PUNC- remifentanil/NN (r_conj) propofol/NN (r_pobj) of/IN (r_prep) anaesthesia/NN (r_pobj) of/IN (r_prep) induction/NN (r_pobj) During/IN (r_prep) achieved/VBN (l_nsubjpass) reduction/NN (l_prep) in/IN (l_pobj) pain/NN -PUNC- remifentanil/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) complications/NNS (r_pobj) without/IN (r_prep) achieved/VBN (l_nsubjpass) reduction/NN (l_prep) in/IN (l_pobj) pain/NN
D015742_D010146 CID propofol/NN (r_pobj) with/IN (r_prep) induction/NN (r_pobj) during/IN (r_prep) Reduction/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- propofol/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) on/IN (r_prep) Pain/NN -PUNC- propofol/JJ (r_amod) pain/NN -PUNC- propofol/JJ (r_amod) infusion/NN (r_dobj) starting/VBG (r_pcomp) before/IN (r_prep) infusing/VBG (r_pcomp) by/IN (r_prep) prevented/VBN (l_nsubjpass) pain/NN -PUNC- propofol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) pain/NN -PUNC- propofol/JJ (r_amod) infusion/NN (r_pobj) during/IN (r_prep) using/VBG (r_advcl) evaluated/VBN (l_nsubjpass) pain/NN -PUNC- propofol/NN (r_pobj) of/IN (r_prep) anaesthesia/NN (r_pobj) of/IN (r_prep) induction/NN (r_pobj) During/IN (r_prep) achieved/VBN (l_nsubjpass) reduction/NN (l_prep) in/IN (l_pobj) pain/NN -PUNC- propofol/JJ (r_amod) pain/NN
7930386
D002997_D012893 CID Clomipramine/NNP (r_npadvmod) induced/VBN (r_amod) disturbance/NN -PUNC- clomipramine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_conj) examine/VB (l_dobj) role/NN (l_prep) of/IN (l_pobj) disturbance/NN
2670794
D000809_D004211 NONE angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_amod) due/IN (l_pobj) coagulation/NN
D002216_D007674 NONE Captopril/NNP (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) damage/NN -PUNC- Captopril/NNP (r_nsubj) reduce/VB (l_advcl) diminishing/VBG (l_prep) with/IN (l_pobj) result/NN (l_acl) deposited/VBN (l_conj) produced/VBN (l_nsubjpass) damage/NN
D000809_D051437 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D014148_D004211 CID acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (l_prep) of/IN (l_pobj) coagulation/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (l_prep) of/IN (l_pobj) coagulation/NN
D002216_D051437 NONE Captopril/NNP (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- Captopril/NNP (r_pobj) of/IN (r_prep) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D014148_D051437 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN
D014148_D014947 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN
D002216_D011665 NONE Captopril/NNP (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- Captopril/NNP (r_pobj) of/IN (r_prep) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D000809_D011665 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) insufficiency/NN -PUNC- angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) Injection/NN (r_nsubj) reduced/VBD (l_dobj) insufficiency/NN
D002216_D004211 NONE Captopril/NNP (r_appos) enzyme/NN (r_dobj) converting/VBG (r_acl) angiotensin/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_amod) due/IN (l_pobj) coagulation/NN
D014148_D011665 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_dobj) rise/NN (l_prep) to/IN (l_pobj) insufficiency/NN
D014508_D007674 NONE urea/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) by/IN (r_agent) reflected/VBN (r_advcl) damage/NN
D014148_D018805 NONE acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN (l_conj) sepsis/NN -PUNC- AMCA/NNP (r_appos) acid/NN (r_conj) thrombin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_prep) Induction/NN (r_nsubj) gives/VBZ (l_advcl) resembling/VBG (l_ccomp) occurring/VBG (l_prep) after/IN (l_pobj) trauma/NN (l_conj) sepsis/NN
12198388
D000109_D012640 NONE acetylcholine/NN (r_compound) release/NN (l_conj) sensitivity/NN (l_prep) in/IN (l_pobj) lines/NNS (l_amod) prone/JJ (l_npadvmod) seizure/NN -PUNC- acetylcholine/NN (r_compound) release/NN (l_conj) sensitivity/NN (l_prep) in/IN (l_pobj) lines/NNS (l_amod) resistant/JJ (l_npadvmod) seizure/NN -PUNC- ACh/NNS (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) testing/VBG (l_prep) for/IN (l_pobj) convulsions/NNS -PUNC- ACh/NNS (r_nsubjpass) measured/VBN (l_prep) during/IN (l_pobj) testing/VBG (l_prep) for/IN (l_pobj) convulsions/NNS -PUNC- ACh/NNS (r_nsubjpass) elevated/JJ (l_advcl) measured/VBN (l_prep) during/IN (l_pobj) testing/VBG (l_prep) for/IN (l_pobj) convulsions/NNS
D002217_D014202 NONE carbachol/NN (r_conj) nicotine/NN (r_dobj) administered/VBN (l_conj) recorded/VBN (l_nsubjpass) latencies/NNS (l_relcl) onset/VB (l_prep) of/IN (l_pobj) tremor/NN
D009388_D014202 NONE neostigmine/JJ (r_conj) carbachol/NN (r_conj) nicotine/NN (r_dobj) administered/VBN (l_conj) recorded/VBN (l_nsubjpass) latencies/NNS (l_relcl) onset/VB (l_prep) of/IN (l_pobj) tremor/NN
D009388_D012640 CID neostigmine/NN (r_conj) Sensitivity/NN (l_prep) to/IN (l_pobj) endpoints/NNS (l_compound) convulsion/NN
D000431_D012640 NONE alcohol/NN (r_compound) na/TO (r_aux) ve/VB (l_dobj) mice/NNS (l_nmod) Prone/NNP (l_compound) Seizure/NN -PUNC- ethanol/NN (r_compound) withdrawal/NN (r_compound) severity/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) differences/NNS (l_prep) in/IN (l_pobj) activity/NN (l_conj) sensitivity/NN (l_prep) to/IN (l_pobj) convulsants/NNS -PUNC- alcohol/NN (r_compound) withdrawal/NN (r_pobj) in/IN (r_prep) mechanisms/NNS (r_dobj) implicate/VB (r_conj) associated/VBN (l_nsubjpass) differences/NNS (l_prep) in/IN (l_pobj) activity/NN (l_conj) sensitivity/NN (l_prep) to/IN (l_pobj) convulsants/NNS
D002217_D012640 CID carbachol/NN (r_conj) nicotine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) endpoints/NNS (l_compound) convulsion/NN
D009538_D012640 CID nicotine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) endpoints/NNS (l_compound) convulsion/NN
D009538_D014202 NONE nicotine/NN (r_dobj) administered/VBN (l_conj) recorded/VBN (l_nsubjpass) latencies/NNS (l_relcl) onset/VB (l_prep) of/IN (l_pobj) tremor/NN
18356633
D000583_D007239 NONE Amikacin/NNP (r_nsubj) is/VBZ (l_attr) aminoglycoside/NN (l_acl) used/VBN (l_xcomp) provide/VB (l_dobj) treatment/NN (l_prep) for/IN (l_pobj) neutropenia/NN (l_conj) infections/NNS
D000583_D009369 NONE amikacin/JJ (r_pobj) to/IN (r_prep) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_amod) consistent/JJ (l_prep) with/IN (l_pobj) disorder/NN
D000583_D007674 CID amikacin/JJ (r_amod) nephrotoxicity/NN -PUNC- amikacin/RB (r_npadvmod) associated/VBN (r_amod) nephrotoxicity/NN -PUNC- amikacin/JJ (r_prep) via/IN (r_prep) evaluation/NN (r_conj) creatinine/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) of/IN (r_prep) means/NNS (r_pobj) by/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D000583_D006402 NONE amikacin/JJ (r_pobj) to/IN (r_prep) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_amod) consistent/JJ (l_prep) with/IN (l_pobj) disorder/NN
D003404_D007674 NONE creatinine/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) of/IN (r_prep) means/NNS (r_pobj) by/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D000617_D007239 NONE aminoglycoside/NN (l_acl) used/VBN (l_xcomp) provide/VB (l_dobj) treatment/NN (l_prep) for/IN (l_pobj) neutropenia/NN (l_conj) infections/NNS
D000617_D006402 NONE aminoglycoside/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) required/VBD (r_relcl) disorder/NN
D000617_D009369 NONE aminoglycoside/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) required/VBD (r_relcl) disorder/NN
D000617_D009503 NONE aminoglycoside/NN (l_acl) used/VBN (l_xcomp) provide/VB (l_dobj) treatment/NN (l_prep) for/IN (l_pobj) neutropenia/NN
D000583_D009503 NONE Amikacin/NNP (r_nsubj) is/VBZ (l_attr) aminoglycoside/NN (l_acl) used/VBN (l_xcomp) provide/VB (l_dobj) treatment/NN (l_prep) for/IN (l_pobj) neutropenia/NN
12443032
D003042_D002637 CID Cocaine/NN (r_nsubj) related/VBN (l_dobj) pain/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) tendency/NN (l_acl) produce/VB (l_dobj) pain/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) tendency/NN (r_nsubj) ought/MD (l_xcomp) be/VB (l_advcl) faced/VBN (l_prep) with/IN (l_pobj) victim/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) mechanism/NN (l_prep) of/IN (l_pobj) pain/NN
9270571
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_dobj) conducted/VBD (l_advcl) evaluate/VB (l_dobj) effects/NNS (l_amod) locomotor/NN (l_conj) dyskinetic/JJ -PUNC- levodopa/NN (r_pobj) as/IN (r_prep) alleviating/VBG (r_pcomp) in/IN (r_prep) efficacious/JJ (r_acomp) was/VBD (l_conj) was/VBD (l_acomp) likely/JJ (l_xcomp) reproduce/VB (l_dobj) dyskinesias/NNS -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) challenge/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) reproduce/VB (l_dobj) dyskinesias/NNS
C095427_D004409 NONE A-86929/NNS (r_punct) ,/, (r_punct) doses/NNS (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) evaluate/VB (r_advcl) conducted/VBD (l_dobj) dyskinesias/NNS -PUNC- A-86929/NNS (r_punct) ,/, (r_punct) doses/NNS (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) on/IN (r_prep) effects/NNS (l_amod) locomotor/NN (l_conj) dyskinetic/JJ -PUNC- 10-diol/JJ (r_punct) )/-RRB- (r_punct) ,/, (r_punct) doses/NNS (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) evaluate/VB (r_advcl) conducted/VBD (l_dobj) dyskinesias/NNS -PUNC- 10-diol/JJ (r_punct) )/-RRB- (r_punct) ,/, (r_punct) doses/NNS (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) on/IN (r_prep) effects/NNS (l_amod) locomotor/NN (l_conj) dyskinetic/JJ -PUNC- A-86929/NNS (r_punct) was/VBD (l_conj) was/VBD (l_acomp) likely/JJ (l_xcomp) reproduce/VB (l_dobj) dyskinesias/NNS
C416545_D020734 NONE LY-171555/NNP (r_conj) levodopa/NN (r_pobj) as/IN (r_prep) alleviating/VBG (l_dobj) parkinsonism/NN -PUNC- LY-171555/NNP (r_amod) challenge/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) reproduce/VB (r_xcomp) likely/JJ (r_acomp) was/VBD (r_conj) was/VBD (l_acomp) efficacious/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) parkinsonism/NN
D004298_D004409 NONE DA/NNP (r_compound) agonist/NN (r_appos) doses/NNS (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) on/IN (r_prep) effects/NNS (r_dobj) evaluate/VB (r_advcl) conducted/VBD (l_dobj) dyskinesias/NNS -PUNC- DA/NNP (r_compound) agonist/NN (r_appos) doses/NNS (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) on/IN (r_prep) effects/NNS (l_amod) locomotor/NN (l_conj) dyskinetic/JJ
D015632_D020734 CID MPTP/NNP (r_npadvmod) induced/VBN (r_amod) parkinsonism/NN
C416545_D004409 NONE LY-171555/NNP (r_conj) levodopa/NN (r_pobj) as/IN (r_prep) alleviating/VBG (r_pcomp) in/IN (r_prep) efficacious/JJ (r_acomp) was/VBD (l_conj) was/VBD (l_acomp) likely/JJ (l_xcomp) reproduce/VB (l_dobj) dyskinesias/NNS -PUNC- LY-171555/NNP (r_amod) challenge/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) reproduce/VB (l_dobj) dyskinesias/NNS
C095427_D010300 NONE A-86929/NNS (r_punct) agents/NNS (r_nsubj) are/VBP (l_attr) tools/NNS (l_prep) in/IN (l_pobj) PD/NNP
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/CD (r_pobj) in/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_dobj) dyskinesias/NNS -PUNC- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/CD (r_pobj) in/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) evaluate/VB (l_dobj) effects/NNS (l_amod) locomotor/NN (l_conj) dyskinetic/JJ -PUNC- MPTP)-exposed/VBN (r_amod) monkeys/NNS (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/CD (r_pobj) in/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_dobj) dyskinesias/NNS -PUNC- MPTP)-exposed/VBN (r_amod) monkeys/NNS (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/CD (r_pobj) in/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) evaluate/VB (l_dobj) effects/NNS (l_amod) locomotor/NN (l_conj) dyskinetic/JJ -PUNC- MPTP/NNP (r_npadvmod) induced/VBN (r_amod) parkinsonism/NN (r_dobj) alleviating/VBG (r_pcomp) in/IN (r_prep) efficacious/JJ (r_acomp) was/VBD (l_conj) was/VBD (l_acomp) likely/JJ (l_xcomp) reproduce/VB (l_dobj) dyskinesias/NNS
C095427_D020734 NONE A-86929/NNS (l_dep) study/NN (l_prep) in/IN (l_pobj) monkeys/NNS (l_amod) parkinsonian/JJ -PUNC- A-86929/NNS (r_punct) was/VBD (l_acomp) efficacious/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) parkinsonism/NN
D007980_D020734 NONE levodopa/NN (r_npadvmod) primed/VBN (r_amod) monkeys/NNS (l_amod) parkinsonian/JJ -PUNC- levodopa/NN (r_pobj) as/IN (r_prep) alleviating/VBG (l_dobj) parkinsonism/NN -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_dobj) reproduce/VB (r_xcomp) likely/JJ (r_acomp) was/VBD (r_conj) was/VBD (l_acomp) efficacious/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) parkinsonism/NN -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) challenge/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) reproduce/VB (r_xcomp) likely/JJ (r_acomp) was/VBD (r_conj) was/VBD (l_acomp) efficacious/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) parkinsonism/NN
D004298_D010300 NONE dopamine/NN (r_pobj) of/IN (r_prep) utility/NN (l_appos) agonists/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- dopamine/NN (r_pobj) of/IN (r_prep) utility/NN (l_appos) agonists/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- DA/NNP (r_nmod) agonists/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- DA/NNP (r_nmod) agonists/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- DA/NNP (r_compound) D1/NN (r_compound) agents/NNS (r_nsubj) are/VBP (l_attr) tools/NNS (l_prep) in/IN (l_pobj) PD/NNP
3780814
D004052_D063646 NONE diethylnitrosamine/NN (r_pobj) with/IN (r_prep) given/VBN (r_prep) action/NN (l_amod) carcinogenic/JJ -PUNC- diethylnitrosamine/JJ (r_pobj) with/IN (r_prep) administered/VBN (r_advcl) elucidate/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) carcinogenesis/NN -PUNC- DEN/NNP (r_parataxis) planned/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) carcinogenesis/NN -PUNC- DEN/NNP (r_pobj) by/IN (r_agent) treated/VBN (l_prep) according/VBG (l_prep) to/IN (l_pobj) schedule/NN (l_prep) for/IN (l_pobj) hepatocarcinogenesis/NN -PUNC- DEN/NNP (r_pobj) by/IN (r_conj) by/IN (r_agent) treated/VBN (l_prep) according/VBG (l_prep) to/IN (l_pobj) schedule/NN (l_prep) for/IN (l_pobj) hepatocarcinogenesis/NN -PUNC- DEN/NNP (r_compound) treatment/NN (r_pobj) after/IN (r_prep) administered/VBN (r_advcl) promotes/VBZ (l_dobj) carcinogenesis/NN -PUNC- DEN/NNP (r_pobj) with/IN (r_prep) given/VBN (r_advcl) reduces/VBZ (l_nsubj) PB/NNP (l_relcl) promotes/VBZ (l_dobj) carcinogenesis/NN
D004052_D009369 NONE DEN/NNP (r_nsubj) treated/VBN (r_ccomp) was/VBD (l_conj) decreased/VBD (l_nsubj) incidence/NN (l_compound) tumor/NN -PUNC- DEN/NNP (r_pobj) by/IN (r_agent) obtained/VBN (r_acl) results/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) as/IN (r_prep) decreased/VBD (l_nsubj) incidence/NN (l_compound) tumor/NN
D010634_D011230 NONE PB/NNP (r_nsubjpass) given/VBN (r_advcl) reduced/VBN (l_nsubjpass) number/NN (l_conj) size/NN (l_prep) of/IN (l_pcomp) induced/VBN (l_dobj) foci/NN
D010634_D009369 NONE PB/NNP (r_conj) DEN/NNP (r_nsubj) treated/VBN (r_ccomp) was/VBD (l_conj) decreased/VBD (l_nsubj) incidence/NN (l_compound) tumor/NN
D004052_D011230 CID DEN/NNP (r_pobj) with/IN (r_prep) given/VBN (r_advcl) reduced/VBN (l_nsubjpass) number/NN (l_conj) size/NN (l_prep) of/IN (l_pcomp) induced/VBN (l_dobj) foci/NN
D010634_D063646 NONE phenobarbital/JJ (r_pobj) of/IN (r_prep) action/NN (l_amod) carcinogenic/JJ -PUNC- phenobarbital/JJ (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) carcinogenesis/NN -PUNC- PB/NNP (r_appos) phenobarbital/JJ (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) carcinogenesis/NN -PUNC- PB/NNP (r_conj) DEN/NNP (r_pobj) by/IN (r_conj) by/IN (r_agent) treated/VBN (l_prep) according/VBG (l_prep) to/IN (l_pobj) schedule/NN (l_prep) for/IN (l_pobj) hepatocarcinogenesis/NN -PUNC- PB/NNP (l_relcl) promotes/VBZ (l_dobj) carcinogenesis/NN
8278214
D009020_D009369 NONE morphine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_compound) cancer/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_compound) cancer/NN
D009020_D009207 CID morphine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) myoclonus/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_conj) myoclonus/NN -PUNC- morphine/NN (r_nsubj) plays/VBZ (r_ccomp) indicates/VBZ (l_advcl) are/VBP (l_nsubj) descriptions/NNS (l_prep) of/IN (l_pobj) relationship/NN (l_prep) between/IN (l_pobj) myoclonus/NN
D009020_D006930 CID morphine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) myoclonus/NN (r_conj) Hyperalgesia/NNP -PUNC- morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) developed/VBN (l_dobj) hyperalgesia/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_conj) myoclonus/NN (l_nmod) hyperalgesia/NN -PUNC- morphine/NN (r_nsubj) plays/VBZ (r_ccomp) indicates/VBZ (l_advcl) are/VBP (l_nsubj) descriptions/NNS (l_prep) of/IN (l_pobj) relationship/NN (l_prep) between/IN (l_pobj) myoclonus/NN (l_nmod) hyperalgesia/NN
7504976
D002231_D056486 CID carbimazole/NN (r_pobj) between/IN (r_prep) reactivity/NN (r_pobj) with/IN (r_prep) one/CD (r_pobj) including/VBG (r_prep) cases/NNS (r_appos) induced/VBN (l_nsubj) hepatitis/NN -PUNC- carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- omercazole/NN (r_appos) carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- carbimazole/NN (l_amod) following/VBG (l_compound) hepatitis/NN -PUNC- carbimazole/NN (r_dobj) replaced/VBN (l_nsubj) experienced/VBD (l_dobj) hepatitis/NN
C019269_D056486 NONE benzylthiouracil/NN (r_conj) carbimazole/NN (r_pobj) between/IN (r_prep) reactivity/NN (r_pobj) with/IN (r_prep) one/CD (r_pobj) including/VBG (r_prep) cases/NNS (r_appos) induced/VBN (l_nsubj) hepatitis/NN -PUNC- Benzylthiouracil/NNP (r_pobj) after/IN (r_prep) appeared/VBD (r_relcl) hepatitis/NN -PUNC- ne/NNP (r_appos) Benzylthiouracil/NNP (r_pobj) after/IN (r_prep) appeared/VBD (r_relcl) hepatitis/NN
D002231_D002779 CID carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- omercazole/NN (r_appos) carbimazole/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN -PUNC- carbimazole/NN (l_amod) mixed/JJ (l_conj) cholestatic/JJ
6111982
D011433_D001145 NONE propranolol/NN (l_conj) pindolol/NN (l_xcomp) inhibiting/VBG (l_dobj) arrhythmia/NN
D010869_D001145 NONE pindolol/NN (l_xcomp) inhibiting/VBG (l_dobj) arrhythmia/NN
D010042_D001145 CID ouabain/JJ (r_compound) arrhythmia/NN
8423889
D005473_D009069 CID fluoxetine/NN (r_amod) medication/NN (r_pobj) after/IN (r_prep) Increase/NNP (l_prep) of/IN (l_pobj) disability/NN -PUNC- fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) of/IN (l_pobj) disability/NN
D005473_D010300 NONE fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- fluoxetine/NN (r_pobj) of/IN (r_prep) capacity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
D000928_D009069 NONE antidepressant/JJ (r_amod) fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) of/IN (l_pobj) disability/NN
D000928_D010300 NONE antidepressant/JJ (r_amod) fluoxetine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) amount/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D004298_D010300 NONE dopamine/NN (r_npadvmod) antagonistic/JJ (r_amod) capacity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
3409645
D008727_D007172 CID methotrexate/NNP (r_pobj) of/IN (r_prep) taking/NN (r_conj) was/VBD (l_nsubj) Impotence/NN
9758264
D005492_D012640 CID acid/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) triggered/VBD (l_dobj) cluster/NN (l_prep) of/IN (l_pobj) seizures/NNS
D005492_D004827 NONE acid/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubj) induces/VBZ (l_dobj) SLE/NNP (l_appos) acid/NN (l_conj) epilepsy/NN -PUNC- acid/NN (l_conj) epilepsy/NN -PUNC- acid/NN (r_npadvmod) containing/VBG (r_amod) supplementation/NN (l_prep) in/IN (l_pobj) women/NNS (l_amod) epileptic/JJ -PUNC- acid/NN (r_npadvmod) containing/VBG (r_amod) supplementation/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) study/VB (l_prep) in/IN (l_pobj) order/NN (l_acl) determine/VB (l_dobj) rate/NN (l_prep) of/IN (l_pobj) defects/NNS (l_conj) effects/NNS (l_amod) related/VBN (l_npadvmod) epilepsy/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) women/NNS (l_amod) epileptic/JJ -PUNC- acid/NN (l_appos) effects/NNS (l_amod) related/VBN (l_npadvmod) epilepsy/NN -PUNC- acid/NN (r_conj) carbamazepine/NN (r_pobj) by/IN (r_agent) treated/VBN (l_nsubjpass) woman/NN (l_amod) epileptic/JJ -PUNC- acid/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) triggered/VBD (l_ccomp) damage/VB (l_nsubj) disease/NN (l_poss) patient/NN (l_amod) epileptic/JJ -PUNC- acid/NN (r_pobj) of/IN (r_prep) mg/NN (r_appos) dose/NN (l_prep) in/IN (l_pobj) women/NNS (l_amod) epileptic/JJ -PUNC- acid/NN (r_pobj) of/IN (r_prep) mg/NN (r_appos) dose/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) seizures/NNS
D002220_D004827 NONE carbamazepine/NN (r_pobj) by/IN (r_agent) treated/VBN (l_nsubjpass) woman/NN (l_amod) epileptic/JJ
D005492_D008180 CID acid/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubj) induces/VBZ (l_dobj) SLE/NNP -PUNC- acid/NN (r_appos) SLE/NNP -PUNC- acid/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) triggered/VBD (l_ccomp) damage/VB (l_nsubj) disease/NN (l_appos) lupus/NN
D005492_D001327 NONE acid/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) triggered/VBD (l_ccomp) damage/VB (l_nsubj) disease/NN -PUNC- acid/NN (r_pobj) of/IN (r_prep) mg/NN (r_appos) dose/NN (l_prep) without/IN (l_pobj) disease/NN
D005492_D000014 NONE acid/NN (r_npadvmod) containing/VBG (r_amod) supplementation/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) study/VB (l_prep) in/IN (l_pobj) order/NN (l_acl) determine/VB (l_dobj) rate/NN (l_prep) of/IN (l_pobj) defects/NNS
15893386
D015742_D008305 NONE propofol/JJ (r_amod) infusion/NN (r_pobj) with/IN (r_prep) continued/VBN (l_advcl) were/VBD (l_acomp) available/JJ (l_xcomp) detect/VB (l_conj) treat/VB (l_dobj) hyperthermia/NN
D013390_D014313 CID Succinylcholine/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- succinylcholine/NN (r_nmod) administration/NN (r_pobj) after/IN (r_prep) describe/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) rigidity/NN -PUNC- succinylcholine/NN (r_nmod) administration/NN (r_pobj) after/IN (r_prep) describe/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) rigidity/NN (l_appos) jaw/NN (l_prep) of/IN (l_pobj) steel/NN -PUNC- Sch/NNP (r_nmod) administration/NN (r_pobj) after/IN (r_prep) describe/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) rigidity/NN -PUNC- Sch/NNP (r_nmod) administration/NN (r_pobj) after/IN (r_prep) describe/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) rigidity/NN (l_appos) jaw/NN (l_prep) of/IN (l_pobj) steel/NN
839274
D003276_D000236 CID contraceptives/NNS (r_pobj) on/IN (r_prep) hyperplasia/NN (r_conj) adenomas/NNS -PUNC- contraceptives/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) one/CD (r_conj) cases/NNS (l_prep) of/IN (l_pobj) adenoma/NN
D003276_D020518 CID contraceptives/NNS (r_pobj) on/IN (r_prep) hyperplasia/NN -PUNC- contraceptives/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) one/CD (l_prep) of/IN (l_pobj) hyperplasia/NN
18503483
C107135_D020968 NONE everolimus/NN (r_pobj) to/TO (r_prep) conversion/NN (r_pobj) after/IN (r_prep) Recovery/NN (l_prep) of/IN (l_pobj) neuritis/NN
D016559_D020968 CID tacrolimus/NN (r_npadvmod) associated/VBN (r_amod) neuritis/NN
8106150
D001418_D004409 NONE Baclofen/NNP (r_nsubj) was/VBD (l_acomp) useful/JJ (l_prep) against/IN (l_pobj) form/NN (l_prep) of/IN (l_pobj) dyskinesia/NN
D001285_D002819 NONE Atropine/NNP (r_nsubj) converted/VBD (l_prep) into/IN (l_pobj) chorea/NN
D003000_D004409 NONE clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D003000_D020734 NONE clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_conj) at/IN (l_pobj) cost/NN (l_prep) of/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) symptomatology/NN (l_amod) parkinsonian/JJ
-1_D020734 NONE 5-MDOT/CD (r_conj) methysergide/NN (r_conj) physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_conj) at/IN (l_pobj) cost/NN (l_prep) of/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) symptomatology/NN (l_amod) parkinsonian/JJ
D011433_D004409 NONE propranolol/NN (r_conj) methysergide/NN (r_conj) physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D015632_D020734 CID MPTP/NNP (r_pobj) with/IN (r_prep) parkinsonian/NN
D011433_D020734 NONE propranolol/NN (r_conj) methysergide/NN (r_conj) physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_conj) at/IN (l_pobj) cost/NN (l_prep) of/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) symptomatology/NN (l_amod) parkinsonian/JJ
D001418_D020821 NONE Baclofen/NNP (r_nsubj) was/VBD (l_acomp) useful/JJ (l_prep) against/IN (l_pobj) form/NN (l_amod) dystonic/JJ
D015632_D004409 NONE MPTP/NNP (r_npadvmod) treated/VBN (r_amod) monkeys/NNS (r_pobj) in/IN (r_prep) dyskinesias/NNS
D007980_D004409 NONE dopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) tested/VBN (l_advcl) see/VB (l_ccomp) modified/VBN (l_nsubjpass) movements/NNS (l_amod) dyskinetic/JJ
D010830_D004409 NONE physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
-1_D004409 NONE 5-MDOT/CD (r_conj) methysergide/NN (r_conj) physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D016291_D004409 NONE MK-801/NNP (r_punct) ,/, (r_punct) reduced/VBD (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D008784_D004409 NONE methysergide/NN (r_conj) physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D015016_D004409 NONE yohimbine/NN (r_nsubj) reduced/VBN (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D016291_D020734 NONE MK-801/NNP (r_punct) ,/, (r_punct) reduced/VBD (l_conj) at/IN (l_pobj) cost/NN (l_prep) of/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) symptomatology/NN (l_amod) parkinsonian/JJ
D008614_D004409 NONE meperidine/RB (r_conj) yohimbine/NN (r_nsubj) reduced/VBN (l_dobj) movements/NNS (l_amod) dyskinetic/JJ
D010830_D020734 NONE physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_conj) at/IN (l_pobj) cost/NN (l_prep) of/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) symptomatology/NN (l_amod) parkinsonian/JJ
D008784_D020734 NONE methysergide/NN (r_conj) physostigmine/NN (r_conj) clonidine/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_nsubj) reduced/VBD (l_conj) at/IN (l_pobj) cost/NN (l_prep) of/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) symptomatology/NN (l_amod) parkinsonian/JJ
D004298_D004409 NONE dopamine/NN (r_pobj) than/IN (r_prep) other/JJ (r_amod) neurotransmitters/NNS (r_pobj) on/IN (r_prep) acting/VBG (r_acl) agents/NNS (r_pobj) of/IN (r_prep) series/NN (r_nsubjpass) tested/VBN (l_advcl) see/VB (l_ccomp) modified/VBN (l_nsubjpass) movements/NNS (l_amod) dyskinetic/JJ
D001285_D020821 NONE Atropine/NNP (r_nsubj) converted/VBD (l_dobj) movements/NNS (l_amod) dystonic/JJ
18513945
D010121_D020521 NONE oxytocin/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) Hypotension/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) decrease/NN (l_conj) increase/NN (l_prep) in/IN (l_pobj) volume/NN (l_compound) stroke/NN
D010121_D006473 NONE Oxytocin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubjpass) attributed/VBN (l_prep) to/IN (l_pobj) loss/NN
D010121_D007022 CID Oxytocin/NN (r_nsubj) is/VBZ (l_attr) uterotonic/NN (l_relcl) cause/VB (l_dobj) hypotension/NN -PUNC- Oxytocin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- oxytocin/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) Hypotension/NN
3615541
D000661_D006948 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D002116_D006948 NONE calcitonin/NN (r_compound) injections/NNS (r_pobj) by/IN (r_prep) antagonism/NN (l_prep) of/IN (l_pobj) hyperactivity/NN
1535072
D012701_D009771 NONE serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (r_relcl) disorders/NNS (r_conj) anxiety/NN (r_conj) trichotillomania/NN (r_conj) disorder/NN
D015016_D014256 NONE yohimbine/NN (r_dobj) given/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) trichotillomania/NN
D012701_D019964 NONE serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (r_relcl) disorders/NNS
D015016_D009771 NONE yohimbine/NN (r_dobj) given/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN
D015016_D020018 NONE Yohimbine/NNP (r_compound) treatment/NN (l_prep) of/IN (l_pobj) effects/NNS -PUNC- yohimbine/NN (r_nsubjpass) used/VBN (l_xcomp) treat/VB (l_dobj) effects/NNS -PUNC- yohimbine/NN (r_dobj) evaluated/VBD (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) effects/NNS -PUNC- yohimbine/NN (r_dobj) given/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) trichotillomania/NN (l_conj) anxiety/NN (l_conj) disorders/NNS (l_relcl) suffered/VBD (l_dobj) effects/NNS -PUNC- yohimbine/NN (r_nsubj) be/VB (l_attr) treatment/NN (l_prep) for/IN (l_pobj) effects/NNS
D012701_D020018 NONE serotonin/NN (r_compound) blockers/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) treatment/NN (l_prep) of/IN (l_pobj) effects/NNS -PUNC- serotonin/NN (r_compound) blockers/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) effects/NNS -PUNC- serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (l_dobj) effects/NNS -PUNC- serotonin/NN (r_compound) blockers/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) effects/NNS
D012701_D014256 NONE serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (r_relcl) disorders/NNS (r_conj) anxiety/NN (r_conj) trichotillomania/NN
D015016_D001008 NONE yohimbine/NN (r_dobj) given/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) trichotillomania/NN (l_conj) anxiety/NN -PUNC- yohimbine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) included/VBD (l_dobj) sweating/NN (l_conj) anxiety/NN
D002997_D020018 CID clomipramine/NN (r_pobj) of/IN (r_prep) effects/NNS
D015016_D019964 NONE yohimbine/NN (r_dobj) given/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) trichotillomania/NN (l_conj) anxiety/NN (l_conj) disorders/NNS
D012701_D001008 NONE serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (r_relcl) disorders/NNS (r_conj) anxiety/NN
D015016_D007172 NONE yohimbine/NN (r_nsubj) facilitates/VBZ (l_conj) be/VB (l_acomp) helpful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) impotence/NN
9523850
D007505_D018771 CID dextran/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) syndrome/NN (l_compound) myalgia/NN (l_compound) arthralgia/JJ
D007505_D063806 NONE dextran/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) syndrome/NN (l_compound) myalgia/NN
D008775_D018771 NONE methylprednisolone/NN (r_pobj) of/IN (r_prep) Value/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) syndrome/NN (l_compound) myalgia/NN (l_compound) arthralgia/JJ -PUNC- MP/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reduces/VBZ (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) syndrome/NN (l_compound) myalgia/NN (l_compound) arthralgia/JJ
D008775_D063806 NONE methylprednisolone/NN (r_pobj) of/IN (r_prep) Value/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) syndrome/NN (l_compound) myalgia/NN -PUNC- MP/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reduces/VBZ (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) syndrome/NN (l_compound) myalgia/NN
6286738
D002762_D064420 NONE D3/NN (r_compound) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) Signs/NNS (r_nsubjpass) observed/VBN (r_ccomp) developed/VBN (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) signs/NNS (r_dobj) developed/VBN (l_ccomp) observed/VBN (l_nsubjpass) Signs/NNS (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- D3/NNP (r_compound) toxicity/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) between/IN (r_prep) safety/NN (r_pobj) of/IN (r_prep) margin/NN (r_conj) toxicity/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (r_ccomp) concluded/VBD (l_prep) Because/IN (l_pobj) toxicity/NN
D002762_D054559 CID D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN (l_conj) hyperphosphatemia/NN -PUNC- D3/NNP (r_appos) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN (l_conj) hyperphosphatemia/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) increases/NNS (r_conj) hyperphosphatemia/NN
D002762_D010319 NONE D3/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cows/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) showed/VBD (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) fever/NN -PUNC- D3/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cows/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) showed/VBD (r_ccomp) developed/VBD (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) fever/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN (l_relcl) induce/VBP (l_dobj) fever/NN -PUNC- D3/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_pobj) Because/IN (r_prep) concluded/VBD (l_ccomp) used/VBN (l_xcomp) prevent/VB (l_dobj) fever/NN -PUNC- D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN -PUNC- D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN (l_relcl) induce/VBP (l_dobj) fever/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) between/IN (r_prep) safety/NN (r_pobj) of/IN (r_prep) margin/NN (r_conj) toxicity/NN (r_pobj) Because/IN (r_prep) concluded/VBD (l_ccomp) used/VBN (l_xcomp) prevent/VB (l_dobj) fever/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (r_ccomp) concluded/VBD (l_prep) Because/IN (l_pobj) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (r_ccomp) concluded/VBD (l_prep) Because/IN (l_pobj) toxicity/NN (l_conj) margin/NN (l_prep) of/IN (l_pobj) safety/NN (l_prep) between/IN (l_pobj) doses/NNS (l_prep) of/IN (l_pobj) D3/NNP (l_relcl) prevent/VBP (l_dobj) fever/NN (l_relcl) induce/VBP (l_dobj) fever/NN -PUNC- D3/NNP (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) fever/NN
D002762_D006934 CID D3/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- D3/NNP (r_appos) doses/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- D3/NNP (r_pobj) of/IN (r_prep) increases/NNS (r_conj) hyperphosphatemia/NN (r_conj) hypercalcemia/NN
9869257
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
C087567_D000647 NONE PG-9/NNP (r_nsubj) administered/VBN (l_conj) prevented/VBN (l_dobj) amnesia/NN -PUNC- PG-9/NNP (r_nmod) microg/NN (r_nsubj) was/VBD (l_acomp) able/JJ (l_xcomp) prevent/VB (l_dobj) amnesia/NN
C098725_D000647 CID S-(-)-ET-126/NNP (r_appos) antagonist/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
17615423
D019821_D058186 CID simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN -PUNC- simvastatin/NN (l_conj) amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN (l_conj) failure/NN
D000638_D012206 CID amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN (r_conj) rhabdomyolysis/NN -PUNC- amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN
C413408_D058186 CID atazanavir/NNS (r_conj) amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN -PUNC- atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN (l_conj) failure/NN
D019821_D015658 NONE Simvastatin/NNP (r_nmod) medications/NNS (l_compound) virus/NN
C413408_D012206 CID atazanavir/NNS (r_conj) amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN (r_conj) rhabdomyolysis/NN -PUNC- atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN
D000638_D058186 CID amiodarone/NN (r_conj) simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN -PUNC- amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN (l_conj) failure/NN
D000638_D015658 NONE amiodarone/NN (r_conj) Simvastatin/NNP (r_nmod) medications/NNS (l_compound) virus/NN
D019821_D012206 CID simvastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) failure/NN (r_conj) rhabdomyolysis/NN -PUNC- simvastatin/NN (l_conj) amiodarone/NN (l_conj) atazanavir/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) rhabdomyolysis/NN -PUNC- simvastatin/NN (r_amod) metabolism/NN (r_dobj) inhibit/VBP (r_relcl) drugs/NNS (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) rhabdomyolysis/NN
20470218
D008727_D020521 NONE methotrexate/NN (r_compound) toxicity/NN (r_conj) syndrome/NN (l_conj) stroke/NN
D008727_D004833 NONE methotrexate/NN (r_compound) toxicity/NN (r_conj) syndrome/NN (l_conj) stroke/NN (l_conj) epilepsy/NN
D008727_D056784 NONE methotrexate/NN (r_compound) toxicity/NN (r_conj) syndrome/NN (l_compound) leukoencephalopathy/JJ
D008727_D007177 NONE methotrexate/NN (r_compound) toxicity/NN (l_conj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN
D008727_D064420 NONE methotrexate/NN (r_compound) toxicity/NN
7977601
7265370
D014223_D006973 NONE triamterene/JJ (r_compound) nephrolithiasis/NN (r_pobj) of/IN (r_prep) case/NN (r_nsubjpass) reported/VBN (l_prep) after/IN (l_pobj) years/NNS (l_prep) for/IN (l_pobj) hypertension/NN
C020743_D053040 NONE dyazide/RB (r_compound) therapy/NN (r_dobj) complicating/VBG (l_nsubj) nephrolithiasis/JJ -PUNC- triamterene/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) years/NNS (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) nephrolithiasis/NN
C020743_D006973 NONE triamterene/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) years/NNS (l_prep) for/IN (l_pobj) hypertension/NN
D014223_D053040 CID Triamterene/JJ (r_compound) nephrolithiasis/JJ -PUNC- triamterene/JJ (r_compound) nephrolithiasis/NN -PUNC- triamterene/JJ (r_compound) nephrolithiasis/NN
20003049
C031942_D008107 NONE argatroban/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) measured/VBN (l_conj) is/VBZ (l_attr) minutes/NNS (l_appos) minutes/NNS (l_prep) with/IN (l_pobj) impairment/NN -PUNC- argatroban/JJ (r_amod) life/NN (r_npadvmod) plasma/NN (r_nsubjpass) observed/VBN (r_conj) measured/VBN (l_conj) is/VBZ (l_attr) minutes/NNS (l_appos) minutes/NNS (l_prep) with/IN (l_pobj) impairment/NN
C031942_D001778 NONE argatroban/JJ (r_amod) concentration/NN (r_nsubj) suggest/VBP (l_ccomp) contributed/VBN (l_prep) to/IN (l_pobj) coagulopathy/NN -PUNC- argatroban/NN (r_amod) levels/NNS (r_nsubj) contributed/VBN (l_prep) to/IN (l_pobj) coagulopathy/NN -PUNC- argatroban/JJ (r_amod) concentration/NN (r_dobj) measure/VB (l_conj) extended/VBN (l_dobj) coagulopathy/NN
C031942_D013921 NONE argatroban/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN -PUNC- argatroban/NN (r_oprd) administered/VBN (l_nsubjpass) patient/JJ (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) HITT/NNP
D006493_D013921 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) HIT/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP
D006493_D013927 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) anticoagulation/NN (r_pobj) of/IN (r_prep) method/NN (r_dobj) provide/VBP (l_conj) HIT/VB (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP
C031942_D013927 NONE argatroban/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- argatroban/NN (r_oprd) administered/VBN (l_nsubjpass) patient/JJ (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) HITT/NNP
C031942_D016638 NONE argatroban/NN (r_oprd) administered/VBN (l_nsubjpass) patient/JJ (l_amod) ill/JJ
6203452
D014748_D002277 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D001761_D002277 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D057049 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN
D002945_D013921 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN (l_conj) thrombocytopenia/JJ -PUNC- cisplatin/VB (r_amod) nephrotoxicity/NN (l_conj) thrombocytopenia/NN
D002945_D002277 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D000740 NONE cisplatin/VB (r_amod) nephrotoxicity/NN (l_conj) anemia/NN
D002945_D007674 CID cisplatin/VB (r_amod) nephrotoxicity/NN
D001761_D013921 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN (l_conj) thrombocytopenia/JJ
D002945_D000743 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN
D014748_D000743 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN
D001761_D000743 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN
D014748_D057049 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN
D001761_D057049 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN
D002945_D051437 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) insufficiency/NN -PUNC- cisplatin/VB (r_amod) nephrotoxicity/NN (r_pobj) to/IN (r_prep) ascribed/VBN (l_nsubjpass) failure/NN
D002945_D001855 NONE cisplatin/VB (r_amod) nephrotoxicity/NN (l_conj) thrombocytopenia/NN (l_prep) to/IN (l_pobj) suppression/NN
D001761_D051437 NONE bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) insufficiency/NN
D014748_D013921 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_conj) anemia/NN (l_conj) thrombocytopenia/JJ
D014748_D051437 NONE alkaloid/NN (r_amod) vinca/JJ (r_conj) bleomycin/NNS (r_conj) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) microangiopathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) insufficiency/NN
3719553
D011241_D004342 NONE prednisone/NNP (r_conj) diphenhydramine/NN (r_nsubj) were/VBD (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) reaction/NN
D005472_D009062 NONE 5-fluorouracil/CD (r_punct) reaction/NN (r_nsubj) occurred/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cavity/NN
D004155_D004342 NONE diphenhydramine/NN (r_nsubj) were/VBD (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) reaction/NN
D005472_D000799 CID 5-fluorouracil/CD (r_punct) reaction/NN (l_acl) consisting/VBG (l_prep) of/IN (l_pobj) edema/NN
D002945_D007674 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN
D005472_D004342 NONE 5-fluorouracil/CD (r_punct) infusion/NN (r_pobj) to/IN (r_prep) reaction/NN -PUNC- 5-fluorouracil/CD (r_punct) reaction/NN
D002945_D004342 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN (r_conj) cavity/NN (r_pobj) of/IN (r_prep) carcinoma/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) reaction/NN
D005472_D005355 NONE 5-fluorouracil/CD (r_punct) reaction/NN (r_nsubj) occurred/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cavity/NN (l_conj) cirrhosis/NN
D005472_D007674 NONE 5-fluorouracil/CD (r_punct) reaction/NN (r_nsubj) occurred/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cavity/NN (l_conj) cirrhosis/NN (l_conj) function/NN
D002945_D005355 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN
D002945_D009062 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN (r_conj) cavity/NN
D002945_D000799 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) function/NN (r_conj) cirrhosis/NN (r_conj) cavity/NN (r_pobj) of/IN (r_prep) carcinoma/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) reaction/NN (l_acl) consisting/VBG (l_prep) of/IN (l_pobj) edema/NN
18182964
D008774_D001289 NONE methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN -PUNC- methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN (l_appos) ADHD/NNP -PUNC- methylphenidate/NN (r_conj) clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- methylphenidate/NN (r_conj) clonidine/NN (r_conj) methylphenidate/NN (r_conj) clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- methylphenidate/NN (r_pobj) with/IN (r_conj) used/VBN (r_acl) Clonidine/NNP (r_nsubj) appears/VBZ (l_conj) tolerated/VBN (l_prep) in/IN (l_pobj) ADHD/NNP
D003000_D001919 CID clonidine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) incidents/NNS (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- clonidine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) incidents/NNS (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- clonidine/NN (r_dobj) prescribing/VBG (r_acl) Physicians/NNS (r_nsubj) monitor/VB (l_prep) for/IN (l_pobj) bradycardia/NN
D003000_D001289 NONE Clonidine/NNP (l_prep) for/IN (l_pobj) disorder/NN -PUNC- clonidine/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) examine/VB (r_csubj) used/VBN (l_conj) with/IN (l_pobj) methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN -PUNC- clonidine/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) examine/VB (r_csubj) used/VBN (l_conj) with/IN (l_pobj) methylphenidate/NN (l_prep) with/IN (l_pobj) disorder/NN (l_appos) ADHD/NNP -PUNC- clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- clonidine/NN (r_conj) methylphenidate/NN (r_conj) clonidine/NN (r_xcomp) assigned/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) ADHD/NNP -PUNC- Clonidine/NNP (r_nsubj) appears/VBZ (l_conj) tolerated/VBN (l_prep) in/IN (l_pobj) ADHD/NNP
D003000_D006970 NONE clonidine/NN (r_pobj) on/IN (r_prep) was/VBD (l_nsubj) Drowsiness/NN -PUNC- clonidine/NN (r_dobj) prescribing/VBG (r_acl) Physicians/NNS (r_nsubj) monitor/VB (l_conj) advise/VB (l_dobj) patients/NNS (l_prep) about/IN (l_pobj) likelihood/NN (l_prep) of/IN (l_pobj) drowsiness/NN
19203554
D012460_D010996 CID sulphasalazine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) restarting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) eyes/NNS (l_conj) effusion/NN -PUNC- sulphasalazine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) cessation/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN (l_appos) eyes/NNS (l_conj) pain/NN (l_conj) titer/NN (l_prep) of/IN (l_pobj) protein/NN (l_prep) of/IN (l_pobj) effusions/NNS -PUNC- sulphasalazine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) cessation/NN (r_nsubj) resulted/VBD (r_advcl) initiated/VBD (l_conj) increased/VBD (l_conj) remained/VBD (l_nsubj) effusion/NN
D012460_D003093 NONE sulphasalazine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) restarting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) colitis/NN
D013256_D005334 NONE steroid/NN (r_compound) therapy/NN (r_dobj) initiated/VBD (l_advcl) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN
D013256_D002637 NONE steroid/NN (r_compound) therapy/NN (r_dobj) initiated/VBD (l_advcl) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN (l_appos) eyes/NNS (l_conj) pain/NN
D012460_D005921 NONE sulphasalazine/JJ (r_compound) treatment/NN (r_dobj) restarting/VBG (r_pcomp) after/IN (r_prep) antibody-(PR3-ANCA/NNS (l_appos) glomerulonephritis/NN -PUNC- sulphasalazine/NN (r_nsubj) induce/VB (l_dobj) glomerulonephritis/NN
D012460_D005334 CID sulphasalazine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) cessation/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN
D012460_D005128 NONE sulphasalazine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) restarting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) eyes/NNS -PUNC- sulphasalazine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) cessation/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN (l_appos) eyes/NNS
D012460_D001745 NONE sulphasalazine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) restarting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) eyes/NNS (l_conj) effusion/NN (l_conj) eosinophilia/NN (l_conj) abnormalities/NNS
D013256_D010996 NONE steroid/NN (r_compound) therapy/NN (r_dobj) initiated/VBD (l_advcl) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN (l_appos) eyes/NNS (l_conj) pain/NN (l_conj) titer/NN (l_prep) of/IN (l_pobj) protein/NN (l_prep) of/IN (l_pobj) effusions/NNS -PUNC- steroid/NN (r_compound) therapy/NN (r_dobj) initiated/VBD (l_conj) increased/VBD (l_conj) remained/VBD (l_nsubj) effusion/NN -PUNC- steroid/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) disappeared/VBD (l_nsubj) effusion/NN
D012460_D002637 NONE sulphasalazine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) cessation/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN (l_appos) eyes/NNS (l_conj) pain/NN
D013256_D005128 NONE steroid/NN (r_compound) therapy/NN (r_dobj) initiated/VBD (l_advcl) resulted/VBD (l_prep) in/IN (l_pobj) improvements/NNS (l_prep) in/IN (l_pobj) fever/NN (l_appos) eyes/NNS
D012460_D004802 NONE sulphasalazine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) restarting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) eyes/NNS (l_conj) effusion/NN (l_conj) eosinophilia/NN
20705401
D012701_D011605 NONE Serotonin/NN (r_nmod) gene/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) psychosis/NN -PUNC- 5-HT6/CD (r_nummod) receptors/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) disorders/NNS -PUNC- 5-HT6/CD (r_nummod) gene/NN (l_prep) with/IN (l_pobj) psychosis/NN
D008694_D012563 NONE methamphetamine/NN (r_pobj) of/IN (r_prep) symptoms/NNS (r_nsubj) are/VBP (l_acomp) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- METH)-induced/JJ (r_amod) psychosis/NN (r_appos) symptoms/NNS (r_nsubj) are/VBP (l_acomp) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_prep) of/IN (l_pobj) schizophrenia/NN
C076029_D006948 NONE olanzapine/NN (r_conj) clozapine/NN (l_conj) hyperactivity/NN
D012701_D012559 NONE 5-HT6/CD (r_nummod) receptors/NNS (r_nsubjpass) involved/VBN (r_ccomp) suggests/VBZ (r_conj) considered/VBN (l_xcomp) reflect/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) schizophrenia/NN
D003024_D006948 NONE clozapine/NN (l_conj) hyperactivity/NN
D012701_D006948 NONE serotonin/NN (r_nsubjpass) targeted/VBN (l_agent) by/IN (l_pobj) antipsychotics/NNS (l_prep) as/IN (l_pobj) clozapine/NN (l_conj) hyperactivity/NN -PUNC- 5-HT6/CD (r_nummod) receptor/NN (r_appos) serotonin/NN (r_nsubjpass) targeted/VBN (l_agent) by/IN (l_pobj) antipsychotics/NNS (l_prep) as/IN (l_pobj) clozapine/NN (l_conj) hyperactivity/NN -PUNC- 5-HT6/CD (r_nummod) antagonist/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) corrected/VBN (r_conj) targeted/VBN (l_agent) by/IN (l_pobj) antipsychotics/NNS (l_prep) as/IN (l_pobj) clozapine/NN (l_conj) hyperactivity/NN
D003913_D006948 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_conj) clozapine/NN (l_conj) hyperactivity/NN
D008694_D011605 CID methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN -PUNC- methamphetamine/NN (r_pobj) of/IN (r_prep) symptoms/NNS (l_appos) psychosis/NN -PUNC- METH)-induced/JJ (r_amod) psychosis/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) psychosis/NN -PUNC- METH/NN (r_npadvmod) induced/VBN (r_amod) patients/NNS (l_compound) psychosis/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) patients/NNS (l_compound) psychosis/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) patients/NNS (l_compound) psychosis/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) psychosis/NN
1967484
D013469_D004421 CID Sulpiride/NNP (r_npadvmod) induced/VBN (l_dobj) dystonia/NN -PUNC- sulpiride/NN (r_compound) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) dystonia/NN -PUNC- sulpiride/NN (r_npadvmod) induced/VBN (r_amod) dystonia/NN
D013469_D004409 NONE sulpiride/NN (r_npadvmod) induced/VBN (l_dobj) dyskinesia/JJ
D013469_D010302 NONE sulpiride/NN (r_npadvmod) induced/VBN (l_dobj) dyskinesia/JJ (l_conj) parkinsonism/NN
1545575
D015080_D003556 NONE mesna/NN (r_pobj) with/IN (r_prep) trial/NN (l_relcl) neutralizes/VBZ (l_dobj) metabolite/NN (l_relcl) causes/VBZ (l_dobj) cystitis/NN -PUNC- mesna/JJ (r_amod) uroprophylaxis/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_nsubj) had/VBD (l_dobj) cystitis/NN
D015080_D006470 NONE mesna/NN (r_pobj) with/IN (r_prep) trial/NN (l_relcl) neutralizes/VBZ (l_dobj) metabolite/NN (l_relcl) causes/VBZ (l_dobj) cystitis/NN -PUNC- mesna/JJ (r_amod) uroprophylaxis/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_nsubj) had/VBD (l_dobj) cystitis/NN
D003520_D006470 CID cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) metabolite/NN (l_relcl) causes/VBZ (l_dobj) cystitis/NN
D003520_D003556 CID cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) metabolite/NN (l_relcl) causes/VBZ (l_dobj) cystitis/NN
2886572
D004837_D006973 CID epinephrine/NN (r_npadvmod) induced/VBN (r_amod) rats/NNS (l_amod) hypertensive/JJ
8424298
D007741_D007022 CID labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- labetalol/NN (l_prep) with/IN (l_pobj) group/NN (l_amod) hypotensive/JJ -PUNC- labetalol/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hypotension/NN
D007530_D007022 CID isoflurane/NN (r_pobj) with/IN (r_prep) labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- isoflurane/JJ (r_amod) group/NN (r_pobj) with/IN (r_prep) labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- isoflurane/JJ (r_amod) group/NN (l_amod) hypotensive/JJ -PUNC- isoflurane/NN (r_pobj) with/IN (r_prep) labetalol/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hypotension/NN
8302922
D000527_D007022 CID E1/NNP (r_pobj) during/IN (r_prep) flow/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN -PUNC- E1/NNP (r_nmod) PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- PGE1/NNP (r_dobj) starting/VBG (r_pcomp) After/IN (r_prep) decreased/VBD (l_conj) remained/VBD (l_nsubj) degree/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- PGE1/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) degree/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- PGE1/NNP (r_nsubj) be/VB (l_acomp) preferable/JJ (l_xcomp) TMP/VB (l_prep) for/IN (l_pobj) anaesthesia/NN (l_amod) hypotensive/JJ
D007530_D007022 NONE isoflurane/JJ (r_amod) anaesthesia/NN (r_pobj) under/IN (r_prep) fusion/NN (r_dobj) underwent/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) using/VBG (r_advcl) measured/VBN (l_advcl) induced/VBN (l_dobj) hypotension/NN
D014294_D007022 CID trimethaphan/RB (r_conj) E1/NNP (r_pobj) during/IN (r_prep) flow/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN -PUNC- trimethaphan/NN (r_conj) PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- TMP/NNP (r_appos) trimethaphan/NN (r_conj) PGE1/NNP (r_pobj) of/IN (r_prep) effect/NN (r_dobj) evaluate/VB (r_csubj) induced/VBN (l_dobj) hypotension/NN -PUNC- TMP/NNP (r_conj) PGE1/NNP (r_dobj) starting/VBG (r_pcomp) After/IN (r_prep) decreased/VBD (l_conj) remained/VBD (l_nsubj) degree/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- TMP/VB (l_prep) for/IN (l_pobj) anaesthesia/NN (l_amod) hypotensive/JJ -PUNC- TMP/NNP (r_nsubj) decreased/VBD (r_advcl) be/VB (l_acomp) preferable/JJ (l_xcomp) TMP/VB (l_prep) for/IN (l_pobj) anaesthesia/NN (l_amod) hypotensive/JJ
9406968
D008094_D011141 NONE lithium/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) investigated/VBN (l_parataxis) polyuria/NN -PUNC- Li)-induced/JJ (r_amod) polyuria/NN
D001127_D003681 NONE AVP/NNP (r_pobj) of/IN (r_prep) elevation/NN (r_pobj) to/IN (r_prep) contribute/VB (l_nsubj) dehydration/NN -PUNC- AVP/NNP (r_compound) expression/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_conj) elevation/NN (r_pobj) to/IN (r_prep) contribute/VB (l_nsubj) dehydration/NN
D014667_D003919 NONE vasopressin/NN (r_compound) gene/NN (l_prep) in/IN (l_pobj) nuclei/NNS (l_prep) of/IN (l_pobj) rat/NN (l_compound) insipidus/NN
D008094_D003681 NONE Li/NNP (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) rat/NN (r_pobj) of/IN (r_prep) SON/NN (r_conj) PVN/NN (r_pobj) in/IN (r_prep) expression/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_conj) elevation/NN (r_pobj) to/IN (r_prep) contribute/VB (l_nsubj) dehydration/NN
D018021_D011141 CID LiCl/NNP (r_dobj) contained/VBD (r_relcl) diet/NN (r_dobj) consuming/VBG (r_acl) rats/NNS (r_nsubj) developed/VBN (l_dobj) polyuria/NN
D008094_D003919 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) rat/NN (l_compound) insipidus/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) rat/NN (l_compound) insipidus/NN
D001127_D003919 NONE AVP/NNP (r_pobj) of/IN (r_prep) elevation/NN (l_conj) upregulation/NN (l_prep) of/IN (l_pobj) expression/NN (l_prep) in/IN (l_pobj) PVN/NN (l_conj) SON/NN (l_prep) of/IN (l_pobj) rat/NN (l_compound) insipidus/NN -PUNC- AVP/NNP (r_compound) expression/NN (l_prep) in/IN (l_pobj) PVN/NN (l_conj) SON/NN (l_prep) of/IN (l_pobj) rat/NN (l_compound) insipidus/NN
D001127_D011141 NONE vasopressin/NN (r_pobj) of/IN (r_prep) expression/NN (r_nsubjpass) investigated/VBN (l_parataxis) polyuria/NN -PUNC- AVP/NNP (r_nmod) gene/NN (r_nsubjpass) investigated/VBN (l_parataxis) polyuria/NN
9766615
D003024_D012735 NONE clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN (l_conj) dysfunction/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN (l_conj) dysfunction/NN
D003024_D015430 NONE clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (l_nsubj) effects/NNS (l_conj) effects/NNS (l_conj) gain/NN
D003024_D001480 NONE clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (r_conj) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) EPS/NNP -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (r_conj) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) EPS/NNP
D003024_D000380 CID clozapine/NN (r_appos) threshold/NN (r_dobj) lowered/VBD (l_conj) agranulocytosis/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN
D003024_D012640 NONE clozapine/NN (r_appos) threshold/NN (l_compound) seizure/NN -PUNC- clozapine/NN (r_appos) agranulocytosis/NN (r_conj) lowered/VBD (l_dobj) threshold/NN (l_compound) seizure/NN
2466960
D005472_D000787 CID 5-FU/CD (r_nummod) infusion/NN (r_pobj) during/IN (r_prep) had/VBD (l_ccomp) were/VBD (l_nsubj) episodes/NNS (l_compound) Anginal/JJ -PUNC- 5-FU/CD (r_nummod) infusion/NN (r_pobj) during/IN (r_prep) had/VBD (l_dobj) angina/NN
D005472_D066126 NONE fluorouracil/NN (r_nmod) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN -PUNC- 5-FU/CD (r_nmod) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN
D005472_D003324 NONE 5-FU/CD (r_compound) infusion/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) increase/NN (l_prep) among/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D005472_D007511 CID 5-FU/CD (r_compound) infusion/NN (r_dobj) undergoing/VBG (r_acl) patients/NNS (r_pobj) on/IN (r_prep) monitoring/NN (r_dobj) performed/VBD (l_prep) in/IN (l_pobj) order/NN (l_acl) assess/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) changes/NNS (l_compound) ST/NNP (l_amod) ischemic/JJ -PUNC- 5-FU/CD (r_nummod) infusion/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) episodes/NNS (l_amod) ischemic/JJ -PUNC- 5-FU/CD (r_nummod) infusion/NN (r_pobj) during/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) episodes/NNS (l_amod) ischemic/JJ -PUNC- 5-FU/CD (r_pobj) before/IN (r_prep) was/VBD (l_ccomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) episodes/NNS (l_amod) ischemic/JJ -PUNC- 5-FU/CD (r_pobj) during/IN (r_prep) was/VBD (l_ccomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) episodes/NNS (l_amod) ischemic/JJ -PUNC- 5-FU/CD (r_compound) infusion/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) deviation/NN (l_amod) suggestive/JJ (l_prep) of/IN (l_pobj) ischemia/NN
D005472_D009369 NONE 5-FU/CD (r_compound) infusion/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS
19445921
D007545_D006331 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN
D000244_D012131 NONE ADP/NNP (r_nmod) O/NNP (r_conj) ratio/NN (r_pobj) by/IN (r_agent) characterized/VBN (r_acl) dysfunction/NN
D007545_D012131 NONE isoproterenol/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) dysfunction/NN
C066201_D006331 NONE A/NN (r_appos) Administration/NN (l_conj) dysfunction/NN
C066201_D009202 NONE A/NN (r_appos) Administration/NN (l_conj) dysfunction/NN (l_conj) injury/NN -PUNC- A/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) against/IN (l_pobj) damage/NN
C066201_D009203 NONE A/NN (l_prep) on/IN (l_pobj) infarction/NN -PUNC- A/NN (r_pobj) of/IN (r_prep) potential/NN (l_prep) on/IN (l_pobj) infarction/NN -PUNC- A/DT (r_appos) salvianolic/JJ (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) against/IN (l_pobj) infarction/NN
D007545_D009202 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (l_conj) injury/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) damage/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
11961407
D011692_D005921 NONE PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) days/NNS (r_npadvmod) analyzed/VBN (l_advcl) include/VB (l_dobj) phase/NN (l_appos) days/NNS (l_conj) phase/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) glomerulosclerosis/NN
D011692_D009401 CID PAN/NNP (r_compound) nephrosis/NN -PUNC- aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- aminonucleoside/NN (r_advmod) induced/VBN (l_nsubjpass) nephrosis/NN -PUNC- PAN/NNP (r_appos) aminonucleoside/NN (r_advmod) induced/VBN (l_nsubjpass) nephrosis/NN
D011692_D011507 CID PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) days/NNS (r_npadvmod) analyzed/VBN (l_advcl) include/VB (l_dobj) phase/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) days/NNS (r_npadvmod) analyzed/VBN (l_advcl) include/VB (l_dobj) phase/NN (l_appos) days/NNS (l_conj) phase/NN (l_prep) of/IN (l_pobj) proteinuria/NN
D014443_D009401 NONE tyrosine/NN (r_compound) phosphatase/NN (l_prep) in/IN (l_pobj) nephrosis/NN
3088349
D016627_-1 NONE 6-OHDA/CD (r_pobj) Following/VBG (r_prep) induced/VBN (l_dobj) lesion/NN
D000661_D009069 CID amphetamine/NN (r_pobj) by/IN (r_prep) exhaustion/NN (r_pobj) to/TO (r_prep) reflects/VBZ (l_nsubj) rotation/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (r_pobj) on/IN (r_prep) examined/VBD (l_prep) In/IN (l_pobj) order/NN (l_acl) clarify/VB (l_dobj) nature/NN (l_prep) of/IN (l_pobj) rotation/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN -PUNC- amphetamine/NN (r_nsubjpass) administered/VBN (r_advcl) was/VBD (l_advcl) indicating/VBG (l_dobj) involvement/NN (l_prep) of/IN (l_pobj) cells/NNS (l_prep) in/IN (l_pobj) rotation/NN -PUNC- amphetamine/NN (r_compound) dose/NN (r_conj) volume/NN (r_pobj) of/IN (r_prep) irrespective/RB (r_conj) duration/NN (r_pobj) of/IN (r_prep) regardless/RB (r_advmod) tended/VBD (l_nsubj) rotation/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) rotation/NN -PUNC- amphetamine/NN (r_compound) injections/NNS (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) circled/VBD (r_conj) tended/VBD (l_nsubj) rotation/NN -PUNC- amphetamine/NN (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) on/IN (l_pobj) pool/NN (l_acl) contributing/VBG (l_prep) to/IN (l_pobj) rotation/NN
D016627_D009069 NONE 6-OHDA/CD (r_pobj) Following/VBG (r_prep) induced/VBN (r_ccomp) reported/VBN (l_nsubjpass) period/NN (l_prep) of/IN (l_pobj) rotation/NN -PUNC- 6-OHDA/CD (r_pobj) Following/VBG (r_prep) induced/VBN (r_ccomp) reported/VBN (l_xcomp) precede/VB (l_dobj) circling/NN
D000661_-1 NONE amphetamine/NN (r_pobj) by/IN (r_prep) exhaustion/NN (r_pobj) to/TO (r_prep) reflects/VBZ (l_nsubj) rotation/NN (l_prep) following/VBG (l_pobj) lesion/NN
9226773
D014667_D011141 NONE vasopressin/NN (r_compound) secretion/NN (r_conj) thirst/NN (r_dobj) have/VB (r_ccomp) showed/VBD (r_conj) remained/VBD (l_acomp) thirsty/JJ (l_conj) polyuric/JJ
D008094_D011141 CID lithium/NN (r_pobj) of/IN (r_prep) cessation/NN (r_pobj) despite/IN (r_prep) polyuric/JJ -PUNC- Lithium/NN (r_nsubj) induced/VBD (r_csubjpass) considered/VBN (l_xcomp) be/VB (l_acomp) reversible/JJ (l_prep) on/IN (l_pobj) cessation/NN (l_prep) of/IN (l_pobj) therapy/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_nsubjpass) stopped/VBN (r_advcl) be/VB (l_acomp) reversible/JJ (l_prep) on/IN (l_pobj) cessation/NN (l_prep) of/IN (l_pobj) therapy/NN (l_conj) polyuria/NN
D008094_D018500 CID lithium/NN (r_compound) therapy/NN (r_dobj) following/VBG (r_prep) insipidus/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_nsubjpass) discontinued/VBN (r_conj) diagnosed/VBN (l_xcomp) have/VB (l_dobj) insipidus/NN -PUNC- lithium/NN (r_pobj) of/IN (r_prep) cessation/NN (r_pobj) despite/IN (r_prep) polyuric/JJ (r_conj) thirsty/JJ (r_acomp) remained/VBD (l_conj) showed/VBD (l_ccomp) have/VB (l_prep) with/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) insipidus/NN -PUNC- Lithium/NN (r_nsubj) induced/VBD (l_dobj) insipidus/NN -PUNC- lithium/NN (r_nsubjpass) stopped/VBN (r_advcl) be/VB (r_xcomp) considered/VBN (l_csubjpass) induced/VBD (l_dobj) insipidus/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN
D014667_D018500 NONE vasopressin/NN (r_compound) secretion/NN (r_conj) thirst/NN (r_dobj) have/VB (l_prep) with/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) insipidus/NN
17491223
D017256_D007511 NONE Sestamibi/NNP (r_nmod) emission/NN (r_dobj) using/VBG (r_conj) detecting/VBG (r_pcomp) for/IN (r_prep) assess/VB (l_conj) computed/VBD (l_advcl) assess/VB (l_dobj) presence/NN (l_prep) of/IN (l_pobj) ischemia/NN
D017256_D017202 NONE Sestamibi/NNP (r_nmod) emission/NN (r_dobj) using/VBG (r_conj) detecting/VBG (l_dobj) ischemia/NN
D004280_D007511 NONE dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN (r_dobj) detecting/VBG (r_pcomp) for/IN (r_prep) assess/VB (l_conj) computed/VBD (l_advcl) assess/VB (l_dobj) presence/NN (l_prep) of/IN (l_pobj) ischemia/NN
D004280_D017202 CID dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- dobutamine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN
347884
D006220_D019967 NONE haloperidol/NN (r_pobj) with/IN (r_prep) study/NN (r_pobj) In/IN (r_prep) found/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) syndromes/NNS (l_acl) belonging/VBG (l_prep) to/IN (l_pobj) group/NN
8012887
D006493_D001791 NONE heparin/JJ (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) used/VBN (l_advcl) induced/VBN (l_dobj) aggregation/NN -PUNC- heparin/NN (r_pobj) to/IN (r_prep) reexposure/NN (r_dobj) require/VBP (r_relcl) aggregation/NN
D006493_D013927 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombosis/NN -PUNC- heparin/JJ (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) used/VBN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_prep) against/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) thrombosis/NN -PUNC- heparin/JJ (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) used/VBN (l_conj) defined/VBN (l_auxpass) is/VBZ (l_nsubj) success/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) developed/VBN (l_dobj) syndrome/NN (l_compound) thrombosis/NN -PUNC- heparin/NN (r_pobj) to/IN (r_prep) reexposure/NN (r_dobj) require/VBP (r_relcl) aggregation/NN (r_dobj) induced/VBN (r_advcl) used/VBN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_prep) against/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_pobj) to/IN (r_prep) reexposure/NN (r_dobj) require/VBP (r_relcl) aggregation/NN (r_dobj) induced/VBN (r_advcl) used/VBN (l_conj) defined/VBN (l_auxpass) is/VBZ (l_nsubj) success/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) developed/VBN (l_dobj) syndrome/NN (l_compound) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombosis/NN
18363626
D010100_D001919 NONE oxygen/NN (r_compound) saturations/NNS (r_conj) range/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) within/IN (r_prep) were/VBD (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) bradycardia/NN
D020927_D001919 CID dexmedetomidine/NN (r_amod) sedation/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) bradycardia/NN
2917114
D006024_D001919 NONE glycopyrronium/NN (r_pobj) of/IN (r_prep) Use/NN (l_acl) given/VBN (l_conj) was/VBD (l_acomp) sufficient/JJ (l_xcomp) minimize/VB (l_dobj) bradycardias/NNS
D004491_D001919 CID edrophonium/NN (r_pobj) before/IN (r_prep) min/NN (r_dobj) given/VBN (l_conj) was/VBD (l_acomp) sufficient/JJ (l_xcomp) minimize/VB (l_dobj) bradycardias/NNS -PUNC- edrophonium/NN (r_npadvmod) induced/VBN (r_amod) bradycardias/NNS
2004015
D015215_C565469 NONE azidothymidine/NN (r_advmod) treated/VBN (l_dobj) mice/NNS (l_amod) immunodeficient/JJ
D015215_D000740 CID 3'-azido-3'dideoxythymidine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anaemia/NN -PUNC- AZT/NNP (r_appos) 3'-azido-3'dideoxythymidine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anaemia/NN -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) anaemia/NN -PUNC- AZT/NNP (r_nsubj) produced/VBD (l_dobj) anaemia/NN -PUNC- AZT/NNP (r_pobj) in/IN (r_prep) e/NNP (r_pobj) of/IN (r_prep) number/NN (r_nsubj) treated/VBD (l_prep) Despite/IN (l_pobj) anaemia/NN -PUNC- AZT/NNP (r_pobj) in/IN (r_prep) observed/VBD (l_conj) were/VBD (l_acomp) appropriate/JJ (l_prep) for/IN (l_pobj) degree/NN (l_prep) of/IN (l_pobj) anaemia/NN -PUNC- AZT/NNP (r_nsubj) treated/VBD (l_prep) with/IN (l_pobj) degrees/NNS (l_prep) of/IN (l_pobj) anaemia/NN -PUNC- AZT/NNP (r_pobj) in/IN (r_prep) observed/VBN (r_acl) degree/NN (l_prep) of/IN (l_pobj) anaemia/NN -PUNC- AZT/NNP (r_npadvmod) induced/VBN (l_dobj) anaemia/NN
D015215_D045262 NONE AZT/NNP (r_pobj) in/IN (r_prep) observed/VBN (r_acl) degree/NN (r_pobj) for/IN (r_prep) inappropriate/JJ (r_acomp) was/VBD (l_nsubj) reticulocytosis/NN
D015215_D007239 NONE AZT/NNP (r_npadvmod) induced/VBN (r_amod) anaemia/NN (r_nsubj) is/VBZ (r_ccomp) determine/VB (r_xcomp) used/VBN (l_dobj) model/NN (l_prep) of/IN (l_pobj) AIDS/NNP (l_appos) infection/NN
C030299_D000740 NONE phenylhydrazine/NN (r_npadvmod) treated/VBD (r_conj) observed/VBD (l_conj) were/VBD (l_acomp) appropriate/JJ (l_prep) for/IN (l_pobj) degree/NN (l_prep) of/IN (l_pobj) anaemia/NN -PUNC- PHZ/NNP (r_nsubj) treated/VBD (r_conj) observed/VBD (l_conj) were/VBD (l_acomp) appropriate/JJ (l_prep) for/IN (l_pobj) degree/NN (l_prep) of/IN (l_pobj) anaemia/NN -PUNC- PHZ/NNP (r_conj) AZT/NNP (r_nsubj) treated/VBD (l_prep) with/IN (l_pobj) degrees/NNS (l_prep) of/IN (l_pobj) anaemia/NN
D015215_D000163 NONE AZT/NNP (r_npadvmod) induced/VBN (r_amod) anaemia/NN (r_nsubj) is/VBZ (r_ccomp) determine/VB (r_xcomp) used/VBN (l_dobj) model/NN (l_prep) of/IN (l_pobj) AIDS/NNP
D015215_D007938 NONE AZT/NNP (r_npadvmod) induced/VBN (r_amod) anaemia/NN (r_nsubj) is/VBZ (r_ccomp) determine/VB (r_xcomp) used/VBN (l_dobj) model/NN (l_prep) of/IN (l_pobj) AIDS/NNP (l_appos) infection/NN (l_prep) of/IN (l_pobj) mice/NNS (l_prep) with/IN (l_pobj) leukaemia/NN
17241657
C107044_D012640 NONE 21/CD (r_nummod) /-)-SM/SYM (r_conj) UMB24/NNP (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) attenuated/VBN (l_dobj) convulsions/NNS
D003042_D012640 CID cocaine/NN (r_pobj) of/IN (r_prep) actions/NNS (l_amod) convulsive/JJ -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
C519696_D012640 NONE UMB24/NNP (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) attenuated/VBN (l_dobj) convulsions/NNS
20619828
D002997_D008569 CID Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN (l_appos) impairment/NN
D002997_D060845 CID Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN (l_appos) impairment/NN (l_conj) hoarding/NN
D002997_D001008 CID Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_dobj) changes/NNS (l_relcl) include/VBP (l_dobj) anxiety/NN
D002997_-1 NONE Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN -PUNC- Clomipramine/NNP (r_compound) exposure/NN (r_nsubj) produced/VBD (l_npadvmod) inflexibility/NN (l_appos) impairment/NN (l_conj) hoarding/NN (l_conj) dysfunction/NN
16680561
C476217_D006261 CID cinacalcet/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN -PUNC- cinacalcet/NN (r_conj) desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN
D003891_D006261 CID desipramine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_acl) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN -PUNC- desipramine/NN (r_dobj) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN -PUNC- desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN (l_conj) headache/NN
D003891_D009325 CID desipramine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_acl) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN -PUNC- desipramine/NN (r_dobj) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN -PUNC- desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN
C476217_D009325 CID cinacalcet/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_pcomp) than/IN (r_prep) alone/RB (r_amod) events/NNS (r_dobj) reported/VBD (r_ccomp) reported/VBN (l_nsubjpass) nausea/NN -PUNC- cinacalcet/NN (r_conj) desipramine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) reported/VBN (l_nsubjpass) nausea/NN
2870085
D007545_D013610 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN
C047847_D002637 NONE flestolol/NN (r_compound) infusion/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) safe/JJ (l_conj) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) pain/NN
C047847_D013610 NONE Flestolol/NNP (r_nsubj) produced/VBD (l_dobj) attenuation/NN (l_prep) of/IN (l_pobj) tachycardia/NN
C047847_D013617 NONE Flestolol/NNP (r_nsubj) reduced/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) tachyarrhythmia/NN
C047847_D000789 NONE flestolol/NN (r_compound) infusion/NN (r_nsubjpass) found/VBN (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN
11027905
D016202_D009437 NONE aspartate/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN -PUNC- NMDA/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN
D016202_D010146 NONE aspartate/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN -PUNC- NMDA/NNP (r_nmod) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D009020_D010146 NONE morphine/NN (r_pobj) to/IN (r_prep) responsive/JJ (r_amod) Pain/NN -PUNC- morphine/NN (r_pobj) by/IN (r_prep) unrelieved/JJ (r_acomp) was/VBD (l_nsubj) pain/NN -PUNC- morphine/NN (r_compound) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D007649_D009437 NONE ketamine/NN (r_pobj) as/IN (r_prep) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN -PUNC- Ketamine/NNP (r_nsubj) improve/VB (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN
D007649_D010146 NONE ketamine/NN (r_pobj) as/IN (r_prep) antagonists/NNS (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) bolus/NN (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_relcl) was/VBD (l_nsubj) pain/NN -PUNC- Ketamine/NN (r_nsubj) reduced/VBD (l_dobj) intensity/NN (l_compound) pain/NN -PUNC- Ketamine/NNP (r_nsubj) improve/VB (l_dobj) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D007649_D009369 NONE ketamine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) bolus/NN (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D009020_D009369 NONE morphine/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) patients/NNS (l_compound) cancer/NN -PUNC- morphine/NN (r_pobj) by/IN (r_prep) unrelieved/JJ (r_acomp) was/VBD (r_relcl) patients/NNS (l_compound) cancer/NN
D009020_D009437 NONE morphine/NN (r_compound) analgesia/NN (l_prep) in/IN (l_pobj) syndromes/NNS (l_prep) as/IN (l_pobj) pain/NN
7707116
D015474_D009447 NONE acid/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) neuroblastoma/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) lines/NNS (l_compound) neuroblastoma/NN -PUNC- RA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) lines/NNS (l_compound) neuroblastoma/NN -PUNC- RA/NNP (r_nsubj) demonstrated/VBN (l_dobj) responses/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) neuroblastoma/NN -PUNC- RA/NNP (r_pobj) of/IN (r_prep) toxicities/NNS (l_acl) administered/VBD (l_prep) on/IN (l_pobj) schedule/NN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) neuroblastoma/NN
D015474_D006934 CID RA/NNP (r_compound) levels/NNS (r_pobj) by/IN (r_agent) predicted/VBN (r_conj) included/VBD (l_dobj) hypercalcemia/NN
D015474_D064420 NONE RA/NNP (r_pobj) of/IN (r_prep) toxicities/NNS -PUNC- RA/NNP (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (l_nsubj) toxicities/NNS
14633084
D007069_D003556 CID ifosfamide/RB (r_advmod) induced/VBN (r_amod) cystitis/NN -PUNC- ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN -PUNC- ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN (l_appos) HC/NNP -PUNC- IFS/NNP (r_appos) ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN -PUNC- IFS/NNP (r_appos) ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN (l_appos) HC/NNP -PUNC- IFS/NNP (r_npadvmod) induced/VBN (r_amod) HC/NN -PUNC- IFS/NNP (r_npadvmod) induced/VBN (r_amod) HC/NN
D007069_D006470 CID ifosfamide/RB (r_advmod) induced/VBN (r_amod) cystitis/NN -PUNC- ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN -PUNC- ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN (l_appos) HC/NNP -PUNC- IFS/NNP (r_appos) ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN -PUNC- IFS/NNP (r_appos) ifosfamide/NN (r_pobj) with/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) AIM/VB (l_appos) cystitis/NN (l_appos) HC/NNP -PUNC- IFS/NNP (r_npadvmod) induced/VBN (r_amod) HC/NN -PUNC- IFS/NNP (r_npadvmod) induced/VBN (r_amod) HC/NN
D015080_D006470 NONE mesna/NN (r_pobj) with/IN (r_prep) Use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- mesna/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) HC/NN -PUNC- mesna/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) Dexamethasone/NN (r_nsubj) was/VBD (l_acomp) efficient/JJ (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) HC/NN -PUNC- mesna/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) replacement/NN (r_nsubj) prevent/VB (l_dobj) HC/NN -PUNC- mesna/JJ (r_amod) doses/NNS (r_pobj) of/IN (r_prep) all/DT (r_conj) saline/NN (r_pobj) with/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) replacement/NN (r_nsubj) prevent/VB (l_dobj) HC/NN
D015080_D003556 NONE mesna/NN (r_pobj) with/IN (r_prep) Use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- mesna/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) HC/NN -PUNC- mesna/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) Dexamethasone/NN (r_nsubj) was/VBD (l_acomp) efficient/JJ (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) HC/NN -PUNC- mesna/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) replacement/NN (r_nsubj) prevent/VB (l_dobj) HC/NN -PUNC- mesna/JJ (r_amod) doses/NNS (r_pobj) of/IN (r_prep) all/DT (r_conj) saline/NN (r_pobj) with/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) replacement/NN (r_nsubj) prevent/VB (l_dobj) HC/NN
D003907_D003556 NONE dexamethasone/NN (r_pobj) of/IN (r_prep) Use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- dexamethasone/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) HC/NN -PUNC- Dexamethasone/NN (r_nsubj) was/VBD (l_acomp) efficient/JJ (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) HC/NN -PUNC- dexamethasone/NN (r_pobj) with/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) all/DT (r_conj) saline/NN (r_pobj) with/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) replacement/NN (r_nsubj) prevent/VB (l_dobj) HC/NN
D003907_D006470 NONE dexamethasone/NN (r_pobj) of/IN (r_prep) Use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- dexamethasone/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) HC/NN -PUNC- Dexamethasone/NN (r_nsubj) was/VBD (l_acomp) efficient/JJ (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) HC/NN -PUNC- dexamethasone/NN (r_pobj) with/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) all/DT (r_conj) saline/NN (r_pobj) with/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) replacement/NN (r_nsubj) prevent/VB (l_dobj) HC/NN
7650771
D004456_D009157 NONE iodide/NN (r_nmod) drops/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) from/IN (r_prep) syndrome/NN (r_dobj) developed/VBD (l_conj) presented/VBN (l_conj) given/VBN (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) gravis/NN
D004456_D018908 CID iodide/NN (r_nmod) drops/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) from/IN (r_prep) syndrome/NN (r_dobj) developed/VBD (l_conj) presented/VBN (l_prep) with/IN (l_pobj) weakness/NN
D004456_D064420 NONE iodide/NN (r_compound) drops/VBZ (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) toxicity/NN
6640832
D004317_D002277 NONE adriamycin/NNS (l_prep) in/IN (l_pobj) carcinoma/NN
D004317_D001749 NONE adriamycin/NNS (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- Adriamycin/NNP (r_nsubjpass) administered/VBN (l_prep) after/IN (l_pobj) resection/NN (l_prep) of/IN (l_pobj) tumors/NNS
9214597
D004967_D010911 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) rat/NN (r_nmod) tumors/NNS -PUNC- estrogen/NN (r_npadvmod) initiated/VBN (r_amod) angiogenesis/NN (r_dobj) mediate/VB (l_prep) Over/IN (l_pobj) expression/NN (l_prep) of/IN (l_pobj) factor/NN (l_conj) receptor/NN (l_prep) during/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) tumors/NNS
D004967_D009369 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) rat/NN (r_nmod) tumors/NNS (r_pobj) of/IN (r_prep) development/NN (r_pobj) during/IN (r_prep) receptor/NN (r_conj) factor/NN (r_pobj) of/IN (r_prep) expression/NN (r_pobj) Over/IN (r_prep) mediate/VB (l_dobj) angiogenesis/NN (l_compound) tumor/NN -PUNC- estrogen/NN (r_npadvmod) initiated/VBN (r_amod) angiogenesis/NN (l_compound) tumor/NN -PUNC- Estrogens/NNP (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) cancers/NNS -PUNC- Estrogens/NNP (r_nsubj) induce/VB (l_dobj) angiogenesis/NN (l_compound) tumor/NN -PUNC- estrogen/NN (r_compound) carcinogenesis/NN (r_pobj) during/IN (r_prep) are/VBP (l_nsubj) details/NNS (l_prep) of/IN (l_pobj) angiogenesis/NN (l_compound) tumor/NN -PUNC- estrogen/NN (r_pobj) of/IN (r_prep) role/NN (r_dobj) elucidate/VB (l_prep) in/IN (l_pobj) regulation/NN (l_prep) of/IN (l_pobj) angiogenesis/NN (l_compound) tumor/NN -PUNC- estrogen/NN (r_pobj) of/IN (r_prep) regulation/NN (r_pobj) of/IN (r_prep) step/NN (r_pobj) in/IN (r_prep) play/VB (r_ccomp) suggest/VBP (l_ccomp) induced/VBN (l_dobj) angiogenesis/NN (l_compound) tumor/NN
D004967_D063646 NONE estrogen/NN (r_compound) carcinogenesis/NN
9754849
D003042_D002819 CID cocaine/NN (r_pobj) with/IN (r_prep) intoxications/NNS (r_pobj) during/IN (r_prep) be/VB (r_xcomp) known/VBN (l_nsubjpass) hyperkinesias/NNS -PUNC- cocaine/NN (r_conj) heroine/NN (r_dobj) abusing/VBG (r_acl) inpatient/NN (r_pobj) in/IN (r_prep) adjustment/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) choreoathetoid/JJ (l_dobj) movements/NNS
D003042_D006948 CID cocaine/NN (r_pobj) with/IN (r_prep) intoxications/NNS (r_pobj) during/IN (r_prep) be/VB (r_xcomp) known/VBN (l_nsubjpass) hyperkinesias/NNS
D003042_D020820 NONE cocaine/NN (r_pobj) with/IN (r_prep) intoxications/NNS (r_pobj) during/IN (r_prep) be/VB (l_attr) abnormalities/NNS
D003932_D002819 NONE heroine/NN (r_dobj) abusing/VBG (r_acl) inpatient/NN (r_pobj) in/IN (r_prep) adjustment/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) choreoathetoid/JJ (l_dobj) movements/NNS
D008691_D002819 CID methadone/NN (r_pobj) to/IN (r_prep) adjustment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) movements/NNS -PUNC- methadone/NN (r_pobj) to/IN (r_prep) adjustment/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) choreoathetoid/JJ (l_dobj) movements/NNS
19346865
D008795_D001927 CID metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) in/IN (r_prep) lesion/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) in/IN (r_prep) lesions/NNS -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) for/IN (r_prep) characteristic/NN (r_pobj) as/IN (r_prep) considered/VBN (l_nsubjpass) lesions/NNS -PUNC- metronidazole/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN
D008795_D007239 NONE metronidazole/NN (r_dobj) taking/VBG (l_advcl) treat/VB (l_dobj) infection/NN
12627929
D013792_D054556 CID thalidomide/NN (r_conj) docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) thromboembolism/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_conj) alone/RB (r_advmod) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_conj) alone/RB (r_advmod) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- thalidomide/NN (r_conj) 9/CD (r_nsubj) developed/VBD (r_advcl) developed/VBN (l_dobj) VTE/NNP -PUNC- thalidomide/NN (r_conj) 9/CD (r_nsubj) developed/VBD (l_dobj) VTE/NNP -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) increases/VBZ (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) VTE/NNP
C067311_D011471 NONE docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- docetaxel/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) cancer/NN -PUNC- docetaxel/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
C067311_D054556 CID docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) thromboembolism/NN -PUNC- docetaxel/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- docetaxel/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) developed/VBN (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) developed/VBN (l_advcl) developed/VBD (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) 9/CD (r_nsubj) developed/VBD (r_advcl) developed/VBN (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) 9/CD (r_nsubj) developed/VBD (l_dobj) VTE/NNP -PUNC- docetaxel/NNS (r_relcl) addition/NN (r_nsubj) increases/VBZ (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) VTE/NNP
D013792_D011471 NONE thalidomide/NN (r_conj) docetaxel/NNS (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_conj) alone/RB (r_advmod) treated/VBN (r_relcl) cancer/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) addition/NN (l_relcl) docetaxel/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
9653867
D013974_D013971 CID Thyroxine/NNP (r_compound) abuse/NN (l_appos) case/NN (l_prep) of/IN (l_pobj) thyrotoxicosis/NN -PUNC- thyroxine/NN (r_compound) abuse/NN (r_nsubjpass) considered/VBN (l_advcl) remains/VBZ (l_nsubj) cause/NN (l_prep) for/IN (l_pobj) thyrotoxicosis/NN
D013974_D001068 NONE thyroxine/NN (r_compound) abuse/NN (r_nsubjpass) considered/VBN (r_ccomp) reminds/VBZ (r_conj) illustrates/VBZ (l_dobj) derangements/NNS (l_prep) of/IN (l_pobj) function/NN (l_acl) seen/VBN (l_prep) with/IN (l_pcomp) eating/VBG (l_dobj) disorders/NNS
6888657
D004967_D010911 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) tumors/NNS
D004054_D010911 CID diethylstilbestrol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) tumors/NNS -PUNC- DES/NNP (r_npadvmod) implanted/VBN (r_parataxis) induced/VBN (l_nsubjpass) tumors/NNS
D004054_D009369 NONE DES/NNP (r_npadvmod) induced/VBN (r_amod) tumor/NN
15517007
D008942_D006331 CID mitoxantrone/NN (r_pobj) as/IN (r_prep) anthracyclines/NNS (r_conj) cyclophosphamide/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) damage/NN
D008942_D012595 NONE mitoxantrone/NN (r_pobj) as/IN (r_prep) anthracyclines/NNS (r_conj) cyclophosphamide/NN (r_nsubjpass) used/VBN (l_dobj) patients/NNS (l_compound) sclerosis/NN
D018943_D012595 NONE anthracyclines/NNS (r_conj) cyclophosphamide/NN (r_nsubjpass) used/VBN (l_dobj) patients/NNS (l_compound) sclerosis/NN
D018943_D006331 NONE anthracyclines/NNS (r_conj) cyclophosphamide/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) damage/NN
D003520_D006331 CID cyclophosphamide/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) damage/NN
D003520_D012595 NONE cyclophosphamide/NN (r_nsubjpass) used/VBN (l_dobj) patients/NNS (l_compound) sclerosis/NN
17466854
D008775_D002386 NONE methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) incidence/NN (r_dobj) assess/VB (l_conj) gentamicin/NN (l_prep) at/IN (l_pobj) end/NN (l_prep) of/IN (l_pobj) surgery/NN (l_compound) cataract/NN
D005839_D006261 CID gentamicin/NN (r_conj) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) headache/NN
D005839_D002386 NONE gentamicin/NN (l_prep) at/IN (l_pobj) end/NN (l_prep) of/IN (l_pobj) surgery/NN (l_compound) cataract/NN
D008775_D006261 CID methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) headache/NN
D008775_D020250 CID methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN
D005839_D020250 CID gentamicin/NN (r_conj) administration/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nausea/NN (l_conj) vomiting/NN
15233872
C007145_D009203 NONE Crataegus/NNP (r_pobj) of/IN (r_prep) tincture/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) infarction/NN -PUNC- TCR/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) infarction/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
17854040
D019259_D015658 NONE lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_punct) :/: (l_punct) infection/NN -PUNC- lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/JJ (r_npadvmod) resistant/JJ (r_amod) virus/NN (r_dobj) investigate/VB (r_acl) study/NN (r_attr) was/VBD (l_punct) ./. (l_punct) in/IN (l_punct) infection/NN -PUNC- lamivudine/NN (r_compound) na/NN (r_aux) ve/VB (r_acl) study/NN (r_attr) was/VBD (l_punct) ./. (l_punct) in/IN (l_punct) infection/NN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (r_nsubjpass) detected/VBN (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (l_prep) in/IN (l_pcomp) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) containing/VBG (r_advcl) emergence/NN (r_pobj) in/IN (r_prep) result/VB (l_conj) applied/VBN (l_advcl) is/VBZ (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) implications/NNS (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_amod) infected/VBN
D012964_D015658 NONE na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_punct) :/: (l_punct) infection/NN -PUNC- na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- na/NN (r_aux) ve/VB (r_acl) study/NN (r_attr) was/VBD (l_punct) ./. (l_punct) in/IN (l_punct) infection/NN -PUNC- na/TO (r_aux) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN
D019259_D006509 NONE lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_amod) infected/JJ -PUNC- lamivudine/NN (r_compound) resistance/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mutations/NNS (r_nsubj) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/JJ (r_npadvmod) resistant/JJ (r_amod) virus/NN (l_compound) B/NN -PUNC- lamivudine/NN (r_compound) na/NN (r_aux) ve/VB (r_acl) study/NN (l_acl) investigate/VB (l_dobj) virus/NN (l_compound) B/NN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (r_nsubjpass) detected/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (r_nsubjpass) detected/VBN (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) resistant/JJ (r_amod) strains/NNS (l_prep) in/IN (l_pcomp) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN -PUNC- lamivudine/NN (r_npadvmod) containing/VBG (r_advcl) emergence/NN (r_pobj) in/IN (r_prep) result/VB (l_conj) applied/VBN (l_advcl) is/VBZ (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) implications/NNS (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_amod) infected/VBN
D012964_D006509 NONE na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_amod) infected/JJ -PUNC- na/TO (r_aux) ve/VB (l_dobj) virus/NN (l_appos) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) implications/NNS (l_conj) patients/NNS (l_amod) infected/VBN -PUNC- na/NN (r_aux) ve/VB (r_acl) study/NN (l_acl) investigate/VB (l_dobj) virus/NN (l_compound) B/NN -PUNC- na/TO (r_aux) ve/VB (l_dobj) patients/NNS (l_amod) infected/VBN
1549199
D007980_D005767 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_conj) hypotension/NN (r_conj) disorders/NNS
D007980_D064420 NONE levodopa/NN (r_compound) therapy/NN (r_pobj) for/IN (r_prep) dose/NN (r_dobj) starting/NN (r_acl) correct/JJ (r_attr) is/VBZ (r_advcl) started/VBN (l_prep) following/VBG (l_pobj) rule/NN (l_relcl) attempt/VB (l_xcomp) titrate/VB (l_dobj) levodopa/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) toxicity/NN -PUNC- levodopa/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) toxicity/NN
D007980_D020447 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (l_conj) disturbances/NNS (l_conj) parasomnias/NNS
D002230_D064420 NONE carbidopa/NN (r_compound) levodopa/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) toxicity/NN
D007980_D011618 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN
D007980_D012893 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (l_conj) disturbances/NNS
D007980_D007024 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_conj) hypotension/NN
7337133
D000082_D017093 CID acetaminophen/NN (r_compound) overdose/NN (r_pobj) in/IN (r_prep) failure/NN -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) failure/NN
D000082_D062787 NONE acetaminophen/NN (r_compound) overdose/NN
D000082_D001929 CID acetaminophen/NN (r_compound) overdose/NN (r_pobj) in/IN (r_prep) failure/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) edema/NN -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) failure/NN (r_pobj) with/IN (r_prep) patient/NN (r_dobj) present/VBP (l_prep) with/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) edema/NN
3015327
D007538_D009422 CID isoniazid/NN (r_compound) neuropathy/NN -PUNC- isoniazid/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neuropathy/NN
19820426
C558899_D066126 NONE ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) toxicity/NN
C558899_D001919 CID ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN (r_conj) block/NN (r_dobj) developed/VBD (l_advcl) developed/VBD (l_dobj) bradycardia/NNS
C558899_D002311 CID ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN
C558899_D006327 CID ritonavir/NNS (r_compound) therapy/NN (r_appos) lopinavir/NNS (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN (r_conj) block/NN
1711760
D010656_D007511 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_nsubj) instituted/VBD (l_advcl) aggravate/VB (l_dobj) edema/NN (l_prep) in/IN (l_pobj) core/NN (l_amod) ischemic/JJ -PUNC- phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_nsubj) instituted/VBD (l_advcl) aggravate/VB (l_dobj) edema/NN (l_acl) improves/VBZ (l_dobj) edema/NN (l_prep) in/IN (l_pobj) periphery/NN (l_prep) of/IN (l_pobj) territory/NN (l_amod) ischemic/JJ
D010656_D020244 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_nsubj) instituted/VBD (l_advcl) aggravate/VB (l_nsubj) MCAO/NNP
D007530_D006973 NONE isoflurane/JJ (r_amod) anesthesia/NN (r_pobj) Under/IN (r_prep) occluded/VBN (l_nsubjpass) MCA/NNP (l_prep) of/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
C009591_D009410 NONE 2,3,5-triphenyltetrazolium/CD (r_nummod) staining/VBG (r_pobj) by/IN (r_agent) determined/VBN (l_nsubjpass) extent/NN (l_prep) of/IN (l_pobj) injury/NN
D010656_D009410 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_nsubj) instituted/VBD (l_advcl) aggravate/VB (l_dobj) edema/NN (l_acl) improves/VBZ (l_conj) reduces/VBZ (l_dobj) area/NN (l_prep) of/IN (l_pobj) dysfunction/NN
D010656_D004487 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_nsubj) instituted/VBD (l_advcl) aggravate/VB (l_dobj) edema/NN -PUNC- phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_nsubj) instituted/VBD (l_advcl) aggravate/VB (l_dobj) edema/NN (l_acl) improves/VBZ (l_dobj) edema/NN
D010656_D006973 CID phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
18754075
D013256_D009404 NONE steroid/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) responding/VBG (l_nsubj) man/NN (l_prep) with/IN (l_pobj) syndrome/NN
D013256_D005923 NONE steroid/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) responding/VBG (l_nsubj) man/NN (l_amod) due/IN (l_pobj) glomerulosclerosis/NN
D019386_D058186 CID alendronate/JJ (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN (l_conj) failure/NN -PUNC- sodium/NN (r_nmod) administration/NN (r_nsubj) increased/VBD (l_prep) with/IN (l_pobj) failure/NN
D004164_D005923 NONE bisphosphonate/NN (r_nmod) administration/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) glomerulosclerosis/NN
D019386_D005923 NONE alendronate/JJ (r_nmod) administration/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) glomerulosclerosis/NN
D019386_D011507 CID alendronate/JJ (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN
D004164_D058186 NONE bisphosphonate/NN (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN (l_conj) failure/NN -PUNC- bisphosphonate/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) Within/IN (r_prep) increased/VBD (l_prep) with/IN (l_pobj) failure/NN -PUNC- bisphosphonates/NNS (r_nsubj) aggravate/VB (l_dobj) proteinuria/NN (l_conj) failure/NN
D004164_D011507 NONE bisphosphonate/NN (r_nmod) administration/NN (r_pobj) after/IN (r_prep) proteinuria/NN -PUNC- bisphosphonates/NNS (r_nsubj) aggravate/VB (l_dobj) proteinuria/NN
16006300
D002118_D006934 NONE calcium/NN (r_dobj) corrected/VBN (r_parataxis) report/VBP (l_dobj) data/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) presented/VBD (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- calcium/NN (r_dobj) corrected/VBN (l_conj) review/VB (l_dobj) literature/NN (l_prep) on/IN (l_pobj) syndrome/NN
C019248_D006996 CID pamidronate/JJ (l_relcl) caused/VBD (l_dobj) hypocalcemia/NN -PUNC- Pamidronate/JJ (r_compound) treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) hypocalcemia/NN
D002119_D064420 NONE carbonate/NN (r_compound) toxicity/NN
C097949_D058186 NONE D/JJ (r_compound) concentrations/NNS (r_conj) peptide/NN (r_conj) hormone/NN (r_conj) alkalosis/NN (r_conj) insufficiency/NN
C097949_D000471 NONE D/JJ (r_compound) concentrations/NNS (r_conj) peptide/NN (r_conj) hormone/NN (r_conj) alkalosis/NN
D002118_D006996 NONE calcium/NN (r_compound) concentrations/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_nsubj) pamidronate/JJ (l_relcl) caused/VBD (l_dobj) hypocalcemia/NN
D002119_D006934 CID carbonate/NN (r_compound) toxicity/NN (l_appos) syndrome/NN -PUNC- carbonate/NN (r_npadvmod) induced/VBN (r_amod) hypercalcemia/NN -PUNC- carbonate/NN (r_npadvmod) induced/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) describe/VB (l_conj) gain/VB (l_dobj) insights/NNS (l_prep) into/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- carbonate/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) by/IN (r_agent) precipitated/VBN (r_conj) be/VB (l_nsubj) syndrome/NN -PUNC- carbonate/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) by/IN (r_agent) precipitated/VBN (r_conj) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN
C019248_D006934 NONE Pamidronate/JJ (r_compound) treatment/NN (r_nsubjpass) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hypercalcemia/NN
1415380
D011803_D006463 CID quinine/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) syndrome/NN -PUNC- quinine/NN (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) syndrome/NN -PUNC- Quinine/NN (r_npadvmod) associated/VBN (r_amod) syndrome/NN
2802551
D012964_D007674 NONE Sodium/NN (r_compound) status/NN (r_nsubj) influences/VBZ (l_dobj) nephrotoxicity/NN
D000666_D007674 CID B/NN (r_compound) nephrotoxicity/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) potential/NN (l_amod) nephrotoxic/JJ
424937
D008750_D008107 NONE methyldopa/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) disease/NN -PUNC- methyldopa/NN (l_conj) dysfunction/NN
D008750_D017114 NONE methyldopa/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_pobj) of/IN (r_prep) episode/NN (r_pobj) after/IN (r_prep) recommenced/VBN (r_advcl) developed/VBD (l_dobj) hepatitis/NN
D008750_D056486 CID methyldopa/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Patterns/NNS (l_prep) of/IN (l_pobj) injury/NN -PUNC- methyldopa/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- methyldopa/NN (r_pobj) between/IN (r_prep) relationship/NN (r_nsubjpass) proved/VBN (l_prep) with/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) hepatitis/NN
D008750_D017093 NONE methyldopa/NN (r_dobj) taking/VBG (r_relcl) another/DT (r_nsubj) showed/VBD (r_conj) presented/VBN (l_prep) in/IN (l_pobj) failure/NN
15325671
D017239_D001943 NONE paclitaxel/NN (l_conj) melphalan/NN (l_conj) cyclophosphamide/NN (l_conj) thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D013852_D001943 NONE thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D003520_D001943 NONE cyclophosphamide/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (l_prep) for/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (l_conj) thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_dobj) receiving/VBG (r_acl) cancer/NN
D018943_D006973 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (l_prep) of/IN (l_pobj) electrocardiogram/NN (l_appos) abnormalities/NNS (l_appos) hypertension/NN
D018943_D003920 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN
D018943_D006333 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (r_appos) characteristics/NNS (r_conj) cancer/NN (l_acl) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (r_appos) characteristics/NNS (r_conj) cancer/NN (l_acl) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN (l_appos) CHF/NNP
D003520_D066126 NONE cyclophosphamide/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) observed/VBD (l_nsubj) toxicity/NN -PUNC- cyclophosphamide/NN (r_npadvmod) related/VBN (r_amod) toxicity/NN
D008558_D001943 NONE melphalan/NN (l_conj) cyclophosphamide/NN (l_conj) thiotepa/NNS (l_conj) carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D018943_D001943 NONE anthracyclines/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) mellitus/NN (r_conj) smoking/NN (r_conj) history/NN (r_appos) presence/NN (r_appos) characteristics/NNS (r_conj) cancer/NN
D003520_D006973 NONE cyclophosphamide/NN (r_dobj) receiving/VBG (r_acl) cancer/NN (l_conj) characteristics/NNS (l_appos) presence/NN (l_prep) of/IN (l_pobj) electrocardiogram/NN (l_appos) abnormalities/NNS (l_appos) hypertension/NN
D003520_D006333 CID cyclophosphamide/NN (r_dobj) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- cyclophosphamide/NN (r_dobj) receiving/VBG (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimen/NN (l_acl) assess/VB (l_dobj) association/NN (l_prep) between/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) failure/NN (l_appos) CHF/NNP -PUNC- cyclophosphamide/NN (r_dobj) following/VBG (r_prep) developed/VBD (l_dobj) grade/NN (l_appos) CHF/NNP -PUNC- cyclophosphamide/NN (r_pobj) during/IN (r_prep) monitoring/NN (r_nsubj) predict/VB (l_dobj) development/NN (l_compound) CHF/NNP
D016190_D001943 NONE carboplatin/VB (l_dobj) regimen/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D003520_D003920 NONE cyclophosphamide/NN (r_dobj) receiving/VBG (r_acl) cancer/NN (l_conj) characteristics/NNS (l_appos) presence/NN (l_appos) history/NN (l_conj) smoking/NN (l_conj) mellitus/NN
3015567
D009599_D007022 CID Nitroprusside/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN
D003345_D007022 NONE corticosterone/NN (r_compound) level/NN (r_pobj) at/IN (r_prep) occurs/VBZ (r_conj) observed/VBN (l_nsubjpass) Suppression/NN (l_appos) secretion/NN (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) hypotension/NN
2557556
D015124_D006930 CID monophosphate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperalgesia/NN
D009020_D006930 NONE Morphine/NNP (r_nsubj) alter/VB (l_dobj) hyperalgesia/NN
D015232_D006930 CID E2-induced/VBN (r_amod) hyperalgesia/NN
11875660
D001374_D009436 NONE 5-azacytidine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) exencephaly/NNS
20698227
D012254_D000740 NONE ribavirin/RB (r_conj) markers/NNS (r_dobj) angiogenesis/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) investigating/VBG (r_acl) study/NN (r_attr) is/VBZ (l_advcl) induced/VBD (l_dobj) anemia/NN
C473478_D006461 CID sunitinib/JJ (r_pobj) as/IN (r_prep) inhibitors/NNS (r_pobj) of/IN (r_prep) number/NN (r_nsubjpass) found/VBN (l_advcl) cause/VB (l_dobj) hemolysis/NN
D012254_D019698 NONE ribavirin/RB (r_conj) 2a/CD (r_pobj) by/IN (r_agent) treated/VBN (l_csubjpass) infected/VBN (l_prep) with/IN (l_pobj) virus/NN -PUNC- ribavirin/RB (r_conj) markers/NNS (r_dobj) angiogenesis/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) investigating/VBG (r_acl) study/NN (r_attr) is/VBZ (l_advcl) induced/VBD (l_dobj) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) C/NNP
C100416_D019698 NONE 2a/CD (r_pobj) by/IN (r_agent) treated/VBN (l_csubjpass) infected/VBN (l_prep) with/IN (l_pobj) virus/NN
D012254_D006461 NONE ribavirin/RB (r_nsubjpass) found/VBN (l_conj) found/VBN (l_advcl) cause/VB (l_dobj) hemolysis/NN
D012254_D000743 NONE ribavirin/RB (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) target/NN (l_acl) associated/VBN (l_dobj) anemia/NN
C471405_D006461 CID sorafenib/NNS (r_conj) sunitinib/JJ (r_pobj) as/IN (r_prep) inhibitors/NNS (r_pobj) of/IN (r_prep) number/NN (r_nsubjpass) found/VBN (l_advcl) cause/VB (l_dobj) hemolysis/NN
15120741
D010862_D013226 CID pilocarpine/NN (r_compound) injection/NN (r_nsubj) causes/VBZ (l_dobj) SE/NNP (l_nmod) epilepticus/NN -PUNC- pilocarpine/NN (r_compound) injection/NN (r_nsubj) causes/VBZ (l_dobj) SE/NNP -PUNC- pilocarpine/NN (r_npadvmod) treated/VBN (r_amod) mice/NNS (r_conj) mice/NNS (r_pobj) from/IN (r_prep) cells/NNS (r_pobj) in/IN (r_prep) spike/NN (l_relcl) experience/VB (l_dobj) SE/NNP
D008274_D013226 NONE Mg(2+)-free/JJ (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) spike/NN (l_relcl) experience/VB (l_dobj) SE/NNP
D018698_D013226 NONE glutamate/NN (r_compound) receptor/NN (r_compound) antagonists/NNS (r_pobj) by/IN (r_agent) blocked/VBN (r_relcl) duration/NN (r_pobj) of/IN (r_prep) afterdischarges/NNS (r_conj) shifts/NNS (r_pobj) by/IN (r_prep) followed/VBD (r_advcl) resulted/VBD (l_prep) In/IN (l_pobj) survivors/NNS (l_compound) SE/NNP -PUNC- glutamate/NN (r_compound) photostimulation/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) responses/NNS (l_prep) of/IN (l_pobj) duration/NN (l_prep) in/IN (l_pobj) slices/NNS (l_prep) from/IN (l_pobj) survivors/NNS (l_compound) SE/NNP
D001640_D013226 NONE bicuculline/NN (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) spike/NN (l_relcl) experience/VB (l_dobj) SE/NNP
D010862_D012640 CID pilocarpine/NN (r_compound) injection/NN (r_nsubj) causes/VBZ (l_dobj) SE/NNP (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS
15266215
C406224_D001168 NONE valdecoxib/NNS (l_prep) versus/IN (l_pobj) agents/NNS (l_conj) placebo/NN (l_prep) on/IN (l_pobj) events/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
C406224_D010003 NONE valdecoxib/NNS (r_pobj) for/IN (r_prep) data/NNS (l_appos) inhibitor/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) osteoarthritis/NN -PUNC- valdecoxib/NNS (r_dobj) analyzing/VBG (r_pcomp) by/IN (r_prep) determined/VBN (l_appos) NSAID/NNP (l_npadvmod) ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_nmod) osteoarthritis/NN -PUNC- valdecoxib/NN (r_compound) doses/NNS (r_conj) treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) relative/JJ (l_prep) to/IN (l_pobj) NSAIDs/NNPS (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) osteoarthritis/NN
D004008_D010003 NONE diclofenac/NN (r_nmod) bid/NN (r_appos) NSAID/NNP (l_npadvmod) ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_nmod) osteoarthritis/NN
D004008_D001172 NONE diclofenac/NN (r_nmod) bid/NN (r_appos) NSAID/NNP (l_npadvmod) ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_compound) arthritis/NN
D004008_D013927 NONE diclofenac/NN (r_nmod) bid/NN (r_appos) NSAID/NNP (r_appos) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- diclofenac/NN (r_nmod) bid/NN (r_appos) NSAID/NNP (r_appos) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_appos) thrombotic/JJ
D009288_D010003 NONE naproxen/NN (r_conj) ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_nmod) osteoarthritis/NN
D009288_D001172 NONE naproxen/NN (r_conj) ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_compound) arthritis/NN
D009288_D013927 NONE naproxen/NN (r_conj) ibuprofen/VBD (r_npadvmod) NSAID/NNP (r_appos) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- naproxen/NN (r_conj) ibuprofen/VBD (r_npadvmod) NSAID/NNP (r_appos) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_appos) thrombotic/JJ
D001241_D013927 CID aspirin/NN (r_compound) users/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) for/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_amod) Thrombotic/JJ -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) nonusers/NNS (r_pobj) than/IN (r_prep) users/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) for/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_amod) Thrombotic/JJ
D007052_D001172 NONE ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_compound) arthritis/NN
D007052_D013927 NONE ibuprofen/VBD (r_npadvmod) NSAID/NNP (r_appos) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- ibuprofen/VBD (r_npadvmod) NSAID/NNP (r_appos) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_appos) thrombotic/JJ
D007052_D010003 NONE ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_nmod) osteoarthritis/NN
C406224_D001172 NONE valdecoxib/NNS (r_pobj) for/IN (r_prep) data/NNS (l_appos) inhibitor/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) osteoarthritis/NN (l_conj) arthritis/NN -PUNC- valdecoxib/NNS (r_dobj) analyzing/VBG (r_pcomp) by/IN (r_prep) determined/VBN (l_appos) NSAID/NNP (l_npadvmod) ibuprofen/VBD (l_conj) data/NNS (l_prep) from/IN (l_pobj) trials/NNS (l_compound) arthritis/NN -PUNC- valdecoxib/NN (r_compound) doses/NNS (r_conj) treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) relative/JJ (l_prep) to/IN (l_pobj) NSAIDs/NNPS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) arthritis/NN
C406224_D013927 NONE valdecoxib/NNS (l_prep) versus/IN (l_pobj) agents/NNS (l_conj) placebo/NN (l_prep) on/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- valdecoxib/NNS (r_dobj) analyzing/VBG (r_pcomp) by/IN (r_prep) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- valdecoxib/NNS (r_dobj) analyzing/VBG (r_pcomp) by/IN (r_prep) determined/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_appos) thrombotic/JJ -PUNC- valdecoxib/NNS (r_pobj) for/IN (r_prep) similar/JJ (r_acomp) were/VBD (l_nsubj) incidences/NNS (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- valdecoxib/NN (r_compound) dose/NN (r_pobj) for/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ -PUNC- valdecoxib/NN (r_conj) placebo/NN (r_appos) nonusers/NNS (r_pobj) than/IN (r_prep) users/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) for/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_amod) Thrombotic/JJ -PUNC- valdecoxib/NN (r_compound) doses/NNS (r_conj) treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) thrombotic/JJ
2004
D011433_D001145 NONE propranolol/NN (r_pobj) of/IN (r_prep) instances/NNS (r_pobj) in/IN (r_prep) required/VBN (l_ccomp) responded/VBD (l_nsubj) arrhythmias/NNS
D002746_D013617 NONE Thorazine/NN (r_dobj) receiving/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) developed/VBN (l_nsubj) tachycardia/NN -PUNC- chlorpromazine/NN (r_appos) Thorazine/NN (r_dobj) receiving/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) developed/VBN (l_nsubj) tachycardia/NN
D010640_D005117 NONE phenothiazines/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) complications/NNS
D008012_D001145 NONE lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) responded/VBD (l_nsubj) arrhythmias/NNS
D013881_D017180 CID Mellaril/NNP (r_nsubj) appeared/VBD (l_xcomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) tachycardia/NN -PUNC- thioridazine/NNP (r_appos) Mellaril/NNP (r_nsubj) appeared/VBD (l_xcomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) tachycardia/NN
D000639_D002037 CID Elavil/NNP (r_conj) Aventyl/NNP (r_nsubj) block/NN -PUNC- amitriptyline/FW (r_appos) Elavil/NNP (r_conj) Aventyl/NNP (r_nsubj) block/NN
D009661_D002037 CID Aventyl/NNP (r_nsubj) block/NN -PUNC- nortriptyline/NN (r_appos) Aventyl/NNP (r_nsubj) block/NN
8475949
D010419_D017180 NONE pentamidine/NN (l_conj) tachycardia/NN -PUNC- isethionate/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) tachyarrhythmias/NNS
D008274_D008133 NONE magnesium/NN (r_compound) supplementation/NN (r_nsubjpass) advocated/VBN (l_advcl) observed/VBN (l_nsubjpass) prolongation/NN
D008274_C537153 NONE magnesium/NN (r_compound) levels/NNS (l_conj) hypomagnesemia/NN
D010419_C537153 NONE Pentamidine/NNP (r_npadvmod) induced/VBN (r_amod) torsade/NN (r_nmod) pointes/FW (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) levels/NNS (l_conj) hypomagnesemia/NN
D010419_D016171 CID isethionate/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) tachyarrhythmias/NNS (l_prep) including/VBG (l_pobj) pointes/FW -PUNC- Pentamidine/NNP (r_npadvmod) induced/VBN (r_amod) torsade/NN (r_nmod) pointes/FW -PUNC- pentamidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) of/IN (r_prep) average/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) pointes/NNS -PUNC- pentamidine/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) without/IN (r_prep) recognized/VBN (r_advcl) treated/VBN (l_nsubjpass) pointes/FW
D008274_D016171 NONE magnesium/NN (r_compound) levels/NNS (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) pointes/FW
12757899
D004958_D012640 NONE Estradiol/NN (r_nsubj) reduces/VBZ (l_dobj) injury/NN (l_amod) induced/VBN (l_npadvmod) seizure/NN -PUNC- estradiol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) threshold/NN (l_compound) seizure/NN
D008094_D013226 CID lithium/NN (r_compound) pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) SE/NNP
D007608_D001930 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) protect/VBP (l_dobj) rats/NNS (l_prep) from/IN (l_pobj) injury/NN
D007608_D013226 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) status/NN (l_appos) SE/NNP (l_amod) epilepticus/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) status/NN (l_appos) SE/NNP
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) SE/NNP
D004958_D013226 NONE estradiol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) rats/NNS (l_acl) subjected/VBN (l_prep) to/IN (l_pobj) SE/NNP
D012834_D013226 NONE silver/NN (r_npadvmod) stained/VBN (r_amod) CA3/NN (r_pobj) of/IN (r_prep) extent/NN (r_nsubjpass) evaluated/VBN (l_prep) after/IN (l_pobj) SE/NNP
D004958_D001930 NONE Estradiol/NN (r_nsubj) reduces/VBZ (l_dobj) injury/NN
19893084
D005839_D058186 CID gentamicin/NN (r_pcomp) by/IN (r_agent) induced/VBN (r_acl) failure/NN
12911170
D002939_D009395 CID Ciprofloxacin/NNP (r_npadvmod) induced/VBN (l_dobj) nephritis/NN -PUNC- Ciprofloxacin/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nephritis/NN -PUNC- ciprofloxacin/NNS (r_npadvmod) induced/VBN (r_amod) nephritis/NN
D002939_D000744 NONE Ciprofloxacin/NNP (r_npadvmod) induced/VBN (l_dobj) nephritis/NN (l_conj) anemia/NN -PUNC- ciprofloxacin/NNS (r_npadvmod) induced/VBN (r_amod) nephritis/NN (l_conj) anemia/NN
D002939_D000743 CID Ciprofloxacin/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) nephritis/NN (l_conj) anemia/NN
D013256_D000743 NONE steroid/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_conj) drug/NN (r_dobj) stopping/VBG (r_pcomp) after/IN (r_prep) improved/VBD (l_nsubj) anemia/NN
9727773
D001067_D006976 CID suppressants/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) incidence/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- suppressant/NN (r_compound) drugs/NNS (r_pobj) of/IN (r_prep) intake/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) disease/NN (r_attr) is/VBZ (l_nsubj) hypertension/NN -PUNC- suppressants/NNS (r_dobj) taken/VBN (l_ccomp) was/VBD (l_nsubj) diagnosis/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- suppressants/NNS (r_pobj) of/IN (r_prep) prescription/NN (r_pobj) of/IN (r_prep) policy/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypertension/NN
3950060
D000583_D007674 CID amikacin/JJ (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) nephrotoxicity/NN -PUNC- amikacin/JJ (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) from/IN (r_prep) Data/NNS (r_nsubjpass) analyzed/VBN (l_prep) for/IN (l_pobj) factors/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) nephrotoxicity/NN
12091028
D003975_D006212 NONE Diazepam/NNP (r_nsubj) remains/VBZ (l_attr) drug/NN (l_relcl) ketamine/NN (l_advcl) buffers/VBZ (l_conj) decreases/VBZ (l_dobj) duration/NN (l_prep) of/IN (l_pobj) hallucinations/NNS
D007649_D006212 CID ketamine/NN (l_advcl) buffers/VBZ (l_conj) decreases/VBZ (l_dobj) duration/NN (l_prep) of/IN (l_pobj) hallucinations/NNS
19957053
D010656_D007022 NONE Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- phenylephrine/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) describe/VBP (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- phenylephrine/NN (r_pobj) of/IN (r_prep) utilization/NN (l_acl) correct/VB (l_dobj) hypotension/NN
D010656_D002534 CID Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN
D004809_D007022 NONE ephedrine/JJ (r_conj) Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- ephedrine/JJ (r_conj) phenylephrine/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) describe/VBP (l_prep) following/VBG (l_dobj) hypotension/NN -PUNC- ephedrine/JJ (r_nsubj) maintains/VBZ (r_advcl) has/VBZ (l_nsubj) utilization/NN (l_acl) correct/VB (l_dobj) hypotension/NN
D004809_D002534 NONE ephedrine/JJ (r_conj) Phenylephrine/NNP (r_nsubj) reduces/VBZ (l_dobj) oxygenation/NN
19759529
D004298_D012559 NONE dopamine/NN (r_compound) neurotransmission/NN (r_pobj) in/IN (r_prep) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) Schizophrenia/NNP
D016202_D012559 NONE aspartate/NNP (r_appos) methyl/NN (r_nmod) receptor/NN (r_pobj) of/IN (r_prep) antagonists/NNS (r_nsubj) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ -PUNC- NMDA/NNP (r_nmod) receptor/NN (r_pobj) of/IN (r_prep) antagonists/NNS (r_nsubj) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ -PUNC- NMDA/NNP (r_compound) receptor/NN (r_pobj) via/IN (r_prep) dysfunctioning/NN (r_pobj) of/IN (r_prep) idea/NN (r_pobj) to/IN (r_prep) led/VBN (l_nsubj) observation/NN (l_relcl) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ
D000661_D006948 CID amphetamine/NN (r_appos) challenge/NN (r_dobj) involving/VBG (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D003024_D006948 NONE clozapine/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
D004298_D006948 NONE dopamine/NN (r_compound) transporter/NN (r_pobj) in/IN (r_prep) observed/VBN (r_conj) failed/VBD (l_xcomp) affect/VB (l_dobj) hyperactivity/NN
D018698_D012559 NONE glutamate/NN (r_nmod) receptor/NN (r_pobj) of/IN (r_prep) antagonists/NNS (r_nsubj) produce/VBP (l_dobj) symptoms/NNS (l_amod) like/JJ (l_npadvmod) schizophrenic/JJ
D006220_D006948 NONE haloperidol/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
C076029_D006948 NONE olanzapine/NN (r_nmod) clozapine/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
-1_D002375 NONE SSR103800/NNP (r_nsubj) produce/VB (l_dobj) catalepsy/NN
C094645_D006948 NONE aripiprazole/NN (r_conj) clozapine/NN (r_nmod) antipsychotics/NNS (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN
D016291_D006948 CID MK-801/NNP (r_punct) )/-RRB- (r_punct) amphetamine/NN (r_appos) challenge/NN (r_dobj) involving/VBG (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- MK-801/NNP (r_punct) and/CC (r_cc) showed/VBD (l_dobj) that/IN (l_punct) hyperactivity/NN -PUNC- MK-801/NNP (r_punct) and/CC (r_cc) showed/VBD (l_conj) reversed/VBD (l_dobj) hyperactivity/NN
-1_D006948 NONE SSR103800/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- SSR103800/NNP (r_nmod) hyperactivity/NN -PUNC- SSR103800/NNP (r_nmod) hyperactivity/NN (r_punct) that/IN (r_dobj) showed/VBD (l_conj) reversed/VBD (l_dobj) hyperactivity/NN -PUNC- SSR103800/NNP (r_nsubj) failed/VBD (l_xcomp) affect/VB (l_dobj) hyperactivity/NN
D016202_D006948 NONE NMDA/NNP (r_compound) Nr1(neo-/-/NNP (r_appos) mice/NNS (r_conj) challenge/NN (r_dobj) involving/VBG (r_prep) properties/NNS (r_dobj) investigating/VBG (l_prep) with/IN (l_pobj) focus/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN (r_punct) that/IN (r_dobj) showed/VBD (l_conj) reversed/VBD (l_dobj) hyperactivity/NN -PUNC- NMDA/NNP (r_nmod) mice/NNS (r_pobj) of/IN (r_prep) hyperactivity/NN (r_dobj) reversed/VBD (r_conj) showed/VBD (l_dobj) that/IN (l_punct) hyperactivity/NN -PUNC- NMDA/NNP (r_nmod) mice/NNS (r_pobj) of/IN (r_prep) hyperactivity/NN
3137399
D004317_D066126 NONE doxorubicin/NN (r_dobj) following/VBG (r_pcomp) given/VBN (r_conj) combined/VBN (r_advcl) suggested/VBN (l_xcomp) be/VB (l_acomp) cardiotoxic/JJ -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) is/VBZ (l_nsubj) cardiotoxicity/NN
D016685_D066126 NONE C./NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) study/NN (l_prep) on/IN (l_pobj) dependency/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- C/NNP (r_nsubjpass) suggested/VBN (l_xcomp) be/VB (l_acomp) cardiotoxic/JJ -PUNC- MMC/NN (r_appos) C/NNP (r_nsubjpass) suggested/VBN (l_xcomp) be/VB (l_acomp) cardiotoxic/JJ -PUNC- MMC/NN (r_npadvmod) related/VBN (r_amod) cardiotoxicity/NN
D004317_D006333 CID doxorubicin/NN (r_conj) MMC/NNP (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) failure/NN
D016685_D006333 CID MMC/NNP (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) failure/NN
14736955
D004317_D009401 CID doxorubicin/NN (r_compound) nephrosis/NN
C102006_D007674 NONE citrate/NN (r_compound) synthase/NN (r_compound) activity/NN (r_conj) activities/NNS (r_appos) lesions/NNS
D013481_D007674 NONE superoxide/JJ (r_amod) production/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_conj) correlated/VBN (l_prep) Among/IN (l_pobj) injury/NN -PUNC- superoxide/NN (l_prep) in/IN (l_pobj) lesions/NNS
D004317_D007674 NONE Doxorubicin/NNP (r_nsubj) induces/VBZ (l_dobj) nephropathy/NN -PUNC- Doxorubicin/NNP (r_nsubj) induces/VBZ (l_dobj) nephropathy/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) lesions/NNS -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) lesions/NNS
15572383
D004317_D009404 NONE adriamycin/NNS (l_pobj) proteinuria/NN (l_amod) nephrotic/JJ
D004317_D005923 NONE adriamycin/NNS (l_pobj) proteinuria/NN (l_conj) damage/NN (l_conj) glomerulosclerosis/NN
D004317_D011507 CID adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) proteinuria/NN -PUNC- adriamycin/NNS (l_pobj) proteinuria/NN -PUNC- adriamycin/NNS (r_advcl) correlated/VBD (l_prep) with/IN (l_pobj) rise/NN (l_prep) in/IN (l_pobj) proteinuria/NN
D004317_D007674 NONE adriamycin/NNS (r_advmod) induced/VBN (r_amod) damage/NN -PUNC- adriamycin/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) severity/NN (l_prep) of/IN (l_pobj) damage/NN -PUNC- adriamycin/NNS (l_pobj) proteinuria/NN (l_conj) damage/NN -PUNC- adriamycin/NNS (r_advmod) induced/VBN (r_amod) damage/NN
14513889
D007654_D009422 NONE Ketoconazole/NNP (r_npadvmod) induced/VBN (l_dobj) sequelae/NNS
6292680
D018943_D009396 NONE anthracycline/NN (r_amod) cardiomyopathy/NN (r_dobj) experienced/VBD (l_nsubj) children/NNS (l_prep) with/IN (l_pobj) tumor/NN
D018943_D009369 NONE anthracycline/NN (r_amod) cardiomyopathy/NN (r_dobj) experienced/VBD (l_prep) after/IN (l_pobj) irradiation/NN (l_prep) to/IN (l_pobj) bed/NN (l_compound) tumor/NN
D004317_D009369 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) dosage/NN (r_conj) bed/NN (l_compound) tumor/NN
D004317_D009202 CID Doxorubicin/JJ (r_nsubj) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) dosage/NN (r_conj) bed/NN (r_pobj) to/IN (r_prep) irradiation/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_dobj) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) interaction/NN (r_pobj) to/IN (r_prep) include/VBP (r_acl) fact/NN (r_pobj) to/IN (r_prep) attributed/VBN (l_nsubjpass) cardiomyopathy/NN
D004317_D009396 NONE Doxorubicin/JJ (r_nsubj) cardiomyopathy/NN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) tumor/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) dosage/NN (r_conj) bed/NN (r_pobj) to/IN (r_prep) irradiation/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_nsubj) children/NNS (l_prep) with/IN (l_pobj) tumor/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) interaction/NN (r_pobj) to/IN (r_prep) include/VBP (l_nsubj) fields/VBZ (l_prep) for/IN (l_pobj) tumor/NN -PUNC- doxorubicin/NN (r_compound) dosage/NN (r_nsubjpass) restricted/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) tumor/NN
D018943_D009202 NONE anthracycline/NN (r_amod) cardiomyopathy/NN
16904497
D013256_D011128 NONE steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) syndrome/NN
D014221_D011128 NONE triamcinolone/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) report/NN (l_prep) of/IN (l_pobj) syndrome/NN
D013256_D017116 NONE steroid/NN (r_compound) injection/NN (r_pobj) for/IN (r_prep) scheduled/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) pain/NN
D013256_D011843 NONE steroid/NN (r_compound) injections/NNS (r_conj) therapy/NN (r_attr) are/VBP (l_nsubj) methods/NNS (l_prep) of/IN (l_pobj) radiculopathy/NN
D002045_D011128 CID bupivacaine/NN (r_conj) triamcinolone/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) report/NN (l_prep) of/IN (l_pobj) syndrome/NN
D013256_D010146 NONE steroid/NN (r_compound) injection/NN (r_pobj) for/IN (r_prep) scheduled/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) pain/NN
D013256_D009422 NONE steroid/NN (r_compound) injections/NNS (r_pobj) after/IN (r_prep) vigilance/NN (l_prep) for/IN (l_pobj) deterioration/NN
6504332
D010634_D009069 NONE Phenobarbital/NN (r_nsubjpass) added/VBN (l_prep) to/IN (l_pobj) list/NN (l_prep) of/IN (l_pobj) drugs/NNS (l_relcl) cause/VB (l_dobj) disorders/NNS
D010634_D004409 CID Phenobarbital/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- phenobarbital/JJ (r_amod) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) dyskinesia/JJ -PUNC- phenobarbital/JJ (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) On/IN (r_prep) recurred/VBD (l_nsubj) dyskinesia/NN
D010634_D012640 NONE phenobarbital/JJ (r_amod) therapy/NN (l_prep) for/IN (l_pobj) seizures/NNS
D010634_D009422 NONE Phenobarbital/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_prep) in/IN (l_pobj) child/NN (l_amod) impaired/VBN -PUNC- phenobarbital/JJ (r_amod) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_nsubj) child/NN (l_prep) with/IN (l_pobj) impairment/NN
7269015
D002066_D003556 CID Busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_amod) cystitis/NN (l_conj) cystitis/NN
D002066_D006470 CID Busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- busulfan/NNS (r_npadvmod) induced/VBN (r_amod) cystitis/NN
D002066_D002277 NONE busulfan/NNS (r_pobj) of/IN (r_prep) tendency/NN (r_pobj) of/IN (r_prep) view/NN (r_pobj) In/IN (l_advcl) induce/VB (l_dobj) atypia/NN (l_conj) carcinoma/NN
D003520_D003556 NONE cyclophosphamide/NN (r_npadvmod) induced/VBN (r_conj) radiation/NN (r_nmod) cystitis/NN (r_conj) cystitis/NN -PUNC- cyclophosphamide/NN (r_npadvmod) induced/VBN (r_conj) radiation/NN (r_nmod) cystitis/NN
18439803
D001224_D012640 NONE aspartate/NN (r_conj) glutamate/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) offset/VBN (r_conj) was/VBD (r_ccomp) suggested/VBN (l_prep) Based/VBN (l_prep) on/IN (l_pobj) finding/NN (l_acl) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- aspartate/NN (r_conj) glutamate/NN (r_pobj) in/IN (r_prep) increases/NNS (r_dobj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
C108761_D012640 NONE N-(2-propylpentanoyl)urea/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) seizure/NN -PUNC- VPU/NNS (r_nsubj) was/VBD (l_advcl) exhibiting/VBG (l_dobj) dose/NN (l_prep) of/IN (l_pobj) mg/kg/NNS (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPU/NNPS (r_nsubj) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPU/NNP (r_nsubj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
D014635_D012640 NONE VPA/NNP (r_pobj) than/IN (r_prep) potent/JJ (r_acomp) was/VBD (l_advcl) exhibiting/VBG (l_dobj) dose/NN (l_prep) of/IN (l_pobj) mg/kg/NNS (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPA/NNP (r_pobj) for/IN (r_prep) value/NN (r_nsubj) was/VBD (r_advcl) exhibiting/VBG (l_dobj) dose/NN (l_prep) of/IN (l_pobj) mg/kg/NNS (l_prep) in/IN (l_pcomp) protecting/VBG (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPA/NNP (r_conj) VPU/NNPS (r_nsubj) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
D000596_D012640 NONE acid/NN (r_compound) neurotransmitters/NNS (r_pobj) on/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) seizure/NN -PUNC- acid/NN (r_compound) neurotransmitters/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_nsubj) was/VBD (r_ccomp) suggested/VBN (l_prep) Based/VBN (l_prep) on/IN (l_pobj) finding/NN (l_acl) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN
D018698_D012640 NONE glutamate/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) offset/VBN (r_conj) was/VBD (r_ccomp) suggested/VBN (l_prep) Based/VBN (l_prep) on/IN (l_pobj) finding/NN (l_acl) protect/VB (l_dobj) animals/NNS (l_prep) against/IN (l_pobj) seizure/NN -PUNC- glutamate/NN (r_pobj) in/IN (r_prep) increases/NNS (r_dobj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_dobj) reduce/VB (r_relcl) finding/NN (r_appos) VPA/NNP (r_pobj) like/IN (r_prep) account/VB (l_prep) for/IN (l_pobj) activity/NN (l_acl) observed/VBN (l_prep) in/IN (l_pobj) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN
19944333
C471405_D003329 CID Sorafenib/NNP (r_npadvmod) induced/VBN (l_prep) due/IN (l_pobj) spasm/NN -PUNC- sorafenib/NN (r_npadvmod) induced/VBN (r_amod) spasm/NN
D020108_D060050 NONE nicorandil/NN (r_pobj) of/IN (r_prep) Addition/NN (r_nsubj) reduced/VBD (l_conj) maintained/VBD (l_dobj) status/NN (l_compound) angina/NN
C471405_D009203 NONE Sorafenib/NNP (r_npadvmod) induced/VBN (l_dobj) infarction/NN
16826348
D003561_D006987 NONE arabinoside/NN (r_pobj) of/IN (r_prep) course/NN (r_nsubj) resulted/VBD (l_conj) complained/VBD (l_prep) of/IN (l_pobj) numbness/NN
D003561_D064420 NONE arabinoside/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- arabinoside/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_nsubjpass) recognized/VBN (l_conj) reported/VBN (l_nsubjpass) toxicity/NN -PUNC- arabinoside/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_nsubjpass) reported/VBN (r_conj) recognized/VBN (l_nsubjpass) toxicity/NN -PUNC- arabinoside/NN (r_pobj) of/IN (r_prep) toxicity/NN
D003561_D010523 CID arabinoside/NN (r_amod) treatment/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neuropathy/NNS -PUNC- arabinoside/NN (r_nsubj) is/VBZ (l_advcl) are/VBP (l_nsubj) mechanisms/NNS (l_prep) of/IN (l_pobj) neuropathy/NN
D008775_D006086 NONE methylprednisolone/NN (r_pobj) to/IN (r_prep) responded/VBD (r_conj) worsened/VBD (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) disease/NN
D003561_D015470 NONE arabinoside/NN (r_amod) treatment/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN
D008775_D009422 NONE methylprednisolone/NN (r_pobj) to/IN (r_prep) responded/VBD (r_conj) worsened/VBD (l_ccomp) received/VBD (l_ccomp) resolving/VBG (l_nsubj) neuropathy/NN
6637851
D000638_D017180 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) efficacy/NN (l_prep) for/IN (l_pobj) tachycardia/NN -PUNC- Amiodarone/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_relcl) sustained/VBN (l_dobj) tachycardia/NN -PUNC- Amiodarone/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_relcl) sustained/VBN (l_dobj) tachycardia/NN (l_appos) VT/NNP -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) continued/VBD (l_conj) had/VBD (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) VT/NNP -PUNC- amiodarone/NN (r_pobj) by/IN (r_agent) managed/VBN (r_conj) had/VBD (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) VT/NNP -PUNC- amiodarone/NN (r_nsubj) is/VBZ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) VT/NNP -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) managed/VBN (l_nsubjpass) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) VT/NNP
D000638_D064420 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- amiodarone/NN (r_nsubj) is/VBZ (r_advcl) causes/VBZ (l_dobj) toxicity/NN
D000638_D014693 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) efficacy/NN (l_prep) for/IN (l_pobj) tachycardia/NN (l_conj) fibrillation/NN -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) continued/VBD (l_conj) had/VBD (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) VT/NNP (l_conj) fibrillation/NN -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) continued/VBD (l_conj) had/VBD (l_dobj) recurrence/NN (l_prep) of/IN (l_pobj) VT/NNP (l_appos) VF/NNP -PUNC- amiodarone/NN (r_nsubj) is/VBZ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) VT/NNP (l_conj) refractory/NN (l_compound) VF/NNP -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) managed/VBN (l_nsubjpass) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) VT/NNP (l_conj) VF/NNP
D000638_D006323 NONE Amiodarone/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_conj) arrest/NN
20621845
D002122_D017545 CID CaCl2-induced/VBN (r_amod) aneurysm/NN -PUNC- chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN -PUNC- chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN (l_appos) TAA/NNP -PUNC- chloride/NN (r_pobj) by/IN (r_prep) establish/VB (r_xcomp) designed/VBN (l_conj) metalloproteinases/NNS (l_conj) inhibitors/NNS (l_prep) in/IN (l_pobj) formation/NN (l_compound) TAA/NNP -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN (r_appos) chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN (r_appos) chloride/NN (r_pobj) by/IN (r_prep) establish/VB (l_dobj) model/NN (l_prep) of/IN (l_pobj) aneurysm/NN (l_appos) TAA/NNP -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN (r_appos) chloride/NN (r_pobj) by/IN (r_prep) establish/VB (r_xcomp) designed/VBN (l_conj) metalloproteinases/NNS (l_conj) inhibitors/NNS (l_prep) in/IN (l_pobj) formation/NN (l_compound) TAA/NNP -PUNC- )/-RRB- (r_punct) establishes/VBZ (l_dobj) model/NN (l_compound) TAA/NNP
D002122_D014652 NONE chloride/NN (l_appos) injury/NN -PUNC- CaCl(2))-induced/VBN (r_amod) injury/NN
8643971
D002945_D010051 NONE cisplatin/NN (r_compound) combination/NN (r_nsubjpass) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D002945_D006258 NONE cisplatin/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) cancers/NNS -PUNC- cisplatin/NN (r_compound) combination/NN (r_nsubjpass) used/VBN (r_conj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- cisplatin/NN (r_pobj) with/IN (r_prep) combined/VBN (l_prep) with/IN (l_pobj) support/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) head/NN (l_conj) carcinoma/NN -PUNC- cisplatin/NN (r_advmod) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) head/NN (l_conj) cancer/NN
D002945_D064420 NONE cisplatin/NN (r_pobj) with/IN (r_prep) combined/VBN (r_acl) doses/NNS (r_pobj) of/IN (r_prep) response/NN (l_conj) toxicity/NN
D017239_D064420 NONE paclitaxel/NN (r_compound) doses/NNS (r_pobj) of/IN (r_prep) response/NN (l_conj) toxicity/NN -PUNC- paclitaxel/NN (r_compound) doses/NNS (r_dobj) incorporate/VBP (l_conj) permitted/VBN (l_advcl) permits/VBZ (l_nsubj) toxicity/NN
D017239_D006258 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_dobj) phase/NN (l_conj) cisplatin/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) cancers/NNS -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- Taxol/NNP (r_appos) paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_nmod) combination/NN (r_nsubjpass) used/VBN (r_conj) reported/VBD (l_dobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_compound) doses/NNS (l_acl) combined/VBN (l_prep) with/IN (l_pobj) support/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) head/NN (l_conj) carcinoma/NN -PUNC- Paclitaxel/NNP (r_nsubj) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) head/NN (l_conj) cancer/NN
D017239_D010051 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_conj) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- Taxol/NNP (r_appos) paclitaxel/NN (r_pobj) of/IN (r_prep) study/NN (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) reported/VBD (l_conj) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- paclitaxel/NN (r_nmod) combination/NN (r_nsubjpass) used/VBN (l_conj) improved/VBN (l_dobj) duration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
20520283
C522667_D001714 NONE Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_conj) of/IN (l_pobj) episodes/NNS (l_amod) manic/JJ -PUNC- Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_conj) of/IN (l_pobj) episodes/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) disorder/NN
C522667_D012559 NONE asenapine/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) exacerbation/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- asenapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) assigned/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN -PUNC- asenapine/NN (r_dep) assigned/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
D006220_D001480 CID haloperidol/NN (r_conj) BID/NN (r_pobj) at/IN (r_prep) %/NN (r_conj) %/NN (r_appos) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_advcl) reported/VBD (l_nsubj) symptoms/NNS -PUNC- haloperidol/NN (r_conj) asenapine/NN (r_pobj) with/IN (r_prep) similar/JJ (r_acomp) was/VBD (r_ccomp) indicated/VBD (r_ccomp) seen/VBN (l_prep) in/IN (l_pobj) AEs/NNS (l_appos) symptoms/NNS
D006220_D012559 NONE haloperidol/NN (r_npadvmod) controlled/VBN (r_amod) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) exacerbation/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- haloperidol/NN (r_conj) placebo/NN (r_conj) BID/NN (r_pobj) at/IN (r_prep) asenapine/NN (r_dep) assigned/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
C522667_D001480 CID asenapine/NN (r_pobj) of/IN (r_prep) %/NN (r_conj) %/NN (r_appos) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_advcl) reported/VBD (l_nsubj) symptoms/NNS -PUNC- asenapine/NN (r_pobj) with/IN (r_prep) similar/JJ (r_acomp) was/VBD (r_ccomp) indicated/VBD (r_ccomp) seen/VBN (l_prep) in/IN (l_pobj) AEs/NNS (l_appos) symptoms/NNS
C522667_D011618 NONE Asenapine/NNP (r_nsubjpass) approved/VBN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) for/IN (l_conj) of/IN (l_pobj) episodes/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) disorder/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) features/NNS (l_amod) psychotic/JJ
3800626
D010423_D005355 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_compound) injection/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) myopathy/NN -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) with/IN (r_prep) woman/NN (r_pobj) In/IN (r_prep) showed/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) myopathy/NN
D010423_D020425 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) due/IN (r_prep) neuropathy/NN (l_prep) of/IN (l_pobj) nerve/NN
D010423_D009408 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) due/IN (r_prep) neuropathy/NN (l_prep) of/IN (l_pobj) nerve/NN -PUNC- pentazocine/NN (r_npadvmod) induced/VBN (r_compound) myopathy/NN (r_pobj) by/IN (r_agent) affected/VBN (r_acl) muscle/NN (r_pobj) due/IN (r_amod) neuropathy/NN
D010423_D009135 CID pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_compound) injection/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) myopathy/NN -PUNC- pentazocine/NN (r_npadvmod) induced/VBN (r_compound) myopathy/NN -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS -PUNC- pentazocine/NN (r_advmod) induced/VBN (r_amod) myopathy/NNS (r_pobj) with/IN (r_prep) woman/NN (r_pobj) In/IN (r_prep) showed/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) myopathy/NN
3732088
D011188_D001145 NONE potassium/NN (l_conj) arrhythmias/NNS -PUNC- potassium/NN (r_pobj) in/IN (r_prep) changes/NNS (r_nsubj) alter/VB (l_dobj) tendency/NN (l_prep) towards/IN (l_pobj) arrhythmias/NNS
D000584_D003324 NONE amiloride/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) known/VBN (l_dobj) disease/NN
D011188_D003327 NONE potassium/NN (r_conj) Diuretics/NNS (l_prep) in/IN (l_pobj) disease/NN
D011188_D006973 NONE potassium/NN (r_conj) Diuretics/NNS (l_prep) in/IN (l_pobj) disease/NN (l_amod) hypertensive/JJ -PUNC- potassium/NN (r_npadvmod) conserving/VBG (r_amod) diuretic/JJ (r_amod) amiloride/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) known/VBN (r_conj) measured/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- potassium/NN (r_npadvmod) losing/VBG (r_amod) chlorthalidone/NN (r_pobj) on/IN (r_prep) period/NN (r_conj) measured/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D002752_D003324 NONE chlorthalidone/NN (r_pobj) on/IN (r_prep) period/NN (r_conj) measured/VBN (l_conj) known/VBN (l_dobj) disease/NN
D011188_D017202 NONE potassium/NN (r_npadvmod) losing/VBG (r_amod) therapy/NN (r_nsubj) increase/VB (l_dobj) excitability/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- potassium/NN (r_compound) concentrations/NNS (r_pobj) in/IN (r_prep) falls/VBZ (l_advcl) increase/VB (l_dobj) excitability/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D011188_D003324 NONE potassium/NN (r_npadvmod) conserving/VBG (r_amod) diuretic/JJ (r_amod) amiloride/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) known/VBN (l_dobj) disease/NN -PUNC- potassium/NN (r_npadvmod) losing/VBG (r_amod) chlorthalidone/NN (r_pobj) on/IN (r_prep) period/NN (r_conj) measured/VBN (l_conj) known/VBN (l_dobj) disease/NN
D002752_D018879 CID chlorthalidone/NN (r_compound) phase/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) frequency/NN (l_prep) of/IN (l_pobj) beats/NNS
D002752_D006973 NONE chlorthalidone/NN (r_pobj) on/IN (r_prep) period/NN (r_conj) measured/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D000584_D006973 NONE amiloride/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) known/VBN (r_conj) measured/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D000584_D018879 NONE amiloride/NN (r_compound) treatment/NN (r_pobj) to/IN (r_prep) Compared/VBN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) frequency/NN (l_prep) of/IN (l_pobj) beats/NNS
983936
D006854_D009202 NONE hydrocortisone/NN (l_prep) on/IN (l_pobj) injury/NN
D004837_D009202 CID epinephrine/NN (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- epinephrine/NN (r_amod) infusion/NN (r_appos) injury/NN
D001241_D009202 NONE acid/NN (l_conj) dipyridamole/NN (l_conj) hydrocortisone/NN (l_prep) on/IN (l_pobj) injury/NN
D004176_D009202 NONE dipyridamole/NN (l_conj) hydrocortisone/NN (l_prep) on/IN (l_pobj) injury/NN
D004837_D009203 NONE epinephrine/NN (r_amod) infusion/NN (r_appos) injury/NN (r_dobj) producing/VBG (r_pcomp) for/IN (r_prep) model/NN (r_nsubjpass) developed/VBN (l_advcl) study/VB (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) agents/NNS (l_relcl) alter/VB (l_dobj) evolution/NN (l_prep) of/IN (l_pobj) infarction/NN
15042318
D004317_D009223 NONE doxorubicin/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) following/VBG (r_prep) fibrillation/NN (r_conj) form/NN (r_appos) dystrophy/NN
D004317_D009136 NONE doxorubicin/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) following/VBG (r_prep) fibrillation/NN (r_conj) form/NN (l_prep) of/IN (l_pobj) dystrophy/NN
D004317_D001281 CID doxorubicin/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) following/VBG (r_prep) fibrillation/NN
D004317_C535648 NONE doxorubicin/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) following/VBG (r_prep) fibrillation/NN (r_conj) form/NN (r_appos) dystrophy/NN (l_nmod) lymphoma/NN
7791169
D016595_D007674 NONE misoprostol/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) induced/VBD (l_dobj) dysfunction/NN -PUNC- misoprostol/NNP (r_pobj) of/IN (r_prep) Addition/NN (r_nsubj) minimize/VB (l_dobj) impairment/NN
D007213_D007674 CID indomethacin/NN (r_pobj) on/IN (r_prep) misoprostol/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) induced/VBD (l_dobj) dysfunction/NN -PUNC- indomethacin/NN (r_nmod) dysfunction/NN
D016595_D010146 NONE misoprostol/NNP (r_pobj) of/IN (r_prep) Addition/NN (r_nsubj) minimize/VB (l_prep) without/IN (l_pcomp) affecting/VBG (l_dobj) control/NN (l_compound) pain/NN
3503576
D003676_D006311 NONE deferoxamine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) studies/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- deferoxamine/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN -PUNC- deferoxamine/NN (r_compound) doses/NNS (r_dobj) receiving/VBG (r_advcl) restarted/VBN (l_prep) with/IN (l_pobj) doses/NNS (l_prep) depending/VBG (l_prep) on/IN (l_pobj) degree/NN (l_prep) of/IN (l_pobj) abnormality/NN -PUNC- deferoxamine/NN (r_dobj) receiving/VBG (r_conj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) demonstrated/VBD (l_prep) provided/VBD (l_pcomp) convincing/JJ (l_dobj) evidence/NN (l_prep) for/IN (l_pobj) relation/NN (l_prep) between/IN (l_pobj) administration/NN (l_conj) ototoxicity/NN -PUNC- deferoxamine/NN (r_compound) administration/NN (l_conj) ototoxicity/NN
D007501_D006311 NONE iron/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN
D007501_D000740 NONE iron/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) anemia/NN
D007501_D014786 NONE iron/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN
D003676_D014786 NONE deferoxamine/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_relcl) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) neurotoxicity/NN
D003676_D064420 NONE deferoxamine/NN (r_compound) doses/NNS (r_dobj) receiving/VBG (r_advcl) restarted/VBN (l_conj) demonstrated/VBN (l_nsubjpass) toxicity/NN
D003676_D000740 NONE deferoxamine/NN (r_pobj) with/IN (r_prep) receiving/VBG (r_relcl) anemia/NN
7890216
D002118_D042882 NONE calcium/NN (r_dobj) containing/VBG (r_acl) stones/NNS (r_conj) duct/NN (r_dobj) have/VB (r_conj) induced/VBN (l_dobj) stones/NNS -PUNC- calcium/NN (r_dobj) containing/VBG (r_acl) stones/NNS (r_conj) duct/NN (r_dobj) have/VB (r_conj) induced/VBN (l_ccomp) are/VBP (l_prep) in/IN (l_pobj) common/JJ (l_prep) with/IN (l_pobj) disease/NN -PUNC- calcium/NN (r_dobj) containing/VBG (r_acl) stones/NNS
D002784_D042882 NONE cholesterol/NN (r_conj) %/NN (r_dobj) contained/VBD (r_ccomp) showed/VBD (l_nsubj) analysis/NN (l_prep) of/IN (l_pobj) stones/NNS -PUNC- cholesterol/NN (r_nsubj) rich/JJ (r_acomp) were/VBD (r_ccomp) suggesting/VBG (r_advcl) showed/VBD (l_dobj) dissolution/NN (l_compound) stone/NN -PUNC- cholesterol/NN (r_conj) multiple/JJ (r_conj) small/JJ (r_acomp) are/VBP (r_ccomp) induced/VBN (l_dobj) stones/NNS -PUNC- cholesterol/NN (r_conj) multiple/JJ (r_conj) small/JJ (r_acomp) are/VBP (l_prep) in/IN (l_pobj) common/JJ (l_prep) with/IN (l_pobj) disease/NN -PUNC- cholesterol/NN (r_conj) multiple/JJ (r_conj) small/JJ (r_acomp) are/VBP (r_ccomp) induced/VBN (l_conj) have/VB (l_dobj) duct/NN (l_conj) stones/NNS
D015282_D000172 NONE Octreotide/NNP (l_appos) treatment/NN (l_prep) for/IN (l_pobj) acromegaly/NNS -PUNC- octreotide/NN (r_pobj) in/IN (r_prep) methods/NNS (r_pobj) by/IN (r_agent) investigated/VBN (l_conj) treated/VBD (l_dobj) patients/NNS (l_compound) acromegalic/JJ
D015282_D042882 CID octreotide/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) stones/NNS -PUNC- Octreotide/NNP (r_nsubj) induces/VBZ (l_dobj) stones/NNS -PUNC- octreotide/NN (r_pobj) in/IN (r_prep) methods/NNS (r_pobj) by/IN (r_agent) investigated/VBN (l_conj) treated/VBD (l_prep) with/IN (l_pobj) stones/NNS -PUNC- octreotide/NN (r_advmod) induced/VBN (l_dobj) stones/NNS -PUNC- octreotide/NN (r_advmod) induced/VBN (l_ccomp) are/VBP (l_prep) in/IN (l_pobj) common/JJ (l_prep) with/IN (l_pobj) disease/NN -PUNC- octreotide/NN (r_advmod) induced/VBN (l_conj) have/VB (l_dobj) duct/NN (l_conj) stones/NNS
D014580_D042882 NONE acid/NN (r_pobj) to/IN (r_prep) response/NN (r_appos) Composition/NN (l_prep) of/IN (l_pobj) stones/NNS
17285209
D000809_D000799 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_pobj) of/IN (r_prep) recognition/NN (r_nsubj) constitutes/VBZ (l_nsubj) angioedema/NN -PUNC- angiotensin/NN (r_compound) blocker/NN (r_conj) enzyme/NN (r_pobj) of/IN (r_prep) recognition/NN (r_nsubj) constitutes/VBZ (l_nsubj) angioedema/NN
C044946_D006973 NONE benazapril/NN (r_compound) mg./CD (r_appos) pill/NN (r_pobj) on/IN (r_prep) started/VBN (r_relcl) female/NN (l_prep) with/IN (l_pobj) hypertension/NN
D000809_D007410 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_pobj) of/IN (r_prep) recognition/NN (r_nsubj) constitutes/VBZ (l_nsubj) angioedema/NN -PUNC- angiotensin/NN (r_compound) blocker/NN (r_conj) enzyme/NN (r_pobj) of/IN (r_prep) recognition/NN (r_nsubj) constitutes/VBZ (l_nsubj) angioedema/NN
D017311_D006973 NONE amlodipine/NN (r_pobj) of/IN (r_prep) pill/NN (r_pobj) on/IN (r_prep) started/VBN (r_relcl) female/NN (l_prep) with/IN (l_pobj) hypertension/NN
11847945
D007530_D056486 CID isoflurane/RB (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) hepatitis/NN -PUNC- isoflurane/RB (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- Isoflurane/NNP (r_nsubj) cause/VB (l_dobj) hepatitis/NN
D007530_D002779 CID isoflurane/RB (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) hepatitis/NN -PUNC- isoflurane/RB (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- Isoflurane/NNP (r_nsubj) cause/VB (l_dobj) hepatitis/NN
D004177_D000699 NONE dipyrone/NN (l_prep) for/IN (l_pobj) analgesia/NN
19917396
D016559_D006332 CID tacrolimus/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypertrophy/NN -PUNC- tacrolimus/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypertrophy/NN -PUNC- tacrolimus/NN (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) reducing/VBG (r_pcomp) upon/IN (r_prep) resolved/VBN (l_nsubj) hypertrophy/NN -PUNC- tacrolimus/NN (r_nsubj) induces/VBZ (l_dobj) hypertrophy/NN
3076126
D015248_D051437 NONE gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
D008148_D009135 NONE lovastatin/NN (r_pobj) with/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D009525_D051437 NONE niacin/NN (r_conj) gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
D008148_D051437 CID lovastatin/NN (r_pobj) with/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
D009525_D009212 NONE niacin/NN (r_conj) gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D016572_D009135 CID cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D015248_D009212 NONE gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D008148_D009212 CID lovastatin/NN (r_pobj) with/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D016572_D009212 NONE cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) myoglobinuria/NNS
D009525_D009135 CID niacin/NN (r_conj) gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D015248_D009135 CID gemfibrozil/NN (r_conj) cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_conj) associated/VBN (r_acl) Myopathy/NNP
D016572_D051437 NONE cyclosporin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) with/IN (l_pobj) failure/NN
19139001
D000518_D064420 NONE DFMO/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) toxicity/NN
D013467_D018256 NONE sulindac/NN (r_conj) difluoromethylornithine/NN (r_pobj) with/IN (r_prep) months/NNS (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) polyps/NNS
D000518_D018256 NONE difluoromethylornithine/NN (r_pobj) with/IN (r_prep) months/NNS (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) polyps/NNS -PUNC- DFMO/NN (r_appos) difluoromethylornithine/NN (r_pobj) with/IN (r_prep) months/NNS (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) polyps/NNS
D013467_D034381 CID sulindac/NN (r_compound) group/NN (l_relcl) experienced/VBD (l_dobj) loss/NN
D000518_D015179 NONE difluoromethylornithine/NN (l_conj) sulindac/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) adenomas/NNS
D013467_D015179 NONE sulindac/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) adenomas/NNS
D000518_D034381 NONE DFMO/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_attr) is/VBZ (l_nsubj) loss/NN -PUNC- DFMO/NN (r_nmod) group/NN (l_relcl) experienced/VBD (l_dobj) loss/NN
19707748
D064704_D012640 CID levofloxacin/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Seizures/NNS -PUNC- levofloxacin/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) initiating/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) seizures/NNS -PUNC- levofloxacin/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) initiating/VBG (r_pcomp) after/IN (r_prep) developed/VBD (r_relcl) patient/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- levofloxacin/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) of/IN (r_prep) patient/NN (l_relcl) developed/VBD (l_dobj) seizures/NNS -PUNC- levofloxacin/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- levofloxacin/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
4812392
D001379_D011565 NONE azathioprine/NN (r_pobj) with/IN (r_prep) psoriasis/NN -PUNC- Azathioprine/JJ (r_det) treatment/NN (r_nsubj) benefited/VBD (l_prep) out/IN (l_prep) of/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) psoriasis/NN
D001379_D056486 NONE azathioprine/JJ (r_amod) therapy/NN (r_nsubjpass) continued/VBN (l_advcl) detected/VBN (l_nsubjpass) damage/NN
8701950
D001241_D000743 NONE aspirin/NN (r_conj) corticosteroids/NNS (r_conj) replacement/NN (r_appos) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP
D016559_D000743 CID FK506/NNP (r_dobj) complicating/VBG (l_nsubj) anemia/NN -PUNC- tacrolimus/NNP (r_nmod) therapy/NN (r_appos) FK506/NNP (r_dobj) complicating/VBG (l_nsubj) anemia/NN -PUNC- FK506/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN -PUNC- FK506/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN (l_appos) MAHA/NNP -PUNC- tacrolimus/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN -PUNC- tacrolimus/NNP (r_nmod) therapy/NN (r_pobj) under/IN (r_prep) recipients/NNS (r_pobj) in/IN (r_prep) episodes/NNS (l_prep) of/IN (l_pobj) anemia/NN (l_appos) MAHA/NNP -PUNC- FK506/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP -PUNC- FK506/NNP (r_pobj) of/IN (r_prep) reintroduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) MAHA/NNP -PUNC- FK506-associated/VBN (r_amod) MAHA/NNP -PUNC- FK506/NNP (r_nsubj) seem/VB (l_oprd) A/NNP (l_appos) drug/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) MAHA/NNP
D016572_D000743 NONE A/NNP (l_appos) drug/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) MAHA/NNP -PUNC- CyA/NN (r_appos) A/NNP (l_appos) drug/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) MAHA/NNP
D004176_D000743 NONE dipyridamole/NN (r_conj) aspirin/NN (r_conj) corticosteroids/NNS (r_conj) replacement/NN (r_appos) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP
D000305_D000743 NONE corticosteroids/NNS (r_conj) replacement/NN (r_appos) discontinuation/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) MAHA/NNP
1527456
D008012_D014012 NONE lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) tinnitus/NN -PUNC- lidocaine/NN (r_appos) lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) tinnitus/NN -PUNC- lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) treating/VBG (l_dobj) IST/NNP -PUNC- lidocaine/NN (r_appos) lignocaine/NN (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) by/IN (r_prep) treating/VBG (l_dobj) IST/NNP
2265898
C009265_D001523 NONE levodopa/JJ (r_compound) preparation/NN (r_dobj) receiving/VBG (l_conj) had/VBD (l_dobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS (l_nmod) hallucinosis/NN
C009265_D004827 CID carbidopa/NN (l_nsubj) epilepsy/NN
C009265_D012640 NONE levodopa/JJ (r_compound) preparation/NN (r_dobj) receiving/VBG (l_conj) had/VBD (l_dobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS
C009265_D007676 NONE levodopa/JJ (r_compound) preparation/NN (r_dobj) receiving/VBG (l_ccomp) had/VBD (l_dobj) failure/NN
11524350
D002045_D001145 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) larger/JJR (r_acomp) were/VBD (r_conj) were/VBD (l_nsubj) doses/NNS (l_relcl) produced/VBD (l_dobj) dysrhythmias/NNS
D002045_D006323 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) larger/JJR (r_acomp) were/VBD (r_conj) were/VBD (l_nsubj) doses/NNS (l_relcl) produced/VBD (l_dobj) dysrhythmias/NNS (l_conj) asystole/NN -PUNC- bupivacaine/NN (r_conj) ropivacaine/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) between/IN (r_prep) intermediate/JJ (r_acomp) is/VBZ (l_advcl) administered/VBN (l_conj) appears/VBZ (l_nsubj) arrest/NN -PUNC- bupivacaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) that/DT (r_pobj) than/IN (r_prep) susceptible/JJ (r_acomp) be/VB (r_xcomp) appears/VBZ (l_nsubj) arrest/NN
D002045_D012640 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) larger/JJR (r_acomp) were/VBD (r_conj) were/VBD (l_nsubj) seizures/NNS
D002045_D064420 NONE bupivacaine-/DT (r_nmod) rats/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- bupivacaine/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- bupivacaine/NN (r_conj) ropivacaine/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) between/IN (r_prep) intermediate/JJ (r_acomp) is/VBZ (l_nsubj) toxicity/NN -PUNC- bupivacaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) that/DT (r_pobj) than/IN (r_prep) susceptible/JJ (r_acomp) be/VB (r_xcomp) appears/VBZ (r_conj) administered/VBN (r_advcl) is/VBZ (l_nsubj) toxicity/NN
C037663_D064420 NONE ropivacaine/NN (r_npadvmod) infused/VBN (r_conj) levobupivacaine-/JJ (r_conj) bupivacaine-/DT (r_nmod) rats/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- ropivacaine/NN (r_conj) levobupivacaine/NN (r_conj) toxicity/NN -PUNC- ropivacaine/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) between/IN (r_prep) intermediate/JJ (r_acomp) is/VBZ (l_nsubj) toxicity/NN -PUNC- ropivacaine/NN (r_npadvmod) induced/VBN (r_amod) arrest/NN (r_nsubj) appears/VBZ (r_conj) administered/VBN (r_advcl) is/VBZ (l_nsubj) toxicity/NN
C476513_D006323 CID levobupivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (l_relcl) produced/VBD (l_dobj) dysrhythmias/NNS (l_conj) asystole/NN -PUNC- levobupivacaine/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_nsubj) is/VBZ (l_advcl) administered/VBN (l_conj) appears/VBZ (l_nsubj) arrest/NN -PUNC- levobupivacaine/NN (r_conj) bupivacaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) that/DT (r_pobj) than/IN (r_prep) susceptible/JJ (r_acomp) be/VB (r_xcomp) appears/VBZ (l_nsubj) arrest/NN
C476513_D012640 CID levobupivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) were/VBD (l_nsubj) seizures/NNS
C037663_D001145 CID ropivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) than/IN (r_prep) smaller/JJR (r_acomp) were/VBD (l_nsubj) doses/NNS (l_relcl) produced/VBD (l_dobj) dysrhythmias/NNS
C476513_D064420 NONE levobupivacaine-/JJ (r_conj) bupivacaine-/DT (r_nmod) rats/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- levobupivacaine/NN (r_conj) toxicity/NN -PUNC- levobupivacaine/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- levobupivacaine/NN (r_conj) bupivacaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) that/DT (r_pobj) than/IN (r_prep) susceptible/JJ (r_acomp) be/VB (r_xcomp) appears/VBZ (r_conj) administered/VBN (r_advcl) is/VBZ (l_nsubj) toxicity/NN
C476513_D001145 CID levobupivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (l_relcl) produced/VBD (l_dobj) dysrhythmias/NNS
C037663_D006323 CID ropivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) than/IN (r_prep) smaller/JJR (r_acomp) were/VBD (l_nsubj) doses/NNS (l_relcl) produced/VBD (l_dobj) dysrhythmias/NNS (l_conj) asystole/NN -PUNC- ropivacaine/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) between/IN (r_prep) intermediate/JJ (r_acomp) is/VBZ (l_advcl) administered/VBN (l_conj) appears/VBZ (l_nsubj) arrest/NN -PUNC- ropivacaine/NN (r_npadvmod) induced/VBN (r_amod) arrest/NN
C037663_D012640 CID ropivacaine/VBP (r_conj) levobupivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) were/VBD (l_nsubj) seizures/NNS
9249847
D014700_D013611 CID verapamil/NN (r_nmod) ablation/NN (r_pobj) after/IN (r_prep) induced/VBD (l_dobj) tachycardia/NN -PUNC- verapamil/NN (r_nmod) block/NN (r_pobj) after/IN (r_prep) beats/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) QRS/UH (r_nsubj) established/VBD (l_dobj) attack/NN (l_compound) AVRT/NN
D014700_D002311 NONE verapamil/NN (r_nmod) ablation/NN (l_conj) cardiomyopathy/NN
D014700_D014927 NONE verapamil/NN (r_nmod) ablation/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) syndrome/NN
19058474
D014859_D006470 NONE warfarin/NN (r_pobj) of/IN (r_prep) dosage/NN (r_dobj) maintaining/VBG (r_advcl) consumed/VBD (r_relcl) man/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) haemorrhage/NN
D014859_D010490 NONE warfarin/NN (r_pobj) with/IN (r_prep) interaction/NN (r_pobj) due/IN (r_prep) haemorrhage/NN (l_nmod) haemopericardium/NN
D014859_D006471 CID warfarin/NN (r_pobj) with/IN (r_prep) interaction/NN (r_pobj) due/IN (r_prep) haemorrhage/NN
15649445
D018698_D004409 NONE glutamate/NN (r_compound) uptake/NN (r_dobj) change/VBP (l_conj) elicit/VBP (l_dobj) dyskinesia/NN -PUNC- glutamate/NN (r_compound) uptake/NN (r_pobj) in/IN (r_prep) decrease/NN (r_nsubj) correlates/VBZ (l_prep) with/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) diskinesia/NN
D012110_D004409 CID reserpine/NN (r_nsubj) change/VBP (l_conj) elicit/VBP (l_dobj) dyskinesia/NN -PUNC- Reserpine-/NNP (l_conj) dyskinesia/NN -PUNC- Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ -PUNC- Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ (l_appos) TD/NN -PUNC- reserpine/NN (r_pobj) by/IN (r_prep) induced/VBD (l_dobj) dyskinesia/NN
D006220_D004409 CID haloperidol/NN (r_compound) change/VBP (l_conj) elicit/VBP (l_dobj) dyskinesia/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_conj) Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_conj) Reserpine-/NNP (r_nsubj) are/VBP (l_attr) models/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ (l_appos) TD/NN -PUNC- haloperidol/NN (r_compound) administration/NN (r_conj) reserpine/NN (r_pobj) by/IN (r_prep) induced/VBD (l_dobj) dyskinesia/NN
18657397
D010400_D004827 CID potassium/NN (r_dobj) injecting/VBG (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubjpass) focus/NN (l_amod) epileptic/JJ
D010406_D004827 NONE penicillin/NN (r_npadvmod) induced/VBN (r_amod) activity/NN -PUNC- Penicillin/NNP (r_compound) model/NN (r_nsubj) is/VBZ (l_attr) model/NN (l_prep) for/IN (l_pobj) research/NN (l_compound) epilepsy/NN -PUNC- penicillin/NN (r_npadvmod) induced/VBN (r_amod) activity/NN -PUNC- penicillin/NN (r_npadvmod) induced/VBN (r_amod) periods/NNS (l_compound) activity/NN
16586083
D016861_D009203 CID inhibitors/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) stroke/NN (r_conj) infarction/NN
D016861_D006973 CID inhibitors/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) stroke/NN (l_conj) hypertension/NN
D016861_D020521 CID inhibitors/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) stroke/NN
D016861_D006333 CID inhibitors/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) stroke/NN (l_conj) hypertension/NN (l_conj) failure/NN
C109794_D002318 NONE peptide/NN (r_pobj) as/IN (r_prep) markers/NNS (r_nsubj) help/VB (l_advcl) avoiding/VBG (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- proBNP/NNP (r_appos) peptide/NN (r_pobj) as/IN (r_prep) markers/NNS (r_nsubj) help/VB (l_advcl) avoiding/VBG (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) toxicity/NN
9545159
D001393_D016171 CID azole/JJ (r_amod) agents/NNS (r_conj) erythromycin/NNP (r_pobj) with/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) torsades/NNS (l_dobj) pointes/FW
D020117_D015835 NONE Cisapride/NNP (r_nsubjpass) prescribed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorders/NNS
D020117_D006973 NONE cisapride/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) hypertension/NN
D001393_D008133 CID azole/JJ (r_amod) agents/NNS (r_conj) erythromycin/NNP (r_pobj) with/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) torsades/NNS (l_nsubj) Prolongation/NN (l_prep) of/IN (l_pobj) interval/NN
D001393_D016757 CID azole/JJ (r_amod) agents/NNS (r_conj) erythromycin/NNP (r_pobj) with/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) torsades/NNS (l_dobj) pointes/FW (l_conj) death/NN
D004917_D016757 CID erythromycin/NNP (r_pobj) with/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) torsades/NNS (l_dobj) pointes/FW (l_conj) death/NN
D004917_D008133 CID erythromycin/NNP (r_pobj) with/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) torsades/NNS (l_nsubj) Prolongation/NN (l_prep) of/IN (l_pobj) interval/NN
D020117_D005764 NONE cisapride/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) disorder/NN
D004110_D005764 NONE diltiazem/NN (r_conj) disorder/NN
D020117_D008133 CID cisapride/NN (r_compound) diltiazem/NN (r_compound) interaction/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) interval/NN
D004110_D006973 NONE diltiazem/NN (r_conj) disorder/NN (r_pobj) for/IN (r_prep) taking/VBG (l_prep) for/IN (l_pobj) hypertension/NN
D004917_D016171 CID erythromycin/NNP (r_pobj) with/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) torsades/NNS (l_dobj) pointes/FW
D004110_D008133 CID diltiazem/NN (r_compound) interaction/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) interval/NN
15188772
D004837_D062787 NONE epinephrine/NN (r_amod) overdose/NN
D004837_D009202 NONE epinephrine/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubj) developed/VBN (l_dobj) markers/NNS (l_prep) of/IN (l_pobj) necrosis/NN
D004837_D017682 CID epinephrine/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubj) developed/VBN (l_dobj) markers/NNS (l_amod) stunning/JJ
D004837_D018487 NONE epinephrine/NN (r_amod) overdose/NN (r_pobj) due/IN (r_prep) dysfunction/NN -PUNC- epinephrine/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubj) developed/VBN (l_dobj) markers/NNS (l_amod) stunning/JJ (l_relcl) characterized/VBN (l_conj) left/VBD (l_dobj) dysfunction/NN
D002395_D009202 NONE Catecholamine/NN (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- catecholamines/NNS (r_pobj) of/IN (r_prep) excess/NN (r_pobj) due/IN (r_prep) cardiomyopathy/NN
15863244
D010894_D006345 NONE piroxicam/NN (r_nmod) inhibitor/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) fetuses/NNS (r_pobj) for/IN (r_prep) performed/VBN (l_nsubjpass) analysis/NN (l_prep) for/IN (l_pobj) defects/NNS
D010894_D064420 NONE piroxicam/NN (r_compound) study/NN (r_conj) DFU/NNP (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- piroxicam/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- piroxicam/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) toxicity/NN
D010894_D009139 CID piroxicam/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) toxicity/NN (l_appos) retardation/NN (l_conj) increase/NN (l_prep) of/IN (l_pobj) variations/NNS
D010894_D009436 NONE piroxicam/NN (r_nmod) inhibitor/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) fetuses/NNS (r_pobj) for/IN (r_prep) performed/VBN (l_nsubjpass) analysis/NN (l_prep) for/IN (l_pobj) defects/NNS
C106876_D064420 NONE DFU/NNP (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- DFU/NNP (r_conj) toxicity/NN -PUNC- phenyl-2(5H)-furanon/XX (l_ccomp) was/VBD (l_xcomp) evaluate/VB (l_dobj) toxicity/NN -PUNC- DFU/NNP (r_nmod) toxicity/NN
D010894_D005317 CID piroxicam/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) toxicity/NN (l_appos) retardation/NN
20331935
D013739_D006966 NONE testosterone/NN (r_compound) concentration/NN (r_nsubj) increased/VBD (l_conj) affected/VBN (l_agent) by/IN (l_pobj) hyperprolactinemia/NN
D018967_D006966 CID risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) %/NN (r_pobj) in/IN (r_prep) present/JJ (r_acomp) was/VBD (l_nsubj) Hyperprolactinemia/NNP -PUNC- risperidone/NN (r_nsubjpass) started/VBN (r_advcl) occurred/VBD (l_conj) occurred/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hyperprolactinemia/NN -PUNC- risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN
D018967_D050723 NONE risperidone/NN (r_nsubjpass) started/VBN (r_advcl) occurred/VBD (l_nsubj) fractures/NNS
869641
D006916_D001919 NONE 5-HTP/NNP (r_nsubj) decreased/VBD (l_conj) decreased/VBD (l_dobj) bradycardia/NN
D005406_D007022 NONE FLA-63/NN (r_mark) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN
D005406_D001919 NONE FLA-63/NN (r_mark) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN (l_appos) effect/NN (l_amod) bradycardia/NN
D004298_D007022 NONE dopamine/NN (r_compound) oxidase/NN (r_compound) inhibitor/NN (r_nsubj) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN
D015103_D001919 NONE dihydroxyphenylserine/NN (r_conj) dopa/NNP (r_pobj) by/IN (r_agent) enhanced/VBN (l_nsubjpass) bradycardia/NN
D007980_D007022 NONE dopa/NNP (r_pobj) of/IN (r_prep) effect/NN (r_appos) hypotension/NN
D004298_D001919 NONE dopamine/NN (r_compound) formation/NN (r_pobj) via/IN (r_prep) Mediation/NN (l_prep) of/IN (l_pobj) bradycardia/NNP -PUNC- dopamine/NN (r_compound) oxidase/NN (r_compound) inhibitor/NN (r_nsubj) have/VB (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN (l_appos) effect/NN (l_amod) bradycardia/NN
D009638_D001919 CID norepinephrine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) bradycardia/NN -PUNC- norepinephrine/NN (r_pobj) to/IN (r_prep) responses/NNS (r_conj) rate/NN (r_conj) pressure/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_conj) enhanced/VBN (l_nsubjpass) bradycardia/NN -PUNC- norepinephrine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) bradycardia/NN -PUNC- norepinephrine/NN (r_pobj) to/IN (r_prep) bradycardia/NN
D007980_D001919 NONE dopa/NN (r_pobj) by/IN (r_prep) Mediation/NN (l_prep) of/IN (l_pobj) bradycardia/NNP -PUNC- dopa/NNP (r_pobj) by/IN (r_agent) enhanced/VBN (l_nsubjpass) bradycardia/NN -PUNC- dopa/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) bradycardia/NN -PUNC- dopa/NNP (r_nsubj) restored/VBD (l_dobj) bradycardia/NN -PUNC- dopa/NNP (r_nsubj) enhances/VBZ (l_dobj) bradycardia/NN
11334364
D000082_D007674 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- acetaminophen/RB (r_advmod) prevent/VB (l_dobj) toxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- AAP)-induced/VBN (r_compound) nephrotoxicity/NN
D004317_D008171 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_conj) toxicity/NN -PUNC- doxorubicin/NN (r_conj) toxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN (r_dobj) doxorubicin/NN (r_conj) toxicity/NN
D000638_D008171 CID amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN -PUNC- amiodarone/NN (r_appos) nephrotoxicity/NN (r_nmod) toxicity/NN -PUNC- AMI)-induced/JJ (r_amod) toxicity/NN
D004317_D009336 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- DOX/NNP (r_conj) AMI/NNP (r_conj) AAP/NNP (r_appos) drugs/NNS (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) necrosis/NN
D000638_D007674 NONE amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN (r_conj) nephrotoxicity/NN -PUNC- amiodarone/NN (r_appos) nephrotoxicity/NN -PUNC- AMI)-induced/JJ (r_amod) toxicity/NN (l_nmod) nephrotoxicity/NN
D004317_D066126 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN
D000082_D009336 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- AAP/NNP (r_appos) drugs/NNS (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) necrosis/NN
D000638_D066126 NONE amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN (l_conj) cardiotoxicity/NN -PUNC- amiodarone/NN (r_appos) nephrotoxicity/NN (r_nmod) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- AMI)-induced/JJ (r_amod) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN
C511402_D017695 NONE GSPE/NNP (r_compound) preexposure/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) in/IN (r_prep) variety/NN (r_pobj) with/IN (r_prep) damage/NN
D000082_D008171 NONE acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) toxicity/NN -PUNC- acetaminophen/RB (r_advmod) prevent/VB (l_dobj) toxicity/NN -PUNC- AAP)-induced/VBN (r_compound) nephrotoxicity/NN (r_nmod) toxicity/NN
D004317_D007674 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN -PUNC- doxorubicin/NN (r_conj) toxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN (r_dobj) doxorubicin/NN (r_conj) toxicity/NN (l_nmod) nephrotoxicity/NN
D000638_D009336 CID amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN (r_conj) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- AMI/NNP (r_conj) AAP/NNP (r_appos) drugs/NNS (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) necrosis/NN
C511402_D066126 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN -PUNC- extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- GSPE/NNP (r_appos) extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN
C511402_D008171 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN -PUNC- extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN -PUNC- GSPE/NNP (r_appos) extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN
D000082_D066126 NONE acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) toxicity/NN (l_conj) cardiotoxicity/NN -PUNC- acetaminophen/RB (r_advmod) prevent/VB (l_dobj) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN -PUNC- AAP)-induced/VBN (r_compound) nephrotoxicity/NN (r_nmod) toxicity/NN (l_conj) doxorubicin/NN (l_dobj) cardiotoxicity/NN
C511402_D009336 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN (r_pobj) during/IN (r_prep) deaths/NNS (l_amod) apoptotic/JJ (l_conj) necrotic/JJ -PUNC- GSPE/NNP (r_pobj) by/IN (r_agent) blocked/VBN (r_relcl) necrosis/NN
C511402_D007674 NONE extract/NN (r_pobj) by/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN (r_conj) nephrotoxicity/NN -PUNC- extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- GSPE/NNP (r_appos) extract/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) prevent/VB (l_dobj) toxicity/NN (l_nmod) nephrotoxicity/NN
20880751
D007980_D004409 CID Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesias/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D018698_D004409 NONE glutamate/NN (r_compound) receptors/NNS (l_conj) systems/NNS (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) dyskinesias/NNS
D004298_D004409 NONE dopamine/NN (r_compound) precursor/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) complicated/VBN (l_agent) by/IN (l_pobj) fluctuations/NNS (l_conj) dyskinesias/NNS -PUNC- dopamine/NN (r_compound) subtypes/NNS (l_conj) receptors/NNS (l_conj) systems/NNS (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) dyskinesias/NNS
D007980_D010300 NONE Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesias/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Levodopa/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN
2071257
D012601_D000647 NONE scopolamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) amnesia/NN
D005997_D000647 NONE phosphorylcholine/NN (r_pobj) of/IN (r_prep) Effect/NN (l_prep) on/IN (l_pobj) amnesia/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN (l_prep) of/IN (l_pobj) attention/NN (l_conj) memory/NN
D005997_D008569 NONE glycerylphosphorylcholine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- GFC/NNP (r_appos) glycerylphosphorylcholine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) impairment/NN
8919272
D014635_D056486 NONE valproate/NNP (r_amod) encephalopathy/NNP (r_pobj) of/IN (r_prep) development/NN (r_pobj) upon/IN (r_prep) hyperammonemia/NN (l_nsubj) influence/NN (l_prep) of/IN (l_pobj) damage/NN
D014635_D022124 NONE valproate/NNP (r_amod) encephalopathy/NNP (r_pobj) of/IN (r_prep) development/NN (r_pobj) upon/IN (r_prep) hyperammonemia/NN
D014635_D001927 CID valproate/NN (l_nsubj) features/NNS (l_prep) of/IN (l_pobj) encephalopathy/NN -PUNC- valproate/NN (l_dobj) disorders/NNS (l_acl) indicating/VBG (l_dobj) damage/NN (l_appos) encephalopathy/JJ -PUNC- valproate/NNP (r_amod) encephalopathy/JJ -PUNC- valproate/NNP (r_amod) encephalopathy/NNP
D014635_D002526 NONE valproate/NN (l_dobj) disorders/NNS (l_acl) indicating/VBG (l_dobj) damage/NN -PUNC- valproate/NNP (r_amod) encephalopathy/JJ (r_appos) damage/NN
D014635_D009422 NONE valproate/NN (l_dobj) disorders/NNS -PUNC- valproate/NNP (r_amod) encephalopathy/JJ (r_appos) damage/NN (r_dobj) indicating/VBG (r_acl) disorders/NNS
10193809
D011692_D011507 CID aminonucleoside/NN (r_amod) Puromycin/NNP (r_nsubjpass) administered/VBN (l_advcl) induce/VB (l_dobj) proteinuria/NN -PUNC- PAN/NNP (r_appos) aminonucleoside/NN (r_amod) Puromycin/NNP (r_nsubjpass) administered/VBN (l_advcl) induce/VB (l_dobj) proteinuria/NN
17020434
C055162_D001281 NONE Clopidogrel/NNP (l_compound) Fibrillation/NNP -PUNC- clopidogrel/JJ (r_dobj) platelet/NN (r_xcomp) superior/JJ (r_acomp) is/VBZ (r_ccomp) demonstrated/VBN (l_nsubj) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D000804_D001281 NONE II/CD (r_nummod) drugs/NNS (r_conj) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN
D014812_D056486 NONE K/NNP (r_compound) drugs/NNS (r_pobj) as/IN (r_prep) efficient/JJ (r_acomp) be/VB (r_xcomp) found/VBN (l_conj) withdrawn/VBN (l_prep) because/IN (l_pobj) tests/NNS (l_compound) function/NN
D001241_D020521 NONE aspirin/NN (r_nsubj) reduces/VBZ (r_conj) reduces/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- aspirin/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) strokes/NNS
D014859_D004617 NONE warfarin/NN (r_nsubj) is/VBZ (l_acomp) superior/JJ (l_xcomp) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
C081309_D004617 NONE Irbesartan/NNP (r_pobj) with/IN (r_prep) Trial/NN (r_nsubj) demonstrated/VBN (l_ccomp) is/VBZ (l_acomp) superior/JJ (l_xcomp) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
C081309_D001281 NONE Irbesartan/NNP (r_pobj) with/IN (r_prep) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D000809_D001281 NONE Angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN
C426686_D004617 NONE Ximelagatran/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) efficient/JJ (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) events/NNS
D000809_D020257 NONE Angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN (l_prep) through/IN (l_pobj) remodelling/NN
D014859_D020521 NONE warfarin/NN (r_nsubj) reduces/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- warfarin/VB (r_nsubj) is/VBZ (l_acomp) superior/JJ (l_prep) to/IN (l_pobj) aspirin/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) strokes/NNS
D014812_D004617 NONE K/NNP (r_compound) drugs/NNS (r_pobj) as/IN (r_prep) efficient/JJ (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) events/NNS
C055162_D004617 NONE Clopidogrel/NNP (r_compound) Trial/NN (r_nsubj) demonstrated/VBN (l_ccomp) is/VBZ (l_acomp) superior/JJ (l_xcomp) platelet/NN (l_prep) in/IN (l_pobj) events/NNS -PUNC- clopidogrel/JJ (r_dobj) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
C426686_D056486 CID Ximelagatran/NN (r_nsubjpass) found/VBN (l_conj) withdrawn/VBN (l_prep) because/IN (l_pobj) tests/NNS (l_compound) function/NN
D001241_D001281 NONE aspirin/NN (r_conj) clopidogrel/JJ (r_dobj) platelet/NN (r_xcomp) superior/JJ (r_acomp) is/VBZ (r_ccomp) demonstrated/VBN (l_nsubj) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D014859_D001281 NONE warfarin/NN (r_nsubj) is/VBZ (r_ccomp) demonstrated/VBN (l_nsubj) Trial/NN (l_compound) Clopidogrel/NNP (l_compound) Fibrillation/NNP
D000804_D020257 NONE II/CD (r_nummod) drugs/NNS (r_conj) inhibitors/NNS (r_nsubj) hold/VBP (l_dobj) promise/NN (l_prep) in/IN (l_pobj) fibrillation/NN (l_prep) through/IN (l_pobj) remodelling/NN
C479958_D001281 NONE Idraparinux/NNP (r_nsubjpass) evaluated/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fibrillation/NN
D001241_D004617 NONE aspirin/NN (r_conj) clopidogrel/JJ (r_dobj) platelet/NN (l_prep) in/IN (l_pobj) events/NNS
6323692
D002118_D003866 NONE calcium/NN (r_pobj) of/IN (r_prep) Addition/NN (r_nsubj) reversed/VBD (l_dobj) depression/NN -PUNC- calcium/NN (r_npadvmod) independent/JJ (r_amod) release/NN (r_nsubjpass) blocked/VBN (r_conj) reversed/VBD (l_dobj) depression/NN
D002395_D003866 NONE catecholamine/NN (r_compound) release/NN (r_nsubjpass) blocked/VBN (r_conj) reversed/VBD (l_dobj) depression/NN
D010433_D000699 NONE metrazol/NN (r_pobj) of/IN (r_prep) action/NN (r_dobj) affected/VBD (r_conj) analgesia-/JJ
D000661_D000699 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_amod) activity/NN (r_dobj) antagonized/VBN (r_conj) analgesia-/JJ
C018824_D000699 NONE NH4Ac/NNP (r_nmod) pretreatment/NN (r_conj) verapamil/NN (r_nsubj) analgesia-/JJ -PUNC- NH4Ac/NNP (r_conj) verapamil/NN (r_nsubj) affected/VBD (r_conj) analgesia-/JJ
D003975_D000699 NONE diazepam/NN (r_npadvmod) induced/VBN (r_amod) incoordination/NN (r_conj) analgesia-/JJ
D009020_D001259 NONE morphine/NN (r_npadvmod) treated/VBN (r_amod) mice/NNS (r_nsubj) remained/VBD (l_conj) incoordination/NN -PUNC- morphine/NN (r_appos) pretreatment/NN (r_conj) verapamil/NN (r_nsubj) analgesia-/JJ (l_conj) incoordination/NN
D009020_D000699 NONE morphine/NN (r_appos) pretreatment/NN (r_conj) verapamil/NN (r_nsubj) analgesia-/JJ
D003975_D001259 CID diazepam/NN (r_pobj) by/IN (r_prep) incoordination/NN -PUNC- diazepam/NN (r_npadvmod) induced/VBN (r_amod) incoordination/NN
D010433_D001259 NONE metrazol/NN (r_pobj) of/IN (r_prep) action/NN (r_dobj) affected/VBD (r_conj) analgesia-/JJ (l_conj) incoordination/NN
D014700_D000699 NONE verapamil/NN (r_nsubj) analgesia-/JJ -PUNC- verapamil/NN (r_nsubj) affected/VBD (r_conj) analgesia-/JJ
C018824_D001259 CID acetate/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) doubled/VBD (l_npadvmod) time/NN (l_relcl) remained/VBD (l_conj) incoordination/NN -PUNC- NH4Ac/NNP (r_appos) acetate/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) doubled/VBD (l_npadvmod) time/NN (l_relcl) remained/VBD (l_conj) incoordination/NN -PUNC- NH4Ac/NNP (r_compound) treatment/NN (r_nsubj) had/VBD (r_conj) remained/VBD (l_conj) incoordination/NN -PUNC- NH4Ac/NNP (r_nmod) pretreatment/NN (r_conj) verapamil/NN (r_nsubj) analgesia-/JJ (l_conj) incoordination/NN -PUNC- NH4Ac/NNP (r_conj) verapamil/NN (r_nsubj) affected/VBD (r_conj) analgesia-/JJ (l_conj) incoordination/NN
C018824_D003866 NONE NH4Ac/NNPS (r_pobj) by/IN (r_agent) blocked/VBN (r_conj) reversed/VBD (l_dobj) depression/NN
D000079_D003866 NONE acetaldehyde/NN (r_pobj) by/IN (r_prep) release/NN (r_nsubjpass) blocked/VBN (r_conj) reversed/VBD (l_dobj) depression/NN
D002118_D022124 NONE calcium/NN (r_compound) channel/NN (r_dobj) exerts/VBZ (l_nsubj) hyperammonemia/NN
D014700_D001259 NONE verapamil/NN (r_nsubj) analgesia-/JJ (l_conj) incoordination/NN -PUNC- verapamil/NN (r_nsubj) affected/VBD (r_conj) analgesia-/JJ (l_conj) incoordination/NN
D000661_D001259 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_amod) activity/NN (r_dobj) antagonized/VBN (r_conj) analgesia-/JJ (l_conj) incoordination/NN
2396046
D010634_D006528 NONE phenobarbital/NN (r_dobj) containing/VBG (r_acl) diet/NN (r_dobj) fed/VBD (r_conj) fed/VBD (l_nsubj) nodules/NNS (l_conj) carcinomas/NNS -PUNC- phenobarbital/NN (r_dobj) containing/VBG (r_acl) diet/NN (r_dobj) fed/VBD (r_conj) fed/VBD (l_advcl) developed/VBN (l_nsubj) nodule/NN (l_conj) carcinoma/NN -PUNC- phenobarbital/RB (r_npadvmod) containing/VBG (r_amod) diet/NN (r_dobj) fed/VBD (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) carcinomas/NNS
D002794_D006528 CID choline/NN (r_npadvmod) supplemented/VBN (r_amod) diet/NN (r_dobj) fed/VBD (l_nsubj) nodules/NNS (l_conj) carcinomas/NNS -PUNC- choline/NN (r_npadvmod) supplemented/VBN (r_amod) diet/NN (r_dobj) fed/VBD (l_advcl) developed/VBN (l_nsubj) nodule/NN (l_conj) carcinoma/NN -PUNC- choline/NN (r_npadvmod) devoid/JJ (r_amod) diet/NN (r_dobj) fed/VBD (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) carcinomas/NNS -PUNC- choline/NN (r_npadvmod) devoid/JJ (r_amod) diet/NN (r_dobj) fed/VBD (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) carcinomas/NNS
20084309
D008874_D000402 NONE MZ/NNP (r_compound) use/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoxia/NN (r_pobj) due/JJ (r_prep) presented/VBD (l_prep) due/IN (l_pobj) obstruction/NN
D008874_D008944 NONE MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN -PUNC- MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP -PUNC- MZ/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_appos) MP/NNP (l_nmod) MR/NNP
D008874_D020521 NONE MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN (r_conj) duration/NN (r_dobj) test/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) variables/NNS (l_appos) age/NN (l_conj) sex/NN (l_conj) stroke/UH
D008874_D000860 CID MZ/NNP (r_compound) use/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoxia/NN (r_pobj) due/JJ (r_prep) presented/VBD (l_dobj) hypoxia/NN -PUNC- MZ/NNP (r_compound) use/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypoxia/NN
D008874_D009202 NONE MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN (r_conj) duration/NN (r_dobj) test/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) variables/NNS (l_appos) age/NN (l_conj) sex/NN (l_conj) stroke/UH (l_conj) MP/NNP (l_amod) myocardiopathy/NN -PUNC- MZ/NNP (r_compound) dose/NN (r_conj) MR/NNP (r_appos) regurgitation/NN (r_conj) duration/NN (r_dobj) test/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) variables/NNS (l_appos) age/NN (l_conj) sex/NN (l_conj) stroke/UH (l_conj) MP/NNP -PUNC- MZ/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_appos) MP/NNP
19996135
D014148_D012640 CID Acid/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- TXA/NNP (r_compound) usage/NN (l_conj) seizures/NNS -PUNC- TXA/NNP (r_compound) intraoperatively/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- TXA/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) seizures/NNS
15858223
D014635_D009336 CID VPA/NNP (r_compound) results/NNS (l_advcl) measured/VBN (l_agent) by/IN (l_pobj) levels/NNS (l_relcl) precedes/VBZ (l_dobj) onset/NN (l_prep) of/IN (l_pobj) necrosis/NN
C075750_D009336 NONE 15-F(2t)-IsoP/CD (r_pobj) of/IN (r_prep) levels/NNS (l_relcl) precedes/VBZ (l_dobj) onset/NN (l_prep) of/IN (l_pobj) necrosis/NN
D014635_D056486 CID acid/NN (r_compound) metabolite/NN (r_amod) levels/NNS (r_conj) toxicity/NN -PUNC- VPA/NNP (r_npadvmod) associated/VBN (r_amod) stress/NN (l_conj) hepatotoxicity/NN -PUNC- VPA/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) determine/VB (l_ccomp) was/VBD (l_attr) relationship/NN (l_prep) between/IN (l_pobj) stress/NN (l_conj) hepatotoxicity/NN
C075750_D005234 NONE 15-F(2t)-IsoP/CD (r_pobj) of/IN (r_prep) levels/NNS (l_relcl) precedes/VBZ (l_dobj) onset/NN (l_prep) of/IN (l_pobj) necrosis/NN (l_conj) steatosis/NN
D005978_D056486 NONE glutathione/NN (r_compound) transferase/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) on/IN (r_prep) based/VBN (r_prep) evaluated/VBN (l_nsubjpass) toxicity/NN
D014635_D005234 CID VPA/NNP (r_compound) results/NNS (l_advcl) measured/VBN (l_agent) by/IN (l_pobj) levels/NNS (l_relcl) precedes/VBZ (l_dobj) onset/NN (l_prep) of/IN (l_pobj) necrosis/NN (l_conj) steatosis/NN
1720453
D007069_D064420 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) m2/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) correlated/VBN (l_nsubjpass) toxicity/NN
D003404_D011507 NONE creatinine/NN (r_compound) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN
D007069_D007674 CID ifosfamide/JJ (r_amod) toxicity/NN
D007069_D009369 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) m2/NN (r_pobj) of/IN (r_prep) dose/NN (l_conj) predominance/NN (l_prep) of/IN (l_pobj) involvement/NN (l_compound) tumor/NN
D010710_D000608 NONE phosphate/NN (r_nmod) reabsorption/NN (r_conj) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ
D010710_D005198 NONE phosphate/NN (r_compound) reabsorption/NN (r_conj) microglobulinuria/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) included/VBD (r_conj) included/VBD (l_dobj) patients/NNS (l_relcl) developed/VBD (l_dobj) toxicity/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- phosphate/NN (r_compound) reabsorption/NN (r_conj) microglobulinuria/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) included/VBD (r_conj) included/VBD (l_dobj) patients/NNS (l_relcl) developed/VBD (l_dobj) toxicity/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) syndrome/NN (l_appos) TDFS/NNP
D003404_D006030 NONE creatinine/NN (r_compound) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN (r_conj) glucosuria/NN
D010710_D011507 NONE phosphate/NN (r_nmod) reabsorption/NN (r_conj) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN
D010710_D064420 NONE phosphate/NN (r_compound) reabsorption/NN (r_conj) microglobulinuria/NN (r_pobj) with/IN (r_prep) patients/NNS (r_dobj) included/VBD (r_conj) included/VBD (l_dobj) patients/NNS (l_relcl) developed/VBD (l_dobj) toxicity/NN
D010710_D006030 NONE phosphate/NN (r_nmod) reabsorption/NN (r_conj) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ (r_conj) proteinuria/NN (r_conj) glucosuria/NN
D007069_C535700 NONE ifosfamide/JJ (r_amod) toxicity/NN (r_pobj) of/IN (r_prep) up/NN (r_nsubj) treated/VBN (l_prep) for/IN (l_pobj) tumors/NNS -PUNC- ifosfamide/JJ (r_compound) protocol/NN (r_dobj) received/VBN (r_relcl) function/NN (l_prep) with/IN (l_pobj) tumors/NNS -PUNC- ifosfamide/JJ (r_compound) protocol/NN (l_appos) Society/NNP (l_prep) of/IN (l_pobj) Study/NNP (l_compound) Tumor/NNP -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS
D003404_D000608 NONE creatinine/NN (r_compound) clearance/NN (r_conj) osmolarity/NN (r_conj) pH/NN (r_conj) aminoaciduria/JJ
7059267
D002747_D009901 CID Chlorpropamide/NN (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- chlorpropamide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) had/VBD (l_dobj) neuropathy/NN -PUNC- Diabenese/NNP (r_appos) chlorpropamide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) had/VBD (l_dobj) neuropathy/NN -PUNC- chlorpropamide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) with/IN (r_prep) resolved/VBD (r_relcl) neuropathy/NN
D002747_D003924 NONE chlorpropamide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- Diabenese/NNP (r_appos) chlorpropamide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- chlorpropamide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) with/IN (r_prep) resolved/VBD (r_relcl) neuropathy/NN (r_dobj) had/VBD (l_csubj) treated/VBN (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) diabetes/NNS
11279304
D003630_D015470 NONE daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN -PUNC- DNR)-containing/NN (r_compound) regimen/NNS (r_appos) daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN -PUNC- DNR/NNP (r_npadvmod) containing/VBG (r_amod) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) leukemia/NN
D018943_D066126 NONE anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- Anthracyclines/NNS (r_nsubj) are/VBP (l_conj) cause/VBP (l_dobj) cardiotoxicity/NN -PUNC- anthracycline/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- anthracycline/NN (r_advmod) induced/VBN (r_compound) cardiotoxicity/NN
D003630_D066126 NONE daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) cardiotoxicity/NN -PUNC- DNR)-containing/NN (r_compound) regimen/NNS (r_appos) daunorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) cardiotoxicity/NN
D018943_D015470 NONE anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) leukemia/NN
D018943_D006331 NONE anthracycline/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN (r_nsubj) highlights/VBZ (l_dobj) need/NN (l_acl) search/VB (l_prep) for/IN (l_pobj) methods/NNS (l_relcl) are/VBP (l_acomp) sensitive/JJ (l_conj) capable/JJ (l_prep) of/IN (l_pcomp) predicting/VBG (l_dobj) dysfunction/NN
D003630_D006333 CID DNR/NNP (r_pobj) given/VBN (r_acl) failure/NN
6436733
D014635_D006970 CID VPA/NNP (r_compound) levels/NNS (r_nsubj) were/VBD (r_advcl) was/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) complained/VBD (l_prep) of/IN (l_pobj) drowsiness/NN
D000641_D006970 CID Ammonia/NN (r_nsubj) was/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) complained/VBD (l_prep) of/IN (l_pobj) drowsiness/NN -PUNC- NH3/NNP (r_appos) Ammonia/NN (r_nsubj) was/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) complained/VBD (l_prep) of/IN (l_pobj) drowsiness/NN
D014635_D004827 NONE acid/NN (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_amod) epileptic/JJ -PUNC- VPA/NNP (r_appos) acid/NN (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_amod) epileptic/JJ
3107448
D013453_D056486 NONE sulfonylureas/NNS (r_pobj) with/IN (r_prep) reported/VBN (l_nsubjpass) hepatotoxicity/NN -PUNC- sulfonylurea/NN (r_nsubj) exist/VBP (l_nsubj) reports/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D005905_D056486 CID Glyburide/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- glyburide/NN (r_pobj) For/IN (r_prep) exist/VBP (l_nsubj) reports/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- glyburide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) syndrome/NN -PUNC- Glyburide/NNP (r_nsubj) produce/VB (l_dobj) illness/NN
D005905_D003924 NONE glyburide/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) mellitus/NN
11185967
D000661_D012640 NONE amphetamine/NN (r_conj) cocaine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) seizure/NN
D000431_D019969 NONE alcohol/NN (r_npadvmod) related/VBN (r_amod) disorder/NN (r_conj) drug/NN (r_pobj) of/IN (r_prep) history/NN (r_appos) demographics/NNS (r_nsubj) estimated/VBN (l_prep) from/IN (l_prep) to/IN (l_pobj) collection/NN (l_conj) history/NN (l_conj) suspicion/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
D000431_D012640 NONE alcohol/NN (r_npadvmod) related/VBN (r_amod) disorder/NN (l_compound) seizure/NN -PUNC- alcohol/NN (r_npadvmod) related/VBN (r_amod) disorder/NN (r_conj) drug/NN (r_pobj) of/IN (r_prep) history/NN (r_appos) demographics/NNS (r_nsubj) estimated/VBN (l_prep) from/IN (l_pobj) seizure/NN
D000662_D012640 NONE amphetamines/NNS (r_conj) cocaine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) seizure/NN
D000431_D019970 NONE alcohol/NN (r_npadvmod) related/VBN (r_amod) disorder/NN (r_conj) drug/NN (r_pobj) of/IN (r_prep) history/NN (r_appos) demographics/NNS (r_nsubj) estimated/VBN (l_prep) from/IN (l_prep) to/IN (l_pobj) collection/NN (l_conj) history/NN (l_conj) suspicion/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
D003042_D012640 NONE cocaine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) seizure/NN -PUNC- cocaine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) seizure/NN
19274460
D003907_D009101 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) definition/NN (l_prep) for/IN (l_pobj) induction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- dexamethasone/NN (r_conj) bortezomib/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) evaluate/VB (l_prep) as/IN (l_pobj) treatment/NN (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- dexamethasone/NN (r_conj) bortezomib/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) evaluate/VB (l_prep) as/IN (l_pobj) treatment/NN (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN (l_appos) MM/NNP -PUNC- dexamethasone/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP
D003520_D009101 NONE cyclophosphamide/NN (r_pobj) for/IN (r_prep) definition/NN (l_prep) for/IN (l_pobj) induction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) evaluate/VB (l_prep) as/IN (l_pobj) treatment/NN (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) evaluate/VB (l_prep) as/IN (l_pobj) treatment/NN (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN (l_appos) MM/NNP -PUNC- cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) bortezomib/NNS (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP
C400082_D009101 NONE bortezomib/NNS (r_amod) dexamethasone/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) definition/NN (l_prep) for/IN (l_pobj) induction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- bortezomib/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) evaluate/VB (l_prep) as/IN (l_pobj) treatment/NN (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- bortezomib/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) evaluate/VB (l_prep) as/IN (l_pobj) treatment/NN (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN (l_appos) MM/NNP -PUNC- bortezomib/NNS (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP
14765563
D011803_D003128 CID quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) status/NN (l_conj) seizures/NNS (l_conj) coma/NN
D011803_D020922 NONE quinine/NN (r_nsubj) is/VBZ (l_advcl) banned/VBD (l_dobj) use/NN (l_prep) for/IN (l_pobj) cramps/NNS
D011803_D002493 NONE quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) complications/NNS
D011803_D012640 CID quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) status/NN (l_conj) seizures/NNS
D011803_D003221 CID quinine/NN (r_dobj) containing/VBG (r_acl) products/NNS (r_nsubj) produce/VB (l_dobj) complications/NNS (l_prep) including/VBG (l_pobj) confusion/NN
7880714
16471092
C099041_D053201 NONE tolterodine/JJ (r_amod) treatment/NN (r_pobj) after/IN (r_prep) symptoms/NNS (l_conj) quality/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) with/IN (l_pobj) bladder/NN -PUNC- tolterodine/JJ (r_amod) treatment/NN (r_pobj) after/IN (r_prep) study/VB (l_dobj) symptoms/NNS (l_conj) quality/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) with/IN (l_pobj) bladder/NN -PUNC- tolterodine/JJ (r_amod) treatment/NN (r_pobj) after/IN (r_prep) study/VB (l_dobj) symptoms/NNS (l_conj) quality/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) with/IN (l_pobj) bladder/NN (l_appos) OAB/NNP -PUNC- Tolterodine/NNP (r_nsubjpass) tolerated/VBN (l_conj) improved/VBD (l_dobj) quality/NN (l_prep) with/IN (l_pobj) OAB/NNP
9205462
D013629_D006106 NONE tamoxifen/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (r_pobj) with/IN (r_prep) Patients/NNS (r_nsubj) be/VB (l_prep) at/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) tumors/NNS -PUNC- tamoxifen/NN (r_compound) metabolism/NN (r_pobj) in/IN (r_prep) alterations/NNS (r_pobj) because/IN (r_prep) be/VB (l_prep) at/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) tumors/NNS
D013629_D001943 NONE tamoxifen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) for/IN (l_pobj) carcinoma/NN
D013629_D017093 CID tamoxifen/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN -PUNC- tamoxifen/NN (r_compound) metabolism/NN (r_pobj) in/IN (r_prep) alterations/NNS (r_pobj) because/IN (r_prep) be/VB (l_nsubj) Patients/NNS (l_prep) with/IN (l_pobj) dysfunction/NN
D013629_D009369 NONE tamoxifen/NN (r_compound) use/NN (l_conj) tumors/NNS
D013629_C537296 CID tamoxifen/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) ovary/NN
D004967_D001943 NONE estrogen/NN (r_compound) carcinoma/NN
18208574
D006493_D013921 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) assay/NN (l_nmod) HIT/NN -PUNC- heparin/JJ (r_compound) concentration/NN (r_pobj) of/IN (r_prep) characteristics/NNS (r_dobj) utilizes/VBZ (l_advcl) correlate/VB (l_dobj) density/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) concentration/NN (r_pobj) of/IN (r_prep) characteristics/NNS (r_dobj) utilizes/VBZ (l_advcl) correlate/VB (l_dobj) density/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN (l_appos) assay/NN (l_nmod) HIT/NN -PUNC- heparin/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) Patients/NNS (l_prep) with/IN (l_pobj) decrease/NN (l_conj) thrombocytopenia/NNP -PUNC- heparin/NN (r_pobj) of/IN (r_prep) concentration/NN (r_pobj) with/IN (r_prep) inhibition/NN (r_dobj) had/VBD (r_relcl) heparin/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) Patients/NNS (l_prep) with/IN (l_pobj) decrease/NN (l_conj) thrombocytopenia/NNP
D006493_D013927 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) assay/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/JJ (r_compound) concentration/NN (r_pobj) of/IN (r_prep) characteristics/NNS (r_dobj) utilizes/VBZ (l_advcl) correlate/VB (l_dobj) density/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN (l_appos) assay/NN (l_prep) with/IN (l_pobj) thrombosis/NN
2840807
D000324_D009069 NONE ACTH/NNP (r_compound) terminal/NN (r_compound) fragments/NNS (r_pobj) by/IN (r_agent) stimulated/VBN (r_ccomp) is/VBZ (l_conj) cause/VB (l_ccomp) resulted/VBD (l_nsubj) depression/NN (l_relcl) resulted/VBD (l_prep) in/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) disorder/NN
D009074_D004421 CID MSH/NNP (r_nmod) ACTH/NNP (r_nmod) stimulation/NN (r_pobj) after/IN (r_prep) syndrome/NN (l_amod) like/JJ (l_npadvmod) dystonia/NN
D000324_D003866 NONE ACTH/NNP (r_compound) terminal/NN (r_compound) fragments/NNS (r_pobj) by/IN (r_agent) stimulated/VBN (r_ccomp) is/VBZ (l_conj) cause/VB (l_ccomp) resulted/VBD (l_nsubj) depression/NN
D000324_D004421 CID ACTH/NNP (r_nmod) stimulation/NN (r_pobj) after/IN (r_prep) syndrome/NN (l_amod) like/JJ (l_npadvmod) dystonia/NN
15764424
D002395_D001523 NONE catecholamines/NNS (r_conj) levels/NNS (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) examine/VB (r_advcl) interviewed/VBN (l_nsubjpass) patients/NNS (l_prep) in/IN (l_pobj) service/NN (l_amod) psychiatric/JJ -PUNC- catecholamine/NN (r_conj) drug/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) assays/NNS (r_pobj) for/IN (r_prep) collected/VBN (r_conj) interviewed/VBN (l_nsubjpass) patients/NNS (l_prep) in/IN (l_pobj) service/NN (l_amod) psychiatric/JJ
D003042_D011605 CID cocaine/NN (r_conj) amphetamine-/JJ (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) with/IN (r_prep) service/NN (r_pobj) in/IN (r_prep) patients/NNS (r_nsubjpass) interviewed/VBN (l_advcl) examine/VB (l_dobj) relationship/NN (l_prep) between/IN (l_pobj) levels/NNS (l_conj) catecholamines/NNS (l_conj) symptoms/NNS -PUNC- cocaine/NN (r_conj) amphetamine-/JJ (r_npadvmod) induced/VBN (r_amod) psychosis/NN
D000661_D001523 NONE amphetamine-/JJ (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) with/IN (r_prep) service/NN (l_amod) psychiatric/JJ
D000661_D006948 CID amphetamine/NN (r_compound) levels/NNS (r_conj) Methamphetamine/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) scores/NNS (l_conj) rating/NN (l_compound) hyperkinesia/NN
D003042_D001523 NONE cocaine/NN (r_conj) amphetamine-/JJ (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) with/IN (r_prep) service/NN (l_amod) psychiatric/JJ
D000661_D011605 CID amphetamine-/JJ (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) with/IN (r_prep) service/NN (r_pobj) in/IN (r_prep) patients/NNS (r_nsubjpass) interviewed/VBN (l_advcl) examine/VB (l_dobj) relationship/NN (l_prep) between/IN (l_pobj) levels/NNS (l_conj) catecholamines/NNS (l_conj) symptoms/NNS -PUNC- amphetamine-/JJ (r_npadvmod) induced/VBN (r_amod) psychosis/NN
D002395_D006948 NONE catecholamines/NNS (l_conj) hyperkinesia/NN
D002395_D011605 NONE catecholamines/NNS (r_conj) severity/NN (r_pobj) to/IN (r_prep) relationship/NN (r_appos) levels/NNS (l_prep) in/IN (l_pobj) psychosis/NN -PUNC- catecholamines/NNS (l_conj) symptoms/NNS -PUNC- catecholamines/NNS (r_conj) levels/NNS (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) examine/VB (r_advcl) interviewed/VBN (l_nsubjpass) patients/NNS (l_prep) in/IN (l_pobj) service/NN (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) psychosis/NN -PUNC- catecholamine/NN (r_conj) drug/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) assays/NNS (r_pobj) for/IN (r_prep) collected/VBN (r_conj) interviewed/VBN (l_advcl) examine/VB (l_dobj) relationship/NN (l_prep) between/IN (l_pobj) levels/NNS (l_conj) catecholamines/NNS (l_conj) symptoms/NNS -PUNC- catecholamine/NN (r_conj) drug/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) assays/NNS (r_pobj) for/IN (r_prep) collected/VBN (r_conj) interviewed/VBN (l_nsubjpass) patients/NNS (l_prep) in/IN (l_pobj) service/NN (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) psychosis/NN
D008694_D006948 CID Methamphetamine/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) scores/NNS (l_conj) rating/NN (l_compound) hyperkinesia/NN
3952818
D005472_D003110 NONE 5-fluorouracil/CD (r_punct) administration/NN (r_pobj) after/IN (r_prep) presented/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- 5-FU/CD (r_nmod) administration/NN (r_pobj) after/IN (r_prep) presented/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN
D005472_D009362 NONE 5-fluorouracil/CD (r_punct) administration/NN (r_pobj) after/IN (r_prep) presented/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_conj) metastasis/NN -PUNC- 5-FU/CD (r_nmod) administration/NN (r_pobj) after/IN (r_prep) presented/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN (l_conj) metastasis/NN
D005472_D003329 NONE 5-FU/CD (r_pobj) to/IN (r_pcomp) due/JJ (r_prep) be/VB (l_nsubj) spasm/NN -PUNC- 5-FU/CD (r_compound) cardiotoxicity/NN (r_pobj) of/IN (r_prep) prevention/NN (r_pobj) in/IN (r_prep) used/VBN (r_conj) be/VB (l_nsubj) spasm/NN
D005472_D066126 NONE 5-fluorouracil/CD (r_punct) ./. (r_punct) toxicity/NN -PUNC- 5-FU/CD (r_pobj) to/IN (r_pcomp) due/JJ (r_prep) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- 5-FU/CD (r_pobj) to/IN (r_pcomp) due/JJ (r_prep) be/VB (l_conj) used/VBN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- 5-FU/CD (r_compound) cardiotoxicity/NN (r_pobj) of/IN (r_prep) prevention/NN (r_pobj) in/IN (r_prep) used/VBN (r_conj) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- 5-FU/CD (r_compound) cardiotoxicity/NN
D002118_D066126 NONE calcium/NN (r_compound) antagonists/NNS (r_nsubjpass) used/VBN (r_conj) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- calcium/NN (r_compound) antagonists/NNS (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN
D009543_D002637 NONE nifedipine/NN (r_pobj) with/IN (r_prep) resolved/VBD (l_nsubj) pain/NN
D009543_D000788 NONE nifedipine/NN (r_pobj) with/IN (r_prep) resolved/VBD (r_conj) was/VBD (l_acomp) similar/JJ (l_prep) to/IN (l_pobj) that/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) angina/NN
D002118_D003329 NONE calcium/NN (r_compound) antagonists/NNS (r_nsubjpass) used/VBN (r_conj) be/VB (l_nsubj) spasm/NN
D005472_D002637 CID 5-fluorouracil/CD (r_punct) administration/NN (r_pobj) after/IN (r_prep) presented/VBD (l_dobj) pain/NN -PUNC- 5-FU/CD (r_nmod) administration/NN (r_pobj) after/IN (r_prep) presented/VBD (l_dobj) pain/NN
8045270
C061282_D002375 CID 21680/CD (r_nummod) CGS/NNP (r_appos) agonist/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) responses/NNS (l_amod) cataleptic/JJ
C081198_D002375 NONE KF17837/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) ameliorated/VBD (l_dobj) responses/NNS (l_amod) cataleptic/JJ -PUNC- KF17837/NN (r_nsubj) reduced/VBD (l_dobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D012110_D002375 CID reserpine/NN (r_pobj) by/IN (r_conj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D000241_D002375 NONE adenosine/NN (r_amod) agonist/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) responses/NNS (l_amod) cataleptic/JJ
C081198_D010302 NONE KF17837/NN (r_nsubj) be/VB (l_attr) drug/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) parkinsonism/NN
1732369
D004317_D006331 NONE doxorubicin/NN (r_pobj) due/IN (r_amod) damage/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) survivors/NNS (r_dobj) differentiate/VB (r_xcomp) using/VBG (r_xcomp) performed/VBN (l_advcl) develop/VB (l_dobj) test/NN (l_prep) for/IN (l_pobj) damage/NN
D004317_D009369 NONE doxorubicin/NN (r_npadvmod) treated/VBN (r_amod) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_pobj) due/IN (r_amod) damage/NN (r_pobj) for/IN (r_prep) test/NN (r_dobj) develop/VB (r_advcl) performed/VBN (l_xcomp) using/VBG (l_xcomp) differentiate/VB (l_dobj) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN
D004280_D009369 NONE Dobutamine/NNP (r_nsubj) stress/VBP (l_appos) indicator/NN (l_prep) of/IN (l_pobj) function/NN (l_prep) in/IN (l_pobj) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- dobutamine/NN (r_compound) infusion/NN (r_dobj) using/VBG (l_xcomp) differentiate/VB (l_dobj) survivors/NNS (l_prep) of/IN (l_pobj) cancer/NN
D004280_D006331 NONE dobutamine/NN (r_compound) infusion/NN (r_dobj) using/VBG (r_xcomp) performed/VBN (l_advcl) develop/VB (l_dobj) test/NN (l_prep) for/IN (l_pobj) damage/NN
D004317_D009202 CID Doxorubicin/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_acl) known/VBN (l_xcomp) cause/VB (l_dobj) cardiomyopathy/NN
2564649
D011224_D009127 NONE prazosin/NN (r_pobj) with/IN (r_prep) lesions/NNS (r_pobj) by/IN (r_agent) reduced/VBN (r_conj) antagonized/VBN (l_nsubjpass) rigidity/NN
D005283_D009127 CID fentanyl/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- fentanyl/NN (r_compound) anesthesia/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) effect/NN (r_attr) is/VBZ (l_nsubj) rigidity/NN -PUNC- fentanyl/NN (r_pobj) by/IN (r_prep) rigidity/NN
3311455
D016572_D007674 CID cyclosporine/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) nephrotoxicity/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) dosages/NNS (r_nsubj) cause/VB (l_dobj) nephrotoxicity/NN
2096243
C017367_D019965 CID Carmofur/NN (r_npadvmod) induced/VBN (r_amod) disorders/NNS -PUNC- carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) period/NN (r_pobj) in/IN (r_prep) female/NN (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) disorder/NN
C017367_D056784 CID carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/NN -PUNC- carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/JJ
C017367_D010554 NONE carmofur/NN (r_npadvmod) induced/VBN (r_amod) leukoencephalopathy/JJ (r_nsubj) result/VB (l_prep) in/IN (l_pobj) syndrome/NN
11705128
D012254_D000743 CID ribavirin/RB (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) induced/VBN (l_dobj) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) induced/VBN (l_dobj) anemia/NN (l_appos) RIHA/NNP -PUNC- ribavirin/JJ (r_compound) dosage/NN (r_pobj) of/IN (r_prep) reduction/NN (r_attr) is/VBZ (l_nsubj) standard/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) RIHA/NNP -PUNC- ribavirin/NN (r_pobj) of/IN (r_prep) dose/NN (l_conj) incidence/NN (l_prep) of/IN (l_pobj) RIHA/NNP
D012254_D019698 NONE ribavirin/RB (r_conj) interferon/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) demonstrated/VBN (l_prep) compared/VBN (l_prep) with/IN (l_pobj) monotherapy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) C/NNP -PUNC- ribavirin/RB (r_conj) interferon/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) demonstrated/VBN (l_prep) compared/VBN (l_prep) with/IN (l_pobj) monotherapy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) C/NNP (l_appos) CHC/NNP
D012254_D006526 NONE ribavirin/RB (r_npadvmod) induced/VBN (r_amod) anemia/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) C/NNP
D016898_D019698 NONE alpha/NN (r_compound) monotherapy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) C/NNP -PUNC- alpha/NN (r_compound) monotherapy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) C/NNP (l_appos) CHC/NNP
11890511
7604176
D017035_D009220 CID pravastatin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) myopathy/NNS
D017035_D006937 NONE pravastatin/RB (r_dobj) assumed/VBD (l_prep) because/IN (l_pobj) hypercholesterolemia/NN
D017035_D009135 NONE Pravastatin/NNP (r_npadvmod) associated/VBN (r_amod) myopathy/NN -PUNC- pravastatin/JJ (r_amod) discontinuation/NN (r_pobj) after/IN (r_prep) resolved/VBD (r_relcl) limbs/NNS (r_pobj) of/IN (r_prep) myopathy/NN -PUNC- pravastatin/RB (r_npadvmod) associated/VBN (r_amod) myopathy/NNS (r_nsubj) represent/VB (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) myopathy/NNS -PUNC- pravastatin/RB (r_npadvmod) associated/VBN (r_amod) myopathy/NNS
D008148_D009135 NONE lovastatin/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) myopathy/NNS -PUNC- lovastatin/NN (r_nsubjpass) associated/VBN (r_advcl) represent/VB (l_nsubj) myopathy/NNS
D019821_D009135 NONE simvastatin/NN (r_conj) lovastatin/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) myopathy/NNS -PUNC- simvastatin/NN (r_conj) lovastatin/NN (r_nsubjpass) associated/VBN (r_advcl) represent/VB (l_nsubj) myopathy/NNS
18343374
D002996_D014786 CID CC/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) on/IN (r_prep) search/NN (r_nsubj) include/VB (l_advcl) is/VBZ (l_nsubj) disturbance/NN -PUNC- CC/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) disturbance/NN
D002996_D007247 NONE CC/NN (r_pobj) with/IN (r_prep) treating/VBG (l_dobj) patients/NNS (l_compound) infertility/NN
D002996_D013923 NONE CC/NN (r_pobj) of/IN (r_prep) complications/NNS (l_compound) thromboembolic/JJ -PUNC- CC/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) disturbance/NN (r_nsubj) is/VBZ (r_advcl) include/VB (l_nsubj) search/NN (l_prep) on/IN (l_pobj) complications/NNS (l_compound) thromboembolic/JJ
D002996_D012170 CID clomiphene/NN (r_npadvmod) induced/VBN (r_amod) ovulation/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN -PUNC- citrate/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN -PUNC- CC/NN (r_appos) citrate/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN -PUNC- CC/NN (r_pobj) with/IN (r_prep) induction/NN (r_pobj) after/IN (r_prep) occlusion/NN -PUNC- CC/NN (r_pobj) of/IN (r_prep) courses/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) occlusion/NN -PUNC- CC/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) occlusion/NN
88336
D009567_D062787 CID nitrazepam/NN (r_pobj) of/IN (r_prep) overdose/NN -PUNC- nitrazepam/JJ (r_amod) overdose/NN
D000431_D062787 NONE alcohol/NN (r_compound) withdrawal/NN (r_compound) symptoms/NNS (r_pobj) for/IN (r_prep) received/VBD (l_conj) took/VBD (l_dobj) overdose/NN
D009567_D013375 NONE nitrazepam/NN (r_pobj) of/IN (r_prep) overdose/NN (r_dobj) took/VBD (r_conj) received/VBD (l_prep) for/IN (l_pobj) symptoms/NNS
D002719_D003128 CID chlormethiazole/NN (r_compound) intoxication/NN (r_pobj) with/IN (r_prep) those/DT (r_pobj) of/IN (r_prep) two/CD (r_conj) overdose/NN (r_pobj) with/IN (r_prep) patient/NN (r_nsubj) conformed/VBD (l_prep) to/IN (l_pobj) criteria/NNS (l_prep) of/IN (l_pobj) coma/NN
D002719_D013375 NONE chlormethiazole/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) received/VBD (l_prep) for/IN (l_pobj) symptoms/NNS
D002719_D062787 NONE chlormethiazole/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) received/VBD (l_conj) took/VBD (l_dobj) overdose/NN -PUNC- chlormethiazole/NN (r_compound) intoxication/NN (r_pobj) with/IN (r_prep) those/DT (r_pobj) of/IN (r_prep) two/CD (r_conj) overdose/NN
D009567_D003128 CID nitrazepam/JJ (r_amod) overdose/NN (r_pobj) with/IN (r_prep) patient/NN (r_nsubj) conformed/VBD (l_prep) to/IN (l_pobj) criteria/NNS (l_prep) of/IN (l_pobj) coma/NN
D000431_D013375 NONE alcohol/NN (r_compound) withdrawal/NN (r_compound) symptoms/NNS
1300436
D003404_D058186 NONE creatinine/NN (r_pobj) in/IN (r_prep) rise/NN (r_pobj) with/IN (r_prep) deteriorated/VBD
D005665_D051437 NONE furosemide/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) loss/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) failure/NN
D005665_D007674 NONE furosemide/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) in/IN (l_pobj) nephropathy/NN -PUNC- furosemide/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) determine/VB (l_prep) in/IN (l_pobj) addition/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) nephropathy/NN -PUNC- Furosemide/NNP (r_nsubj) be/VB (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D005665_D015431 NONE furosemide/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) loss/NN
D005665_D058186 CID furosemide/NN (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) group/NN (r_pobj) in/IN (r_prep) deteriorated/VBD
2435991
C032151_D007022 NONE cibenzoline/NN (r_nsubj) had/VBD (l_dobj) effects/NNS (l_nmod) node/NN (l_amod) hypotensive/JJ
C032151_D003866 NONE cibenzoline/NN (r_nsubj) had/VBD (l_dobj) effects/NNS (l_amod) depressive/JJ
D004071_D001145 CID digitalis-/NN (r_conj) ligation-/JJ (r_nmod) arrhythmias/NNS -PUNC- digitalis-/NN (r_conj) ligation-/JJ (r_nmod) arrhythmias/NNS (r_dobj) Using/VBG (r_advcl) examined/VBN (l_conj) determined/VBN (l_nsubjpass) concentration/NN (l_prep) for/IN (l_pobj) model/NN (l_compound) arrhythmia/NN -PUNC- digitalis/NN (r_conj) ligation/NN (r_appos) ligation/NN (r_pobj) by/IN (r_agent) induced/VBN (r_conj) suppressed/VBD (l_dobj) arrhythmias/NNS -PUNC- digitalis/NN (r_conj) ligation/NN (r_appos) ligation/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) concentrations/NNS (l_prep) for/IN (l_pobj) arrhythmias/NNS
D004837_D001145 CID adrenaline/RB (r_npadvmod) induced/VBN (r_conj) digitalis-/NN (r_conj) ligation-/JJ (r_nmod) arrhythmias/NNS -PUNC- adrenaline/RB (r_npadvmod) induced/VBN (r_conj) digitalis-/NN (r_conj) ligation-/JJ (r_nmod) arrhythmias/NNS (r_dobj) Using/VBG (r_advcl) examined/VBN (l_conj) determined/VBN (l_nsubjpass) concentration/NN (l_prep) for/IN (l_pobj) model/NN (l_compound) arrhythmia/NN -PUNC- adrenaline/NN (r_conj) digitalis/NN (r_conj) ligation/NN (r_appos) ligation/NN (r_pobj) by/IN (r_agent) induced/VBN (r_conj) suppressed/VBD (l_dobj) arrhythmias/NNS -PUNC- adrenaline/NN (r_conj) digitalis/NN (r_conj) ligation/NN (r_appos) ligation/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) concentrations/NNS (l_prep) for/IN (l_pobj) arrhythmias/NNS -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) arrhythmia/NN -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) arrhythmia/NN (r_pobj) for/IN (r_prep) concentration/NN (r_nsubj) was/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) those/DT (l_prep) for/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) arrhythmias/NNS
C032151_D001145 NONE cibenzoline/NN (r_pobj) of/IN (r_prep) concentrations/NNS (l_prep) on/IN (l_pobj) arrhythmias/NNS -PUNC- cibenzoline/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_advcl) Using/VBG (l_dobj) arrhythmias/NNS -PUNC- cibenzoline/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_conj) determined/VBN (l_nsubjpass) concentration/NN (l_prep) for/IN (l_pobj) model/NN (l_compound) arrhythmia/NN -PUNC- Cibenzoline/NNP (r_nsubj) suppressed/VBD (l_dobj) arrhythmias/NNS -PUNC- Cibenzoline/NNP (r_nsubj) suppressed/VBD (l_conj) induced/VBN (l_nsubj) concentrations/NNS (l_prep) for/IN (l_pobj) arrhythmias/NNS -PUNC- cibenzoline/NN (r_nsubj) had/VBD (l_advcl) given/VBN (l_prep) to/IN (l_pobj) dogs/NNS (l_compound) arrhythmia/NN
3535719
D014031_D064420 NONE tobramycin/JJ (l_nsubj) efficacy/NN (l_conj) toxicity/NN
D009428_D007239 NONE sulfate/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compared/VBD (l_prep) in/IN (l_pobj) conjunction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infections/NNS
D014031_D006311 CID tobramycin/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) occurred/VBD (l_nsubj) Ototoxicity/NN -PUNC- tobramycin/NNS (r_pobj) with/IN (r_prep) than/IN (r_prep) reversible/JJ (r_conj) severe/JJ (r_acomp) was/VBD (l_nsubj) ototoxicity/NN
D010878_D006311 CID piperacillin/VB (r_conj) netilmicin/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Ototoxicity/NN -PUNC- piperacillin/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_conj) tobramycin/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) occurred/VBD (l_nsubj) Ototoxicity/NN
D009428_D007674 CID netilmicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) proportion/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Nephrotoxicity/NN
D014031_D007239 NONE sulfate/NN (r_conj) sulfate/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) compared/VBD (l_prep) in/IN (l_pobj) conjunction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infections/NNS
D000617_D006311 NONE aminoglycoside/NN (r_npadvmod) associated/VBN (r_amod) ototoxicity/NN
D014031_D007674 CID tobramycin/JJ (r_conj) netilmicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) proportion/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Nephrotoxicity/NN
D010878_D007239 NONE sodium/NN (r_pobj) with/IN (r_prep) conjunction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infections/NNS
D009428_D006311 CID netilmicin/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Ototoxicity/NN -PUNC- netilmicin/NNS (r_pobj) with/IN (r_prep) reversible/JJ (r_conj) severe/JJ (r_acomp) was/VBD (l_nsubj) ototoxicity/NN
D009428_D064420 NONE netilmicin/NNS (r_pobj) of/IN (r_prep) toxicity/NN
8864707
D010672_D062787 CID phenytoin/NNP (r_compound) overdosages/NNS -PUNC- phenytoin/JJ (r_compound) overdosage/NN -PUNC- phenytoin/JJ (r_compound) medication/NN (r_nsubj) was/VBD (r_ccomp) is/VBZ (r_conj) result/VB (l_nsubj) overdosage/NN
D010672_D002526 NONE phenytoin/JJ (r_compound) medication/NN (l_conj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) overdosage/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) overdosage/NN (r_nsubj) result/VB (l_conj) is/VBZ (l_ccomp) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) medication/NN (r_nsubj) was/VBD (r_ccomp) is/VBZ (r_conj) result/VB (l_prep) in/IN (l_pobj) atrophy/NN -PUNC- phenytoin/JJ (r_compound) medication/NN (r_nsubj) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) atrophy/NN
D010672_D012640 NONE phenytoin/JJ (r_compound) levels/NNS (r_pobj) of/IN (r_prep) elevation/NN (r_conj) duration/NN (l_compound) seizure/NN
D010672_D004827 NONE phenytoin/NNP (r_compound) overdosages/NNS (r_pobj) after/IN (r_prep) volumetry/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) epileptic/JJ
20552622
D000420_D013610 NONE salbutamol/NN (r_pobj) like/IN (r_prep) agonist/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) tachycardia/NN
D001262_D013610 NONE atenolol/NN (r_pobj) as/IN (r_prep) blocker/NN (r_nsubj) relieve/VB (r_conj) swallowing/VBG (r_advcl) be/VB (l_nsubj) agonist/NN (l_acl) known/VBN (l_xcomp) induce/VB (l_dobj) tachycardia/NN
D001262_D001145 NONE atenolol/NN (r_pobj) with/IN (r_prep) resolved/VBD (l_nsubj) arrhythmia/NN -PUNC- atenolol/NN (r_pobj) with/IN (r_prep) week/NN (r_pobj) after/IN (r_prep) disappeared/VBD (l_nsubj) arrhythmia/NN
D000420_D013617 CID salbutamol/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_acl) tachyarrhythmia/NN -PUNC- Salbutamol/NNP (r_nsubjpass) presented/VBN (l_prep) as/IN (l_pobj) trigger/NN (l_prep) for/IN (l_pobj) SIAT/NNP
8267029
D010396_D001172 NONE Penicillamine/NN (r_nsubj) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- penicillamine/NN (r_nmod) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) presented/VBD (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) arthritis/NN
D010396_D005921 CID Penicillamine/NN (r_nsubj) induced/VBN (l_dobj) glomerulonephritis/NN -PUNC- penicillamine/NN (r_nmod) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) presented/VBD (l_dobj) glomerulonephritis/NN -PUNC- penicillamine/NN (r_nmod) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) presented/VBD (l_dobj) glomerulonephritis/NN (l_appos) RPGN/NNP -PUNC- penicillamine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) RPGN/NNP
D010396_D011507 NONE penicillamine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) in/IN (r_prep) case/NN (r_nsubj) emphasizes/VBZ (l_dobj) need/NN (l_prep) for/IN (l_pobj) monitoring/NN (l_prep) of/IN (l_pobj) function/NN (l_conj) evaluation/NN (l_prep) of/IN (l_pobj) sediment/NN (l_conj) proteinuria/NN
19631624
D018817_D008569 CID ecstasy/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) deficits/NNS -PUNC- ecstasy/NN (r_compound) users/NNS (r_nsubj) display/VBP (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) performance/NN (l_nmod) learning/NN (l_conj) memory/NN
D018817_D007859 CID ecstasy/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) deficits/NNS -PUNC- ecstasy/NN (r_compound) users/NNS (r_nsubj) display/VBP (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) performance/NN (l_nmod) learning/NN (l_conj) memory/NN
D002188_D007859 NONE cannabis/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) hypoactivity/NN (r_conj) hyperactivity/NN (r_appos) Deficits/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) memory/NN
D018817_D006948 NONE ecstasy/NN (r_npadvmod) specific/JJ (r_amod) hyperactivity/NN
D002188_D008569 NONE cannabis/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) hypoactivity/NN (r_conj) hyperactivity/NN (r_appos) Deficits/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) memory/NN
D002188_D006948 NONE cannabis/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) hypoactivity/NN (r_conj) hyperactivity/NN
D018817_D020258 NONE ecstasy/NN (r_npadvmod) specific/JJ (r_amod) effects/NNS (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) vulnerability/NN (l_prep) to/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- ecstasy/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) neurotoxic/JJ
9660111
D012110_D007035 CID reserpine/NN (r_compound) hypothermia/VBN
D003000_D010554 NONE clonidine/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) aggressiveness/NN
D004298_D006948 NONE dopamine/NN (r_compound) D2/NN (r_appos) dipropyloaminotetralin/NN (r_conj) quinpirole/NN (r_conj) amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D014299_D007035 NONE TRI/NNP (r_nsubj) antagonize/VB (l_dobj) hypothermia/VBN
D014299_D006948 CID TRI/NNP (r_nsubj) increases/VBZ (l_dobj) hyperactivity/NN
D019257_D006948 CID quinpirole/NN (r_conj) amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D010656_D010554 NONE phenylephrine/NN (l_acl) evaluated/VBN (l_conj) aggressiveness/NN
D003913_D006948 CID amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
D006916_D007035 NONE 5-hydroxytryptophan/JJ (r_poss) head/NN (r_compound) twitches/NNS (r_dobj) potentiate/VB (r_conj) antagonize/VB (l_dobj) hypothermia/VBN
7282516
D004317_D009202 CID doxorubicin/NN (r_compound) cardiomyopathy/NN -PUNC- doxorubicin/NN (l_nsubj) CM/NNP (l_amod) cardiomyopathy/NN -PUNC- doxorubicin/NN (l_nsubj) CM/NNP -PUNC- DXR/NN (r_appos) doxorubicin/NN (l_nsubj) CM/NNP (l_amod) cardiomyopathy/NN -PUNC- DXR/NN (r_appos) doxorubicin/NN (l_nsubj) CM/NNP -PUNC- Adriamycin/NNP (r_nsubj) provides/VBZ (l_dobj) opportunity/NN (l_acl) analyze/VB (l_dobj) relationships/NNS (l_prep) during/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- DXR/NNP (r_compound) CM/NNP -PUNC- DXR/NNP (r_compound) CM/NNP (r_nmod) damage/NN -PUNC- DXR/NNP (r_compound) dose/NN (r_appos) insult/NN (r_pobj) of/IN (r_prep) degree/NN (r_pobj) to/IN (r_prep) proportional/JJ (r_acomp) is/VBZ (l_prep) In/IN (l_pobj) damage/NN (l_nmod) CM/NNP -PUNC- DXR/NNP (r_compound) dose/NN (r_appos) insult/NN (r_pobj) of/IN (r_prep) degree/NN (r_pobj) to/IN (r_prep) proportional/JJ (r_acomp) is/VBZ (l_prep) In/IN (l_pobj) damage/NN
12820454
D016729_D000740 CID acetate/NN (r_dobj) received/VBD (l_conj) evaluated/VBN (l_prep) for/IN (l_pobj) anemia/NN -PUNC- A/NNP (r_appos) acetate/NN (r_dobj) received/VBD (l_conj) evaluated/VBN (l_prep) for/IN (l_pobj) anemia/NN
D005485_D000740 CID flutamide/NN (r_nmod) tid/NN (r_conj) days/NNS (r_appos) acetate/NN (r_dobj) received/VBD (l_conj) evaluated/VBN (l_prep) for/IN (l_pobj) anemia/NN
14975762
D004317_D009369 NONE Doxorubicin/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_compound) tumor/NN
D004317_D006333 CID doxorubicin/RB (r_compound) induced/VBN (r_pobj) from/IN (r_prep) myocytes/NNS (r_pobj) of/IN (r_prep) overexpression/NN (r_nsubj) apoptosis/NN (l_conj) reduces/VBZ (l_dobj) extent/NN (l_prep) of/IN (l_pobj) failure/NN
11007689
D016559_D057049 CID tacrolimus/NN (r_npadvmod) associated/VBN (r_amod) microangiopathy/NN -PUNC- tacrolimus/NN (r_pobj) to/IN (r_prep) switching/VBG (r_nsubjpass) reported/VBN (l_xcomp) be/VB (l_attr) option/NN (l_prep) in/IN (l_pobj) setting/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- tacrolimus/NN (r_pobj) of/IN (r_prep) application/NN (r_pobj) With/IN (r_prep) recognized/VBN (l_nsubjpass) TMA/NNP -PUNC- tacrolimus/NN (r_npadvmod) associated/VBN (r_amod) TMA/NNP -PUNC- tacrolimus/NN (r_conj) cyclosporine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) recurrence/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- tacrolimus/NN (r_pobj) of/IN (r_prep) Introduction/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- tacrolimus/NN (r_pobj) to/IN (r_prep) switched/VBN (r_relcl) Patients/NNS (r_nsubjpass) monitored/VBN (l_prep) for/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) TMA/NNP
D016572_D057049 CID Cyclosporine/NN (l_conj) microangiopathy/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) microangiopathy/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) microangiopathy/NN (l_appos) TMA/NNP -PUNC- cyclosporine/NN (r_npadvmod) induced/VBN (r_amod) TMA/NNP -PUNC- cyclosporine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) recurrence/NN (l_prep) of/IN (l_pobj) TMA/NNP -PUNC- cyclosporine/NN (r_npadvmod) induced/VBN (r_amod) TMA/NNP -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) to/IN (r_prep) responded/VBD (r_relcl) TMA/NNP -PUNC- cyclosporine/NN (r_pobj) from/IN (r_prep) switched/VBN (r_relcl) Patients/NNS (r_nsubjpass) monitored/VBN (l_prep) for/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) TMA/NNP
2951327
D006830_D013610 NONE hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) in/IN (r_prep) is/VBZ (r_advcl) observed/VBN (r_conj) was/VBD (l_appos) +/-/NN (l_conj) tachycardia/NN
D005996_D013610 NONE nitroglycerin/NN (r_conj) hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) in/IN (r_prep) is/VBZ (r_advcl) observed/VBN (r_conj) was/VBD (l_appos) +/-/NN (l_conj) tachycardia/NN
D009638_D007022 NONE norepinephrine/NN (r_amod) rate/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_conj) tachycardia/NN (r_conj) +/-/NN (r_appos) was/VBD (l_conj) observed/VBN (l_advcl) is/VBZ (l_prep) in/IN (l_pobj) contrast/NN (l_prep) to/IN (l_pobj) hypotension/NN
D005996_D007022 CID nitroglycerin/NN (r_conj) hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN
D006830_D007022 CID hydralazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN
D009638_D013610 NONE norepinephrine/NN (r_amod) rate/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_conj) tachycardia/NN
3865016
D005047_D017254 NONE etoposide/NN (r_nmod) A/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) eradication/NN (l_prep) of/IN (l_pobj) infiltration/NN
D016572_D017254 NONE A/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) eradication/NN (l_prep) of/IN (l_pobj) infiltration/NN
D016572_D054218 NONE A/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) observed/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN
D005047_D054218 NONE etoposide/NN (r_nmod) A/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) observed/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN
3057041
C020976_D013651 CID azelastine/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) Drowsiness/VB (l_conj) perception/NN
C020976_D006970 CID azelastine/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) Drowsiness/VB
C020976_D006255 NONE azelastine/NN (r_pobj) of/IN (r_prep) trial/NN (r_conj) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) rhinitis/NN -PUNC- Azelastine/NNP (r_nsubjpass) compared/VBN (l_prep) with/IN (l_pobj) maleate/NN (l_prep) for/IN (l_pobj) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) rhinitis/NN -PUNC- Azelastine/NNP (r_nsubj) appears/VBZ (l_xcomp) be/VB (l_attr) medication/NN (l_prep) for/IN (l_pobj) rhinitis/NN
D002744_D006255 NONE chlorpheniramine/NN (r_conj) azelastine/NN (r_pobj) of/IN (r_prep) trial/NN (r_conj) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) rhinitis/NN -PUNC- maleate/NN (l_prep) for/IN (l_pobj) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) rhinitis/NN
6538499
D011092_D064420 NONE 400/CD (r_nummod) glycol/NN (l_advcl) adriamycin/JJ (l_dobj) toxicity/NN
D004317_D007939 NONE ADR/NNP (r_compound) activity/NN (l_prep) in/IN (l_pobj) leukemia/NN
D004317_D002286 NONE ADR/NNP (r_compound) activity/NN (l_relcl) tumor/NN
D004317_D064420 NONE adriamycin/JJ (l_dobj) toxicity/NN
D004317_D009202 CID ADR/NNP (r_npadvmod) induced/VBN (r_amod) alterations/NNS
220563
C023470_D010523 CID maleate/NN (l_conj) neuropathy/NN -PUNC- maleate/NN (r_pobj) with/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) noted/VBN (l_nsubjpass) neuropathy/NN
C023470_D000787 NONE maleate/NN (r_pobj) with/IN (r_prep) complication/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pectoris/NN
16428221
D008774_D019969 NONE methylphenidate/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) reported/VBN (r_conj) documented/VBN (l_nsubjpass) vasculitis/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) abuse/NN
D008774_D002544 NONE methylphenidate/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) stroke/NN -PUNC- methylphenidate/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) suffered/VBD (l_prep) from/IN (l_pobj) strokes/NNS
D008774_D014657 NONE methylphenidate/NN (l_dobj) vasculitis/NN -PUNC- methylphenidate/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) history/NN (r_conj) symptoms/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) considered/VBN (l_nsubjpass) methylphenidate/NN (l_dobj) vasculitis/NN
D008774_D020293 CID methylphenidate/NN (r_compound) intake/NN (r_dobj) following/VBG (r_prep) vasculitis/NNS -PUNC- methylphenidate/NN (r_compound) intake/NN (r_pobj) after/IN (r_prep) reported/VBN (r_conj) documented/VBN (l_nsubjpass) vasculitis/NN
D008774_D006948 NONE methylphenidate/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) due/IN (l_pobj) hyperactivity/NN
6666578
D010396_D001018 CID penicillamine/NN (r_compound) induced/VBN (l_advmod) angiopathy/NN
6386793
D000639_D014786 CID amitriptyline/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN
D000639_D003866 NONE amitriptyline/NN (r_conj) dothiepin/JJ (r_nsubjpass) compared/VBN (l_prep) to/IN (l_pobj) placebo/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ -PUNC- amitriptyline/NN (r_conj) Dothiepin/JJ (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) illness/NN -PUNC- amitriptyline/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ
D000639_D014987 CID amitriptyline/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN (l_conj) mouth/NN
D000928_D003866 NONE antidepressant/NN (r_amod) drug/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) than/IN (l_pobj) amitriptyline/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ
D004308_D003866 NONE hydrochloride/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN -PUNC- dothiepin/JJ (r_nsubjpass) compared/VBN (l_prep) to/IN (l_pobj) placebo/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ -PUNC- Dothiepin/JJ (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) alleviating/VBG (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) illness/NN -PUNC- Dothiepin/NNP (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_attr) drug/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) than/IN (l_pobj) amitriptyline/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) outpatients/NNS (l_amod) depressed/JJ
D004308_D014987 NONE dothiepin/JJ (r_pobj) with/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN (l_conj) mouth/NN
D004308_D014786 NONE dothiepin/JJ (r_pobj) with/IN (r_prep) less/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) effects/NNS (l_conj) frequency/NN (l_prep) of/IN (l_pobj) vision/NN
3762968
D014042_D014899 CID tolazamide/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- tolazamide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (l_dobj) encephalopathy/NN -PUNC- tolazamide/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN
D013831_D003920 NONE thiamine/NN (r_npadvmod) dependent/JJ (r_amod) enzyme/NN (r_dobj) studied/VBD (l_prep) from/IN (l_pobj) fibroblasts/NNS (l_prep) of/IN (l_pobj) patient/NN (l_amod) diabetic/JJ
D013831_D014899 NONE thiamine/NN (r_npadvmod) dependent/JJ (r_amod) enzyme/NN (r_dobj) studied/VBD (l_prep) from/IN (l_pobj) fibroblasts/NNS (l_prep) of/IN (l_pobj) patient/NN (l_relcl) developed/VBD (l_dobj) encephalopathy/NN
D013835_D020915 NONE pyrophosphate/NN (r_pobj) for/IN (r_prep) Km/NNP (r_appos) abnormality/NN (r_dobj) had/VBD (l_advcl) reported/VBN (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- TPP/NNP (r_appos) pyrophosphate/NN (r_pobj) for/IN (r_prep) Km/NNP (r_appos) abnormality/NN (r_dobj) had/VBD (l_advcl) reported/VBN (l_prep) in/IN (l_pobj) syndrome/NN
D013835_D003920 NONE pyrophosphate/NN (r_pobj) for/IN (r_prep) Km/NNP (r_appos) abnormality/NN (r_dobj) had/VBD (r_ccomp) delineate/VB (r_acl) order/NN (r_pobj) in/IN (r_prep) studied/VBD (l_prep) from/IN (l_pobj) fibroblasts/NNS (l_prep) of/IN (l_pobj) patient/NN (l_amod) diabetic/JJ -PUNC- TPP/NNP (r_appos) pyrophosphate/NN (r_pobj) for/IN (r_prep) Km/NNP (r_appos) abnormality/NN (r_dobj) had/VBD (r_ccomp) delineate/VB (r_acl) order/NN (r_pobj) in/IN (r_prep) studied/VBD (l_prep) from/IN (l_pobj) fibroblasts/NNS (l_prep) of/IN (l_pobj) patient/NN (l_amod) diabetic/JJ -PUNC- TPP/NNP (r_pobj) for/IN (r_prep) Km/NNP (r_pobj) by/IN (r_agent) determined/VBN (r_advcl) had/VBD (l_nsubj) patient/NN (l_conj) one/CD (l_prep) of/IN (l_pobj) kindreds/NNS (l_amod) diabetic/JJ
D014042_D003920 NONE tolazamide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (r_relcl) patient/NN (l_amod) diabetic/JJ
D014042_D020915 NONE tolazamide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (r_relcl) patient/NN (r_pobj) of/IN (r_prep) fibroblasts/NNS (r_pobj) from/IN (r_prep) studied/VBD (l_prep) in/IN (l_pobj) order/NN (l_acl) delineate/VB (l_ccomp) had/VBD (l_advcl) reported/VBN (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- tolazamide/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_pobj) with/IN (r_prep) patient/NN (r_conj) syndrome/NN
D013831_D020915 NONE thiamine/NN (r_npadvmod) dependent/JJ (r_amod) enzyme/NN (r_dobj) studied/VBD (l_prep) in/IN (l_pobj) order/NN (l_acl) delineate/VB (l_ccomp) had/VBD (l_advcl) reported/VBN (l_prep) in/IN (l_pobj) syndrome/NN
D013835_D014899 NONE pyrophosphate/NN (r_pobj) for/IN (r_prep) Km/NNP (r_appos) abnormality/NN (r_dobj) had/VBD (r_ccomp) delineate/VB (r_acl) order/NN (r_pobj) in/IN (r_prep) studied/VBD (l_prep) from/IN (l_pobj) fibroblasts/NNS (l_prep) of/IN (l_pobj) patient/NN (l_relcl) developed/VBD (l_dobj) encephalopathy/NN -PUNC- TPP/NNP (r_appos) pyrophosphate/NN (r_pobj) for/IN (r_prep) Km/NNP (r_appos) abnormality/NN (r_dobj) had/VBD (r_ccomp) delineate/VB (r_acl) order/NN (r_pobj) in/IN (r_prep) studied/VBD (l_prep) from/IN (l_pobj) fibroblasts/NNS (l_prep) of/IN (l_pobj) patient/NN (l_relcl) developed/VBD (l_dobj) encephalopathy/NN -PUNC- TPP/NNP (r_pobj) for/IN (r_prep) Km/NNP (r_pobj) by/IN (r_agent) determined/VBN (r_advcl) had/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) encephalopathy/NN
8073369
C007112_D009140 NONE coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS -PUNC- coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS (r_nsubj) were/VBD (l_attr) flexion/NN (l_prep) of/IN (l_pobj) toes/NNS
D009538_D002543 CID nicotine/NN (r_nmod) chicks/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) hemorrhage/NN
D009538_D009140 NONE nicotine/NN (r_compound) sulfate/NN (r_conj) coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS -PUNC- nicotine/NN (r_compound) sulfate/NN (r_conj) coniine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deformations/NNS (r_nsubj) were/VBD (l_attr) flexion/NN (l_prep) of/IN (l_pobj) toes/NNS
C007112_D001176 CID coniine/NN (r_nsubj) failed/VBN (l_xcomp) produce/VB (l_dobj) arthrogryposis/NN -PUNC- coniine/RB (r_npadvmod) induced/VBN (r_amod) arthrogryposis/NN
9067481
D002725_D066126 NONE CHCl3/NNP (l_conj) acetaminophen/RB (l_conj) against/IN (l_pobj) lethal/JJ (l_conj) effect/NN (l_amod) cardiotoxic/JJ
C013440_D056486 NONE hemisuccinate/NN (r_conj) rigidifier/NN (r_pobj) as/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) addition/NN (r_pobj) In/IN (r_prep) shown/VBN (l_xcomp) protect/VB (l_prep) from/IN (l_pobj) effects/NNS (l_amod) hepatotoxic/JJ
D004317_D056486 NONE adriamycin/NNS (r_amod) administration/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) lethal/JJ (r_pobj) against/IN (r_conj) acetaminophen/RB (r_conj) CHCl3/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hepatotoxic/JJ
D002251_D064420 NONE tetrachloride-/NN (l_appos) toxicity/NN
-1_D056486 NONE salt/NN (r_nmod) administration/NN (r_conj) hemisuccinate/NN (r_conj) rigidifier/NN (r_pobj) as/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) addition/NN (r_pobj) In/IN (r_prep) shown/VBN (l_xcomp) protect/VB (l_prep) from/IN (l_pobj) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- CS/NNP (r_nmod) administration/NN (r_conj) hemisuccinate/NN (r_conj) rigidifier/NN (r_pobj) as/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) addition/NN (r_pobj) In/IN (r_prep) shown/VBN (l_xcomp) protect/VB (l_prep) from/IN (l_pobj) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- CS/NNP (r_nmod) kg/NNS (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) protection/NN (l_prep) against/IN (l_pobj) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- CS/NNP (r_compound) protection/NN (r_pobj) of/IN (r_prep) mechanism/NN (r_nsubj) appear/VB (l_xcomp) be/VB (l_acomp) dependent/JJ (l_prep) on/IN (l_pobj) inhibition/NN (l_prep) to/IN (l_pobj) in/IN (l_pobj) light/NN (l_prep) of/IN (l_pobj) protection/NN (l_acl) observed/VBN (l_prep) against/IN (l_pobj) hepatotoxicity/NN
-1_D064420 NONE CS/NNP (r_compound) cytoprotection/NN (r_pobj) of/IN (r_prep) mechanism/NN (r_pobj) of/IN (r_prep) understanding/NN (r_dobj) further/VB (r_advmod) examined/VBD (l_conj) mice/NNS (l_dobj) abilities/NNS (l_prep) of/IN (l_pobj) CS/NNP (l_conj) form/NN (l_prep) of/IN (l_pobj) CS/NNP (l_conj) acid/NN (l_conj) salt/NN (l_prep) against/IN (l_pobj) tetrachloride-/NN (l_appos) toxicity/NN -PUNC- CS/NNP (l_conj) form/NN (l_prep) of/IN (l_pobj) CS/NNP (l_conj) acid/NN (l_conj) salt/NN (l_prep) against/IN (l_pobj) tetrachloride-/NN (l_appos) toxicity/NN -PUNC- CS/NNP (l_conj) acid/NN (l_conj) salt/NN (l_prep) against/IN (l_pobj) tetrachloride-/NN (l_appos) toxicity/NN -PUNC- salt/NN (l_prep) against/IN (l_pobj) tetrachloride-/NN (l_appos) toxicity/NN -PUNC- CSE/NNP (r_appos) salt/NN (l_prep) against/IN (l_pobj) tetrachloride-/NN (l_appos) toxicity/NN
D000082_D064420 NONE acetaminophen-/NN (r_nmod) tetrachloride-/NN (l_appos) toxicity/NN
D002725_D056486 CID CHCl3/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hepatotoxic/JJ
-1_D066126 NONE CS/NNP (r_nmod) kg/NNS (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) protection/NN (l_prep) against/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) CHCl3/NNP (l_conj) acetaminophen/RB (l_conj) against/IN (l_pobj) lethal/JJ (l_conj) effect/NN (l_amod) cardiotoxic/JJ
D002725_D064420 NONE chloroform-/JJ (r_nmod) toxicity/NN
D002251_D056486 CID tetrachloride/NN (r_advmod) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- CCl4/NNP (r_appos) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- CCl4/NNP (r_nmod) CHCl3/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hepatotoxic/JJ
D002251_D066126 NONE CCl4/NNP (r_nmod) CHCl3/NNP (l_conj) acetaminophen/RB (l_conj) against/IN (l_pobj) lethal/JJ (l_conj) effect/NN (l_amod) cardiotoxic/JJ
C103872_D064420 NONE acid/NN (l_conj) salt/NN (l_prep) against/IN (l_pobj) tetrachloride-/NN (l_appos) toxicity/NN
D005688_D056486 CID galactosamine/NN (r_conj) acetaminophen/RB (r_conj) CHCl3/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- galactosamine/NN (r_amod) hepatotoxicity/NN
D004317_D064420 NONE adriamycin-/JJ (r_conj) acetaminophen-/NN (r_nmod) tetrachloride-/NN (l_appos) toxicity/NN
D004317_D066126 CID adriamycin/NNS (r_amod) administration/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) cardiotoxic/JJ
D005688_D066126 NONE galactosamine/NN (r_conj) acetaminophen/RB (l_conj) against/IN (l_pobj) lethal/JJ (l_conj) effect/NN (l_amod) cardiotoxic/JJ
D005688_D064420 NONE galactosamine/NN (r_npadvmod) induced/VBN (r_conj) chloroform-/JJ (r_nmod) toxicity/NN
D000082_D066126 NONE acetaminophen/RB (l_conj) against/IN (l_pobj) lethal/JJ (l_conj) effect/NN (l_amod) cardiotoxic/JJ
D000082_D056486 CID acetaminophen/RB (r_conj) CHCl3/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hepatotoxic/JJ
9100294
D020748_D018376 CID 5967/CD (r_prep) 40/CD (r_nummod) Ro/NNP (r_appos) blocker/NN (r_nsubj) induced/VBD (l_dobj) alterations/NNS
D002118_D018376 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) alterations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_nsubj) induced/VBD (l_dobj) alterations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubj) induce/VBP (l_dobj) malformations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) one/CD (r_dobj) administered/VBN (l_prep) during/IN (l_pobj) period/NN (l_prep) of/IN (l_pobj) morphogenesis/NN (l_conj) offspring/NN (l_acl) examined/VBD (l_prep) on/IN (l_pobj) day/NN (l_prep) of/IN (l_pobj) gestation/NN (l_prep) for/IN (l_pobj) malformations/NNS -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) each/DT (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) observed/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) malformations/NNS
D014700_D018376 CID verapamil/NN (r_pobj) for/IN (r_prep) significant/JJ (r_acomp) was/VBD (r_conj) observed/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) malformations/NNS
D009543_D018376 CID nifedipine/NN (r_conj) verapamil/NN (r_pobj) for/IN (r_prep) significant/JJ (r_acomp) was/VBD (r_conj) observed/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) malformations/NNS
2611118
D004008_D006521 NONE sodium/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatitis/NN -PUNC- sodium/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN
D004008_D056486 CID diclofenac/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_conj) recorded/VBN (l_nsubjpass) abnormalities/NNS (l_prep) of/IN (l_pobj) function/NN -PUNC- diclofenac/NNP (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hepatitis/NN
8441146
D006046_D000741 CID gold/NN (r_pobj) by/IN (r_agent) caused/VBN (r_relcl) anemia/NN
D010396_D000741 CID penicillamine/NN (r_conj) case/NN (r_pobj) in/IN (r_prep) caused/VBN (r_relcl) anemia/NN
12789195
D008914_D004194 NONE minoxidil/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Pseudoacromegaly/NNS -PUNC- minoxidil/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) from/IN (r_prep) resulted/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) pseudoacromegaly/NNS -PUNC- minoxidil/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) as/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) pseudoacromegaly/NNS
16330766
C040029_D009437 NONE gabapentin/NN (l_appos) drug/NN (l_amod) effective/JJ (l_prep) in/IN (l_pobj) patients/NNS (l_compound) pain/NN
D002211_D006930 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN
C040029_D006930 NONE gabapentin/NN (r_npadvmod) induced/VBN (r_amod) modulation/NN (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) stimulation/NN (l_prep) of/IN (l_pobj) skin/NN (l_conj) hyperalgesia/NN
14976857
D011405_D062787 NONE propafenone/NN (r_compound) overdose/NN -PUNC- propafenone/NN (r_compound) overdose/NN
D011405_D004437 NONE propafenone/NN (r_compound) overdose/NN (l_prep) in/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) anomaly/NN
D011405_D054092 NONE propafenone/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) precipitated/VBN (r_conj) occurred/VBD (l_nsubj) shunt/NN (l_prep) via/IN (l_pobj) ovale/NN
D011405_-1 NONE propafenone/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) syndrome/NN
7197363
D011814_D001523 NONE quipazine/NN (r_npadvmod) induced/VBN (r_amod) head/NN (r_compound) twitches/NNS (r_conj) aggressiveness/NN -PUNC- quipazine/NN (r_pobj) of/IN (r_prep) completing/VBG (r_pcomp) after/IN (r_prep) increased/VBN (r_conj) reduced/VBN (r_conj) increased/VBD (l_dobj) aggressiveness/NN
D001058_D009069 NONE apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (l_conj) twitches/NNS -PUNC- apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (r_dobj) increased/VBD (l_conj) twitches/NNS
D011814_D009069 CID quipazine/NN (r_npadvmod) induced/VBN (r_amod) head/NN (r_compound) twitches/NNS -PUNC- quipazine/NN (r_pobj) of/IN (r_prep) completing/VBG (r_pcomp) after/IN (r_prep) increased/VBN (r_conj) reduced/VBN (r_conj) increased/VBD (l_conj) twitches/NNS
D001058_D001523 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN -PUNC- apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN
D011814_D012892 NONE quipazine/NN (r_npadvmod) induced/VBN (r_amod) head/NN (r_compound) twitches/NNS (r_conj) aggressiveness/NN (r_pobj) on/IN (r_prep) effects/NNS (l_prep) of/IN (l_pobj) deprivation/NN -PUNC- quipazine/NN (r_npadvmod) induced/VBN (r_amod) head/NN (r_compound) twitches/NNS (r_conj) aggressiveness/NN (r_pobj) on/IN (r_prep) effects/NNS (l_prep) of/IN (l_pobj) deprivation/NN (l_appos) REMD/NNP -PUNC- quipazine/NN (r_pobj) of/IN (r_prep) completing/VBG (r_pcomp) after/IN (r_prep) increased/VBN (r_conj) reduced/VBN (r_conj) increased/VBD (l_nsubj) hr/NN (l_prep) of/IN (l_pobj) REMD/NNP -PUNC- quipazine/NN (r_pobj) of/IN (r_prep) completing/VBG (r_pcomp) after/IN (r_prep) increased/VBN (r_conj) reduced/VBN (l_prep) after/IN (l_pcomp) completing/VBG (l_prep) of/IN (l_pobj) REMD/NNP -PUNC- quipazine/NN (l_nmod) REMD/NNP
D001058_D012892 NONE apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (r_pobj) on/IN (r_prep) effects/NNS (l_prep) of/IN (l_pobj) deprivation/NN -PUNC- apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (r_pobj) on/IN (r_prep) effects/NNS (l_prep) of/IN (l_pobj) deprivation/NN (l_appos) REMD/NNP -PUNC- apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (r_dobj) increased/VBD (l_nsubj) hr/NN (l_prep) of/IN (l_pobj) REMD/NNP -PUNC- apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (r_dobj) increased/VBD (l_conj) reduced/VBN (l_prep) after/IN (l_pcomp) completing/VBG (l_prep) of/IN (l_pobj) REMD/NNP -PUNC- apomorphine/NN (r_npadvmod) induced/VBN (r_amod) aggressiveness/NN (r_dobj) increased/VBD (l_conj) reduced/VBN (l_conj) increased/VBN (l_prep) after/IN (l_pcomp) completing/VBG (l_prep) of/IN (l_pobj) quipazine/NN (l_nmod) REMD/NNP
8410199
C028911_D009410 NONE violet/NN (r_compound) staining/NN (l_conj) methods/NNS (l_compound) degeneration/NN -PUNC- violet/NN (r_compound) staining/NN (r_pobj) including/VBG (r_prep) studies/NNS (r_nsubj) suggested/VBD (l_ccomp) related/VBN (l_prep) to/IN (l_pobj) loss/NN
D018698_D012640 NONE glutamate/NN (r_compound) decarboxylase/NN (r_nmod) neurons/NNS (r_pobj) of/IN (r_prep) Loss/NN (l_prep) following/VBG (l_pobj) seizures/NNS -PUNC- acid/NN (r_compound) decarboxylase/NN (r_nsubj) are/VBP (l_acomp) vulnerable/JJ (l_prep) to/IN (l_pobj) damage/NN (l_amod) induced/VBN (l_npadvmod) seizure/NN -PUNC- acid/NN (r_compound) decarboxylase/NN (r_nsubj) are/VBP (l_acomp) vulnerable/JJ (l_prep) to/IN (l_pobj) damage/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) with/IN (r_prep) injected/VBN (l_conj) studied/VBN (l_conj) intervals/NNS (l_prep) after/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
2572625
C084599_D056486 CID Clotiazepam/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- clotiazepam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- clotiazepam/NN (r_xcomp) related/VBN (r_acl) administration/NN (r_nsubj) interfere/VB (l_conj) induce/VB (l_dobj) relapse/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- clotiazepam/NN (r_nsubj) induce/VB (l_dobj) hepatitis/NN -PUNC- clotiazepam/NN (r_nsubj) induce/VB (l_conj) suggests/VBZ (l_ccomp) is/VBZ (l_attr) hepatotoxicity/NN -PUNC- clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN (r_attr) is/VBZ (r_ccomp) suggests/VBZ (r_conj) induce/VB (l_dobj) hepatitis/NN -PUNC- clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN
D001569_D056486 NONE benzodiazepines/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) interfere/VB (l_conj) induce/VB (l_dobj) relapse/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- benzodiazepines/NNS (r_conj) clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN (r_attr) is/VBZ (r_ccomp) suggests/VBZ (r_conj) induce/VB (l_dobj) hepatitis/NN -PUNC- benzodiazepines/NNS (r_conj) clotiazepam/NN (r_pobj) between/IN (r_prep) hepatotoxicity/NN
C084599_D047508 NONE clotiazepam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) developed/VBD (l_prep) with/IN (l_pobj) necrosis/NN
C013295_D047508 NONE thienodiazepine/NN (r_amod) derivative/NN (r_appos) patient/NN (l_relcl) developed/VBD (l_prep) with/IN (l_pobj) necrosis/NN
C013295_D056486 NONE thienodiazepine/NN (r_amod) derivative/NN (r_appos) patient/NN (l_relcl) developed/VBD (l_dobj) hepatitis/NN
21029050
D013390_D001049 CID succinylcholine/NN (r_pobj) after/IN (r_prep) mutations/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) apnea/NN -PUNC- succinylcholine/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) eleven/CD (r_nsubj) had/VBD (l_advcl) indicating/VBG (l_ccomp) is/VBZ (l_attr) reason/NN (l_prep) for/IN (l_pobj) period/NN (l_prep) of/IN (l_pobj) apnea/NN
11827497
D006493_D013923 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_nsubj) became/VBD (l_prep) on/IN (l_pobj) presentation/NN (l_prep) with/IN (l_pobj) complications/NNS (l_compound) thromboembolic/JJ -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_nmod) factor/NN (r_pobj) of/IN (r_prep) results/NNS (r_appos) counts/VBZ (l_appos) onset/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- heparin/JJ (r_compound) exposure/NN (r_dobj) included/VBN (r_relcl) hospitalizations/NNS (r_pobj) after/IN (r_prep) went/VBD (l_advcl) return/VB (l_prep) with/IN (l_pobj) complications/NNS (l_compound) thromboembolic/JJ -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_dobj) consider/VB (l_advcl) returns/NNS (l_prep) with/IN (l_pobj) thromboembolism/NN -PUNC- heparin/VBN (r_appos) anticoagulants/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_nsubjpass) initiated/VBN (l_ccomp) consider/VB (l_advcl) returns/NNS (l_prep) with/IN (l_pobj) thromboembolism/NN
D006493_D013921 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) exposure/NN (r_pobj) after/IN (r_prep) presents/VBZ (l_nsubj) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) exposure/NN (r_dobj) included/VBN (r_relcl) hospitalizations/NNS (r_pobj) after/IN (r_prep) went/VBD (l_prep) with/IN (l_pobj) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/VBN (r_appos) anticoagulants/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_nsubjpass) initiated/VBN (l_ccomp) consider/VB (l_dobj) thrombocytopenia/NN
D006493_D054556 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_nsubj) presents/VBZ (l_prep) after/IN (l_pobj) exposure/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) thromboemboli/NN -PUNC- heparin/JJ (r_compound) exposure/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) thromboemboli/NN
D006493_D001157 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_nsubj) presents/VBZ (l_prep) after/IN (l_pobj) exposure/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) thromboemboli/NN -PUNC- heparin/JJ (r_compound) exposure/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) thromboemboli/NN
15338796
D000420_D008173 NONE salbutamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) disease/NN
D000420_D014202 CID salbutamol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) Tremor/NNP -PUNC- salbutamol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) tremor/JJ -PUNC- salbutamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) disease/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) assessed/VBD (l_dobj) tremor/NN -PUNC- Salbutamol/NNP (r_nsubj) increased/VBD (l_dobj) severity/NN (l_compound) tremor/NN
16960342
D019259_D005355 NONE lamivudine/NN (r_amod) monotherapy/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) improvement/NN (l_prep) of/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN -PUNC- lamivudine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cirrhosis/NN
D019259_D006509 NONE lamivudine/NN (r_amod) monotherapy/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) improvement/NN (l_prep) of/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cirrhosis/NN (l_amod) related/VBN (l_npadvmod) virus/NN (l_compound) B/NNP
20973483
D006220_D010300 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN (r_pobj) of/IN (r_prep) models/NNS (r_pobj) including/VBG (r_prep) disease/NN
D012110_D010300 NONE reserpine/NN (r_npadvmod) induced/VBN (r_compound) akinesia/NN (r_pobj) of/IN (r_prep) model/NN (r_appos) catalepsy/NN (r_pobj) of/IN (r_prep) models/NNS (r_pobj) including/VBG (r_prep) disease/NN
D015632_D010300 NONE MPTP/NNP (r_npadvmod) treated/VBN (r_amod) model/NN (r_conj) across/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) disease/NN
D012110_D004409 CID reserpine/NN (r_npadvmod) induced/VBN (r_compound) akinesia/NN
D016627_D002375 NONE 6-hydroxydopamine/NN (r_nmod) 6-OHDA/CD (r_nummod) model/NN (r_appos) catalepsy/NN -PUNC- 6-OHDA/CD (r_nummod) model/NN (r_appos) catalepsy/NN
D015632_D004409 NONE MPTP/NNP (r_npadvmod) treated/VBN (r_amod) model/NN (r_conj) across/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) disease/NN (l_prep) including/VBG (l_pobj) models/NNS (l_prep) of/IN (l_pobj) catalepsy/NN (l_appos) model/NN (l_prep) of/IN (l_pobj) akinesia/NN
D016627_D010300 NONE 6-hydroxydopamine/NN (r_nmod) 6-OHDA/CD (r_nummod) model/NN (r_appos) catalepsy/NN (r_pobj) of/IN (r_prep) models/NNS (r_pobj) including/VBG (r_prep) disease/NN -PUNC- 6-OHDA/CD (r_nummod) model/NN (r_appos) catalepsy/NN (r_pobj) of/IN (r_prep) models/NNS (r_pobj) including/VBG (r_prep) disease/NN
D006220_D004409 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN (l_appos) model/NN (l_prep) of/IN (l_pobj) akinesia/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
D012110_D002375 NONE reserpine/NN (r_npadvmod) induced/VBN (r_compound) akinesia/NN (r_pobj) of/IN (r_prep) model/NN (r_appos) catalepsy/NN
D016627_D004409 NONE 6-hydroxydopamine/NN (r_nmod) 6-OHDA/CD (r_nummod) model/NN (r_appos) catalepsy/NN (l_appos) model/NN (l_prep) of/IN (l_pobj) akinesia/NN -PUNC- 6-OHDA/CD (r_nummod) model/NN (r_appos) catalepsy/NN (l_appos) model/NN (l_prep) of/IN (l_pobj) akinesia/NN
D058915_D010300 NONE antagonist/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) disease/NN -PUNC- antagonist/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) disease/NN
D015632_D002375 NONE MPTP/NNP (r_npadvmod) treated/VBN (r_amod) model/NN (r_conj) across/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) disease/NN (l_prep) including/VBG (l_pobj) models/NNS (l_prep) of/IN (l_pobj) catalepsy/NN
19308880
D014635_D003221 CID acid/NN (r_pobj) with/IN (r_prep) reaction/NN (r_appos) Confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) observed/VBD (r_acl) reaction/NN (r_attr) is/VBZ (l_nsubj) Confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) reported/VBN (r_acl) confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) reported/VBN (l_nsubjpass) cases/NNS (l_prep) of/IN (l_pobj) confusion/NN -PUNC- acid/NN (r_compound) exposure/NN (r_pobj) following/VBG (r_prep) weeks/NNS (r_pobj) during/IN (r_prep) occurred/VBD (l_nsubj) Confusion/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) confusion/NN
9799166
D000661_D020521 CID amphetamine/NN (r_conj) cocaine/NN (r_conj) Stroke/NN -PUNC- amphetamine/NN (r_compound) use/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) association/NN (l_prep) with/IN (l_pobj) stroke/NN -PUNC- amphetamine/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_conj) stroke/NN -PUNC- amphetamine/NN (r_conj) cocaine/NN (r_dobj) using/VBG (r_pcomp) to/IN (r_prep) admitted/VBD (r_relcl) stroke/NN -PUNC- amphetamine/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) for/IN (l_pobj) stroke/NN
D000661_D007511 NONE amphetamine/NN (r_compound) use/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) association/NN (l_prep) with/IN (l_pobj) stroke/NN (l_amod) hemorrhagic/JJ (l_conj) ischemic/JJ
D003042_D020521 CID cocaine/NN (r_conj) Stroke/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) association/NN (l_prep) with/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_conj) stroke/NN -PUNC- cocaine/NN (r_dobj) using/VBG (r_pcomp) to/IN (r_prep) admitted/VBD (r_relcl) stroke/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) for/IN (l_pobj) stroke/NN
D003042_D007511 NONE cocaine/NN (r_pobj) of/IN (r_prep) association/NN (l_prep) with/IN (l_pobj) stroke/NN (l_amod) hemorrhagic/JJ (l_conj) ischemic/JJ
9952311
D004317_D001145 NONE ADR/NNP (r_pobj) with/IN (r_prep) mice/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) caused/VBD (l_dobj) arrhythmias/NNS
D004317_D002318 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) limited/VBN (l_prep) due/IN (l_pcomp) to/IN (l_pobj) toxicity/NN -PUNC- ADR/NNP (r_appos) adriamycin/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) limited/VBN (l_prep) due/IN (l_pcomp) to/IN (l_pobj) toxicity/NN
D004317_D028361 CID adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) in/IN (r_prep) impairment/NN (l_prep) of/IN (l_pobj) mitochondria/NN -PUNC- ADR/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) involve/VBP (l_dobj) impairment/NN
D004317_D004487 NONE ADR/NNP (r_pobj) with/IN (r_prep) mice/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) caused/VBD (l_ccomp) swelling/NN
D004317_D009369 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_compound) cancer/NN -PUNC- ADR/NNP (r_appos) adriamycin/NNS (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_compound) cancer/NN
D004317_D001919 CID ADR/NNP (r_pobj) with/IN (r_prep) mice/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) caused/VBD (l_dobj) arrhythmias/NNS (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) bradycardia/NNP
D004317_D009202 NONE adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN
1079693
D002738_D012164 NONE chloroquine/NN (r_xcomp) used/VBD (l_conj) found/VBD (l_dobj) case/NN (l_prep) of/IN (l_pobj) chorioretinopathy/JJ
D006886_D012164 CID hydroxychloroquine/NN (r_conj) chloroquine/NN (r_xcomp) used/VBD (l_conj) found/VBD (l_dobj) case/NN (l_prep) of/IN (l_pobj) chorioretinopathy/JJ
D000305_D002386 NONE corticosteroids/NNS (r_dobj) administered/VBN (r_csubjpass) used/VBN (r_ccomp) found/VBN (l_nsubjpass) number/NN (l_prep) of/IN (l_pobj) cataracts/NNS
D000305_D014605 NONE corticosteroids/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) to/IN (r_prep) respond/VB (l_nsubj) %/NN (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) uveitis/NN
2632720
D006854_D006973 NONE cortisol/NN (r_compound) levels/NNS (r_nsubjpass) achieved/VBN (l_conj) demonstrated/VBD (l_dobj) hypertension/NN
D007654_D006973 CID ketoconazole/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) hypertension/NN -PUNC- ketoconazole/JJ (r_pobj) with/IN (r_prep) basis/NN (r_pobj) on/IN (r_prep) treated/VBN (l_advcl) developed/VBN (l_dobj) hypertension/NN -PUNC- ketoconazole/JJ (r_compound) therapy/NN (r_dobj) following/VBG (r_prep) achieved/VBN (l_conj) demonstrated/VBD (l_dobj) hypertension/NN -PUNC- ketoconazole/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) induce/VB (l_dobj) blockade/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) hypertension/NN
D007654_D003480 NONE ketoconazole/JJ (r_pobj) with/IN (r_prep) basis/NN (r_pobj) on/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN
16867021
D000661_D002375 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_amod) activities/NNS (r_conj) behavior/NN (r_dobj) study/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) ligands/NNS (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- amphetamine/NN (r_conj) apomorphine/NN (r_nsubjpass) used/VBN (r_advcl) induced/VBN (l_nsubjpass) Catalepsy/NNP -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_dobj) reducing/VBG (r_conj) potentiating/VBG (l_dobj) catalepsy/NN
D006220_D006948 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN (r_dobj) potentiating/VBG (l_conj) reducing/VBG (l_dobj) hyperactivity/NN
D000661_D006948 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) Catalepsy/NNP -PUNC- haloperidol/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) resulted/VBD (l_prep) in/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
C052075_D006948 NONE THP/NNP (r_nmod) time/NN (r_npadvmod) traveled/VBD (l_prep) On/IN (l_pobj) hyperactivity/NN -PUNC- THP/NNP (r_nsubj) exhibited/VBD (l_dobj) profile/NN (l_prep) by/IN (l_pcomp) potentiating/VBG (l_conj) reducing/VBG (l_dobj) hyperactivity/NN
D001058_D002375 NONE apomorphine/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (r_dobj) study/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) ligands/NNS (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- apomorphine/NN (r_nsubjpass) used/VBN (r_advcl) induced/VBN (l_nsubjpass) Catalepsy/NNP -PUNC- apomorphine/NN (r_dobj) reducing/VBG (r_conj) reducing/VBG (r_conj) potentiating/VBG (l_dobj) catalepsy/NN
C052075_D002375 CID thioperamide/JJ (r_conj) microg/NN (r_parataxis) methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN -PUNC- THP/NNP (r_appos) thioperamide/JJ (r_conj) microg/NN (r_parataxis) methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN -PUNC- THP/NNP (r_nsubj) exhibited/VBD (l_dobj) profile/NN (l_prep) by/IN (l_pcomp) potentiating/VBG (l_dobj) catalepsy/NN
D006632_D002375 NONE histamine/NN (r_nmod) ligands/NNS (l_prep) on/IN (l_pobj) catalepsy/NN
D001058_D006948 NONE apomorphine/NN (r_dobj) reducing/VBG (r_conj) reducing/VBG (l_dobj) hyperactivity/NN
C069357_D002375 NONE methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN -PUNC- RAMH/NNP (r_appos) methylhistamine/NN (r_nsubj) cause/VB (l_dobj) catalepsy/NN
6203632
D007545_D006984 NONE ISO/NN (r_pobj) to/IN (r_prep) response/NN (r_nsubj) shows/VBZ (l_dobj) phase/NN (l_amod) hypertrophic/JJ
D007545_D006332 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) hypertrophy/NN -PUNC- isoproterenol/NN (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) following/VBG (r_prep) studied/VBN (l_nsubjpass) development/NN (l_prep) of/IN (l_pobj) hypertrophy/NN -PUNC- ISO/NN (r_appos) injections/NNS (r_pobj) following/VBG (r_prep) studied/VBN (l_nsubjpass) development/NN (l_prep) of/IN (l_pobj) hypertrophy/NN
17490864
D000661_D006948 CID Amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
783197
D010042_D003324 NONE ouabain/NN (l_prep) on/IN (l_pobj) supply/NN (l_conj) demand/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- ouabain/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- ouabain/JJ (r_compound) administration/NN (r_pobj) after/IN (r_prep) falls/VBZ (r_conj) conclude/VBP (l_ccomp) left/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D010042_D006333 NONE ouabain/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_prep) without/IN (l_pobj) failure/NN -PUNC- ouabain/JJ (r_compound) administration/NN (r_pobj) after/IN (r_prep) falls/VBZ (r_conj) conclude/VBP (l_ccomp) left/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_relcl) are/VBP (l_prep) in/IN (l_pobj) failure/NN
D010042_D002303 CID ouabain/JJ (r_compound) administration/NN (r_pobj) after/IN (r_prep) falls/VBZ
D004071_D003324 NONE glycosides/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_prep) of/IN (l_pobj) interest/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) disease/NN
D010100_D003324 NONE oxygen/NN (r_compound) supply/NN (l_conj) demand/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- oxygen/NN (r_compound) supply/NN (r_pobj) on/IN (r_prep) glycosides/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_prep) of/IN (l_pobj) interest/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) disease/NN
1610717
D003042_D012640 CID Cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
19269743
D002211_D010146 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) pain/NN -PUNC- capsaicin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) injections/NNS (r_dobj) received/VBD (l_prep) In/IN (l_pobj) order/NN (l_acl) address/VB (l_dobj) memory/NN (l_compound) pain/NN -PUNC- capsaicin/NN (r_compound) doses/NNS (r_pobj) across/IN (r_prep) discriminate/VB (l_dobj) magnitude/NN (l_compound) pain/NN
8690168
C015445_D003920 NONE blue/JJ (r_dobj) employing/VBG (r_advcl) studied/VBN (l_prep) after/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) diabetes/NNS
D013311_D003920 NONE streptozotocin/NNS (r_pobj) by/IN (r_prep) induction/NN (l_prep) of/IN (l_pobj) diabetes/NNS -PUNC- streptozotocin/JJ (r_amod) diabetic/JJ
D013311_D003928 CID streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D006497_D003928 NONE sulphate/NN (r_npadvmod) associated/VBN (r_amod) sites/NNS (l_prep) in/IN (l_pobj) membrane/NN (l_prep) of/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) nephropathy/NN
D006497_D003920 NONE sulphate/NN (r_npadvmod) associated/VBN (r_amod) sites/NNS (r_nsubjpass) studied/VBN (l_prep) after/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) diabetes/NNS -PUNC- sulphate/NN (r_compound) charge/NN (r_compound) density/NN (r_nsubjpass) found/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
6747681
D000431_D014786 NONE ethanol/NN (r_compound) diluent/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubjpass) lowered/VBN (r_advcl) decreased/VBD (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) loss/NN
D002330_D005910 NONE BCNU/NNP (r_compound) chemotherapy/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) gliomas/NNS -PUNC- BCNU/NNP (r_nmod) 1,3-bis-(2-chloroethyl)-1-nitrosourea/NN (r_pobj) of/IN (r_prep) clearance/NN (r_pobj) Because/IN (r_prep) provide/VB (l_dobj) advantage/NN (l_prep) over/IN (l_pobj) administration/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) gliomas/NNS -PUNC- 1,3-bis-(2-chloroethyl)-1-nitrosourea/NN (r_pobj) of/IN (r_prep) clearance/NN (r_pobj) Because/IN (r_prep) provide/VB (l_dobj) advantage/NN (l_prep) over/IN (l_pobj) administration/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) gliomas/NNS
D002330_D001254 NONE BCNU/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) courses/NNS (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) to/IN (l_pobj) astrocytomas/NN
12574103
D003907_D006973 CID dexamethasone/NN (r_compound) programs/NNS (r_compound) hypertension/NN -PUNC- dexamethasone/NN (r_nsubj) programmed/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- dexamethasone/NN (r_dobj) received/VBD (r_relcl) rats/NNS (r_nsubj) elevated/VBN (l_dobj) pressures/NNS -PUNC- dexamethasone/NN (r_nsubj) results/VBZ (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN (l_conj) glomerulosclerosis/NN (l_conj) hypertension/NN
D003907_D005921 NONE dexamethasone/NN (r_dobj) given/VBN (l_advcl) had/VBD (l_dobj) glomeruli/NNS (l_prep) with/IN (l_pobj) glomerulosclerosis/NN -PUNC- dexamethasone/NN (r_nsubj) results/VBZ (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN (l_conj) glomerulosclerosis/NN
D003907_D007674 CID dexamethasone/NN (r_compound) programs/NNS (r_compound) hypertension/NN (l_conj) injury/NN -PUNC- dexamethasone/NN (r_nsubj) programmed/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN (l_conj) injury/NN -PUNC- dexamethasone/NN (r_dobj) administered/VBN (r_csubj) had/VBD (l_dobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN -PUNC- dexamethasone/NN (r_dobj) received/VBD (r_relcl) rats/NNS (r_nsubj) elevated/VBN (r_ccomp) have/VB (l_dobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN -PUNC- dexamethasone/NN (r_nsubj) results/VBZ (l_prep) in/IN (l_pobj) reduction/NN (l_prep) in/IN (l_pobj) number/NN
663266
D003973_D014693 NONE diatrizoate/JJ (r_pobj) from/IN (r_prep) fibrillation/NN
D003974_D064420 NONE Renografin/NNP (r_pobj) with/IN (r_prep) occurred/VBD (l_advcl) suggesting/VBG (l_ccomp) contribute/VBP (l_prep) to/IN (l_pobj) toxicity/NN
D003974_D014693 NONE Renografin/NNP (r_pobj) with/IN (r_prep) occurred/VBD (l_nsubj) fibrillation/NN
C027278_D064420 NONE %/NN (r_appos) toxicity/NN -PUNC- %/NN (r_npadvmod) compared/VBN (l_nsubjpass) toxicity/NN
9579567
D013629_D016889 CID tamoxifen/NN (r_compound) use/NN (r_conj) cancer/NN -PUNC- tamoxifen/NN (r_dobj) received/VBN (r_relcl) Women/NNS (r_nsubj) were/VBD (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) cancer/NN -PUNC- tamoxifen/NN (r_advmod) received/VBN (r_conj) had/VBD (l_dobj) cancer/NN -PUNC- tamoxifen/NN (r_advmod) received/VBN (r_conj) had/VBD (r_relcl) Women/NNS (r_nsubj) had/VBD (l_dobj) disease/NN (l_conj) prognosis/NN (l_prep) than/IN (l_pobj) those/DT (l_prep) with/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) women/NNS (r_pobj) in/IN (r_prep) diagnosed/VBD (r_acl) cancers/NNS
D013629_D001943 NONE tamoxifen/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_compound) cancer/NN -PUNC- tamoxifen/NN (r_nsubjpass) used/VBN (l_conj) proposed/VBN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_compound) use/NN (r_conj) cancer/NN (r_pobj) between/IN (r_prep) association/NN (l_acl) treated/VBN (l_prep) for/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) of/IN (r_prep) role/NN (r_dobj) suggest/VBP (l_advcl) used/VBN (l_xcomp) proposed/VBN (l_prep) for/IN (l_pobj) prevention/NN (l_compound) cancer/NN -PUNC- tamoxifen/NN (r_dobj) receive/VBP (l_prep) for/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) of/IN (r_prep) ratio/NN (r_pobj) of/IN (r_prep) evaluation/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) cancer/NN
D013629_D020178 NONE tamoxifen/NN (r_advmod) received/VBN (r_conj) had/VBD (r_relcl) Women/NNS (r_nsubj) had/VBD (l_dobj) disease/NN
7420681
D014031_D051437 CID sulfate/NN (r_conj) sulfate/NN (r_pobj) of/IN (r_prep) day/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) patients/NNS (r_nsubjpass) followed/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- tobramycin/RB (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) of/IN (r_prep) Five/CD (r_nsubj) had/VBD (l_dobj) failure/NN -PUNC- tobramycin/JJ (r_acomp) was/VBD (r_advcl) associated/VBN (l_prep) with/IN (l_pobj) failure/NN
D005839_D007674 NONE gentamicin/NN (r_conj) nephrotoxicity/NN -PUNC- sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN (l_conj) nephrotoxicity/NN
D014031_D006311 NONE sulfate/NN (r_conj) sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN
D005839_D051437 CID sulfate/NN (r_pobj) of/IN (r_prep) day/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) patients/NNS (r_nsubjpass) followed/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- gentamicin/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) of/IN (r_prep) 16/CD (r_nsubj) had/VBD (l_dobj) failure/NN -PUNC- gentamicin/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) failure/NN
D000617_D051437 NONE aminoglycoside/NN (r_npadvmod) related/VBN (r_amod) failure/NN
D014031_D007674 NONE tobramycin/JJ (r_pobj) of/IN (r_prep) nephrotoxicity/NN -PUNC- sulfate/NN (r_conj) sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN (l_conj) nephrotoxicity/NN
D005839_D006311 NONE sulfate/NN (r_nsubj) continue/VBP (l_xcomp) demonstrate/VB (l_dobj) ototoxicity/NN
1592014
C005618_D003643 NONE BE/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_nsubj) were/VBD (l_advcl) characterized/VBN (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN -PUNC- BE/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_nsubj) were/VBD (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN
D003042_D003643 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_nsubjpass) characterized/VBN (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_nsubjpass) characterized/VBN (r_advcl) were/VBD (l_conj) resulted/VBD (l_prep) in/IN (l_pobj) death/NN
C005618_D012640 CID benzoylecgonine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Seizures/NNS -PUNC- benzoylecgonine/NN (r_appos) metabolite/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) evaluated/VBD (l_advcl) cause/VB (l_dobj) seizures/NNS -PUNC- BE/VB (r_appos) metabolite/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) evaluated/VBD (l_advcl) cause/VB (l_dobj) seizures/NNS -PUNC- BE/VB (r_advmod) Induced/VBN (r_amod) seizures/NNS -PUNC- BE/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_nsubj) were/VBD (l_advcl) characterized/VBN (l_nsubjpass) seizures/NNS -PUNC- BE/VB (r_advmod) Injected/VBN (r_amod) rats/NNS (l_relcl) have/VB (l_dobj) seizures/NNS -PUNC- BE/VB (r_advmod) Injected/VBN (r_amod) rats/NNS (r_nsubj) had/VBD (l_prep) without/IN (l_pobj) seizures/NNS -PUNC- BE/VB (r_advmod) induced/VBN (r_conj) cocaine-/NN (r_nmod) seizures/NNS -PUNC- BE/VB (r_advmod) induced/VBN (r_conj) cocaine-/NN (r_nmod) seizures/NNS (r_nsubj) differ/VBP (r_relcl) finding/NN (r_nsubj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- BE/VB (r_conj) emphasizes/VBZ (r_conj) suggests/VBZ (l_nsubj) finding/NN (l_relcl) differ/VBP (l_nsubj) seizures/NNS -PUNC- BE/VB (r_conj) emphasizes/VBZ (r_conj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS
D003042_D012640 CID cocaine/NN (r_compound) metabolite/NN (r_amod) benzoylecgonine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) t1/2/NN (r_appos) life/NN (r_nsubj) is/VBZ (l_conj) occur/VB (l_nsubj) some/DT (l_prep) of/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) use/NN (l_prep) as/IN (l_pobj) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) metabolite/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) evaluated/VBD (l_advcl) cause/VB (l_dobj) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) those/DT (r_pobj) than/IN (r_prep) latencies/NNS (r_dobj) had/VBD (r_conj) occurred/VBD (l_nsubj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) injected/VBN (r_amod) animals/NNS (r_pobj) than/IN (r_prep) activity/NN (r_dobj) had/VBD (l_nsubj) rats/NNS (l_relcl) have/VB (l_dobj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) injected/VBN (r_amod) animals/NNS (r_pobj) than/IN (r_prep) activity/NN (r_dobj) had/VBD (l_prep) without/IN (l_pobj) seizures/NNS -PUNC- cocaine-/NN (r_nmod) seizures/NNS -PUNC- cocaine-/NN (r_nmod) seizures/NNS (r_nsubj) differ/VBP (r_relcl) finding/NN (r_nsubj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) for/IN (r_prep) mechanism/NN (r_dobj) suggests/VBZ (l_nsubj) finding/NN (l_relcl) differ/VBP (l_nsubj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_compound) metabolite/NN (r_pobj) of/IN (r_prep) importance/NN (r_dobj) emphasizes/VBZ (r_conj) suggests/VBZ (l_nsubj) finding/NN (l_relcl) differ/VBP (l_nsubj) seizures/NNS -PUNC- cocaine/NN (r_compound) metabolite/NN (r_pobj) of/IN (r_prep) importance/NN (r_dobj) emphasizes/VBZ (r_conj) suggests/VBZ (l_dobj) mechanism/NN (l_prep) for/IN (l_pobj) seizures/NNS
D003042_D020521 NONE cocaine/NN (r_pobj) of/IN (r_prep) t1/2/NN (r_appos) life/NN (r_nsubj) is/VBZ (l_conj) occur/VB (l_nsubj) some/DT (l_prep) of/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) use/NN (l_prep) as/IN (l_pobj) seizures/NNS (l_conj) strokes/NNS
137340
D009388_D006948 NONE neostigmine/NN (r_conj) methscopolamine/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hyperactivity/NN
D010134_D006948 NONE chlorophenylalamine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) caused/VBD (l_dobj) change/NN (l_prep) in/IN (l_pobj) hyperactivity/NN
D012601_D006948 CID scopolamine/NN (r_pobj) by/IN (r_agent) potentiated/VBN (l_nsubjpass) hyperactivity/NN
D010830_D006948 NONE physostigmine/NN (r_pobj) by/IN (r_agent) attenuated/VBN (r_conj) potentiated/VBN (l_nsubjpass) hyperactivity/NN
D012701_D006948 NONE serotonin/NN (r_compound) depletor/NN (r_nsubj) caused/VBD (l_dobj) change/NN (l_prep) in/IN (l_pobj) hyperactivity/NN
D019832_D006948 NONE methscopolamine/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) hyperactivity/NN
D009020_D006948 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- morphine/NN (r_compound) HC1/NNP (r_pobj) of/IN (r_prep) mg/kg/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) produced/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) hyperactivity/NN
7858459
D002955_D013274 NONE acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
D005472_D003221 CID 5-fluorouracil/CD (r_punct) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) confusion/NN -PUNC- 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN -PUNC- 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN
D002945_D013274 NONE cisplatinum/NN (l_appos) hours/NNS (l_conj) acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
C007744_D020258 NONE fluorocitrate/NN (r_conj) fluoroacetate/NN (r_pobj) by/IN (r_prep) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D005472_D001523 NONE 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN (l_conj) irritability/NN
D002955_D001523 NONE acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN (l_conj) irritability/NN
D005472_D020258 NONE 5-fluorouracil/CD (r_punct) suspected/VBN (l_nsubjpass) neurotoxicity/NN -PUNC- 5-fluorouracil/CD (r_punct) neurotoxicity/NN
D005463_D020258 NONE fluoroacetate/NN (r_pobj) by/IN (r_prep) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D005472_D003128 CID 5-fluorouracil/CD (r_punct) of/IN (r_prep) dose/NN (r_nmod) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (l_prep) into/IN (l_pobj) coma/NN
D002955_D003128 CID acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (l_prep) into/IN (l_pobj) coma/NN
D005047_D013274 NONE etoposide/NN (r_conj) cisplatinum/NN (l_appos) hours/NNS (l_conj) acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
D002955_D003221 CID acid/NN (r_conj) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) confusion/NN -PUNC- acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN -PUNC- acid/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) lasting/VBG (r_advcl) lapsed/VBD (r_conj) developed/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) confusion/NN (l_conj) disorientation/NN
D005472_D009369 NONE 5-fluorouracil/CD (r_punct) folinic/JJ (r_amod) therapy/NN (r_nsubj) become/VBN (l_attr) regimen/NN (l_prep) for/IN (l_pobj) cancers/NNS
D002955_D020258 NONE acid/NN (r_nsubj) was/VBD (r_advcl) suspected/VBN (l_nsubjpass) neurotoxicity/NN
D013831_D020258 NONE thiamine/NN (r_compound) deficiency/NN (r_conj) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D002955_D009369 NONE acid/NN (r_compound) infusion/NN (r_compound) therapy/NN (r_nsubj) become/VBN (l_attr) regimen/NN (l_prep) for/IN (l_pobj) cancers/NNS
D005472_D013274 NONE 5-fluorouracil/CD (r_punct) m2/24/NN (r_compound) hours/NNS (l_conj) acid/NN (l_prep) for/IN (l_pobj) adenocarcinoma/NN
C007419_D020258 NONE dihydrouracil/VBN (r_compound) dehydrogenase/NN (r_compound) deficiency/NN (r_conj) deficiency/NN (r_conj) blockade/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (l_nsubj) pathogenesis/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
7072798
D002701_D000741 CID chloramphenicol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) anemia/NN -PUNC- chloramphenicol/NN (r_pobj) with/IN (r_prep) therapy/NN (r_dobj) beginning/VBG (r_conj) undergoing/VBG (r_pcomp) after/IN (r_prep) died/VBD (l_prep) of/IN (l_pobj) anemia/NN -PUNC- chloramphenicol/NN (r_acl) response/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) pattern/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- chloramphenicol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) anemia/NN
D002701_D005128 NONE chloramphenicol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN
D002701_D001855 NONE chloramphenicol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) report/NN (r_attr) was/VBD (l_advcl) reported/VBN (l_nsubjpass) cases/NNS (l_prep) of/IN (l_pobj) hypoplasia/NN
D002701_D002386 NONE chloramphenicol/NN (r_pobj) with/IN (r_prep) therapy/NN (r_dobj) beginning/VBG (r_conj) undergoing/VBG (l_dobj) extraction/NN (l_compound) cataract/NN
11078231
D000109_D023921 NONE acetylcholine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_conj) documented/VBN (l_nsubjpass) stenosis/NN
D004280_D003329 CID dobutamine/NN (r_compound) stress/NN (r_compound) echocardiography/RB (r_pobj) during/IN (r_prep) spasm/NN -PUNC- dobutamine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) ischemia/NN (l_amod) due/IN (l_pcomp) to/IN (l_pobj) spasm/NN -PUNC- dobutamine/NN (r_nsubj) provoke/VB (l_dobj) spasm/NN
D004280_D017202 NONE dobutamine/NN (r_compound) stress/NN (r_compound) echocardiography/RB (r_pobj) during/IN (r_prep) spasm/NN (r_pobj) due/IN (r_amod) ischemia/NN -PUNC- Dobutamine/NNP (r_nsubj) stress/NN (r_nsubj) is/VBZ (l_attr) test/NN (l_prep) for/IN (l_pobj) ischemia/NN -PUNC- dobutamine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) ischemia/NN
D004280_D000788 CID dobutamine/NN (r_nsubj) provoke/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN
6674249
D015119_D009336 CID acid/NN (r_nmod) EACA/NNP (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) necrotizing/VBG (l_advmod) myopathy/NNS -PUNC- EACA/NNP (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) necrotizing/VBG (l_advmod) myopathy/NNS
D015119_D013345 NONE acid/NN (r_nmod) EACA/NNP (r_nmod) treatment/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) haemorrhage/NN -PUNC- acid/NN (r_nmod) EACA/NNP (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) necrotizing/VBG (r_pcomp) of/IN (r_prep) case/NN (r_nsubjpass) described/VBN (l_punct) (/-LRB- (l_preconj) SAH/NNP -PUNC- EACA/NNP (r_nmod) treatment/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) haemorrhage/NN -PUNC- EACA/NNP (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) necrotizing/VBG (r_pcomp) of/IN (r_prep) case/NN (r_nsubjpass) described/VBN (l_punct) (/-LRB- (l_preconj) SAH/NNP
D015119_D009135 CID acid/NN (r_nsubj) induce/VBP (l_dobj) myopathy/NNS -PUNC- EACA/NNP (r_appos) acid/NN (r_nsubj) induce/VBP (l_dobj) myopathy/NNS -PUNC- acid/NN (r_nmod) EACA/NNP (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) necrotizing/VBG (l_advmod) myopathy/NNS -PUNC- EACA/NNP (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) necrotizing/VBG (l_advmod) myopathy/NNS
343678
D006514_D006509 NONE antigen/NN (r_nmod) donors/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) preventing/VBG (r_pcomp) in/IN (r_prep) efficacies/NNS (r_dobj) assess/VB (r_advcl) examined/VBN (l_nsubjpass) globulin/NN (l_compound) B/NN -PUNC- antigen/NN (r_nmod) donors/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) preventing/VBG (l_dobj) hepatitis/NN -PUNC- HBsAG)-positive/JJ (r_compound) donors/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) preventing/VBG (r_pcomp) in/IN (r_prep) efficacies/NNS (r_dobj) assess/VB (r_advcl) examined/VBN (l_nsubjpass) globulin/NN (l_compound) B/NN -PUNC- HBsAG)-positive/JJ (r_compound) donors/NNS (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) preventing/VBG (l_dobj) hepatitis/NN
16740173
20667451
D002220_D003072 CID carbamazepine/NN (r_conj) phenobarbitone/NN (r_pobj) in/IN (r_prep) damage/NN (r_conj) dysfunction/NN -PUNC- carbamazepine/NN (r_conj) phenobarbitone/NN (r_conj) drugs/NNS (r_nsubj) are/VBP (l_acomp) known/JJ (l_xcomp) cause/VB (l_dobj) impairment/NN -PUNC- carbamazepine/NN (r_npadvmod) induced/VBN (r_conj) phenobarbitone-/JJ (r_nmod) impairment/NN -PUNC- carbamazepine/NN (r_conj) phenobarbitone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- carbamazepine/NN (r_conj) phenobarbitone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) damage/NN (r_conj) functions/NNS -PUNC- carbamazepine/NN (r_compound) therapy/NN (r_conj) phenobarbitone/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) impairment/NN
D010634_D003072 CID phenobarbitone/NN (r_pobj) in/IN (r_prep) damage/NN (r_conj) dysfunction/NN -PUNC- phenobarbitone/NN (r_conj) drugs/NNS (r_nsubj) are/VBP (l_acomp) known/JJ (l_xcomp) cause/VB (l_dobj) impairment/NN -PUNC- phenobarbitone-/JJ (r_nmod) impairment/NN -PUNC- phenobarbitone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- phenobarbitone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) damage/NN (r_conj) functions/NNS -PUNC- phenobarbitone/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) impairment/NN
D003474_D003072 NONE Curcumin/NN (r_nsubj) ameliorates/VBZ (l_dobj) dysfunction/NN -PUNC- curcumin/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) impairment/NN -PUNC- curcumin/NN (r_compound) administration/NN (r_nsubj) prevented/VBD (l_dobj) impairment/NN -PUNC- curcumin/NN (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) in/IN (l_pcomp) mitigating/VBG (l_dobj) deterioration/NN (l_prep) of/IN (l_pobj) functions/NNS -PUNC- curcumin/NN (r_nsubjpass) considered/VBN (l_advcl) phenobarbitone/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) impairment/NN
10807237
D003042_D000783 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) aneurysms/NNS -PUNC- cocaine/NN (r_npadvmod) related/VBN (r_amod) aneurysms/NNS -PUNC- Cocaine/NN (r_compound) use/NN (r_nsubj) predisposed/VBN (l_prep) at/IN (l_conj) in/IN (l_pobj) aneurysms/NNS
D003042_D017542 CID Cocaine/NN (r_compound) use/NN (r_nsubj) predisposed/VBN (l_dobj) rupture/NN
8111719
D007069_D020258 NONE ifosfamide/RB (r_advmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) are/VBP (l_nsubj) Hallucinations/NNS (l_prep) as/IN (l_pobj) symptom/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- ifosfamide/RB (r_npadvmod) induced/VBN (r_amod) hallucinations/NNS (l_relcl) occur/VB (l_prep) without/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN
D006220_D011595 NONE haloperidol/NN (r_appos) neuroleptics/NNS (l_amod) marked/JJ (l_auxpass) becomes/VBZ (l_nsubj) agitation/NN
D007069_D006212 CID ifosfamide/RB (r_advmod) induced/VBN (r_amod) neurotoxicity/NN (r_conj) Hallucinations/NNS -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) are/VBP (l_nsubj) Hallucinations/NNS -PUNC- ifosfamide/RB (r_npadvmod) induced/VBN (r_amod) hallucinations/NNS -PUNC- ifosfamide/RB (r_npadvmod) induced/VBN (r_amod) hallucinations/NNS -PUNC- ifosfamide/RB (r_npadvmod) induced/VBN (r_amod) hallucinations/NNS
18627295
D004317_D066126 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) limited/VBN (l_agent) by/IN (l_pobj) effects/NNS (l_amod) cardiotoxic/JJ -PUNC- DOX/NNP (r_appos) doxorubicin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) limited/VBN (l_agent) by/IN (l_pobj) effects/NNS (l_amod) cardiotoxic/JJ
D004317_D006331 NONE DOX/NN (r_compound) control/NN (r_compound) mice/NNS (r_nsubj) showed/VBD (l_dobj) dysfunction/NN -PUNC- DOX/NNP (r_nmod) mice/NNS (r_pobj) In/IN (r_prep) improved/VBN (l_nsubjpass) dysfunction/NN -PUNC- DOX/NNP (r_compound) mice/NNS (r_pobj) to/IN (r_prep) compared/VBN (r_prep) improved/VBN (l_nsubjpass) dysfunction/NN
D004317_D007249 NONE Doxorubicin/NNP (l_dobj) inflammation/NN -PUNC- DOX/NNP (r_compound) cardiomyopathy/NN (r_pobj) of/IN (r_prep) development/NN (r_pobj) during/IN (r_prep) elucidate/VB (r_advcl) studied/VBD (l_prep) by/IN (l_pcomp) investigating/VBG (l_dobj) inflammation/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) of/IN (r_prep) induction/NN (r_pobj) after/IN (r_prep) apoptosis/NN (r_conj) investigating/VBG (l_dobj) inflammation/NN
D018943_D066126 NONE anthracycline/NN (r_amod) doxorubicin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) limited/VBN (l_agent) by/IN (l_pobj) effects/NNS (l_amod) cardiotoxic/JJ
D004317_D009202 CID Doxorubicin/NNP (l_dobj) inflammation/NN (l_amod) induced/VBN (l_npadvmod) cardiomyopathy/NN -PUNC- DOX/NNP (r_compound) cardiomyopathy/NN -PUNC- DOX/NNP (r_compound) cardiomyopathy/NN (r_pobj) of/IN (r_prep) development/NN (r_pobj) during/IN (r_prep) elucidate/VB (r_advcl) studied/VBD (l_prep) by/IN (l_pcomp) investigating/VBG (l_conj) apoptosis/NN (l_prep) after/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) cardiomyopathy/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) of/IN (r_prep) induction/NN (r_pobj) after/IN (r_prep) apoptosis/NN (r_conj) investigating/VBG (r_pcomp) by/IN (r_prep) studied/VBD (l_advcl) elucidate/VB (l_prep) during/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cardiomyopathy/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- DOX/NNP (r_pobj) in/IN (r_prep) is/VBZ (l_acl) cardiomyopathy/NN -PUNC- DOX/NNP (r_compound) cardiomyopathy/NN
12084448
D007069_D009207 CID ifosfamide/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) after/IN (r_prep) disabling/VBG (l_dobj) myoclonus/NN -PUNC- ifosfamide/JJ (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) during/IN (r_prep) presence/NN (r_nsubj) suggest/VBP (l_ccomp) associated/VBN (l_nsubjpass) myoclonus/NN -PUNC- IFX/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) myoclonus/NN
D007069_D010954 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) infusion/NN (l_prep) for/IN (l_pobj) plasmacytoma/NN
D007069_D020820 NONE Ifosfamide/NNP (r_compound) encephalopathy/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) asterixis/NNS -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) discontinued/VBN (l_conj) resolved/VBD (l_nsubj) asterixis/NNS -PUNC- ifosfamide/JJ (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) during/IN (r_prep) presence/NN (l_prep) of/IN (l_pobj) asterixis/NNS -PUNC- IFX/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_ccomp) suggest/VBP (l_nsubj) presence/NN (l_prep) of/IN (l_pobj) asterixis/NNS
D007069_D001927 CID Ifosfamide/NNP (r_compound) encephalopathy/NN
2533791
D017325_D006509 NONE vaccine/NN (r_dobj) derived/VBN (r_conj) treated/VBN (l_prep) with/IN (l_pobj) injections/NNS (l_prep) of/IN (l_pobj) globulin/NN (l_compound) B/NNP
18261172
D000806_D007674 NONE ACEi/NNP (r_nmod) therapy/NN (r_pobj) with/IN (r_prep) used/VBN (l_conj) increased/VBD (l_dobj) dysfunction/NN
D020123_D007674 NONE sirolmus/NN (r_nsubj) lacks/VBZ (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- Srl/NNP (r_appos) sirolmus/NN (r_nsubj) lacks/VBZ (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- Srl/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) proteinuria/NN (r_nsubjpass) reported/VBN (l_ccomp) lacks/VBZ (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- Srl/NNP (r_nsubjpass) used/VBN (l_conj) increased/VBD (l_dobj) dysfunction/NN
D000806_D011507 NONE inhibitor/NN (r_nsubj) reduced/VBN (l_dobj) development/NN (l_compound) proteinuria/NN -PUNC- ACEi/NNP (r_nmod) therapy/NN (l_acl) monitored/VBD (l_prep) for/IN (l_pobj) proteinuria/NN
D057911_D011507 NONE blocker/NN (r_nmod) therapy/NN (r_conj) inhibitor/NN (r_nsubj) reduced/VBN (l_dobj) development/NN (l_compound) proteinuria/NN -PUNC- ARB/NNP (r_nmod) therapy/NN (r_conj) inhibitor/NN (r_nsubj) reduced/VBN (l_dobj) development/NN (l_compound) proteinuria/NN -PUNC- ARB/NNP (r_compound) therapy/NN (l_acl) monitored/VBD (l_prep) for/IN (l_pobj) proteinuria/NN
D057911_D007674 NONE ARB/NNP (r_compound) therapy/NN (r_pobj) with/IN (r_prep) used/VBN (l_conj) increased/VBD (l_dobj) dysfunction/NN
D020123_D011507 CID sirolimus/NN (r_npadvmod) based/VBN (r_amod) immunosuppression/NN (r_pobj) to/IN (r_prep) switch/NN (r_pobj) after/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolmus/NN (r_nsubj) lacks/VBZ (r_ccomp) reported/VBN (l_nsubjpass) proteinuria/NN -PUNC- Srl/NNP (r_appos) sirolmus/NN (r_nsubj) lacks/VBZ (r_ccomp) reported/VBN (l_nsubjpass) proteinuria/NN -PUNC- Srl/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) proteinuria/NN -PUNC- Srl/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) incidence/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- Srl/NNP (r_pobj) to/IN (r_prep) switch/NN (r_pobj) after/IN (r_prep) develop/VB (l_nsubj) proteinuria/NN -PUNC- Srl/NNP (r_nsubjpass) used/VBN (l_prep) with/IN (l_pobj) therapy/NN (l_acl) monitored/VBD (l_prep) for/IN (l_pobj) proteinuria/NN
19135948
C107135_D014652 CID everolimus/NN (r_pobj) with/IN (r_prep) prophylaxis/VBN (r_nsubjpass) associated/VBN (l_conj) microangiopathy/NN
C107135_D009190 NONE everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) leukemia/NN (l_nmod) MDS/NNP
D008727_D006086 NONE methotrexate/NNP (r_pobj) with/IN (r_prep) combined/VBN (r_acl) inhibitor/NN (r_nsubj) is/VBZ (l_attr) prophylaxis/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- methotrexate/NNP (r_pobj) with/IN (r_prep) combined/VBN (r_acl) inhibitor/NN (r_nsubj) is/VBZ (l_attr) prophylaxis/NN (l_prep) for/IN (l_pobj) disease/NN (l_appos) GVHD/NNP
D016559_D006086 NONE tacrolimus/NN (r_conj) everolimus/NN (r_pobj) with/IN (r_prep) prophylaxis/VBN (l_compound) disease/NN
D016559_D015470 NONE tacrolimus/NN (r_conj) everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) leukemia/NN -PUNC- tacrolimus/NN (r_conj) everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) leukemia/NN (l_appos) AML/NNP
D016559_D014652 CID tacrolimus/NN (r_conj) everolimus/NN (r_pobj) with/IN (r_prep) prophylaxis/VBN (r_nsubjpass) associated/VBN (l_conj) microangiopathy/NN
D016559_D009190 NONE tacrolimus/NN (r_conj) everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- tacrolimus/NN (r_conj) everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) leukemia/NN (l_nmod) MDS/NNP
C107135_D006504 CID everolimus/NN (r_pobj) with/IN (r_prep) prophylaxis/VBN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) syndrome/NN
C107135_D006086 NONE everolimus/NN (r_pobj) with/IN (r_prep) prophylaxis/VBN (l_compound) disease/NN
C107135_D015470 NONE everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) leukemia/NN -PUNC- everolimus/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) leukemia/NN (l_appos) AML/NNP
D016559_D006504 CID tacrolimus/NN (r_conj) everolimus/NN (r_pobj) with/IN (r_prep) prophylaxis/VBN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) syndrome/NN
8617710
D006220_D003072 CID haloperidol/NN (r_pobj) with/IN (r_prep) impairment/NN -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) observed/VBN (l_nsubjpass) Impairment/NN (l_prep) of/IN (l_pobj) function/NN -PUNC- Haloperidol/NNP (r_nsubj) produced/VBD (l_dobj) profile/NN (l_prep) of/IN (l_pobj) impairment/NN
D020280_D003072 NONE sertraline/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) sensitization/NN (l_prep) of/IN (l_pobj) impairment/NN -PUNC- sertraline/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) worsened/VBN (r_relcl) profile/NN (l_prep) of/IN (l_pobj) impairment/NN
10743446
D002211_D006930 CID capsaicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (l_prep) of/IN (l_pobj) ketamine/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- capsaicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effect/NN (l_prep) of/IN (l_pobj) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN
D007649_D006930 NONE ketamine/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- Ketamine/NN (r_nsubj) reduced/VBD (l_dobj) area/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) suggest/VBP (l_ccomp) mediated/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN
D007649_D010146 NONE ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN (l_nmod) pain/NN -PUNC- Ketamine/NN (r_nsubj) reduced/VBD (l_conj) tended/VBD (l_xcomp) reduce/VB (l_dobj) pain/NN
D008012_D010146 NONE lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN (l_nmod) pain/NN
D002211_D010146 CID capsaicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effect/NN (l_prep) of/IN (l_pobj) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN (l_nmod) pain/NN
D008012_D006930 NONE lidocaine/NN (r_conj) ketamine/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- Lidocaine/NN (r_nsubj) reduced/VBD (l_dobj) area/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) hyperalgesia/NN -PUNC- lidocaine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) suggest/VBP (l_ccomp) mediated/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN
9105126
D013256_D018658 CID steroid/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) defect/NN -PUNC- steroid/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) rupture/NN -PUNC- steroid/NN (r_compound) therapy/NN (l_conj) rupture/NN
9522143
D011318_D034381 CID prilocaine/NN (r_dobj) given/VBN (r_acl) Patients/NNS (r_nsubj) were/VBD (l_acomp) likely/JJ (l_xcomp) develop/VB (l_xcomp) hearing/VBG (l_dobj) loss/NN -PUNC- prilocaine/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) loss/NN
D002045_D034381 CID bupivacaine/NN (r_pobj) than/IN (r_prep) loss/NN -PUNC- bupivacaine/NN (r_pobj) after/IN (r_prep) dB/NN (r_conj) prilocaine/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) loss/NN
19729346
D010098_D010146 NONE oxycodone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) measured/VBD (l_dobj) adults/NNS (l_relcl) suffering/VBG (l_prep) from/IN (l_pobj) pain/NN
D010098_D059350 NONE oxycodone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) suffering/VBG (l_prep) from/IN (l_pobj) pain/NN
3173180
D008795_D006463 CID metronidazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) syndrome/NN -PUNC- metronidazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) syndrome/NN -PUNC- metronidazole/NN (r_pobj) of/IN (r_prep) involvement/NN (l_prep) in/IN (l_pobj) aetiology/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_pobj) of/IN (r_prep) involvement/NN (r_nsubjpass) established/VBN (r_advcl) suggest/VBP (l_nsubj) action/NN (l_conj) evidence/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_pobj) of/IN (r_prep) involvement/NN (r_nsubjpass) established/VBN (r_advcl) suggest/VBP (l_dobj) link/NN (l_prep) between/IN (l_pobj) treatment/NN (l_conj) cases/NNS (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_amod) treatment/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) suggest/VBP (l_advcl) established/VBN (l_nsubjpass) involvement/NN (l_prep) in/IN (l_pobj) aetiology/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_amod) treatment/NN (r_pobj) between/IN (r_prep) link/NN (r_dobj) suggest/VBP (l_nsubj) action/NN (l_conj) evidence/NN (l_prep) of/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- metronidazole/NN (r_amod) treatment/NN (l_conj) cases/NNS (l_prep) of/IN (l_pobj) syndrome/NN
7352670
D006221_D007022 CID halothane/NN (r_compound) anesthesia/NN (l_conj) nitroprusside/NN (l_parataxis) evaluated/VBN (l_nsubjpass) hypotension/NN -PUNC- halothane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hypotensive/JJ
D000809_D007022 NONE angiotensin/NN (r_compound) system/NN (l_prep) in/IN (l_pobj) maintenance/NN (l_prep) during/IN (l_pobj) anesthesia/NN (l_conj) nitroprusside/NN (l_parataxis) evaluated/VBN (l_nsubjpass) hypotension/NN -PUNC- angiotensin/NN (r_compound) system/NN (l_prep) in/IN (l_pcomp) antagonizing/VBG (l_dobj) effects/NNS (l_amod) hypotensive/JJ
D009599_D007022 CID nitroprusside/NN (l_parataxis) evaluated/VBN (l_nsubjpass) hypotension/NN -PUNC- SNP)-induced/VBN (r_amod) hypotension/NN -PUNC- SNP/NNP (r_conj) halothane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hypotensive/JJ
D009599_D006973 NONE nitroprusside/NN (r_advmod) hypertensive/JJ -PUNC- SNP/NNP (r_compound) infusion/NN (r_pobj) During/IN (r_prep) demonstrated/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
D012504_D006973 NONE saralasin/NN (r_pobj) by/IN (r_agent) prevented/VBN (r_acl) hypertensive/JJ -PUNC- saralasin/NN (r_npadvmod) treated/VBN (r_amod) animals/NNS (r_nsubj) showed/VBD (r_advcl) demonstrated/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
2234245
D003676_D014786 NONE desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) During/IN (r_prep) monitored/VBN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D003676_D006311 NONE desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) During/IN (r_prep) monitored/VBN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- desferrioxamine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D003676_D064420 NONE desferrioxamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) appeared/VBD (l_nsubj) toxicity/NN
-1_D064420 NONE aluminium/NN (r_conj) ferritin/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) normalization/NN (r_pobj) with/IN (r_prep) coincided/VBD (r_conj) appeared/VBD (l_nsubj) toxicity/NN
D003676_D034381 NONE Desferrioxamine/NNP (r_compound) withdrawal/NN (r_nsubj) resulted/VBD (l_conj) reversal/NN (l_prep) of/IN (l_pcomp) hearing/NN (l_dobj) loss/NN
10539815
D004656_D018487 NONE enalapril/NN (r_pobj) of/IN (r_prep) trial/NN (r_appos) Dysfunction/NNP
D003404_D006973 NONE creatinine/NN (r_conj) fraction/NN (r_conj) age/NN (l_appos) history/NN (l_prep) of/IN (l_pobj) hypertension/NN
D004656_D051437 CID enalapril/NN (r_pobj) to/IN (r_prep) assigned/VBN (r_acl) Patients/NNS (r_nsubj) had/VBD (l_dobj) likelihood/NN (l_prep) of/IN (l_pobj) function/NN -PUNC- enalapril/NN (r_compound) groups/NNS (r_conj) placebo/NN (r_pobj) in/IN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) function/NN -PUNC- enalapril/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) more/RBR (r_conj) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) function/NN -PUNC- enalapril/NN (r_dep) ratio/NN (r_appos) group/NN (r_pobj) in/IN (r_prep) more/RBR (r_conj) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) function/NN -PUNC- enalapril/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) function/NN -PUNC- Enalapril/NNP (r_compound) use/NN (r_nsubj) caused/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) function/NN -PUNC- enalapril/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) reduced/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) impairment/NN
D000809_D051437 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) function/NN -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_nsubj) reduces/VBZ (r_advcl) cause/VB (l_dobj) function/NN -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_dobj) prescribed/VBN (r_relcl) CHF/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) reduction/NN (l_prep) in/IN (l_pobj) function/NN
D004656_D003920 NONE enalapril/NN (r_compound) groups/NNS (r_conj) placebo/NN (l_conj) age/NN (l_conj) therapy/NN (l_conj) diabetes/NNS -PUNC- enalapril/NN (r_nsubj) had/VBD (l_npadvmod) RR/NN (l_nummod) 1.33/CD (l_prep) compared/VBN (l_prep) with/IN (l_pobj) placebo/NN (l_appos) CI/NNP (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- enalapril/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) reduced/VBN (r_conj) associated/VBN (l_nsubjpass) Diabetes/NN
D004232_D051437 CID diuretic/JJ (r_amod) therapy/NN (r_conj) age/NN (r_conj) placebo/NN (r_pobj) in/IN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) function/NN -PUNC- Diuretic/JJ (r_compound) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) function/NN
D004656_D006333 NONE enalapril/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) CHF/NNP -PUNC- Enalapril/NNP (r_compound) use/NN (r_nsubj) caused/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) function/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) CHF/NNP -PUNC- enalapril/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) reduced/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) impairment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) CHF/NNP
D000809_D018487 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) function/NN (r_pobj) of/IN (r_prep) Predictors/NNS (r_dep) results/NNS (l_prep) from/IN (l_pobj) studies/NNS (l_prep) of/IN (l_pobj) dysfunction/NN
D000809_D006333 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_nsubj) reduces/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_nsubj) reduces/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_appos) CHF/NNP -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) enzyme/NN (r_compound) therapy/NN (r_dobj) prescribed/VBN (r_relcl) CHF/NNP
D004232_D003920 NONE diuretic/JJ (r_conj) antiplatelet/JJ (r_pobj) of/IN (r_prep) use/NN (r_conj) diabetes/NNS -PUNC- diuretic/JJ (r_amod) therapy/NN (l_conj) diabetes/NNS
D004232_D006973 NONE diuretic/JJ (r_conj) antiplatelet/JJ (r_pobj) of/IN (r_prep) use/NN (r_conj) diabetes/NNS (r_conj) hypertension/NN
D003404_D051437 NONE creatinine/NN (r_pobj) in/IN (r_prep) rise/NN (r_pobj) as/IN (r_prep) defined/VBN (l_nsubjpass) function/NN
D003404_D003920 NONE creatinine/NN (r_conj) fraction/NN (r_conj) age/NN (l_appos) history/NN (l_prep) of/IN (l_pobj) hypertension/NN (l_conj) diabetes/NNS
1595783
D000638_D011014 CID Amiodarone/NN (r_nsubj) is/VBZ (l_attr) agent/NN (l_appos) being/VBG (l_attr) pneumonitis/NN
D000638_D004342 NONE amiodarone/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_nsubjpass) thought/VBN (l_xcomp) result/VB (l_prep) from/IN (l_pobj) injury/NN (l_acl) related/VBN (l_prep) to/IN (l_pobj) accumulation/NN (l_prep) of/IN (l_pobj) pneumonitis/NN
D000638_D008171 NONE Amiodarone/NN (r_amod) toxicity/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D000638_D000542 NONE amiodarone/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_nsubjpass) thought/VBN (l_xcomp) result/VB (l_prep) from/IN (l_pobj) injury/NN (l_acl) related/VBN (l_prep) to/IN (l_pobj) accumulation/NN (l_prep) of/IN (l_pobj) pneumonitis/NN
3183120
C033706_D001927 CID tiazofurin/NN (r_compound) usage/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) lesions/NNS
3461217
D013739_D011471 NONE testosterone/NN (r_conj) methylurea/NN (r_pobj) with/IN (r_prep) treatments/NNS (r_pobj) by/IN (r_prep) Production/NN (l_prep) of/IN (l_pobj) cancer/NN
D043343_D009369 NONE TP/NNP (r_nsubj) acted/VBD (l_prep) as/IN (l_pobj) agent/NN (l_compound) enhancement/NN (l_compound) tumor/NN
D008770_D011471 CID methylurea/NN (r_pobj) with/IN (r_prep) treatments/NNS (r_pobj) by/IN (r_prep) Production/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- methylurea/NN (r_pobj) with/IN (r_prep) treatments/NNS (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) PAs/FW (l_nmod) adenocarcinomas/NNS -PUNC- methylurea/NN (r_pobj) with/IN (r_prep) treatments/NNS (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) PAs/FW
D043343_D011471 CID propionate/NN (r_conj) CAS/NN (r_appos) methylurea/NN (r_pobj) with/IN (r_prep) treatments/NNS (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) PAs/FW (l_nmod) adenocarcinomas/NNS -PUNC- propionate/NN (r_conj) CAS/NN (r_appos) methylurea/NN (r_pobj) with/IN (r_prep) treatments/NNS (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) PAs/FW -PUNC- TP/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (l_dobj) PA/NNP -PUNC- TP/NNP (r_nsubj) acted/VBD (l_prep) with/IN (l_pobj) emphasis/NN (l_prep) on/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cancer/NN
6695415
D010665_D020521 CID Phenylpropanolamine/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) stroke/NN -PUNC- PPA/NNP (r_appos) Phenylpropanolamine/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) effects/NNS (l_prep) including/VBG (l_pobj) stroke/NN -PUNC- PPA/NNP (r_nmod) caffeine/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) stroke/NN
D002110_D020521 NONE caffeine/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) stroke/NN
D010665_D006973 CID PPA/NNP (r_nmod) caffeine/NN (r_nsubj) lead/VB (l_prep) in/IN (l_pobj) rats/NNS (l_amod) normotensive/NN (l_conj) hypertensive/JJ -PUNC- PPA/NNP (r_nmod) caffeine/NN (r_compound) administration/NN (r_nsubj) lead/NN (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- PPA/NNP (r_nmod) caffeine/NN (r_compound) administration/NN (r_nsubj) lead/NN (l_prep) to/IN (l_pobj) hypertension/NN (l_prep) in/IN (l_pobj) animals/NNS (l_amod) normotensive/NN (l_conj) hypertensive/JJ -PUNC- PPA/NNP (r_nmod) caffeine/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) hemorrhage/NN (l_prep) in/IN (l_pobj) animals/NNS (l_amod) hypertensive/JJ
D002110_D002543 CID caffeine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) associated/VBN (r_acl) hemorrhage/NN -PUNC- caffeine/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) hemorrhage/NN
D002110_D006973 CID caffeine/NN (r_nsubj) lead/VB (l_prep) in/IN (l_pobj) rats/NNS (l_amod) normotensive/NN (l_conj) hypertensive/JJ -PUNC- caffeine/NN (r_compound) administration/NN (r_nsubj) lead/NN (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- caffeine/NN (r_compound) administration/NN (r_nsubj) lead/NN (l_prep) to/IN (l_pobj) hypertension/NN (l_prep) in/IN (l_pobj) animals/NNS (l_amod) normotensive/NN (l_conj) hypertensive/JJ -PUNC- caffeine/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) hemorrhage/NN (l_prep) in/IN (l_pobj) animals/NNS (l_amod) hypertensive/JJ
D010665_D002543 CID phenylpropanolamine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hemorrhage/NN -PUNC- PPA/NNP (r_nmod) caffeine/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) hemorrhage/NN
9293063
D003613_D006222 CID danazol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) hamartoma/NN -PUNC- danazol/NN (r_compound) treatment/NN (r_pobj) on/IN (r_prep) been/VBN (r_relcl) patient/NN (r_pobj) in/IN (r_prep) developed/VBD (r_relcl) hamartoma/NN
D003613_D001650 CID danazol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) hamartoma/NN -PUNC- danazol/NN (r_compound) treatment/NN (r_pobj) on/IN (r_prep) been/VBN (r_relcl) patient/NN (r_pobj) in/IN (r_prep) developed/VBD (r_relcl) hamartoma/NN
1255900
D006493_D013924 NONE heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (l_prep) for/IN (l_pobj) thrombophlebitis/NN
2576810
D016666_D006948 CID fluvoxamine/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) potentiated/VBN (l_dobj) hyperactivity/NN -PUNC- fluvoxamine/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) remained/VBD (l_nsubj) hyperactivity/NN
D000661_D006948 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D009627_D006948 CID nomifensine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
20042557
D015742_D011183 CID propofol/NN (r_amod) sedation/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) decreased/VBD (l_dobj) prevalence/NN (l_prep) of/IN (l_pobj) delirium/NN
D015742_D003693 CID propofol/NN (r_amod) sedation/NN (r_pobj) with/IN (r_prep) anesthesia/NN (r_pobj) under/IN (r_prep) repair/NN (r_dobj) underwent/VBD (r_relcl) delirium/NN -PUNC- propofol/NN (r_amod) sedation/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) decreased/VBD (l_dobj) prevalence/NN (l_prep) of/IN (l_pobj) delirium/NN
D015742_D003704 NONE propofol/NN (r_amod) sedation/NN (r_pobj) with/IN (r_prep) anesthesia/NN (r_pobj) under/IN (r_prep) repair/NN (r_dobj) underwent/VBD (r_relcl) delirium/NN (l_conj) dementia/NN
D015742_D006620 NONE propofol/NN (r_amod) sedation/NN (r_pobj) with/IN (r_prep) anesthesia/NN (r_pobj) under/IN (r_prep) repair/NN (l_compound) fracture/NN
6308277
D002110_D064420 NONE caffeine/NN (r_compound) toxicity/NN -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) augment/VB (r_xcomp) reported/VBN (r_advcl) focused/VBN (l_prep) on/IN (l_pobj) possibility/NN (l_acl) reduced/VBD (l_dobj) toxicity/NN -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) toxicity/NN
D000082_D012640 NONE acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) increased/VBD (l_dobj) interval/NN (l_prep) between/IN (l_pobj) administration/NN (l_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) increased/VBD (l_conj) reduced/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- acetaminophen/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) onset/NN (r_conj) administration/NN (r_pobj) between/IN (r_prep) interval/NN (r_dobj) increased/VBD (l_conj) reduced/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acetaminophen/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_nsubjpass) frequency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acetaminophen/FW (r_nsubj) modify/VB (l_dobj) seizures/NNS
D002110_D012640 CID caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (l_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) between/IN (r_prep) interval/NN (r_dobj) increased/VBD (l_conj) reduced/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) produced/VBN (r_acl) seizures/NNS (r_pobj) of/IN (r_prep) incidence/NN (r_dobj) reduced/VBD (r_conj) increased/VBD (l_dobj) interval/NN (l_prep) between/IN (l_pobj) administration/NN (l_conj) onset/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) produced/VBN (r_acl) seizures/NNS -PUNC- caffeine/NN (r_pobj) after/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) In/IN (r_prep) modify/VB (l_dobj) seizures/NNS
D000082_D064420 NONE acetaminophen/NN (r_pobj) by/IN (r_prep) Reduction/NN (l_prep) in/IN (l_pobj) toxicity/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) presence/NN (r_nsubj) reduced/VBD (l_dobj) toxicity/NN
D010433_D012640 CID pentylenetetrezol/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) alter/VB (r_conj) modify/VB (l_dobj) seizures/NNS
10526274
C056507_D064420 NONE GEM/NNP (r_nsubj) obtain/VB (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN
D002945_D002289 NONE cisplatin/NN (r_dobj) receive/VB (r_relcl) years/NNS (r_npadvmod) age/NN (l_nsubj) Gemcitabine/NNP (l_conj) vinorelbine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) carcinoma/NN -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_pcomp) to/IN (r_prep) contraindication/NN (r_pobj) with/IN (r_prep) those/DT (r_conj) NSCLC/NNP -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_pcomp) to/IN (r_prep) contraindication/NN (r_dobj) had/VBD (r_conj) were/VBD (r_conj) /=/NFP (r_punct) included/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP
D002945_D064420 NONE cisplatin/NN (r_dobj) receiving/VBG (r_pcomp) to/IN (r_prep) contraindication/NN (r_pobj) with/IN (r_prep) those/DT (r_conj) NSCLC/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN
C056507_D002289 NONE Gemcitabine/NNP (l_conj) vinorelbine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) carcinoma/NN -PUNC- GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP
C030852_D002289 NONE vinorelbine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) carcinoma/NN -PUNC- VNB/NNP (r_conj) GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP
C030852_D064420 NONE VNB/NNP (r_conj) GEM/NNP (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN
2375138
D008874_D006323 CID midazolam/RB (r_npadvmod) associated/VBN (r_amod) arrest/NN -PUNC- midazolam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) arrest/NN
D008874_D003643 NONE midazolam/RB (r_npadvmod) associated/VBN (r_amod) arrest/NN (l_conj) death/NN -PUNC- midazolam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) arrest/NN (l_conj) death/NN
8600333
C053519_D001859 NONE protocol/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) treated/VBN (r_relcl) survivors/NNS (l_prep) of/IN (l_pobj) tumors/NNS
D004317_D066126 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN
D004317_D001859 NONE doxorubicin/NN (r_pobj) including/VBG (r_prep) both/DT (r_appos) protocol/NN (r_pobj) to/IN (r_prep) according/VBG (r_prep) treated/VBN (r_relcl) survivors/NNS (l_prep) of/IN (l_pobj) tumors/NNS
9564988
D064704_D012852 NONE levofloxacin/NN (r_pobj) of/IN (r_prep) assessment/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) sinusitis/NN -PUNC- levofloxacin/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) evaluate/VB (l_prep) in/IN (l_pcomp) treating/VBG (l_prep) with/IN (l_pobj) sinusitis/NN -PUNC- levofloxacin/VBZ (r_ccomp) indicate/VBP (l_ccomp) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) sinusitis/NN
18161408
D002996_D002637 NONE CC/NN (r_dobj) received/VBN (l_conj) presented/VBD (l_prep) with/IN (l_pobj) pain/NN
D002996_D013927 NONE CC/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) be/VB (l_nsubj) Thrombosis/NN
D002996_D013923 CID CC/NN (r_pobj) with/IN (r_prep) induction/NN (r_pobj) after/IN (r_prep) reported/VBN (r_relcl) complication/NN (r_attr) is/VBZ (l_nsubj) Thromboembolism/NN
D002996_D009203 CID citrate/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) infarction/NN -PUNC- CC/NN (l_conj) infarction/NN
891050
D006493_D001002 NONE heparin/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_conj) rose/VBD (l_conj) stopped/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) anuria/NN
D003276_D006463 CID contraceptives/NNS (r_dobj) taking/VBG (r_acl) woman/NN (r_pobj) in/IN (r_prep) syndrome/NN -PUNC- contraceptives/NNS (r_dobj) taking/VBG (r_acl) woman/NN (r_pobj) in/IN (r_prep) syndrome/NN (l_appos) HUS/NNP
D004176_D001002 NONE dipyridamole/NN (r_conj) heparin/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_conj) rose/VBD (l_conj) stopped/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) anuria/NN
12483326
D016190_D064420 NONE carboplatin/NN (r_amod) toxicity/NN
D002945_D009916 NONE cisplatin/NN (r_pcomp) than/IN (r_prep) effects/NNS (r_dobj) have/VB (r_xcomp) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN
D016190_D009916 NONE carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) toxicity/NN -PUNC- carboplatin/NN (r_nsubjpass) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_dobj) case/NN (l_prep) of/IN (l_pobj) toxicity/NN
D016190_D005909 NONE carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (l_prep) for/IN (l_pobj) glioblastomas/NNS -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (l_prep) for/IN (l_pobj) glioblastomas/NNS
D016190_D005128 NONE carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) toxicity/NN -PUNC- carboplatin/NN (r_nsubjpass) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_dobj) case/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) performing/VBG (r_advcl) be/VB (l_acomp) aware/JJ (l_prep) of/IN (l_pobj) toxicity/NN
D002945_D005128 NONE cisplatin/NN (r_pcomp) than/IN (r_prep) effects/NNS (r_dobj) have/VB (r_xcomp) said/VBN (l_ccomp) known/JJ (l_auxpass) are/VBP (l_nsubj) toxicity/NN
9351491
D006220_D010302 CID haloperidol/NN (r_conj) risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) parkinsonism/NN
D018967_D010302 CID risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) parkinsonism/NN
D018967_D011618 NONE risperidone/NN (r_poss) profile/NN (r_nsubj) produce/VB (l_dobj) efficacy/NN (l_prep) for/IN (l_pobj) symptoms/NNS
17612891
D003024_D012559 NONE clozapine/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) male/NN (l_prep) with/IN (l_pobj) schizophrenia/NN
D003024_D009205 CID clozapine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) myocarditis/NN -PUNC- clozapine/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) myocarditis/NN -PUNC- clozapine/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) onset/NN (l_prep) of/IN (l_pobj) myocarditis/NN -PUNC- clozapine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complication/NN (r_attr) is/VBZ (l_nsubj) Myocarditis/NNP
D003024_D011618 NONE clozapine/NN (r_pobj) Considering/VBG (r_csubj) remains/VBZ (l_attr) standard/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) psychosis/NN
234669
D000628_D007040 NONE aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_advcl) produced/VBN (l_agent) by/IN (l_pobj) hypoventilation/NN
D002245_D014693 NONE dioxide/NN (r_conj) PO2/NNP (r_appos) oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN -PUNC- CO2/NNP (r_appos) dioxide/NN (r_conj) PO2/NNP (r_appos) oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN
D000628_D014693 CID aminophylline/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) for/IN (l_pcomp) initiating/VBG (l_dobj) fibrillation/NN -PUNC- aminophylline/NN (l_prep) on/IN (l_pobj) threshold/NN (l_compound) fibrillation/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) During/IN (r_prep) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) threshold/NN (l_compound) fibrillation/NN
C093415_D014693 NONE PO2/NNP (r_appos) oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN
D010100_D014693 NONE oxygen/NN (r_pobj) of/IN (r_prep) pressures/NNS (r_nsubjpass) kept/VBN (r_advcl) reduced/VBN (l_nsubjpass) threshold/NN (l_compound) fibrillation/NN
D000628_D001145 NONE aminophylline/NN (r_appos) agents/NNS (r_nsubj) play/VB (l_advcl) contribute/VB (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS
D000628_D012131 NONE aminophylline/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) for/IN (l_pcomp) initiating/VBG (l_prep) during/IN (l_pobj) failure/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) during/IN (l_pobj) failure/NN -PUNC- aminophylline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_advcl) produced/VBN (l_nsubjpass) failure/NN -PUNC- aminophylline/NN (r_appos) agents/NNS (r_nsubj) play/VB (l_advcl) contribute/VB (l_prep) to/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS (l_prep) in/IN (l_pobj) failure/NN
12684739
D020888_D005128 CID GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP
D020888_D019966 NONE GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN
D003042_D019966 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_pobj) on/IN (r_prep) GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN
D004298_D019966 NONE dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN -PUNC- DA/NNP (r_appos) dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN
D003042_D005128 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_pobj) on/IN (r_prep) GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) increases/NNS (r_pobj) on/IN (r_prep) GVG/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP
D004298_D005128 NONE dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP -PUNC- DA/NNP (r_appos) dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS -PUNC- DA/NNP (r_appos) dopamine/NN (r_appos) accumbens/NNS (r_oprd) explored/VBD (l_prep) Given/VBN (l_pobj) success/NN (l_prep) for/IN (l_pcomp) treating/VBG (l_dobj) abuse/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) defects/NNS (l_appos) VFD/NNP
2070391
D008012_D010146 CID lidocaine/NN (r_dobj) using/VBG (r_acl) Reduction/NN (l_prep) in/IN (l_pobj) pain/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pain/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) pH/NN (r_dobj) adjust/VB (r_relcl) solution/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) reduce/VB (l_dobj) pain/NN -PUNC- lidocaine/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) quantify/VB (l_dobj) severity/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- lidocaine/NN (r_conj) receiving/VBG (r_pcomp) after/IN (r_prep) quantify/VB (l_dobj) severity/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- lidocaine/NN (r_pobj) for/IN (r_prep) score/NN (l_compound) pain/NN -PUNC- lidocaine/NN (r_pobj) for/IN (r_prep) score/NN (r_pobj) than/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) score/NN (l_compound) pain/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) adjustment/NN (r_nsubjpass) accomplished/VBN (l_prep) in/IN (l_pobj) laboratory/NN (l_prep) before/IN (l_pobj) injection/NN (l_prep) in/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) pain/NN
17879945
D019438_D050197 CID ritonavir/VBZ (r_compound) treatment/NN (r_nsubj) increases/VBZ (l_dobj) formation/NN (l_compound) lesion/NN
10739826
D003276_D054556 CID contraceptives/NNS (l_conj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_appos) contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- OC/NNP (r_appos) contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_compound) use/NN (r_pobj) of/IN (r_prep) patterns/NNS (r_pobj) between/IN (r_prep) distinguish/VB (l_nsubj) studies/NNS (l_relcl) assessed/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- OC/NNP (r_compound) use/NN (r_pobj) of/IN (r_prep) patterns/NNS (r_pobj) between/IN (r_prep) distinguish/VB (l_nsubj) studies/NNS (l_relcl) assessed/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) for/IN (r_prep) ratio/NN (l_prep) of/IN (l_pobj) VTE/NN
10406016
C007789_D002543 NONE fucoidan/JJ (r_compound) treatment/NN (l_prep) on/IN (l_pobj) hemorrhage/NN -PUNC- fucoidan/RB (r_dobj) tested/VBD (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) hemorrhage/NN
C007789_D001925 NONE fucoidan/RB (l_relcl) reported/VBN (l_xcomp) reduce/VB (l_dobj) damage/NN
C007789_D007249 NONE Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_conj) had/VBD (l_conj) tended/VBD (l_xcomp) have/VB (l_dobj) inflammation/NN
C007789_D020141 CID Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) clotting/NN -PUNC- Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) clotting/NN (l_conj) hemodilution/NN
C007789_D006406 NONE Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_conj) had/VBD (l_dobj) hematomas/NNS -PUNC- Fucoidan/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) exhibited/VBD (l_conj) had/VBD (l_conj) tended/VBD (l_xcomp) have/VB (l_dobj) inflammation/NN (l_prep) in/IN (l_pobj) vicinity/NN (l_prep) of/IN (l_pobj) hematoma/NN
18410508
D015632_D020258 NONE MPTP/NNP (r_conj) METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (l_prep) for/IN (l_pobj) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- MPTP/NNP (r_conj) METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (r_advcl) hypothesized/VBD (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D004298_D020258 NONE DA/NNP (r_compound) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- DA/NNP (r_compound) system/NN (r_pobj) for/IN (r_prep) is/VBZ (r_advcl) hypothesized/VBD (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D004298_D009422 NONE DA/NNP (r_compound) neurons/NNS (r_pobj) of/IN (r_prep) neurodegeneration/NN -PUNC- DA/NNP (r_compound) system/NN (r_pobj) for/IN (r_prep) is/VBZ (l_nsubj) damage/NN
D015632_D009422 CID MPTP/NNP (r_npadvmod) induced/VBN (r_amod) neurodegeneration/NN -PUNC- MPTP/NNP (r_conj) METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN
D008694_D009422 CID METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) plays/VBZ (r_ccomp) hypothesized/VBD (l_advcl) is/VBZ (l_nsubj) damage/NN
D008694_D020258 NONE Methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) activation/NN (l_nmod) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (l_prep) for/IN (l_pobj) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) damage/NN (r_nsubj) is/VBZ (r_advcl) hypothesized/VBD (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) plays/VBZ (r_ccomp) hypothesized/VBD (l_advcl) is/VBZ (l_prep) for/IN (l_pobj) system/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- METH/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_conj) examined/VBN (l_prep) for/IN (l_pobj) neurotoxicity/NN -PUNC- METH/NNP (r_compound) neurotoxicity/NN
7423039
D004317_D066126 CID adriamycin/JJ (r_amod) cardiotoxicity/NN -PUNC- adriamycin/NNS (r_pobj) of/IN (r_prep) effects/NNS (l_amod) cardiotoxic/JJ
1423339
D011433_D064420 NONE propranolol/JJ (r_amod) toxicity/NN -PUNC- propranolol/JJ (r_amod) toxicity/NN
D011433_D000647 CID propranolol/JJ (r_amod) toxicity/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) syndrome/NN
D011433_D000544 NONE propranolol/JJ (r_amod) toxicity/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) developed/VBD (l_dobj) dementia/NN (l_amod) like/JJ (l_npadvmod) Alzheimer/NNP
D011433_D003704 NONE propranolol/JJ (r_amod) toxicity/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) developed/VBD (l_dobj) dementia/NN
19889778
1147734
D011441_D008107 NONE propylthiouracil/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) disease/NN
D011441_D006521 CID propylthiouracil/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hepatitis/NN
3125768
C032943_D009127 NONE metocurine/NN (r_pobj) with/IN (r_prep) abolished/VBN (l_nsubjpass) rigidity/NN
D015760_D009127 CID alfentanil/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- alfentanil/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- alfentanil/NN (r_advcl) prevented/VBN (l_nsubjpass) rigidity/NN
10910842
D000109_D001284 NONE acetylcholine/NN (r_compound) expression/NN (r_pobj) by/IN (r_prep) than/IN (r_prep) atrophy/NN
D011239_D001284 NONE Prednisolone/NNP (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (r_nsubjpass) caused/VBN (l_agent) by/IN (l_pobj) atrophy/NN
D014403_D013746 NONE tubocurarine/NN (r_pobj) of/IN (r_prep) curves/NNS (r_conj) fatigability/NN (r_conj) tensions/NNS (l_compound) tetanic/JJ
D000109_D009133 NONE acetylcholine/NN (r_compound) expression/NN (r_pobj) in/IN (r_prep) changes/NNS (r_pobj) from/IN (r_prep) less/JJR (r_advmod) derive/VB (r_conj) derive/VBP (l_prep) from/IN (l_pobj) atrophy/NN
D011239_D009133 CID prednisolone/NN (r_pobj) after/IN (r_prep) dysfunction/NN (r_nsubj) is/VBZ (l_conj) derives/VBZ (l_prep) from/IN (l_pobj) atrophy/NN
D011239_D009468 NONE prednisolone/NN (r_pobj) after/IN (r_prep) dysfunction/NN
D000109_D018908 NONE acetylcholine/NN (r_compound) expression/NN (r_pobj) by/IN (r_prep) than/IN (r_prep) atrophy/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) dysfunction/NN
D011239_D018908 CID Prednisolone/NNP (r_npadvmod) induced/VBN (r_amod) dysfunction/NN
10683478
D001058_D007035 CID Apomorphine/NNP (r_nsubjpass) selected/VBN (l_dobj) ability/NN (l_acl) induce/VB (l_dobj) hypothermia/NN -PUNC- apomorphine/NN (l_prep) as/IN (l_pobj) hypothermia/NN
D004298_D007035 NONE dopamine/NN (r_relcl) changes/NNS (r_dobj) produce/VB (r_conj) induce/VB (l_dobj) hypothermia/NN
D001058_D006948 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D018491_D007035 NONE agonist/NN (r_appos) Apomorphine/NNP (r_nsubjpass) selected/VBN (l_dobj) ability/NN (l_acl) induce/VB (l_dobj) hypothermia/NN
9098464
D012701_D006966 NONE serotonin/NN (r_compound) inhibitor/NN (r_appos) hydrochloride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- serotonin/NN (r_compound) inhibitor/NN (r_appos) Fluoxetine/NNP (r_nsubjpass) given/VBN (l_advcl) produce/VB (l_dobj) hyperprolactinemia/NN
D005473_D062788 CID hydrochloride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (r_appos) model/NN (l_prep) of/IN (l_pobj) adenomyosis/NN -PUNC- hydrochloride/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) on/IN (l_pobj) induction/NN (l_compound) adenomyosis/NN -PUNC- fluoxetine/NN (r_nsubj) caused/VBD (l_dobj) hyperprolactinemia/NN (l_conj) effects/NNS (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) adenomyosis/NN -PUNC- fluoxetine/NN (r_dobj) receiving/VBG (r_acl) group/NN (r_pobj) within/IN (r_prep) revealed/VBD (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) adenomyosis/NN
D005473_D006966 CID hydrochloride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- fluoxetine/NN (r_nsubj) caused/VBD (l_dobj) hyperprolactinemia/NN -PUNC- Fluoxetine/NNP (r_nsubjpass) given/VBN (l_advcl) produce/VB (l_dobj) hyperprolactinemia/NN
D012701_D062788 NONE serotonin/NN (r_compound) inhibitor/NN (r_appos) hydrochloride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (r_appos) model/NN (l_prep) of/IN (l_pobj) adenomyosis/NN -PUNC- serotonin/NN (r_compound) inhibitor/NN (r_appos) hydrochloride/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) on/IN (l_pobj) induction/NN (l_compound) adenomyosis/NN
11243580
D001120_D012640 NONE arginine/NN (r_conj) inhibitor/NN (r_appos) oxide/NN (r_appos) ester/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) investigated/VBN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- arginine/NN (r_compound) treatment/NN (r_nsubj) increased/VBD (l_dobj) incidence/NN (l_appos) convulsions/NNS
D019331_D012640 NONE ester/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) investigated/VBN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- NAME/NN (r_appos) ester/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) investigated/VBN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- NAME/NNP (r_nsubj) decreased/VBD (l_dobj) incidence/NN (l_appos) convulsions/NNS
D003975_D012640 NONE diazepam/NN (r_conj) NAME/NNP (r_nsubj) decreased/VBD (l_dobj) incidence/NN (l_appos) convulsions/NNS
D008012_D012640 CID lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsion/NN -PUNC- lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) incidence/NN (l_appos) convulsions/NNS -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) incidence/NN (l_appos) convulsions/NNS -PUNC- lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
D009569_D012640 NONE oxide/NN (r_appos) ester/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) investigated/VBN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- NO/NNP (r_intj) inhibitor/NN (r_appos) oxide/NN (r_appos) ester/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) investigated/VBN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- NO/JJ (r_det) precursor/NN (r_appos) oxide/NN (r_appos) ester/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) investigated/VBN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- NO/DT (r_nsubj) is/VBZ (l_attr) mediator/NN (l_prep) in/IN (l_pobj) convulsions/NNS
10721819
D001971_D001919 NONE Bromocriptine/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubj) was/VBD (l_advcl) reversed/VBN (l_prep) to/IN (l_pobj) bradycardia/NNS -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN (r_dobj) reversed/VBD (l_prep) to/IN (l_pobj) bradycardia/NNP -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) tachycardia/NN (r_nsubj) appears/VBZ (l_xcomp) predominate/VB (l_conj) mask/VB (l_dobj) bradycardia/NN
D001971_D007022 CID bromocriptine/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN -PUNC- Bromocriptine/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN
D007545_D001919 CID isoproterenol/JJ (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) was/VBD (l_advcl) reversed/VBN (l_prep) to/IN (l_pobj) bradycardia/NNS -PUNC- isoproterenol/JJ (r_compound) pretreatment/NN (r_nsubj) abolished/VBD (l_conj) reversed/VBD (l_prep) to/IN (l_pobj) bradycardia/NNP
D004298_D013610 NONE dopamine/NN (r_compound) D2/NN (r_compound) receptors/NNS (r_pobj) at/IN (r_prep) bradycardia/NN (r_dobj) mask/VB (r_conj) predominate/VB (r_xcomp) appears/VBZ (l_nsubj) tachycardia/NN
D007545_D013610 NONE isoproterenol/NN (l_prep) on/IN (l_pobj) tachycardia/NN -PUNC- isoproterenol/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) abolish/VB (l_dobj) tachycardia/NN -PUNC- isoproterenol/JJ (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) was/VBD (l_advcl) reversed/VBN (l_nsubjpass) tachycardia/NN -PUNC- isoproterenol/JJ (r_compound) pretreatment/NN (r_nsubj) abolished/VBD (l_conj) reversed/VBD (l_dobj) tachycardia/NN
D004294_D013610 NONE domperidone/NN (r_pobj) by/IN (r_agent) reduced/VBN (r_relcl) effect/NN (r_npadvmod) reversed/VBN (l_nsubjpass) tachycardia/NN
D004294_D007022 NONE domperidone/NN (r_pobj) by/IN (r_agent) reduced/VBN (r_relcl) effect/NN (r_npadvmod) reversed/VBN (r_advcl) was/VBD (l_nsubj) hypotension/NN
D007545_D007022 NONE isoproterenol/JJ (r_compound) pretreatment/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) was/VBD (l_nsubj) hypotension/NN
D004298_D001919 NONE dopamine/NN (r_compound) D2/NN (r_compound) receptors/NNS (r_pobj) at/IN (r_prep) bradycardia/NN
D004294_D001919 CID domperidone/NN (r_pobj) by/IN (r_agent) reduced/VBN (r_relcl) effect/NN (r_npadvmod) reversed/VBN (l_prep) to/IN (l_pobj) bradycardia/NNS
D001971_D013610 CID bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_nsubj) induced/VBD (l_dobj) hypotension/NN (l_conj) tachycardia/NN -PUNC- Bromocriptine/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubj) was/VBD (l_advcl) reversed/VBN (l_nsubjpass) tachycardia/NN -PUNC- bromocriptine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) tachycardia/NN
D007545_D006332 CID Isoproterenol/JJ (r_compound) pretreatment/NN (r_nsubj) caused/VBD (l_dobj) hypertrophy/NN
15275829
D000109_D012640 NONE acetylcholine/NN (r_compound) subunits/NNS (r_nsubj) are/VBP (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- acetylcholine/NN (r_compound) receptors/NNS (r_pobj) to/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS
D009538_D006948 NONE nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_conj) hypolocomotion/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) in/IN (r_prep) subunits/NNS (l_conj) hypolocomotion/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_conj) hypolocomotion/NN
D000109_D006948 NONE acetylcholine/NN (r_compound) subunits/NNS (r_nsubj) are/VBP (l_prep) for/IN (l_pobj) seizures/NNS (l_conj) hypolocomotion/NN
D000109_D014202 NONE acetylcholine/NN (r_compound) receptors/NNS (r_pobj) to/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) from/IN (l_pobj) exploration/NN (l_conj) sedation/NN (l_conj) tremors/NNS
D000109_D003643 NONE acetylcholine/NN (r_compound) receptors/NNS (r_pobj) to/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS (l_conj) death/NN
D009538_D012640 CID nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) were/VBD (l_advcl) measured/VBN (l_conj) measured/VBN (l_prep) as/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D009538_D014202 NONE nicotine/NN (r_pobj) of/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) from/IN (l_pobj) exploration/NN (l_conj) sedation/NN (l_conj) tremors/NNS
D009538_D003643 NONE nicotine/NN (r_pobj) of/IN (r_prep) Binding/NN (r_nsubj) elicits/VBZ (l_dobj) series/NN (l_prep) of/IN (l_pobj) behaviors/NNS (l_relcl) go/VBP (l_prep) to/IN (l_pobj) seizures/NNS (l_conj) death/NN
8473723
D016666_D012640 CID fluvoxamine/NN (r_compound) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Seizures/NNS -PUNC- fluvoxamine/NN (r_nmod) seizures/NNS
D008728_D012640 CID levomepromazine/JJ (r_amod) fluvoxamine/NN (r_compound) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Seizures/NNS -PUNC- levomepromazine/JJ (r_amod) fluvoxamine/NN (r_nmod) seizures/NNS
9549528
D007980_D004409 CID dopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- dopa/NN (r_compound) medication/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) groups/NNS (r_pobj) of/IN (r_prep) cortex/NN (r_pobj) in/IN (r_prep) execution/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) changes/NNS (r_conj) flow/NN (r_dobj) studied/VBN (l_conj) induced/VBD (l_dobj) dyskinesia/NN -PUNC- dopa/NN (r_compound) medication/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) groups/NNS (r_pobj) of/IN (r_prep) cortex/NN (r_pobj) in/IN (r_prep) execution/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) changes/NNS (r_conj) flow/NN (r_dobj) studied/VBN (l_conj) induced/VBD (l_dobj) dyskinesia/NN (l_conj) other/JJ (l_prep) with/IN (l_pobj) dyskinesia/NN -PUNC- dopa/NN (r_pobj) without/IN (r_prep) one/NN (r_nsubj) induced/VBD (l_dobj) dyskinesia/NN -PUNC- dopa/NN (r_pobj) without/IN (r_prep) one/NN (r_nsubj) induced/VBD (l_dobj) dyskinesia/NN (l_conj) other/JJ (l_prep) with/IN (l_pobj) dyskinesia/NN -PUNC- dopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_pobj) like/IN (r_prep) movement/NN -PUNC- dopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN
D007980_D020734 NONE dopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_pobj) with/IN (r_prep) patients/NNS (l_amod) parkinsonian/JJ -PUNC- dopa/NN (r_compound) medication/NN (r_pobj) on/IN (r_prep) patients/NNS (l_amod) parkinsonian/JJ -PUNC- dopa/NN (r_pobj) without/IN (r_prep) one/NN (r_nsubj) induced/VBD (r_conj) studied/VBN (l_dobj) flow/NN (l_conj) changes/NNS (l_acl) induced/VBN (l_agent) by/IN (l_pobj) execution/NN (l_prep) in/IN (l_pobj) cortex/NN (l_prep) of/IN (l_pobj) groups/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_amod) parkinsonian/JJ
D007980_D006948 NONE dopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_pobj) like/IN (r_prep) movement/NN (l_amod) hyperkinetic/JJ
10706004
D012964_D006973 NONE sodium/NN (r_nmod) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (r_pobj) of/IN (r_prep) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- sodium/NN (r_compound) level/NN (r_pobj) of/IN (r_prep) elevation/NN (r_nsubjpass) documented/VBN (l_prep) In/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- Na+/NNP (r_pobj) of/IN (r_prep) transport/NN (r_pobj) in/IN (r_prep) disturbances/NNS (r_pobj) of/IN (r_prep) basis/NN (r_dobj) assess/VB (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- Na/NNP (r_npadvmod) increased/VBD (r_parataxis) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN -PUNC- Na+-extrusion/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_acl) hypertension/NN -PUNC- Na+-binding/NN (r_compound) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (r_acl) hypertension/NN -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (r_acl) hypertension/NN
D011188_D006973 NONE K)-ATPase/NNP (r_pobj) of/IN (r_prep) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- K)-ATPase/NNP (r_nsubj) increased/VBD (r_parataxis) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN -PUNC- K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (r_acl) hypertension/NN
D009569_D006973 CID oxide/NN (r_npadvmod) deficient/JJ (r_amod) hypertension/NN -PUNC- NO/DT (r_det) synthesis/NN (r_pobj) of/IN (r_prep) Inhibition/NN (r_nsubj) induces/VBZ (l_dobj) hypertension/NN -PUNC- NO/JJ (r_npadvmod) deficient/JJ (r_amod) hypertension/NN -PUNC- NO/JJ (r_compound) synthase/NN (r_compound) inhibition/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- NO/JJ (r_compound) synthase/NN (r_pobj) of/IN (r_prep) Inhibition/NN (r_nsubj) induced/VBD (l_dobj) hypertension/NN
D009569_D003866 NONE NO/JJ (r_compound) synthase/NN (r_pobj) of/IN (r_prep) Inhibition/NN (r_nsubj) induced/VBD (l_dobj) hypertension/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ
D011188_D003866 NONE K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ
D019331_D006973 NONE ester/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) inhibition/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- NAME/NNP (r_appos) ester/NN (r_appos) kg/NNS (r_pobj) with/IN (r_prep) inhibition/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) studied/VBD (l_dobj) response/NN (l_prep) of/IN (l_pobj) K)-ATPase/NNP (l_prep) to/IN (l_pobj) hypertension/NN
D000255_D006973 NONE ATP/NNP (r_conj) sodium/NN (r_nmod) affinities/NNS (r_pobj) of/IN (r_prep) Changes/NNS (l_prep) during/IN (l_conj) after/IN (l_pobj) hypertension/NN -PUNC- ATP/NNP (r_npadvmod) binding/VBG (r_amod) site/NN (r_pobj) of/IN (r_prep) affinity/NN (r_pobj) due/IN (r_prep) increased/VBD (r_parataxis) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN -PUNC- ATP/NNP (r_pobj) for/IN (r_prep) value/NN (r_pobj) from/IN (r_prep) revealed/VBN (r_advcl) activity/NN (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hypertension/NN
D012964_D003866 NONE Na+-extrusion/NN (l_amod) depressed/JJ -PUNC- Na+-binding/NN (r_compound) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ -PUNC- Na/UH (r_nmod) K)-ATPase/NNP (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) accompanied/VBN (l_agent) by/IN (l_pobj) Na+-extrusion/NN (l_amod) depressed/JJ
19940105
C507346_D010300 NONE AMN082/NNP (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) PD/NNP -PUNC- AMN082/NNP (r_nsubj) reverses/VBZ (l_prep) In/IN (l_pobj) task/NN (l_acl) used/VBN (l_xcomp) evaluate/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_compound) PD/NNP -PUNC- AMN082/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) have/VBP (l_dobj) effect/NN (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) PD/NNP
D016627_D010300 NONE 6-OHDA/CD (r_advmod) lesioned/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) cue/NN (r_pobj) to/IN (r_prep) respond/VB (r_xcomp) reverses/VBZ (l_prep) In/IN (l_pobj) task/NN (l_acl) used/VBN (l_xcomp) evaluate/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_compound) PD/NNP
C507346_D018476 NONE AMN082/NNP (r_nsubj) reverses/VBZ (l_prep) In/IN (l_pobj) task/NN (l_acl) used/VBN (l_xcomp) evaluate/VB (l_dobj) symptoms/NNS (l_amod) akinetic/JJ
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
C507346_D002375 NONE AMN082/NNP (r_pobj) of/IN (r_prep) administration/NN (r_dobj) intrastriatal/JJ (r_csubj) reverses/VBZ (l_dobj) catalepsy/NN -PUNC- AMN082/NNP (r_nsubj) reduces/VBZ (l_dobj) duration/NN (l_prep) of/IN (l_pobj) catalepsy/NN
D016627_D018476 NONE 6-OHDA/CD (r_advmod) lesioned/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) cue/NN (r_pobj) to/IN (r_prep) respond/VB (r_xcomp) reverses/VBZ (l_prep) In/IN (l_pobj) task/NN (l_acl) used/VBN (l_xcomp) evaluate/VB (l_dobj) symptoms/NNS (l_amod) akinetic/JJ
D018698_D010300 NONE glutamate/NN (r_nmod) subtype/NN (r_nsubj) modulates/VBZ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) disease/NN -PUNC- glutamate/NN (r_nmod) receptors/NNS (r_nsubj) modulate/VBP (l_conj) represent/VBP (l_dobj) targets/NNS (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- glutamate/NN (r_nmod) receptors/NNS (r_nsubj) modulate/VBP (l_conj) represent/VBP (l_dobj) targets/NNS (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) PD/NNP
2893236
D018698_D012131 NONE glutamate/NN (r_pobj) in/IN (r_prep) decrease/NN (r_conj) increase/NN (r_pobj) with/IN (r_prep) arrest/NN
D005680_D012133 NONE GABA/NNP (r_compound) involvement/NN (r_nsubj) induced/VBN (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) paralysis/NN -PUNC- GABA/NNP (r_conj) glutamate/NN (r_conj) paralysis/NN -PUNC- GABA/NNP (r_dobj) involves/VBZ (r_conj) reverses/VBZ (l_dobj) paralysis/NN
D018698_D012133 NONE glutamate/NN (r_conj) paralysis/NN
D009270_D012133 NONE naloxone/NN (r_pobj) in/IN (r_prep) involvement/NN (r_nsubj) induced/VBN (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) paralysis/NN -PUNC- naloxone/NN (r_nsubj) reversed/VBD (l_dobj) paralysis/NN -PUNC- Naloxone/NN (r_nsubj) reversed/VBD (l_dobj) paralysis/NN -PUNC- naloxone/NN (r_nsubj) reverses/VBZ (l_dobj) paralysis/NN
D005680_D012131 NONE GABA/NNP (r_pobj) in/IN (r_prep) increase/NN (r_pobj) with/IN (r_prep) arrest/NN
D013874_D012131 NONE thiopental/NN (r_npadvmod) produced/VBD (r_amod) arrest/NN
D013874_D012133 CID thiopental/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) paralysis/NN -PUNC- thiopental/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) paralysis/NN -PUNC- thiopental/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) paralysis/NN
D000596_D012131 NONE acids/NNS (r_pobj) of/IN (r_prep) any/DT (r_dobj) affecting/VBG (r_pcomp) without/IN (r_prep) stem/NN (l_nsubj) arrest/NN
20558148
D016291_D002375 NONE MK-801/NNP (r_punct) microl/NN (r_dobj) challenged/VBN (l_nsubjpass) catalepsy/NN -PUNC- MK-801/NNP (r_punct) and/CC (r_cc) microinjection/NN (r_dobj) showed/VBD (l_ccomp) attenuated/VBD (l_dobj) catalepsy/NN
D000596_D002375 NONE acid/NN (r_npadvmod) mediated/VBN (r_amod) mechanisms/NNS (r_pobj) of/IN (r_prep) influence/NN (l_prep) on/IN (l_pobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_appos) blocker/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- Haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) to/IN (r_prep) previous/JJ (r_amod) AP7/RB (r_conj) microinjection/NN (r_dobj) showed/VBD (l_ccomp) attenuated/VBD (l_dobj) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
C031231_D002375 NONE AP7/RB (r_conj) microl/NN (r_dobj) challenged/VBN (l_nsubjpass) catalepsy/NN -PUNC- AP7/RB (r_conj) microinjection/NN (r_dobj) showed/VBD (l_ccomp) attenuated/VBD (l_dobj) catalepsy/NN
D018698_D002375 NONE glutamate/NN (r_compound) antagonists/NNS (r_pobj) of/IN (r_prep) microinjections/NNS (r_pobj) with/IN (r_prep) challenged/VBN (l_nsubjpass) catalepsy/NN -PUNC- glutamate/NN (r_npadvmod) mediated/VBN (r_amod) mechanisms/NNS (l_prep) in/IN (l_pobj) circuits/NNS (l_prep) at/IN (l_pobj) catalepsy/NN
D016202_D002375 NONE NMDA/NNP (r_compound) receptors/NNS (r_pobj) by/IN (r_agent) mediated/VBN (r_acl) neurotransmission/NN (r_nsubj) modulate/VB (l_dobj) catalepsy/NN -PUNC- NMDA/NNP (r_compound) receptor/NN (r_compound) antagonists/NNS (r_pobj) of/IN (r_prep) microinjections/NNS (r_pobj) with/IN (r_prep) challenged/VBN (l_nsubjpass) catalepsy/NN -PUNC- NMDA/NNP (r_compound) receptor/NN (r_pobj) of/IN (r_prep) microl/NN (r_dobj) challenged/VBN (l_nsubjpass) catalepsy/NN -PUNC- aspartate/NNP (r_nmod) NMDA/NNP (r_appos) receptor/NN (r_pobj) of/IN (r_prep) microl/NN (r_dobj) challenged/VBN (l_nsubjpass) catalepsy/NN -PUNC- NMDA/NNP (r_appos) receptor/NN (r_pobj) of/IN (r_prep) microl/NN (r_dobj) challenged/VBN (l_nsubjpass) catalepsy/NN
D004298_D002375 NONE dopamine/NN (r_compound) receptor/NN (r_compound) blocker/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
4008111
D000638_D012848 CID Amiodarone/NN (r_npadvmod) induced/VBN (r_amod) block/NN -PUNC- amiodarone/NN (r_compound) administration/NN (r_pobj) due/JJ (r_prep) observed/VBD (l_dobj) block/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) dosage/NN (r_pobj) in/IN (r_prep) Reduction/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) disappearance/NN (l_prep) of/IN (l_pobj) block/NN
D000638_D013617 NONE amiodarone/NN (r_compound) administration/NN (r_pobj) due/JJ (r_prep) observed/VBD (l_dobj) syndrome/NN (l_conj) tachycardia/NN
D000638_D009202 NONE amiodarone/NN (r_compound) administration/NN (l_prep) in/IN (l_pobj) boy/NN (l_prep) with/IN (l_pobj) cardiomyopathy/NN
D000638_D014927 NONE amiodarone/NN (r_compound) administration/NN (r_pobj) due/JJ (r_prep) observed/VBD (l_dobj) syndrome/NN
D000638_D012804 NONE amiodarone/NN (r_pobj) of/IN (r_prep) dosage/NN (r_pobj) in/IN (r_prep) Reduction/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) disappearance/NN (l_conj) persistence/NN (l_prep) of/IN (l_pobj) bradycardia/NNP
11858397
D020117_D016171 CID cisapride/RB (r_nsubjpass) given/VBN (r_advcl) developed/VBD (l_dobj) pointes/FW
D008787_D002037 NONE metoclopramide/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) with/IN (l_pobj) block/NN -PUNC- metoclopramide/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) block/NN
D004917_D016171 CID erythromycin/NNP (r_conj) cisapride/RB (r_nsubjpass) given/VBN (r_advcl) developed/VBD (l_dobj) pointes/FW
D008787_D016171 CID metoclopramide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) pointes/NNS -PUNC- metoclopramide/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) pointes/NNS -PUNC- metoclopramide/NN (r_nsubj) provokes/VBZ (l_dobj) pointes/FW -PUNC- Metoclopramide/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) pointes/FW
11587867
D014750_-1 NONE vincristine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) areas/NNS (r_pobj) in/IN (r_prep) transformation/NN
D014750_D054198 NONE vincristine/NN (r_compound) instillation/NN (l_prep) in/IN (l_pobj) girl/NN (l_prep) with/IN (l_pobj) leucemia/NN -PUNC- vincristine/NN (r_compound) instillation/NN (l_prep) in/IN (l_pobj) girl/NN (l_prep) with/IN (l_pobj) leucemia/NN (l_conj) man/NN (l_prep) with/IN (l_pobj) lymphoma/NN
D014750_D003711 CID vincristine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) areas/NNS (r_pobj) in/IN (r_prep) transformation/NN (r_conj) degeneration/NN (l_prep) of/IN (l_pobj) myelin/NN (l_conj) axons/NNS
D014750_D001927 NONE vincristin/NN (r_compound) administration/NN (r_pobj) due/IN (r_prep) myeloencephalopathy/NN
D014750_D009410 CID vincristine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) areas/NNS (r_pobj) in/IN (r_prep) transformation/NN (r_conj) degeneration/NN (l_prep) of/IN (l_pobj) myelin/NN (l_conj) axons/NNS
18703024
D016291_D002375 NONE MK-801-induced/JJ (r_compound) locomotion/NN (r_conj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
12041669
D010396_D000741 CID penicillamine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- penicillamine/NN (r_compound) therapy/NN (r_nsubjpass) described/VBN (l_nsubjpass) patient/NN (l_relcl) received/VBD (l_prep) for/IN (l_pobj) anemia/NN -PUNC- penicillamine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN
D000961_D000741 NONE globulin/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- globulin/NN (r_compound) therapy/NN (r_dobj) received/VBD (l_prep) for/IN (l_pobj) anemia/NN -PUNC- globulin/NN (r_dobj) Use/NN (r_nsubj) be/VB (l_attr) treatment/NN (l_prep) of/IN (l_pobj) anemia/NN
1749407
D003042_D013927 NONE cocaine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) thrombotic/JJ
D003042_D009203 CID Cocaine/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- cocaine/NN (r_nsubj) result/VB (l_prep) in/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) demand/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) infarction/NN
D003042_D013035 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) vasoconstriction/NN (r_pobj) of/IN (r_prep) locus/NN (r_nsubj) remains/VBZ (r_conj) are/VBP (l_prep) With/IN (l_pobj) regard/NN (l_prep) to/IN (l_pobj) spasm/NN
D010100_D009203 NONE oxygen/NN (r_compound) demand/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) infarction/NN
20510337
D002945_D009336 NONE cisplatin/JJ (r_amod) administration/NN (r_pobj) from/IN (r_prep) resulted/VBD (r_advcl) attenuated/VBD (r_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) necrosis/NN
D012643_D009336 NONE selenium/NN (r_nmod) ions/NNS (r_pobj) of/IN (r_prep) reductions/NNS (r_dobj) attenuated/VBD (r_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) necrosis/NN
D002945_D058186 CID cisplatin/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) investigated/VBN (l_prep) in/IN (l_pobj) mice/NNS (l_prep) with/IN (l_pobj) injury/NN
D002945_D007674 NONE cisplatin/NN (r_amod) nephrotoxicity/NN -PUNC- cisplatin/NN (r_pobj) by/IN (r_agent) mediated/VBN (r_acl) damage/NN -PUNC- cisplatin/NN (r_amod) nephrotoxicity/NN
D015032_D009336 NONE zinc/NN (r_conj) selenium/NN (r_nmod) ions/NNS (r_pobj) of/IN (r_prep) reductions/NNS (r_dobj) attenuated/VBD (r_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) necrosis/NN
D005978_D009369 NONE glutathione/NN (r_compound) level/NN (r_dobj) compensated/VBD (l_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) tumor/NN
C024989_D009336 NONE Q10/NNP (r_nsubj) compensated/VBD (l_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) necrosis/NN
D002945_D009369 NONE cisplatin/JJ (r_amod) administration/NN (r_pobj) from/IN (r_prep) resulted/VBD (r_advcl) attenuated/VBD (r_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) tumor/NN
D009569_D009336 NONE oxide/NN (r_conj) alpha/NN (r_appos) factor/NN (l_compound) necrosis/NN
D013481_D009369 NONE superoxide/NN (r_amod) activity/NN (r_conj) level/NN (r_dobj) compensated/VBD (l_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) tumor/NN
C024989_D007674 NONE Q10/NNP (r_compound) treatment/NN (r_nsubj) ameliorates/VBZ (l_dobj) nephrotoxicity/NN -PUNC- Q10/NNP (r_compound) treatment/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (l_nsubjpass) damage/NN -PUNC- Q10/NNP (r_nsubj) represents/VBZ (l_dobj) option/NN (l_acl) protect/VB (l_prep) against/IN (l_pobj) nephrotoxicity/NN
D005978_D009336 NONE glutathione/NN (r_compound) level/NN (r_dobj) compensated/VBD (l_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) necrosis/NN
C024989_D058186 NONE Q10/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) investigated/VBN (l_prep) in/IN (l_pobj) mice/NNS (l_prep) with/IN (l_pobj) injury/NN
D012643_D009369 NONE selenium/NN (r_nmod) ions/NNS (r_pobj) of/IN (r_prep) reductions/NNS (r_dobj) attenuated/VBD (r_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) tumor/NN
D010984_D009336 NONE platinum/NN (r_compound) ion/NN (r_compound) concentration/NN (r_conj) oxide/NN (r_conj) alpha/NN (r_appos) factor/NN (l_compound) necrosis/NN
C024989_D009369 NONE Q10/NNP (r_nsubj) compensated/VBD (l_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) tumor/NN
D015032_D009369 NONE zinc/NN (r_conj) selenium/NN (r_nmod) ions/NNS (r_pobj) of/IN (r_prep) reductions/NNS (r_dobj) attenuated/VBD (r_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) tumor/NN
D013481_D009336 NONE superoxide/NN (r_amod) activity/NN (r_conj) level/NN (r_dobj) compensated/VBD (l_conj) decreased/VBD (l_dobj) elevations/NNS (l_prep) of/IN (l_pobj) factor/NN (l_compound) necrosis/NN
D009569_D009369 NONE oxide/NN (r_conj) alpha/NN (r_appos) factor/NN (l_compound) tumor/NN
D010984_D009369 NONE platinum/NN (r_compound) ion/NN (r_compound) concentration/NN (r_conj) oxide/NN (r_conj) alpha/NN (r_appos) factor/NN (l_compound) tumor/NN
8742498
D000431_D056486 CID ethanol/NN (r_compound) consumption/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) evaluates/VBZ (r_conj) acts/VBZ (l_prep) in/IN (l_pobj) mice/NNS (l_prep) with/IN (l_pobj) hepatitis/NN -PUNC- ethanol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) exacerbation/NN (r_pobj) unlike/IN (r_prep) inhibited/VBN (l_nsubjpass) damage/NN -PUNC- ethanol/NN (r_pobj) by/IN (r_prep) %/NN (r_pobj) by/IN (r_agent) inhibited/VBN (l_nsubjpass) damage/NN -PUNC- ethanol/NN (r_nmod) mice/NNS (r_pobj) to/IN (r_dative) given/VBN (r_advcl) observed/VBN (l_nsubjpass) reduction/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ethanol/NN (r_pobj) by/IN (r_prep) exacerbation/NN (r_conj) hepatitis/NN
D018698_D056486 NONE glutamate/NN (r_compound) oxaloacetate/NN (r_compound) transaminase/NN (r_pobj) of/IN (r_prep) activities/NNS (r_pobj) as/IN (r_prep) quantified/VBN (l_nsubjpass) injuries/NNS -PUNC- glutamate/NN (r_npadvmod) pyruvate/NN (r_compound) transaminase/NN (r_conj) transaminase/NN (r_pobj) of/IN (r_prep) activities/NNS (r_pobj) as/IN (r_prep) quantified/VBN (l_nsubjpass) injuries/NNS
D062907_D056486 NONE oxaloacetate/NN (r_compound) transaminase/NN (r_pobj) of/IN (r_prep) activities/NNS (r_pobj) as/IN (r_prep) quantified/VBN (l_nsubjpass) injuries/NNS
D000082_D056486 CID acetaminophen/NN (r_pobj) on/IN (l_pobj) hepatotoxicity/NN -PUNC- acetaminophen/NN (r_pobj) from/IN (r_prep) suffering/VBG (r_pcomp) on/IN (r_prep) inhibitor/NN (r_appos) amide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) demonstrated/VBD (l_npadvmod) AAP)-hepatitis/NNP -PUNC- acetaminophen/NN (r_pobj) from/IN (r_prep) suffering/VBG (r_pcomp) on/IN (r_prep) inhibitor/NN (r_appos) amide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) demonstrated/VBD (l_advcl) suggesting/VBG (l_ccomp) involves/VBZ (l_nsubj) injury/NN -PUNC- AAP)-hepatitis/NNP -PUNC- AAP)-hepatitis/NNP (r_npadvmod) demonstrated/VBD (l_advcl) suggesting/VBG (l_ccomp) involves/VBZ (l_nsubj) injury/NN -PUNC- AAP/NNP (r_npadvmod) induced/VBN (r_amod) injury/NN (r_nsubj) involves/VBZ (r_ccomp) suggesting/VBG (r_advcl) demonstrated/VBD (l_npadvmod) AAP)-hepatitis/NNP -PUNC- AAP/NNP (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- AAP/NNP (r_compound) hepatitis/NN -PUNC- AAP/NNP (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) measured/VBN (l_conj) inhibited/VBN (l_nsubjpass) damage/NN -PUNC- AAP/NNP (r_compound) mice/NNS (r_pobj) to/IN (r_dative) given/VBN (r_advcl) observed/VBN (l_nsubjpass) reduction/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- AAP/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) preparations/NNS (r_pobj) in/IN (r_prep) use/NN (r_pobj) for/IN (r_prep) as/IN (r_prep) see/VBP (l_prep) in/IN (l_pobj) order/NN (l_acl) avoid/VB (l_dobj) damage/NN
D011064_D056486 NONE )/-RRB- (r_punct) polymerase/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) amide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) demonstrated/VBD (l_npadvmod) AAP)-hepatitis/NNP -PUNC- )/-RRB- (r_punct) polymerase/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) amide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) demonstrated/VBD (l_advcl) suggesting/VBG (l_ccomp) involves/VBZ (l_nsubj) injury/NN
D009243_D056486 NONE NAD/NNP (r_compound) precursors/NNS (r_pobj) of/IN (r_prep) free/JJ (l_prep) on/IN (l_pobj) hepatotoxicity/NN -PUNC- NAD/NNP (l_appos) substrate/NN (l_relcl) acts/VBZ (l_prep) in/IN (l_pobj) mice/NNS (l_prep) with/IN (l_pobj) hepatitis/NN -PUNC- NAD/NNP (r_appos) substrate/NN (r_pobj) of/IN (r_prep) depletion/NN (r_pobj) by/IN (r_conj) by/IN (r_prep) inhibition/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_nsubjpass) hepatitis/NN
D019289_D056486 NONE pyruvate/NN (r_compound) transaminase/NN (r_conj) transaminase/NN (r_pobj) of/IN (r_prep) activities/NNS (r_pobj) as/IN (r_prep) quantified/VBN (l_nsubjpass) injuries/NNS
D009536_D056486 NONE amide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) demonstrated/VBD (l_npadvmod) AAP)-hepatitis/NNP -PUNC- amide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) demonstrated/VBD (l_advcl) suggesting/VBG (l_ccomp) involves/VBZ (l_nsubj) injury/NN -PUNC- NAA/NNP (r_nsubjpass) given/VBN (r_advcl) observed/VBN (l_nsubjpass) reduction/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- NAA/NNP (r_pobj) by/IN (r_prep) inhibition/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_nsubjpass) hepatitis/NN -PUNC- NAA/NNP (r_pobj) of/IN (r_prep) application/NN (r_dobj) see/VBP (l_prep) in/IN (l_pobj) order/NN (l_acl) avoid/VB (l_dobj) damage/NN
20098969
D008694_-1 NONE methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN (l_conj) caries/NNS (l_appos) mouth/NN -PUNC- methamphetamines/NNS (r_dobj) abusing/VBG (r_relcl) patients/NNS (r_dobj) manage/VBP (r_conj) recognize/VBP (r_ccomp) help/VB (r_advcl) presented/VBN (l_nsubjpass) case/NN (l_acl) showing/VBG (l_dobj) manifestations/NNS (l_prep) of/IN (l_pobj) mouth/NN
D008694_D003731 CID methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN (l_conj) caries/NNS -PUNC- methamphetamine/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) reported/VBD (l_conj) experienced/VBN (l_dobj) episodes/NNS
D008694_D014987 NONE methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN
D008694_D006212 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS (l_conj) hypertension/NN (l_conj) hallucinations/NNS
D008694_D001523 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS (l_conj) hypertension/NN (l_conj) hallucinations/NNS (l_conj) behavior/NN
D008694_D001145 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS
D008694_D006973 NONE Methamphetamine/NN (r_nsubj) is/VBZ (l_attr) stimulant/NN (l_relcl) increases/VBZ (l_conj) produce/VB (l_dobj) effects/NNS (l_prep) as/IN (l_pobj) dysrhythmias/NNS (l_conj) hypertension/NN
D008694_D057085 NONE methamphetamine/NN (r_dobj) abusing/VBG (r_acl) patients/NNS (r_nsubj) present/VB (l_prep) with/IN (l_pobj) hygiene/NN (l_conj) xerostomia/NN (l_conj) caries/NNS (l_conj) wear/NN
15009014
D001285_D006940 NONE atropine/NN (r_pobj) by/IN (r_agent) abolished/VBN (l_nsubjpass) increases/NNS (l_prep) in/IN (l_pobj) flow/NN
D002211_D006940 CID Capsaicin/NNS (r_nsubj) applied/VBN (l_conj) induced/VBN (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) flow/NN
85485
C012282_D006528 NONE chlorophenoxyisobutyrate/NN (r_appos) alpha/NN (r_appos) ethyl/NN (r_pobj) to/IN (r_prep) respond/VB (l_advcl) were/VBD (l_nsubj) most/JJS (l_prep) of/IN (l_pobj) hepatomas/NNS
D001556_D017093 NONE hexachloride/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Peroxisomes/NNS (l_prep) in/IN (l_pobj) lesions/NNS
D001556_D006528 CID hexachloride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Changes/NNS (l_prep) in/IN (l_pobj) peroxisomes/NNS (l_prep) in/IN (l_pobj) liver/NN (l_conj) hepatoma/NN -PUNC- hexachloride/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Peroxisomes/NNS (l_prep) in/IN (l_pobj) hepatomas/NNS
C012282_D009369 NONE chlorophenoxyisobutyrate/NN (r_appos) alpha/NN (r_appos) ethyl/NN (r_pobj) to/IN (r_prep) respond/VB (l_advcl) were/VBD (l_attr) tumors/NNS -PUNC- chlorophenoxyisobutyrate/NN (r_appos) alpha/NN (r_appos) ethyl/NN (r_pobj) to/IN (r_prep) respond/VB (l_nsubj) cells/NNS (l_compound) tumor/NN
2422478
D015116_D007022 NONE 5,7-dihydroxytryptamine/CD (r_appos) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_dobj) hypotension/NN -PUNC- 5,7-DHT/NNP (r_appos) 5,7-dihydroxytryptamine/CD (r_appos) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_dobj) hypotension/NN -PUNC- 5,7-DHT/CD (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) affect/VB (l_dobj) hypotension/NN
D008750_D007022 CID methyldopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ -PUNC- methyldopa/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_nsubj) elicits/VBZ (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- methyldopa/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_conj) rats/NNS (r_pobj) In/IN (r_prep) caused/VBD (l_dobj) hypotension/NN -PUNC- methyldopa/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- methyldopa/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_dobj) mediate/VBP (r_relcl) cells/NNS (r_pobj) unlike/IN (r_prep) contribute/VB (l_prep) to/IN (l_pobj) action/NN (l_amod) hypotensive/JJ -PUNC- methyldopa/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) to/IN (r_prep) contribute/VB (l_prep) unlike/IN (l_pobj) cells/NNS (l_relcl) mediate/VBP (l_dobj) hypotension/NN -PUNC- methyldopa/NN (r_pobj) of/IN (r_prep) action/NN (l_amod) hypotensive/JJ
D015116_D006973 NONE 5,7-dihydroxytryptamine/CD (r_appos) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- 5,7-DHT/NNP (r_appos) 5,7-dihydroxytryptamine/CD (r_appos) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D012701_D020521 NONE serotonin/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) area/NN (r_pobj) into/IN (r_prep) microinjection/NN (r_conj) rats/NNS (l_amod) prone/JJ (l_npadvmod) stroke/NN -PUNC- serotonin/NN (r_compound) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_amod) prone/JJ (l_npadvmod) stroke/NN
D012701_D007022 NONE serotonin/NN (r_compound) nerves/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) effect/NN (l_amod) hypotensive/JJ -PUNC- serotonin/NN (r_compound) neurons/NNS (r_pobj) of/IN (r_prep) cells/NNS (r_pobj) onto/IN (r_prep) microinjection/NN (r_nsubj) elicits/VBZ (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- serotonin/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) area/NN (r_pobj) into/IN (r_prep) microinjection/NN (r_conj) rats/NNS (r_pobj) In/IN (r_prep) caused/VBD (l_dobj) hypotension/NN -PUNC- serotonin/NN (r_compound) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_dobj) hypotension/NN -PUNC- serotonin/NN (r_compound) projections/NNS (r_dobj) descending/VBG (r_pcomp) of/IN (r_prep) lesion/NN (r_dobj) produce/VB (r_relcl) injection/NN (r_nsubj) affect/VB (l_dobj) hypotension/NN -PUNC- serotonin/NN (r_compound) cells/NNS (r_nsubj) contribute/VB (l_prep) unlike/IN (l_pobj) cells/NNS (l_relcl) mediate/VBP (l_dobj) hypotension/NN -PUNC- serotonin/NN (r_compound) cells/NNS (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) action/NN (l_amod) hypotensive/JJ
D012701_D006973 NONE serotonin/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) area/NN (r_pobj) into/IN (r_prep) microinjection/NN (r_conj) rats/NNS (l_amod) hypertensive/JJ -PUNC- serotonin/NN (r_compound) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D015116_D020521 NONE 5,7-dihydroxytryptamine/CD (r_appos) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_amod) prone/JJ (l_npadvmod) stroke/NN -PUNC- 5,7-DHT/NNP (r_appos) 5,7-dihydroxytryptamine/CD (r_appos) neurotoxin/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_conj) caused/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_amod) prone/JJ (l_npadvmod) stroke/NN
D008750_D020521 NONE methyldopa/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_conj) rats/NNS (l_amod) prone/JJ (l_npadvmod) stroke/NN
D008750_D006973 NONE methyldopa/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_conj) rats/NNS (l_amod) hypertensive/JJ
7862923
D003024_D012559 NONE clozapine/NN (r_conj) chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) schizophrenic/JJ
D002220_D019965 NONE Carbamazepine/NNP (r_nsubjpass) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) psychotic/JJ
D002220_D012559 NONE Carbamazepine/NNP (r_nsubjpass) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ
D006220_D019965 NONE haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) psychotic/JJ
D002746_D012559 NONE chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) schizophrenic/JJ
D002746_D019965 NONE chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) psychotic/JJ
D003024_D019965 NONE clozapine/NN (r_conj) chlorpromazine/NN (r_conj) haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) psychotic/JJ
D006220_D012559 NONE haloperidol/NN (r_dobj) using/VBG (r_acl) patients/NNS (l_amod) schizophrenic/JJ
C036006_D019965 NONE oxcarbazepine/NN (r_pobj) to/IN (r_prep) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) psychotic/JJ
C036006_D012559 NONE oxcarbazepine/NN (r_pobj) to/IN (r_prep) switched/VBN (l_prep) among/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ
6433367
D010433_D012640 CID pentetrazol/NNP (r_nmod) PTZ/NNP (r_conj) picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_advcl) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- pentetrazol/NNP (r_nmod) PTZ/NNP (r_conj) picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- PTZ/NNP (r_conj) picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_advcl) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_conj) picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- PTZ/NNP (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- PTZ/NNP (r_npadvmod) induced/VBN (r_amod) convulsions/NNS (r_conj) fluorthyl-/NNS (r_pobj) in/IN (r_prep) involved/VBN (l_conj) picrotoxin-/XX (l_pobj) convulsions/NNS
D005481_D012640 CID flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_advcl) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- fluorthyl-/NNS (l_conj) convulsions/NNS -PUNC- fluorthyl-/NNS (r_pobj) in/IN (r_prep) involved/VBN (l_conj) picrotoxin-/XX (l_pobj) convulsions/NNS
D010852_D012640 CID picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_advcl) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- picrotoxin-/XX (r_conj) involved/VBN (l_prep) in/IN (l_pobj) fluorthyl-/NNS (l_conj) convulsions/NNS -PUNC- picrotoxin-/XX (l_pobj) convulsions/NNS
D001640_D012640 CID bicuculline/NN (r_conj) electroshock/NN (r_conj) PTZ/NNP (r_conj) picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_advcl) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- bicuculline/NN (r_conj) electroshock/NN (r_conj) PTZ/NNP (r_conj) picrotoxin/JJ (r_conj) flurothyl/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- bicuculline/NN (r_advmod) induced/VBN (r_conj) electroshock-/XX (r_conj) picrotoxin-/XX (r_conj) involved/VBN (l_prep) in/IN (l_pobj) fluorthyl-/NNS (l_conj) convulsions/NNS -PUNC- bicuculline/NN (r_advmod) induced/VBN (r_conj) electroshock-/XX (r_conj) picrotoxin-/XX (l_pobj) convulsions/NNS
D011453_D012640 NONE prostaglandin/JJ (r_amod) inhibitors/NNS (r_pobj) of/IN (r_prep) Effect/NN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- prostaglandins/NNS (r_pobj) of/IN (r_prep) relationship/NN (r_dobj) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- prostaglandins/NNS (r_pobj) of/IN (r_prep) relationship/NN (r_dobj) investigate/VB (r_advcl) evaluated/VBN (l_nsubjpass) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- PGs/NNS (r_appos) prostaglandins/NNS (r_pobj) of/IN (r_prep) relationship/NN (r_dobj) investigate/VB (l_prep) to/TO (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- PGs/NNS (r_appos) prostaglandins/NNS (r_pobj) of/IN (r_prep) relationship/NN (r_dobj) investigate/VB (r_advcl) evaluated/VBN (l_nsubjpass) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- PGs/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) fluorthyl-/NNS (l_conj) convulsions/NNS -PUNC- PGs/NNS (r_nsubjpass) involved/VBN (l_conj) picrotoxin-/XX (l_pobj) convulsions/NNS
6817363
D012601_D000647 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN (r_pobj) of/IN (r_prep) prevention/NN (l_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN
D012601_D003072 NONE scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN (r_pobj) of/IN (r_prep) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (r_appos) effects/NNS (r_dobj) produced/VBD (r_conj) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS
C036466_D006935 NONE aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_conj) protection/NN (l_conj) prevention/NN (l_conj) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_conj) protection/NN (l_conj) prevention/NN (l_conj) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN -PUNC- 1-anisoyl-2-pyrrolidinone/CD (r_appos) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- 1-anisoyl-2-pyrrolidinone/CD (r_appos) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_conj) protection/NN (l_conj) prevention/NN (l_conj) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN
D002701_D000647 NONE chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN
D012601_D006935 NONE scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN (r_pobj) of/IN (r_prep) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN (r_pobj) of/IN (r_prep) prevention/NN (l_conj) protection/NN (l_conj) prevention/NN (l_conj) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN
D002701_D003072 NONE chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (r_appos) effects/NNS (r_dobj) produced/VBD (r_conj) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS
C036466_D008569 NONE aniracetam/RB (l_appos) Ro/NNP (l_prep) upon/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (l_prep) upon/IN (l_pobj) learning/NN (l_conj) memory/NN
C036466_D007859 NONE aniracetam/RB (l_appos) Ro/NNP (l_prep) upon/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (l_prep) upon/IN (l_pobj) learning/NN (l_conj) memory/NN
C036466_D003072 NONE aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS -PUNC- 1-anisoyl-2-pyrrolidinone/CD (r_appos) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS -PUNC- aniracetam/JJ (r_amod) doses/NNS (r_pobj) at/IN (r_prep) seen/VBN (l_nsubjpass) improvements/NNS (l_conj) normalizations/NNS (l_prep) of/IN (l_pobj) functions/NNS
D003513_D003072 NONE cycloheximide/NN (r_conj) chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (r_appos) effects/NNS (r_dobj) produced/VBD (r_conj) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS -PUNC- cycloheximide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) of/IN (r_prep) retention/NN (r_pobj) in/IN (r_prep) deficit/NN (r_pobj) of/IN (r_prep) reversal/NN (r_conj) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (r_appos) effects/NNS (r_dobj) produced/VBD (r_conj) studied/VBN (l_prep) on/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) functions/NNS
C036466_D000647 NONE aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- 5057/CD (r_prep) 13/CD (r_nummod) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN -PUNC- 1-anisoyl-2-pyrrolidinone/CD (r_appos) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- 1-anisoyl-2-pyrrolidinone/CD (r_appos) Ro/NNP (r_appos) aniracetam/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_conj) produced/VBD (l_dobj) effects/NNS (l_appos) prevention/NN (l_conj) rats/NNS (l_conj) prevention/NN (l_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN
D002701_D006935 NONE chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (l_conj) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN
D003513_D000647 NONE cycloheximide/NN (r_conj) chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- cycloheximide/NN (r_conj) chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN -PUNC- cycloheximide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) of/IN (r_prep) retention/NN (r_pobj) in/IN (r_prep) deficit/NN (r_pobj) of/IN (r_prep) reversal/NN (r_conj) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- cycloheximide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) of/IN (r_prep) retention/NN (r_pobj) in/IN (r_prep) deficit/NN (r_pobj) of/IN (r_prep) reversal/NN (r_conj) prevention/NN (r_conj) protection/NN (l_prep) against/IN (l_pobj) amnesia/NN
D003513_D006935 NONE cycloheximide/NN (r_conj) chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- cycloheximide/NN (r_conj) chloramphenicol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) for/IN (r_prep) prevention/NN (l_conj) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN -PUNC- cycloheximide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) of/IN (r_prep) retention/NN (r_pobj) in/IN (r_prep) deficit/NN (r_pobj) of/IN (r_prep) reversal/NN (r_conj) prevention/NN (r_conj) protection/NN (r_conj) prevention/NN (r_conj) rats/NNS (r_conj) prevention/NN (l_prep) of/IN (l_pobj) incapacity/NN (l_acl) learn/VB (l_dobj) response/NN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) exposed/VBN (l_prep) to/IN (l_pobj) hypercapnia/NN -PUNC- cycloheximide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) task/NN (r_pobj) of/IN (r_prep) retention/NN (r_pobj) in/IN (r_prep) deficit/NN (r_pobj) of/IN (r_prep) reversal/NN (l_conj) prevention/NN (l_prep) in/IN (l_pobj) retrieval/NN (l_prep) of/IN (l_pobj) task/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) electroshock/NN (l_conj) hypercapnia/NN
84204
D002927_D051437 NONE cimetidine/FW (r_conj) dysfunction/NN
D002927_D008107 NONE cimetidine/FW (r_conj) dysfunction/NN
D002927_D003221 CID cimetidine/NN (r_npadvmod) associated/VBN (r_amod) confusion/NN -PUNC- cimetidine/NN (r_npadvmod) associated/VBN (r_amod) confusion/NN
18308784
C035054_D007859 NONE Rg1/NNP (r_nsubj) restores/VBZ (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/VBG -PUNC- Rg1/NNP (l_advcl) ameliorate/VB (l_dobj) impairment/NN -PUNC- Rg1/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) impairment/NN
D009020_D007859 CID morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN (l_prep) of/IN (l_pobj) learning/VBG -PUNC- morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_prep) impairment/NN
D036145_D007859 NONE ginsenoside/NN (r_pobj) as/IN (r_prep) ameliorate/VB (l_dobj) impairment/NN
10524660
D009569_D010146 NONE oxide/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) mechanisms/NNS (l_compound) pain/NN -PUNC- NO/NNP (r_appos) oxide/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) mechanisms/NNS (l_compound) pain/NN -PUNC- NO/DT (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) mechanisms/NNS (l_compound) pain/NN
D009569_D020326 CID oxide/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) mechanisms/NNS (l_prep) without/IN (l_pobj) aura/NN -PUNC- NO/NNP (r_appos) oxide/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) mechanisms/NNS (l_prep) without/IN (l_pobj) aura/NN
D009569_D006261 NONE NO/DT (r_intj) liberate/VB (r_xcomp) shown/VBN (r_advcl) help/VB (l_dobj) understanding/NN (l_prep) of/IN (l_pobj) coupling/NN (l_prep) between/IN (l_pobj) depression/NN (l_conj) headache/NN
D005996_D020325 NONE trinitrate/NN (r_nsubj) induces/VBZ (l_dobj) attacks/NNS (l_prep) without/IN (l_pobj) aura/NN (l_prep) in/IN (l_pobj) sufferers/NNS (l_prep) with/IN (l_pobj) aura/NN -PUNC- trinitrate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) response/NN (r_dobj) examined/VBD (l_prep) In/IN (l_pobj) order/NN (l_acl) clarify/VB (l_ccomp) is/VBZ (l_acomp) true/JJ (l_prep) for/IN (l_pobj) migraine/NN (l_prep) with/IN (l_pobj) aura/NN -PUNC- trinitrate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) response/NN (r_dobj) examined/VBD (l_parataxis) min/NN (l_prep) in/IN (l_pobj) sufferers/NNS (l_prep) with/IN (l_pobj) aura/NN -PUNC- GTN/NNP (r_appos) trinitrate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) response/NN (r_dobj) examined/VBD (l_prep) In/IN (l_pobj) order/NN (l_acl) clarify/VB (l_ccomp) is/VBZ (l_acomp) true/JJ (l_prep) for/IN (l_pobj) migraine/NN (l_prep) with/IN (l_pobj) aura/NN -PUNC- GTN/NNP (r_appos) trinitrate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) response/NN (r_dobj) examined/VBD (l_parataxis) min/NN (l_prep) in/IN (l_pobj) sufferers/NNS (l_prep) with/IN (l_pobj) aura/NN
D005996_D008881 NONE GTN/NNP (r_compound) infusion/NN (r_advcl) was/VBD (l_acomp) severe/JJ (l_prep) in/IN (l_pobj) migraineurs/NNS -PUNC- GTN/NNP (r_npadvmod) induced/VBN (r_amod) headache/NN (r_nsubj) disappeared/VBD (l_advcl) peak/JJ (l_prep) in/IN (l_pobj) migraineurs/NNS
D009569_D020325 NONE NO/DT (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) mechanisms/NNS (l_prep) with/IN (l_pobj) aura/NN -PUNC- NO/DT (r_intj) liberate/VB (r_xcomp) shown/VBN (r_advcl) help/VB (l_dobj) understanding/NN (l_prep) of/IN (l_pobj) coupling/NN (l_prep) between/IN (l_pobj) depression/NN (l_conj) headache/NN (l_prep) with/IN (l_pobj) aura/NN
D005996_D020326 CID trinitrate/NN (r_nsubj) induces/VBZ (l_dobj) attacks/NNS (l_prep) without/IN (l_pobj) aura/NN
D005996_D006261 NONE trinitrate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) response/NN (l_compound) headache/NN -PUNC- GTN/NNP (r_appos) trinitrate/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) response/NN (l_compound) headache/NN -PUNC- GTN/NNP (r_compound) infusion/NN (r_advcl) was/VBD (l_nsubj) Headache/NNP -PUNC- GTN/NNP (r_npadvmod) induced/VBN (r_amod) headache/NN -PUNC- GTN/NNP (r_npadvmod) induced/VBN (r_amod) headache/NN (r_nsubj) disappeared/VBD (l_advcl) peak/JJ (l_ccomp) occurred/VBD (l_nsubj) intensity/NN (l_compound) headache/NN
D009569_D003866 NONE NO/DT (r_intj) liberate/VB (r_xcomp) shown/VBN (l_nsubjpass) depression/NN -PUNC- NO/DT (r_intj) liberate/VB (r_xcomp) shown/VBN (r_advcl) help/VB (l_dobj) understanding/NN (l_prep) of/IN (l_pobj) coupling/NN (l_prep) between/IN (l_pobj) depression/NN
11099450
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LID/NNP -PUNC- levodopa/JJ (r_compound) responsiveness/NN (r_pobj) between/IN (r_prep) correlations/NNS (r_dobj) found/VBD (l_advcl) was/VBD (l_attr) correlation/NN (l_prep) with/IN (l_pobj) improvement/NN (l_prep) in/IN (l_pobj) LID/NNP -PUNC- levodopa/JJ (r_compound) responsiveness/NN (r_conj) responsiveness/NN (r_pobj) between/IN (r_prep) correlations/NNS (r_dobj) found/VBD (l_advcl) was/VBD (l_attr) correlation/NN (l_prep) with/IN (l_pobj) improvement/NN (l_prep) in/IN (l_pobj) LID/NNP -PUNC- levodopa/JJ (r_compound) responsiveness/NN (l_prep) for/IN (l_pobj) outcome/NN (l_prep) of/IN (l_pobj) signs/NNS (l_conj) LID/NNP -PUNC- levodopa/JJ (r_compound) responsiveness/NN (l_prep) for/IN (l_pobj) outcome/NN (l_prep) of/IN (l_pobj) signs/NNS (l_conj) LID/NNP (l_conj) correlations/NNS (l_prep) of/IN (l_pobj) volume/NN (l_prep) with/IN (l_pobj) dyskinesias/NNS -PUNC- levodopa/JJ (r_compound) responsiveness/NN (r_pobj) of/IN (r_prep) value/NN (r_nsubj) indicate/VBP (l_ccomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) signs/NNS (l_conj) dyskinesias/NNS
D007980_D010300 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) signs/NNS (l_poss) parkinsonian/NN -PUNC- levodopa/JJ (r_compound) responsiveness/NN (l_prep) for/IN (l_pobj) outcome/NN (l_prep) of/IN (l_pobj) signs/NNS (l_poss) parkinsonian/NN -PUNC- levodopa/JJ (r_compound) responsiveness/NN (l_prep) for/IN (l_pobj) outcome/NN (l_prep) of/IN (l_pobj) signs/NNS (l_conj) LID/NNP (l_conj) correlations/NNS (l_prep) of/IN (l_pobj) volume/NN (l_prep) with/IN (l_pobj) dyskinesias/NNS (l_conj) parkinsonian/NN -PUNC- levodopa/JJ (r_compound) responsiveness/NN (r_pobj) of/IN (r_prep) value/NN (r_nsubj) indicate/VBP (l_ccomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) generation/NN (l_prep) of/IN (l_pobj) parkinsonian/NN
3173179
D014700_D009203 CID Verapamil/NNP (r_compound) withdrawal/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_conj) introduction/NN (r_pobj) with/IN (r_prep) coincided/VBD (l_nsubj) infarction/NN
D014700_D006973 NONE Verapamil/NNP (r_compound) withdrawal/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) infarction/NN (l_prep) in/IN (l_pobj) woman/NN (l_amod) hypertensive/JJ -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) withdrawal/NN (l_prep) in/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) hypertension/NN
D002216_D009203 NONE captopril/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) with/IN (r_prep) coincided/VBD (l_nsubj) infarction/NN
D002216_D006973 NONE captopril/NN (r_pobj) of/IN (r_prep) introduction/NN (l_conj) withdrawal/NN (l_prep) in/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) hypertension/NN
20394767
D015016_D012021 CID yohimbine/NN (r_nsubj) increased/VBN (l_dobj) startle/NN -PUNC- yohimbine/NN (r_nsubj) increased/VBN (l_conj) suppressed/VBD (l_dobj) startle/NN -PUNC- yohimbine/NN (r_nsubj) increased/VBN (l_conj) suppressed/VBD (l_conj) suppressed/VBD (l_dobj) startle/NN
D010433_D012021 CID PTZ/NNP (r_nsubj) suppressed/VBD (r_conj) suppressed/VBD (r_conj) increased/VBN (l_dobj) startle/NN -PUNC- PTZ/NNP (r_nsubj) suppressed/VBD (r_conj) suppressed/VBD (l_dobj) startle/NN -PUNC- PTZ/NNP (r_nsubj) suppressed/VBD (l_dobj) startle/NN
C015068_D012021 CID mCPP/NNS (r_advcl) increased/VBN (l_dobj) startle/NN -PUNC- mCPP/NNS (r_advcl) increased/VBN (l_conj) suppressed/VBD (l_dobj) startle/NN -PUNC- mCPP/NNS (r_advcl) increased/VBN (l_conj) suppressed/VBD (l_conj) suppressed/VBD (l_dobj) startle/NN
18417364
D010100_D009759 NONE oxygen/NN (r_nmod) levels/NNS (r_pobj) with/IN (r_prep) correlated/VBD (l_nsubj) NIN/NNP
D009538_D009759 CID Nicotine/NN (r_npadvmod) induced/VBN (r_amod) nystagmus/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) nystagmus/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) nystagmus/NN (l_appos) NIN/NNP
809711
D005996_D007022 CID Nitroglycerin/NNP (r_nsubjpass) shown/VBN (r_ccomp) potentiated/VBN (l_agent) by/IN (l_pobj) agents/NNS (l_relcl) reverse/VBP (l_dobj) hypotension/NN -PUNC- nitroglycerin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN
D005996_D009203 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- Nitroglycerin/NNP (r_nsubjpass) shown/VBN (l_xcomp) reduce/VB (l_prep) during/IN (l_pobj) infarction/NN -PUNC- nitroglycerin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_dobj) reverse/VBP (r_relcl) agents/NNS (r_pobj) by/IN (r_agent) potentiated/VBN (l_ccomp) shown/VBN (l_xcomp) reduce/VB (l_prep) during/IN (l_pobj) infarction/NN -PUNC- nitroglycerin/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) infarctions/NNS -PUNC- nitroglycerin/NN (r_pobj) to/IN (r_prep) phenylephrine/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) is/VBZ (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
D010656_D009203 NONE phenylephrine/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- phenylephrine/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) is/VBZ (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
19581773
C417083_D019698 NONE interferon/NN (r_nmod) treatment/NN (l_prep) for/IN (l_pobj) C./NNP -PUNC- alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP -PUNC- alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP (l_appos) CHC/NNP -PUNC- alpha-2b/CD (l_prep) for/IN (l_pobj) CHC/NNP -PUNC- IFN/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) review/NN (r_pobj) with/IN (r_prep) present/VBP (l_ccomp) reported/VBN (l_nsubjpass) myasthenia/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) therapy/NN (l_prep) of/IN (l_pobj) alpha-2b/CD (l_prep) for/IN (l_pobj) CHC/NNP
D012254_D004172 NONE ribavirin/RB (r_conj) alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN
D012254_D019698 NONE ribavirin/JJ (r_conj) interferon/NN (r_nmod) treatment/NN (l_prep) for/IN (l_pobj) C./NNP -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN (l_prep) for/IN (l_pobj) C/NNP (l_appos) CHC/NNP -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (l_prep) for/IN (l_pobj) CHC/NNP
D012254_D009157 CID ribavirin/JJ (r_conj) interferon/NN (r_nmod) treatment/NN (r_pobj) during/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) myasthenia/NN -PUNC- ribavirin/RB (r_conj) alpha-2b/CD (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) myasthenia/NN
C417083_D009157 CID interferon/NN (r_nmod) treatment/NN (r_pobj) during/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) myasthenia/NN -PUNC- alpha-2b/CD (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) myasthenia/NN -PUNC- IFN/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) review/NN (r_pobj) with/IN (r_prep) present/VBP (l_ccomp) reported/VBN (l_nsubjpass) myasthenia/NN
C417083_D004172 NONE alpha-2b/CD (r_conj) IFN/NNP (r_appos) interferon/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) diplopia/NN
11208990
D009569_D009401 NONE NO/UH (r_intj) between/IN (r_prep) interactions/NNS (r_nsubj) are/VBP (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) nephrosis/NN
D009569_D007674 NONE oxide/NN (r_compound) production/NN (r_pobj) of/IN (r_prep) Association/NN (l_conj) apoptosis/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D004317_D009404 CID adriamycin/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- ADR/NNP (r_appos) adriamycin/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_prep) of/IN (l_pobj) syndrome/NN
D004317_D009395 NONE ADR/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) of/IN (r_prep) kidneys/NNS (r_pobj) of/IN (r_prep) examination/NN (r_nsubj) revealed/VBD (l_dobj) areas/NNS (l_prep) of/IN (l_pobj) proliferation/NN (l_conj) inflammation/NN
D009569_D009404 NONE NO/DT (r_intj) of/IN (l_pobj) association/NN (l_prep) with/IN (l_pobj) apoptosis/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) syndrome/NN
D004317_D007674 NONE ADR/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- ADR/NNP (r_compound) nephropathy/NN -PUNC- ADR/NNP (r_compound) nephropathy/NN -PUNC- ADR/NNP (r_compound) nephropathy/NN
D009573_D007674 NONE nitrite/NN (r_compound) levels/NNS (r_nsubjpass) increased/VBN (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN
D010656_D007674 NONE phenylephrine/NN (r_nmod) responses/NNS (r_pobj) In/IN (r_prep) were/VBD (l_acomp) impaired/VBN (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN
D004317_C537346 NONE ADR/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) of/IN (r_prep) kidneys/NNS (r_pobj) of/IN (r_prep) examination/NN (r_nsubj) revealed/VBD (l_dobj) areas/NNS (l_prep) of/IN (l_pobj) proliferation/NN
D000109_D007674 NONE acetylcholine/NN (r_npadvmod) related/VBN (r_conj) phenylephrine/NN (r_nmod) responses/NNS (r_pobj) In/IN (r_prep) were/VBD (l_acomp) impaired/VBN (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN
D004317_D009401 NONE ADR/NNP (r_npadvmod) induced/VBN (r_amod) nephrosis/NN
1732442
D004317_C536522 NONE adriamycin/JJ (r_amod) treatment/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) to/IN (r_prep) relation/NN (r_pobj) in/IN (r_prep) analyzed/VBN (l_nsubjpass) degree/NN (l_prep) of/IN (l_pobj) degeneration/NN (l_prep) of/IN (l_pobj) cells/NNS -PUNC- adriamycin/NNS (r_amod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) of/IN (r_prep) detection/NN (r_pobj) for/IN (r_prep) method/NN (r_attr) be/VB (r_ccomp) indicates/VBZ (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) impairment/NN (l_appos) degeneration/NN
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine/NNP (r_pcomp) with/IN (r_prep) cardiomyopathy/NN -PUNC- MIBG/NNP (r_compound) scintigraphy/NN (r_nsubj) be/VB (r_ccomp) indicates/VBZ (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) impairment/NN -PUNC- MIBG/NNP (r_compound) scintigraphy/NN (r_nsubj) be/VB (l_attr) method/NN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) cardiomyopathy/NN
D019797_C536522 NONE MIBG/NNP (r_compound) scintigraphy/NN (r_nsubj) be/VB (r_ccomp) indicates/VBZ (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) impairment/NN (l_appos) degeneration/NN
D004317_D009202 CID adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- adriamycin/NNS (r_amod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- adriamycin/NNS (r_amod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) of/IN (r_prep) model/NN (r_dobj) Using/VBG (r_advcl) tested/VBD (l_dobj) hypothesis/NN (l_acl) appear/VB (l_conj) exacerbated/VBN (l_advmod) dependently/RB (l_prep) in/IN (l_pobj) cardiomyopathy/NN -PUNC- adriamycin/FW (r_amod) cardiomyopathy/NN (r_pobj) in/IN (r_prep) dependently/RB (r_advmod) exacerbated/VBN (r_conj) appear/VB (r_acl) hypothesis/NN (r_dobj) tested/VBD (l_advcl) Using/VBG (l_dobj) model/NN (l_prep) of/IN (l_pobj) cardiomyopathy/NN -PUNC- adriamycin/FW (r_amod) cardiomyopathy/NN -PUNC- adriamycin/NNS (r_amod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) of/IN (r_prep) detection/NN (r_pobj) for/IN (r_prep) method/NN (r_attr) be/VB (r_ccomp) indicates/VBZ (l_nsubj) appearance/NN (l_prep) of/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) impairment/NN -PUNC- adriamycin/NNS (r_amod) induced/VBN (r_amod) cardiomyopathy/NN
761833
D000643_D003128 CID NH4CL/NN (r_pobj) of/IN (r_prep) intraperitonealinjection/NN (r_pobj) of/IN (r_prep) minutes/NNS (r_pobj) within/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) produced/VBN (l_nsubjpass) coma/NN
D007980_D003128 NONE dopa/NNP (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) coma/NN -PUNC- dopa/NN (r_pobj) with/IN (r_prep) prevented/VBN (l_nsubjpass) coma/NN -PUNC- dopa/NN (l_conj) coma/NN -PUNC- dopa/NNP (r_pobj) after/IN (r_prep) prevention/NN (l_prep) of/IN (l_pobj) coma/NN
D007980_D001927 NONE dopa/NNP (r_dobj) receiving/VBG (r_acl) patients/NNS (l_amod) encephalopathic/JJ
D000641_D003128 NONE ammonia/NN (r_compound) coma/NN -PUNC- Ammonia/NN (r_compound) coma/NN -PUNC- ammonia/NN (r_compound) coma/NN -PUNC- ammonia/NN (r_compound) concentrations/NNS (r_dobj) affect/VB (r_conj) prevent/VB (l_dobj) coma/NN -PUNC- ammonia/NN (r_pobj) on/IN (r_prep) dopa/NN (l_conj) coma/NN -PUNC- ammonia/NN (r_compound) coma/NN -PUNC- ammonia/NN (r_pobj) in/IN (r_prep) reduction/NN (l_conj) prevention/NN (l_prep) of/IN (l_pobj) coma/NN -PUNC- ammonia/NN (r_compound) coma/NN
D064751_D003128 NONE salt/NN (r_compound) injection/NN (r_pobj) before/IN (r_prep) prevented/VBN (l_nsubjpass) coma/NN
D004298_D003128 NONE dopamine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) sufficient/JJ (l_conj) prevent/VB (l_dobj) coma/NN -PUNC- dopamine/NN (r_dobj) raise/VB (r_xcomp) sufficient/JJ (l_conj) prevent/VB (l_dobj) coma/NN -PUNC- dopamine/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) by/IN (r_agent) accounted/VBN (l_nsubjpass) reduction/NN (l_conj) prevention/NN (l_prep) of/IN (l_pobj) coma/NN
9390208
D005472_D064420 NONE 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN
D008942_D001943 NONE mitoxantrone/NN (r_pobj) by/IN (r_prep) cancer/NN -PUNC- mitoxantrone/NN (r_pobj) by/IN (r_prep) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D002955_D064420 NONE leucovorin/NN (r_conj) 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN
C085788_D064420 NONE MFL/NNP (r_appos) 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN -PUNC- regimen/NN (r_nsubj) achieves/VBZ (l_conj) induces/VBZ (l_dobj) toxicity/NN
D008942_D064420 NONE mitoxantrone/NN (r_pobj) by/IN (r_prep) cancer/NN (r_pobj) of/IN (r_prep) Treatment/NN (l_conj) infusion/NN (l_prep) of/IN (l_pobj) 5-FU/CD (l_conj) benefit/NN (l_conj) toxicity/NN
D005472_D001943 NONE 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) day/NN (r_pobj) on/IN (r_prep) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D002955_D001943 NONE leucovorin/NN (r_conj) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- leucovorin/NN (r_pobj) with/IN (r_prep) treated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
C085788_D001943 NONE MFL/NNP (r_appos) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_conj) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
11263551
D016572_D010146 CID cyclosporine-/NN (r_nmod) levels/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) relief/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_compound) Pain/NNP
D016559_-1 NONE tacrolimus/NN (r_conj) cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_appos) CIPS/NNP
D002118_D010146 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) administration/NN (r_conj) reduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) relief/NN (l_prep) of/IN (l_pobj) pain/NN
D016559_D010146 CID tacrolimus/VB (r_compound) trough/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) relief/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- tacrolimus/NN (r_conj) cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_compound) Pain/NNP
D016572_-1 NONE cyclosporine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Syndrome/NNP (l_appos) CIPS/NNP
12109865
11391224
D003042_D057049 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN (r_conj) nephritis/NN (r_dobj) lupus/NN (l_nsubj) microangiopathy/NN
D003042_D058186 CID cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN
D003042_D008181 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN (r_conj) nephritis/NN
D003042_D006974 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN (r_conj) nephritis/NN (r_dobj) lupus/NN (r_conj) included/VBD (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) hypertension/NN
D003042_D011695 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN (r_conj) nephritis/NN
D003042_D005921 NONE cocaine/NN (r_npadvmod) related/VBN (r_amod) failure/NN (r_conj) glomerulonephritis/NN
20477932
D003042_D007859 CID Cocaine/NN (r_nsubj) causes/VBZ (l_dobj) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D003042_D064420 NONE cocaine/NN (r_compound) toxicity/NN -PUNC- cocaine/NN (r_conj) brain/NN (r_nmod) behaviour/NN (r_pobj) in/IN (r_prep) status/NN (r_pobj) between/IN (r_prep) association/NN (r_conj) increase/NN (r_pobj) including/VBG (r_prep) toxicity/NN
C052342_D007859 NONE topiramate/NN (r_pobj) by/IN (r_prep) prevention/NN (r_conj) involvement/NN (r_appos) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D003042_D008569 CID Cocaine/NN (r_nsubj) causes/VBZ (l_dobj) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D009569_D019970 NONE oxide/NN (r_compound) synthase/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) addiction/NN
C052342_D019970 NONE topiramate/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) learning/NN (r_conj) activity/NN (r_conj) synthase/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) addiction/NN
C052342_D008569 NONE topiramate/NN (r_pobj) by/IN (r_prep) prevention/NN (r_conj) involvement/NN (r_appos) memory/NN (l_conj) learning/VBG (l_dobj) impairments/NNS
D003042_D019970 NONE cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) evaluated/VBN (l_nsubjpass) activity/NN (l_appos) stress/NN (l_conj) synthase/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) addiction/NN
3123611
D003276_D002819 CID contraception/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Chorea/NNP -PUNC- contraceptives/NNS (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) chorea/NN -PUNC- contraception/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) chorea/NN
D000661_D002819 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) chorea/NN
15930398
D015742_D000647 CID propofol/NN (r_pobj) with/IN (r_prep) sedation/NN (r_pobj) during/IN (r_prep) onset/NN (l_prep) of/IN (l_pobj) amnesia/NN
1639466
D004656_D006973 NONE enalapril/NN (r_npadvmod) treated/VBN (r_amod) 8)/CD (r_appos) controls/NNS (r_appos) groups/NNS (r_pobj) to/IN (r_prep) assigned/VBN (l_prep) after/IN (l_pobj) clipping/VBG (l_prep) of/IN (l_pobj) artery/NN (l_appos) rats/NNS (l_amod) hypertensive/JJ -PUNC- enalapril/NN (r_npadvmod) treated/VBN (r_amod) 8)/CD (r_appos) controls/NNS (l_amod) hypertensive/JJ -PUNC- enalapril/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) lower/JJR (l_prep) compared/VBN (l_prep) with/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ
D009568_D006978 NONE nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- nitrendipine/NN (r_appos) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D004656_D000419 NONE enalapril/NN (r_dobj) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN
D000809_D006978 NONE angiotensin/NN (r_conj) nitrendipine/NN (r_appos) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D004656_D005921 NONE enalapril/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) change/VB (l_nsubj) excretion/NN (l_conj) glomerulosclerosis/NN
D002118_D006978 NONE calcium/NN (r_compound) channel/NN (r_pobj) of/IN (r_prep) effect/NN (l_appos) nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- calcium/NN (r_compound) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D004656_D006978 NONE enalapril/NN (r_dobj) converting/VBG (r_acl) angiotensin/NN (r_conj) nitrendipine/NN (r_appos) channel/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) kidney/NN (l_appos) hypertension/NN
D009568_D000419 CID nitrendipine/NN (l_conj) angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) albuminuria/NN
D009568_D006973 NONE nitrendipine/NN (r_advmod) treated/VBN (r_conj) 8)/CD (r_appos) controls/NNS (r_appos) groups/NNS (r_pobj) to/IN (r_prep) assigned/VBN (l_prep) after/IN (l_pobj) clipping/VBG (l_prep) of/IN (l_pobj) artery/NN (l_appos) rats/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_advmod) treated/VBN (r_conj) 8)/CD (r_appos) controls/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) albuminuria/NN (r_pobj) in/IN (r_prep) increased/VBD (l_prep) compared/VBN (l_prep) with/IN (l_pobj) hr/NN (l_prep) in/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) increased/VBN (l_prep) compared/VBN (l_prep) with/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ -PUNC- nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) was/VBD (l_conj) lower/JJR (l_prep) compared/VBN (l_prep) with/IN (l_pobj) controls/NNS (l_amod) hypertensive/JJ
D002118_D000419 NONE calcium/NN (r_compound) channel/NN (l_appos) nitrendipine/NN (l_conj) angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN
D002118_D009400 NONE calcium/NN (r_compound) channel/NN (r_pobj) of/IN (r_prep) effect/NN (l_appos) nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN
D009568_D005921 NONE nitrendipine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) index/NN (l_compound) glomerulosclerosis/NN
D000809_D000419 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) on/IN (l_pobj) pressure/NN (l_conj) albuminuria/NN
D009568_D009400 CID nitrendipine/NN (l_prep) on/IN (l_pobj) nephrosclerosis/NN
6454943
D002216_D011507 NONE captopril/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) proteinuria/NN -PUNC- captopril/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Proteinuria/NNP -PUNC- captopril/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) failed/VBD (l_xcomp) aggravate/VB (l_dobj) proteinuria/JJ -PUNC- captopril/NN (r_compound) treatment/NN (r_nsubj) failed/VBD (l_xcomp) potentiate/VB (l_conj) facilitate/VB (l_dobj) development/NN (l_prep) of/IN (l_pobj) proteinuria/NN
D002216_D006973 NONE captopril/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- captopril/NN (r_compound) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) hypertensive/JJ
D011692_D011507 CID aminonucleoside/RB (r_punct) -/HYPH (r_punct) induced/VBN (l_dobj) proteinuria/NN -PUNC- aminonucleoside/NN (r_amod) puromycin/NNS (r_pobj) by/IN (r_agent) invoked/VBN (r_acl) proteinuria/NN
D002216_D007674 NONE captopril/NN (r_pobj) with/IN (r_prep) abnormality/NN
D011692_D006973 NONE aminonucleoside/RB (r_punct) -/HYPH (r_punct) induced/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
1601297
D003042_D009202 NONE cocaine/NN (r_compound) abusers/NNS (r_pobj) in/IN (r_prep) injury/NN -PUNC- cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN
D003042_D012559 NONE cocaine/NN (r_npadvmod) abusing/VBG (r_amod) patients/NNS (r_pobj) of/IN (r_prep) ECG/NNP (r_appos) electrocardiograms/NNS (r_nsubjpass) compared/VBN (l_prep) with/IN (l_pobj) ECGs/NNS (l_prep) of/IN (l_pobj) controls/NNS (l_amod) schizophrenic/JJ
D003042_D002037 CID cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN (l_acl) defined/VBN (l_prep) as/IN (l_pobj) infarction/NN (l_conj) ischemia/NN (l_conj) block/NN
D003042_D009203 CID cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN (l_acl) defined/VBN (l_prep) as/IN (l_pobj) infarction/NN
D003042_D007511 NONE cocaine/NN (r_compound) abusers/NNS (r_pobj) of/IN (r_prep) Eleven/CD (r_nsubj) had/VBD (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN (l_acl) defined/VBN (l_prep) as/IN (l_pobj) infarction/NN (l_conj) ischemia/NN
8092427
-1_D007645 NONE BPO/NNP (r_pobj) to/IN (r_prep) negative/JJ (r_amod) test/NN (r_attr) were/VBD (r_ccomp) were/VBD (l_acomp) negative/JJ (l_prep) to/IN (l_pobj) MDM/NNP
D010400_D004342 NONE PG/NNP (r_pobj) of/IN (r_prep) tolerance/NN (r_pobj) with/IN (r_prep) allergy/NN -PUNC- PG/NNP (r_dobj) tolerated/VBN (r_relcl) patients/NNS (l_amod) allergic/JJ
D000658_D004342 CID amoxicillin/NNP (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (r_dobj) had/VBD (r_conj) used/VBN (l_xcomp) establish/VB (l_ccomp) allergic/JJ -PUNC- amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (l_amod) allergic/JJ -PUNC- AX/NN (r_appos) amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (r_dobj) had/VBD (r_conj) used/VBN (l_xcomp) establish/VB (l_ccomp) allergic/JJ -PUNC- AX/NN (r_appos) amoxicillin/NNP (r_pobj) to/IN (r_prep) responses/NNS (l_amod) allergic/JJ -PUNC- AX/NNP (r_compound) allergy/NN -PUNC- AX/NN (r_pobj) with/IN (r_prep) tests/NNS (r_nsubjpass) performed/VBN (l_advcl) establish/VB (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) reaction/NN -PUNC- AX/NN (r_pobj) to/IN (r_prep) reaction/NN -PUNC- AX/NN (r_pobj) for/IN (r_prep) RAST/NNP (r_conj) test/NN (r_appos) %/NN (r_nsubj) were/VBD (r_conj) performed/VBN (l_advcl) establish/VB (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) reaction/NN -PUNC- AX/NN (r_npadvmod) allergic/JJ
D010400_D007645 NONE PG/NNP (r_pobj) to/IN (r_prep) 44/CD (r_conj) were/VBD (l_acomp) negative/JJ (l_prep) to/IN (l_pobj) MDM/NNP
D047090_D004342 NONE lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) allergic/JJ -PUNC- lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) allergic/JJ (r_ccomp) establish/VB (r_xcomp) used/VBN (l_conj) had/VBD (l_dobj) responses/NNS (l_amod) allergic/JJ -PUNC- lactam/NN (r_amod) antibiotics/NNS (r_pobj) to/IN (r_prep) allergic/JJ
D010406_D004342 NONE penicillin/NN (r_compound) derivatives/NNS (r_pobj) with/IN (r_prep) reacting/VBG (r_acomp) were/VBD (r_conj) had/VBD (r_conj) used/VBN (l_xcomp) establish/VB (l_ccomp) allergic/JJ -PUNC- penicillin/NN (r_compound) derivatives/NNS (r_pobj) with/IN (r_prep) reacting/VBG (r_acomp) were/VBD (r_conj) had/VBD (l_dobj) responses/NNS (l_amod) allergic/JJ
19387625
D002211_D006930 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) untreated/VBN (r_amod) condition/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) is/VBZ (l_nsubj) magnitude/NN (l_prep) of/IN (l_pobj) modulation/NN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- capsaicin/NN (r_compound) treatment/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) showing/VBG (r_csubj) suggest/VBP (l_ccomp) affect/VB (l_nsubj) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN
D002211_D010146 NONE capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_pobj) in/IN (r_prep) intensity/NN (l_compound) pain/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_pobj) in/IN (r_prep) attention/NN (r_pobj) by/IN (r_agent) affected/VBN (l_nsubjpass) ratings/NNS (l_compound) intensity/NN (l_compound) pain/NN -PUNC- capsaicin/NN (r_compound) treatment/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) showing/VBG (r_csubj) suggest/VBP (l_ccomp) affect/VB (l_dobj) pain/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_nsubj) affect/VB (l_dobj) pain/NN
1833784
D004298_D006948 NONE dopamine/NN (r_conj) D1/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) involvement/NN (l_prep) in/IN (l_pcomp) mediating/VBG (l_dobj) hyperactivity/NN
C534628_D006948 NONE 23390/CD (r_nummod) SCH/NNP (r_appos) antagonist/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) hyperactivity/NN
D005476_D006948 NONE fluphenazine/NN (r_conj) raclopride/NN (l_ccomp) blocked/VBN (l_nsubjpass) hyperactivity/NN
D009538_D006948 CID nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- Nicotine/NNP (r_nsubj) caused/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) activity/NN -PUNC- Nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- nicotine/NN (r_compound) injection/NN (r_nsubj) induces/VBZ (l_dobj) hyperactivity/NN
D020891_D006948 NONE raclopride/NN (l_ccomp) blocked/VBN (l_nsubjpass) hyperactivity/NN
D015647_D006948 NONE 38393/CD (r_nummod) SKF/NNP (r_appos) agonist/NN (r_nsubj) had/VBD (r_advcl) Pretreatment/NN (l_prep) with/IN (l_pobj) agonist/NN (l_appos) hyperactivity/NN
-1_D006948 NONE PHNO/NNP (r_npadvmod) enhanced/VBN (r_amod) hyperactivity/NN
9088814
D000527_D007022 CID E1-induced/JJ (r_amod) hypotension/NN -PUNC- E1/NN (l_appos) hypotension/NN -PUNC- PGE1)-induced/JJ (r_amod) hypotension/NN -PUNC- PGE1/NNP (r_pobj) with/IN (r_prep) induced/VBN (l_nsubjpass) hypotension/NN -PUNC- PGE1-induced/JJ (r_amod) hypotension/NN
D001663_D007022 NONE bilirubin/NN (r_conj) LDH/NNP (r_conj) SGPT/NNP (r_appos) SGOT/NNP (r_nsubj) showed/VBD (r_conj) showed/VBD (l_prep) after/IN (l_pobj) start/NN (l_prep) of/IN (l_pobj) hypotension/NN
D003911_D020141 NONE dextran/NN (r_amod) solution/NN (r_pobj) of/IN (r_prep) amount/NN (r_pobj) with/IN (r_prep) replacing/VBG (r_conj) withdrawing/VBG (r_pcomp) by/IN (r_prep) produced/VBN (l_nsubjpass) Haemodilution/NN
D000527_D020141 NONE E1-induced/JJ (r_amod) hypotension/NN (l_conj) haemodilution/NN -PUNC- E1/NN (l_appos) hypotension/NN (l_conj) haemodilution/NN -PUNC- PGE1)-induced/JJ (r_amod) hypotension/NN (l_conj) haemodilution/NN -PUNC- PGE1-induced/JJ (r_amod) hypotension/NN (l_conj) haemodilution/NN
D000527_D008107 CID PGE1-induced/JJ (r_amod) hypotension/NN (r_pobj) of/IN (r_prep) min/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) cause/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) function/NN
12369736
C065046_D009069 CID 93129/CD (r_nummod) CP/NNP (r_appos) agonist/NN (r_conj) modification/NN (r_conj) shell/NN (r_pobj) into/IN (r_prep) microinjected/VBN (r_acl) ligands/NNS (r_pobj) by/IN (r_agent) modified/VBN (l_nsubjpass) hyperlocomotion/NN
D003042_D009069 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- cocaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) administered/VBN (l_conj) attenuated/VBD (l_dobj) hyperactivity/NN -PUNC- cocaine/NN (r_nsubj) induced/VBN (r_ccomp) indicate/VBP (l_ccomp) modified/VBN (l_nsubjpass) hyperlocomotion/NN
C103477_D009069 NONE 55562/CD (r_nummod) GR/NNP (r_nsubj) administered/VBN (l_conj) attenuated/VBD (l_dobj) hyperactivity/NN -PUNC- 55562/CD (r_nummod) GR/NNP (r_appos) antagonist/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) in/IN (r_prep) consisting/VBG (r_acl) modification/NN (r_conj) shell/NN (r_pobj) into/IN (r_prep) microinjected/VBN (r_acl) ligands/NNS (r_pobj) by/IN (r_agent) modified/VBN (l_nsubjpass) hyperlocomotion/NN
9431903
D009388_D046628 CID prostigmine/JJ (r_compound) morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) spasm/NN -PUNC- prostigmine/JJ (r_compound) morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- prostigmine/JJ (r_compound) morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (r_pobj) on/IN (r_prep) trinitrate/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) evaluated/VBN (l_prep) with/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) dyskinesia/NN -PUNC- prostigmine/JJ (r_compound) morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- prostigmine/NN (r_parataxis) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN
D009388_D013035 CID prostigmine/JJ (r_compound) morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) spasm/NN -PUNC- prostigmine/JJ (r_compound) morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- prostigmine/JJ (r_compound) morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- prostigmine/NN (r_parataxis) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- Prostigmine/JJ (r_compound) morphine/NN (r_compound) provocation/NN (r_nsubj) caused/VBD (l_advcl) indicating/VBG (l_dobj) spasm/NN
D005996_D046628 NONE trinitrate/NN (l_prep) on/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- trinitrate/NN (l_prep) on/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- trinitrate/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) evaluated/VBN (l_prep) with/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) dyskinesia/NN -PUNC- trinitrate/NN (l_prep) on/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- trinitrate/NN (r_nsubj) is/VBZ (r_advcl) be/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) dyskinesia/NN
D005996_D013035 NONE trinitrate/NN (l_prep) on/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- trinitrate/NN (l_prep) on/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- trinitrate/NN (l_prep) on/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN
D009020_D046628 CID morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) spasm/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (r_pobj) on/IN (r_prep) trinitrate/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) evaluated/VBN (l_prep) with/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) dyskinesia/NN -PUNC- morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- morphine/NN (r_conj) prostigmine/NN (r_parataxis) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) overcome/VB (r_xcomp) able/JJ (r_acomp) is/VBZ (r_advcl) be/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) sphincter/NN (l_prep) of/IN (l_pobj) dyskinesia/NN
D009020_D013035 CID morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) spasm/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN -PUNC- morphine/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- morphine/NN (r_conj) prostigmine/NN (r_parataxis) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) spasm/NN -PUNC- morphine/NN (r_compound) provocation/NN (r_nsubj) caused/VBD (l_advcl) indicating/VBG (l_dobj) spasm/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) sphincter/NN (l_prep) of/IN (l_pobj) spasm/NN
10840460
D009020_D001523 NONE Morphine/NNP (r_nsubj) reversed/VBD (l_dobj) disorders/NNS
D003520_D010146 CID CP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN (r_pobj) of/IN (r_prep) model/NN (r_nsubj) be/VB (l_advcl) allowing/VBG (l_dobj) understanding/NN (l_prep) of/IN (l_pobj) syndromes/NNS
D009020_D004487 NONE morphine/NN (r_pobj) of/IN (r_prep) administration/NN (l_appos) modifications/NNS (l_prep) as/IN (l_pobj) edema/NN
D003520_D059265 NONE Cyclophosphamide/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN (l_appos) approach/NN (l_prep) to/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- CP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN (r_pobj) of/IN (r_prep) model/NN (r_nsubj) be/VB (l_attr) model/NN (l_prep) of/IN (l_pobj) pain/NN
D000171_D003556 NONE acrolein/NN (r_pobj) through/IN (r_prep) produce/VB (r_xcomp) known/VBN (r_acl) agent/NN (r_appos) Cyclophosphamide/NNP (r_nsubjpass) used/VBN (l_xcomp) induce/VB (l_dobj) cystitis/NN
D003520_D003556 CID Cyclophosphamide/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- Cyclophosphamide/NNP (r_nsubjpass) used/VBN (l_xcomp) induce/VB (l_dobj) cystitis/NN -PUNC- CP/NNP (r_appos) Cyclophosphamide/NNP (r_nsubjpass) used/VBN (l_xcomp) induce/VB (l_dobj) cystitis/NN -PUNC- CP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN
12584269
D016559_D007674 CID FK506/NNP (r_nsubjpass) tolerated/VBN (r_advcl) demonstrated/VBD (l_dobj) effect/NN (l_amod) nephrotoxic/JJ
D016559_D005355 NONE FK506/NNP (r_nmod) combination/NN (r_nsubj) showed/VBD (l_dobj) degree/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D020123_D007674 CID SRL/NN (r_nsubj) seems/VBZ (r_conj) are/VBP (l_acomp) nephrotoxic/JJ -PUNC- SRL/NN (r_nsubj) seems/VBZ (l_xcomp) act/VB (l_advcl) displaying/VBG (l_dobj) effects/NNS (l_amod) nephrotoxic/JJ -PUNC- SRL/NN (r_nsubjpass) combined/VBN (l_prep) with/IN (l_pobj) indications/NNS (l_prep) of/IN (l_pobj) effect/NN (l_amod) nephrotoxic/JJ -PUNC- SRL/NNP (r_conj) CsA/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) nephrotoxic/JJ -PUNC- SRL/NNP (r_conj) FK506/NNP (r_nsubjpass) tolerated/VBN (r_advcl) demonstrated/VBD (l_dobj) effect/NN (l_amod) nephrotoxic/JJ
D020123_D005355 NONE SRL/NNP (r_compound) combination/NN (r_nsubj) showed/VBD (l_dobj) degree/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D016572_D007674 CID CsA/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) nephrotoxic/JJ
9625142
D047090_-1 NONE lactam/NN (r_compound) antibiotic/NN (r_dobj) withholding/VBG (r_pcomp) after/IN (r_prep) returned/VBD (r_advcl) was/VBD (l_attr) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN (l_conj) erythroblastocytopenia/NN
D001663_-1 NONE bilirubin/NN (r_pobj) in/IN (r_prep) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN (l_conj) erythroblastocytopenia/NN
D002443_D000744 CID ceftriaxone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NNP (l_appos) anemia/NN
D002443_D056486 CID ceftriaxone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NNP -PUNC- ceftriaxone/NN (r_dobj) ingesting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN
D002443_-1 NONE ceftriaxone/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NNP (l_appos) anemia/NN (l_conj) erythroblastocytopenia/NN
D001663_D000744 NONE bilirubin/NN (r_pobj) in/IN (r_prep) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN
D047090_D000744 NONE lactam/NN (r_compound) antibiotic/NN (r_dobj) withholding/VBG (r_pcomp) after/IN (r_prep) returned/VBD (r_advcl) was/VBD (l_attr) increase/NN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) concentration/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) anemia/NN
20727411
D016202_D012559 NONE aspartate/NNP (r_nmod) receptor/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- NMDA/NNP (r_nmod) receptor/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_compound) ketamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) symptoms/NNS (l_amod) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) schizophrenia/NN -PUNC- NMDA/NNP (r_compound) dysfunction/NN (l_prep) in/IN (l_pobj) pathophysiology/NN (l_prep) of/IN (l_pobj) schizophrenia/NN
D007649_D012559 NONE ketamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) symptoms/NNS (l_amod) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) schizophrenia/NN -PUNC- ketamine/NN (r_nsubj) exacerbates/VBZ (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN -PUNC- Ketamine/NN (r_nsubj) induces/VBZ (l_dobj) changes/NNS (l_prep) in/IN (l_pobj) subjects/NNS (l_amod) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
D007649_D011605 CID Ketamine/NN (r_nsubj) elicited/VBD (l_dobj) psychosis/NN
-1_D011605 NONE ketamine/NN (r_pobj) of/IN (r_prep) correlates/NNS (r_nsubj) induced/VBD (l_dobj) psychosis/NN
D007649_D018754 NONE ketamine/NN (r_nsubj) exacerbates/VBZ (l_advcl) supporting/VBG (l_dobj) hypothesis/NN (l_prep) of/IN (l_pobj) dysfunction/NN
1728915
D002220_D062787 NONE carbamazepine/NN (r_compound) overdose/NN
D002220_D001523 NONE carbamazepine/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) conditions/NNS (l_amod) neurologic/JJ (l_conj) psychiatric/JJ
D002220_D006331 NONE Carbamazepine/NNP (r_npadvmod) induced/VBN (r_amod) dysfunction/NN -PUNC- carbamazepine/NN (r_npadvmod) associated/VBN (r_amod) dysfunction/NN
D002220_D013616 CID carbamazepine/NN (r_compound) overdose/NN (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) developed/VBD (l_dobj) tachycardias/NNS
D002220_D001919 CID carbamazepine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patient/NN (l_prep) with/IN (l_pobj) bradycardia/NNP -PUNC- carbamazepine/NN (r_compound) levels/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_advcl) consisted/VBD (l_advmod) exclusively/RB (l_prep) of/IN (l_pobj) women/NNS (l_relcl) developed/VBD (l_dobj) bradyarrhythmias/NNS
D002220_D054537 CID carbamazepine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patient/NN (l_prep) with/IN (l_pobj) bradycardia/NNP (l_conj) block/NN -PUNC- carbamazepine/NN (r_compound) levels/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_advcl) consisted/VBD (l_advmod) exclusively/RB (l_prep) of/IN (l_pobj) women/NNS (l_relcl) developed/VBD (l_dobj) bradyarrhythmias/NNS (l_conj) delay/NN
3708922
D005839_D064420 NONE gentamicin/NN (r_pobj) as/IN (r_prep) potential/NN (r_pobj) with/IN (r_prep) administration/NN (r_nsubj) aggravate/VB (l_ccomp) induced/VBN (l_dobj) toxicity/NN
D000666_D064420 NONE B/NN (r_conj) gentamicin/NN (r_pobj) as/IN (r_prep) potential/NN (r_pobj) with/IN (r_prep) administration/NN (r_nsubj) aggravate/VB (l_ccomp) induced/VBN (l_dobj) toxicity/NN
D005839_D007674 NONE gentamicin/NN (r_pobj) as/IN (r_prep) potential/NN (l_amod) nephrotoxic/JJ -PUNC- Gentamicin/NNP (r_nsubj) increased/VBD (l_dobj) nephrotoxicity/NN
D007654_D007674 NONE ketoconazole/NN (r_conj) B/NN (r_conj) gentamicin/NN (r_pobj) as/IN (r_prep) potential/NN (l_amod) nephrotoxic/JJ
D007654_D064420 NONE ketoconazole/NN (r_conj) B/NN (r_conj) gentamicin/NN (r_pobj) as/IN (r_prep) potential/NN (r_pobj) with/IN (r_prep) administration/NN (r_nsubj) aggravate/VB (l_ccomp) induced/VBN (l_dobj) toxicity/NN
D016572_D064420 NONE CSA/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) aggravate/VB (l_ccomp) induced/VBN (l_dobj) toxicity/NN -PUNC- CSA/NNP (r_dobj) aggravate/VB (l_ccomp) induced/VBN (l_dobj) toxicity/NN
D016572_D007674 CID cyclosporine/NN (r_compound) nephrotoxicity/NN -PUNC- cyclosporine/NN (r_pobj) of/IN (l_conj) in/IN (l_pobj) combination/NN (l_prep) with/IN (l_pobj) chemotherapeutics/NNS (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- CSA/NNP (r_appos) cyclosporine/NN (r_pobj) of/IN (l_conj) in/IN (l_pobj) combination/NN (l_prep) with/IN (l_pobj) chemotherapeutics/NNS (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- CSA/NNP (r_pobj) of/IN (r_prep) administration/NN (l_prep) with/IN (l_pobj) potential/NN (l_amod) nephrotoxic/JJ -PUNC- CSA/NNP (r_dobj) aggravate/VB (l_nsubj) administration/NN (l_prep) with/IN (l_pobj) potential/NN (l_amod) nephrotoxic/JJ -PUNC- CSA/NNP (r_compound) nephrotoxicity/NN -PUNC- CSA/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) nephrotoxicity/NN
D000666_D007674 NONE B/NN (r_conj) gentamicin/NN (r_pobj) as/IN (r_prep) potential/NN (l_amod) nephrotoxic/JJ
3961813
D003345_D009422 NONE corticosterone/NN (l_prep) on/IN (l_pobj) neuropathy/NN -PUNC- corticosterone/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubj) had/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) neuropathy/NN
D010755_D009422 NONE organophosphorus/NN (r_npadvmod) induced/VBN (r_amod) neuropathy/NN
D007531_D009422 CID DFP/NNP (r_conj) TOTP/NNP (r_pobj) given/VBN (r_acl) signs/NNS (r_dobj) had/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) neuropathy/NN
D007531_D009410 CID DFP/NNP (r_conj) TOTP/NNP (r_pobj) given/VBN (r_prep) were/VBD (l_nsubj) fibers/NNS
C025541_D020258 NONE TOTP/NNP (r_pobj) after/IN (r_prep) activities/NNS (l_compound) esterase/NN (l_amod) Neurotoxic/JJ
D007531_D020258 NONE DFP/NNP (r_conj) TOTP/NNP (r_pobj) after/IN (r_prep) activities/NNS (l_compound) esterase/NN (l_amod) Neurotoxic/JJ
C025541_D009410 CID TOTP/NNP (r_pobj) given/VBN (r_prep) were/VBD (l_nsubj) fibers/NNS
C025541_D009422 CID TOTP/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- TOTP/NNP (r_pobj) given/VBN (r_acl) signs/NNS (r_dobj) had/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) neuropathy/NN
D010755_D020258 NONE organophosphorous/JJ (r_amod) compounds/NNS (r_dobj) given/VBN (r_prep) were/VBD (l_nsubj) activities/NNS (l_compound) esterase/NN (l_amod) Neurotoxic/JJ
20635749
D000638_D006333 NONE amiodarone/NN (r_pobj) on/IN (r_prep) patient/NN (l_compound) failure/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hypothyroidism/NN (r_pobj) to/IN (r_prep) coma/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) failure/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hypothyroidism/NN (r_pobj) to/IN (r_prep) coma/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) failure/NN (l_appos) CHF/NNP -PUNC- amiodarone/NN (r_pobj) on/IN (r_prep) Patients/NNS (l_prep) with/IN (l_pobj) CHF/NNP -PUNC- amiodarone/NN (l_prep) among/IN (l_pobj) patients/NNS (l_compound) CHF/NNP
D000638_D003128 CID amiodarone/NN (r_pobj) on/IN (l_pcomp) presenting/VBG (l_prep) with/IN (l_pobj) coma/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hypothyroidism/NN (r_pobj) to/IN (r_prep) coma/NN -PUNC- amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) coma/NN
D000638_D007037 CID amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hypothyroidism/NN -PUNC- amiodarone/NN (r_pobj) on/IN (r_prep) Patients/NNS (r_nsubj) suffer/VB (l_dobj) morbidity/NN (l_prep) from/IN (l_pobj) hypothyroidism/NN
D000638_D009230 CID amiodarone/NN (r_pobj) on/IN (l_pcomp) presenting/VBG (l_prep) with/IN (l_pobj) coma/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hypothyroidism/NN (r_pobj) to/IN (r_prep) coma/NN -PUNC- amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) coma/NN
11419773
D002110_D014693 CID caffeine/NN (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) containing/VBG (r_acl) drink/NN (r_dobj) consuming/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) fibrillation/NN
D002110_D008945 NONE caffeine/NN (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) containing/VBG (r_acl) drink/NN (r_dobj) consuming/VBG (r_pcomp) after/IN (r_prep) developed/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) prolapse/NN
D002110_D001145 NONE Caffeine/NN (r_nsubj) induced/VBN (r_amod) arrhythmia/NN
9041081
D000305_D009798 CID corticosteroid/NN (r_compound) therapy/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (r_relcl) IOP/NNP (r_appos) pressure/NN
D013256_D009798 NONE steroid/NN (r_npadvmod) induced/VBN (r_amod) pressure/NN -PUNC- steroid/NN (r_npadvmod) induced/VBN (r_amod) rise/NN
2549018
D000928_D017109 NONE antidepressant/NN (r_npadvmod) induced/VBN (r_amod) jitteriness/NN (r_conj) akathisia/NN (r_pobj) of/IN (r_prep) pathophysiology/NN (r_nsubj) be/VB (r_conj) caused/VBN (l_nsubjpass) akathisia/NN -PUNC- antidepressant/NN (r_npadvmod) induced/VBN (r_amod) jitteriness/NN (r_conj) akathisia/NN
D011433_D017109 NONE propranolol/NN (r_acl) antagonist/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) responded/VBD (r_conj) appeared/VBD (l_nsubj) Akathisia/NNP
D005473_D009771 NONE fluoxetine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN
D005473_D001008 NONE fluoxetine/NN (r_npadvmod) induced/VBN (r_amod) symptoms/NNS (l_prep) of/IN (l_pobj) restlessness/NN (l_conj) pacing/NN (l_conj) movements/NNS (l_conj) anxiety/NN
D005473_D017109 CID Fluoxetine/NNP (r_npadvmod) induced/VBN (r_amod) akathisia/NN -PUNC- fluoxetine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) developed/VBD (l_dobj) akathisia/NN -PUNC- fluoxetine/NN (r_npadvmod) induced/VBN (r_amod) symptoms/NNS (r_nsubj) were/VBD (l_acomp) indistinguishable/JJ (l_prep) from/IN (l_pobj) those/DT (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN (r_pobj) of/IN (r_prep) symptoms/NNS (r_nsubj) were/VBD (r_ccomp) reported/VBD (l_nsubj) patients/NNS (l_relcl) experienced/VBN (l_dobj) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN -PUNC- fluoxetine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) be/VB (r_xcomp) appeared/VBD (l_nsubj) Akathisia/NNP -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN (r_nsubjpass) caused/VBN (l_conj) be/VB (l_nsubj) pathophysiology/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN (r_pobj) of/IN (r_prep) pathophysiology/NN (r_nsubj) be/VB (r_conj) caused/VBN (l_nsubjpass) akathisia/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) akathisia/NN
D005473_D003865 NONE fluoxetine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN (l_conj) depression/NN
9401499
D013988_D000380 CID ticlopidine/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) Agranulocytosis/NN
D013988_D000741 CID Ticlopidine/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN
3220106
D004298_D006948 NONE DA/NNP (r_compound) concentration/NN (r_conj) receptors/NNS (r_pobj) of/IN (r_prep) density/NN (r_pobj) of/IN (r_prep) increases/NNS (r_pobj) due/JJ (r_prep) develop/VBP (l_dobj) hyperactivity/NN -PUNC- DA/NNP (r_compound) supersensitivity/NN (r_dobj) inducing/VBG (r_pcomp) by/IN (r_agent) followed/VBN (r_advcl) suggest/VBP (l_ccomp) develop/VBP (l_dobj) hyperactivity/NN
D009538_D006948 CID nicotine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- nicotine/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) hyperactivity/NN -PUNC- nicotine/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) develop/VBP (l_dobj) hyperactivity/NN -PUNC- nicotine/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) develop/VBP (l_dobj) hyperactivity/NN
8638206
-1_D010243 NONE benzylisoquinolinium/NN (r_amod) NMBA/NNP (r_appos) besylate/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) paralysis/NN
D014673_D010243 CID bromide/NN (r_pobj) as/IN (r_prep) NMBAs/NNS (r_dobj) involved/VBN (l_nsubj) Reports/NNS (l_prep) of/IN (l_pobj) paralysis/NN
D001279_D010243 CID atracurium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) paralysis/NN -PUNC- besylate/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) paralysis/NN -PUNC- atracurium/NN (r_npadvmod) related/VBN (r_amod) paralysis/NN
10565806
C076029_D001714 CID olanzapine/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Hypomania/NNP -PUNC- olanzapine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) hypomania/NN
C076029_D011618 NONE olanzapine/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) disorder/NN
11027904
D008691_D010146 NONE methadone/NN (r_npadvmod) maintained/VBN (r_amod) abusers/NNS (r_pobj) in/IN (r_prep) responses/NNS (l_compound) Pain/NN -PUNC- methadone/NN (r_compound) maintenance/NN (r_nmod) treatment/NN (r_pobj) in/IN (r_prep) stabilized/VBD (r_acl) sample/NN (r_pobj) in/IN (r_prep) tolerance/NN (l_compound) pain/NN
D004091_D010146 NONE hydromorphone/NN (r_parataxis) opioid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_conj) before/IN (r_advmod) examined/VBN (l_prep) By/IN (l_pcomp) using/VBG (l_dobj) tolerance/NN (l_prep) to/IN (l_pobj) pain/NN
D008691_D009293 NONE methadone/NN (r_compound) maintenance/NN (r_nmod) treatment/NN (r_pobj) in/IN (r_prep) stabilized/VBD (r_acl) sample/NN (l_prep) of/IN (l_pobj) addicts/NNS
D020910_D010146 NONE ketorolac/RB (r_nmod) agents/NNS (r_conj) examined/VBN (l_prep) By/IN (l_pcomp) using/VBG (l_dobj) tolerance/NN (l_prep) to/IN (l_pobj) pain/NN
8305357
D003630_D012514 NONE daunorubicin/NN (l_dobj) sarcoma/NN -PUNC- daunorubicin/NN (r_pobj) of/IN (r_prep) safety/NN (r_conj) efficacy/NN (r_dobj) assess/VB (r_relcl) trial/NN (r_dobj) report/VBP (l_ccomp) related/VBD (l_dobj) sarcoma/NN -PUNC- daunorubicin/NN (r_nsubj) was/VBD (l_attr) agent/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) sarcoma/NN
D003630_D000163 NONE daunorubicin/NN (r_pobj) of/IN (r_prep) safety/NN (r_conj) efficacy/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) AIDS/NNP
7161250
D008140_D017109 NONE lorazepam/NN (r_pobj) by/IN (r_agent) controlled/VBN (l_nsubjpass) Akathisia/NNP
D006220_D010302 CID haloperidol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) at/IN (r_prep) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) parkinsonism/NN
D001569_D017109 NONE benzodiazepine/JJ (r_amod) lorazepam/NN (r_pobj) by/IN (r_agent) controlled/VBN (l_nsubjpass) Akathisia/NNP
3856631
D008727_D008577 NONE methotrexate/NNP (r_pobj) with/IN (r_prep) leukemia/NN
D008727_D054198 NONE methotrexate/NNP (r_compound) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NNP (r_compound) concentrations/NNS (r_dobj) maintain/VB (r_conj) achieve/VB (r_xcomp) designed/VBN (r_relcl) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) induction/NN (l_prep) after/IN (l_pobj) relapse/NN (l_prep) in/IN (l_pobj) leukemia/NN
D001663_D064420 NONE bilirubin/NN (r_amod) elevations/NNS (r_conj) transaminase/NN (r_attr) were/VBD (l_nsubj) toxicities/NNS
D001663_D052016 NONE bilirubin/NN (r_amod) elevations/NNS (r_conj) transaminase/NN (l_appos) neutropenia/NN (l_conj) mucositis/NN
D008727_D002493 NONE methotrexate/NNP (r_compound) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_relcl) developed/VBD (l_dobj) disease/NN -PUNC- methotrexate/NNP (r_compound) concentrations/NNS (r_dobj) maintain/VB (r_conj) achieve/VB (r_xcomp) designed/VBN (r_relcl) regimen/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) children/NNS (l_relcl) developed/VBD (l_dobj) disease/NN
D001663_D009503 NONE bilirubin/NN (r_amod) elevations/NNS (r_conj) transaminase/NN (l_appos) neutropenia/NN
6727060
D008787_D004409 CID metoclopramide/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dyskinesia/JJ -PUNC- metoclopramide/RB (r_dobj) took/VBD (r_advcl) appeared/VBD (l_nsubj) movements/NNS -PUNC- metoclopramide/JJ (r_compound) administration/NN (r_nsubjpass) discontinued/VBN (r_advcl) improved/VBD (l_nsubj) movements/NNS
D008787_D005767 NONE metoclopramide/RB (r_dobj) took/VBD (l_prep) for/IN (l_pobj) disorder/NN
17490790
D007501_D010300 NONE Iron/NN (r_compound) accumulation/NN (r_nsubjpass) considered/VBN (l_xcomp) involved/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) disease/NN
D007505_D009410 CID dextran/NN (r_nsubj) induced/VBD (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS -PUNC- dextran/NN (r_amod) animals/NNS (r_pobj) of/IN (r_prep) SN/NN (r_pobj) in/IN (r_prep) content/NN (r_conj) staining/NN (l_conj) detection/NN (l_acl) study/VB (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS -PUNC- dextran/NN (r_nsubj) increase/VB (l_dobj) level/NN (l_relcl) causes/VBZ (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS
D007501_D009410 NONE iron/NN (r_compound) overload/NN (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) demonstrate/VB (r_advcl) used/VBD (l_dobj) voltammetry/NN (l_conj) immunohistochemistry/NN (l_conj) staining/NN (l_conj) detection/NN (l_acl) study/VB (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS -PUNC- iron/NN (r_compound) staining/NN (l_conj) detection/NN (l_acl) study/VB (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS -PUNC- iron/NN (r_compound) content/NN (r_conj) staining/NN (l_conj) detection/NN (l_acl) study/VB (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS -PUNC- iron/NN (r_compound) level/NN (l_relcl) causes/VBZ (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS -PUNC- iron/NN (r_nsubj) causes/VBZ (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS
D014443_D009410 NONE tyrosine/NN (r_det) immunohistochemistry/NN (l_conj) staining/NN (l_conj) detection/NN (l_acl) study/VB (l_dobj) degeneration/NN (l_prep) of/IN (l_pobj) neurons/NNS
16160878
D014579_D001919 NONE II/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) causes/NNS (l_dobj) hypertension/NN (l_conj) bradycardia/NN
D001058_D010409 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) erection/NN
D014579_D001523 NONE II/NNP (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) aspects/NNS (l_prep) of/IN (l_pobj) disorders/NNS
D014579_D010409 NONE II/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) had/VBD (l_dobj) erection/NN
D003345_D010409 NONE corticosterone/NN (r_compound) level/NN (r_conj) had/VBD (l_dobj) erection/NN
D014579_D006973 NONE II/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) causes/NNS (l_dobj) hypertension/NN
16225977
C012052_D020820 NONE amisulpride/JJ (r_amod) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) movements/NNS
C012052_D013981 CID Amisulpride/NNP (r_amod) symptoms/NNS -PUNC- amisulpride/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) reduced/VBD (r_advcl) resolved/VBN (l_nsubj) symptoms/NNS -PUNC- amisulpride/NN (r_conj) clozapine/NN (r_conj) quetiapine/NN (r_pobj) as/IN (r_prep) antipsychotics/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) occur/VB (l_nsubj) symptoms/NNS
C069541_D013981 NONE quetiapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) occurring/VBG (r_xcomp) show/VBP (l_dobj) symptoms/NNS -PUNC- quetiapine/NN (r_pobj) as/IN (r_prep) antipsychotics/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) occur/VB (l_nsubj) symptoms/NNS
C092292_D013981 NONE ziprasidone/NN (r_conj) olanzapine/NN (r_conj) risperidone/NN (r_pobj) as/IN (r_prep) antipsychotics/NNS (r_pobj) by/IN (r_agent) treated/VBN (l_nsubjpass) disorders/NNS
D018967_D013981 NONE risperidone/NN (r_pobj) as/IN (r_prep) antipsychotics/NNS (r_pobj) by/IN (r_agent) treated/VBN (l_nsubjpass) disorders/NNS
C012052_D012559 NONE Amisulpride/NNP (r_amod) symptoms/NNS (l_prep) in/IN (l_pobj) schizophrenic/NN -PUNC- amisulpride/JJ (r_amod) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) schizophrenic/NN
C076029_D013981 NONE olanzapine/NN (r_conj) risperidone/NN (r_pobj) as/IN (r_prep) antipsychotics/NNS (r_pobj) by/IN (r_agent) treated/VBN (l_nsubjpass) disorders/NNS
D003024_D013981 NONE clozapine/NN (r_conj) quetiapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) occurring/VBG (r_xcomp) show/VBP (l_dobj) symptoms/NNS -PUNC- clozapine/NN (r_conj) quetiapine/NN (r_pobj) as/IN (r_prep) antipsychotics/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) occur/VB (l_nsubj) symptoms/NNS
6861444
D009638_D006973 CID noradrenaline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) caused/VBD (l_dobj) hypertension/NN -PUNC- noradrenaline/NN (r_amod) infusion/NN (r_pobj) after/IN (r_prep) hypertension/NN -PUNC- noradrenaline/NN (r_dobj) circulating/VBG (r_pcomp) of/IN (r_prep) levels/NNS (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) hypertension/NN
16629641
D012254_D000740 NONE ribavirin/RB (r_npadvmod) induced/VBN (r_amod) hemolysis/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) decrease/VBP (l_conj) be/VB (l_nsubj) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) associated/VBN (r_amod) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) associated/VBN (r_amod) anemia/NN
D012254_D000743 CID ribavirin/NN (r_pobj) of/IN (r_prep) prodrug/NN (r_appos) Viramidine/NNP (r_nsubj) has/VBZ (l_dobj) potential/NN (l_acl) maintain/VB (l_advcl) decreasing/VBG (l_dobj) risk/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- ribavirin/RB (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) maintain/VB (l_advcl) decreasing/VBG (l_dobj) risk/NN (l_prep) of/IN (l_pobj) anemia/NN
C026956_D000743 NONE Viramidine/NNP (r_nsubj) has/VBZ (l_dobj) potential/NN (l_acl) maintain/VB (l_advcl) decreasing/VBG (l_dobj) risk/NN (l_prep) of/IN (l_pobj) anemia/NN
C026956_D019698 NONE Viramidine/NNP (r_nsubj) has/VBZ (l_dobj) potential/NN (l_acl) maintain/VB (l_advcl) decreasing/VBG (l_dobj) risk/NN (l_prep) of/IN (l_pobj) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) C./NNP
D012254_D002318 NONE ribavirin/RB (r_npadvmod) induced/VBN (r_amod) hemolysis/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) decrease/VBP (l_conj) be/VB (l_conj) comorbid/VBN (l_dobj) disorders/NNS
D012254_D007674 NONE ribavirin/RB (r_npadvmod) induced/VBN (r_amod) hemolysis/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) decrease/VBP (l_conj) be/VB (l_conj) comorbid/VBN (l_dobj) disorders/NNS
D007372_D006526 NONE interferon/NN (r_pobj) with/IN (r_prep) therapy/NN (r_attr) is/VBZ (l_nsubj) treatment/NN (l_prep) for/IN (l_pobj) infection/NN
D012254_D006461 NONE ribavirin/RB (r_npadvmod) induced/VBN (r_amod) hemolysis/NN
D012254_D019698 NONE ribavirin/NN (r_pobj) of/IN (r_prep) prodrug/NN (r_appos) Viramidine/NNP (r_nsubj) has/VBZ (l_dobj) potential/NN (l_acl) maintain/VB (l_advcl) decreasing/VBG (l_dobj) risk/NN (l_prep) of/IN (l_pobj) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) C./NNP -PUNC- ribavirin/RB (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) maintain/VB (l_advcl) decreasing/VBG (l_dobj) risk/NN (l_prep) of/IN (l_pobj) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) C./NNP
D012254_D006526 NONE ribavirin/NN (r_conj) interferon/NN (r_pobj) with/IN (r_prep) therapy/NN (r_attr) is/VBZ (l_nsubj) treatment/NN (l_prep) for/IN (l_pobj) infection/NN -PUNC- ribavirin/RB (r_npadvmod) induced/VBN (r_amod) hemolysis/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) decrease/VBP (l_conj) be/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infection/NN
15632880
D013148_D006947 CID Spironolactone/NNP (r_npadvmod) induced/VBN (l_dobj) insufficiency/NN (l_conj) hyperkalemia/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) evaluating/VBG (r_acl) trial/NN (r_nsubj) reported/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) insufficiency/NN (r_conj) hyperkalemia/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_dobj) required/VBD (l_prep) due/IN (l_pobj) hyperkalemia/NN -PUNC- Spironolactone/NNP (r_npadvmod) induced/VBN (r_amod) hyperkalemia/NN
D013148_D051437 CID Spironolactone/NNP (r_npadvmod) induced/VBN (l_dobj) insufficiency/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) evaluating/VBG (r_acl) trial/NN (r_nsubj) reported/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN (l_conj) insufficiency/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) insufficiency/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_dobj) required/VBD (l_prep) due/IN (l_pobj) hyperkalemia/NN (l_conj) failure/NN -PUNC- Spironolactone/NNP (r_npadvmod) induced/VBN (r_amod) hyperkalemia/NN (r_nmod) insufficiency/NN
D011188_D051437 NONE K(+/NNP (r_appos) hyperkalemia/NN (r_dobj) developed/VBD (r_relcl) patients/NNS (r_attr) were/VBD (l_nsubj) Cases/NNS (l_appos) L/NN (l_conj) insufficiency/NN
D011188_D006947 NONE K(+/NNP (r_appos) hyperkalemia/NN -PUNC- potassium/NN (r_compound) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) hyperkalemia/NN -PUNC- potassium/NN (r_compound) supplement/NN (r_compound) doses/NNS (r_conj) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) hyperkalemia/NN
D003404_D051437 NONE creatinine/NN (r_conj) weight/NN (r_dobj) had/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) insufficiency/NN
D049971_D051437 NONE thiazide/NN (r_amod) diuretics/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_xcomp) likely/JJ (r_acomp) were/VBD (r_conj) required/VBD (r_conj) had/VBD (l_nsubj) Patients/NNS (l_relcl) developed/VBD (l_dobj) insufficiency/NN
D013148_D006333 NONE Spironolactone/NNP (r_npadvmod) induced/VBN (l_dobj) insufficiency/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- spironolactone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) failure/NN -PUNC- spironolactone/NN (r_pobj) of/IN (r_prep) benefits/NNS (r_nsubjpass) reported/VBN (r_advcl) changed/VBN (l_nsubj) treatments/NNS (l_prep) for/IN (l_pobj) failure/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_compound) failure/NN -PUNC- spironolactone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_compound) failure/NN
D011188_D003920 NONE potassium/NN (r_compound) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_acomp) older/JJR (l_conj) likely/JJ (l_xcomp) have/VB (l_dobj) diabetes/NNS -PUNC- potassium/NN (r_compound) supplement/NN (r_compound) doses/NNS (r_conj) levels/NNS (r_dobj) had/VBD (r_conj) were/VBD (l_acomp) older/JJR (l_conj) likely/JJ (l_xcomp) have/VB (l_dobj) diabetes/NNS
15686794
D000638_D017116 CID amiodarone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) during/IN (r_prep) pain/NN -PUNC- amiodarone/NN (r_compound) loading/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) experienced/VBD (l_dobj) pain/NN
D000638_D001281 NONE Amiodarone/NNP (r_nsubj) represents/VBZ (l_dobj) drug/NN (l_prep) for/IN (l_pobj) cardioversion/NN (l_prep) of/IN (l_pobj) fibrillation/NN -PUNC- Amiodarone/NNP (r_nsubj) represents/VBZ (l_dobj) drug/NN (l_prep) for/IN (l_pobj) cardioversion/NN (l_prep) of/IN (l_pobj) fibrillation/NN (l_appos) AF/NNP -PUNC- amiodarone/NN (r_compound) loading/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) experienced/VBD (r_relcl) fibrillation/NN
11581460
D005283_D001745 CID fentanyl/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) mimicking/VBG (r_acl) dilatation/NN (r_pobj) to/IN (r_prep) leading/VBG (r_acl) cases/NNS (l_prep) of/IN (l_pobj) retention/NN
D005283_D001919 CID fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN (l_conj) hypotension/NN (l_conj) depression/NN (l_conj) bradycardia/NN
D005283_D012131 CID fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN (l_conj) hypotension/NN (l_conj) depression/NN
D005283_D016055 CID fentanyl/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) retention/NN (l_prep) of/IN (l_pobj) urine/NN
D005283_D009127 NONE fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN
D005283_D007022 CID fentanyl/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) rigidity/NN (l_conj) hypotension/NN
D005283_D006869 NONE fentanyl/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) mimicking/VBG (l_dobj) hydronephrosis/NN
2594614
C045856_D002318 NONE 52021/CD (r_nummod) BN/NNP (r_appos) antagonist/NN (l_prep) on/IN (l_pobj) impairments/NNS -PUNC- 52021/CD (r_nummod) BN/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) alter/VB (r_advcl) demonstrate/VBP (l_dobj) action/NN (l_prep) against/IN (l_pobj) toxicity/NN -PUNC- 52021/CD (r_nummod) BN/NNP (r_pobj) of/IN (r_prep) action/NN (l_prep) against/IN (l_pobj) toxicity/NN
D002045_D007022 CID bupivacaine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) elicited/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) pressure/NN (l_appos) MBP/NNP (l_conj) rate/NN (l_punct) )/-RRB- -PUNC- bupivacaine/NN (r_compound) administration/NN (r_pobj) before/IN (r_prep) min/NN (r_appos) injection/NN (r_nsubj) suppressed/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN -PUNC- bupivacaine/NN (r_pobj) after/IN (r_prep) injected/VBN (r_advcl) observed/VBN (l_nsubjpass) reversion/NN (l_prep) of/IN (l_pobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN
C045856_D001919 NONE 52021/CD (r_appos) antagonist/NN (r_appos) injection/NN (r_nsubj) suppressed/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN -PUNC- 52021/CD (r_nummod) BN/NNP (r_nsubjpass) injected/VBN (r_advcl) observed/VBN (l_nsubjpass) reversion/NN (l_prep) of/IN (l_pobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN
D002045_D018376 NONE bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) alterations/NNS
D002045_D001919 CID bupivacaine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) elicited/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) pressure/NN (l_appos) MBP/NNP (l_conj) rate/NN (l_punct) )/-RRB- -PUNC- bupivacaine/NN (r_compound) administration/NN (r_pobj) before/IN (r_prep) min/NN (r_appos) injection/NN (r_nsubj) suppressed/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN -PUNC- bupivacaine/NN (r_pobj) after/IN (r_prep) injected/VBN (r_advcl) observed/VBN (l_nsubjpass) reversion/NN (l_prep) of/IN (l_pobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN
C045856_D007022 NONE 52021/CD (r_appos) antagonist/NN (r_appos) injection/NN (r_nsubj) suppressed/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN -PUNC- 52021/CD (r_nummod) BN/NNP (r_nsubjpass) injected/VBN (r_advcl) observed/VBN (l_nsubjpass) reversion/NN (l_prep) of/IN (l_pobj) decrease/NN (l_prep) of/IN (l_pobj) MBP/NNP (l_conj) HR/NN
D002045_D002318 NONE bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) impairments/NNS -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
3782049
D008972_D012206 CID molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN -PUNC- molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN
D008972_D058186 CID molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN (l_conj) failure/NN
D008972_D012559 NONE molindone/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) rhabdomyolysis/NN (r_dobj) illustrate/VB (r_xcomp) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) patient/NN (l_amod) schizophrenic/JJ
3653576
D011692_D058186 CID aminonucleoside/NN (r_nmod) PAN/NNP (r_npadvmod) puromycin/NNS (l_ccomp) produced/VBN (l_nsubjpass) models/NNS (l_prep) of/IN (l_pobj) damage/NN -PUNC- PAN/NNP (r_npadvmod) puromycin/NNS (l_ccomp) produced/VBN (l_nsubjpass) models/NNS (l_prep) of/IN (l_pobj) damage/NN
C004504_D007674 NONE BEA/NNP (r_conj) HCBD/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) damage/NN (r_nsubjpass) discriminated/VBN (l_prep) from/IN (l_pobj) damage/NN
D011692_D007674 NONE PAN/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) damage/NN
C001335_D007674 NONE HCBD/NNP (r_pobj) by/IN (r_agent) produced/VBN (r_acl) damage/NN (r_nsubjpass) discriminated/VBN (l_prep) from/IN (l_pobj) damage/NN
C001335_D058186 CID hexachloro-1:3-butadiene/, (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) models/NNS (l_prep) of/IN (l_pobj) damage/NN -PUNC- HCBD/NNP (r_appos) hexachloro-1:3-butadiene/, (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) models/NNS (l_prep) of/IN (l_pobj) damage/NN
C004504_D058186 CID 2-bromoethylamine/NN (r_punct) ./. (r_punct) puromycin/NNS (l_ccomp) produced/VBN (l_nsubjpass) models/NNS (l_prep) of/IN (l_pobj) damage/NN -PUNC- BEA/NNP (r_nmod) 2-bromoethylamine/NN (r_punct) ./. (r_punct) puromycin/NNS (l_ccomp) produced/VBN (l_nsubjpass) models/NNS (l_prep) of/IN (l_pobj) damage/NN
12448656
D013792_D064420 NONE thalidomide/NN (r_pobj) of/IN (r_prep) toxicity/NN
D013792_D002292 NONE thalidomide/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_dobj) evaluate/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) of/IN (r_prep) level/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- thalidomide/NN (l_prep) for/IN (l_pobj) carcinoma/NN
3300918
D002118_D008881 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) advent/NN (r_pobj) Despite/IN (r_prep) continue/VBP (l_xcomp) play/VB (l_dobj) role/NN (l_prep) in/IN (l_pobj) therapy/NN (l_compound) migraine/NN
D004876_D008881 CID ergot/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) of/IN (r_prep) discussion/NN (r_nsubj) includes/VBZ (l_dobj) discovery/NN (l_appos) epidemics/NNS (l_relcl) caused/VBN (l_prep) through/IN (l_pobj) ages/NNS (l_conj) role/NN (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) headache/NN -PUNC- ergot/NN (r_compound) preparations/NNS (r_nsubj) continue/VBP (l_xcomp) play/VB (l_dobj) role/NN (l_prep) in/IN (l_pobj) therapy/NN (l_compound) migraine/NN
D002118_D004881 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) advent/NN (r_pobj) Despite/IN (r_prep) continue/VBP (l_advcl) persists/VBZ (l_nsubj) danger/NN (l_prep) of/IN (l_pobj) fire/NN
D008784_D014652 CID methysergide/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) to/IN (r_prep) described/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) vasospasm/NN
D004876_D005734 NONE ergot/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) of/IN (r_prep) discussion/NN (r_nsubj) includes/VBZ (l_dobj) discovery/NN (l_appos) epidemics/NNS (l_prep) of/IN (l_pobj) gangrene/NN
D004876_D004881 NONE ergot/NN (r_compound) preparations/NNS (r_nsubj) continue/VBP (l_advcl) persists/VBZ (l_nsubj) danger/NN (l_prep) of/IN (l_pobj) fire/NN
16132524
D017239_D005909 NONE paclitaxel/NN (r_nmod) carboplatin/VB (r_amod) phases/NNS (l_prep) for/IN (l_pobj) glioblastoma/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) application/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) safety/NN (r_conj) feasibility/NN (r_nsubjpass) examined/VBN (l_prep) For/IN (l_pobj) recurrences/NNS (l_compound) glioblastoma/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) application/NN (r_dobj) received/VBD (r_conj) underwent/VBN (r_acl) multiforme/NN (l_compound) glioblastoma/NN
D016190_D005909 NONE carboplatin/VB (r_amod) phases/NNS (l_prep) for/IN (l_pobj) glioblastoma/NN -PUNC- carboplatin/NN (r_advmod) encapsulated/VBN (r_conj) effects/NNS (r_conj) safety/NN (r_conj) feasibility/NN (r_nsubjpass) examined/VBN (l_prep) For/IN (l_pobj) recurrences/NNS (l_compound) glioblastoma/NN -PUNC- carboplatin/VB (r_amod) phases/NNS (r_conj) received/VBD (r_conj) underwent/VBN (r_acl) multiforme/NN (l_compound) glioblastoma/NN
D017239_D001929 CID paclitaxel/NN (r_dobj) received/VBD (l_conj) suffered/VBD (l_prep) from/IN (l_prep) to/TO (l_pobj) edema/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) total/NN (r_dobj) received/VBD (r_advcl) suffered/VBD (l_prep) from/IN (l_prep) to/TO (l_pobj) edema/NN
12063090
D004177_D059350 NONE metamizol/NN (r_conj) morphine/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) show/VBP (l_advcl) suggesting/VBG (l_ccomp) be/VB (l_acomp) useful/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN
D009020_D003248 CID morphine/NN (r_compound) antinociception/NN (l_conj) constipation/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) antinociceptive/NN (l_conj) constipating/JJ -PUNC- morphine/NN (r_nsubj) inhibited/VBD (l_advcl) suggesting/VBG (l_ccomp) develop/VB (l_prep) to/IN (l_pobj) effects/NNS (l_amod) constipating/JJ -PUNC- morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_amod) transit/NN (r_dobj) inhibited/VBD (l_advcl) suggesting/VBG (l_ccomp) potentiate/VB (l_dobj) constipation/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) constipation/NN
D004177_D003248 NONE Metamizol/NNP (r_nsubj) potentiates/VBZ (l_dobj) antinociception/NN (l_conj) constipation/NN -PUNC- metamizol/NN (r_pobj) with/IN (r_prep) effects/NNS (l_amod) antinociceptive/NN (l_conj) constipating/JJ -PUNC- metamizol/NN (r_nsubj) potentiate/VB (l_dobj) constipation/NN
D002606_D010146 NONE charcoal/NN (r_compound) meal/NN (r_compound) test/NN (r_nsubjpass) used/VBN (r_conj) assessed/VBN (l_conj) model/NN (l_amod) induced/VBN (l_npadvmod) pain/NN
D009020_D059350 NONE morphine/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) show/VBP (l_advcl) suggesting/VBG (l_ccomp) be/VB (l_acomp) useful/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN
18997632
D002110_D018879 CID caffeine/NN (r_nsubjpass) used/VBN (l_conj) tolerated/VBN (l_prep) from/IN (l_pobj) reports/NNS (l_prep) of/IN (l_pobj) ectopy/NN
D002110_D012640 CID caffeine/NN (r_nsubjpass) used/VBN (l_xcomp) improve/VB (l_dobj) duration/NN (l_compound) seizure/NN
D002110_D017180 CID caffeine/NN (r_compound) pretreatment/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) tachycardia/NN -PUNC- caffeine/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) bigeminy/JJ (l_conj) runs/NNS (l_prep) of/IN (l_pobj) tachycardia/NN
D002110_D001145 NONE caffeine/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) disease/NN (l_conj) arrhythmia/NN -PUNC- caffeine/NN (r_nsubjpass) tolerated/VBN (r_advcl) be/VB (l_acomp) aware/JJ (l_prep) of/IN (l_pobj) potential/NN (l_prep) for/IN (l_pobj) arrhythmias/NNS
D002110_D006331 NONE caffeine/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) disease/NN
8558192
C030852_C562729 NONE vinorelbine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- vinorelbine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) rate/NN (l_acl) administered/VBN (l_prep) as/IN (l_pobj) agent/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- VNB/NNP (r_appos) vinorelbine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) rate/NN (l_acl) administered/VBN (l_prep) as/IN (l_pobj) agent/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- VNB/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) in/IN (l_pobj) carcinoma/NN
D002945_D064420 NONE cisplatin/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) with/IN (r_prep) pretreated/VBN (r_csubj) were/VBD (l_acomp) assessable/JJ (l_prep) for/IN (l_pobj) toxicity/NN
C030852_D064420 NONE VNB/NNP (r_nsubjpass) tolerated/VBN (l_conj) occurred/VBD (l_nsubj) toxicity/NN -PUNC- VNB/NNP (r_pobj) of/IN (r_prep) evaluation/NN (r_nsubjpass) warranted/VBN (l_prep) Given/VBN (l_pobj) profile/NN (l_conj) toxicity/NN
19719056
D019342_D010146 NONE acid/NN (r_dobj) using/VBG (r_advcl) ascertained/VBN (l_conj) induced/VBD (l_xcomp) writhing/VBG
D002351_D004487 CID carrageenan/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) edema/NN
D002351_D010146 CID carrageenan/NN (r_npadvmod) induced/VBN (r_amod) model/NN (r_conj) mice/NNS (r_appos) model/NN (r_attr) writhing/VBG
D019342_D004487 NONE acid/NN (r_dobj) using/VBG (r_advcl) ascertained/VBN (l_conj) induced/VBD (l_xcomp) writhing/VBG (l_attr) model/NN (l_appos) mice/NNS (l_conj) model/NN (l_compound) edema/NN
15859940
D016572_D064420 NONE cyclosporine/NN (r_nmod) toxicity/NN
D016559_D064420 NONE tacrolimus/NN (r_conj) cyclosporine/NN (r_nmod) toxicity/NN
D016572_D057049 CID cyclosporine/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) related/VBN (r_acomp) was/VBD (l_nsubj) cause/NN (l_prep) of/IN (l_pobj) microangiopathy/NN
10027919
C051883_-1 NONE OCT/NNP (r_nsubj) reversed/VBD (l_dobj) formation/NN (l_prep) as/IN (l_pobj) osteoid/NN
C051883_D005355 NONE OCT/NNP (r_nsubj) reversed/VBD (l_dobj) formation/NN (l_prep) as/IN (l_pobj) osteoid/NN (l_conj) fibrosis/NN
C051883_D006962 NONE 22-oxacalcitriol/JJ (r_nsubj) suppresses/VBZ (l_dobj) hyperparathyroidism/NN -PUNC- OCT/NNP (r_nsubj) stabilized/VBD (l_prep) In/IN (l_pobj) hyperparathyroidism/NN -PUNC- OCT/NNP (r_nsubj) prevent/VB (r_advcl) be/VB (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) hyperparathyroidism/NN
C051883_D006934 CID OCT/NNP (r_nsubj) prevent/VB (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN
D002117_D001851 CID Calcitriol/NNP (r_compound) therapy/NN (r_nsubj) suppresses/VBZ (l_conj) has/VBZ (l_dobj) drawbacks/NNS (l_prep) including/VBG (l_pobj) hypercalcemia/NN (l_conj) suppression/NN (l_prep) of/IN (l_pobj) turnover/NN -PUNC- Calcitriol/NNP (r_compound) therapy/NN (r_nsubj) suppresses/VBZ (l_conj) has/VBZ (l_dobj) drawbacks/NNS (l_prep) including/VBG (l_pobj) hypercalcemia/NN (l_conj) suppression/NN (l_prep) of/IN (l_pobj) turnover/NN (l_relcl) lead/VB (l_prep) to/IN (l_pobj) disease/NN
C051883_D001851 NONE 22-oxacalcitriol/JJ (r_nsubj) suppresses/VBZ (l_prep) without/IN (l_pcomp) inducing/VBG (l_dobj) turnover/NN -PUNC- OCT/NNP (r_nsubj) prevent/VB (r_advcl) be/VB (l_advcl) induce/VB (l_dobj) turnover/NN -PUNC- OCT/NNP (r_nsubj) prevent/VB (r_advcl) be/VB (l_advcl) induce/VB (l_conj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) disease/NN
C051883_D051437 NONE 22-oxacalcitriol/JJ (r_nsubj) suppresses/VBZ (l_prep) without/IN (l_pcomp) inducing/VBG (l_dobj) turnover/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- OCT/NNP (r_nsubj) decreased/VBD (l_prep) after/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) insufficiency/NN -PUNC- OCT/NNP (r_nsubj) prevent/VB (l_dobj) occurrence/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) insufficiency/NN
C051883_D007674 NONE OCT/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) levels/NNS (l_conj) turnover/NN (l_prep) in/IN (l_pobj) states/NNS (l_prep) of/IN (l_pobj) function/NN
D002117_D006934 CID Calcitriol/NNP (r_compound) therapy/NN (r_nsubj) suppresses/VBZ (l_conj) has/VBZ (l_dobj) drawbacks/NNS (l_prep) including/VBG (l_pobj) hypercalcemia/NN
D002117_D051437 NONE Calcitriol/NNP (r_compound) therapy/NN (r_nsubj) suppresses/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
16938416
D004967_D050197 NONE estrogen/NN (r_compound) testosterone/NN (r_compound) therapy/NN (l_conj) atherosclerosis/NN
D002784_D003920 NONE cholesterol/NN (r_compound) level/NN (r_conj) diabetes/NNS
D013739_D050197 CID testosterone/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- testosterone/NN (r_compound) therapy/NN (l_conj) atherosclerosis/NN -PUNC- testosterone/NN (r_compound) therapy/NN (r_nsubj) affect/VB (l_dobj) atherosclerosis/NN
C032109_D050197 NONE esters/NNS (r_appos) therapy/NN (l_conj) atherosclerosis/NN
D000431_D003920 NONE alcohol/NN (r_compound) use/NN (r_conj) pressure/NN (r_conj) level/NN (r_conj) diabetes/NNS
2505783
C004656_D001745 NONE CAA/NNP (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) damage/NN
C004656_D006470 CID chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_appos) chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_pobj) of/IN (r_prep) role/NN (r_dobj) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN
C004656_D003556 CID chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_appos) chloroacetaldehyde/NN (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_relcl) carried/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN -PUNC- CAA/NNP (r_pobj) of/IN (r_prep) role/NN (r_dobj) elucidate/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cystitis/NN
12042105
C020243_D053040 NONE phosphate/NN (r_compound) nephrolithiasis/NN
C052342_D053040 CID Topiramate/NNP (r_npadvmod) induced/VBN (r_amod) nephrolithiasis/NN -PUNC- topiramate/RB (r_npadvmod) induced/VBN (r_amod) nephrolithiasis/NN
C052342_D004827 NONE Topiramate/NNP (r_nsubj) is/VBZ (l_attr) medication/NN (l_relcl) becoming/VBG (l_prep) because/IN (l_pobj) efficacy/NN (l_prep) in/IN (l_pcomp) treating/VBG (l_dobj) seizures/NNS
6103707
D005445_D010146 CID flunitrazepam/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) on/IN (r_prep) pain/NN
7416947
D004077_D020018 CID digoxin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) dysfunction/NN
D004077_D012214 NONE digoxin/NN (r_pobj) without/IN (r_prep) group/NN (r_pobj) of/IN (r_prep) patients/NNS (r_nsubj) were/VBD (l_conj) selected/VBN (l_prep) from/IN (l_pobj) patients/NNS (l_compound) disease/NN
8231633
D002045_D064420 NONE bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D015764_D012640 NONE bepridil/NN (r_pcomp) with/IN (r_prep) pronounced/VBN (r_acomp) was/VBD (l_ccomp) modified/VBN (l_conj) decreased/VBD (l_dobj) time/NN (l_relcl) obtain/VB (l_dobj) convulsions/NNS
D002045_D012640 CID bupivacaine/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubj) was/VBD (r_auxpass) modified/VBN (l_conj) decreased/VBD (l_dobj) time/NN (l_relcl) obtain/VB (l_dobj) convulsions/NNS -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
D002118_D012640 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubj) decreased/VBD (l_dobj) time/NN (l_relcl) obtain/VB (l_dobj) convulsions/NNS
D002118_D064420 NONE calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (l_prep) on/IN (l_pobj) toxicity/NN -PUNC- calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (l_prep) on/IN (l_pobj) toxicity/NN
2440413
D010433_D012640 CID PTZ/NNP (r_pobj) to/TO (r_prep) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (l_compound) Seizure/NN -PUNC- PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (r_nsubjpass) decreased/VBN (r_ccomp) was/VBD (l_nsubj) activity/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (l_compound) seizure/NN -PUNC- PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (r_pobj) to/IN (r_prep) occur/VB (l_advcl) decreased/VBN (l_nsubjpass) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN
C034818_D012640 CID carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- DMCM/NNP (r_appos) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- DMCM/NNP (r_appos) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D010852_D012640 CID picrotoxin/NN (r_conj) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (l_compound) Seizure/NN -PUNC- picrotoxin/NN (r_conj) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (r_nsubjpass) decreased/VBN (r_ccomp) was/VBD (l_nsubj) activity/NN (l_compound) seizure/NN -PUNC- PTX/NNP (r_appos) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (l_compound) Seizure/NN -PUNC- PTX/NNP (r_appos) PTZ/NNP (r_pobj) due/IN (r_amod) activity/NN (r_nsubjpass) decreased/VBN (r_ccomp) was/VBD (l_nsubj) activity/NN (l_compound) seizure/NN -PUNC- PTX/NNP (r_conj) PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (l_compound) seizure/NN -PUNC- PTX/NNP (r_conj) PTZ/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) activity/NN (r_pobj) to/IN (r_prep) occur/VB (l_advcl) decreased/VBN (l_nsubjpass) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN
D001640_D012640 CID bicuculline/NN (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- bicuculline/NN (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- BCC/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- BCC/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D005680_D012640 NONE GABA/NNP (r_compound) A/NNP (r_nmod) channel/NN (r_attr) be/VB (l_nsubj) site/NN (l_amod) responsible/JJ (l_prep) for/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) activity/NN (l_compound) seizure/NN
D013331_D012640 CID strychnine/NN (r_conj) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- strychnine/NN (r_conj) carboline-3-carboxylate/NNP (r_conj) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- STR/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- STR/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D015097_D012640 CID acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN -PUNC- MPA/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (r_nsubj) was/VBD (l_ccomp) decreased/VBN (l_nsubjpass) activity/NN (l_compound) Seizure/NN -PUNC- MPA/NNP (r_appos) acid/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) activity/NN (l_compound) seizure/NN
D001556_D012640 NONE hexachlorocyclohexane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- lindane/NN (r_appos) hexachlorocyclohexane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- hexachlorocyclohexane/NN (r_nsubjpass) shown/VBN (l_xcomp) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- HCH/NNP (r_appos) hexachlorocyclohexane/NN (r_nsubjpass) shown/VBN (l_xcomp) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- lindane/NN (r_pobj) of/IN (r_prep) ingredient/NN (r_appos) hexachlorocyclohexane/NN (r_nsubjpass) shown/VBN (l_xcomp) decrease/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- HCH/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) h/NN (l_conj) increase/VB (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- HCH/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) h/NN (l_dep) h/NN (l_conj) increase/VB (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- HCH/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) tested/VBN (l_nsubjpass) severity/NN (l_prep) of/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) increased/VBN (l_nsubjpass) activity/NN (l_prep) of/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_appos) h/NN (r_dep) observed/VBN (l_advcl) increased/VBN (l_nsubjpass) activity/NN (l_prep) of/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) occur/VB (l_prep) to/IN (l_pobj) activity/NN (l_compound) seizure/NN -PUNC- HCH/NNP (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) occur/VB (l_advcl) decreased/VBN (l_nsubjpass) response/NN (l_prep) to/IN (l_pobj) agents/NNS (l_amod) inducing/VBG (l_npadvmod) seizure/NN -PUNC- HCH/NNP (r_nsubj) be/VB (l_nsubj) site/NN (l_amod) responsible/JJ (l_prep) for/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) activity/NN (l_compound) seizure/NN
8643966
D017239_D064420 NONE paclitaxel/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_conj) toxicity/NN -PUNC- Paclitaxel/NNP (r_nsubj) is/VBZ (l_prep) with/IN (l_pobj) infusion/NN (l_acl) proving/VBG (l_oprd) effective/JJ (l_prep) to/IN (l_pobj) infusion/NN (l_conj) superior/JJ (l_prep) in/IN (l_pobj) terms/NNS (l_prep) of/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) toxicity/NN
D017239_D002289 NONE paclitaxel/NN (r_pobj) with/IN (r_prep) cancer/NN -PUNC- paclitaxel/NN (r_compound) infusions/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) IIIB/NNS (l_conj) cancer/NN -PUNC- paclitaxel/NN (r_compound) infusions/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) IIIB/NNS (l_conj) cancer/NN (l_appos) NSCLC/NNP -PUNC- paclitaxel/NN (r_compound) infusion/NN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) IIIB/NNS (l_conj) NSCLC/NNP -PUNC- paclitaxel/NN (r_pobj) with/IN (r_prep) studies/NNS (l_acl) combined/VBN (l_prep) with/IN (l_pobj) drugs/NNS (l_amod) active/JJ (l_prep) against/IN (l_pobj) NSCLC/NNP -PUNC- paclitaxel/NN (r_dobj) comparing/VBG (r_acl) studies/NNS (r_dobj) phase/NN (r_conj) indicated/VBN (l_nsubjpass) phase/NN (l_dobj) studies/NNS (l_acl) combined/VBN (l_prep) with/IN (l_pobj) drugs/NNS (l_amod) active/JJ (l_prep) against/IN (l_pobj) NSCLC/NNP
D017239_D009369 NONE Paclitaxel/NNP (r_nsubj) demonstrated/VBN (l_dobj) activity/NN (l_prep) against/IN (l_pobj) types/NNS (l_compound) tumor/NN -PUNC- Taxol/NNP (r_appos) Paclitaxel/NNP (r_nsubj) demonstrated/VBN (l_dobj) activity/NN (l_prep) against/IN (l_pobj) types/NNS (l_compound) tumor/NN
D017239_D010051 NONE Paclitaxel/NNP (r_nsubj) demonstrated/VBN (l_dobj) activity/NN (l_prep) against/IN (l_pobj) types/NNS (l_appos) carcinoma/NN -PUNC- Taxol/NNP (r_appos) Paclitaxel/NNP (r_nsubj) demonstrated/VBN (l_dobj) activity/NN (l_prep) against/IN (l_pobj) types/NNS (l_appos) carcinoma/NN
D017239_D001943 NONE Paclitaxel/NNP (r_nsubj) demonstrated/VBN (l_dobj) activity/NN (l_prep) against/IN (l_pobj) types/NNS (l_appos) carcinoma/NN -PUNC- Taxol/NNP (r_appos) Paclitaxel/NNP (r_nsubj) demonstrated/VBN (l_dobj) activity/NN (l_prep) against/IN (l_pobj) types/NNS (l_appos) carcinoma/NN
11573852
D000431_D000437 NONE alcohol/NN (r_compound) intake/NN (r_conj) history/NN (l_prep) of/IN (l_pobj) abuse/NN
D000666_D012640 CID B/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- B/NNP (r_compound) infusion/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) episodes/NNS (l_prep) of/IN (l_pobj) activity/NN (l_compound) seizure/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) during/IN (r_prep) experienced/VBD (l_conj) stopped/VBN (l_nsubjpass) seizures/NNS -PUNC- B/NNP (r_compound) administration/NN (r_pobj) during/IN (r_prep) occurred/VBD (r_conj) persisted/VBD (l_nsubj) seizures/NNS -PUNC- B/NNP (r_nsubj) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- B/NNP (r_nsubj) seems/VBZ (l_xcomp) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- B/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) seizures/NNS
D010672_D012640 NONE phenytoin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) Despite/IN (r_prep) persisted/VBD (l_nsubj) seizures/NNS
D008140_D012640 NONE lorazepam/NN (r_conj) phenytoin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) Despite/IN (r_prep) persisted/VBD (l_nsubj) seizures/NNS
D000431_D012640 NONE alcohol/NN (r_compound) intake/NN (r_conj) history/NN (r_dobj) had/VBD (l_conj) cause/VB (l_dobj) seizures/NNS
D000666_D000163 NONE B/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) AIDS/NNP -PUNC- B/NNP (r_compound) infusion/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) episodes/NNS (l_prep) in/IN (l_pobj) patent/NN (l_compound) AIDS/NNP -PUNC- B/NNP (r_nsubj) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) seizures/NNS (l_prep) in/IN (l_pobj) patient/NN (l_compound) AIDS/NNP
D000666_D004830 NONE B/NNP (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) during/IN (r_prep) experienced/VBD (l_dobj) seizures/NNS
D016049_D012640 NONE Didanosine/NNP (r_nsubj) has/VBZ (l_dobj) potential/NN (l_prep) for/IN (l_pcomp) inducing/VBG (l_dobj) seizures/NNS
17574447
D010634_D002761 CID phenobarbital/JJ (r_amod) therapy/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) Hepatonecrosis/NNP (l_conj) cholangitis/NN
D010634_D006323 NONE PB/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) history/NN (r_pobj) with/IN (r_prep) report/VBP (l_appos) one/CD (l_prep) as/IN (l_pobj) consequence/NN (l_prep) of/IN (l_pobj) arrest/NN
D010634_D001996 NONE PB/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) history/NN (r_pobj) with/IN (r_prep) report/VBP (l_appos) one/CD (l_appos) other/JJ (l_prep) of/IN (l_pobj) bronchopneumonia/NN
D010634_D008107 CID Phenobarbital/NNP (r_nsubj) has/VBZ (l_conj) believed/VBN (l_ccomp) indicate/VB (l_conj) predict/VB (l_dobj) development/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- PB/NNP (r_appos) Phenobarbital/NNP (r_nsubj) has/VBZ (l_conj) believed/VBN (l_ccomp) indicate/VB (l_conj) predict/VB (l_dobj) development/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- PB/NNP (r_npadvmod) related/VBN (r_amod) increases/NNS (r_nsubj) indicate/VB (l_conj) predict/VB (l_dobj) development/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- PB/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) damage/NN
D010634_D056487 NONE PB/NNP (r_npadvmod) related/VBN (r_amod) dysfunction/NN
D010634_-1 NONE phenobarbital/JJ (r_amod) therapy/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) Hepatonecrosis/NNP
D010634_D004827 NONE PB/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) history/NN (l_prep) of/IN (l_pobj) epilepsy/NN
567256
D004054_D006394 CID diethylstilbestrol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) liver/NN -PUNC- diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN (r_pobj) of/IN (r_prep) adenocarcinoma/NN (r_pobj) for/IN (r_prep) treated/VBN (r_relcl) man/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Angiosarcoma/NNP (l_prep) of/IN (l_pobj) liver/NN
D004054_D000230 NONE diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN
D004054_D008113 CID diethylstilbestrol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) liver/NN -PUNC- diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN (r_pobj) of/IN (r_prep) adenocarcinoma/NN (r_pobj) for/IN (r_prep) treated/VBN (r_relcl) man/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Angiosarcoma/NNP (l_prep) of/IN (l_pobj) liver/NN
D004054_D008113 NONE diethylstilbestrol/NN (r_pobj) with/IN (r_prep) liver/NN
15579441
D011692_D000860 CID aminonucleoside/NN (r_advmod) induced/VBN (r_amod) syndrome/NN (r_appos) puromycin/NNS (r_pobj) in/IN (r_prep) identify/VB (l_dobj) hypoxia/NN -PUNC- aminonucleoside/NN (r_advmod) induced/VBN (r_amod) syndrome/NN (l_conj) hypoxia/NN -PUNC- aminonucleoside/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) reaching/VBG (r_advcl) increased/VBD (l_nsubj) Expression/NN (l_prep) of/IN (l_pobj) transgene/NN (l_amod) responsive/JJ (l_npadvmod) hypoxia/NN
D011692_D009404 CID aminonucleoside/NN (r_advmod) induced/VBN (r_amod) syndrome/NN
7053303
D002927_D007674 NONE cimetidine/NN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) disease/NN -PUNC- cimetidine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (r_relcl) disease/NN
D002927_D008107 NONE cimetidine/NN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) disease/NN -PUNC- cimetidine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (r_relcl) disease/NN
D002927_D003704 CID cimetidine/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) dementia/NN -PUNC- cimetidine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (r_relcl) disease/NN (r_pobj) without/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) in/IN (r_prep) cimetidine/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) dementia/NN -PUNC- cimetidine/NN (r_compound) levels/NNS (r_nsubj) induce/VB (l_dobj) dementia/NN
12139551
D008787_D006323 CID metoclopramide/NN (r_compound) case/NN (r_pobj) after/IN (r_prep) arrest/NN -PUNC- metoclopramide/NN (r_compound) case/NN (l_acl) causing/VBG (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) arrest/NN -PUNC- metoclopramide/NN (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) of/IN (r_prep) case/NN (r_pobj) after/IN (r_prep) arrest/NN -PUNC- metoclopramide/NN (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) of/IN (r_prep) case/NN (l_acl) causing/VBG (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) arrest/NN -PUNC- metoclopramide/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubjpass) followed/VBN (l_agent) by/IN (l_pobj) asystole/NN -PUNC- metoclopramide/JJ (r_dobj) received/VBD (r_ccomp) is/VBZ (l_advcl) followed/VBN (l_agent) by/IN (l_pobj) asystole/NN -PUNC- metoclopramide/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) was/VBD (r_ccomp) is/VBZ (l_advcl) followed/VBN (l_agent) by/IN (l_pobj) asystole/NN -PUNC- metoclopramide/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) episodes/NNS (l_prep) of/IN (l_pobj) arrest/NN
33969
D011352_D001008 NONE procyclindine/JJ (r_compound) treatment/NN (r_pobj) during/IN (r_prep) condition/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) had/VBD (l_conj) treated/VBN (l_nsubj) anxiety/NN
D011352_D004409 NONE procyclindine/JJ (r_compound) treatment/NN (r_pobj) during/IN (r_prep) condition/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) had/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) dyskinesia/JJ
D001590_D010302 NONE benztropine/NN (l_prep) in/IN (l_pobj) parkinsonism/NN -PUNC- benztropine/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) parkinsonism/NN -PUNC- benztropine/NN (r_conj) Ethopropazine/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) symptoms/NNS -PUNC- benztropine/NN (r_nsubj) is/VBZ (l_attr) drug/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) symptoms/NNS
C084820_D003866 NONE ethopropazine/NN (r_pobj) than/IN (r_mark) treated/VBN (l_nsubj) anxiety/NN (l_conj) depression/NN
D001590_D004409 CID benztropine/NN (r_nsubj) had/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) dyskinesia/JJ
D001590_D012559 NONE benztropine/VB (l_advcl) induced/VBN (l_agent) by/IN (l_pobj) fluphenazine/JJ (l_amod) enanthate/NN (l_prep) in/IN (l_pobj) outpatients/NNS (l_amod) schizophrenic/JJ
C084820_D004409 NONE ethopropazine/NN (r_pobj) than/IN (r_mark) treated/VBN (r_conj) had/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) dyskinesia/JJ
D011352_D003866 NONE procyclindine/JJ (r_compound) treatment/NN (r_pobj) during/IN (r_prep) condition/NN (r_pobj) to/IN (r_prep) compared/VBN (r_prep) had/VBD (l_conj) treated/VBN (l_nsubj) anxiety/NN (l_conj) depression/NN
C084820_D012559 NONE ethopropazine/NN (r_pobj) In/IN (r_prep) compared/VBN (l_xcomp) benztropine/VB (l_advcl) induced/VBN (l_agent) by/IN (l_pobj) fluphenazine/JJ (l_amod) enanthate/NN (l_prep) in/IN (l_pobj) outpatients/NNS (l_amod) schizophrenic/JJ
D001590_D001008 CID benztropine/NN (r_nsubj) had/VBD (l_conj) treated/VBN (l_nsubj) anxiety/NN
C084820_D010302 NONE Ethopropazine/NN (l_conj) benztropine/NN (l_prep) in/IN (l_pobj) parkinsonism/NN -PUNC- ethopropazine/NN (r_pobj) In/IN (r_prep) compared/VBN (l_xcomp) benztropine/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) parkinsonism/NN -PUNC- Ethopropazine/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) symptoms/NNS
D001590_D003866 CID benztropine/NN (r_nsubj) had/VBD (l_conj) treated/VBN (l_nsubj) anxiety/NN (l_conj) depression/NN
C084820_D001008 NONE ethopropazine/NN (r_pobj) than/IN (r_mark) treated/VBN (l_nsubj) anxiety/NN
C017610_D012559 NONE enanthate/NN (l_prep) in/IN (l_pobj) outpatients/NNS (l_amod) schizophrenic/JJ
D011352_D010302 NONE procyclidine/NN (r_pobj) as/IN (r_prep) efficacious/JJ (r_acomp) were/VBD (r_conj) found/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) symptoms/NNS
C017610_D010302 CID enanthate/NN (r_amod) fluphenazine/JJ (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) benztropine/VB (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) parkinsonism/NN
7910951
D000305_D018908 NONE corticosteroids/NNS (r_pobj) due/IN (r_prep) likely/JJ (r_parataxis) likely/JJ (r_parataxis) pathology/NN (r_pobj) due/JJ (r_acomp) is/VBZ (l_nsubj) weakness/NN
D003473_D010243 NONE agents/NNS (r_appos) neuromuscular/JJ (r_pobj) due/IN (r_prep) paralysis/NN
D003473_D012131 NONE NMBAs/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) following/VBG (r_prep) weakness/NN (r_dobj) developed/VBD (r_relcl) insufficiency/NN
D000305_D010243 NONE corticosteroids/NNS (r_conj) agents/NNS (r_appos) neuromuscular/JJ (r_pobj) due/IN (r_prep) paralysis/NN
D003473_D009468 CID NMBA/NNP (r_pobj) due/IN (r_prep) likely/JJ (r_parataxis) pathology/NN (l_prep) at/IN (l_pobj) junction/NN
D000305_D009468 NONE corticosteroids/NNS (r_pobj) due/IN (r_prep) likely/JJ (r_parataxis) likely/JJ (r_parataxis) pathology/NN (l_prep) at/IN (l_pobj) junction/NN
D003473_D018908 CID agents/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) implicated/VBN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) weakness/NN -PUNC- NMBA/NNP (r_appos) agents/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) implicated/VBN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) weakness/NN -PUNC- NMBAs/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) following/VBG (r_prep) weakness/NN -PUNC- NMBA/NNP (r_pobj) due/IN (r_prep) likely/JJ (r_parataxis) pathology/NN (r_pobj) due/JJ (r_acomp) is/VBZ (l_nsubj) weakness/NN
16005948
-1_D062787 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) Evaluation/NN (l_prep) as/IN (l_pobj) immunotherapy/NN (l_prep) for/IN (l_pobj) overdose/NN -PUNC- GNC92H2/NNP (r_pobj) of/IN (r_prep) potential/NN (r_nsubjpass) examined/VBN (l_advcl) using/VBG (l_dobj) model/NN (l_prep) of/IN (l_pobj) overdose/NN -PUNC- GNC92H2/NNP (r_pobj) of/IN (r_prep) potential/NN (l_prep) as/IN (l_pobj) tool/NN (l_prep) against/IN (l_pobj) overdose/NN
D003042_D064420 NONE cocaine/NN (r_compound) toxicity/NN
-1_D003643 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) dose/NN (l_appos) seizures/NNS (l_prt) up/IN (l_prep) to/TO (l_pobj) %/NN (l_conj) death/NN -PUNC- GNC92H2/NNP (r_nsubj) prevented/VBD (l_dobj) death/NN
D003042_D062787 NONE cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) continues/VBZ (l_prep) in/IN (l_pobj) proportions/NNS (l_conj) treatment/NN (l_prep) for/IN (l_pobj) overdose/NN
-1_D064420 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) blockade/NN (l_prep) of/IN (l_pobj) toxicity/NN
D003042_D003643 NONE cocaine/NN (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubjpass) observed/VBN (l_prep) with/IN (l_pobj) dose/NN (l_appos) seizures/NNS (l_prt) up/IN (l_prep) to/TO (l_pobj) %/NN (l_conj) death/NN -PUNC- cocaine/NN (r_compound) injection/NN (r_dobj) prevented/VBD (l_dobj) death/NN
D003042_D012640 CID cocaine/NN (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubjpass) observed/VBN (l_prep) with/IN (l_pobj) dose/NN (l_appos) seizures/NNS
-1_D012640 NONE GNC92H2/NNP (r_pobj) of/IN (r_prep) dose/NN (l_appos) seizures/NNS
12481039
D012964_D012640 NONE sodium/NN (r_compound) channel/NN (r_compound) density/NN (l_appos) dependence/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- sodium/NN (r_compound) channel/NN (r_compound) 2-subunits/NNS (r_dobj) lacking/VBG (r_pcomp) in/IN (r_prep) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) for/IN (r_prep) threshold/NN (r_conj) latency/NN (r_pobj) by/IN (r_agent) indicated/VBN (r_advcl) displayed/VBD (l_dobj) susceptibility/NN (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
1141447
D008094_D003919 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN
10354657
D008094_D001714 NONE lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (l_nsubj) disorder/NN
D008094_D013959 NONE lithium/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) to/IN (r_prep) respect/NN (r_pobj) with/IN (r_prep) evaluated/VBN (l_parataxis) had/VBD (l_dobj) relative/NN (l_prep) with/IN (l_pobj) disease/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) accelerated/VBN (l_nsubj) patients/NNS (l_acl) having/VBG (l_dobj) relatives/NNS (l_acl) affected/VBN (l_agent) by/IN (l_pobj) illness/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) accelerated/VBN (l_nsubj) patients/NNS (l_acl) having/VBG (l_dobj) relatives/NNS (l_acl) affected/VBN (l_agent) by/IN (l_pobj) illness/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) factor/NN (r_attr) is/VBZ (l_nsubj) illness/NN
D008094_D006934 NONE lithium/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) factor/NN (l_prep) for/IN (l_pobj) hypothyroidism/NN (l_conj) hypercalcemia/NN
D008094_D007037 CID lithium/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) accelerated/VBN (l_dobj) onset/NN (l_prep) of/IN (l_pobj) hypothyroidism/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) after/IN (r_prep) accelerated/VBN (l_dobj) onset/NN (l_prep) of/IN (l_pobj) hypothyroidism/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) factor/NN (l_prep) for/IN (l_pobj) hypothyroidism/NN
20080419
D010862_D004827 CID pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
2826064
D013726_D007008 CID terbutaline/NN (r_npadvmod) induced/VBN (r_amod) hypokalemia/NN -PUNC- terbutaline/JJ (r_compound) concentrations/NNS (r_pobj) of/IN (r_prep) spite/NN (r_pobj) In/IN (r_prep) antagonized/VBN (l_nsubjpass) hypokalemia/NN
D010096_D007008 NONE oxprenolol/NN (r_pobj) by/IN (r_prep) abolishment/NN (r_conj) hypokalemia/NN -PUNC- oxprenolol/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) investigated/VBD (l_prep) in/IN (l_pcomp) antagonizing/VBG (l_dobj) hypokalemia/NN -PUNC- oxprenolol/NN (r_amod) pretreatment/NN (r_pobj) after/IN (r_prep) concentrations/NNS (r_pobj) of/IN (r_prep) spite/NN (r_pobj) In/IN (r_prep) antagonized/VBN (l_nsubjpass) hypokalemia/NN
1919871
D001241_D007681 CID aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN -PUNC- aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN (l_appos) RPN/NNP
D000082_D007681 CID paracetamol/JJ (r_conj) aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN -PUNC- paracetamol/JJ (r_conj) aspirin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) developed/VBN (r_acl) ability/NN (r_conj) necrosis/NN (l_appos) RPN/NNP
9931093
C079574_D006973 NONE 139317/CD (r_nummod) FR/NNP (l_prep) on/IN (l_pobj) hypertension/NN
D016559_D006973 CID 506-induced/JJ (r_nummod) hypertension/NN -PUNC- 506/CD (r_nummod) FK/NNP (r_pobj) of/IN (r_prep) utility/NN (r_nsubjpass) complicated/VBN (l_agent) by/IN (l_pobj) hypertension/NN -PUNC- 506-induced/JJ (r_compound) hypertension/NN -PUNC- 506/CD (r_nummod) FK/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) studied/VBD (l_advcl) clarify/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- 506-induced/JJ (r_nummod) FK/NNP (r_poss) hypertension/NN -PUNC- 506-induced/JJ (r_nummod) hypertension/NN
D009569_D006973 NONE oxide/NN (r_compound) synthase/NN (r_conj) expression/NN (r_dobj) studied/VBD (l_advcl) clarify/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
D016559_D007674 NONE 506/CD (r_nummod) FK/NNP (r_pobj) of/IN (r_prep) utility/NN (r_nsubjpass) complicated/VBN (l_agent) by/IN (l_pobj) hypertension/NN (l_conj) nephrotoxicity/NN
20882060
D009496_D010302 NONE neurotensin/NN (l_prep) on/IN (l_pobj) symptoms/NNS
D006220_D010302 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) symptoms/NNS
D009496_D002375 NONE neurotensin/NN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- neurotensin/NN (r_pobj) of/IN (r_prep) infusions/NNS (r_nsubj) reversed/VBD (l_dobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
15130900
D003520_D014890 NONE cyclophosphamide/NN (r_pobj) to/IN (r_prep) risks/NNS (r_appos) granulomatosis/NN -PUNC- cyclophosphamide/NN (r_pobj) to/IN (r_prep) relation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) granulomatosis/NN -PUNC- cyclophosphamide/NN (r_pobj) between/IN (r_prep) relationship/NN (l_conj) risk/NN (l_conj) risks/NNS (l_conj) possibility/NN (l_prep) of/IN (l_pobj) factors/NNS (l_acl) operating/VBG (l_prep) before/IN (l_pobj) granulomatosis/NN
D003520_D001749 CID cyclophosphamide/NN (r_pobj) to/IN (r_prep) risks/NNS (r_appos) granulomatosis/NN (r_pobj) in/IN (r_prep) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) to/IN (r_prep) relation/NN (r_conj) assess/VB (l_conj) characterise/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (l_conj) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) in/IN (r_prep) increment/NN (r_pobj) for/IN (r_prep) doubled/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) between/IN (r_prep) relationship/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN
6466532
D006024_D001919 NONE glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN (l_conj) bradycardia/NNP
D013390_D001145 NONE suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) bradycardia/NN (l_conj) arrhythmias/NNS -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) arrhythmia/NN
D001285_D001919 NONE atropine/NN (r_conj) glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- atropine/NN (r_conj) kg-1/NNS (r_dobj) glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN (l_conj) bradycardia/NNP
D001285_D001145 NONE atropine/NN (r_conj) glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN (l_conj) arrhythmias/NNS -PUNC- atropine/NN (r_conj) kg-1/NNS (r_dobj) glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN
D006024_D001145 NONE glycopyrrolate/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) bradycardia/NN (l_conj) arrhythmias/NNS -PUNC- glycopyrrolate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_acl) prevent/VB (l_dobj) arrhythmia/NN
D013390_D001919 CID suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) bradycardia/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) following/VBG (r_prep) prevent/VB (l_dobj) arrhythmia/NN (l_conj) bradycardia/NNP
2476560
D001556_D012532 NONE lindane/NN (r_dobj) consider/VBP (l_ccomp) initiated/VBN (l_nsubjpass) Treatment/NN (l_prep) for/IN (l_pobj) scabies/NNS -PUNC- hexachloride/NN (r_appos) lindane/NN (r_dobj) consider/VBP (l_ccomp) initiated/VBN (l_nsubjpass) Treatment/NN (l_prep) for/IN (l_pobj) scabies/NNS
D001556_D002493 CID lindane/NN (r_dobj) accumulating/VBG (r_csubj) be/VB (l_acomp) toxic/JJ (l_prep) to/IN (l_pobj) system/NN
D001556_D000741 CID lindane/NN (r_dobj) accumulating/VBG (r_csubj) be/VB (l_conj) associated/VBN (l_prep) with/IN (l_pobj) anaemia/NN
6118280
C014896_D009207 NONE MK-212/NNP (r_punct) and/CC (r_punct) -)-baclofen/: (r_punct) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) myoclonus/NN
D001418_D009207 NONE baclofen/JJ (r_compound) block/NN (r_conj) benzodiazepines/NNS (r_conj) drugs/NNS (r_nsubj) induced/VBN (l_dobj) jerks/NNS -PUNC- -)-baclofen/: (r_punct) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) myoclonus/NN
D009118_D009207 CID muscimol/NNS (r_npadvmod) induced/VBN (l_dobj) jerks/NNS -PUNC- muscimol/NNS (r_nsubj) produced/VBD (l_dobj) jerks/NNS -PUNC- muscimol/NN (r_npadvmod) induced/VBN (r_amod) myoclonus/NN (r_appos) myoclonus/NN -PUNC- muscimol/NN (r_npadvmod) induced/VBN (r_amod) myoclonus/NN
D002998_D009207 NONE clonazepam/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) jerks/NNS
D003975_D009207 NONE diazepam/NN (r_pobj) than/IN (r_prep) potent/JJ (r_acomp) be/VB (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) jerks/NNS
D006916_D009207 NONE 5-HTP/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) myoclonus/NN -PUNC- 5-HTP/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) myoclonus/NN (l_appos) myoclonus/NN
D001569_D009207 NONE benzodiazepines/NNS (r_conj) drugs/NNS (r_nsubj) induced/VBN (l_dobj) jerks/NNS -PUNC- benzodiazepines/NNS (r_pobj) Of/IN (r_prep) found/VBN (l_xcomp) be/VB (l_prep) in/IN (l_pcomp) blocking/VBG (l_dobj) jerks/NNS -PUNC- benzodiazepines/NNS (r_conj) 5-HTP/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) myoclonus/NN -PUNC- benzodiazepines/NNS (r_conj) 5-HTP/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) myoclonus/NN (l_appos) myoclonus/NN
12180796
D013806_D009369 NONE theophylline/NN (r_conj) fenoldopam/NN (r_npadvmod) induced/VBN (l_conj) examined/VBN (l_prep) for/IN (l_pobj) expressions/NNS (l_prep) of/IN (l_pobj) type/NN (l_prep) of/IN (l_pobj) synthase/NN (l_appos) factor/NN (l_conj) beta1/NNP (l_compound) factor/NN (l_compound) tumor/NN
D013806_D001167 CID theophylline/NN (r_conj) fenoldopam/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (l_nsubj) beta1/NNP (l_prep) in/IN (l_pobj) arteritis/NN -PUNC- theophylline/NN (r_conj) fenoldopam/NN (r_npadvmod) induced/VBN (l_nsubj) Arteritis/NNP
D018818_D009369 NONE fenoldopam/NN (r_npadvmod) induced/VBN (l_conj) examined/VBN (l_prep) for/IN (l_pobj) expressions/NNS (l_prep) of/IN (l_pobj) type/NN (l_prep) of/IN (l_pobj) synthase/NN (l_appos) factor/NN (l_conj) beta1/NNP (l_compound) factor/NN (l_compound) tumor/NN
D009569_D001167 NONE oxide/NN (r_compound) synthase/NN (r_pobj) of/IN (r_prep) type/NN (r_pobj) of/IN (r_prep) expressions/NNS (r_pobj) for/IN (r_prep) examined/VBN (r_conj) induced/VBN (l_nsubj) Arteritis/NNP
D018818_D001167 CID fenoldopam/NN (r_pobj) by/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (l_nsubj) beta1/NNP (l_prep) in/IN (l_pobj) arteritis/NN -PUNC- fenoldopam/NN (r_npadvmod) induced/VBN (l_nsubj) Arteritis/NNP
D009569_D009369 NONE oxide/NN (l_appos) factor/NN (l_conj) growth/NN (l_compound) tumor/NN -PUNC- oxide/NN (r_compound) synthase/NN (l_appos) factor/NN (l_conj) beta1/NNP (l_compound) factor/NN (l_compound) tumor/NN
16337777
D010862_D004827 NONE pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D013226 NONE pilocarpine/NN (r_amod) model/NN (r_pobj) of/IN (r_prep) phase/NN (r_pobj) in/IN (r_prep) provoke/VB (r_xcomp) sufficient/JJ (r_acomp) be/VB (l_nsubj) generation/NN (l_prep) during/IN (l_pobj) epilepticus/NN
D010862_D004833 CID pilocarpine/NN (r_amod) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
133615
D003276_D013923 NONE contraceptive/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (l_amod) Thromboembolic/JJ
D003276_D001778 CID contraceptive/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (l_prep) in/IN (l_pobj) relationship/NN (l_prep) to/IN (l_pobj) levels/NNS (l_prep) of/IN (l_pobj) factors/NNS (l_compound) coagulation/NN
19356053
D003404_D011507 NONE creatinine/NN (r_compound) ratios/NNS (r_conj) measurement/NN (r_pobj) by/IN (r_agent) assessed/VBN (l_nsubjpass) magnitude/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- creatinine/NN (r_compound) ratios/NNS (l_appos) estimate/NN (l_prep) of/IN (l_pobj) grams/NNS (l_prep) of/IN (l_pobj) proteinuria/NN
D020123_D009404 NONE sirolimus/NN (r_pobj) of/IN (r_prep) initiation/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) proteinuria/NN (l_compound) range/NN (l_amod) nephrotic/JJ
D020123_D007674 NONE Sirolimus/NNP (r_nsubj) is/VBZ (l_conj) have/VB (l_dobj) nephrotoxicity/NN
D020123_D011507 CID sirolimus/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) linked/VBN (r_acl) proteinuria/NN -PUNC- sirolimus/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (l_conj) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) commencement/NN (r_pobj) between/IN (r_prep) association/NN (r_nsubj) implicated/VBN (l_prep) as/IN (l_pobj) etiology/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_dobj) implicated/VBN (l_nsubj) association/NN (l_prep) between/IN (l_pobj) commencement/NN (l_prep) of/IN (l_pobj) therapy/NN (l_conj) proteinuria/NN -PUNC- sirolimus/NN (r_dobj) implicated/VBN (l_prep) as/IN (l_pobj) etiology/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) initiation/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBD (l_nsubj) Proteinuria/NNP -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_nsubj) resulted/VBD (l_conj) resolution/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- Sirolimus/NNP (r_nsubj) induces/VBZ (l_conj) aggravates/VBZ (l_dobj) proteinuria/NN -PUNC- sirolimus/NN (r_nsubjpass) withdrawn/VBN (r_advcl) resolve/VB (r_conj) improve/VB (l_nsubj) Proteinuria/NNP
4069770
D005839_D058186 CID gentamicin/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) after/IN (r_prep) died/VBD (l_prep) of/IN (l_pobj) failure/NN
D010406_D058186 NONE penicillin/NN (r_conj) therapy/NN (r_pobj) after/IN (r_prep) died/VBD (l_prep) of/IN (l_pobj) failure/NN
D005839_D001002 NONE gentamicin/NN (r_compound) concentration/NN (r_nsubj) reached/VBN (l_advcl) developed/VBD (l_nsubj) anuria/NN
D005839_D007674 NONE Gentamicin/NNP (r_amod) nephropathy/NN
11337188
D010068_D018366 CID oxacillin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) vasculitis/NN -PUNC- Oxacillin/NNP (r_nsubjpass) included/VBN (l_prep) among/IN (l_pobj) drugs/NNS (l_relcl) cause/VB (l_dobj) vasculitis/NN
D010068_D016470 NONE oxacillin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) because/IN (l_pobj) bacteremia/NN
D010068_D011693 NONE oxacillin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) failure/NN (l_appos) lesions/NNS
D010068_D051437 CID oxacillin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) failure/NN
D010068_D013203 NONE oxacillin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) because/IN (l_pobj) bacteremia/NN
7919560
D000667_D004892 CID ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubj) multiforme/NN -PUNC- ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) multiforme/NNS
D000667_D018805 NONE ampicillin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) gentamicin/NN (l_prep) because/IN (l_pobj) septicemia/NN
D000667_D009205 CID ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubj) multiforme/NN (l_conj) myocarditis/NN -PUNC- ampicillin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) multiforme/NNS (l_conj) myocarditis/NN
D010406_D009205 NONE penicillins/NNS (r_pobj) to/IN (r_prep) is/VBZ (l_nsubj) myocarditis/NN
D010406_D004342 NONE penicillins/NNS (r_pobj) to/IN (r_prep) is/VBZ (l_attr) manifestation/NN (l_prep) of/IN (l_pobj) allergy/NN
D005839_D018805 NONE gentamicin/NN (l_prep) because/IN (l_pobj) septicemia/NN
2515254
D005996_D010146 NONE nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) seems/VBZ (l_xcomp) depend/VB (l_prep) on/IN (l_pobj) stimulation/NN (l_prep) of/IN (l_pobj) site/NN (l_prep) of/IN (l_pobj) pain/NN
D005996_D008881 CID nitroglycerin/NN (r_pobj) of/IN (r_prep) application/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_compound) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) attacks/NNS (l_compound) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) with/IN (r_prep) attack/NN (r_dobj) developed/VBD (r_relcl) patients/NNS (l_compound) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) inducing/VBG (l_npadvmod) migraine/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) seems/VBZ (l_advcl) suggesting/VBG (l_ccomp) is/VBZ (l_prep) of/IN (l_pobj) importance/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) crisis/NN (l_compound) migraine/JJ
11063349
D016559_D056486 NONE Tac/NNP (r_compound) nephrotoxicity/NN (r_conj) CsA/NNP (l_conj) hepatotoxicity/NN -PUNC- Tac/NNP (r_compound) toxicity/NN (r_conj) CsA/NNP (r_conj) nephrotoxicity/NN (r_conj) CsA/NNP (l_conj) hepatotoxicity/NN
D016572_D008232 NONE CsA/NNP (l_conj) nephrotoxicity/NN (l_conj) disorder/NN -PUNC- CsA/NNP (l_conj) nephrotoxicity/NN (l_conj) disorder/NN (l_appos) PTLD/NN -PUNC- CsA/NNP (r_conj) nephrotoxicity/NN (l_conj) disorder/NN -PUNC- CsA/NNP (r_conj) nephrotoxicity/NN (l_conj) disorder/NN (l_appos) PTLD/NN
D016559_-1 NONE Tac/NNP (r_compound) nephrotoxicity/NN (l_conj) CsA/NNP (l_conj) dysmorphism/NN -PUNC- Tac/NNP (r_compound) toxicity/NN (r_conj) CsA/NNP (l_conj) dysmorphism/NN
D016559_D008232 NONE Tac/NNP (r_compound) nephrotoxicity/NN (l_conj) disorder/NN -PUNC- Tac/NNP (r_compound) nephrotoxicity/NN (l_conj) disorder/NN (l_appos) PTLD/NN -PUNC- Tac/NNP (r_compound) toxicity/NN (r_conj) CsA/NNP (r_conj) nephrotoxicity/NN (l_conj) disorder/NN -PUNC- Tac/NNP (r_compound) toxicity/NN (r_conj) CsA/NNP (r_conj) nephrotoxicity/NN (l_conj) disorder/NN (l_appos) PTLD/NN
D016572_D056486 NONE CsA/NNP (l_conj) hepatotoxicity/NN -PUNC- CsA/NNP (r_conj) nephrotoxicity/NN (r_conj) CsA/NNP (l_conj) hepatotoxicity/NN
D016559_D007674 CID Tac/NNP (r_compound) nephrotoxicity/NN -PUNC- Tac/NNP (r_compound) toxicity/NN (r_conj) CsA/NNP (r_conj) nephrotoxicity/NN
D003404_D007674 NONE creatinine/NN (r_pobj) in/IN (r_prep) decrease/NN (r_attr) was/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_acl) switched/VBD (l_prep) because/IN (l_pobj) nephrotoxicity/NN
D020123_D013281 NONE RAPA/NNP (r_nsubjpass) discontinued/VBN (l_appos) PTLD/NN (l_conj) ulcers/NNS
D020123_D011014 NONE RAPA/NNP (r_nsubjpass) discontinued/VBN (l_prep) because/IN (l_pobj) pneumonia/NN
D020123_D011020 NONE RAPA/NNP (r_compound) levels/NNS (r_pobj) to/IN (r_prep) converting/VBG (r_csubjpass) monitored/VBN (r_advcl) given/VBN (l_nsubjpass) prophylaxis/NN (l_compound) pneumonia/NN
D020123_D008232 NONE RAPA/NNP (r_nsubjpass) discontinued/VBN (l_appos) PTLD/NN
D016559_D064420 NONE tacrolimus/NN (r_nmod) toxicity/NN -PUNC- Tac/NN (r_nmod) toxicity/NN -PUNC- Tac/NNP (r_compound) nephrotoxicity/NN (l_conj) CsA/NNP (l_conj) toxicity/NN -PUNC- Tac/NNP (r_compound) toxicity/NN
D016572_D064420 NONE cyclosporine/NN (l_appos) CsA/NNP (l_conj) toxicity/NN -PUNC- CsA/NNP (l_conj) toxicity/NN -PUNC- CsA/NNP (l_conj) nephrotoxicity/NN (l_conj) CsA/NNP (l_conj) toxicity/NN -PUNC- CsA/NNP (l_conj) toxicity/NN
D016572_D007674 CID CsA/NNP (l_conj) nephrotoxicity/NN -PUNC- CsA/NNP (r_conj) nephrotoxicity/NN
D016572_-1 NONE CsA/NNP (l_conj) nephrotoxicity/NN (l_conj) CsA/NNP (l_conj) dysmorphism/NN -PUNC- CsA/NNP (l_conj) dysmorphism/NN
D020123_D064420 NONE RAPA/NNP (r_compound) conversion/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) undergoing/VBG (l_dobj) cyclosporine/NN (l_appos) CsA/NNP (l_conj) toxicity/NN
19300402
D013311_D003929 CID streptozotocin/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
D013311_D006930 CID streptozotocin/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- streptozotocin/JJ (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- streptozotocin/JJ (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_pobj) In/IN (r_prep) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN
D009569_D006930 NONE oxide/NN (r_compound) synthase/NN (r_compound) inhibitors/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_det) synthase/NN (r_conj) inhibition/NN (r_nsubj) reduces/VBZ (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_det) activity/NN (r_nsubj) reduces/VBZ (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_compound) synthase/NN (r_pobj) of/IN (r_prep) products/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_det) activation/NN (r_conj) synthase/NN (r_pobj) of/IN (r_prep) products/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_compound) synthase/NN (r_nsubj) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_compound) synthase/NN (r_nsubj) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN -PUNC- NO/DT (r_det) pathway/NN (r_dobj) activate/VB (r_xcomp) seemed/VBD (r_conj) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- NO/DT (r_det) pathway/NN (r_dobj) activate/VB (r_xcomp) seemed/VBD (r_conj) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN
D014750_D006930 CID vincristine/NN (r_pobj) in/IN (r_prep) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- vincristine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) hyperalgesia/NN -PUNC- vincristine/NN (r_pobj) in/IN (r_prep) induced/VBN (r_advcl) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- vincristine/NN (r_pobj) in/IN (r_prep) induced/VBN (l_dobj) hyperalgesia/NN
D009569_D003929 NONE oxide/NN (r_compound) synthase/NN (r_compound) inhibitors/NNS (r_conj) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
D001920_D006930 NONE Bradykinin/NN (r_compound) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) inhibition/NN (r_nsubj) reduces/VBZ (l_dobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_conj) activation/NN (r_conj) synthase/NN (r_pobj) of/IN (r_prep) products/NNS (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) in/IN (r_prep) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) in/IN (r_prep) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_nsubj) seemed/VBD (r_conj) participates/VBZ (l_prep) In/IN (l_pobj) hyperalgesia/NN -PUNC- bradykinin/NN (r_nsubj) seemed/VBD (r_conj) participates/VBZ (l_advcl) induced/VBN (l_dobj) hyperalgesia/NN
D001920_D009437 NONE bradykinin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) alleviation/NN (l_prep) of/IN (l_pobj) pain/NN
D009569_D009437 NONE NO/DT (r_det) inhibitors/NNS (r_conj) antagonists/NNS (r_dobj) bradykinin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) alleviation/NN (l_prep) of/IN (l_pobj) pain/NN
D001920_D003929 NONE Bradykinin/NN (r_compound) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
D014750_D003929 NONE vincristine/NN (r_pobj) in/IN (r_prep) antagonists/NNS (r_nsubj) induced/VBD (l_dobj) hyperalgesia/NN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_conj) model/NN (l_compound) rat/NN (l_compound) neuropathy/NN
2673163
D003042_D002544 CID cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_dobj) that/DT (l_prep) of/IN (l_pobj) infarction/NN
D003042_D001165 NONE cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS (l_conj) malformations/NNS
D003042_D020300 NONE cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (l_prep) of/IN (l_pobj) hemorrhage/NN
D003042_D020521 NONE cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_dobj) followed/VBD (l_nsubj) Stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (l_ccomp) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (l_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (r_advcl) stroke/NN (l_conj) 5/CD (l_prep) in/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_ccomp) indicate/VBP (l_ccomp) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_ccomp) occurs/VBZ (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (r_nmod) frequency/NN (r_nsubj) exceeds/VBZ (l_ccomp) follow/VB (l_nsubj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN
D003042_D002532 NONE cocaine/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) stroke/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) increasing/VBG (r_ccomp) indicate/VBP (r_ccomp) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_nsubj) occurs/VBZ (r_ccomp) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) route/NN (r_dobj) follow/VB (r_ccomp) exceeds/VBZ (l_nsubj) frequency/NN (l_nmod) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) stroke/NN (r_pobj) in/IN (r_prep) 5/CD (r_conj) stroke/NN (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) aneurysms/NNS
7582165
D010248_D004342 NONE paramethasone/NN (r_pobj) from/IN (r_prep) different/JJ (r_amod) Corticosteroids/NNS (r_nsubj) produced/VBD (l_dobj) reactions/NNS (l_compound) hypersensitivity/NN -PUNC- paramethasone/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) allergy/NN
D000305_D004342 NONE corticosteroids/NNS (r_pobj) to/IN (r_prep) reactions/NNS
15897593
D003630_D066126 NONE daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN (l_conj) toxicity/NN
D005047_D009362 NONE etoposide/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) combining/VBG (r_acl) metastases/NNS
D005047_D001855 NONE etoposide/NN (r_advmod) protects/VBZ (l_prep) against/IN (l_pobj) myelosuppression/NN -PUNC- etoposide/NN (r_appos) epipodophyllotoxin/NN (r_conj) doxorubicin/NN (r_conj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN -PUNC- etoposide/RB (r_conj) daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN -PUNC- etoposide/RB (r_conj) daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN
D003630_D006402 CID daunorubicin/NNS (r_conj) etoposide/VB (r_pobj) to/TO (r_prep) Sensitivity/NN (r_nsubjpass) determined/VBN (l_advcl) investigated/VBN (l_nsubjpass) toxicity/NN
D005047_D064420 NONE etoposide/RB (r_conj) daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN (l_conj) cytotoxicity/NN
D011034_D066126 NONE epipodophyllotoxin/NN (r_conj) doxorubicin/NN (r_conj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN (l_conj) toxicity/NN
D005047_D015431 CID etoposide/RB (r_conj) daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN (l_conj) loss/NN -PUNC- etoposide/RB (r_conj) daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN
D018943_D066126 NONE anthracyclines/NNS (r_nsubj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN (l_conj) toxicity/NN -PUNC- anthracycline/NN (r_advmod) induced/VBN (r_amod) cardiotoxicity/NN
D004317_D015431 CID doxorubicin/NN (r_pobj) from/IN (r_prep) cytotoxicity/NN (r_conj) loss/NN (r_conj) myelosuppression/NN (r_dobj) dexrazoxane/NN (l_nsubj) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN (l_conj) loss/NN -PUNC- doxorubicin/NN (r_pobj) from/IN (r_prep) cytotoxicity/NN (r_conj) loss/NN
D064730_D001855 NONE Dexrazoxane/NNP (r_nsubj) protects/VBZ (l_prep) against/IN (l_pobj) myelosuppression/NN -PUNC- dexrazoxane/NN (r_npadvmod) reduced/VBN (r_amod) myelosuppression/NN -PUNC- dexrazoxane/NN (r_npadvmod) reduced/VBN (r_amod) myelosuppression/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN -PUNC- dexrazoxane/NN (l_nsubj) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN -PUNC- dexrazoxane/NN (l_dobj) myelosuppression/NN
D004317_D001855 NONE doxorubicin/RB (r_conj) etoposide/NN (r_advmod) protects/VBZ (l_prep) against/IN (l_pobj) myelosuppression/NN -PUNC- doxorubicin/NN (r_conj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN -PUNC- doxorubicin/NN (r_pobj) from/IN (r_prep) cytotoxicity/NN (r_conj) loss/NN (r_conj) myelosuppression/NN (r_dobj) dexrazoxane/NN (l_nsubj) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN -PUNC- doxorubicin/NN (r_pobj) from/IN (r_prep) cytotoxicity/NN (r_conj) loss/NN (r_conj) myelosuppression/NN
D064730_D009362 NONE dexrazoxane/NN (r_nmod) doses/NNS (r_dobj) combining/VBG (r_acl) metastases/NNS
D003630_D064420 NONE daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN (l_conj) cytotoxicity/NN
D004317_D006402 CID doxorubicin/NN (r_conj) daunorubicin/NNS (r_conj) etoposide/VB (r_pobj) to/TO (r_prep) Sensitivity/NN (r_nsubjpass) determined/VBN (l_advcl) investigated/VBN (l_nsubjpass) toxicity/NN
D003630_D001855 NONE daunorubicin/NNS (r_conj) etoposide/NN (r_advmod) protects/VBZ (l_prep) against/IN (l_pobj) myelosuppression/NN -PUNC- daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN -PUNC- daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN -PUNC- daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN
D004317_D066126 NONE doxorubicin/NN (r_conj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN (l_conj) toxicity/NN
D011034_D001855 NONE epipodophyllotoxin/NN (r_conj) doxorubicin/NN (r_conj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN
D005047_D066126 NONE etoposide/NN (r_appos) epipodophyllotoxin/NN (r_conj) doxorubicin/NN (r_conj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN (l_conj) toxicity/NN
D005047_D006402 CID etoposide/VB (r_pobj) to/TO (r_prep) Sensitivity/NN (r_nsubjpass) determined/VBN (l_advcl) investigated/VBN (l_nsubjpass) toxicity/NN -PUNC- etoposide/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) combining/VBG (r_acl) metastases/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) trials/NNS (r_nsubj) is/VBZ (l_acomp) ongoing/JJ (l_prep) with/IN (l_pobj) aim/NN (l_prep) of/IN (l_pcomp) improving/VBG (l_prep) without/IN (l_pcomp) aggravating/VBG (l_dobj) toxicity/NN
D018943_D001855 NONE anthracyclines/NNS (r_nsubj) daunorubicin/NN (r_ccomp) limit/VBP (l_nsubj) myelosuppression/NN
D064730_D015431 NONE dexrazoxane/NN (r_npadvmod) reduced/VBN (r_amod) myelosuppression/NN (l_conj) loss/NN -PUNC- dexrazoxane/NN (r_npadvmod) reduced/VBN (r_amod) myelosuppression/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN -PUNC- dexrazoxane/NN (l_nsubj) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN (l_conj) loss/NN -PUNC- dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN
D004317_D064420 NONE doxorubicin/NN (r_pobj) from/IN (r_prep) cytotoxicity/NN
D064730_D064420 NONE dexrazoxane/NN (r_npadvmod) reduced/VBN (r_amod) myelosuppression/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN (l_conj) cytotoxicity/NN -PUNC- dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN (l_conj) cytotoxicity/NN
D003630_D015431 CID daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (l_prep) of/IN (l_pobj) myelosuppression/NN (l_conj) loss/NN -PUNC- daunorubicin/NN (r_pobj) from/IN (r_prep) doses/NNS (r_nsubj) dexrazoxane/NN (l_dobj) myelosuppression/NN (l_conj) loss/NN
D064730_D006402 NONE dexrazoxane/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) following/VBG (r_prep) toxicity/NN -PUNC- dexrazoxane/NN (r_dobj) doxorubicin/NN (r_conj) daunorubicin/NNS (r_conj) etoposide/VB (r_pobj) to/TO (r_prep) Sensitivity/NN (r_nsubjpass) determined/VBN (l_advcl) investigated/VBN (l_nsubjpass) toxicity/NN -PUNC- dexrazoxane/NN (r_nmod) doses/NNS (r_dobj) combining/VBG (r_acl) metastases/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) trials/NNS (r_nsubj) is/VBZ (l_acomp) ongoing/JJ (l_prep) with/IN (l_pobj) aim/NN (l_prep) of/IN (l_pcomp) improving/VBG (l_prep) without/IN (l_pcomp) aggravating/VBG (l_dobj) toxicity/NN
D064730_D066126 NONE Dexrazoxane/NNP (r_nsubjpass) recommended/VBN (l_prep) for/IN (l_pobj) protection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN -PUNC- ICRF-187/NN (r_appos) Dexrazoxane/NNP (r_nsubjpass) recommended/VBN (l_prep) for/IN (l_pobj) protection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN
2024540
D011224_D006333 NONE prazosin/NN (r_conj) enalapril/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D000806_D006333 NONE inhibitors/NNS (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) into/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D011224_D007022 CID prazosin/NN (r_npadvmod) controlled/VBN (r_amod) trial/NN (r_nsubjpass) designed/VBN (l_prep) compared/VBD (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- prazosin/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) than/IN (r_prep) hypotension/NN
D004656_D007022 NONE enalapril/NN (r_appos) inhibitor/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) assess/VB (r_advcl) designed/VBN (l_prep) compared/VBD (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- enalapril/RB (r_dobj) received/VBD (r_relcl) Patients/NNS (r_nsubj) experienced/VBD (l_dobj) hypotension/NN
D000806_D007022 CID inhibitors/NNS (r_appos) enzyme/NN (r_dobj) converting/VBG (l_prep) into/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_conj) cases/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- inhibitor/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) assess/VB (r_advcl) designed/VBN (l_prep) compared/VBD (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) hypotension/NN
D004656_D006333 NONE enalapril/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
3425586
D003622_D006461 NONE dapsone/NN (r_pobj) of/IN (r_prep) dose/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hemolysis/NN
D003622_D000743 CID Dapsone/NN (r_npadvmod) associated/VBN (r_amod) anemia/NN -PUNC- dapsone/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) taking/VBG (r_advcl) developed/VBD (l_dobj) anemia/NN -PUNC- dapsone/NN (r_nsubj) cause/VB (l_dobj) anemia/NN
D003622_D007918 NONE dapsone/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) taking/VBG (r_advcl) developed/VBD (l_nsubj) woman/NN (l_conj) leprosy/NN
14659530
D012701_D008881 NONE serotonin/NN (r_compound) release/NN (r_pobj) with/IN (r_prep) correlation/NN (r_conj) concentration/NN (r_appos) peptide/NN (r_pobj) in/IN (r_prep) increase/NN (r_appos) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- 5-hydroxytriptamine/NN (r_punct) ,/, (r_punct) 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- 5-HT/CD (r_nummod) content/NN (r_nsubj) tended/VBD (l_xcomp) be/VB (l_prep) in/IN (l_pobj) subjects/NNS (l_relcl) experienced/VBD (l_dobj) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_compound) content/NN (r_nsubj) decreased/VBD (l_prep) after/IN (l_pobj) nitroglycerin/NN (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_compound) content/NN (r_nsubj) decreased/VBD (l_conj) observed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- serotonin/NN (r_compound) release/NN (r_nsubj) provoke/VB (l_dobj) migraine/NN
D005996_D008881 NONE nitroglycerin/NN (r_pobj) by/IN (r_agent) provoked/VBN (r_acl) attack/NN (l_compound) migraine/JJ -PUNC- nitroglycerin/NN (r_compound) application/NN (r_pobj) after/IN (r_conj) before/RB (r_advmod) collected/VBN (l_conj) min/NN (l_prep) after/IN (l_pobj) beginning/NN (l_prep) of/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- nitroglycerin/NN (l_prep) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- nitroglycerin/NN (r_pobj) after/IN (r_prep) decreased/VBD (l_conj) observed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ
D005996_D006261 NONE nitroglycerin/NN (r_pobj) by/IN (r_agent) provoked/VBN (r_acl) attack/NN (r_conj) investigate/VB (l_dobj) changes/NNS (l_prep) during/IN (l_pobj) headache/NN
D012701_D006261 NONE serotonin/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- 5-hydroxytriptamine/NN (r_punct) ,/, (r_punct) 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- 5-HT/CD (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- serotonin/NN (r_compound) release/NN (r_nsubj) provoke/VB (r_ccomp) counteract/VB (l_dobj) headache/NN
D015740_D008881 NONE peptide/NN (r_pobj) in/IN (r_prep) increase/NN (r_appos) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_nmod) concentration/NN (r_appos) peptide/NN (r_pobj) in/IN (r_prep) increase/NN (r_appos) attack/NN (l_compound) migraine/JJ -PUNC- peptide/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_nmod) concentration/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (r_dobj) investigate/VB (l_conj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) increased/VBD (l_prep) during/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) increased/VBD (l_conj) returned/VBD (l_prep) after/IN (l_pobj) cessation/NN (l_prep) of/IN (l_pobj) migraine/NN -PUNC- CGRP/NNP (r_compound) concentrations/NNS (r_nsubj) failed/VBD (l_xcomp) change/VB (l_prep) during/IN (l_conj) in/IN (l_pobj) subjects/NNS (l_prep) with/IN (l_pobj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NNP (r_compound) concentration/NN (r_nsubj) was/VBD (l_conj) platelet/NN (l_ccomp) tended/VBD (l_xcomp) be/VB (l_prep) in/IN (l_pobj) subjects/NNS (l_relcl) experienced/VBD (l_dobj) attack/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) correlates/VBZ (r_acl) fact/NN (r_nsubj) suggests/VBZ (l_dobj) relationship/NN (l_prep) between/IN (l_pobj) CGRP/NN (l_conj) migraine/NN -PUNC- CGRP/NN (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) suggests/VBZ (l_nsubj) fact/NN (l_acl) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN (l_compound) migraine/JJ -PUNC- CGRP/NN (l_conj) migraine/NN -PUNC- CGRP/NN (r_compound) release/NN (r_conj) headache/NN (r_dobj) counteract/VB (l_ccomp) provoke/VB (l_dobj) migraine/NN
D009569_D008881 NONE NO/RB (r_intj) induced/VBN (r_amod) attack/NN (l_compound) migraine/JJ
D015740_D006261 NONE peptide/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_nmod) concentration/NN (r_nmod) content/NN (r_pobj) in/IN (r_prep) changes/NNS (l_prep) during/IN (l_pobj) headache/NN -PUNC- CGRP/NNP (r_compound) concentrations/NNS (r_nsubj) failed/VBD (l_xcomp) change/VB (l_prep) during/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_compound) concentration/NN (r_nsubj) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) suggests/VBZ (l_nsubj) fact/NN (l_acl) correlates/VBZ (l_prep) with/IN (l_pobj) timing/NN (l_prep) of/IN (l_pobj) headache/NN -PUNC- CGRP/NN (r_compound) release/NN (r_conj) headache/NN
11166519
D003042_D012640 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
3120485
6287825
D012256_D010523 CID riboflavin/NN (r_conj) thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS -PUNC- riboflavin/NN (r_conj) thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS (r_nsubj) was/VBD (l_conj) presented/VBN (l_prep) as/IN (l_pobj) neuropathy/NN
D013831_D044342 NONE thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN
D007538_D009422 NONE Isoniazid/NNP (r_nsubj) was/VBD (l_attr) agent/NN (l_prep) in/IN (l_pobj) neuropathy/NN
D012256_D044342 NONE riboflavin/NN (r_conj) thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN
D013831_D010523 CID thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS -PUNC- thiamine/NN (r_pobj) of/IN (r_prep) deficiency/NN (r_pobj) due/IN (r_prep) neuropathy/NNS (r_nsubj) was/VBD (l_conj) presented/VBN (l_prep) as/IN (l_pobj) neuropathy/NN
21418164
D008130_D001932 NONE CCNU/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) lymphoma/NN (l_conj) tumour/NN (l_conj) tumour/NN
D008130_D064420 NONE CCNU/NNP (r_npadvmod) lomustine/NN (l_dobj) toxicity/NN -PUNC- lomustine/NN (l_dobj) toxicity/NN -PUNC- CCNU/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) dogs/NNS (r_pobj) Of/IN (r_prep) met/VBD (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) class/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- CCNU/NN (r_npadvmod) associated/VBN (r_amod) toxicity/NN
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea/JJ (r_nmod) CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS -PUNC- CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea/JJ (r_nmod) CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS -PUNC- CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea/JJ (r_nmod) CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS -PUNC- CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea/JJ (r_nmod) CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS -PUNC- CCNU/NNP (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) in/IN (r_prep) toxicities/NNS
D008130_D008223 NONE CCNU/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) lymphoma/NN -PUNC- CCNU/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) lymphoma/NN (l_conj) tumour/NN (l_conj) tumour/NN (l_conj) tumours/NNS (l_conj) lymphoma/NN
D008130_D034801 NONE CCNU/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) lymphoma/NN (l_conj) tumour/NN
D000409_D064420 NONE alanine/NN (r_compound) transaminase/NN (r_nmod) concentration/NN (r_conj) toxicity/NN
D008130_D015620 NONE CCNU/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) lymphoma/NN (l_conj) tumour/NN (l_conj) tumour/NN (l_conj) tumours/NNS
921394
D007649_D003866 NONE ketamine/NN (r_pobj) of/IN (r_prep) Injections/NNS (l_dep) mg/NN (l_prep) into/IN (l_pobj) artery/NN (l_acl) produced/VBD (l_dobj) depression/NN
D007649_D013610 CID ketamine/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN
16116131
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN
D001058_D004409 NONE apomorphine/NN (r_compound) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) state/NN (l_amod) dyskinetic/JJ
D001058_D010300 NONE apomorphine/NN (r_compound) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) state/NN (r_pobj) of/IN (r_prep) modification/NN (r_pobj) in/IN (r_prep) result/VB (r_ccomp) investigated/VBN (l_advcl) Using/VBG (l_parataxis) rTMS/NN (l_prep) over/IN (l_pobj) area/NN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
7542793
D016572_D006984 NONE A/NNP (r_nsubj) caused/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) rate/NN (l_appos) changes/NNS (l_conj) hypertrophy/NN -PUNC- CsA/NNP (r_appos) A/NNP (r_nsubj) caused/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) rate/NN (l_appos) changes/NNS (l_conj) hypertrophy/NN
D016559_D064420 NONE FK506/NNP (r_compound) toxicity/NN
D018942_D006984 NONE macrolide/NN (r_amod) rapamycin/NNS (r_conj) Fujimycine/NNP (r_conj) mg/kg/NN (r_appos) A/NNP (r_nsubj) caused/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) rate/NN (l_appos) changes/NNS (l_conj) hypertrophy/NN
D016559_D006984 NONE Fujimycine/NNP (r_conj) mg/kg/NN (r_appos) A/NNP (r_nsubj) caused/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) rate/NN (l_appos) changes/NNS (l_conj) hypertrophy/NN -PUNC- FK506/NNP (r_appos) Fujimycine/NNP (r_conj) mg/kg/NN (r_appos) A/NNP (r_nsubj) caused/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) rate/NN (l_appos) changes/NNS (l_conj) hypertrophy/NN
D016559_D007674 CID FK506/NNP (r_conj) Nephrotoxicity/NN -PUNC- FK506/NNP (r_nsubjpass) mediated/VBN (l_nsubjpass) effects/NNS (l_amod) nephrotoxic/JJ
D016572_D064420 NONE CsA/NNP (l_conj) toxicity/NN
D016572_D007674 CID A/NNP (r_pobj) of/IN (r_prep) Nephrotoxicity/NN -PUNC- CsA/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) nephrotoxic/JJ
D020123_D006984 NONE rapamycin/NNS (r_conj) Fujimycine/NNP (r_conj) mg/kg/NN (r_appos) A/NNP (r_nsubj) caused/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) rate/NN (l_appos) changes/NNS (l_conj) hypertrophy/NN
1987816
D008094_D011141 CID Lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN
2334179
D010396_D051437 NONE Penicillamine/NN (r_nsubj) caused/VBD (r_ccomp) developed/VBD (l_dobj) insufficiency/NN
D010396_D009404 CID Penicillamine/NN (r_nsubj) caused/VBD (l_dobj) syndrome/NN
D010396_D012594 NONE penicillamine/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) scleroderma/NN -PUNC- penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) scleroderma/NN -PUNC- penicillamine/NN (r_nsubj) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) scleroderma/NN
D010396_D011507 CID Penicillamine/NN (r_nsubj) caused/VBD (l_prep) in/IN (l_pobj) patient/NN (l_conj) proteinuria/NN
7834920
D012293_D014397 NONE rifampin/NN (r_amod) therapy/NN (l_prep) for/IN (l_pobj) tuberculosis/NN -PUNC- rifampin/NN (r_pobj) of/IN (r_prep) regimen/NN (r_dobj) underwent/VBD (l_conj) isoniazid/NN (l_prep) for/IN (l_pobj) tuberculosis/NN
D012293_D051437 CID rifampin/NN (r_pobj) of/IN (r_prep) regimen/NN (r_dobj) underwent/VBD (l_conj) discovered/VBN (l_xcomp) developed/VBN (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) failure/NN
D007538_D051437 NONE isoniazid/NN (r_conj) underwent/VBD (l_conj) discovered/VBN (l_xcomp) developed/VBN (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) failure/NN
D007538_D014397 NONE isoniazid/NN (l_prep) for/IN (l_pobj) tuberculosis/NN
D012293_D005921 CID rifampin/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) glomerulonephritis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) finding/NN (l_prep) of/IN (l_pobj) glomerulonephritis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) glomerulonephritis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) glomerulonephritis/NN (l_prep) with/IN (l_pobj) crescents/NNS (l_conj) glomerulonephritis/NN
17439425
D003907_D015431 CID Dex/NNP (r_nsubj) increased/VBD (l_dep) P/NN (l_conj) decreased/VBN (l_dobj) thymus/NN (l_conj) bodyweights/NNS
D003907_D006973 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (l_appos) HT/NNP -PUNC- dex/NN (r_compound) HT/NNP (r_appos) hypertension/NN -PUNC- dex/NN (r_compound) HT/NNP -PUNC- Dex/NNP (r_nsubj) increased/VBD (l_dobj) SBP/NNP -PUNC- dex/NN (r_compound) HT/NNP
D000493_D006973 NONE Allopurinol/NNP (r_nsubj) prevent/VB (l_dobj) HT/NNP -PUNC- allopurinol/NN (r_nsubj) failed/VBD (r_acl) findings/NNS (r_pobj) with/IN (r_prep) induced/VBN (l_dobj) hypertension/NN -PUNC- allopurinol/NN (r_nsubj) failed/VBD (r_acl) findings/NNS (r_pobj) with/IN (r_prep) induced/VBN (r_ccomp) suggests/VBZ (l_ccomp) is/VBZ (l_attr) determinant/NN (l_prep) of/IN (l_pobj) HT/NNP
D009569_D006973 NONE oxide/NN (r_compound) redox/NN (r_compound) imbalance/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) hypertension/NN -PUNC- oxide/NN (r_compound) redox/NN (r_compound) imbalance/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) hypertension/NN (l_appos) HT/NNP
D019820_D006973 NONE xanthine/NN (r_compound) oxidase/NN (r_pobj) of/IN (r_prep) Role/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- xanthine/NN (r_compound) oxidase/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- xanthine/NN (r_compound) oxidase/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) hypertension/NN (l_appos) HT/NNP
7724492
D004317_D011507 CID DX/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) those/DT (r_pobj) in/IN (r_prep) than/IN (r_prep) treated/VBN (r_acl) animals/NNS (r_pobj) in/IN (r_prep) appeared/VBD (l_nsubj) proteinuria/NN -PUNC- doxorubicin/NN (r_compound) treatment/NN (r_pobj) after/IN (r_prep) prolonged/VBN (r_conj) intense/JJ (r_acomp) was/VBD (r_conj) appeared/VBD (l_nsubj) Proteinuria/NNP -PUNC- DX/NNP (r_conj) DXNP/NNP (r_pobj) between/IN (r_prep) difference/NN (r_pobj) without/IN (r_prep) was/VBD (r_conj) appeared/VBD (l_nsubj) Proteinuria/NNP
D003487_D007674 NONE cyanoacrylate/JJ (r_compound) nanoparticles/NNS (r_pobj) of/IN (r_prep) toxicity/NN
D004317_D005921 NONE doxorubicin/NN (r_npadvmod) loaded/VBN (r_amod) nanoparticle/NN (r_nmod) toxicity/NN (r_nsubjpass) explored/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_conj) rats/NNS (l_prep) with/IN (l_pobj) glomerulonephritis/NN -PUNC- DX/NNP (r_pobj) given/VBN (r_prep) rats/NNS (r_nsubj) died/VBD (l_prep) In/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) glomerulonephritis/NN
D004317_D007674 NONE doxorubicin/NN (r_nmod) nanoparticles/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- adriamycin)-loaded/VBN (r_amod) nanoparticles/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- doxorubicin/NN (r_npadvmod) loaded/VBN (r_amod) nanoparticle/NN (r_nmod) toxicity/NN -PUNC- DX/NNP (r_pobj) than/IN (r_prep) animals/NNS (r_dobj) killed/VBD (l_prep) despite/IN (l_prep) of/IN (l_pobj) toxicity/NN
9672936
D008614_D010149 NONE Pethidine/NNP (r_npadvmod) associated/VBN (r_amod) seizure/NN (l_prep) in/IN (l_pobj) adolescent/JJ (l_acl) receiving/VBG (l_prep) for/IN (l_pobj) control/NN (l_compound) pain/NN -PUNC- pethidine/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) control/NN (l_compound) pain/NN -PUNC- pethidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) pump/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) control/NN (l_compound) pain/NN
D008614_D012640 CID Pethidine/NNP (r_npadvmod) associated/VBN (r_amod) seizure/NN -PUNC- pethidine/NN (r_dobj) receiving/VBG (r_acl) adolescent/JJ (r_pobj) in/IN (r_prep) seizure/NN
873132
D004997_D002779 CID estradiol/NN (r_npadvmod) induced/VBN (r_amod) cholestasis/NN
D003840_D002779 NONE acid/NN (r_pobj) of/IN (r_prep) hydroxylation/NN (r_dobj) decreased/VBD (l_dobj) cholestasis/NN
3437726
D013034_D064420 NONE sparteine/NN (r_nmod) debrisoquine/JJ (r_compound) polymorphism/NN (r_pobj) of/IN (r_prep) phenotype/NN (r_pobj) to/IN (r_prep) belonging/VBG (r_acl) patients/NNS (r_nsubj) experience/VB (l_dobj) reactions/NNS
D003647_D064420 NONE debrisoquine/JJ (r_compound) polymorphism/NN (r_pobj) of/IN (r_prep) phenotype/NN (r_pobj) to/IN (r_prep) belonging/VBG (r_acl) patients/NNS (r_nsubj) experience/VB (l_dobj) reactions/NNS
7083920
D000638_D013617 NONE amiodarone/NN (r_compound) treatment/NN (l_prep) for/IN (l_pobj) tachycardia/NNS
D000638_D006345 NONE amiodarone/NN (r_compound) treatment/NN (r_pobj) under/IN (r_prep) occurring/VBG (l_prep) without/IN (l_pobj) abnormalities/NNS
D000638_D006327 CID amiodarone/NN (r_compound) treatment/NN (r_pobj) under/IN (r_prep) occurring/VBG (r_acl) block/NN
D000638_D001282 NONE amiodarone/NN (r_compound) discontinuation/NN (r_pobj) after/IN (r_prep) showed/VBD (l_dobj) flutter/NN
8682684
D000082_D002318 NONE acetaminophen/NN (r_pobj) for/IN (r_prep) potential/NN (l_acl) produce/VB (l_dobj) toxicities/NNS
D000082_D000707 NONE acetaminophen/RB (r_nsubjpass) demonstrated/VBN (l_xcomp) produce/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) anaphylaxis/NN
D000082_D016638 NONE acetaminophen/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBN (r_relcl) patients/NNS (l_amod) ill/JJ
D000082_D007022 CID Acetaminophen/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- acetaminophen/RB (r_nsubjpass) demonstrated/VBN (l_xcomp) produce/VB (l_dobj) symptoms/NNS (l_prep) including/VBG (l_pobj) hypotension/NN -PUNC- acetaminophen/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBN (l_nsubj) episodes/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- acetaminophen/NN (r_dobj) consider/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypotension/NN
18821488
C068820_D008708 NONE WR242511/NNP (l_relcl) produced/VBD (l_dobj) methemoglobinemia/NN
C068820_D006456 CID WR242511/NNP (r_pobj) of/IN (r_prep) postinjection/NN (r_dobj) noted/VBN (l_nsubjpass) hemoglobinuria/NN
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline/NNP (r_nmod) WR242511/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) Toxicity/NN -PUNC- WR242511/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) Toxicity/NN -PUNC- WR242511/NNP (r_nsubjpass) pursued/VBN (l_advcl) dissociated/VBN (l_prep) from/IN (l_pobj) those/DT (l_acl) producing/VBG (l_dobj) toxicity/NN
C080436_D064420 NONE 8-aminoquinoline/JJ (r_compound) 8-[(4-amino/CD (r_compound) l/NN (r_compound) methylbutyl)amino]-/NN (r_punct) WR242511/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) Toxicity/NN
C068820_D011041 NONE WR242511/NNP (r_nsubjpass) pursued/VBN (l_prep) as/IN (l_pobj) pretreatment/NN (l_prep) for/IN (l_pobj) poisoning/NN
2716967
D007649_D000699 NONE ketamine/NN (r_nsubj) induced/VBN (l_dobj) analgesia/NN -PUNC- ketamine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (r_amod) tolerance/NN (r_dobj) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN -PUNC- ketamine/NN (r_pobj) to/IN (r_prep) tolerance/NN (r_dobj) induce/VB (r_advcl) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN
D007649_D002375 CID ketamine/NN (r_pobj) of/IN (r_prep) combinations/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Catalepsy/NNP -PUNC- ketamine/NN (r_nsubj) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- ketamine/NN (r_nsubj) induced/VBN (r_ccomp) demonstrated/VBD (l_advcl) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ -PUNC- ketamine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (r_amod) tolerance/NN (r_dobj) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- ketamine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (r_amod) tolerance/NN (r_dobj) demonstrated/VBD (l_advcl) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ -PUNC- ketamine/NN (r_pobj) to/IN (r_prep) tolerance/NN (r_dobj) induce/VB (r_advcl) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- ketamine/NN (r_pobj) to/IN (r_prep) tolerance/NN (r_dobj) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ
D007649_D009127 NONE ketamine/NN (r_pobj) of/IN (r_prep) predominance/NN (r_dobj) reflected/VBD (l_nsubj) Latency/NN (l_prep) to/IN (l_pobj) loss/NN (l_prep) of/IN (l_pobj) reflex/NN (l_conj) rigidity/NN
D009270_D002375 NONE Naloxone/NN (r_nsubj) inhibited/VBD (l_dobj) effects/NNS (l_amod) cataleptic/JJ -PUNC- naloxone/NN (r_pobj) for/IN (r_prep) ID50/NNP (r_conj) asymmetry/NN (r_conj) differences/NNS (r_conj) catalepsy/NN
D009020_D002375 CID morphine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) combinations/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Catalepsy/NNP -PUNC- morphine/NN (r_conj) ketamine/NN (r_nsubj) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- morphine/NN (r_conj) ketamine/NN (r_nsubj) induced/VBN (r_ccomp) demonstrated/VBD (l_advcl) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ -PUNC- morphine/NN (r_pobj) to/IN (r_prep) tolerance/NN (r_dobj) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- morphine/NN (r_pobj) to/IN (r_prep) tolerance/NN (r_dobj) demonstrated/VBD (l_advcl) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ -PUNC- morphine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) induce/VB (r_advcl) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- morphine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ -PUNC- morphine/NN (r_pobj) to/IN (r_prep) attributed/VBN (l_ccomp) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN (l_conj) catalepsy/NN -PUNC- morphine/NN (r_pobj) to/IN (r_prep) attributed/VBN (l_ccomp) demonstrated/VBD (l_advcl) induce/VB (l_conj) augmented/VBD (l_dobj) response/NN (l_amod) cataleptic/JJ
D009020_D000699 NONE morphine/NN (r_conj) ketamine/NN (r_nsubj) induced/VBN (l_dobj) analgesia/NN -PUNC- morphine/NN (r_pobj) to/IN (r_prep) tolerance/NN (r_dobj) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN -PUNC- morphine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) induce/VB (r_advcl) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN -PUNC- morphine/NN (r_pobj) to/IN (r_prep) attributed/VBN (l_ccomp) demonstrated/VBD (l_ccomp) induced/VBN (l_dobj) analgesia/NN
D009020_D009127 NONE morphine/NN (r_conj) ketamine/NN (r_pobj) of/IN (r_prep) predominance/NN (r_dobj) reflected/VBD (l_nsubj) Latency/NN (l_prep) to/IN (l_pobj) loss/NN (l_prep) of/IN (l_pobj) reflex/NN (l_conj) rigidity/NN
D009270_D009127 NONE naloxone/NN (r_pobj) for/IN (r_prep) ID50/NNP (r_conj) asymmetry/NN (r_conj) differences/NNS (l_prep) in/IN (l_pobj) latency/NN (l_conj) rigidity/NN
17923537
D005446_D014605 NONE acetonide/NN (r_compound) implants/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) pressure/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) uveitis/NN -PUNC- acetonide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) uveitis/NN -PUNC- FA/NNP (r_nmod) implant/NN (r_appos) acetonide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) uveitis/NN
D005446_D009798 CID acetonide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) pressure/NN -PUNC- FA/NNP (r_nmod) implant/NN (r_appos) acetonide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) pressure/NN
2696505
D007741_D007022 CID labetalol/NN (l_conj) nitroprusside/RB (l_prep) for/IN (l_pobj) hypotension/NN -PUNC- labetalol/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- labetalol/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_conj) hypotension/NN
D009599_D016534 CID nitroprusside/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) observed/VBN (l_ccomp) associated/VBN (l_advcl) increase/NN (l_prep) in/IN (l_pobj) rate/NN (l_conj) output/NN
D009599_D007022 CID nitroprusside/RB (l_prep) for/IN (l_pobj) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN (r_conj) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN
D009599_D006973 NONE nitroprusside/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) observed/VBN (l_nsubjpass) hypertension/NN
8595686
D008012_D010146 NONE lidocaine/NN (r_nsubj) reduces/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D013874_D010146 NONE Thiopentone/NN (r_compound) pretreatment/NN (l_prep) for/IN (l_pobj) pain/NN -PUNC- thiopentone/NN (r_nsubj) reduces/VBZ (r_advcl) reduces/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D015742_D010146 CID propofol/JJ (r_amod) pain/NN -PUNC- propofol/JJ (r_amod) pain/NN -PUNC- propofol/JJ (r_amod) pain/NN
7189975
C004616_D012640 CID chloroprocaine/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) dose/NN (l_appos) convulsions/NNS -PUNC- chloroprocaine/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) was/VBD (l_prep) in/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) seizures/NNS
D008012_D012640 CID lidocaine/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) was/VBD (l_nsubj) dose/NN (l_appos) convulsions/NNS -PUNC- lidocaine/NN (r_compound) group/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) was/VBD (l_prep) in/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) seizures/NNS
D002045_D012640 CID bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) dose/NN (l_appos) convulsions/NNS -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
16047871
D014859_D012871 NONE warfarin/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (r_relcl) eruptions/NNS -PUNC- warfarin/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (r_acl) lesions/NNS (r_dobj) confirming/VBG (r_advcl) were/VBD (l_nsubj) results/NNS (l_prep) of/IN (l_pobj) biopsies/NNS (l_compound) lesion/NN
D014859_D018366 CID warfarin/NN (r_nsubjpass) discontinued/VBN (r_advcl) resolved/VBD (r_acl) lesions/NNS
D014859_C535509 NONE Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN -PUNC- warfarin/NN (r_pobj) due/JJ (r_amod) patients/NNS (l_prep) with/IN (l_pobj) LV/NNP -PUNC- warfarin/JJ (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) reaction/NN (r_attr) be/VB (l_nsubj) LV/NNP
6229975
D013999_D001919 NONE timolol/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN
D013999_D009203 NONE timolol/NN (r_compound) treatment/NN (l_prep) after/IN (l_pobj) infarction/NN -PUNC- timolol/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) after/IN (l_pobj) infarction/NN -PUNC- timolol/NN (r_conj) evaluated/VBN (l_nsubjpass) effect/NN (l_prep) after/IN (l_pobj) infarction/NN
D013999_D007238 NONE timolol/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) remained/VBD (r_conj) increased/VBD (l_punct) ,/, (l_punct) infarction/NN
15804801
D017239_D003323 CID paclitaxel/NN (r_compound) eluting/VBG (r_amod) stent/NN (r_pobj) of/IN (r_prep) implantation/NN (r_pobj) after/IN (r_prep) aneurysm/NN -PUNC- paclitaxel/NN (r_compound) eluting/VBG (r_amod) stent/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) aneurysm/NN
16274958
D017255_D055154 CID acitretin/NN (r_conj) dysphonia/NN -PUNC- acitretin/NN (r_pobj) by/IN (r_agent) treated/VBN (r_advcl) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) woman/NN (l_acl) complaining/VBG (l_prep) of/IN (l_pobj) dysphonia/NN -PUNC- acitretin/NN (r_advmod) induced/VBN (r_amod) dysphonia/NN
2445283
D012254_D000740 CID ribavirin/NN (r_nsubj) has/VBZ (l_conj) managed/VBN (l_nsubjpass) anemia/NN
D012254_D006478 NONE ribavirin/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) Tolerance/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fever/NN -PUNC- ribavirin/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) Tolerance/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fever/NN -PUNC- ribavirin/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) Tolerance/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fever/NN (l_appos) AHF/NNP -PUNC- ribavirin/NN (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) AHF/NNP -PUNC- ribavirin/RB (r_pobj) of/IN (r_prep) effect/NN (l_prep) during/IN (l_pobj) days/NNS (l_prep) of/IN (l_pobj) AHF/NNP
D012254_D014766 NONE ribavirin/RB (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) neutralization/NN (l_prep) of/IN (l_pobj) viremia/NN
15580403
D007372_D006461 NONE interferon/NN (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) hemolysis/NN
D012254_D019698 NONE ribavirin/JJ (r_compound) reduction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hemolysis/NN (l_prep) during/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) C./NNP -PUNC- ribavirin/RB (r_conj) interferon/NN (r_pobj) of/IN (r_prep) therapy/NN (l_prep) for/IN (l_pobj) C./NNP
D007372_D019698 NONE interferon/NN (r_pobj) of/IN (r_prep) therapy/NN (l_prep) for/IN (l_pobj) C./NNP
D012254_D006461 NONE ribavirin/JJ (r_compound) reduction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hemolysis/NN -PUNC- ribavirin/RB (r_conj) interferon/NN (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) hemolysis/NN -PUNC- ribavirin/JJ (r_compound) reduction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hemolysis/NN
D012254_D000743 CID ribavirin/NN (r_conj) interferon/NN (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) events/NNS (r_pobj) of/IN (r_prep) one/CD (r_attr) is/VBZ (l_nsubj) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) related/VBN (r_amod) anemia/NN
D012254_D000740 NONE ribavirin/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) with/IN (r_prep) patients/NNS (r_nsubj) continue/VB (l_advcl) decreased/VBD (l_conj) occurred/VBD (l_nsubj) effects/NNS (l_amod) related/VBN (l_npadvmod) anemia/NN
D007372_D000743 CID interferon/NN (r_pobj) of/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) events/NNS (r_pobj) of/IN (r_prep) one/CD (r_attr) is/VBZ (l_nsubj) anemia/NN
15602202
D017963_D009395 CID azithromycin/PRP (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) nephritis/NN -PUNC- azithromycin/RB (r_advmod) induced/VBN (r_amod) nephritis/NN
803783
D010121_D001247 NONE Oxytocin/NN (r_compound) administration/NN (r_nsubjpass) advocated/VBN (l_advcl) carried/VBN (l_conj) instructed/VBD (l_xcomp) watch/VB (l_conj) report/VB (l_dobj) signs/NNS (l_prep) as/IN (l_pobj) asthenia/NNP
D010121_D000031 NONE oxytocin/NN (r_compound) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (l_prep) during/IN (l_pobj) abortion/NN -PUNC- oxytocin/NN (r_compound) administration/NN (r_pobj) with/IN (r_prep) connection/NN (l_prep) during/IN (l_pobj) abortions/NNS -PUNC- Oxytocin/NN (r_compound) administration/NN (l_prep) during/IN (l_pobj) abortions/NNS
D010121_D014869 CID oxytocin/NN (r_compound) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) intoxication/NN -PUNC- oxytocin/NN (r_compound) administration/NN (r_pobj) with/IN (r_prep) connection/NN (r_pobj) in/IN (r_prep) intoxication/NN -PUNC- Oxytocin/NN (r_compound) administration/NN (r_nsubjpass) advocated/VBN (l_advcl) carried/VBN (l_advcl) aware/JJ (l_prep) of/IN (l_pobj) symptoms/NNS (l_prep) of/IN (l_pobj) intoxication/NN
D010121_D006261 NONE Oxytocin/NN (r_compound) administration/NN (r_nsubjpass) advocated/VBN (l_advcl) carried/VBN (l_conj) instructed/VBD (l_xcomp) watch/VB (l_conj) report/VB (l_dobj) signs/NNS (l_prep) as/IN (l_pobj) asthenia/NNP (l_conj) irritability/NN (l_conj) headaches/NNS
D010121_D001523 NONE Oxytocin/NN (r_compound) administration/NN (r_nsubjpass) advocated/VBN (l_advcl) carried/VBN (l_conj) instructed/VBD (l_xcomp) watch/VB (l_conj) report/VB (l_dobj) signs/NNS (l_prep) as/IN (l_pobj) asthenia/NNP (l_conj) irritability/NN
1009330
C005253_D003556 NONE Picloxydine/NNP (r_compound) irrigations/NNS (r_nsubj) appeared/VBD (l_xcomp) have/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) cystitis/NN
D007612_D003556 CID kanamycin/NN (r_compound) colistin/NN (r_nmod) irrigations/NNS (r_pobj) of/IN (r_prep) percentage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cystitis/NN
D011206_D003556 CID iodine/NN (r_conj) colistin/NN (r_nmod) irrigations/NNS (r_pobj) of/IN (r_prep) percentage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cystitis/NN
C010882_D003556 CID digluconate/NN (r_npadvmod) associated/VBN (r_amod) cystitis/NN
D003091_D003556 CID colistin/NN (r_nmod) irrigations/NNS (r_pobj) of/IN (r_prep) percentage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cystitis/NN
C004658_D003556 NONE choloroaniline/NN (r_appos) product/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) cystitis/NN
11009181
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D001058_D001523 NONE apomorphine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) related/VBN (l_advcl) play/VBP (l_nsubj) sedation/NN (l_conj) complications/NNS (l_amod) psychiatric/JJ
D001058_D004409 NONE apomorphine/NN (r_compound) infusions/NNS (r_pobj) with/IN (r_prep) monotherapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) reductions/NNS (l_prep) of/IN (l_pobj) dyskinesias/NNS
D001058_D010300 NONE Apomorphine/NNP (l_appos) therapy/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- Apomorphine/NNP (r_nsubj) was/VBD (l_attr) drug/NN (l_acl) used/VBN (l_xcomp) treat/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) disease/NN -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) treating/VBG (l_dobj) disease/NN -PUNC- apomorphine/NN (r_compound) treatment/NN (l_prep) in/IN (l_pobj) disease/NN
8514073
D008874_D010146 NONE midazolam/JJ (r_amod) group/NN (r_pobj) in/IN (r_prep) %/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) occurred/VBD (l_nsubj) Pain/NN
D003975_D014652 CID diazepam/NN (r_pobj) versus/FW (r_prep) midazolam/FW (r_pobj) of/IN (r_prep) complications/NNS -PUNC- diazepam/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) midazolam/DT (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) complications/NNS -PUNC- diazepam/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) complications/NNS -PUNC- diazepam/NN (r_pobj) with/IN (r_prep) frequent/JJ (r_acomp) were/VBD (l_nsubj) complications/NNS
D003975_D010146 NONE diazepam/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Pain/NN
D000431_D010146 NONE alcohol/NN (r_compound) use/NN (l_conj) pain/NN
D000431_D014652 NONE alcohol/NN (r_compound) use/NN (r_conj) time/NN (r_conj) site/NN (r_conj) use/NN (r_appos) Smoking/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) complications/NNS
D008874_D014652 CID midazolam/FW (r_pobj) of/IN (r_prep) complications/NNS -PUNC- midazolam/DT (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) complications/NNS -PUNC- midazolam/NN (r_conj) diazepam/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) complications/NNS -PUNC- midazolam/NNP (r_pobj) with/IN (r_prep) than/IN (r_prep) 22/CD (r_npadvmod) were/VBD (l_nsubj) complications/NNS
11706060
D019259_D000163 NONE lamivudine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) mice/NNS (l_compound) AIDS/NNP
D019469_D000163 NONE indinavir/NNS (r_conj) lamivudine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) mice/NNS (l_compound) AIDS/NNP
D019344_D009202 NONE lactate/NN (r_dobj) elevates/VBZ (r_conj) causes/VBZ (l_advmod) cardiomyopathy/NN -PUNC- lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP (l_amod) cardiomyopathy/NN -PUNC- lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP -PUNC- LA/NNP (r_appos) lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP (l_amod) cardiomyopathy/NN -PUNC- LA/NNP (r_appos) lactate/NN (r_pobj) in/IN (r_conj) in/IN (l_pobj) CM/NNP -PUNC- LA/NNP (r_pobj) of/IN (r_prep) determination/NN (r_conj) underwent/VBD (l_dobj) echocardiography/RB (l_appos) quantitation/NN (l_prep) of/IN (l_pobj) abundance/NN (l_prep) of/IN (l_pobj) markers/NNS (l_prep) of/IN (l_pobj) CM/NNP -PUNC- LA/NNP (r_pobj) with/IN (r_prep) CM/NNP
D019344_D028361 NONE lactate/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) implicated/VBN (l_prep) through/IN (l_pobj) mechanisms/NNS (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- LA/NNP (r_appos) lactate/NN (r_pobj) in/IN (r_conj) in/IN (r_prep) implicated/VBN (l_prep) through/IN (l_pobj) mechanisms/NNS (l_prep) of/IN (l_pobj) dysfunction/NN
D002118_D009202 NONE calcium/NN (r_compound) ATPase/NNP (r_conj) encoding/VBG (r_parataxis) quantitation/NN (l_prep) of/IN (l_pobj) abundance/NN (l_prep) of/IN (l_pobj) markers/NNS (l_prep) of/IN (l_pobj) CM/NNP
D019344_D000163 NONE lactate/NN (r_dobj) elevates/VBZ (l_prep) in/IN (l_pobj) mice/NNS (l_compound) AIDS/NNP -PUNC- lactate/NN (l_prep) in/IN (l_pobj) AIDS/NNP -PUNC- LA/NNP (r_appos) lactate/NN (l_prep) in/IN (l_pobj) AIDS/NNP -PUNC- LA/NNP (l_prep) in/IN (l_pobj) mice/NNS (l_compound) transgenic/JJ (l_compound) AIDS/NNP
D015215_D000163 NONE zidovudine/NN (r_nmod) lamivudine/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) mice/NNS (l_compound) AIDS/NNP
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin/NNP (r_dobj) bolus/NN (r_appos) Phase/NN (r_nsubjpass) done/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) status/NN (l_prep) with/IN (l_pobj) tumors/NNS -PUNC- Pirarubicin/NNP (r_appos) 4'-0-tetrahydropyranyladriamycin/NNP (r_dobj) bolus/NN (r_appos) Phase/NN (r_nsubjpass) done/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) status/NN (l_prep) with/IN (l_pobj) tumors/NNS
9209318
D015215_D000748 CID AZT/NNP (r_nsubj) induced/VBN (l_dobj) anemia/NN -PUNC- AZT/NNP (r_compound) therapy/NN (r_appos) term/NN (r_pobj) on/IN (r_prep) anemia/NN
D015215_D000163 NONE AZT/NNP (r_nsubj) induced/VBN (l_dobj) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) AIDS/NNP -PUNC- AZT/NNP (r_compound) therapy/NN (r_appos) term/NN (r_pobj) on/IN (r_prep) anemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) AIDS/NNP
D015215_D009190 CID azidothymidine/NN (r_pcomp) with/IN (r_prep) treatment/NN (r_nsubj) produces/VBZ (l_dobj) myelodysplasia/NN -PUNC- AZT/NNP (r_appos) treatment/NN (r_nsubj) produces/VBZ (l_dobj) myelodysplasia/NN -PUNC- AZT/NNP (r_compound) incorporation/NN (r_nsubj) induced/VBN (l_dobj) hemopoiesis/NN (l_prep) in/IN (l_pobj) cells/NNS (l_relcl) known/VBN (l_xcomp) seen/VBN (l_prep) in/IN (l_pobj) syndrome/NN
7066357
D005227_D009404 NONE acids/NNS (r_pobj) of/IN (r_prep) level/NN (r_nsubj) decreased/VBD (l_prep) In/IN (l_pobj) stage/NN (l_amod) nephrotic/JJ
D011692_D009404 CID aminonucleoside/RB (r_advmod) induced/VBN (l_nsubj) Plasma/NN (l_prep) during/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- aminonucleoside/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) alterations/NNS (l_prep) of/IN (l_pobj) lipoproteins/NNS (l_acl) found/VBN (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- aminonucleoside/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) alterations/NNS (r_nsubj) were/VBD (l_acomp) due/JJ (l_prep) to/IN (l_pobj) syndrome/NN -PUNC- aminonucleoside/NN (r_pobj) to/IN (r_prep) were/VBD (l_nsubj) alterations/NNS (l_prep) of/IN (l_pobj) lipoproteins/NNS (l_acl) found/VBN (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- aminonucleoside/NN (r_pobj) to/IN (r_prep) were/VBD (l_acomp) due/JJ (l_prep) to/IN (l_pobj) syndrome/NN -PUNC- aminonucleoside/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) syndrome/NN
D014280_D009404 NONE triacylglycerol/NN (r_conj) acids/NNS (r_pobj) of/IN (r_prep) level/NN (r_nsubj) decreased/VBD (l_prep) In/IN (l_pobj) stage/NN (l_amod) nephrotic/JJ
D002788_D009404 NONE esters/NNS (r_nsubj) remained/VBD (r_advcl) decreased/VBD (l_prep) In/IN (l_pobj) stage/NN (l_amod) nephrotic/JJ
48362
D011802_D056486 CID Quinidine/NN (r_compound) hepatitis/NN -PUNC- quinidine/VBN (r_poss) hepatotoxicity/NN
18405372
D012460_D056486 CID sulfasalazine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Hepatotoxicity/NN -PUNC- sulfasalazine/NN (r_pobj) on/IN (r_prep) had/VBD (l_dobj) hepatotoxicity/NN -PUNC- sulfasalazine/NN (r_pobj) with/IN (r_prep) hepatotoxicity/NN -PUNC- sulfasalazine/NN (r_pobj) with/IN (r_prep) hepatotoxicity/NN -PUNC- sulfasalazine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hepatotoxicity/NN
D012460_D001168 NONE sulfasalazine/NN (l_prep) in/IN (l_pobj) arthritis/NN
7647582
D007530_D056486 CID isoflurane/RB (r_conj) enflurane/NN (r_conj) anesthetics/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) injury/NN -PUNC- isoflurane/NN (r_conj) enflurane/NN (r_nsubj) produce/VB (l_dobj) condition/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) that/DT (l_prep) of/IN (l_pobj) hepatitis/NN
D006221_D056486 CID halothane/NN (r_relcl) exposure/NN (r_pobj) following/VBG (r_agent) associated/VBN (l_prep) with/IN (l_pobj) injury/NN -PUNC- Halothane/NNP (r_compound) hepatitis/NN -PUNC- halothane/NN (r_amod) patients/NNS (l_compound) hepatitis/NN -PUNC- halothane/NN (r_compound) hepatitis/NN -PUNC- halothane/NN (r_advcl) produce/VB (l_dobj) condition/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) that/DT (l_prep) of/IN (l_pobj) hepatitis/NN
D007530_D004342 NONE isoflurane/RB (l_prep) with/IN (l_pobj) hypersensitivity/NN -PUNC- isoflurane/NN (r_conj) enflurane/NN (r_nsubj) produce/VB (l_dobj) condition/NN (l_compound) hypersensitivity/NN
D014269_D056486 NONE trifluoroacetyl/JJ (r_compound) adduct/NN (r_appos) product/NN (r_pobj) to/IN (r_prep) response/NN (r_nsubjpass) detected/VBN (l_prep) on/IN (l_pobj) patients/NNS (l_compound) hepatitis/NN
D004737_D004342 NONE enflurane/NN (l_conj) isoflurane/RB (l_prep) with/IN (l_pobj) hypersensitivity/NN -PUNC- enflurane/NN (r_nsubj) produce/VB (l_dobj) condition/NN (l_compound) hypersensitivity/NN
D006221_D004342 NONE halothane/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypersensitivity/NN -PUNC- halothane/NN (r_compound) hepatitis/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_amod) condition/NN (l_compound) hypersensitivity/NN -PUNC- halothane/NN (r_advcl) produce/VB (l_dobj) condition/NN (l_compound) hypersensitivity/NN
D004737_D056486 CID enflurane/NN (r_conj) anesthetics/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) injury/NN -PUNC- enflurane/NN (r_nsubj) produce/VB (l_dobj) condition/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) that/DT (l_prep) of/IN (l_pobj) hepatitis/NN
11807648
D014148_D012640 CID tAMCA/NN (r_nsubj) retains/VBZ (l_dobj) action/NN (l_amod) convulsive/JJ -PUNC- tAMCA/NN (r_appos) FINDINGS/NNS (r_nsubj) caused/VBD (l_dobj) activity/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) behaviours/NNS (l_amod) convulsive/JJ -PUNC- tAMCA/CD (r_pobj) of/IN (r_prep) concentration/NN (r_pobj) with/IN (r_prep) increased/VBD (l_nsubj) degree/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- tAMCA/NN (r_advmod) evoked/VBD (l_dobj) seizures/NNS -PUNC- tAMCA/NN (r_advmod) evoked/VBD (l_advcl) evoked/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) potentials/NNS (l_amod) convulsive/JJ -PUNC- tAMCA/NN (r_nmod) ml/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) evoked/VBD (r_advcl) evoked/VBD (l_dobj) seizures/NNS -PUNC- tAMCA/NN (r_nmod) ml/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) evoked/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) potentials/NNS (l_amod) convulsive/JJ -PUNC- acid/NN (r_nsubj) retains/VBZ (l_dobj) action/NN (l_amod) convulsive/JJ
D014148_D004827 NONE acid/NN (r_dobj) containing/VBG (r_acl) sealants/NNS (r_pobj) of/IN (r_prep) application/NN (r_dobj) following/VBG (r_prep) seizures/NNS -PUNC- tAMCA/NN (r_nsubjpass) shown/VBN (l_xcomp) cause/VB (l_dobj) seizures/NNS
2051906
D001379_D002779 CID azathioprine/JJ (r_amod) therapy/NN (r_pobj) following/VBG (r_prep) cholestasis/NN -PUNC- azathioprine/JJ (r_amod) therapy/NN (r_pobj) following/VBG (r_prep) cholestasis/NN (l_prep) with/IN (l_pobj) injury/NN -PUNC- azathioprine/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) features/NNS (l_prep) of/IN (l_pobj) cholestasis/NN -PUNC- azathioprine/RB (r_advmod) induced/VBN (r_amod) cholestasis/NN -PUNC- azathioprine/RB (r_advmod) induced/VBN (r_amod) cholestasis/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) injury/NN
D001379_D008107 NONE azathioprine/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) disease/NN
D001379_D017285 NONE azathioprine/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) polymyositis/NN
18464113
D019259_D009369 NONE Lamivudine/NNP (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) reactivation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- lamivudine/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN -PUNC- lamivudine/NN (r_dobj) receive/VB (r_relcl) group/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) received/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN -PUNC- lamivudine/NN (r_nsubj) decreases/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) reactivation/NN (l_conj) morbidity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D019259_D006509 NONE Lamivudine/NNP (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) reactivation/NN (l_compound) virus/NN (l_compound) B/NNP -PUNC- lamivudine/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS (l_prep) with/IN (l_pobj) infection/NN -PUNC- lamivudine/NN (r_dobj) receive/VB (r_relcl) group/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS (l_prep) with/IN (l_pobj) infection/NN
D019259_D056486 NONE lamivudine/NN (r_compound) group/NN (r_pobj) In/IN (r_prep) observed/VBN (l_nsubjpass) hepatitis/NN
D006514_D009369 NONE antigen/NN (r_nmod) patients/NNS (l_compound) cancer/NN -PUNC- HBSAG/NNP (r_nmod) patients/NNS (l_compound) cancer/NN
D019259_D019337 NONE lamivudine/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS -PUNC- lamivudine/NN (r_dobj) receive/VB (r_relcl) group/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) received/VBD (l_nsubj) patients/NNS (l_relcl) have/VBP (l_dobj) malignancies/NNS
D006514_D006509 CID antigen/NN (r_nmod) patients/NNS (r_pobj) in/IN (r_prep) reactivation/NN (l_compound) virus/NN (l_compound) B/NNP -PUNC- HBSAG/NNP (r_nmod) patients/NNS (r_pobj) in/IN (r_prep) reactivation/NN (l_compound) virus/NN (l_compound) B/NNP
12716030
D006493_D006470 NONE heparin/VBN (r_nsubj) enhanced/VBD (l_dobj) volume/NN (l_prep) over/IN (l_pobj) that/DT (l_acl) seen/VBN (l_prep) in/IN (l_pobj) control/NN (l_dobj) animals/NNS (l_conj) bleeding/NN
D006493_D002543 NONE heparin/VBN (r_nsubj) enhanced/VBD (l_prep) In/IN (l_pobj) induction/NN (l_compound) ICH/NNP -PUNC- heparin/VBN (r_nsubj) enhanced/VBD (l_dobj) volume/NN (l_prep) over/IN (l_pobj) that/DT (l_acl) seen/VBN (l_prep) in/IN (l_pobj) control/NN (l_dobj) animals/NNS (l_compound) ICH/NNP
D006493_D006406 CID heparin/VBN (r_nsubj) enhanced/VBD (l_dobj) volume/NN (l_compound) hematoma/NN
2578334
D001374_D011230 CID 5-azacytidine/RB (r_nsubj) potentiates/VBZ (l_dobj) initiation/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) carcinogens/NNS -PUNC- 5-azacytidine/JJ (r_punct) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN -PUNC- 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
D019813_D011230 CID 1,2-dimethylhydrazine/CD (r_conj) 60/CD (r_appos) nitrosourea/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN -PUNC- 1,2-DMH/NNP (r_appos) nitrosourea/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
D008770_D011230 CID nitrosourea/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
D001564_D011230 CID benzo[a]-pyrene/NN (r_appos) carcinogens/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) phase/NN (r_pobj) during/IN (r_prep) given/VBN (l_nsubjpass) 5-AzC/CD (l_advcl) test/VB (l_dobj) validity/NN (l_prep) of/IN (l_pobj) hypothesis/NN (l_acl) plays/VBZ (l_prep) in/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) process/NN
150790
D007538_D001523 NONE isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (r_conj) irritability/NN
D007538_D002653 CID isoniazid/NN (r_pobj) by/IN (r_agent) unmasked/VBD (r_acl) disorder/NN -PUNC- isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (r_conj) irritability/NN (r_conj) hyperkinesis/NN (r_pobj) with/IN (r_prep) had/VBD (l_dobj) deterioration/NN
D007538_D006948 CID isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (r_conj) irritability/NN (r_conj) hyperkinesis/NN
D007538_D012893 NONE isoniazid/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) sleeping/VBG (l_dobj) difficulties/NNS
D011736_D006948 NONE pyridoxine/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) return/NN (l_prep) of/IN (l_pobj) hyperkinesis/NN
D011736_D002653 NONE pyridoxine/JJ (r_advmod) dependent/JJ (r_amod) disorder/NN
11532387
D012701_D001480 NONE serotonin/NN (r_compound) dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_advcl) suggesting/VBG (l_dobj) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) suggesting/VBG (r_advcl) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN
D004298_D013375 NONE dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN
D012701_D013375 NONE serotonin/NN (r_compound) dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- serotonin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) suggesting/VBG (r_advcl) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN
D018967_D013375 CID risperidone/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) during/IN (r_prep) syndrome/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN
D018967_D001480 CID risperidone/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) during/IN (r_prep) syndrome/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) during/IN (r_prep) developed/VBN (l_dobj) RS/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_advcl) suggesting/VBG (l_dobj) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN
D004298_D001480 NONE dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) mechanism/NN (l_prep) of/IN (l_pobj) RS/NN -PUNC- dopamine/NN (r_compound) antagonist/NN (r_appos) risperidone/NN (r_pobj) of/IN (r_prep) profile/NN (r_pobj) to/IN (r_prep) related/VBN (l_advcl) suggesting/VBG (l_dobj) influence/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) RS/NN
15458908
D020849_D016889 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dep) disease/NN (l_appos) CI/NNP (l_appos) hyperplasia/NN (l_appos) %/NN (l_conj) cancer/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS (l_conj) disease/NN (l_conj) hyperplasia/NN (l_conj) cancer/NN
D020849_D010024 NONE Raloxifene/NNP (r_compound) Evaluation/NNP (r_pobj) of/IN (r_prep) Outcomes/NNPS (r_nsubj) enrolled/VBD (l_prep) with/IN (l_pobj) osteoporosis/NN
D020849_D004714 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dep) disease/NN (l_appos) CI/NNP (l_appos) hyperplasia/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS (l_conj) disease/NN (l_conj) hyperplasia/NN
D020849_D002386 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS
D020849_D005705 NONE Raloxifene/NNP (r_nsubj) increase/VB (l_dep) disease/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_conj) was/VBD (l_attr) risk/NN (l_prep) for/IN (l_pobj) cataracts/NNS (l_conj) disease/NN
D020849_D054556 CID raloxifene/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) thromboembolism/NN -PUNC- Raloxifene/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) thromboembolism/NN
17639754
D014859_D006470 CID warfarin/NN (r_pobj) between/IN (r_prep) interaction/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) be/VB (r_xcomp) appear/VBP (r_relcl) complications/NNS (l_compound) bleeding/NN
D064704_D006470 CID levofloxacin/JJ (r_conj) warfarin/NN (r_pobj) between/IN (r_prep) interaction/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) be/VB (r_xcomp) appear/VBP (r_relcl) complications/NNS (l_compound) bleeding/NN
11198499
D017706_D009128 NONE lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_prep) following/VBG (l_pobj) addition/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) spasticity/NN
D017706_D006973 NONE lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN
C023754_D009128 NONE tizanidine/NN (r_pobj) of/IN (r_prep) addition/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) spasticity/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) interaction/NN (r_nsubjpass) kept/VBN (l_advcl) prescribing/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN (l_conj) spasticity/NN
C023754_D006973 NONE tizanidine/NN (r_pobj) of/IN (r_prep) initiation/NN (l_prep) in/IN (l_pobj) patient/NN (l_acl) treated/VBN (l_prep) with/IN (l_pobj) angiotensin/NN (l_acl) converting/VBG (l_prep) for/IN (l_pobj) hypertension/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) following/VBG (r_prep) developed/VBD (r_relcl) hypertension/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) interaction/NN (r_nsubjpass) kept/VBN (l_advcl) prescribing/VBG (l_xcomp) treat/VB (l_dobj) hypertension/NN
D000809_D009128 NONE angiotensin/NN (r_appos) lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_prep) following/VBG (l_pobj) addition/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) spasticity/NN
C023754_D007022 CID tizanidine/NN (r_pobj) of/IN (r_prep) initiation/NN (r_dobj) following/VBG (r_acl) Hypotension/NN -PUNC- tizanidine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) hypotension/NN
D000809_D007022 NONE angiotensin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) initiation/NN (r_dobj) following/VBG (r_acl) Hypotension/NN -PUNC- angiotensin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VB (l_dobj) ability/NN (l_acl) respond/VB (l_prep) to/IN (l_pobj) hypotension/NN -PUNC- angiotensin/NN (r_appos) lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_dobj) hypotension/NN
D017706_D007022 CID lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN (l_relcl) developed/VBD (l_dobj) hypotension/NN
D000809_D006973 NONE angiotensin/NN (l_acl) converting/VBG (l_prep) for/IN (l_pobj) hypertension/NN -PUNC- angiotensin/NN (r_appos) lisinopril/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) boy/NN (r_dobj) present/VBP (l_advcl) control/VB (l_dobj) hypertension/NN
17175308
D020123_D007674 NONE SRL/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_prep) due/IN (l_pobj) nephropathy/NN (l_advmod) CAN/VB
D020123_D051436 NONE SRL/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_prep) due/IN (l_pobj) nephropathy/NN
D020123_D011507 CID sirolimus/VB (r_pobj) to/TO (r_prep) conversion/NN (r_pobj) after/IN (r_prep) Proteinuria/NNP -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) consequence/NN (r_pobj) as/IN (r_prep) reported/VBN (l_nsubjpass) proteinuria/NN -PUNC- SRL/NN (r_compound) conversion/NN (r_pobj) after/IN (r_prep) displayed/VBD (l_dobj) proteinuria/NN -PUNC- SRL/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) proteinuria/NN
12905102
D003024_D003693 CID clozapine/NN (r_amod) treatment/NN (r_pobj) during/IN (r_prep) Delirium/NN -PUNC- clozapine/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) factors/NNS (l_prep) for/IN (l_pobj) delirium/NN -PUNC- clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) inpatients/NNS (r_dobj) identify/VB (r_xcomp) used/VBD (l_conj) reviewed/VBD (l_advcl) score/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) delirium/NN -PUNC- clozapine/NN (r_npadvmod) treated/VBN (r_amod) inpatients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) Delirium/NNP
D003024_D001523 NONE clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) inpatients/NNS (l_amod) psychiatric/JJ
11672959
D012460_D056486 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN (l_conj) fever/NN (l_conj) lymphadenopathy/NN (l_conj) hepatitis/NN
D012460_D008206 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN (l_conj) fever/NN (l_conj) lymphadenopathy/NN
D012460_D001172 NONE sulphasalazine/NN (l_prep) for/IN (l_pobj) arthritis/NN
D012460_D003872 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN
D012460_D005334 CID sulphasalazine/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) on/IN (r_prep) beginning/VBG (r_advcl) developed/VBD (l_dobj) constellation/NN (l_prep) of/IN (l_pobj) dermatitis/NN (l_conj) fever/NN
12549952
D016642_D017093 NONE bupropion/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) failure/NN
D016642_D017114 CID bupropion/NN (r_pobj) with/IN (r_prep) failure/NN -PUNC- bupropion/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) evidence/NN (r_dobj) increasing/VBG (r_advcl) is/VBZ (l_attr) case/NN (l_relcl) resulted/VBN (l_prep) from/IN (l_pobj) failure/NN -PUNC- bupropion/NN (r_dobj) receiving/VBG (r_acl) patient/JJ (r_pobj) in/IN (r_prep) failure/NN -PUNC- bupropion/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) insult/NN
D011433_D006980 NONE propranolol/NN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
D002231_D017114 CID carbimazole/NN (r_compound) therapy/NN (r_conj) bupropion/NN (r_pobj) with/IN (r_prep) failure/NN -PUNC- carbimazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_prep) resulted/VBN (l_prep) from/IN (l_pobj) failure/NN
D002231_D056486 CID carbimazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_prep) resulted/VBN (r_relcl) case/NN (r_attr) is/VBZ (l_advcl) increasing/VBG (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D016642_D056486 CID bupropion/NN (r_nsubj) induced/VBD (l_dobj) hepatotoxicity/NN -PUNC- bupropion/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) evidence/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- bupropion/NN (r_dobj) receiving/VBG (r_acl) patient/JJ (r_pobj) in/IN (r_prep) failure/NN (r_pobj) from/IN (r_prep) resulted/VBN (r_relcl) case/NN (r_attr) is/VBZ (l_advcl) increasing/VBG (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- bupropion/NN (l_acl) given/VBN (l_prep) with/IN (l_pobj) drugs/NNS (l_amod) hepatotoxic/JJ
D002231_D006980 NONE carbimazole/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
D002231_D017093 NONE carbimazole/NN (r_conj) bupropion/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) failure/NN
6503301
D003606_D008545 NONE dacarbazine/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN -PUNC- DTIC/NNP (r_appos) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN -PUNC- dacarbazine/NN (r_nmod) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN -PUNC- DTIC/NNP (r_nmod) therapy/NN (l_prep) for/IN (l_pobj) melanoma/NN
D003606_D006504 CID dacarbazine/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) disease/NN -PUNC- DTIC/NNP (r_appos) therapy/NN (r_pobj) after/IN (r_prep) disease/NN -PUNC- dacarbazine/NN (r_nmod) therapy/NN (r_nsubjpass) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) disease/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- DTIC/NNP (r_nmod) therapy/NN (r_nsubjpass) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) disease/NN (l_prep) of/IN (l_pobj) liver/NN
2528969
1564236
D004176_D023921 NONE dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN (r_pobj) During/IN (r_prep) had/VBD (l_nsubj) 12/CD (l_prep) of/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN
D004176_D006940 CID dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN -PUNC- dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) hyperemia/NN
D013793_D023921 NONE thallium-201/JJ (r_amod) tomography/NN (r_pobj) with/IN (r_prep) correlation/NN (r_appos) observed/VBN (l_prep) with/IN (l_pobj) contrast/NN (l_prep) to/IN (l_pobj) severity/NN (l_prep) of/IN (l_pobj) stenosis/NN
1848636
D013726_D007008 CID terbutaline/NN (r_npadvmod) induced/VBN (r_amod) hypokalemia/NN
D008790_D007008 NONE metoprolol/NN (l_prep) of/IN (l_pobj) hypokalemia/NN
3969369
D013739_D011471 CID testosterone/NN (r_pobj) with/IN (r_prep) implanted/VBN (r_acl) rats/NNS (r_nsubj) developed/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- testosterone/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (l_relcl) fed/VBN (l_dobj) diet/NN (l_relcl) supplemented/VBN (l_dobj) fat/NN (l_conj) cancer/NN
D013739_D063646 NONE testosterone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) carcinogenesis/NN
D013739_D009369 NONE testosterone/NN (r_pobj) with/IN (r_prep) implanted/VBN (r_acl) rats/NNS (r_nsubj) developed/VBD (r_ccomp) developed/VBN (l_dobj) tumors/NNS -PUNC- testosterone/NN (r_pobj) with/IN (r_prep) implanted/VBN (r_acl) rats/NNS (r_nsubj) developed/VBD (r_ccomp) developed/VBN (l_conj) %/NN (l_advcl) included/VBD (l_dobj) tumors/NNS
D013739_D011472 CID testosterone/NN (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) developed/VBD (l_dobj) prostatitis/NN
12851669
D016912_D054556 NONE levonorgestrel/NN (r_npadvmod) containing/VBG (r_amod) COCs/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) years/NNS (r_pobj) per/IN (r_prep) range/NN (r_attr) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D003277_D054556 CID contraceptives/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_conj) achieve/VB (l_dobj) estimates/NNS (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_conj) achieve/VB (l_dobj) estimates/NNS (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- COCs/NNPS (r_appos) contraceptives/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_conj) achieve/VB (l_dobj) estimates/NNS (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- COCs/NNPS (r_appos) contraceptives/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_conj) achieve/VB (l_dobj) estimates/NNS (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- COCs/NNS (r_pobj) on/IN (r_advcl) had/VBN (l_dobj) VTE/NNP -PUNC- COCs/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) years/NNS (r_pobj) per/IN (r_prep) 3.1/CD (r_npadvmod) range/NN (r_appos) range/NN (r_attr) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- COCs/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) years/NNS (r_pobj) per/IN (r_prep) range/NN (r_attr) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- COCs/NNS (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D004997_D054556 NONE ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) in/IN (r_prep) thromboembolism/NN -PUNC- ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN -PUNC- ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN (l_appos) VTE/NNP -PUNC- EE/NNP (r_appos) ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN -PUNC- EE/NNP (r_appos) ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN (l_appos) VTE/NNP -PUNC- EE/NNP (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) years/NNS (r_pobj) per/IN (r_prep) range/NN (r_conj) range/NN (r_attr) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- EE/NNP (r_dobj) taking/VBG (r_acl) women/NNS (r_pobj) among/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) is/VBZ (r_ccomp) suggest/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D017373_D054556 NONE acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) in/IN (r_prep) thromboembolism/NN -PUNC- acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN -PUNC- acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN (l_appos) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) ethinylestradiol/NN (r_conj) acetate/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) thromboembolism/NN (l_appos) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) years/NNS (r_pobj) per/IN (r_prep) range/NN (r_conj) range/NN (r_attr) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_dobj) taking/VBG (r_acl) women/NNS (r_pobj) among/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) is/VBZ (r_ccomp) suggest/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
18441470
D008094_D013575 NONE lithium/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) developed/VBD (l_nsubj) block/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- lithium/NN (r_compound) levels/NNS (r_nsubj) remained/VBD (l_prep) during/IN (l_pobj) attacks/NNS
D008094_D012804 CID lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) among/IN (r_prep) reported/VBN (l_nsubjpass) dysfunction/NN
D008094_D054537 CID lithium/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) block/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) developed/VBD (l_nsubj) block/NN
15036754
D003975_D064420 NONE diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D000109_D064420 NONE acetylcholine/NN (r_nmod) levels/NNS (r_dobj) elevates/VBZ (r_relcl) system/NN (r_pobj) in/IN (r_prep) AChEs/NNP (r_pobj) with/IN (r_prep) binding/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN -PUNC- ACh/NNS (r_nmod) levels/NNS (r_dobj) elevates/VBZ (r_relcl) system/NN (r_pobj) in/IN (r_prep) AChEs/NNP (r_pobj) with/IN (r_prep) binding/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
D011220_D064420 NONE 2PAM/CD (r_conj) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D003975_D011041 NONE diazepam/NN (r_nsubjpass) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
C048599_D064420 NONE CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D001285_D064420 NONE atropine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_dobj) signs/NNS (l_compound) toxicity/NN -PUNC- Atropine/NNP (r_compound) MK801/NNP (r_nsubj) offer/VB (l_dobj) protection/NN (l_prep) against/IN (l_pobj) toxicity/NN -PUNC- atropine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_conj) reduced/VBD (l_dobj) toxicity/NN
D016291_D064420 NONE MK801/NNP (r_nsubj) offer/VB (l_dobj) protection/NN (l_prep) against/IN (l_pobj) toxicity/NN
D001285_D011041 NONE atropine/NN (r_pobj) after/IN (r_prep) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- atropine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
D011220_D011041 NONE 2PAM/CD (r_conj) diazepam/NN (r_nsubjpass) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- 2PAM/CD (r_conj) diazepam/NN (r_conj) CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
D007531_D064420 NONE DFP/NNP (r_compound) atropine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_dobj) signs/NNS (l_compound) toxicity/NN -PUNC- DFP/NNP (r_compound) toxicity/NN -PUNC- DFP/NNP (r_pobj) of/IN (r_prep) toxicity/NN
D010755_D012640 NONE Organophosphate/NNP (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
D010755_D004194 NONE Organophosphate/NNP (r_npadvmod) induced/VBN (r_amod) convulsions/NNS (l_prep) of/IN (l_pobj) damages/NNS
D010755_D064420 NONE OPs/NNS (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- OP/NN (r_npadvmod) induced/VBN (r_amod) signs/NNS (l_compound) toxicity/NN
C048599_D011041 NONE CPA/NN (r_nsubjpass) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- CPA/NN (r_nsubj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
D007531_D011041 NONE DFP/NNP (r_compound) atropine/NN (r_pobj) after/IN (r_prep) given/VBN (r_advcl) prevented/VBD (l_conj) delayed/VBN (l_conj) shortened/VBN (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN -PUNC- DFP/NNP (r_pobj) of/IN (r_prep) toxicity/NN (r_dobj) reduced/VBD (r_conj) prevented/VBD (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) poisoning/NN
14742097
D017374_D020018 CID paroxetine/NN (r_conj) sertraline/NN (r_conj) fluoxetine/NN (r_dobj) receiving/VBG (r_acl) women/NNS (l_amod) dysfunctional/JJ
D020280_D020018 CID sertraline/NN (r_conj) fluoxetine/NN (r_dobj) receiving/VBG (r_acl) women/NNS (l_amod) dysfunctional/JJ
D005473_D020018 CID fluoxetine/NN (r_dobj) receiving/VBG (r_acl) women/NNS (l_amod) dysfunctional/JJ
D004809_D020018 NONE ephedrine/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) for/IN (l_pobj) dysfunction/NN -PUNC- ephedrine/NN (r_nsubj) has/VBZ (l_dobj) effects/NNS (l_prep) in/IN (l_pcomp) reversing/VBG (l_dobj) dysfunction/NN -PUNC- ephedrine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) study/NN (r_pobj) in/IN (r_prep) participated/VBD (l_nsubj) women/NNS (l_amod) dysfunctional/JJ
20080983
D003042_D012893 CID cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) sleepiness/NN -PUNC- cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) sleepiness/NN
C048833_D012893 NONE modafinil/NN (l_conj) sleepiness/NN -PUNC- Modafinil/NNP (r_nsubjpass) associated/VBN (l_advcl) measured/VBN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) sleepiness/NN -PUNC- modafinil/NN (r_nsubj) promotes/VBZ (l_conj) normalizes/VBZ (l_conj) decreases/VBZ (l_dobj) sleepiness/NN
16844102
D003676_D005334 NONE DFO/NNP (r_conj) TC/NNP (r_nsubj) attenuated/VBD (l_dobj) hyperthermia/NN
D024502_D005334 NONE TC/NNP (r_nsubj) attenuated/VBD (l_dobj) hyperthermia/NN
D024502_D020258 NONE tocopherol/NN (l_conj) deferoxamine/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN -PUNC- tocopherol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN -PUNC- TC/NNP (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN
D008694_D009422 CID MA/NNP (r_npadvmod) induced/VBN (r_amod) damage/NN
D010100_D020258 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) scavenger/NN (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN
D003676_D009422 NONE DFO/NNP (r_conj) TC/NNP (r_nsubj) ameliorate/VB (l_dobj) damage/NN
D008694_D005334 CID MA/NNP (r_npadvmod) induced/VBN (r_amod) hyperthermia/NN
D003676_D020258 NONE deferoxamine/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN -PUNC- deferoxamine/NN (r_nmod) DFO/NNP (r_conj) scavenger/NN (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN -PUNC- DFO/NNP (r_conj) scavenger/NN (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN
D007501_D020258 NONE iron/NN (r_compound) chelator/NN (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) neurotoxicity/NN
D024502_D009422 NONE TC/NNP (r_nsubj) ameliorate/VB (l_dobj) damage/NN
D008694_D020258 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- Methamphetamine/NN (l_appos) neurotoxicity/NN -PUNC- MA)-induced/VBN (r_amod) neurotoxicity/NN -PUNC- MA/NNP (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
12202650
D002211_D063806 NONE Capsaicin/NN (r_npadvmod) induced/VBN (r_amod) pain/NN
D002211_D010146 CID Capsaicin/NNS (r_nsubjpass) injected/VBN (l_advcl) induce/VB (l_dobj) pain/NN
19037603
D019259_D012216 NONE lamivudine/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) with/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) disorders/NNS -PUNC- lamivudine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (r_pobj) concerning/VBG (r_prep) report/VB (r_xcomp) was/VBD (l_attr) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- lamivudine/JJ (r_compound) therapies/NNS (r_pobj) on/IN (r_prep) were/VBD (r_relcl) diseases/NNS
D006514_D012216 NONE antigen/NN (r_pobj) in/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (r_pobj) concerning/VBG (r_prep) report/VB (r_xcomp) was/VBD (l_attr) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Ag/NNP (r_appos) antigen/NN (r_pobj) in/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effectiveness/NN (r_pobj) concerning/VBG (r_prep) report/VB (r_xcomp) was/VBD (l_attr) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Ag/NNP (r_nmod) patients/NNS (l_prep) with/IN (l_pobj) diseases/NNS
17019386
D008353_D009362 NONE Mannitol/NN (r_appos) METHODS/NNS (r_nsubjpass) administered/VBN (l_parataxis) had/VBD (l_dobj) glioma/NN (l_conj) metastases/NNS -PUNC- mannitol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (l_compound) patients/NNS (l_nmod) meningioma/NN (l_conj) metastases/NNS
D008353_D001932 NONE mannitol/NN (r_pobj) of/IN (r_prep) use/NN (l_acl) reduce/VB (l_dobj) edema/NN (l_conj) ICP/NNP (l_prep) in/IN (l_pobj) patients/NNS (l_compound) tumor/NN -PUNC- mannitol/NN (r_pobj) of/IN (r_prep) passage/NN (r_dobj) research/VB (l_prep) to/IN (l_pobj) patients/NNS (l_compound) tumor/NN
D008353_D004487 NONE mannitol/NN (r_nsubj) leak/VB (l_advcl) reversing/VBG (l_conj) aggravating/VBG (l_dobj) edema/NN
D008353_D019586 CID mannitol/NN (r_pobj) of/IN (r_prep) use/NN (l_acl) reduce/VB (l_dobj) edema/NN (l_conj) ICP/NNP
D008353_D008579 NONE Mannitol/NN (r_appos) METHODS/NNS (r_nsubjpass) administered/VBN (l_parataxis) had/VBD (l_dobj) glioma/NN (l_conj) metastases/NNS (l_conj) meningioma/NN -PUNC- mannitol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (l_compound) patients/NNS (l_nmod) meningioma/NN
D008353_D005910 NONE mannitol/NN (r_pobj) of/IN (r_prep) Passage/NN (r_nsubj) gliomas/NNS -PUNC- Mannitol/NN (r_appos) METHODS/NNS (r_nsubjpass) administered/VBN (l_parataxis) had/VBD (l_dobj) glioma/NN -PUNC- mannitol/NN (r_amod) concentrations/NNS (r_nsubj) were/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_compound) glioma/NN -PUNC- mannitol/NN (r_nsubj) leak/VB (l_prep) near/IN (l_pobj) gliomas/NNS
D008353_D001929 NONE mannitol/NN (r_pobj) of/IN (r_prep) use/NN (l_acl) reduce/VB (l_dobj) edema/NN
19657887
D000431_D004417 CID alcohol/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) hour/NN (r_pobj) In/IN (r_prep) developed/VBD (l_dobj) malaise/NN (l_prep) with/IN (l_pobj) flushing/NN (l_prep) of/IN (l_pobj) face/NN (l_conj) tachycardia/NN (l_conj) dyspnea/NN
D004221_D005483 NONE disulfiram/NN (r_npadvmod) like/JJ (r_amod) syndrome/NN (l_prep) with/IN (l_pcomp) flushing/NN
D004221_D013610 NONE disulfiram/NN (r_npadvmod) like/JJ (r_amod) syndrome/NN (l_prep) with/IN (l_pcomp) flushing/NN (l_conj) tachycardia/NN
D000431_D005483 CID alcohol/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) hour/NN (r_pobj) In/IN (r_prep) developed/VBD (l_dobj) malaise/NN (l_prep) with/IN (l_pobj) flushing/NN (l_prep) of/IN (l_pobj) face/NN
D004221_D007022 NONE disulfiram/NN (r_npadvmod) like/JJ (r_amod) syndrome/NN (l_prep) with/IN (l_pcomp) flushing/NN (l_conj) tachycardia/NN (l_conj) hypotension/NN
D000431_D013610 CID alcohol/NN (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) hour/NN (r_pobj) In/IN (r_prep) developed/VBD (l_dobj) malaise/NN (l_prep) with/IN (l_pobj) flushing/NN (l_prep) of/IN (l_pobj) face/NN (l_conj) tachycardia/NN
2819587
17400887
D013726_D001321 CID terbutaline/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) abnormalities/NNS (l_appos) implications/NNS (l_prep) for/IN (l_pobj) autism/NN -PUNC- Terbutaline/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) concordance/NN (l_prep) for/IN (l_pobj) autism/NN
D013726_D001523 NONE terbutaline/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) abnormalities/NNS
D013726_D007752 NONE Terbutaline/NNP (l_appos) agonist/NN (l_acl) used/VBN (l_xcomp) arrest/VB (l_dobj) labor/NN
D013726_D020078 NONE terbutaline/JJ (r_compound) treatment/NN (r_pobj) after/IN (r_prep) abnormalities/NNS (l_nmod) Neuroinflammation/NN
458486
D008787_D010300 NONE metoclopramide/NN (r_pobj) to/IN (r_prep) related/JJ (r_acl) derivative/JJ (r_amod) movements/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) movements/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) peak/NN (r_nmod) movements/NNS -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D063325_D004421 NONE Tiapride/NNP (r_nsubj) had/VBD (l_advcl) induced/VBN (l_prep) of/IN (l_pobj) dystonia/NN
D063325_D004409 NONE Tiapride/NNP (l_prep) in/IN (l_pobj) movements/NNS -PUNC- Tiapride/NNP (l_appos) movements/NNS
C037689_D004409 NONE benzamide/RB (r_amod) derivative/JJ (r_amod) movements/NNS
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) peak/NN (r_nmod) movements/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D063325_D010300 NONE Tiapride/NNP (l_appos) movements/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D007980_D004421 NONE levodopa/NN (r_npadvmod) induced/VBN (l_prep) of/IN (l_pobj) dystonia/NN
C037689_D010300 NONE benzamide/RB (r_amod) derivative/JJ (r_amod) movements/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D008787_D004409 NONE metoclopramide/NN (r_pobj) to/IN (r_prep) related/JJ (r_acl) derivative/JJ (r_amod) movements/NNS
D004298_D004409 NONE dopamine/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) of/IN (r_prep) overstimulation/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) dyskinesias/NNS
16428827
D012601_D000647 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN
D002794_D000647 NONE choline/NN (r_compound) acetyltransferase/NN (r_dobj) activates/VBZ (l_conj) improves/VBZ (l_dobj) amnesia/NN
C004742_D007859 NONE daidzein/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) from/IN (l_pobj) thunbergiana/NNS (l_prep) on/IN (l_pobj) impairments/NNS (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D012601_D008569 NONE scopolamine/NN (r_npadvmod) induced/VBN (r_amod) impairments/NNS (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D000109_D000647 NONE acetylcholine/NN (r_compound) biosynthesis/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) play/VB (l_conj) ameliorates/VBZ (l_dobj) amnesia/NN
D012601_D007859 NONE scopolamine/NN (r_npadvmod) induced/VBN (r_amod) impairments/NNS (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
C004742_D008569 NONE daidzein/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) from/IN (l_pobj) thunbergiana/NNS (l_prep) on/IN (l_pobj) impairments/NNS (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
C004742_D000647 NONE Daidzein/NNP (r_nsubj) activates/VBZ (l_conj) improves/VBZ (l_dobj) amnesia/NN -PUNC- daidzein/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) shown/VBN (l_xcomp) reverse/VB (l_dobj) amnesia/NN -PUNC- daidzein/NN (r_nsubj) play/VB (l_conj) ameliorates/VBZ (l_dobj) amnesia/NN
D002794_D000544 NONE choline/NN (r_compound) acetyltransferase/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- choline/NN (r_compound) acetyltransferase/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) AD/NN
D000109_D000544 NONE acetylcholine/NN (r_nmod) ACh/NNS (r_pobj) of/IN (r_prep) production/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_pobj) via/IN (r_prep) enhances/VBZ (r_relcl) activator/NN (r_appos) acetyltransferase/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- acetylcholine/NN (r_nmod) ACh/NNS (r_pobj) of/IN (r_prep) production/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_pobj) via/IN (r_prep) enhances/VBZ (r_relcl) activator/NN (r_appos) acetyltransferase/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) AD/NN -PUNC- ACh/NNS (r_pobj) of/IN (r_prep) production/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_pobj) via/IN (r_prep) enhances/VBZ (r_relcl) activator/NN (r_appos) acetyltransferase/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- ACh/NNS (r_pobj) of/IN (r_prep) production/NN (r_pobj) of/IN (r_prep) augmentation/NN (r_pobj) via/IN (r_prep) enhances/VBZ (r_relcl) activator/NN (r_appos) acetyltransferase/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) AD/NN
7199841
C004616_D013118 CID CE/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) of/IN (r_prep) cords/NNS (r_pobj) Of/IN (r_prep) 13/CD (r_nsubj) showed/VBD (l_dobj) necrosis/NN
C004616_D010243 CID CE/NN (r_nmod) %/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) Of/IN (r_prep) paralysis/NN
D002045_D010243 NONE bupivacaine/NN (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) of/IN (r_prep) None/NN (r_nsubj) titrated/VBN (l_prep) to/IN (l_pobj) paralysis/NN
10414674
D000082_D017542 NONE acetaminophen/RB (r_advmod) NSAID/NNP (r_conj) group/NN (r_dobj) receive/VB (l_parataxis) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP (l_amod) aneurysmal/JJ -PUNC- acetaminophen/NN (r_compound) group/NN (r_nsubj) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP (l_amod) aneurysmal/JJ
D007660_D017542 NONE ketoprofen/JJ (r_dobj) receive/VB (l_parataxis) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP (l_amod) aneurysmal/JJ -PUNC- ketoprofen/JJ (r_compound) group/NN (r_dobj) receive/VB (l_parataxis) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP (l_amod) aneurysmal/JJ
D007660_D006406 CID ketoprofen/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) patient/NN (r_nsubj) developed/VBD (l_dobj) hematoma/NN
D000082_D001791 NONE acetaminophen/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) increased/VBD (l_nsubj) aggregation/NN -PUNC- acetaminophen/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) increased/VBD (l_advcl) compared/VBN (l_prep) with/IN (l_pobj) results/NNS (l_compound) aggregation/NN
D007660_D001791 CID ketoprofen/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) decreased/VBD (r_conj) induced/VBN (l_nsubj) aggregation/NN
D000082_D013345 NONE acetaminophen/RB (r_advmod) NSAID/NNP (r_conj) group/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hemorrhage/NN -PUNC- acetaminophen/RB (r_advmod) NSAID/NNP (r_conj) group/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_punct) (/-LRB- (l_preconj) SAH/NNP -PUNC- acetaminophen/RB (r_advmod) NSAID/NNP (r_conj) group/NN (r_dobj) receive/VB (l_parataxis) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP -PUNC- acetaminophen/NN (r_compound) group/NN (r_nsubj) starting/VBG (r_parataxis) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hemorrhage/NN -PUNC- acetaminophen/NN (r_compound) group/NN (r_nsubj) starting/VBG (r_parataxis) receive/VB (r_xcomp) randomized/VBN (l_punct) (/-LRB- (l_preconj) SAH/NNP -PUNC- acetaminophen/NN (r_compound) group/NN (r_nsubj) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP -PUNC- acetaminophen/RB (l_dobj) function/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) SAH/NNP
D007660_D013345 NONE ketoprofen/JJ (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hemorrhage/NN -PUNC- ketoprofen/JJ (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_punct) (/-LRB- (l_preconj) SAH/NNP -PUNC- ketoprofen/JJ (r_dobj) receive/VB (l_parataxis) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP -PUNC- ketoprofen/JJ (r_compound) group/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hemorrhage/NN -PUNC- ketoprofen/JJ (r_compound) group/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_punct) (/-LRB- (l_preconj) SAH/NNP -PUNC- ketoprofen/JJ (r_compound) group/NN (r_dobj) receive/VB (l_parataxis) starting/VBG (l_prep) after/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SAH/NNP -PUNC- Ketoprofen/NNP (l_conj) acetaminophen/RB (l_dobj) function/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) SAH/NNP
D007660_D006470 NONE ketoprofen/NN (r_nsubjpass) used/VBN (r_advcl) pose/VB (l_dobj) factor/NN (l_prep) for/IN (l_pobj) hemorrhage/NN
D000244_D001791 NONE diphosphate/NN (r_pobj) of/IN (r_prep) microM/NNS (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) aggregation/NN
D007660_D002532 NONE ketoprofen/NN (r_nsubjpass) used/VBN (l_prep) on/IN (l_pobj) aneurysms/NNS
6293644
D001058_D002375 NONE apomorphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_pobj) of/IN (r_prep) prevention/NN (r_conj) potentiation/NN (l_prep) of/IN (l_pobj) catalepsy/NN
D006220_D006948 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN (r_pobj) of/IN (r_prep) potentiation/NN (l_conj) prevention/NN (l_prep) of/IN (l_pobj) hyperactivity/NN
D001058_D006948 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
2055425
D000255_D003920 NONE ATP/NNP (r_conj) stimulation/NN (r_pobj) to/TO (r_prep) responses/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ -PUNC- ATP/NNP (r_conj) stimulation/NN (r_pobj) to/TO (r_prep) responses/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
D018723_D003920 NONE bethanechol/NN (r_conj) ATP/NNP (r_conj) stimulation/NN (r_pobj) to/TO (r_prep) responses/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ -PUNC- bethanechol/NN (r_conj) ATP/NNP (r_conj) stimulation/NN (r_pobj) to/TO (r_prep) responses/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
D013311_D003920 CID streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) mellitus/NN -PUNC- streptozotocin/JJ (r_npadvmod) diabetic/JJ -PUNC- streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NNS
11284996
D009569_D006261 CID oxide/NN (r_npadvmod) induced/VBN (r_amod) headache/NN -PUNC- oxide/NN (r_nsubj) induced/VBN (l_ccomp) associated/VBN (l_nsubjpass) headache/NN -PUNC- NO/NNP (r_intj) oxide/NN (r_nsubj) induced/VBN (l_ccomp) associated/VBN (l_nsubjpass) headache/NN -PUNC- NO/JJ (r_det) trinitrate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) headache/NN -PUNC- NO/RB (r_intj) induced/VBN (r_amod) headache/NN
D005996_D006261 CID trinitrate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) headache/NN -PUNC- GTN/NNP (r_appos) trinitrate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) headache/NN -PUNC- GTN/NNP (l_conj) placebo/NN (l_prep) over/IN (l_pobj) min/NN (l_prep) on/IN (l_pobj) days/NNS (l_amod) free/JJ (l_npadvmod) headache/NN -PUNC- GTN/NNP (r_compound) day/NN (r_pobj) on/IN (r_prep) headache/NN -PUNC- GTN/NNP (r_compound) day/NN (r_pobj) on/IN (r_prep) headache/NN (r_dobj) developed/VBD (l_conj) was/VBD (l_nsubj) headache/NN
D005996_D018781 NONE trinitrate/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) headache/NN -PUNC- GTN/NNP (r_appos) trinitrate/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) headache/NN
D009569_D018781 NONE oxide/NN (r_npadvmod) induced/VBN (r_amod) headache/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) headache/NN -PUNC- NO/JJ (r_det) trinitrate/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) headache/NN
D009569_D051270 NONE oxide/NN (r_nsubj) induced/VBN (l_ccomp) associated/VBN (l_nsubjpass) headache/NN (l_prep) in/IN (l_pobj) headaches/NNS -PUNC- NO/NNP (r_intj) oxide/NN (r_nsubj) induced/VBN (l_ccomp) associated/VBN (l_nsubjpass) headache/NN (l_prep) in/IN (l_pobj) headaches/NNS
10091617
D012642_D010300 NONE Selegiline/NNP (r_advmod) induced/VBN (l_dobj) hypotension/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- selegiline/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (r_acl) mortality/NN (r_dobj) found/VBD (l_nsubj) trial/NN (l_nmod) Group/NNP (l_compound) Disease/NNP -PUNC- selegiline/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (r_acl) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- selegiline/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (r_acl) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- selegiline/RB (r_dobj) receiving/VBG (r_acl) patients/NNS (l_compound) PD/NNP -PUNC- selegiline/NN (r_pobj) on/IN (r_prep) marked/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP
D007980_D007024 NONE dopa/NNP (r_conj) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN -PUNC- dopa/NNP (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) selegiline/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN
D012642_D007024 CID Selegiline/NNP (r_advmod) induced/VBN (l_dobj) hypotension/NN -PUNC- selegiline/NN (r_pobj) with/IN (r_prep) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN -PUNC- selegiline/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) by/IN (r_agent) abolished/VBN (r_relcl) hypotension/NN -PUNC- selegiline/NN (r_dobj) stopping/VBG (l_prep) in/IN (l_pobj) expectation/NN (l_acl) shed/VB (l_prep) on/IN (l_pobj) mechanisms/NNS (l_relcl) causes/VBZ (l_dobj) hypotension/NN -PUNC- selegiline/NN (r_pobj) on/IN (r_prep) marked/VBN (r_relcl) hypotension/NN -PUNC- selegiline/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) after/IN (r_prep) ameliorated/VBN (l_nsubjpass) hypotension/NN -PUNC- selegiline/NN (r_dobj) Stopping/VBG (r_csubj) reduced/VBD (l_dobj) pressures/NNS -PUNC- selegiline/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hypotension/NN
D007980_D010300 NONE dopa/NN (r_nsubj) compared/VBN (r_conj) found/VBD (l_nsubj) trial/NN (l_nmod) Group/NNP (l_compound) Disease/NNP -PUNC- dopa/NN (r_nsubj) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dopa/NN (r_nsubj) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- dopa/NN (r_dobj) taking/VBG (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) found/VBD (l_nsubj) trial/NN (l_nmod) Group/NNP (l_compound) Disease/NNP -PUNC- dopa/NN (r_dobj) taking/VBG (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dopa/NN (r_dobj) taking/VBG (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) found/VBD (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP
10704919
D024502_D006461 NONE tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- T/NNP (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- T/NNP (r_appos) tocopherol/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- TAc/NNS (r_appos) acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- TAc/NNS (r_appos) acetate/NN (r_conj) concentrations/NNS (r_pobj) by/IN (r_agent) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN
D017665_D006461 NONE hydroxyl/NN (r_dobj) inactivated/VBN (r_parataxis) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- hydroxyl/NN (r_dobj) inactivated/VBN (r_parataxis) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN
D013629_D006461 CID tamoxifen/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Hemolysis/NNP -PUNC- TAM/NNP (r_nsubj) induces/VBZ (l_dobj) hemolysis/NN -PUNC- TAM/NNP (r_nsubj) induces/VBZ (r_conj) is/VBZ (l_nsubj) extension/NN (l_prep) of/IN (l_pobj) hemolysis/NN -PUNC- TAM/NNP (r_nsubj) induces/VBZ (l_dobj) hemolysis/NN -PUNC- TAM/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) hemolytic/JJ -PUNC- TAM/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) prevented/VBN (l_advcl) indicating/VBG (l_ccomp) related/VBN (l_nsubjpass) hemolysis/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) hemolysis/NN (r_nsubjpass) related/VBN (r_ccomp) indicating/VBG (r_advcl) prevented/VBN (l_nsubjpass) effect/NN (l_amod) hemolytic/JJ -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) hemolysis/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) hemolysis/NN -PUNC- TAM/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Hemolysis/NNP -PUNC- TAM/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Hemolysis/NNP (r_nsubjpass) preceded/VBN (l_prep) excluding/VBG (l_pobj) mechanism/NN (l_prep) of/IN (l_pobj) hemolysis/NN -PUNC- TAM/NNP (r_compound) incorporation/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) protection/NN (l_prep) from/IN (l_pobj) hemolysis/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) results/NNS (l_compound) hemolysis/NN
D024505_D006461 NONE tocopherols/NNS (r_pobj) by/IN (r_prep) protection/NN (l_prep) from/IN (l_pobj) hemolysis/NN
D011188_D006461 NONE K(+/NNP (r_pobj) of/IN (r_prep) leakage/NN (r_pobj) by/IN (r_agent) preceded/VBN (l_nsubjpass) Hemolysis/NNP -PUNC- K(+/NNP (r_pobj) of/IN (r_prep) leakage/NN (r_pobj) by/IN (r_agent) preceded/VBN (l_prep) excluding/VBG (l_pobj) mechanism/NN (l_prep) of/IN (l_pobj) hemolysis/NN
D013629_D000743 CID Tamoxifen/NNP (r_nsubj) induces/VBZ (l_dobj) changes/NNS (l_prep) in/IN (l_pobj) shape/NN (l_prep) of/IN (l_pobj) erythrocytes/NNS (l_conj) anemia/NN -PUNC- TAM/NNP (r_appos) Tamoxifen/NNP (r_nsubj) induces/VBZ (l_dobj) changes/NNS (l_prep) in/IN (l_pobj) shape/NN (l_prep) of/IN (l_pobj) erythrocytes/NNS (l_conj) anemia/NN -PUNC- TAM/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) evaluates/VBZ (l_advcl) attempting/VBG (l_xcomp) identify/VB (l_dobj) mechanisms/NNS (l_prep) on/IN (l_pobj) anemia/NN -PUNC- TAM/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- TAM/NNP (r_pobj) by/IN (r_agent) promoted/VBN (r_acl) stability/NN (r_dobj) decreased/VBD (l_conj) resulting/VBG (l_prep) in/IN (l_pobj) anemia/NN
D010100_D006461 NONE oxygen/NN (r_compound) consumption/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) by/IN (r_agent) evidenced/VBN (l_conj) determined/VBN (l_prep) in/IN (l_pobj) parallel/NN (l_prep) with/IN (l_pobj) hemolysis/NN
D013629_D001943 NONE Tamoxifen/NNP (r_nsubj) induces/VBZ (l_nsubj) drug/NN (l_acl) prescribed/VBN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- TAM/NNP (r_appos) Tamoxifen/NNP (r_nsubj) induces/VBZ (l_nsubj) drug/NN (l_acl) prescribed/VBN (l_prep) in/IN (l_pobj) chemotherapy/NN (l_prep) of/IN (l_pobj) cancer/NN
2273650
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) Amnesia/NNP -PUNC- scopolamine/NN (r_nsubj) reversed/VBD (l_dobj) amnesia/NN -PUNC- scopolamine/NN (r_nsubj) reversed/VBD (l_conj) failed/VBD (l_xcomp) reverse/VB (l_dobj) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN (r_dobj) reversed/VBD (l_conj) failed/VBD (l_xcomp) reverse/VB (l_dobj) amnesia/NN
D003513_D000647 CID cycloheximide/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) Amnesia/NNP -PUNC- cycloheximide/NN (r_nsubj) failed/VBD (r_conj) reversed/VBD (l_dobj) amnesia/NN -PUNC- cycloheximide/NN (r_nsubj) failed/VBD (l_xcomp) reverse/VB (l_dobj) amnesia/NN -PUNC- cycloheximide/RB (r_advmod) induced/VBN (r_amod) amnesia/NN (r_dobj) reverse/VB (r_xcomp) failed/VBD (r_conj) reversed/VBD (l_dobj) amnesia/NN -PUNC- cycloheximide/RB (r_advmod) induced/VBN (r_amod) amnesia/NN
D009270_D000647 NONE naloxone/NN (r_dobj) administered/VBN (r_acl) retrieval/NN (r_dobj) facilitated/VBD (r_conj) reversed/VBN (l_nsubjpass) Amnesia/NNP
D009020_D000647 NONE morphine/NN (r_pobj) by/IN (r_agent) reversed/VBN (l_nsubjpass) Amnesia/NNP -PUNC- morphine/NN (r_nsubj) facilitated/VBD (r_conj) reversed/VBN (l_nsubjpass) Amnesia/NNP
10342929
D000806_D000799 CID inhibitors/NNS (r_pobj) to/IN (r_pcomp) due/IN (r_prep) Angioedema/NNP -PUNC- inhibitor/NN (r_compound) treatment/NN (r_nsubj) is/VBZ (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) angioedema/NN
18726058
D010208_D003389 NONE papaverine/NN (r_pobj) with/IN (r_prep) cases/NNS (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) dysfunction/NN -PUNC- papaverine/NN (r_pobj) from/IN (r_prep) deficits/NNS
D010208_D020301 NONE hydrochloride/NN (r_nsubj) is/VBZ (l_attr) vasodilator/NN (l_acl) used/VBD (l_xcomp) manage/VB (l_dobj) vasospasm/NN -PUNC- papaverine/NN (r_dobj) received/VBD (l_prep) for/IN (l_pobj) vasospasm/NN -PUNC- papaverine/NN (r_nsubjpass) used/VBN (l_prep) as/IN (l_pobj) action/NN (l_acl) manage/VB (l_dobj) vasospasm/NN -PUNC- papaverine/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) vasospasm/NN
7619765
D005047_D009203 CID Etoposide/RB (r_npadvmod) related/VBN (r_amod) infarction/NN -PUNC- etoposide/RB (r_dobj) containing/VBG (r_acl) chemotherapy/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) occurrence/NN (l_prep) of/IN (l_pobj) infarction/NN
D005047_D003327 NONE etoposide/RB (r_dobj) containing/VBG (r_acl) chemotherapy/NN (r_pobj) after/IN (r_prep) reported/VBN (l_prep) in/IN (l_pobj) man/NN (l_prep) with/IN (l_pobj) factors/NNS (l_prep) for/IN (l_pobj) disease/NN
15638391
D006220_D006966 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) process/NN (l_prep) of/IN (l_pobj) cells/NNS (l_prep) of/IN (l_pobj) lobe/NN (l_prep) in/IN (l_pobj) hyperprolactinemia/NN -PUNC- haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) was/VBD (l_xcomp) examine/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- HAL/NNP (r_appos) haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) was/VBD (l_xcomp) examine/VB (l_dobj) influence/NN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
384871
D004977_D064420 NONE ethambutol/NN (r_pobj) due/IN (r_amod) hazards/NNS (l_prep) of/IN (l_pobj) toxicity/NN
D007538_D009901 CID isoniazid/NN (r_conj) ethambutol/NN (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) neuropathy/NN
D004977_D009901 CID ethambutol/NN (r_nmod) treatment/NN (r_pobj) due/IN (r_prep) neuropathy/NN
9721172
D007052_D013262 CID ibuprofen/JJ (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) child/NN (l_relcl) described/VBN (l_nsubjpass) syndrome/NN
D014580_D002779 NONE acid/NN (l_conj) prednisone/NN (l_conj) tacrolimus/VB (l_conj) disease/NN
D016559_D002779 NONE tacrolimus/VB (l_conj) disease/NN
D014580_D005355 NONE acid/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) Despite/IN (r_prep) was/VBD (l_prep) with/IN (l_pobj) cirrhosis/NN
D011241_D002779 NONE prednisone/NN (l_conj) tacrolimus/VB (l_conj) disease/NN
D007052_D001649 NONE ibuprofen/JJ (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) child/NN (l_relcl) developed/VBD (l_dobj) syndrome/NN
D011241_D005355 NONE prednisone/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) Despite/IN (r_prep) was/VBD (l_prep) with/IN (l_pobj) cirrhosis/NN
D016559_D005355 NONE tacrolimus/VB (r_conj) prednisone/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) Despite/IN (r_prep) was/VBD (l_prep) with/IN (l_pobj) cirrhosis/NN
1445986
D015313_D000740 NONE cefotetan/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) anemia/NN
D015313_D000743 CID Cefotetan/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN
D010406_D000743 NONE penicillins/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) anemia/NN
D002511_D000743 NONE cephalosporins/NNS (r_conj) penicillins/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) anemia/NN
10365197
D003042_D001523 NONE Cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (l_appos) rates/NNS (l_conj) symptoms/NNS (l_amod) psychiatric/JJ -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) sample/NN (r_pobj) in/IN (r_prep) rates/NNS (l_conj) symptoms/NNS (l_amod) psychiatric/JJ -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (r_nsubjpass) compared/VBN (l_prep) on/IN (l_pobj) measures/NNS (l_prep) of/IN (l_pobj) symptoms/NNS (l_amod) psychiatric/JJ -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (r_pobj) with/IN (r_prep) outpatients/NNS (r_nsubjpass) compared/VBN (l_prep) on/IN (l_pobj) measures/NNS (l_prep) of/IN (l_pobj) symptoms/NNS (l_amod) psychiatric/JJ
D003042_D019964 CID Cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) sample/NN (r_pobj) in/IN (r_prep) rates/NNS (r_appos) disorder/NN -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_conj) disorders/NNS -PUNC- cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_conj) disorders/NNS (l_conj) disorder/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (r_pobj) with/IN (r_prep) outpatients/NNS (l_conj) disorders/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (r_pobj) with/IN (r_prep) outpatients/NNS (l_conj) disorders/NNS (l_conj) disorder/NN
D003042_D019970 NONE cocaine/NN (r_npadvmod) dependent/JJ (r_amod) outpatients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_appos) CIMD/NNP -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) disorder/NN (l_appos) CIMD/NNP
14657095
D000666_D003047 NONE B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_prep) for/IN (l_pobj) coccidioidomycosis/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_prep) for/IN (l_pobj) coccidioidomycosis/NN
D000666_D002311 CID B/NNP (r_compound) therapy/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) cardiomyopathy/NN -PUNC- B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN (l_amod) cardiomyopathy/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN (l_amod) cardiomyopathy/NN
D000666_D006333 CID B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN -PUNC- AmB/NNP (r_appos) B/NNP (r_pobj) with/IN (r_prep) developed/VBD (l_dobj) failure/NN -PUNC- AmB./NN (r_pobj) for/IN (r_prep) substituted/VBN (r_advcl) resolved/VBD (r_acl) abnormalities/NNS (l_conj) failure/NN
D000666_D064420 NONE AmB./NN (r_pobj) of/IN (r_prep) toxicity/NN
C101425_D006333 NONE posaconazole/NN (r_nsubjpass) substituted/VBN (r_advcl) resolved/VBD (r_acl) abnormalities/NNS (l_conj) failure/NN
12013711
D008238_D012559 NONE LSD/NNP (r_compound) abuse/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) disturbances/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ -PUNC- LSD/NNP (r_compound) abuse/NN (r_pobj) of/IN (r_prep) history/NN (r_dobj) had/VBD (r_relcl) patients/NNS (l_amod) schizophrenic/JJ
D008238_D001480 NONE LSD/NNP (r_compound) abuse/NN (r_pobj) of/IN (r_prep) history/NN (r_dobj) had/VBD (l_conj) developed/VBN (l_dobj) EPS/NNP
D018967_D012559 NONE Risperidone/NNP (r_npadvmod) associated/VBN (r_amod) disturbances/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_amod) schizophrenic/JJ
D008238_D010468 NONE LSD/NNP (r_compound) abuse/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) disturbances/NNS -PUNC- LSD/NNP (r_compound) consumption/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) flashbacks/NNS (r_pobj) as/IN (r_prep) experienced/VBN (r_acl) disturbances/NNS
D018967_D010468 CID Risperidone/NNP (r_npadvmod) associated/VBN (r_amod) disturbances/NNS -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) appeared/VBD (r_relcl) disturbances/NNS -PUNC- Risperidone/NNP (r_compound) administration/NN (r_nsubjpass) continued/VBN (l_conj) wore/VBD (l_nsubj) disturbances/NNS
D018967_D001480 NONE risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_relcl) had/VBD (l_conj) developed/VBN (l_dobj) EPS/NNP
12639165
D013988_D056486 CID Ticlopidine/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) complication/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN -PUNC- ticlopidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_conj) showed/VBD (l_dobj) characteristics/NNS (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ticlopidine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN
D013988_D002779 CID Ticlopidine/NNP (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- ticlopidine/NN (r_advmod) complication/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN -PUNC- ticlopidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_conj) showed/VBD (l_dobj) characteristics/NNS (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ticlopidine/NN (r_npadvmod) induced/VBN (r_amod) cholestasis/NN -PUNC- ticlopidine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) hepatitis/NN
D013988_D007565 CID ticlopidine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) jaundice/NN
19299179
D015662_D011020 NONE trimoxazole/NN (r_amod) treatment/NN (l_prep) for/IN (l_pobj) pneumonia/NN -PUNC- trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN -PUNC- trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN (l_appos) PCP/NNP -PUNC- trimoxazole/NN (r_amod) treatment/NN (l_prep) for/IN (l_pobj) PCP/NNP
D015662_D002780 CID trimoxazole/NN (r_amod) treatment/NN (r_dobj) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_relcl) developed/VBD (l_dobj) cholestasis/NN
D015662_D015658 NONE trimoxazole/NN (r_amod) treatment/NN (l_prep) for/IN (l_pobj) pneumonia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) infected/VBN -PUNC- trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN (l_appos) infection/NN (l_prep) in/IN (l_pobj) individuals/NNS (l_amod) infected/VBN -PUNC- trimoxazole/NN (r_amod) treatment/NN (r_dobj) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_amod) infected/VBN
D015662_D008100 NONE trimoxazole/NN (r_amod) treatment/NN (r_dobj) report/VBP (l_dobj) cases/NNS (l_conj) in/IN (l_pobj) lesions/NNS (l_acl) mimicking/VBG (l_dobj) formation/NN (l_compound) abscess/NN
D015662_D002779 NONE trimoxazole/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) cholestasis/NN
D015662_D009894 NONE trimoxazole/NN (r_punct) ./. (r_punct) treated/VBN (l_nsubjpass) pneumonia/NN (l_appos) infection/NN
17261653
D003000_D001919 CID Clonidine/NNP (r_npadvmod) induced/VBN (l_dobj) bradycardia/NN
1420741
D005672_D015212 NONE acid/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) at/IN (l_pobj) level/NN (l_prep) in/IN (l_pobj) disease/NN
D016572_D003424 NONE cyclosporin/NN (r_pobj) to/IN (r_prep) similar/JJ (r_amod) properties/NNS (r_pobj) with/IN (r_prep) antibiotic/NN (r_appos) Treatment/NN (l_prep) of/IN (l_pobj) disease/NN
D005672_D003424 NONE acid/NN (r_pobj) with/IN (r_prep) disease/NN -PUNC- acid/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_conj) pharmacodynamics/NNS (r_dobj) estimate/VB (r_advcl) undertaken/VBN (l_prep) Because/IN (l_pobj) need/NN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) treatments/NNS (l_prep) for/IN (l_pobj) disease/NN -PUNC- acid/NN (r_nsubj) be/VB (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN
7444978
D013307_D020258 NONE streptomycin/NNS (r_pobj) of/IN (r_prep) effects/NNS (l_amod) neurotoxic/JJ
D013307_D004409 CID streptomycin/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) is/VBZ (r_ccomp) indicating/VBG (r_advcl) occurred/VBD (l_ccomp) occurred/VBD (l_nsubj) movements/NNS -PUNC- streptomycin/NNS (l_prep) than/IN (l_pobj) site/NN (l_amod) responsible/JJ (l_prep) for/IN (l_pobj) dyskinesias/NNS
D013307_D003638 CID streptomycin/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) is/VBZ (r_ccomp) indicating/VBG (r_advcl) occurred/VBD (l_ccomp) occurred/VBD (l_nsubj) movements/NNS (l_conj) deafness/NN
7088431
D004054_D014625 CID diethylstilbestrol/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) women/NNS (r_pobj) in/IN (r_prep) up/NN (r_pobj) at/IN (r_prep) detected/VBD (l_nsubj) cases/NNS (l_prep) of/IN (l_pobj) adenocarcinoma/NN (l_prep) of/IN (l_pobj) vagina/NN
D004054_D018262 CID DES/NNP (r_npadvmod) exposed/VBN (r_amod) offspring/NN (r_pobj) in/IN (r_prep) Development/NN (l_prep) of/IN (l_pobj) adenocarcinoma/NN -PUNC- diethylstilbestrol/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) women/NNS (r_pobj) in/IN (r_prep) up/NN (r_pobj) at/IN (r_prep) detected/VBD (l_nsubj) cases/NNS (l_prep) of/IN (l_pobj) adenocarcinoma/NN (l_prep) of/IN (l_pobj) vagina/NN
18221780
D016202_D010146 NONE NMDA/NNP (r_compound) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- NMDA/NNP (r_compound) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN
D009020_D010146 NONE morphine/NN (r_compound) antihyperalgesia/NN (r_pobj) of/IN (r_prep) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- morphine/NN (r_conj) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN
D002211_D059787 NONE capsaicin/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) differences/NNS (l_appos) comparisons/NNS (l_prep) to/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D002211_D010146 NONE capsaicin/NN (r_compound) model/NN (l_prep) of/IN (l_pobj) pain/NN
D003915_D059787 NONE dextromethorphan/NNP (r_pobj) by/IN (r_prep) Enhancement/NN (r_nsubjpass) seen/VBN (l_prep) in/IN (l_pobj) males/NNS (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D016202_D059787 NONE NMDA/NNP (r_compound) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_appos) comparisons/NNS (l_prep) to/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- aspartate/NNP (r_nmod) antagonists/NNS (r_nsubj) enhance/VBP (l_prep) In/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- NMDA/NNP (r_nmod) antagonists/NNS (r_nsubj) enhance/VBP (l_prep) In/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- NMDA/NNP (r_compound) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_relcl) distinguished/VBN (l_prep) from/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D002211_D006930 CID capsaicin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) hyperalgesia/NN
D009020_D059787 NONE morphine/NN (r_compound) antihyperalgesia/NN (r_pobj) of/IN (r_prep) enhancement/NN (r_pobj) in/IN (r_prep) differences/NNS (l_appos) comparisons/NNS (l_prep) to/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) enhance/VBP (l_prep) In/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- morphine/NN (r_compound) antinociception/NN (r_pobj) of/IN (r_prep) Enhancement/NN (r_nsubjpass) seen/VBN (l_prep) in/IN (l_pobj) males/NNS (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- morphine/NN (r_conj) antagonists/NNS (r_pobj) between/IN (r_prep) interaction/NN (l_prep) in/IN (l_pobj) model/NN (l_relcl) distinguished/VBN (l_prep) from/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
17242861
D010862_D004833 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (l_appos) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D012640 NONE pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) to/IN (r_prep) susceptibility/NN (r_pobj) for/IN (r_prep) QTLs/NNS (r_nsubjpass) reported/VBN (l_conj) used/VBN (l_xcomp) localize/VB (l_dobj) genes/NNS (l_compound) susceptibility/NN (l_compound) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
7785794
D014700_D006327 CID verapamil/NN (r_compound) SR/NNP (r_pobj) after/IN (r_prep) shock/NN (l_conj) block/NN -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) block/NN
D004298_D006327 NONE dopamine/NN (r_pobj) as/IN (r_prep) agents/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_conj) uses/NNS (r_pobj) with/IN (r_prep) remain/VB (l_acomp) hypotensive/JJ (l_prep) with/IN (l_pobj) block/NN
D008790_D012770 NONE metoprolol/NN (r_conj) shock/NN
D002122_D007022 NONE chloride/NN (l_conj) hypotension/NN
D004280_D006327 NONE dobutamine/NN (r_conj) dopamine/NN (r_pobj) as/IN (r_prep) agents/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_conj) uses/NNS (r_pobj) with/IN (r_prep) remain/VB (l_acomp) hypotensive/JJ (l_prep) with/IN (l_pobj) block/NN
D008790_D007022 CID metoprolol/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) block/NN (l_conj) hypotension/NN
D001285_D006327 NONE atropine/NN (r_pobj) of/IN (r_prep) uses/NNS (r_pobj) with/IN (r_prep) remain/VB (l_acomp) hypotensive/JJ (l_prep) with/IN (l_pobj) block/NN
D001285_D007022 NONE atropine/NN (r_pobj) of/IN (r_prep) uses/NNS (r_pobj) with/IN (r_prep) remain/VB (l_acomp) hypotensive/JJ
D002122_D006327 NONE chloride/NN (l_conj) hypotension/NN (l_conj) block/NN
D014700_D007022 CID verapamil/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) block/NN (l_conj) hypotension/NN
D008790_D006327 CID metoprolol/NN (r_conj) shock/NN (l_conj) block/NN -PUNC- metoprolol/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) block/NN
D014700_D012770 NONE verapamil/NN (r_compound) SR/NNP (r_pobj) after/IN (r_prep) shock/NN
D004280_D007022 NONE dobutamine/NN (r_conj) dopamine/NN (r_pobj) as/IN (r_prep) agents/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_conj) uses/NNS (r_pobj) with/IN (r_prep) remain/VB (l_acomp) hypotensive/JJ
D004298_D007022 NONE dopamine/NN (r_pobj) as/IN (r_prep) agents/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_conj) uses/NNS (r_pobj) with/IN (r_prep) remain/VB (l_acomp) hypotensive/JJ
19289093
D002809_D007022 CID sulfate/NN (r_nmod) derivative/NN (l_relcl) elicit/VB (l_dobj) response/NN (l_amod) hypotensive/JJ
D006493_D007022 NONE heparin/JJ (r_compound) products/NNS (r_pobj) of/IN (r_prep) lots/NNS (r_pobj) of/IN (r_prep) number/NN (r_nsubjpass) found/VBN (l_xcomp) contaminated/VBN (l_prep) with/IN (l_pobj) derivative/NN (l_relcl) elicit/VB (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- heparin/JJ (r_compound) products/NNS (r_dobj) Using/VBG (r_advcl) showed/VBD (l_ccomp) produces/VBZ (l_dobj) hypotension/NN
8546130
D017291_D007676 NONE Clarithromycin/NN (r_npadvmod) associated/VBN (r_amod) hallucinations/NNS (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) failure/NN -PUNC- clarithromycin/NN (r_pobj) of/IN (r_prep) dose/NN (l_prep) in/IN (l_pobj) face/NN (l_prep) of/IN (l_pobj) failure/NN
D000535_D007676 NONE aluminum/NN (r_compound) intoxication/NN (r_pobj) with/IN (r_prep) combination/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) in/IN (l_pobj) face/NN (l_prep) of/IN (l_pobj) failure/NN
D018942_D006212 NONE macrolide/NN (r_amod) antibiotic/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) hallucinations/NNS
D000535_D020258 NONE aluminum/NN (r_compound) intoxication/NN (r_pobj) with/IN (r_prep) combination/NN (r_nsubj) facilitated/VBN (l_dobj) appearance/NN (l_prep) of/IN (l_pobj) effect/NN (l_amod) neurotoxic/JJ
D017291_D006212 CID Clarithromycin/NN (r_npadvmod) associated/VBN (r_amod) hallucinations/NNS -PUNC- clarithromycin/NN (r_appos) antibiotic/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) occurring/VBG (r_acl) hallucinations/NNS
D017291_D020258 NONE clarithromycin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) facilitated/VBN (l_dobj) appearance/NN (l_prep) of/IN (l_pobj) effect/NN (l_amod) neurotoxic/JJ
6892185
D002217_D004830 CID carbachol/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS -PUNC- carbachol/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS -PUNC- carbachol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS
D010830_D015878 CID eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS (r_conj) tremor/NN (r_conj) mydriasis/NN -PUNC- eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) mydriasis/NN -PUNC- eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN
D010830_D014202 CID eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS (r_conj) tremor/NN -PUNC- eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) mydriasis/NN (l_conj) tremor/NN -PUNC- eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN (l_conj) tremor/NN
D002217_D014202 CID carbachol/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS (r_conj) tremor/NN -PUNC- carbachol/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) mydriasis/NN (l_conj) tremor/NN -PUNC- carbachol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN (l_conj) tremor/NN
D002122_D014202 NONE chloride/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) injected/VBD (l_advcl) fighting/VBG (l_conj) mydriasis/NN (l_conj) tremor/NN -PUNC- chloride/NN (r_pobj) by/IN (r_agent) changed/VBN (l_nsubjpass) mydriasis/NN (l_conj) tremor/NN -PUNC- chloride/NN (r_nsubj) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN (l_conj) tremor/NN
D002122_D004830 NONE chloride/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) injected/VBD (l_advcl) fighting/VBG (l_conj) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS -PUNC- chloride/NN (r_pobj) by/IN (r_agent) changed/VBN (l_nsubjpass) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS -PUNC- chloride/NN (r_nsubj) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS
D002217_D015878 CID carbachol/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS (r_conj) tremor/NN (r_conj) mydriasis/NN -PUNC- carbachol/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) mydriasis/NN -PUNC- carbachol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN
D002122_D015878 NONE chloride/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) injected/VBD (l_advcl) fighting/VBG (l_conj) mydriasis/NN -PUNC- chloride/NN (r_pobj) by/IN (r_agent) changed/VBN (l_nsubjpass) mydriasis/NN -PUNC- chloride/NN (r_nsubj) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN
D010830_D004830 CID eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS -PUNC- eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) evoked/VBN (r_acl) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS -PUNC- eserine/NN (r_conj) carbachol/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) dissociate/VB (l_prep) from/IN (l_pobj) phenomena/NNS (l_prep) as/IN (l_pobj) mydriasis/NN (l_conj) tremor/NN (l_conj) convulsions/NNS
12090760
D015215_D000740 CID azidothymidine/RB (r_advmod) induced/VBN (r_amod) anemia/NN -PUNC- Azidothymidine/NNP (r_nsubjpass) reversed/VBN (l_nsubjpass) anemia/NN -PUNC- AZT)-induced/VBN (r_compound) anemia/NN
17049862
D010672_D001919 CID phenytoin/JJ (r_compound) administration/NN (r_pobj) Following/VBG (r_prep) developed/VBD (l_dobj) bradycardia/NN
D004837_D001919 NONE adrenaline/NN (r_conj) atropine/NN (r_pobj) to/IN (r_prep) refractory/JJ (r_advcl) developed/VBD (l_dobj) bradycardia/NN
D001285_D001919 NONE atropine/NN (r_pobj) to/IN (r_prep) refractory/JJ (r_advcl) developed/VBD (l_dobj) bradycardia/NN
D010672_D012640 NONE phenytoin/NN (r_nsubjpass) administered/VBN (l_prep) during/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) surgery/NN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_compound) seizure/NN
D010672_D007035 NONE phenytoin/JJ (r_compound) administration/NN (r_nsubj) Is/VBZ (l_acomp) safe/JJ (l_prep) in/IN (l_pobj) child/NN (l_amod) hypothermic/JJ -PUNC- phenytoin/NN (l_conj) hypothermia/NN -PUNC- phenytoin/NN (r_pobj) of/IN (r_prep) Administration/NN (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) hypothermia/NN
16167916
D020849_D054556 CID raloxifene/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (r_amod) thromboembolism/NN
6769133
D004317_D006333 CID adriamycin/NNS (r_compound) dose/NN (r_pobj) at/IN (r_prep) developed/VBD (l_dobj) failure/NN
D004317_D007938 NONE adriamycin/NN (r_nsubj) is/VBZ (l_conj) be/VB (l_nsubj) leukemia/NN
D004317_D066126 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_conj) Cardiotoxic/NNP
D018943_D009202 NONE anthracycline/NN (r_amod) induced/VBN (r_amod) cardiomyopathy/NN
D018943_D001768 NONE anthracycline/NN (r_amod) induced/VBN (r_amod) cardiomyopathy/NN (r_pobj) in/IN (r_prep) found/VBN (r_acl) those/DT (r_dobj) resembled/VBD (l_nsubj) lesions/NNS
D004317_D015470 CID adriamycin/NNS (r_pobj) of/IN (r_prep) m2/CD (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) leukemia/NN
7437994
1436384
D000596_D020258 NONE acid/NN (r_compound) antagonist/NN (r_appos) LY274614/NNP (r_pobj) by/IN (r_prep) rodents/NNS (r_pobj) in/IN (r_prep) neurons/NNS (r_pobj) toward/IN (r_prep) neurotoxicity/NN
C070935_D020258 NONE LY274614/NNP (r_pobj) by/IN (r_prep) rodents/NNS (r_pobj) in/IN (r_prep) neurons/NNS (r_pobj) toward/IN (r_prep) neurotoxicity/NN -PUNC- LY274614/NNP (r_nsubj) is/VBZ (r_conj) involves/VBZ (l_nsubj) effect/NN (l_amod) neurotoxic/JJ
D004298_D020258 NONE dopamine/NN (r_compound) neurons/NNS (r_pobj) toward/IN (r_prep) neurotoxicity/NN -PUNC- dopamine/NN (r_compound) neurons/NNS (r_pobj) toward/IN (r_prep) compounds/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) neurotoxic/JJ
D000661_D020258 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- amphetamine/NN (r_nmod) compounds/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) neurotoxic/JJ
D016202_D020258 NONE NMDA/NNP (r_compound) receptors/NNS (r_dobj) involves/VBZ (l_nsubj) effect/NN (l_amod) neurotoxic/JJ -PUNC- NMDA/NNP (r_compound) antagonist/NN (r_attr) is/VBZ (r_conj) involves/VBZ (l_nsubj) effect/NN (l_amod) neurotoxic/JJ
7752389
D015320_D053201 NONE tachykinins/NNS (r_pobj) of/IN (r_prep) involvement/NN (r_appos) rats/NNS (r_pobj) in/IN (r_prep) hyperactivity/NN -PUNC- tachykinins/NNS (r_pobj) of/IN (r_prep) release/NN (r_pobj) via/IN (r_prep) contribute/VBP (l_prep) to/IN (l_pobj) urge/VB (l_conj) hyperactivity/NN
D015232_D053201 CID E2-induced/JJ (r_amod) hyperactivity/NN
D011453_D053201 NONE Prostanoids/NNS (r_nsubj) contribute/VBP (l_prep) to/IN (l_pobj) urge/VB (l_conj) hyperactivity/NN
17042884
C069541_D001714 NONE quetiapine/NN (l_prep) in/IN (l_pobj) studies/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) mania/NN -PUNC- quetiapine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) mania/NN -PUNC- quetiapine/NN (r_amod) therapy/NN (r_nsubj) is/VBZ (l_prep) In/IN (l_pobj) mania/NN
D006220_D017109 CID Haloperidol/NNP (r_nsubj) induced/VBD (l_dobj) incidence/NN (l_appos) 0.001/CD (l_prep) of/IN (l_pobj) akathisia/NN
D014635_D017109 NONE DVP/NNP (r_conj) QTP/NNP (r_pobj) with/IN (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- DVP/NNP (r_conj) PBO/NNP (r_conj) DVP/NNP (r_conj) QTP/NNP (r_pobj) with/IN (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN
D008094_D001480 CID Li/NNP (r_nmod) DVP/NNP (r_conj) QTP/NNP (r_pobj) with/IN (r_prep) events/NNS (l_amod) related/VBN (l_npadvmod) EPS/NNP -PUNC- Li/NNP (r_nmod) DVP/NNP (r_conj) PBO/NNP (r_pobj) with/IN (r_prep) than/IN (r_prep) different/JJ (r_acomp) were/VBD (l_nsubj) events/NNS (l_amod) related/VBN (l_npadvmod) EPS/NNP -PUNC- lithium/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) whereas/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) events/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) EPS/NNP
D006220_D001480 CID haloperidol/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) events/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) EPS/NNP -PUNC- Haloperidol/NNP (r_nsubj) induced/VBD (l_npadvmod) tremor/NN (l_conj) syndrome/NN
D008094_D014202 CID Lithium/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_appos) 0.05/CD (l_prep) of/IN (l_pobj) tremor/NN -PUNC- Lithium/NN (r_nsubjpass) associated/VBN (r_ccomp) contributed/VBN (l_nsubj) tremor/NN -PUNC- Lithium/NN (r_nsubjpass) associated/VBN (r_ccomp) contributed/VBN (l_prep) to/IN (l_pobj) rate/NN (l_prep) of/IN (l_pobj) tremor/NN -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) tremor/NN (r_nsubj) contributed/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_appos) 0.05/CD (l_prep) of/IN (l_pobj) tremor/NN -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) tremor/NN -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (r_relcl) tremor/NN (r_nsubj) contributed/VBN (l_prep) to/IN (l_pobj) rate/NN (l_prep) of/IN (l_pobj) tremor/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) rate/NN (r_pobj) to/IN (r_prep) contributed/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_appos) 0.05/CD (l_prep) of/IN (l_pobj) tremor/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) rate/NN (r_pobj) to/IN (r_prep) contributed/VBN (l_nsubj) tremor/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) rate/NN (l_prep) of/IN (l_pobj) tremor/NN
C069541_D001480 NONE quetiapine/NN (r_pobj) with/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) symptoms/NNS -PUNC- quetiapine/NN (r_pobj) with/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) symptoms/NNS (l_appos) EPS/NNP -PUNC- quetiapine/NN (r_pobj) with/IN (r_prep) including/VBG (r_prep) evaluate/VB (l_dobj) symptoms/NNS -PUNC- quetiapine/NN (r_pobj) with/IN (r_prep) including/VBG (r_prep) evaluate/VB (l_dobj) symptoms/NNS (l_appos) EPS/NNP -PUNC- quetiapine/NN (r_amod) monotherapy/NN (r_pobj) with/IN (r_prep) different/JJ (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) events/NNS (l_amod) related/VBN (l_npadvmod) EPS/NNP -PUNC- QTP/NNP (r_pobj) with/IN (r_prep) events/NNS (l_amod) related/VBN (l_npadvmod) EPS/NNP -PUNC- quetiapine/NN (r_pcomp) than/IN (r_prep) tremor/NN (l_conj) syndrome/NN -PUNC- quetiapine/NN (r_amod) therapy/NN (r_nsubj) is/VBZ (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) EPS/NNP
D008094_D017109 NONE Li/NNP (r_nmod) DVP/NNP (r_conj) QTP/NNP (r_pobj) with/IN (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- Li/NNP (r_compound) DVP/NNP (r_conj) PBO/NNP (r_conj) DVP/NNP (r_conj) QTP/NNP (r_pobj) with/IN (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN
D006220_D014202 CID Haloperidol/NNP (r_nsubj) induced/VBD (l_npadvmod) tremor/NN
C069541_D014202 NONE quetiapine/NN (r_pobj) than/IN (r_prep) incidence/NN (l_appos) 0.05/CD (l_prep) of/IN (l_pobj) tremor/NN -PUNC- quetiapine/NN (r_pobj) than/IN (r_prep) incidence/NN (r_pobj) with/IN (r_prep) associated/VBN (r_ccomp) contributed/VBN (l_nsubj) tremor/NN -PUNC- quetiapine/NN (r_pobj) than/IN (r_prep) incidence/NN (r_pobj) with/IN (r_prep) associated/VBN (r_ccomp) contributed/VBN (l_prep) to/IN (l_pobj) rate/NN (l_prep) of/IN (l_pobj) tremor/NN -PUNC- quetiapine/NN (r_pcomp) than/IN (r_prep) tremor/NN
D014635_D001480 NONE DVP/NNP (r_conj) QTP/NNP (r_pobj) with/IN (r_prep) events/NNS (l_amod) related/VBN (l_npadvmod) EPS/NNP -PUNC- DVP/NNP (r_conj) PBO/NNP (r_pobj) with/IN (r_prep) than/IN (r_prep) different/JJ (r_acomp) were/VBD (l_nsubj) events/NNS (l_amod) related/VBN (l_npadvmod) EPS/NNP
C069541_D017109 NONE quetiapine/NN (r_pobj) with/IN (r_prep) including/VBG (l_pobj) akathisia/NN -PUNC- quetiapine/NN (r_amod) monotherapy/NN (r_pobj) with/IN (r_prep) different/JJ (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) including/VBG (l_pobj) akathisia/NN -PUNC- quetiapine/NN (r_amod) monotherapy/NN (r_pobj) with/IN (r_prep) similar/JJ (r_conj) low/JJ (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- QTP/NNP (r_pobj) with/IN (r_conj) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- quetiapine/NN (r_pcomp) than/IN (r_prep) tremor/NN (r_npadvmod) induced/VBD (l_dobj) incidence/NN (l_appos) 0.001/CD (l_prep) of/IN (l_pobj) akathisia/NN -PUNC- quetiapine/NN (r_amod) therapy/NN (r_nsubj) is/VBZ (l_nsubj) incidence/NN (l_prep) including/VBG (l_pobj) akathisia/NN
16574712
D018817_D008569 NONE MDMA/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) deficits/NNS -PUNC- 3,4-methylenedioxymethamphetamine/CD (r_intj) MDMA/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) deficits/NNS -PUNC- ecstasy/NN (r_appos) MDMA/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) deficits/NNS
D018817_D003072 CID MDMA/NN (r_compound) users/NNS (r_nsubj) show/VBP (l_dobj) impairments/NNS (l_acl) coupled/VBN (l_prep) with/IN (l_pobj) processes/NNS
17147461
D000809_D011507 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN
D020123_D007674 CID Sirolimus/NNP (r_npadvmod) associated/VBN (r_amod) proteinuria/NN (l_conj) dysfunction/NN -PUNC- Sirolimus/NNP (r_nsubj) represents/VBZ (l_dobj) advance/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) rejection/NN (l_conj) nephropathy/NN -PUNC- sirolimus/NN (r_nsubj) share/VB (r_advcl) designated/VBN (l_oprd) drug/NN (l_amod) nephrotoxic/JJ
D020123_D058186 NONE sirolimus/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN (l_conj) dysfunction/NN -PUNC- sirolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dysfunction/NN
D000804_D011507 NONE II/CD (r_compound) blockers/NNS (r_conj) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- II/CD (r_compound) blockers/NNS (r_conj) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN
D020123_D011507 CID Sirolimus/NNP (r_npadvmod) associated/VBN (r_amod) proteinuria/NN -PUNC- sirolimus/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_npadvmod) associated/VBN (r_amod) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) knowledge/NN (r_pobj) by/IN (r_agent) minimised/VBN (l_dep) use/NN (l_appos) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) knowledge/NN (r_pobj) by/IN (r_agent) minimised/VBN (l_dep) use/NN (l_appos) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) use/NN (l_appos) monitoring/NN (l_prep) of/IN (l_pobj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) use/NN (l_appos) monitoring/NN (l_advcl) occurs/VBZ (l_nsubj) proteinuria/NN
6518066
D008094_D006331 NONE lithium/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_csubj) provide/VB (l_dobj) assessment/NN (l_prep) of/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) malformations/NNS -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) malformations/NNS
D008094_D004437 CID lithium/NN (l_conj) anomaly/NN
17943461
D015215_D009202 CID AZT/NNP (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN
D015215_D002311 CID zidovudine/NNP (r_appos) component/NN (r_nsubj) triggers/VBZ (l_conj) cause/VB (l_dobj) disruption/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) DCM/NNP -PUNC- 3'-azido-2',3'-deoxythymidine/CD (r_appos) zidovudine/NNP (r_appos) component/NN (r_nsubj) triggers/VBZ (l_conj) cause/VB (l_dobj) disruption/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) DCM/NNP -PUNC- AZT/NNP (r_appos) component/NN (r_nsubj) triggers/VBZ (l_conj) cause/VB (l_dobj) disruption/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) DCM/NNP -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) containing/VBG (r_acl) libitum/NN (r_dobj) received/VBD (l_prep) In/IN (l_pobj) order/NN (l_acl) investigate/VB (l_ccomp) triggers/VBZ (l_conj) cause/VB (l_dobj) disruption/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) DCM/NNP -PUNC- AZT/NNP (r_npadvmod) treated/VBN (r_amod) FasL/NNPS (r_compound) mice/NNS (r_nsubj) developed/VBD (l_dobj) dilation/NN
18560792
D010479_D006349 NONE pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) abnormalities/NNS -PUNC- pergolide/NN (r_pobj) of/IN (r_prep) role/NN (r_pobj) of/IN (r_prep) suggestive/JJ (r_amod) pattern/NN (l_prep) of/IN (l_pobj) regurgitation/NN -PUNC- Pergolide/NNP (r_nsubjpass) discontinued/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN
D004298_D006349 NONE dopamine/NN (r_compound) agonists/NNS (r_pobj) to/IN (r_prep) converted/VBN (r_advcl) is/VBZ (r_ccomp) reveals/VBZ (r_conj) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN
D010479_D006333 NONE pergolide/NN (r_pobj) of/IN (r_prep) role/NN (r_pobj) of/IN (r_prep) suggestive/JJ (r_amod) pattern/NN (r_nsubjpass) observed/VBN (l_dobj) patients/NNS (l_prep) including/VBG (l_pobj) two/CD (l_prep) with/IN (l_pobj) failure/NN -PUNC- Pergolide/NNP (r_nsubjpass) discontinued/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) grade/NN (l_prep) at/IN (l_pobj) transthoracic/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D004298_D010300 NONE dopamine/NN (r_compound) agonists/NNS (r_pobj) to/IN (r_prep) converted/VBN (r_advcl) is/VBZ (r_ccomp) reveals/VBZ (r_conj) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP
D010479_D010300 NONE pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) disease/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_compound) PD/NNP -PUNC- pergolide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) frequency/NN (l_prep) of/IN (l_pobj) regurgitation/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP
9669632
D020117_D010146 NONE cisapride/NN (r_compound) therapy/NN (r_nmod) score/NN (r_advcl) had/VBD (l_dobj) score/NN (l_compound) pain/NN -PUNC- cisapride/NN (r_conj) score/NN (r_advcl) had/VBD (l_dobj) score/NN (l_compound) pain/NN
D020117_D003248 NONE cisapride/NN (r_conj) before/IN (r_advmod) underwent/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) IBS/NNP (l_appos) predominant/JJ (l_compound) constipation/NN -PUNC- cisapride/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) were/VBD (l_nsubj) scores/NNS (l_acl) relating/VBG (l_prep) to/IN (l_pobj) severity/NN (l_prep) of/IN (l_pobj) constipation/NN -PUNC- cisapride/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_amod) predominant/JJ (l_compound) constipation/NN
D020117_D043183 NONE cisapride/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_conj) function/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- cisapride/NN (l_prep) on/IN (l_pobj) motility/NN (l_prep) in/IN (l_pobj) syndrome/NN -PUNC- cisapride/NN (l_prep) on/IN (l_pobj) motility/NN (l_prep) in/IN (l_pobj) syndrome/NN (l_appos) IBS/NNP -PUNC- cisapride/NN (r_conj) before/IN (r_advmod) underwent/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) IBS/NNP -PUNC- cisapride/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_compound) IBS/NNP -PUNC- cisapride/NN (r_compound) therapy/NN (r_nmod) score/NN (r_advcl) had/VBD (l_nsubj) patients/NNS (l_compound) IBS/NNP -PUNC- cisapride/NN (r_conj) score/NN (r_advcl) had/VBD (l_nsubj) patients/NNS (l_compound) IBS/NNP -PUNC- Cisapride/NNP (r_nsubj) affects/VBZ (l_dobj) characteristics/NNS (l_conj) symptoms/NNS (l_prep) in/IN (l_pobj) IBS/NNP
D020117_D003967 NONE cisapride/NN (r_conj) before/IN (r_advmod) underwent/VBD (l_punct) ;/: (l_preconj) predominant/JJ (l_compound) diarrhoea/NN -PUNC- cisapride/NN (r_nmod) groups/NNS (r_pobj) between/IN (r_prep) observed/VBN (l_prep) In/IN (l_pobj) patients/NNS (l_amod) predominant/JJ (l_npadvmod) diarrhoea/NN -PUNC- cisapride/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_amod) predominant/JJ (l_npadvmod) diarrhoea/NN -PUNC- cisapride/NN (r_compound) therapy/NN (r_nmod) score/NN (r_advcl) had/VBD (l_nsubj) patients/NNS (l_amod) predominant/JJ (l_npadvmod) Diarrhoea/NN -PUNC- cisapride/NN (r_conj) score/NN (r_advcl) had/VBD (l_nsubj) patients/NNS (l_amod) predominant/JJ (l_npadvmod) Diarrhoea/NN
15515654
D003676_D006311 NONE DFO/NNP (r_pobj) than/IN (r_prep) other/JJ (r_amod) factor/NN (l_compound) ototoxic/JJ
D003676_D034381 NONE DFO/NNP (r_poss) role/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) impairment/NN
D003676_D006319 CID DFO/NNP (r_compound) reduction/NN (r_pobj) to/IN (r_prep) submitted/VBN (l_nsubjpass) Subjects/NNS (l_prep) with/IN (l_pobj) SNHL/NNP
19211690
D013739_D007674 NONE testosterone/NN (r_pobj) by/IN (r_agent) mediated/VBN (r_acl) angiotensinogen/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_pobj) in/IN (r_prep) dimorphism/NN (l_relcl) causes/VBZ (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) BP/NNP (l_conj) injury/NN -PUNC- Testosterone/NN (r_compound) replacement/NN (r_nsubj) increased/VBD (l_npadvmod) BP/NNP (l_appos) injury/NN -PUNC- Testosterone/NN (r_nsubj) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN (l_conj) injury/NN
D017673_D006973 NONE salt/NN (r_npadvmod) sensitive/JJ (r_amod) rats/NNS (r_pobj) in/IN (r_prep) upregulation/NN (r_conj) hypertension/NN
D000809_D006973 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_pobj) through/IN (r_prep) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN
D000809_D007674 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) upregulation/NN (r_pobj) through/IN (r_prep) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN (l_conj) injury/NN
D013739_D006973 NONE Testosterone/NN (r_npadvmod) dependent/JJ (r_amod) hypertension/NN -PUNC- Testosterone/NN (r_nsubj) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypertension/NN
430165
D010672_D001927 NONE DPH/NNP (r_compound) toxicity/NN (r_dobj) manifest/VB (r_xcomp) liable/JJ (r_acomp) are/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) damage/NN
D010672_D064420 NONE diphenylhydantoin/JJ (r_compound) toxicity/NN -PUNC- DPH/NNP (r_compound) toxicity/NN
D010672_D010291 CID diphenylhydantoin/JJ (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) manifestation/NN (r_appos) hemiparesis/NN -PUNC- DPH/NNP (r_compound) overdose/NN (r_pobj) due/IN (r_prep) suffered/VBD (l_dobj) hemiparesis/NN
D010672_D062787 CID diphenylhydantoin/NN (r_nmod) overdose/NN -PUNC- DPH/NNP (r_nmod) overdose/NN -PUNC- DPH/NNP (r_compound) overdose/NN
D010672_D002526 CID diphenylhydantoin/NN (r_nmod) overdose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) Among/IN (r_prep) are/VBP (l_nsubj) those/DT (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- DPH/NNP (r_nmod) overdose/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) Among/IN (r_prep) are/VBP (l_nsubj) those/DT (l_prep) of/IN (l_pobj) dysfunction/NN
11912119
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) to/IN (r_prep) relationship/NN (r_conj) disease/NN (r_pobj) in/IN (r_prep) assessed/VBD (l_prep) to/IN (l_pobj) dyskinesias/NNS -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) to/IN (r_prep) relationship/NN (r_conj) disease/NN (r_pobj) in/IN (r_prep) assessed/VBD (l_prep) to/IN (l_pobj) dyskinesias/NNS (l_appos) LID/NNP -PUNC- levodopa/VB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/VB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LID/NNP -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_pobj) without/IN (r_conj) with/IN (l_pobj) disease/NN (l_conj) LID/NNP -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LID/NNP -PUNC- levodopa/RB (r_dobj) assessed/VBN (l_nsubjpass) score/NN (l_prep) of/IN (l_pobj) Scale/NNP (l_appos) score/NN (l_compound) dyskinesia/JJ -PUNC- levodopa/NN (r_pobj) by/IN (r_agent) increased/VBN (l_prep) In/IN (l_pobj) disease/NN (l_conj) LID/NNP
D007980_D010300 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_prep) in/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) to/IN (r_prep) relationship/NN (r_conj) disease/NN -PUNC- levodopa/VB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_pobj) to/IN (r_prep) assessed/VBD (l_prep) in/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_pobj) without/IN (r_conj) with/IN (r_prep) studied/VBD (l_dobj) groups/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_compound) disease/NN -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_pobj) without/IN (r_conj) with/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LID/NNP (l_compound) disease/NN -PUNC- levodopa/RB (r_dobj) assessed/VBN (l_nsubjpass) score/NN (l_prep) of/IN (l_pobj) Scale/NNP (l_compound) Rating/NNP (l_compound) Disease/NNP -PUNC- levodopa/NN (r_pobj) by/IN (r_agent) increased/VBN (l_prep) In/IN (l_pobj) disease/NN
7516729
D014700_D001919 CID verapamil/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) bradycardia/NNS
3412544
D000082_D014516 NONE paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN -PUNC- paracetamol/JJ (r_compound) consumption/NN (r_pobj) from/IN (r_prep) risk/NN (r_dobj) substantiate/VB (r_xcomp) unable/JJ (r_acomp) were/VBD (l_advcl) was/VBD (l_attr) suggestion/NN (l_prep) of/IN (l_pobj) association/NN (l_prep) with/IN (l_pobj) cancer/NN (l_prep) of/IN (l_pobj) ureter/NN
D000082_D001749 NONE paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D010615_D014516 NONE phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (l_relcl) increased/VBD (l_conj) for/IN (l_pobj) cancer/NN
D000082_D007680 NONE paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D000082_D009369 NONE paracetamol/JJ (r_compound) consumption/NN (r_pobj) from/IN (r_prep) risk/NN (l_conj) any/DT (l_prep) of/IN (l_pobj) cancers/NNS
D010615_D007681 CID phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (r_pobj) of/IN (r_prep) necrosis/NN -PUNC- phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) by/IN (r_agent) increased/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) necrosis/NN
D000082_D014523 NONE paracetamol/JJ (r_nsubj) cause/VB (l_dobj) cancer/NN
D010615_D007680 CID phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (l_relcl) increased/VBD (l_dobj) risk/NN (l_prep) for/IN (l_pobj) cancer/NN (l_prep) of/IN (l_pobj) pelvis/NN (l_conj) bladder/NN
D010615_D007680 NONE phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D010615_D001749 CID phenacetin/NN (r_pobj) of/IN (r_prep) consumption/NN (l_relcl) increased/VBD (l_dobj) risk/NN (l_prep) for/IN (l_pobj) cancer/NN (l_prep) of/IN (l_pobj) pelvis/NN (l_conj) bladder/NN
D010615_D001749 NONE phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (l_conj) ureter/NN (l_conj) bladder/NN
D000082_D007681 NONE paracetamol/JJ (r_nsubj) cause/VB (l_dobj) cancer/NN (l_conj) necrosis/NN -PUNC- paracetamol/NNP (r_conj) phenacetin/JJ (r_pobj) of/IN (r_prep) consumption/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pelvis/NN (r_pobj) of/IN (r_prep) necrosis/NN -PUNC- paracetamol/JJ (r_compound) consumption/NN (r_pobj) from/IN (r_prep) risk/NN (l_prep) for/IN (l_pobj) necrosis/NN
16596970
D010862_D013226 CID Pilocarpine/NN (r_nsubj) induced/VBN (l_advmod) epilepticus/NN -PUNC- Pilocarpine/NN (r_nsubj) induced/VBN (r_ccomp) resulted/VBD (l_nsubj) epilepticus/NN
D010862_D001308 CID Pilocarpine/NNP (r_amod) seizures/NNS (r_nsubj) cause/IN (l_dobj) impairment/NN (l_prep) in/IN (l_pobj) discrimination/NN
D010862_D012640 NONE Pilocarpine/NNP (r_amod) seizures/NNS -PUNC- Pilocarpine/NN (r_nsubj) induced/VBN (r_ccomp) resulted/VBD (l_prep) in/IN (l_pobj) loss/NN (l_conj) seizures/NNS -PUNC- Pilocarpine/NN (r_nsubj) induced/VBN (r_ccomp) resulted/VBD (l_advcl) had/VBD (l_dobj) loss/NN (l_conj) seizures/NNS
3358181
D012312_D002318 NONE ritodrine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) of/IN (r_prep) cessation/NN (r_pobj) after/IN (r_prep) complications/NNS
D012312_D007752 NONE ritodrine/RB (l_prep) for/IN (l_pobj) labor/NN -PUNC- ritodrine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) between/IN (r_prep) interactions/NNS (r_dobj) risk/VB (l_nsubj) patients/NNS (l_acl) receiving/VBG (l_dobj) ritodrine/RB (l_prep) for/IN (l_pobj) labor/NN
D012312_D014693 CID ritodrine/JJ (r_compound) therapy/NN (r_pobj) after/IN (r_prep) section/NN (r_pobj) during/IN (r_prep) tachyarrhythmias/NNS
D010656_D007022 NONE phenylephrine/NN (l_relcl) treat/VB (l_dobj) patients/NNS (l_amod) hypotensive/JJ
D010656_D013610 NONE phenylephrine/NN (l_relcl) treat/VB (l_prep) with/IN (l_pobj) tachycardia/NNS
6308526
C024224_D002375 NONE naloxazone/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) blocked/VBD (l_npadvmod) analgesia/NN (l_conj) catalepsy/NN
C024224_D012131 NONE naloxazone/NN (r_nsubj) attenuated/VBD (l_dobj) depression/NN
C024224_D007035 NONE naloxazone/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) blocked/VBD (l_npadvmod) analgesia/NN (l_conj) catalepsy/NN (l_conj) hypothermia/VBN
D009020_D007035 CID morphine/NN (r_dobj) blocked/VBD (l_npadvmod) analgesia/NN (l_conj) catalepsy/NN (l_conj) hypothermia/VBN
C024224_D007022 NONE naloxazone/NN (r_nsubj) attenuated/VBD (l_dobj) depression/NN (l_nmod) hypotension/NN
D009020_D000699 NONE morphine/NN (r_dobj) blocked/VBD (l_npadvmod) analgesia/NN
C024224_D001919 NONE naloxazone/NN (r_nsubj) attenuated/VBD (l_advcl) was/VBD (l_nsubj) bradycardia/NN
D009020_D007022 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) depression/NN (l_nmod) hypotension/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN (r_nsubj) was/VBD (r_advcl) attenuated/VBD (l_dobj) depression/NN (l_nmod) hypotension/NN
D009020_D012131 NONE morphine/NN (r_npadvmod) induced/VBN (r_amod) depression/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN (r_nsubj) was/VBD (r_advcl) attenuated/VBD (l_dobj) depression/NN
D009020_D002375 CID morphine/NN (r_dobj) blocked/VBD (l_npadvmod) analgesia/NN (l_conj) catalepsy/NN
D009020_D001919 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) depression/NN (r_dobj) attenuated/VBD (l_advcl) was/VBD (l_nsubj) bradycardia/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN
C024224_D000699 NONE naloxazone/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) blocked/VBD (l_npadvmod) analgesia/NN
18217897
D013792_D009101 NONE Thalidomide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) with/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) myeloma/NN
D013792_D009369 NONE Thalidomide/NNP (r_nsubj) limited/VBN (l_prep) in/IN (l_pobj) lymphomas/NNS (l_appos) trial/NN (l_prep) of/IN (l_pobj) Cancer/NNP
D013792_D008228 NONE Thalidomide/NNP (r_nsubj) limited/VBN (l_prep) in/IN (l_pobj) lymphomas/NNS
C467567_D008223 NONE lenalidomide/NN (r_appos) agent/NN (r_pobj) with/IN (r_prep) reported/VBN (r_acl) level/NN (r_pobj) with/IN (r_prep) contrast/NN (r_conj) demonstrate/VB (l_dobj) rate/NN (l_prep) in/IN (l_pobj) lymphomas/NNS
D013792_D007938 NONE Thalidomide/NNP (r_nsubj) limited/VBN (l_prep) in/IN (l_pobj) lymphomas/NNS (l_appos) trial/NN (l_prep) of/IN (l_pobj) Cancer/NNP (l_conj) B./NNP (l_compound) Leukemia/NNP
D013792_D020522 NONE Thalidomide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) with/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) myeloma/NN (l_conj) lymphoma/NN
D013792_D008223 NONE Thalidomide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) with/IN (l_pobj) activity/NN (l_prep) in/IN (l_pobj) myeloma/NN (l_conj) lymphoma/NN (l_conj) lymphoma/NN -PUNC- thalidomide/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) lymphomas/NNS -PUNC- thalidomide/NN (r_pobj) to/IN (r_prep) rate/NN (l_prep) in/IN (l_pobj) lymphomas/NNS
18631865
D020123_D051436 NONE rapamycin/NNS (r_nmod) inhibitors/NNS (r_pobj) of/IN (r_prep) target/NN (r_pobj) to/IN (r_prep) conversion/NN (l_prep) in/IN (l_pobj) recipients/NNS (l_prep) with/IN (l_pobj) nephropathy/NN -PUNC- sirolimus/NN (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) target/NN (r_pobj) to/IN (r_prep) conversion/NN (l_prep) in/IN (l_pobj) recipients/NNS (l_prep) with/IN (l_pobj) nephropathy/NN
D020123_D011507 CID sirolimus/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) was/VBD (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) was/VBD (r_csubj) remained/VBD (l_advcl) observed/VBN (l_nsubjpass) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) observed/VBN (r_advcl) remained/VBD (l_csubj) was/VBD (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) observed/VBN (l_nsubjpass) proteinuria/NN -PUNC- sirolimus/NN (r_nmod) novo/NNP (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_conj) in/IN (r_prep) observed/VBN (r_advcl) remained/VBD (l_csubj) was/VBD (l_nsubj) proteinuria/NN -PUNC- sirolimus/NN (r_nmod) novo/NNP (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_conj) in/IN (r_prep) observed/VBN (l_nsubjpass) proteinuria/NN
18177388
D000661_D054549 CID amphetamine/NN (r_compound) use/NN (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) woman/NN (r_pobj) in/IN (r_prep) left/VBN (l_dobj) syndrome/NN -PUNC- amphetamine/NN (r_compound) use/NN (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) woman/NN (r_pobj) in/IN (r_prep) left/VBN (l_oprd) cardiomyopathy/NN -PUNC- amphetamine/NN (r_compound) use/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_acl) type/NN (l_prep) of/IN (l_pobj) syndrome/NN
6115999
D001539_D006073 CID bendrofluazide/NN (r_amod) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tolerance/NN (l_prep) in/IN (l_pobj) men/NNS (l_conj) women/NNS (l_conj) gout/NN
D011433_D011928 CID propranolol/NN (r_dobj) taking/VBG (r_acl) men/NNS (r_pobj) in/IN (r_prep) phenomenon/NN
D001539_D007172 CID bendrofluazide/JJ (r_amod) treatment/NN (l_conj) impotence/NN -PUNC- bendrofluazide/JJ (r_amod) treatment/NN (r_pobj) between/IN (r_prep) association/NN (r_dobj) show/VBP (l_conj) occurred/VBD (l_nsubj) impotence/NN
D011433_D003316 NONE propranolol/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) occurred/VBN (r_xcomp) known/VBN (l_nsubjpass) disease/NN
D011433_D007172 CID propranolol/RB (r_dobj) taking/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) show/VBP (l_dobj) association/NN (l_prep) between/IN (l_pobj) treatment/NN (l_conj) impotence/NN -PUNC- propranolol/RB (r_dobj) taking/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) impotence/NN
D011433_D006973 NONE propranolol/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- propranolol/NN (r_conj) bendrofluazide/NN (r_amod) groups/NNS (r_pobj) of/IN (r_prep) one/CD (r_pobj) to/IN (r_prep) allocated/VBN (l_nsubjpass) Participants/NNS (l_prep) in/IN (l_pobj) trial/NN (l_prep) for/IN (l_pobj) hypertension/NN
D001539_D004417 NONE bendrofluazide/NN (r_amod) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tolerance/NN (l_conj) phenomenon/NN (l_conj) dyspnoea/NN
D011433_D006073 NONE propranolol/NN (r_dobj) taking/VBG (r_acl) men/NNS (r_pobj) in/IN (r_prep) phenomenon/NN (r_conj) tolerance/NN (l_prep) in/IN (l_pobj) men/NNS (l_conj) women/NNS (l_conj) gout/NN
D011433_D004417 CID propranolol/NN (r_dobj) taking/VBG (r_acl) men/NNS (r_pobj) in/IN (r_prep) phenomenon/NN (l_conj) dyspnoea/NN
D001539_D018149 CID bendrofluazide/NN (r_amod) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tolerance/NN
D001539_D006973 NONE bendrofluazide/VB (l_conj) propranolol/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- bendrofluazide/NN (r_amod) groups/NNS (r_pobj) of/IN (r_prep) one/CD (r_pobj) to/IN (r_prep) allocated/VBN (l_nsubjpass) Participants/NNS (l_prep) in/IN (l_pobj) trial/NN (l_prep) for/IN (l_pobj) hypertension/NN
D011433_D018149 NONE propranolol/NN (r_dobj) taking/VBG (r_acl) men/NNS (r_pobj) in/IN (r_prep) phenomenon/NN (r_conj) tolerance/NN
D001539_D011928 NONE bendrofluazide/NN (r_amod) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tolerance/NN (l_conj) phenomenon/NN
2343592
D010672_D012640 NONE phenytoin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) controlled/VBN (l_nsubjpass) seizures/NNS
C044650_D007674 NONE cilastatin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_advcl) developed/VBN (l_nsubj) evidence/NN (l_prep) of/IN (l_pobj) disease/NN
C044650_D020521 NONE cilastatin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_advcl) developed/VBN (r_conj) head/NN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) accident/NN -PUNC- cilastatin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_advcl) developed/VBN (r_conj) head/NN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) accident/NN (l_appos) CVA/NNP
D015378_D012640 NONE imipenem/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) activity/NN (l_compound) Seizure/NN
D047090_D012640 NONE lactam/NN (r_compound) antibiotics/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) received/VBN (l_prep) without/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) activity/NN (l_compound) seizure/NN
C044650_D006259 NONE cilastatin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_advcl) developed/VBN (r_conj) head/NN (l_dobj) trauma/NN
C044650_D012640 CID cilastatin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_advcl) developed/VBN (l_dobj) seizures/NNS
10328196
D020123_D011565 NONE sirolimus/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) toxicity/NN (l_prep) for/IN (l_pobj) psoriasis/NN -PUNC- rapamycin/VBZ (r_appos) toxicity/NN (l_prep) for/IN (l_pobj) psoriasis/NN -PUNC- sirolimus/NN (r_nmod) cells/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_acl) syndrome/NN (r_dobj) developed/VBD (l_nsubj) individuals/NNS (l_prep) with/IN (l_pobj) psoriasis/NN -PUNC- sirolimus/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) from/IN (r_prep) specimen/NN (r_nsubj) had/VBD (l_prep) compared/VBN (l_prep) with/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) psoriasis/NN -PUNC- sirolimus/NN (r_npadvmod) treated/VBN (r_amod) patient/NN (l_prep) with/IN (l_pobj) psoriasis/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) did/VBD (r_advcl) apoptosis/NN (r_oprd) exhibit/VB (r_xcomp) tended/VBD (r_ccomp) Activated/VBN (l_dobj) cells/NNS (l_prep) from/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psoriasis/NN
D003907_D011565 NONE dexamethasone/NN (r_npadvmod) induced/VBN (r_conj) spontaneous/JJ (r_amod) apoptosis/NN (r_oprd) exhibit/VB (r_xcomp) tended/VBD (r_ccomp) Activated/VBN (l_dobj) cells/NNS (l_prep) from/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psoriasis/NN
D020123_D000740 NONE sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) fever/NN (l_conj) anemia/NN
D020123_D005334 NONE sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) fever/NN
D020123_D019559 CID sirolimus/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) toxicity/NN (l_appos) association/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- rapamycin/VBZ (r_appos) toxicity/NN (l_appos) association/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- sirolimus/NN (r_nmod) cells/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_acl) syndrome/NN -PUNC- sirolimus/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- sirolimus/NN (r_npadvmod) treated/VBN (r_amod) patient/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) had/VBD (l_nsubj) specimen/NN (l_prep) from/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- sirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) fever/NN (l_conj) anemia/NN (l_conj) syndrome/NN
D020123_D064420 NONE sirolimus/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) toxicity/NN -PUNC- rapamycin/VBZ (r_appos) toxicity/NN
7565311
D016190_D058186 CID carboplatin/NN (r_compound) chemotherapy/NN (r_pobj) in/IN (r_prep) failure/NN -PUNC- Carboplatin/NNP (r_nsubjpass) reported/VBN (l_xcomp) cause/VB (l_dobj) failure/NN
D016190_D018233 NONE carboplatin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) for/IN (l_pobj) rhabdomyosarcoma/NN
3693336
D014229_D003866 NONE Triazolam/NNP (r_npadvmod) induced/VBN (l_dobj) episodes/NNS (l_prep) in/IN (l_pobj) patient/NN (l_amod) depressed/JJ -PUNC- triazolam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) induced/VBD (l_dobj) episodes/NNS (l_prep) in/IN (l_pobj) woman/NN (l_amod) depressed/JJ
D014229_D001714 CID Triazolam/NNP (r_npadvmod) induced/VBN (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) mania/NN -PUNC- triazolam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) induced/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) mania/NN -PUNC- triazolam/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) coincident/JJ (r_acomp) was/VBD (l_nsubj) excitement/NN (l_amod) Manic/JJ
2304736
D011224_D014550 CID Prazosin/NN (r_npadvmod) induced/VBN (r_amod) incontinence/NN -PUNC- prazosin/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) incontinence/NN -PUNC- prazosin/NN (r_dobj) taking/VBG (r_advcl) present/VBP (l_prep) with/IN (l_pobj) incontinence/NN
D011224_D014549 NONE prazosin/NN (r_dobj) taking/VBG (r_advcl) present/VBP (r_relcl) Patients/NNS (r_nsubj) change/VB (l_advcl) resolve/VB (l_nsubj) incontinence/NN
11745184
D004999_D006311 NONE amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN
D004999_D001943 NONE WR-2721/NNP (r_nmod) amifostine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- amifostine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) study/NN (r_nsubjpass) conducted/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D064420 NONE cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS -PUNC- cisplatin/NN (r_pcomp) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS -PUNC- cisplatin/VB (r_acl) amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_conj) reduced/VBN (l_dobj) toxicity/NN
D002945_D020258 NONE cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pcomp) cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neurotoxicity/NN -PUNC- cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neurotoxicity/NN
D002945_D007674 CID cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pcomp) cisplatin/NN (l_preconj) nephrotoxicity/NN -PUNC- cisplatin/NN (l_preconj) nephrotoxicity/NN -PUNC- cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN
D004999_D009422 NONE amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neuropathy/NN
D002945_D009369 NONE cisplatin/VB (r_acl) amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_amod) protective/JJ (l_npadvmod) tumor/NN
D002945_D001943 NONE cisplatin/NN (r_nmod) amifostine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- Cisplatin/NNP (r_nsubj) has/VBZ (l_advcl) used/VBN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) carcinoma/NN -PUNC- cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_dobj) use/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- cisplatin/NN (r_pcomp) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS (r_nsubj) limited/VBN (l_dobj) use/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) carcinoma/NN -PUNC- cisplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) study/NN (r_nsubjpass) conducted/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D009422 CID cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neuropathy/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) ototoxicity/NN (l_conj) neuropathy/NN
D004999_D064420 NONE amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_conj) reduced/VBN (l_dobj) toxicity/NN
D002945_D006311 CID cisplatin/NN (r_pobj) with/IN (r_prep) observed/VBN (r_advcl) limited/VBN (l_nsubj) toxicities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pcomp) cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN -PUNC- cisplatin/NN (l_preconj) nephrotoxicity/NN (l_conj) ototoxicity/NN -PUNC- cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN (l_conj) ototoxicity/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_conj) ototoxicity/NN
D004999_D007674 NONE amifostine/NN (r_conj) cisplatin/NN (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) suggested/VBD (l_ccomp) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D004999_D009369 NONE amifostine/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) effect/NN (l_amod) protective/JJ (l_npadvmod) tumor/NN
18619688
C025946_D006333 NONE 3-methyladenine/LS (r_appos) METHODS/NNS (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) model/NN (l_compound) failure/NN -PUNC- 3MA/VBN (r_appos) 3-methyladenine/LS (r_appos) METHODS/NNS (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) model/NN (l_compound) failure/NN
D004317_D003643 NONE Adriamycin/NNP (r_advmod) induced/VBN (r_amod) death/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) plays/VBZ (l_nsubj) death/NN
D004317_D006333 CID Adriamycin/NNP (r_advmod) induced/VBN (r_amod) death/NN (r_nsubj) plays/VBZ (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) progression/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) progression/NN (r_pobj) in/IN (r_prep) involved/VBN (r_ccomp) investigate/VB (l_advcl) develop/VB (l_dobj) strategy/NN (l_prep) for/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) model/NN (l_compound) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) plays/VBZ (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- adriamycin/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) failure/NN
326460
D013999_D007008 NONE timolol/NN (r_pobj) by/IN (r_prep) Amelioration/NN (l_prep) of/IN (l_pobj) hypokalemia/NN -PUNC- timolol/NN (r_appos) drug/NN (r_nsubj) tended/VBD (l_xcomp) correct/VB (l_dobj) hypokalemia/NN
D001539_D007008 CID bendrofluazide/NN (r_advmod) induced/VBN (r_amod) hypokalemia/NN -PUNC- bendrofluazide/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) hypokalemia/NN
19058010
D010936_D009203 NONE tea/NN (r_nmod) combination/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) infarction/NN -PUNC- tea/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_xcomp) aimed/VBN (l_parataxis) ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- tea/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) indicate/VBP (l_ccomp) induced/VBN (l_dobj) infarction/NN
D014810_D009203 NONE E/NN (r_conj) tea/NN (r_nmod) combination/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) infarction/NN -PUNC- E/NN (r_conj) tea/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_xcomp) aimed/VBN (l_parataxis) ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- E/NN (r_conj) tea/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) indicate/VBP (l_ccomp) induced/VBN (l_dobj) infarction/NN
D007545_D009203 CID isoproterenol/JJ (r_pobj) in/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) infarction/NN -PUNC- isoproterenol/NN (r_pobj) in/IN (r_prep) bound/VBN (r_acl) effects/NNS (r_dobj) investigate/VB (r_xcomp) aimed/VBN (l_parataxis) ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- ISO)-induced/VBN (l_dobj) infarction/NN -PUNC- ISO/NN (r_pobj) during/IN (r_prep) effect/NN (r_dobj) indicate/VBP (l_ccomp) induced/VBN (l_dobj) infarction/NN
3670965
D012459_D012202 NONE salicylates/NNS (r_pobj) with/IN (r_prep) association/NN (r_pobj) of/IN (r_prep) lack/NN (r_pobj) despite/IN (r_prep) disappearing/VBG (l_nsubj) syndrome/NN
D001241_D012202 CID aspirin/JJ (r_compound) ingestion/NN (r_conj) salicylates/NNS (r_pobj) with/IN (r_prep) association/NN (r_pobj) of/IN (r_prep) lack/NN (r_pobj) despite/IN (r_prep) disappearing/VBG (l_nsubj) syndrome/NN
3084782
D010396_D009393 NONE Penicillamine/NN (r_appos) Tiopronin/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN
D006046_D003872 CID gold/NN (r_compound) thiosulphate/NN (r_pobj) due/IN (r_prep) between/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN (l_conj) dermatitis/NN -PUNC- gold/NN (r_compound) thiosulphate/NN (r_pobj) due/IN (r_prep) between/IN (l_pobj) dermatitis/NN
D006046_D009393 NONE gold/NN (r_compound) thiosulphate/NN (r_pobj) due/IN (r_prep) between/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN
D008625_D001172 NONE Tiopronin/NNP (r_npadvmod) related/VBN (r_amod) group/NN (r_pobj) for/IN (r_prep) except/IN (r_prep) patients/NNS (l_prep) with/IN (l_pobj) RA/NNP
-1_D009393 NONE thiosulphate/NN (r_pobj) due/IN (r_prep) between/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN
-1_D003872 NONE thiosulphate/NN (r_pobj) due/IN (r_prep) between/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN (l_conj) dermatitis/NN -PUNC- thiosulphate/NN (r_pobj) due/IN (r_prep) between/IN (l_pobj) dermatitis/NN
D010396_D003872 NONE Penicillamine/NN (r_appos) Tiopronin/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN (l_conj) dermatitis/NN -PUNC- Penicillamine/NN (r_appos) Tiopronin/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) dermatitis/NN
D008625_D003872 CID Tiopronin/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN (l_conj) dermatitis/NN -PUNC- Tiopronin/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) dermatitis/NN
D008625_D009393 CID Tiopronin/NNP (r_pobj) to/IN (r_pcomp) due/IN (r_prep) found/VBN (l_prep) between/IN (l_pobj) nephritis/NN -PUNC- Tiopronin/NNP (r_npadvmod) related/VBN (r_amod) group/NN (l_compound) nephritis/NN
12907309
C121465_D020258 NONE MPEP/NNP (r_pobj) of/IN (r_prep) action/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D004298_D005334 NONE dopamine/NN (r_compound) outflow/NN (l_conj) inhibition/NN (l_prep) of/IN (l_pobj) hyperthermia/NN -PUNC- dopamine/NN (r_compound) efflux/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_conj) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) hyperthermia/NN
C121465_D064420 NONE MPEP/NNP (r_pobj) by/IN (r_prep) blockade/NN (r_nsubj) protect/VB (l_dobj) neurones/NNS (l_prep) against/IN (l_pobj) toxicity/NN
C121465_D005334 NONE MPEP/NNP (r_pobj) of/IN (r_prep) action/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) outflow/NN (l_conj) inhibition/NN (l_prep) of/IN (l_pobj) hyperthermia/NN -PUNC- MPEP/NNP (r_pobj) by/IN (r_agent) rendered/VBN (r_acl) Neuroprotection/NNP (r_nsubjpass) associated/VBN (l_conj) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) hyperthermia/NN
D008694_D005334 CID methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN (r_pobj) in/IN (r_prep) action/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) outflow/NN (l_conj) inhibition/NN (l_prep) of/IN (l_pobj) hyperthermia/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) efflux/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_conj) with/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) hyperthermia/NN
D008694_D064420 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D004298_D020258 NONE dopamine/NN (r_compound) outflow/NN (r_pobj) in/IN (r_prep) decrease/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) action/NN (l_prep) in/IN (l_pobj) neurotoxicity/NN
D008694_D020258 NONE methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
8387218
D015215_D064420 NONE zidovudine/NNP (r_pobj) to/IN (r_prep) intolerant/JJ (r_amod) individuals/NNS (r_pobj) in/IN (r_prep) didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN -PUNC- AZT/NNP (r_appos) individuals/NNS (r_pobj) in/IN (r_prep) didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN
D015215_D015658 NONE zidovudine/NNP (r_pobj) to/IN (r_prep) intolerant/JJ (r_amod) individuals/NNS (l_amod) positive/JJ -PUNC- AZT/NNP (r_appos) individuals/NNS (l_amod) positive/JJ
D016049_D003920 NONE didanosine/NN (r_dobj) ceasing/VBG (r_pcomp) on/IN (r_prep) returned/VBN (r_conj) require/VB (r_conj) developed/VBD (l_dobj) curves/VBZ (l_amod) characteristic/JJ (l_prep) of/IN (l_pobj) diabetes/NNS
D016049_D064420 NONE didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN -PUNC- ddI/NN (r_appos) didanosine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) toxicity/NN
D016049_D015658 NONE didanosine/NN (l_prep) in/IN (l_pobj) individuals/NNS (l_amod) positive/JJ -PUNC- ddI/NN (r_appos) didanosine/NN (l_prep) in/IN (l_pobj) individuals/NNS (l_amod) positive/JJ
D016049_D018149 CID didanosine/NN (r_dobj) ceasing/VBG (r_pcomp) on/IN (r_prep) returned/VBN (r_conj) require/VB (r_conj) developed/VBD (l_dobj) curves/VBZ
12617329
D005839_D058186 CID gentamicin/NN (r_nmod) nephrotoxicity/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN -PUNC- GM/NNP (r_nmod) nephrotoxicity/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN
D006170_D007674 NONE Arabic/JJ (r_pobj) with/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) nephrotoxicity/NN -PUNC- Arabic/JJ (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) of/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) failure/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) nephrotoxicity/NN -PUNC- Arabic/JJ (r_amod) treatment/NN (r_nsubj) induced/VBN (l_dobj) amelioration/NN (l_prep) of/IN (l_pobj) some/DT (l_prep) of/IN (l_pobj) indices/NNS (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D005839_D007674 NONE gentamicin/NN (r_amod) nephrotoxicity/NN -PUNC- gentamicin/NN (r_nmod) nephrotoxicity/NN -PUNC- GM/NNP (r_nmod) nephrotoxicity/NN -PUNC- GM/NNP (r_compound) nephrotoxicity/NN
D006170_D007683 NONE Arabic/JJ (r_pobj) with/IN (r_prep) given/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) severe/JJ (r_acomp) be/VB (r_xcomp) appeared/VBD (l_nsubj) necrosis/NN
D005978_D007674 NONE glutathione/NN (r_conj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN -PUNC- GSH/NNP (r_appos) glutathione/NN (r_conj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN
D005839_D007683 NONE GM/NNP (r_npadvmod) induced/VBN (r_amod) necrosis/NN -PUNC- GM/NNP (r_dobj) given/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) severe/JJ (r_acomp) be/VB (r_xcomp) appeared/VBD (l_nsubj) necrosis/NN -PUNC- GM/NNP (r_pobj) given/VBN (r_acl) those/DT (r_pobj) in/IN (r_prep) than/IN (r_prep) given/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) severe/JJ (r_acomp) be/VB (r_xcomp) appeared/VBD (l_nsubj) necrosis/NN
D003404_D007674 NONE creatinine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN
D006170_D058186 CID Arabic/JJ (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) of/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) failure/NN
D014508_D007674 NONE urea/NN (r_conj) creatinine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_dobj) measuring/VBG (r_pcomp) by/IN (r_prep) assessed/VBN (l_nsubjpass) Nephrotoxicity/NN
10737864
D003000_D001919 CID clonidine/NN (r_pobj) given/VBN (r_prep) induces/VBZ (l_dobj) withdrawal/NN (l_conj) bradycardia/NNP -PUNC- clonidine/NN (r_poss) effects/NNS (r_nsubj) mirror/VB (r_ccomp) hypothesized/VBD (l_ccomp) exhibits/VBZ (l_conj) induces/VBZ (l_dobj) withdrawal/NN (l_conj) bradycardia/NNP -PUNC- clonidine/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN
2425813
D011239_D009133 CID prednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) occurred/VBD (l_nsubj) enlargement/NN (l_conj) wastage/NN
D011239_D006529 CID prednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) occurred/VBD (l_nsubj) enlargement/NN
17786501
D004221_D010523 NONE Disulfiram/NNP (r_npadvmod) induced/VBN (r_amod) optic/JJ (l_conj) neuropathy/NN -PUNC- disulfiram/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) report/VB (l_dobj) case/NN (l_prep) of/IN (l_pobj) optic/JJ (l_conj) neuropathy/NN
D004221_D000437 NONE disulfiram/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) management/NN (l_compound) dependence/NN -PUNC- disulfiram/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) dependence/NN
D004221_D009901 NONE Disulfiram/NNP (r_npadvmod) induced/VBN (r_amod) optic/JJ (l_conj) neuropathy/NN -PUNC- disulfiram/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) report/VB (l_dobj) case/NN (l_prep) of/IN (l_pobj) optic/JJ (l_conj) neuropathy/NN
2484011
D009638_D011596 NONE norepinephrine/NN (r_pobj) of/IN (r_prep) methylation/NN (r_pobj) in/IN (r_prep) increase/NN (l_relcl) account/VB (l_prep) for/IN (l_pobj) depression/NN
D000588_D011596 NONE amines/NNS (r_pobj) of/IN (r_prep) results/NNS (r_nsubj) suggest/VBP (l_dobj) decrease/NN (l_conj) increase/NN (l_relcl) account/VB (l_prep) for/IN (l_pobj) depression/NN
D002395_D011596 NONE catecholamine/NN (r_compound) rate/NN (r_pobj) of/IN (r_prep) decrease/NN (l_conj) increase/NN (l_relcl) account/VB (l_prep) for/IN (l_pobj) depression/NN
D000547_D011596 CID amantadine/NN (r_pobj) of/IN (r_prep) Readministration/NN (r_nsubj) increased/VBN (l_prep) with/IN (l_pobj) exception/NN (l_prep) of/IN (l_pobj) mice/NNS (l_relcl) occurred/VBD (l_nsubj) suppression/NN (l_prep) of/IN (l_pobj) motility/NN -PUNC- amantadine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) depression/NN
D000547_D003866 NONE amantadine/JJ (r_nmod) activity/NN (l_amod) depressed/JJ
3031535
D013759_D002375 CID 9-tetrahydrocannabinol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) involvement/NN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- THC/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) manifestation/NN (l_prep) of/IN (l_pobj) catalepsy/NN -PUNC- THC/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) manifestation/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) have/VBP (l_advcl) are/VBP (l_prep) in/IN (l_pobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) are/VBP (r_advcl) have/VBP (l_dobj) role/NN (l_prep) in/IN (l_pobj) manifestation/NN (l_prep) of/IN (l_pobj) catalepsy/NN -PUNC- haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) are/VBP (l_prep) in/IN (l_pobj) catalepsy/NN
3780846
D006220_D009127 CID haloperidol/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) order/NN (l_acl) block/VB (l_conj) estimate/VB (l_dobj) degree/NN (l_prep) of/IN (l_pobj) tolerance/NN (l_prep) to/IN (l_pobj) rigidity/NN -PUNC- Haloperidol/NNP (r_nsubj) enhanced/VBD (l_dobj) rigidity/NN
D009020_D018476 CID morphine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_prep) after/IN (l_pobj) dose/NN (l_relcl) was/VBD (l_conj) were/VBD (l_acomp) akinetic/JJ -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (l_relcl) was/VBD (l_conj) were/VBD (l_acomp) akinetic/JJ
D009020_D009127 CID morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) rigidity/NN -PUNC- morphine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) rigidity/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) given/VBN (r_csubj) showed/VBD (l_dobj) rigidity/NN -PUNC- morphine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) showed/VBD (l_dobj) rigidity/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) showed/VBD (l_dobj) rigidity/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (r_xcomp) assumed/VBN (r_relcl) rigidity/NN
6133211
D012460_D015212 NONE sulphasalazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) received/VBD (r_relcl) disease/NN
D012460_D000013 NONE sulphasalazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) received/VBD (r_relcl) disease/NN (r_pobj) with/IN (r_prep) mothers/NNS (r_pobj) of/IN (r_prep) born/VBN (r_acl) infants/NNS (r_nsubjpass) found/VBN (l_xcomp) have/VB (l_dobj) anomalies/NNS
18081909
C026098_C562694 NONE LEV/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) epilepsy/NN
D014635_C562694 NONE valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) epilepsy/NN -PUNC- VPA/NNP (r_dobj) valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) epilepsy/NN
D014635_D012640 NONE valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- VPA/NNP (r_dobj) valproate/VB (r_xcomp) added/VBN (r_conj) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) seizures/NNS
C026098_D012640 NONE LEV/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- LEV/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) Following/VBG (l_preconj) improved/VBN (l_conj) decreased/VBD (l_nsubj) frequency/NN (l_compound) seizure/NN
C026098_D001927 CID levetiracetam/NN (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubj) Encephalopathy/JJ -PUNC- levetiracetam/FW (r_amod) encephalopathy/JJ -PUNC- LEV)-induced/VBN (r_amod) encephalopathy/JJ
D014635_D001927 CID valproate/VB (r_xcomp) added/VBN (r_conj) induced/VBN (l_nsubj) Encephalopathy/JJ
14648024
D014212_D010146 NONE ATRA/NNP (r_compound) therapy/NN (r_pobj) after/IN (r_prep) nodules/NNS (l_amod) painful/JJ
D013256_D004893 NONE steroid/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) is/VBZ (l_prep) in/IN (l_pobj) nodosum/NN
D014212_D015473 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) erythema/NN (r_compound) nodosum/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) associated/VBD (l_prep) for/IN (l_pobj) leukemia/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) associated/VBD (l_prep) for/IN (l_pobj) leukemia/NN (l_appos) APL/NNP -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) associated/VBD (l_prep) for/IN (l_pobj) leukemia/NN -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) associated/VBD (l_prep) for/IN (l_pobj) leukemia/NN (l_appos) APL/NNP -PUNC- ATRA/NNP (r_compound) therapy/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) APL/NNP
D014212_D005334 CID ATRA/NNP (r_compound) therapy/NN (r_pobj) after/IN (r_prep) nodules/NNS (r_conj) Fever/NN
D014212_D004893 CID acid/NN (r_npadvmod) induced/VBN (r_amod) erythema/NN (r_compound) nodosum/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) nodosum/NN -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) nodosum/NN -PUNC- ATRA/NNP (r_compound) therapy/NN (r_pobj) during/IN (r_prep) developed/VBD (l_dobj) nodosum/NN -PUNC- ATRA/NNP (r_compound) therapy/NN (r_pobj) after/IN (r_prep) nodules/NNS -PUNC- ATRA/NNP (r_nsubj) seemed/VBD (l_xcomp) be/VB (l_attr) etiology/NN (l_prep) of/IN (l_pobj) nodosum/NN -PUNC- ATRA/NNP (r_npadvmod) induced/VBN (r_amod) nodosum/NN
19767176
D010100_D009410 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) production/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) damage/NN -PUNC- oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) generation/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) damage/NN
C020972_D013226 NONE dithiocarbamate/NN (r_nsubj) protects/VBZ (l_dobj) cortex/NN (l_prep) in/IN (l_pobj) model/NN (l_amod) epilepticus/NN -PUNC- PDTC/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) loss/NN (l_amod) associated/VBN (l_npadvmod) epilepticus/NN -PUNC- PDTC/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) increased/VBD (l_advmod) epilepticus/NN -PUNC- PDTC/NNP (r_nmod) dose/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) exert/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) epilepticus/NN -PUNC- PDTC/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_conj) vehicle-/NN (r_pobj) in/IN (r_prep) identified/VBN (l_prep) following/VBG (l_pobj) epilepticus/NN
D010100_D012640 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) generation/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) damage/NN (l_amod) associated/VBN (l_npadvmod) seizure/NN
C020972_D009410 NONE PDTC/NNP (r_conj) inhibitor/NN (r_nsubj) protected/VBD (l_advcl) affect/VB (l_dobj) loss/NN
D010862_D013226 CID pilocarpine/NN (r_amod) model/NN (l_amod) epilepticus/NN -PUNC- pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) evaluated/VBN (l_nsubjpass) effect/NN (l_prep) on/IN (l_pobj) loss/NN (l_amod) associated/VBN (l_npadvmod) epilepticus/NN
12101159
D004110_D062787 CID diltiazem/NN (r_compound) overdose/NN -PUNC- diltiazem/NN (r_pobj) of/IN (r_prep) g/NN (r_pobj) including/VBG (r_prep) overdose/NN -PUNC- diltiazem/NN (r_compound) overdose/NN -PUNC- diltiazem/NN (r_compound) overdose/NN
D000431_D062787 NONE alcohol/NN (r_conj) nitrate/NN (r_conj) aspirin/NN (r_conj) paracetamol/JJ (r_conj) diltiazem/NN (r_pobj) of/IN (r_prep) g/NN (r_pobj) including/VBG (r_prep) overdose/NN
D007547_D062787 NONE isosorbide/JJ (r_compound) nitrate/NN (r_conj) aspirin/NN (r_conj) paracetamol/JJ (r_conj) diltiazem/NN (r_pobj) of/IN (r_prep) g/NN (r_pobj) including/VBG (r_prep) overdose/NN
D002118_D062787 NONE calcium/NN (r_pobj) with/IN (r_prep) resuscitation/NN (r_dep) Delayed/VBN (l_dobj) arrest/NN (l_prep) after/IN (l_pobj) overdose/NN -PUNC- calcium/NN (r_compound) therapy/NN (l_prep) in/IN (l_pobj) overdose/NN
D004110_D006323 CID diltiazem/NN (r_compound) overdose/NN (r_pobj) after/IN (r_prep) arrest/NN (l_amod) asystolic/JJ -PUNC- diltiazem/NN (r_compound) overdose/NN (r_pobj) after/IN (r_prep) arrest/NN -PUNC- diltiazem/NN (r_compound) overdose/NN (r_pobj) in/IN (r_prep) therapy/NN (r_pobj) for/IN (r_prep) role/NN (l_prep) with/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) asystole/NN -PUNC- diltiazem/NN (r_compound) overdose/NN (r_pobj) after/IN (r_prep) cases/NNS (l_prep) of/IN (l_pobj) arrest/NN
D000082_D062787 NONE paracetamol/JJ (r_conj) diltiazem/NN (r_pobj) of/IN (r_prep) g/NN (r_pobj) including/VBG (r_prep) overdose/NN
D001241_D062787 NONE aspirin/NN (r_conj) paracetamol/JJ (r_conj) diltiazem/NN (r_pobj) of/IN (r_prep) g/NN (r_pobj) including/VBG (r_prep) overdose/NN
D009566_D062787 NONE nitrate/NN (r_conj) aspirin/NN (r_conj) paracetamol/JJ (r_conj) diltiazem/NN (r_pobj) of/IN (r_prep) g/NN (r_pobj) including/VBG (r_prep) overdose/NN
D002118_D006323 NONE calcium/NN (r_pobj) with/IN (r_prep) resuscitation/NN (r_dep) Delayed/VBN (l_dobj) arrest/NN (l_amod) asystolic/JJ -PUNC- calcium/NN (r_pobj) with/IN (r_prep) resuscitation/NN (r_dep) Delayed/VBN (l_dobj) arrest/NN -PUNC- calcium/NN (r_compound) therapy/NN (r_pobj) for/IN (r_prep) role/NN (l_prep) with/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) asystole/NN
2924746
D002220_D064420 NONE carbamazepine/NN (r_compound) treatment/NN (l_appos) efficacy/NN (l_conj) toxicity/NN
D019946_D012640 NONE glycol/NN (r_appos) vehicle/NN (r_nsubjpass) found/VBN (l_xcomp) exhibit/VB (l_dobj) properties/NNS (l_prep) against/IN (l_pobj) seizures/NNS
D005492_D064420 NONE folate/JJ (r_compound) concentrations/NNS (r_conj) plasma/NN (r_pobj) on/IN (r_prep) effect/NN (r_conj) toxicity/NN
D005481_D015430 NONE HFDE/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS (r_pobj) against/IN (r_prep) protective/JJ (r_acomp) was/VBD (l_conj) was/VBD (l_advcl) measured/VBN (l_agent) by/IN (l_pobj) gain/NN
D002220_D012640 NONE CBZ/NN (r_pobj) by/IN (r_prep) protection/NN (r_pobj) of/IN (r_prep) measure/NN (r_attr) be/VB (r_xcomp) found/VBN (r_conj) induced/VBN (l_nsubj) Seizures/NNS -PUNC- CBZ/NN (r_pobj) by/IN (r_prep) protection/NN (r_pobj) of/IN (r_prep) measure/NN (r_attr) be/VB (l_prep) than/IN (l_pobj) seizures/NNS -PUNC- CBZ/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) was/VBD (l_acomp) protective/JJ (l_prep) against/IN (l_pobj) seizures/NNS
D002220_D015430 NONE CBZ/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) was/VBD (l_conj) was/VBD (l_advcl) measured/VBN (l_agent) by/IN (l_pobj) gain/NN
D005481_D012640 CID ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Seizures/NNS -PUNC- ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_conj) found/VBN (l_xcomp) be/VB (l_prep) than/IN (l_pobj) seizures/NNS -PUNC- HFDE/NNP (r_appos) ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Seizures/NNS -PUNC- HFDE/NNP (r_appos) ether/NN (r_pobj) by/IN (r_prep) induced/VBN (l_conj) found/VBN (l_xcomp) be/VB (l_prep) than/IN (l_pobj) seizures/NNS -PUNC- HFDE/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D019946_D015430 NONE glycol/NN (r_appos) vehicle/NN (r_nsubjpass) found/VBN (l_xcomp) exhibit/VB (l_dobj) properties/NNS (l_prep) against/IN (l_pobj) seizures/NNS (l_conj) gain/NN
7292072
D003891_D064420 NONE desipramine/JJ (r_amod) toxicity/NN -PUNC- desipramine/NN (r_amod) toxicity/NN
D003891_D017180 CID desipramine/JJ (r_amod) toxicity/NN (r_pobj) in/IN (r_prep) tachycardia/NN -PUNC- desipramine/NN (r_amod) toxicity/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) tachycardia/NN
2220369
C015173_D005901 NONE epinephrine/NN (l_prep) for/IN (l_pobj) glaucoma/NN
C015173_D020246 CID epinephrine/NN (r_conj) thrombosis/NN -PUNC- epinephrine/NN (r_pobj) with/IN (r_prep) started/VBN (r_pcomp) after/IN (r_prep) acquired/VBD (l_dobj) thrombosis/NN
1700207
D010424_D001145 NONE pentobarbital/NN (r_npadvmod) anesthetized/VBN (r_amod) dogs/NNS (r_pobj) in/IN (r_prep) injection/NN (r_appos) intravenous/JJ (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) arrhythmia/NN
C032151_D001145 NONE cibenzoline/NN (l_prep) on/IN (l_pobj) arrhythmias/NNS -PUNC- -cibenzoline/: (r_conj) of/IN (r_prep) effects/NNS (l_conj) examined/VBN (l_advcl) using/VBG (l_dobj) models/NNS (l_compound) arrhythmia/NN -PUNC- -)-cibenzoline/: (r_nsubjpass) examined/VBN (l_advcl) using/VBG (l_dobj) models/NNS (l_compound) arrhythmia/NN -PUNC- -cibenzoline/, (r_punct) suppressed/VBN (r_amod) arrhythmias/NNS -PUNC- -cibenzoline/: (r_punct) for/IN (l_pobj) arrhythmias/NNS -PUNC- -)-cibenzoline/NNP (r_nsubj) suppressed/VBD (l_dobj) arrhythmia/NN -PUNC- -)-cibenzoline/NNP (r_nsubj) suppressed/VBD (r_pcomp) of/IN (r_prep) i.v./NN (r_appos) dose/NN (r_nsubjpass) needed/VBN (l_advcl) suppress/VB (l_dobj) arrhythmias/NNS -PUNC- -)-cibenzoline/: (l_prep) for/IN (l_pobj) arrhythmia/NN
D004837_D001145 CID adrenaline/NN (r_amod) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) arrhythmia/NN -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_conj) digitalis-/NN (r_amod) arrhythmias/NNS -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_conj) digitalis-/NN (r_amod) arrhythmias/NNS -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) arrhythmias/NNS (r_dobj) suppress/VB (r_advcl) needed/VBN (l_nsubjpass) dose/NN (l_appos) i.v./NN (l_prep) of/IN (l_pcomp) suppressed/VBD (l_dobj) arrhythmia/NN -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) arrhythmias/NNS -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_conj) digitalis-/NN (r_amod) arrhythmia/NN
D004070_D001145 NONE Digitalis/NNP (r_compound) arrhythmia/NN -PUNC- digitalis-/NN (r_amod) arrhythmias/NNS -PUNC- digitalis-/NN (r_amod) arrhythmias/NNS -PUNC- digitalis/NN (r_npadvmod) induced/VBN (r_amod) arrhythmia/NN -PUNC- digitalis/NN (r_npadvmod) induced/VBN (r_amod) arrhythmia/NN (r_dobj) suppressed/VBD (r_pcomp) of/IN (r_prep) i.v./NN (r_appos) dose/NN (r_nsubjpass) needed/VBN (l_advcl) suppress/VB (l_dobj) arrhythmias/NNS -PUNC- digitalis-/NN (r_amod) arrhythmia/NN
D012964_D001145 NONE Na/NNP (r_compound) blockers/NNS (r_pobj) by/IN (r_agent) suppressed/VBN (r_relcl) arrhythmia/NN
D010042_D001145 CID ouabain/NN (r_pobj) of/IN (r_prep) injection/NN (r_appos) intravenous/JJ (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) arrhythmia/NN
D006221_D001145 NONE halothane/NN (r_npadvmod) anesthetized/VBN (r_amod) dogs/NNS (r_pobj) in/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) arrhythmia/NN
D002118_D001145 NONE Ca/NNP (r_aux) channel/NN (r_compound) blockers/NNS (r_pobj) by/IN (r_agent) suppressed/VBN (r_relcl) arrhythmia/NN
8911359
D003520_D014523 NONE cyclophosphamide/NN (r_pobj) of/IN (r_prep) etiology/NN (r_pobj) of/IN (r_prep) knowledge/NN (r_dobj) gained/VBD (l_dobj) cancer/NN
D003520_D001749 CID Cyclophosphamide/NN (r_nmod) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) with/IN (l_pobj) cancer/NN -PUNC- Cyclophosphamide/NN (r_nmod) tumor/NN
2750819
D008274_D064420 NONE magnesium/NN (r_pobj) of/IN (r_prep) toxicity/NN
D009543_D064420 NONE nifedipine/NN (r_nsubj) potentiate/VB (l_dobj) toxicity/NN
D008278_D020879 CID sulfate/NN (r_pobj) with/IN (r_prep) blockade/NN -PUNC- sulfate/NN (r_pobj) of/IN (r_prep) mg/NN (r_nsubjpass) administered/VBN (l_nsubjpass) patient/NN (l_relcl) received/VBD (l_dobj) tocolysis/NN (l_prep) with/IN (l_pobj) blockade/NN
D009543_D020879 CID nifedipine/NN (r_conj) sulfate/NN (r_pobj) with/IN (r_prep) blockade/NN -PUNC- nifedipine/NN (r_nmod) blockade/NN
4090988
D000082_D009369 NONE paracetamol/JJ (r_compound) feeding/NN (r_dobj) following/VBG (r_prep) arose/VBD (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) tumours/NNS
D000082_D001744 NONE paracetamol/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) developed/VBD (l_dobj) hyperplasia/NN (l_prep) of/IN (l_pobj) epithelium/NN (l_relcl) was/VBD (l_acomp) coincident/JJ (l_prep) with/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) calculi/NNS
D000082_D006965 CID paracetamol/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) developed/VBD (l_dobj) hyperplasia/NN
D000082_D008113 CID paracetamol/NN (l_prep) of/IN (l_pobj) tumours/NNS -PUNC- paracetamol/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) livers/NNS (r_pobj) of/IN (r_prep) study/NN (r_nsubj) revealed/VBD (l_dobj) changes/NNS (l_relcl) resemble/VBP (l_dobj) those/DT (l_relcl) result/NN (l_prep) from/IN (l_pobj) exposure/NN (l_prep) to/IN (l_pobj) variety/NN (l_prep) of/IN (l_pobj) hepatocarcinogens/NNS
D000082_D001749 CID paracetamol/NN (l_prep) of/IN (l_pobj) tumours/NNS -PUNC- paracetamol/RB (r_npadvmod) treated/VBN (r_amod) groups/NNS (r_pobj) in/IN (r_prep) developed/VBN (l_conj) bore/VBD (l_dobj) carcinomas/NNS
D000082_D010212 NONE paracetamol/RB (r_npadvmod) treated/VBN (r_amod) groups/NNS (r_pobj) in/IN (r_prep) developed/VBN (l_nsubj) Papillomas/NNP
3403780
D000082_D003128 NONE Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN
D000082_D017114 CID paracetamol/JJ (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) failure/NN (l_conj) failure/NN
D000082_D000138 CID Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN (l_appos) acidosis/NN -PUNC- paracetamol/JJ (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) failure/NN (r_nsubjpass) presented/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) acidosis/NN
D000082_D017093 NONE Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN (l_appos) acidosis/NN (l_conj) failure/NN
D000082_D058186 CID paracetamol/JJ (r_compound) ingestion/NN (r_pobj) following/VBG (r_prep) failure/NN (l_conj) failure/NN
D000082_D058186 NONE Paracetamol/NN (r_npadvmod) associated/VBN (r_amod) coma/NN (l_appos) acidosis/NN (l_conj) failure/NN
9154656
D011692_D009404 CID nucleoside/NN (r_nmod) PAN/NNP (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) NS/NNP -PUNC- PAN/NNP (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) NS/NNP -PUNC- PAN/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) observed/VBN (r_advcl) change/VB (l_advcl) established/VBN (l_nsubjpass) NS/NNP -PUNC- PAN/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) development/NN (l_prep) of/IN (l_pobj) NS/NNP
D000809_D009404 NONE angiotensin/NN (r_compound) proteins/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- angiotensin/NN (r_compound) proteins/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) syndrome/NN (l_appos) NS/NNP
10074612
D008775_D003645 NONE methylprednisolone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) reviews/VBZ (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) death/NN -PUNC- IVMP/NN (r_appos) methylprednisolone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) reviews/VBZ (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) death/NN
D008775_D006323 CID methylprednisolone/NN (r_pobj) after/IN (r_prep) asystole/NN -PUNC- methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) asystole/NN
D008775_D001919 CID methylprednisolone/NN (r_pobj) after/IN (r_prep) asystole/NN (r_conj) bradycardia/NNP -PUNC- methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) asystole/NN (r_conj) bradycardia/NNP
D008775_D007022 CID methylprednisolone/NN (r_pobj) after/IN (r_prep) asystole/NN (r_conj) bradycardia/NNP (r_conj) Hypotension/NN -PUNC- methylprednisolone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) asystole/NN (r_conj) bradycardia/NNP (r_conj) hypotension/NN
15899738
D003401_D001281 CID creatine/NN (r_compound) supplementation/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) fibrillation/NN
D003401_D001145 NONE creatine/NN (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) arrhythmia/NN
10411803
D015313_D000743 CID cefotetan/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) anemia/NN -PUNC- cefotetan/JJ (r_appos) cephalosporins/NNS (r_conj) Second-/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anemia/NN -PUNC- cefotetan/NN (r_npadvmod) induced/VBN (r_amod) anemias/NNS -PUNC- cefotetan/JJ (r_dobj) received/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) were/VBD (l_nsubj) 10/CD (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) anemias/NNS
D002511_D000743 NONE cephalosporins/NNS (r_conj) Second-/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anemia/NN
2907585
-1_D002375 NONE piperazine/NN (r_nmod) drugs/NNS (r_pobj) by/IN (r_prep) Reversal/NN (l_prep) of/IN (l_pobj) catalepsy/NN -PUNC- piperazine/NN (r_compound) analogues/NNS (r_pobj) of/IN (r_prep) series/NN (r_nsubjpass) tested/VBN (l_conj) induced/VBN (l_dobj) catalepsy/NN
D058825_D002375 NONE agonists/NNS (r_conj) buspirone/NN (r_pobj) of/IN (r_prep) analogues/NNS (r_pobj) of/IN (r_prep) series/NN (r_nsubjpass) tested/VBN (l_conj) induced/VBN (l_dobj) catalepsy/NN
D012701_D002375 NONE 5-hydroxytryptamine1a/CD (r_compound) receptors/NNS (r_pobj) for/IN (r_prep) affinity/NN (r_pobj) with/IN (r_prep) drugs/NNS (r_nsubj) were/VBD (l_acomp) able/JJ (l_xcomp) reverse/VB (l_dobj) catalepsy/NN -PUNC- 5-HT/CD (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) inhibition/NN (r_nsubj) inhibited/VBN (l_conj) potentiated/VBN (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- haloperidol/NN (r_dobj) reverse/VB (r_acl) ability/NN (r_pobj) for/IN (r_prep) tested/VBN (l_conj) induced/VBN (l_dobj) catalepsy/NN
D002065_D002375 NONE buspirone/NN (r_appos) drug/NN (r_nsubj) reverses/VBZ (l_dobj) catalepsy/NN -PUNC- buspirone/NN (r_pobj) of/IN (r_prep) analogues/NNS (r_pobj) of/IN (r_prep) series/NN (r_nsubjpass) tested/VBN (l_conj) induced/VBN (l_dobj) catalepsy/NN
6127992
D014700_D017202 NONE verapamil/NN (r_nmod) drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN (r_conj) hypotension/NN (r_conj) failure/NN (r_dobj) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D000319_D017202 NONE drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN (r_conj) hypotension/NN (r_conj) failure/NN (r_dobj) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D000319_D001919 CID drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN
D000319_D006333 CID drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN (r_conj) hypotension/NN (r_conj) failure/NN
D014700_D001919 CID verapamil/NN (r_nmod) drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN
D014700_D007022 CID verapamil/NN (r_nmod) drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN (r_conj) hypotension/NN
D000319_D007022 CID drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN (r_conj) hypotension/NN
D014700_D006333 CID verapamil/NN (r_nmod) drugs/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) bradycardia/NN (r_conj) hypotension/NN (r_conj) failure/NN
603022
D005702_D062787 NONE hydrobromide/RB (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) patient/JJ (l_acl) demonstrating/NN (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) overdosage/NN
D012601_D062787 CID scopolamine/NN (r_nmod) overdosage/NN -PUNC- hyoscine/NN (r_nmod) overdosage/NN
1664218
D000677_D002289 NONE amsacrine/NN (r_compound) analogue/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) in/IN (l_pobj) cancer/NN
C042315_D002289 NONE CI-921/NNP (r_punct) (/-LRB- (r_punct) NSC/NNP (r_appos) study/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- 343499/CD (r_nummod) NSC/NNP (r_appos) study/NN (l_prep) in/IN (l_pobj) cancer/NN
18951540
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_prep) in/IN (l_pobj) disease/NN
6728084
D000617_D007674 NONE aminoglycoside/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) Nephrotoxic/JJ -PUNC- aminoglycosides/NNS (r_nsubj) act/VB (l_prep) as/IN (l_pobj) nephrotoxicants/NNS (l_prep) at/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) reabsorption/NN
3131282
D002083_D063646 NONE hydroxyanisole/NN (r_pobj) with/IN (r_prep) induced/VBN (l_nsubj) effect/NN (l_amod) carcinogenic/JJ
C009166_D010212 NONE RA/NNP (r_nsubj) increased/VBD (l_dobj) incidence/NN (l_appos) papilloma/NN -PUNC- RA/NNP (r_npadvmod) free/JJ (r_amod) water/NN (r_dobj) given/VBN (r_acl) group/NN (r_pobj) in/IN (r_prep) from/IN (r_prep) increased/VBD (l_dobj) incidence/NN (l_appos) papilloma/NN -PUNC- RA/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (l_nsubjpass) Tumors/NNS (l_appos) papillomas/NNS -PUNC- RA/NNP (r_compound) administration/NN (r_punct) ./. (r_punct) induced/VBN (l_nsubjpass) Tumors/NNS (l_appos) papillomas/NNS
D002083_D010212 NONE BHA/NNP (r_dobj) given/VBN (r_acl) groups/NNS (r_pobj) In/IN (r_prep) observed/VBN (l_conj) increased/VBD (l_dobj) incidence/NN (l_appos) papilloma/NN
C009166_D063646 NONE acetate/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) carcinogenic/JJ
D002083_D002277 NONE BHA/NNP (r_dobj) given/VBN (r_acl) groups/NNS (r_pobj) In/IN (r_prep) observed/VBN (l_conj) increased/VBD (l_dobj) incidence/NN (l_appos) papilloma/NN (l_conj) carcinoma/NN -PUNC- BHA/NNP (r_dobj) given/VBN (r_acl) groups/NNS (r_pobj) In/IN (r_prep) observed/VBN (l_conj) increased/VBD (l_prep) to/IN (l_pobj) %/NN (l_appos) rats/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- BHA/NNP (r_dobj) given/VBN (r_acl) groups/NNS (r_pobj) In/IN (r_prep) observed/VBN (l_conj) increased/VBD (l_prep) from/IN (l_pobj) %/NN (l_appos) rat/NN (l_prep) with/IN (l_pobj) carcinoma/NN
C009166_D017573 NONE RA/NNP (r_punct) co/NNP (r_punct) -/HYPH (r_punct) administered/VBN (r_punct) at/IN (r_prep) given/VBN (r_acl) rats/NNS (r_pobj) In/IN (r_prep) showed/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hyperplasia/NN
D002083_D017573 NONE BHA/NNP (r_dobj) given/VBN (r_acl) rats/NNS (r_pobj) In/IN (r_prep) showed/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hyperplasia/NN -PUNC- BHA/NNP (r_npadvmod) induced/VBN (r_amod) hyperplasia/NN
C009166_D009369 NONE RA/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) induced/VBN (l_nsubjpass) Tumors/NNS -PUNC- RA/NNP (r_compound) administration/NN (r_punct) ./. (r_punct) induced/VBN (l_nsubjpass) Tumors/NNS
C009166_D013274 NONE acetate/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) carcinogenesis/NN -PUNC- acetate/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) examined/VBN (l_nsubjpass) tumorigenesis/NN -PUNC- RA/NNP (r_appos) acetate/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) examined/VBN (l_nsubjpass) tumorigenesis/NN -PUNC- RA/NNP (r_nsubj) increased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- RA/NNP (r_npadvmod) free/JJ (r_amod) water/NN (r_dobj) given/VBN (r_acl) group/NN (r_pobj) in/IN (r_prep) from/IN (r_prep) increased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- RA/NNP (r_nsubj) acted/VBD (l_dobj) carcinogenesis/NN
D002083_D013274 CID hydroxyanisole/NN (r_pobj) with/IN (r_prep) induced/VBN (l_nsubj) effect/NN (l_prep) on/IN (l_pobj) carcinogenesis/NN -PUNC- hydroxyanisole/NN (r_pobj) on/IN (r_prep) effect/NN (r_nsubjpass) examined/VBN (l_nsubjpass) tumorigenesis/NN -PUNC- BHA)-induced/JJ (r_amod) rat/NN (r_compound) tumorigenesis/NN -PUNC- BHA/NNP (r_dobj) given/VBN (r_acl) groups/NNS (r_pobj) In/IN (r_prep) observed/VBN (l_conj) increased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- BHA/NNP (r_compound) carcinogenesis/NN
C009166_D002277 NONE RA/NNP (r_nsubj) increased/VBD (l_dobj) incidence/NN (l_appos) papilloma/NN (l_conj) carcinoma/NN -PUNC- RA/NNP (r_nsubj) increased/VBD (l_prep) to/IN (l_pobj) %/NN (l_appos) rats/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- RA/NNP (r_nsubj) increased/VBD (l_prep) from/IN (l_pobj) %/NN (l_appos) rat/NN (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- RA/NNP (r_npadvmod) free/JJ (r_amod) water/NN (r_dobj) given/VBN (r_acl) group/NN (r_pobj) in/IN (r_prep) from/IN (r_prep) increased/VBD (l_dobj) incidence/NN (l_appos) papilloma/NN (l_conj) carcinoma/NN -PUNC- RA/NNP (r_npadvmod) free/JJ (r_amod) water/NN (r_dobj) given/VBN (r_acl) group/NN (r_pobj) in/IN (r_prep) from/IN (r_prep) increased/VBD (l_prep) to/IN (l_pobj) %/NN (l_appos) rats/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- RA/NNP (r_npadvmod) free/JJ (r_amod) water/NN (r_dobj) given/VBN (r_acl) group/NN (r_pobj) in/IN (r_prep) from/IN (l_pobj) %/NN (l_appos) rat/NN (l_prep) with/IN (l_pobj) carcinoma/NN
12842176
D001556_D020258 NONE lindane/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubj) induced/VBN (l_dobj) neurotoxicity/NN -PUNC- lindane/NN (r_pobj) in/IN (r_prep) modulation/NN (r_pobj) of/IN (r_prep) influence/NN (r_nsubj) induced/VBN (l_dobj) neurotoxicity/NN
D000431_D064420 NONE ethanol/NN (r_conj) PB/NNP (r_nmod) isoenzymes/NNS (r_pobj) by/IN (r_agent) formed/VBN (r_acl) metabolites/NNS (r_conj) lindane/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) toxicity/NN
D010634_D012640 NONE phenobarbital/JJ (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) convulsions/NNS -PUNC- phenobarbital/JJ (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) convulsions/NNS (r_dobj) induced/VBN (r_ccomp) shown/VBN (r_ccomp) increased/VBD (l_advcl) induced/VBN (l_dobj) convulsions/NNS
C018021_D012640 NONE chloride/NN (r_compound) incidence/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D001556_D064420 NONE lindane/NN (r_pobj) of/IN (r_prep) metabolism/NN (r_nsubjpass) blocked/VBN (r_advcl) increased/VBN (l_advcl) indicating/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) toxicity/NN -PUNC- lindane/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) animals/NNS (r_pobj) in/IN (r_prep) increased/VBN (l_advcl) indicating/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) toxicity/NN -PUNC- lindane/NN (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) toxicity/NN
D000431_D012640 NONE ethanol/NN (r_conj) inducer/NN (r_appos) phenobarbital/JJ (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) convulsions/NNS -PUNC- ethanol/NN (r_conj) inducer/NN (r_appos) phenobarbital/JJ (r_pobj) with/IN (r_prep) pretreatment/NN (r_conj) convulsions/NNS (r_dobj) induced/VBN (r_ccomp) shown/VBN (r_ccomp) increased/VBD (l_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- ethanol/NN (r_conj) PB/NNP (r_nmod) isoenzymes/NNS (r_pobj) by/IN (r_agent) formed/VBN (r_acl) metabolites/NNS (r_conj) lindane/NN (r_nsubjpass) involved/VBN (r_ccomp) indicating/VBG (r_advcl) increased/VBN (l_advcl) blocked/VBN (l_agent) by/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D001556_D012640 CID lindane/NN (r_pobj) of/IN (r_prep) incidence/NN (r_pobj) in/IN (r_prep) effect/NN (r_dobj) produce/VB (r_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- lindane/NN (r_pobj) of/IN (r_prep) incidence/NN (r_pobj) in/IN (r_prep) effect/NN (r_dobj) produce/VB (r_advcl) induced/VBN (r_ccomp) shown/VBN (r_ccomp) increased/VBD (l_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- lindane/NN (r_pobj) of/IN (r_prep) incidence/NN (r_dobj) increased/VBD (l_ccomp) shown/VBN (l_ccomp) induced/VBN (l_dobj) convulsions/NNS -PUNC- lindane/NN (r_pobj) of/IN (r_prep) incidence/NN (r_dobj) increased/VBD (l_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- lindane/NN (r_pobj) of/IN (r_prep) metabolism/NN (r_nsubjpass) blocked/VBN (l_agent) by/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- lindane/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) animals/NNS (r_pobj) in/IN (r_prep) increased/VBN (l_advcl) blocked/VBN (l_agent) by/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- lindane/NN (r_nsubjpass) involved/VBN (r_ccomp) indicating/VBG (r_advcl) increased/VBN (l_advcl) blocked/VBN (l_agent) by/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D008748_D012640 NONE 3-methylcholanthrene/NN (r_pobj) of/IN (r_prep) pretreatment/NN (r_nsubj) produce/VB (r_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- 3-methylcholanthrene/NN (r_pobj) of/IN (r_prep) pretreatment/NN (r_nsubj) produce/VB (r_advcl) induced/VBN (r_ccomp) shown/VBN (r_ccomp) increased/VBD (l_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- MC/NNP (r_pobj) of/IN (r_prep) pretreatment/NN (r_nsubj) produce/VB (r_advcl) induced/VBN (l_dobj) convulsions/NNS -PUNC- MC/NNP (r_pobj) of/IN (r_prep) pretreatment/NN (r_nsubj) produce/VB (r_advcl) induced/VBN (r_ccomp) shown/VBN (r_ccomp) increased/VBD (l_advcl) induced/VBN (l_dobj) convulsions/NNS
C018021_D064420 NONE chloride/NN (r_compound) incidence/NN (r_pobj) by/IN (r_agent) blocked/VBN (r_advcl) increased/VBN (l_advcl) indicating/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) toxicity/NN
19843802
D004837_D006973 CID epinephrine/NN (r_pobj) of/IN (r_prep) bolus/NN (r_nsubj) provoked/VBD (l_dobj) crisis/NN (l_amod) hypertensive/JJ
8372922
2980315
D008794_D014693 CID metrizoate/NN (r_pobj) after/IN (r_prep) than/IN (r_prep) were/VBD (l_nsubj) Frequencies/NNS (l_prep) of/IN (l_pobj) fibrillation/NN
C053571_D014693 NONE iopentol/NN (r_pobj) after/IN (r_prep) 0.05/CD (r_parataxis) were/VBD (l_nsubj) Frequencies/NNS (l_prep) of/IN (l_pobj) fibrillation/NN
D007472_D014693 NONE iohexol/NN (r_conj) iopentol/NN (r_pobj) after/IN (r_prep) 0.05/CD (r_parataxis) were/VBD (l_nsubj) Frequencies/NNS (l_prep) of/IN (l_pobj) fibrillation/NN
11861791
D004317_D006331 NONE DOX/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) dysfunction/NN
D004317_D005117 NONE DOX/NNP (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complications/NNS
D004317_D006333 CID doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
D018943_D066126 NONE anthracycline/NN (r_amod) antibiotic/NN (r_appos) doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN
C434926_D006331 NONE PJ34/NNP (r_pobj) with/IN (r_prep) inhibition/NN (r_conj) deletion/NN (r_pobj) by/IN (r_prep) Using/VBG (r_advcl) demonstrate/VBP (l_dobj) role/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- PJ34/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) improved/VBD (l_dobj) dysfunction/NN
D004317_D066126 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- DOX/NNP (r_appos) doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- DOX/NNP (r_pobj) of/IN (r_prep) cardiotoxicity/NN
D011064_D006333 NONE )/-RRB- (r_punct) polymerase/NN (r_pobj) of/IN (r_prep) Activation/NN (r_nsubj) contributes/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN
6216862
D010396_D001172 NONE penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
D010396_D005076 CID penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) as/IN (r_prep) recorded/VBN (l_nsubjpass) rashes/NNS
D010396_D006527 NONE penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_conj) reported/VBN (l_prep) as/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D010396_D017285 CID penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) as/IN (r_prep) recorded/VBN (l_nsubjpass) rashes/NNS (l_conj) proteinuria/NN (l_conj) erythematosus/NN (l_conj) polymyositis/NN
D010396_C536202 NONE penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_conj) reported/VBN (r_relcl) serpiginosa/NN
D010396_D009157 CID penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) as/IN (r_prep) recorded/VBN (l_nsubjpass) rashes/NNS (l_conj) proteinuria/NN (l_conj) erythematosus/NN (l_conj) polymyositis/NN (l_conj) gravis/NN
D010396_D008180 CID penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) as/IN (r_prep) recorded/VBN (l_nsubjpass) rashes/NNS (l_conj) proteinuria/NN (l_conj) erythematosus/NN
D010396_D012871 NONE penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_conj) reported/VBN (r_relcl) serpiginosa/NN (r_dobj) resembled/VBD (l_nsubj) lesion/NN
D010396_D011507 CID penicillamine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) as/IN (r_prep) recorded/VBN (l_nsubjpass) rashes/NNS (l_conj) proteinuria/NN
11206082
D001569_D012640 NONE benzodiazepine/NN (r_amod) site/NN (r_pobj) of/IN (r_prep) agonist/NN (r_appos) carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D010433_D012640 CID pentylenetetrazol/NN (r_npadvmod) induced/VBN (r_conj) picrotoxin-/NN (r_amod) seizures/NNS
C036150_D012640 CID carboline/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- CCM/NNP (r_appos) carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D003975_D012640 NONE diazepam/NN (r_npadvmod) induced/VBN (r_amod) anxiolysis/NN (r_dobj) measured/VBD (l_dobj) sedation/NN (l_prep) by/IN (l_pcomp) recording/VBG (l_dobj) states/NNS (l_conj) seizures/NNS -PUNC- diazepam/NN (r_npadvmod) induced/VBN (r_amod) sedation/NN (l_prep) by/IN (l_pcomp) recording/VBG (l_dobj) states/NNS (l_conj) seizures/NNS
D005680_D012640 NONE GABA(A/NNP (r_nmod) ligands/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) are/VBP (l_nsubj) lines/NNS (l_acl) selected/VBN (l_prep) for/IN (l_pobj) sensitivities/NNS (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- GABA(A/NNP (r_nmod) site/NN (r_pobj) of/IN (r_prep) agonist/NN (r_appos) carboline-3-carboxylate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS
D010852_D012640 CID picrotoxin-/NN (r_amod) seizures/NNS
11147747
C047426_D014549 CID venlafaxine/NN (r_dobj) taking/VBG (r_advcl) experienced/VBD (l_dobj) incontinence/NN -PUNC- venlafaxine/NNP (r_pobj) on/IN (r_prep) developed/VBD (r_relcl) third/NN (r_conj) paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
D018490_D014549 CID antidepressants/NNS (l_conj) incontinence/NN -PUNC- antidepressants/NNS (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) incontinence/NN
D016651_D014549 CID carbonate/NN (r_dobj) taking/VBG (r_relcl) cases/NNS (r_pobj) of/IN (r_prep) 2/CD (r_pobj) In/IN (r_prep) contributed/VBN (l_prep) to/IN (l_pobj) incontinence/NN
D017374_D014549 CID paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
D012701_D014549 NONE serotonin/NN (r_compound) paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
D020280_D014549 CID sertraline/NN (r_conj) paroxetine/NN (r_pobj) to/IN (r_prep) developed/VBD (l_dobj) secondary/JJ (l_compound) incontinence/NN
16330293
14596845
D000661_D019966 NONE amphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) sensitization/NN (r_dobj) causes/VBZ (l_nsubj) diet/NN (l_acl) promoting/VBG (l_dobj) dependency/NN
D013395_D006948 CID sucrose/NN (r_dobj) experienced/VBN (r_relcl) animals/NNS (r_nsubj) were/VBD (l_acomp) hyperactive/JJ -PUNC- sucrose/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- sucrose/NN (r_conj) amphetamine/NN (r_pobj) with/IN (r_prep) chow/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ
D000661_D006948 CID amphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) sensitization/NN -PUNC- amphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) show/VB (l_dobj) sensitization/NN -PUNC- amphetamine/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- amphetamine/NN (r_compound) injection/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) sucrose/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- amphetamine/NN (r_compound) injection/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) chow/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ -PUNC- amphetamine/NN (r_pobj) with/IN (r_prep) chow/NN (r_appos) groups/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_acomp) hyperactive/JJ
8958188
C045894_D009369 NONE lometrexol/NN (r_nsubj) has/VBZ (l_dobj) activity/NN (l_prep) against/IN (l_pobj) tumours/NNS
D008727_D009369 NONE methotrexate/NNP (r_appos) drugs/NNS (r_pobj) to/IN (r_prep) refractory/JJ (r_acomp) are/VBP (r_relcl) tumours/NNS
D005492_D064420 NONE acid/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) prevented/VBN (l_nsubjpass) toxicity/NN -PUNC- acid/NN (r_compound) supplementation/NN (l_relcl) confirmed/VBN (l_ccomp) reduced/VBN (l_nsubjpass) toxicity/NN -PUNC- acid/NN (r_compound) supplementation/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_nsubjpass) toxicity/NN -PUNC- folate/JJ (r_compound) elevation/NN (r_pobj) of/IN (r_prep) extent/NN (r_conj) toxicity/NN -PUNC- acid/NN (r_compound) administration/NN (r_pobj) by/IN (r_agent) altered/VBN (l_advcl) indicating/VBG (l_ccomp) is/VBZ (l_acomp) unlikely/JJ (l_xcomp) reduce/VB (l_dobj) toxicity/NN
C045894_D064420 NONE lometrexol/NN (r_pobj) of/IN (r_prep) development/NN (r_nsubjpass) curtailed/VBN (l_prep) because/IN (l_pobj) toxicities/NNS -PUNC- lometrexol/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- lometrexol/NN (r_pobj) of/IN (r_prep) study/NN (l_acl) given/VBN (l_prep) with/IN (l_pobj) supplementation/NN (l_relcl) confirmed/VBN (l_ccomp) reduced/VBN (l_nsubjpass) toxicity/NN -PUNC- lometrexol/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- lometrexol/NN (r_compound) plasma/NN (r_compound) pharmacokinetics/NNS (r_nsubjpass) altered/VBN (l_advcl) indicating/VBG (l_ccomp) is/VBZ (l_acomp) unlikely/JJ (l_xcomp) reduce/VB (l_dobj) toxicity/NN -PUNC- lometrexol/NN (r_compound) plasma/NN (r_compound) clearance/NN (r_dobj) enhancing/VBG (r_pcomp) by/IN (r_prep) reduce/VB (l_dobj) toxicity/NN
8643973
D016190_D010051 NONE carboplatin/NN (r_pobj) with/IN (r_prep) combined/VBD (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- carboplatin/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) infusion/NN (l_acl) administered/VBN (l_prep) to/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN
D017239_D010051 NONE Paclitaxel/NNP (l_acl) combined/VBD (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) determine/VB (l_prep) given/VBN (l_prep) as/IN (l_pobj) infusion/NN (l_acl) administered/VBN (l_prep) to/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- Taxol/NNP (r_appos) dose/NN (r_dobj) determine/VB (l_prep) given/VBN (l_prep) as/IN (l_pobj) infusion/NN (l_acl) administered/VBN (l_prep) to/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_compound) doses/NNS (r_nsubjpass) escalated/VBN (r_conj) study/VBP (l_xcomp) determine/VB (l_prep) given/VBN (l_prep) as/IN (l_pobj) infusion/NN (l_acl) administered/VBN (l_prep) to/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN
19642243
C096918_D051437 NONE Tenofovir/NNP (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) syndrome/NN (l_conj) insufficiency/NN -PUNC- tenofovir/NNS (r_nsubj) raise/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) failure/NN
C418563_D051437 NONE fumarate/NN (r_dobj) receiving/VBG (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) course/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) failure/NN
D014640_D051437 NONE vancomycin/NNP (r_amod) therapy/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) failure/NN -PUNC- vancomycin/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) during/IN (r_prep) raise/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) failure/NN
D014640_D058186 CID vancomycin/NNP (r_amod) course/NN (r_dobj) receiving/VBG (r_advcl) failure/NN
D014640_D007674 NONE Vancomycin/NNP (r_compound) nephrotoxicity/NN -PUNC- Vancomycin/NNP (r_compound) nephrotoxicity/NN (r_nsubj) is/VBZ (l_conj) result/VB (l_prep) from/IN (l_pobj) coadministration/NN (l_prep) with/IN (l_pobj) agent/NN (l_amod) nephrotoxic/JJ
C096918_D005198 NONE Tenofovir/NNP (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) syndrome/NN
D014640_D000163 NONE vancomycin/NNP (r_amod) course/NN (r_dobj) receiving/VBG (r_advcl) failure/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) AIDS/NNP
C096918_D058186 NONE tenofovir/NNS (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) failure/NN
C096918_D010019 NONE tenofovir/NNS (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) failure/NN (l_advcl) receiving/VBG (l_prep) for/IN (l_pobj) osteomyelitis/NN
D014640_D010019 NONE vancomycin/NNP (r_amod) course/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) osteomyelitis/NN
C096918_D000163 NONE tenofovir/NNS (r_pobj) on/IN (r_prep) patients/NNS (l_prep) with/IN (l_pobj) AIDS/NNP
2339463
D015119_D013923 NONE acid/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) reported/VBN (l_nsubjpass) risk/NN (l_prep) of/IN (l_pobj) disease/NN
D015119_D020227 NONE acid/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thrombosis/NN
D015119_D020225 NONE acid/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thrombosis/NN
D015119_D008595 NONE acid/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) menorrhagia/NN
D015119_D012851 NONE acid/NN (l_appos) thrombosis/NN
7988234
D017706_D000799 CID lisinopril/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) history/NN (l_prep) of/IN (l_pobj) angioedema/NN
D004155_D000799 NONE diphenhydramine/NN (r_conj) steroids/NNS (r_pobj) with/IN (r_prep) resolved/VBD (l_nsubj) angioedema/NN
D008790_D000799 CID metoprolol/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) Angioedema/NNP -PUNC- metoprolol/NN (r_nsubjpass) given/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) angioedema/NN
D013256_D000799 NONE steroids/NNS (r_pobj) with/IN (r_prep) resolved/VBD (l_nsubj) angioedema/NN
591536
D006493_D001791 NONE heparin/VBN (r_npadvmod) induced/VBN (r_amod) aggregation/NN
D006493_D001157 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_pcomp) by/IN (r_prep) occlusion/NN
D006493_D013923 NONE heparin/JJ (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) thromboembolism/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complication/NN (r_appos) thromboembolism/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) thromboembolism/NN -PUNC- heparin/VBN (r_npadvmod) induced/VBN (r_amod) aggregation/NN (r_attr) is/VBZ (l_nsubj) factor/NN (l_acl) relating/VBG (l_dobj) thromboembolism/NN
D006493_D013921 CID heparin/JJ (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) thromboembolism/NN (l_appos) complication/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_pcomp) by/IN (r_prep) occlusion/NN (l_acl) preceded/VBN (l_agent) by/IN (l_pobj) thrombocytopenia/NN -PUNC- heparin/VBN (r_npadvmod) induced/VBN (r_amod) aggregation/NN (r_attr) is/VBZ (l_nsubj) factor/NN (l_acl) relating/VBG (l_dobj) thromboembolism/NN (l_conj) thrombocytopenia/NN
D006493_D013927 NONE heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_pcomp) by/IN (l_pobj) thrombi/NN
D006493_D007511 NONE heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_pcomp) by/IN (l_pobj) thrombi/NN (l_prep) with/IN (l_pobj) ischemia/NN
1378968
D003404_D051437 NONE creatinine/NN (r_compound) levels/NNS (r_dobj) decrease/NN (r_conj) increase/VB (r_xcomp) tended/VBD (r_conj) failed/VBD (l_xcomp) accentuante/NN (l_dobj) progression/NN (l_prep) of/IN (l_pobj) failure/NN
D008094_D007676 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
D008094_D006973 CID Lithium/NN (r_nsubj) caused/VBD (l_dobj) proteinuria/NN (l_conj) hypertension/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN (l_conj) hypertension/NN
D008094_D011507 CID Lithium/NN (r_nsubj) caused/VBD (l_dobj) proteinuria/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) proteinuria/NN
D008094_D051437 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_pobj) with/IN (r_prep) Rats/NNS (r_nsubjpass) subjected/VBN (l_prep) in/IN (l_pobj) attempt/NN (l_acl) induce/VB (l_dobj) hyperfiltration/NN (l_conj) progression/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- lithium/NN (r_nmod) rats/NNS (r_pobj) in/IN (r_prep) levels/NNS (r_dobj) decrease/NN (r_conj) increase/VB (r_xcomp) tended/VBD (r_conj) failed/VBD (l_xcomp) accentuante/NN (l_dobj) progression/NN (l_prep) of/IN (l_pobj) failure/NN
D008094_D005921 NONE Lithium/NN (r_nsubj) caused/VBD (l_prep) in/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN
D008094_D007674 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- Li/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
16820346
D003907_D006973 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (l_appos) hypertension/NN -PUNC- dex)-induced/VBN (r_amod) hypertension/NN -PUNC- dex/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
D013481_D006973 NONE superoxide/RB (r_advmod) decreased/VBD (r_conj) reversed/VBN (l_dobj) hypertension/NN
C065179_D006973 NONE Atorvastatin/NNS (r_nsubj) prevented/VBD (l_conj) reversed/VBD (l_dobj) hypertension/NN -PUNC- atorvastatin/NN (r_nmod) atorva/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) dexamethasone/NN (l_appos) hypertension/NN -PUNC- atorva/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) dexamethasone/NN (l_appos) hypertension/NN -PUNC- atorva/NN (r_nmod) water/NN (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) assess/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) dexamethasone/NN (l_appos) hypertension/NN -PUNC- Atorva/NN (r_nsubj) reversed/VBN (l_dobj) hypertension/NN -PUNC- atorvastatin/NN (r_nsubj) prevented/VBN (l_conj) reversed/VBN (l_dobj) hypertension/NN
17343925
D012906_D034381 CID smoking/NN (r_pobj) of/IN (r_prep) influence/NN (r_nsubjpass) estimated/VBN (l_advcl) associated/VBN (l_prep) with/IN (l_pcomp) hearing/VBG (l_dobj) loss/NN -PUNC- smoking/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pcomp) hearing/VBG (l_dobj) loss/NN
19923525
D005996_D007022 CID nitroglycerin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- nitroglycerin/NN (r_pobj) of/IN (r_prep) onset/NN (r_pobj) at/IN (r_prep) administered/VBN (r_acl) hypothesis/NN (r_dobj) tested/VBD (r_ccomp) preserve/VB (l_nsubj) hypotension/NN -PUNC- NTG)-induced/JJ (r_amod) hypotension/NN -PUNC- NTG/NNP (r_appos) saline/NN (r_pobj) with/IN (r_prep) injected/VBN (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) showed/VBD (r_conj) subjected/VBN (l_prep) to/IN (l_pobj) episodes/NNS (l_amod) hypotensive/JJ -PUNC- NTG/NNP (r_dobj) delayed/VBN (r_conj) showed/VBD (r_conj) subjected/VBN (l_prep) to/IN (l_pobj) episodes/NNS (l_amod) hypotensive/JJ -PUNC- NTG/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) produced/VBD (l_conj) had/VBD (l_advcl) delayed/VBN (l_dobj) hypotension/NN -PUNC- NTG/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) memory/NN (r_pobj) of/IN (r_prep) consolidation/NN (r_pobj) in/IN (r_prep) disruption/NN (r_dobj) attenuated/VBD (l_conj) improve/VB (l_prep) in/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) hypotension/NN
D005996_D008569 CID nitroglycerin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) impairment/NN
D009553_D008569 NONE Nimodipine/NNP (r_nsubj) prevents/VBZ (l_dobj) impairment/NN
D002118_D007022 NONE calcium/NN (r_compound) homeostasis/NN (r_pobj) of/IN (r_prep) preservation/NN (l_prep) during/IN (l_pobj) hypotension/NN
D009553_D007022 NONE Nimodipine/NNP (r_nsubj) prevents/VBZ (l_dobj) impairment/NN (l_acl) caused/VBN (l_agent) by/IN (l_pobj) hypotension/NN -PUNC- nimodipine/NN (r_nsubj) administered/VBN (r_acl) hypothesis/NN (r_dobj) tested/VBD (r_ccomp) preserve/VB (l_nsubj) hypotension/NN -PUNC- NIMO/NNP (r_appos) nimodipine/NN (r_nsubj) administered/VBN (r_acl) hypothesis/NN (r_dobj) tested/VBD (r_ccomp) preserve/VB (l_nsubj) hypotension/NN -PUNC- NIMO/NN (r_conj) NTG/NNP (r_appos) saline/NN (r_pobj) with/IN (r_prep) injected/VBN (r_acl) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) showed/VBD (r_conj) subjected/VBN (l_prep) to/IN (l_pobj) episodes/NNS (l_amod) hypotensive/JJ -PUNC- NIMO/NN (r_advmod) attenuated/VBD (l_conj) improve/VB (l_prep) in/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- NIMO/NNP (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) been/VBN (l_acomp) attributable/JJ (l_prep) to/IN (l_pobj) preservation/NN (l_prep) during/IN (l_pobj) hypotension/NN
16563323
D005045_D009325 NONE etomidate/NN (l_prep) without/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) sedation/NN (l_conj) apnea/NN (l_conj) nausea/NN
C071741_D009325 NONE remifentanil/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) etomidate/NN (l_prep) without/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) sedation/NN (l_conj) apnea/NN (l_conj) nausea/NN
D005045_D001049 NONE etomidate/NN (l_prep) without/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) sedation/NN (l_conj) apnea/NN
C071741_D011537 NONE remifentanil/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) etomidate/NN (l_prep) without/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) sedation/NN (l_conj) apnea/NN (l_conj) nausea/NN (l_conj) pruritus/NN
C071741_D009207 NONE Remifentanil/NNP (r_compound) pretreatment/NN (r_nsubj) reduces/VBZ (l_dobj) myoclonus/NN -PUNC- remifentanil/NN (r_nmod) kg/NNS (r_pobj) with/IN (r_prep) pretreatment/NN (l_conj) effect/NN (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) myoclonus/NN -PUNC- remifentanil/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) myoclonus/NN -PUNC- remifentanil/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (l_appos) myoclonus/NN
D005045_D011537 NONE etomidate/NN (l_prep) without/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) sedation/NN (l_conj) apnea/NN (l_conj) nausea/NN (l_conj) pruritus/NN
C071741_D001049 NONE remifentanil/NN (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) etomidate/NN (l_prep) without/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) sedation/NN (l_conj) apnea/NN
D005045_D009207 CID etomidate/NN (r_advcl) reduces/VBZ (l_dobj) myoclonus/NN -PUNC- etomidate/NN (r_pobj) with/IN (r_prep) induction/NN (r_amod) anesthesia/NN (r_pobj) after/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) myoclonus/NN -PUNC- etomidate/NN (r_advcl) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) myoclonus/NN -PUNC- etomidate/NN (l_nsubj) Pretreatment/NN (l_appos) myoclonus/NN -PUNC- etomidate/NN (r_advcl) increased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) myoclonus/NN
8800187
D002122_D002493 NONE CaCl2/NNP (r_compound) therapy/NN (r_nsubj) worsen/VB (l_dobj) toxicity/NN
D002122_D012640 NONE CaCl2/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) seizures/NNS
D015761_D007022 NONE 4-aminopyridine/NN (r_punct) did/VBD (r_aux) reverse/VB (l_dobj) hypotension/NN
D002118_D007022 NONE calcium/NN (r_compound) channel/NN (r_compound) blockade/NN (l_prep) in/IN (l_pobj) hypotension/NN -PUNC- calcium/NN (r_compound) channel/NN (r_compound) inhibition/NN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) hypotension/NN
D002122_D001145 CID CaCl2/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) seizures/NNS (r_conj) arrhythmias/NNS
D015761_D064420 NONE 4-aminopyridine/CD (r_compound) therapy/NN (l_prep) on/IN (l_pobj) toxicity/NN
D002118_D062787 NONE calcium/NN (r_compound) channel/NN (r_compound) overdose/NN
D003891_D064420 NONE desipramine/JJ (r_amod) toxicity/NN
D002122_D064420 NONE chloride/NN (l_conj) therapy/NN (l_prep) on/IN (l_pobj) toxicity/NN
D002122_D007022 NONE CaCl2/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reverse/VB (l_dobj) hypotension/NN
D017693_D007022 NONE NaHCO3/NNP (r_nsubj) reversed/VBD (l_dobj) hypotension/NN
D002122_D002318 NONE CaCl2/NNP (r_compound) therapy/NN (r_nsubj) worsen/VB (l_dobj) toxicity/NN
D003891_D001919 CID desipramine/NN (r_compound) IP/NNP (r_dobj) received/VBD (l_advcl) produce/VB (l_dobj) prolongation/NN (l_conj) bradycardia/NN
D003891_D007022 CID desipramine/NN (r_compound) IP/NNP (r_dobj) received/VBD (l_advcl) produce/VB (l_dobj) hypotension/NN
3108839
D016685_D013274 NONE C/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_advcl) describe/VBP (l_prep) in/IN (l_pobj) man/NN (l_prep) with/IN (l_pobj) adenocarcinoma/NN
D016685_D006463 CID C/NNP (r_nsubj) associated/VBD (l_dobj) syndrome/NN -PUNC- C/NNP (r_nsubj) associated/VBD (l_dobj) Syndrome/NNP -PUNC- C/NNP (r_nsubj) associated/VBD (l_dobj) Syndrome/NNP (l_appos) HUS/NNP
D016685_D011654 NONE C/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) start/NN (r_pobj) after/IN (r_prep) develops/VBZ (l_conj) is/VBZ (l_attr) %/NN (l_prep) from/IN (l_pobj) failure/NN (l_conj) edema/NN -PUNC- C/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_advcl) describe/VBP (l_conj) died/VBD (l_prep) in/IN (l_pobj) edema/NN
D016685_D000743 NONE C/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) failure/NN (r_conj) thrombocytopenia/JJ (r_conj) anemia/NN
D016685_D051437 CID C/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) failure/NN -PUNC- C/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) start/NN (r_pobj) after/IN (r_prep) develops/VBZ (l_nsubj) failure/NN -PUNC- C/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) start/NN (r_pobj) after/IN (r_prep) develops/VBZ (l_conj) is/VBZ (l_attr) %/NN (l_prep) from/IN (l_pobj) failure/NN -PUNC- C/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_advcl) describe/VBP (l_prep) in/IN (l_pobj) man/NN (l_relcl) developed/VBD (l_dobj) failure/NN
D016685_D013921 NONE C/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) failure/NN (r_conj) thrombocytopenia/JJ -PUNC- C/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_advcl) describe/VBP (l_prep) in/IN (l_pobj) man/NN (l_relcl) developed/VBD (l_conj) thrombocytopenia/NN
12691807
D007980_D004409 NONE Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D007980_D010300 NONE Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_nsubjpass) reported/VBN (l_prep) in/IN (l_pobj) disease/NN
D007980_D004421 CID Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dystonia/NN
D007980_D013494 NONE Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dystonia/NN (l_prep) in/IN (l_pobj) palsy/JJ -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dystonia/NN (r_pobj) of/IN (r_prep) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_compound) PSP/NNP -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dystonia/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) describe/VBP (l_advcl) highlight/VB (l_dobj) importance/NN (l_prep) of/IN (l_pcomp) recognizing/VBG (l_dobj) complication/NN (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) PSP/NNP
D007980_D008538 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dystonia/NN -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dystonia/NN (l_appos) OMD/NNP
D007980_D019578 NONE Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_nsubjpass) reported/VBN (l_prep) in/IN (l_pobj) disease/NN (l_conj) atrophy/NN
17965424
D004008_D006973 NONE diclofenac/NNP (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) discontinuations/NNS (l_prep) for/IN (l_pobj) AEs/NNS (l_amod) related/VBN (l_npadvmod) hypertension/NN -PUNC- diclofenac/NNP (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_dep) p<0.001/VB (l_prep) for/IN (l_pobj) hypertension/NN
C422649_D004487 CID etoricoxib/NN (r_pobj) with/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) discontinuations/NNS (l_prep) for/IN (l_pobj) AEs/NNS (l_amod) related/VBN (l_conj) related/VBN (l_npadvmod) oedema/NN -PUNC- etoricoxib/NN (r_pobj) with/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_dep) p<0.001/VB (l_prep) for/IN (l_pobj) hypertension/NN (l_conj) p<0.01/NN (l_prep) for/IN (l_pobj) oedema/NN
D004008_D004487 NONE diclofenac/NNP (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) discontinuations/NNS (l_prep) for/IN (l_pobj) AEs/NNS (l_amod) related/VBN (l_conj) related/VBN (l_npadvmod) oedema/NN -PUNC- diclofenac/NNP (r_pobj) with/IN (r_prep) compared/VBN (r_prep) were/VBD (l_dep) p<0.001/VB (l_prep) for/IN (l_pobj) hypertension/NN (l_conj) p<0.01/NN (l_prep) for/IN (l_pobj) oedema/NN
C422649_D006973 CID etoricoxib/NN (r_pobj) with/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) discontinuations/NNS (l_prep) for/IN (l_pobj) AEs/NNS (l_amod) related/VBN (l_npadvmod) hypertension/NN -PUNC- etoricoxib/NN (r_pobj) with/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_dep) p<0.001/VB (l_prep) for/IN (l_pobj) hypertension/NN
D004008_D005767 CID diclofenac/NNP (r_pobj) than/IN (r_prep) etoricoxib/NN (r_pobj) with/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) rate/NN (l_amod) due/IN (l_pcomp) to/IN (l_pobj) AEs/NNS -PUNC- diclofenac/NNP (r_nmod) Discontinuations/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) discontinuing/VBG (l_prep) due/IN (l_pcomp) to/IN (l_pobj) AEs/NNS -PUNC- diclofenac/NNP (r_nmod) Discontinuations/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) discontinuing/VBG (r_pcomp) for/IN (r_prep) risk/NN (r_dobj) demonstrated/VBD (l_advcl) common/JJ (l_prep) than/IN (l_pobj) discontinuations/NNS (l_prep) from/IN (l_pobj) AEs/NNS
D004008_D001172 NONE sodium/NN (r_compound) tolerability/NN (r_pobj) vs/IN (r_prep) etoricoxib/NN (r_pobj) of/IN (r_prep) results/NNS (r_appos) tolerability/NN (l_prep) of/IN (l_pobj) etoricoxib/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) arthritis/NN -PUNC- diclofenac/NN (r_conj) etoricoxib/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- diclofenac/NN (r_conj) etoricoxib/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN (l_appos) RA/NNP -PUNC- diclofenac/NN (r_nmod) mg/NN (r_compound) twice/RB (r_conj) enrolled/VBN (l_nsubjpass) years/NNS (l_acl) diagnosed/VBD (l_prep) with/IN (l_pobj) RA/NNP
C422649_D001172 NONE etoricoxib/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) arthritis/NN -PUNC- etoricoxib/NN (r_pobj) of/IN (r_prep) results/NNS (r_appos) tolerability/NN (l_prep) of/IN (l_pobj) etoricoxib/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) arthritis/NN -PUNC- etoricoxib/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- etoricoxib/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) compare/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN (l_appos) RA/NNP -PUNC- etoricoxib/RB (r_dobj) received/VBN (r_conj) enrolled/VBN (l_nsubjpass) years/NNS (l_acl) diagnosed/VBD (l_prep) with/IN (l_pobj) RA/NNP
C422649_D005767 NONE etoricoxib/NN (r_pobj) with/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) rate/NN (l_amod) due/IN (l_pcomp) to/IN (l_pobj) AEs/NNS -PUNC- Etoricoxib/NNP (r_nsubj) demonstrated/VBD (l_dobj) risk/NN (l_prep) for/IN (l_pcomp) discontinuing/VBG (l_prep) due/IN (l_pcomp) to/IN (l_pobj) AEs/NNS -PUNC- Etoricoxib/NNP (r_nsubj) demonstrated/VBD (l_advcl) common/JJ (l_prep) than/IN (l_pobj) discontinuations/NNS (l_prep) from/IN (l_pobj) AEs/NNS -PUNC- etoricoxib/NN (r_pobj) with/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_ccomp) demonstrated/VBD (l_dobj) risk/NN (l_prep) for/IN (l_pcomp) discontinuing/VBG (l_prep) due/IN (l_pcomp) to/IN (l_pobj) AEs/NNS -PUNC- etoricoxib/NN (r_pobj) with/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_ccomp) demonstrated/VBD (l_advcl) common/JJ (l_prep) than/IN (l_pobj) discontinuations/NNS (l_prep) from/IN (l_pobj) AEs/NNS
17532790
D007980_D004409 CID DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_appos) LID/NNP -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (r_relcl) complications/NNS (r_pobj) among/IN (r_prep) is/VBZ (l_nsubj) dyskinesia/NN -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (r_relcl) complications/NNS (r_pobj) among/IN (r_prep) is/VBZ (l_nsubj) dyskinesia/NN (l_appos) LID/NNP -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treated/VBD (l_conj) allocated/VBN (l_prep) to/IN (l_pobj) groups/NNS (l_acl) based/VBN (l_prep) on/IN (l_pobj) presence/NN (l_conj) absence/NN (l_prep) of/IN (l_pobj) LID/NNP
D016627_D010300 NONE 6-hydroxydopamine/CD (r_compound) lesion/NN (r_compound) rat/NN (r_compound) model/NN (l_prep) of/IN (l_pobj) PD/NNP
D001971_D010300 NONE bromocriptine/NN (r_conj) DOPA/NNP (r_appos) changes/NNS (l_acl) occurring/VBG (l_prep) at/IN (l_pobj) level/NN (l_acl) obtained/VBN (l_prep) from/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) PD/NNP
D007980_D010300 NONE DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_nsubj) is/VBZ (l_prep) among/IN (l_pobj) complications/NNS (l_relcl) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) disease/NN -PUNC- DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_nsubj) is/VBZ (l_prep) among/IN (l_pobj) complications/NNS (l_relcl) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) PD/NNP -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) disease/NN -PUNC- DOPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) arise/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_nmod) PD/NNP -PUNC- DOPA/NNP (r_appos) changes/NNS (l_acl) occurring/VBG (l_prep) at/IN (l_pobj) level/NN (l_acl) obtained/VBN (l_prep) from/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) PD/NNP
2257294
D014529_D007970 NONE Urd/NNP (r_compound) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS (r_pobj) Because/IN (r_prep) assessed/VBN (l_nsubjpass) anemia/NN (l_conj) leukopenia/NN
D015215_D064420 NONE AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN (r_nsubjpass) assessed/VBN (l_prep) Because/IN (l_pobj) toxicities/NNS
C034753_D001855 NONE Benzylacyclouridine/NN (r_nsubj) reverses/VBZ (l_dobj) suppression/NN -PUNC- BAU/NNP (r_nsubj) reduced/VBD (l_dobj) toxicity/NN
D014529_D000740 NONE Urd/NNP (r_compound) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS (r_pobj) Because/IN (r_prep) assessed/VBN (l_nsubjpass) anemia/NN
D015215_D007970 CID AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN (l_conj) leukopenia/NN -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) leukopenic/JJ -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) leukopenic/JJ (r_conj) rendered/VBD (r_acl) mice/NNS (r_pobj) In/IN (r_prep) reversed/VBD (l_dobj) anemia/NN (l_conj) leukopenia/NN -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_prep) In/IN (l_pobj) mice/NNS (l_acl) rendered/VBD (l_conj) leukopenic/JJ -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) anemia/NN (l_conj) leukopenia/NN -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN (r_dobj) reversed/VBD (l_prep) In/IN (l_pobj) mice/NNS (l_acl) rendered/VBD (l_conj) leukopenic/JJ -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN (l_conj) leukopenia/NN
D015215_D007153 NONE azidothymidine/RB (r_advmod) induced/VBN (r_amod) suppression/NN (r_dobj) reverses/VBZ (l_prep) without/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) activity/NN (l_compound) virus/NN (l_compound) immunodeficiency/NN -PUNC- azidothymidine/NN (r_advmod) vitro/FW (r_amod) in/IN (r_prep) reduce/VB (l_dobj) inhibition/NN (l_prep) without/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) virus/NN (l_compound) immunodeficiency/NN -PUNC- AZT)-induced/JJ (r_compound) inhibition/NN (l_prep) without/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) virus/NN (l_compound) immunodeficiency/NN
C034753_-1 NONE BAU/NNP (r_conj) AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_conj) increased/VBN (l_conj) improved/VBN (l_dobj) megaloblastosis/NN
D015215_-1 NONE AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) leukopenic/JJ (r_conj) rendered/VBD (r_acl) mice/NNS (r_pobj) In/IN (r_prep) reversed/VBD (l_conj) increased/VBN (l_conj) improved/VBN (l_dobj) megaloblastosis/NN -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_conj) increased/VBN (l_conj) improved/VBN (l_dobj) megaloblastosis/NN -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN (r_dobj) reversed/VBD (l_conj) increased/VBN (l_conj) improved/VBN (l_dobj) megaloblastosis/NN
C034753_D064420 NONE benzylacyclouridine/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) assessed/VBN (l_prep) Because/IN (l_pobj) toxicities/NNS -PUNC- BAU/NNP (r_appos) benzylacyclouridine/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) assessed/VBN (l_prep) Because/IN (l_pobj) toxicities/NNS
C034753_D000740 NONE benzylacyclouridine/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) assessed/VBN (l_nsubjpass) anemia/NN -PUNC- BAU/NNP (r_appos) benzylacyclouridine/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) assessed/VBN (l_nsubjpass) anemia/NN -PUNC- BAU/NNP (r_conj) AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_prep) In/IN (l_pobj) mice/NNS (l_acl) rendered/VBD (l_oprd) anemic/JJ -PUNC- BAU/NNP (r_conj) AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) anemia/NN
C034753_D007153 NONE Benzylacyclouridine/NN (r_nsubj) reverses/VBZ (l_prep) without/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) activity/NN (l_compound) virus/NN (l_compound) immunodeficiency/NN
D014529_D007153 NONE uridine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) reported/VBN (l_xcomp) reduce/VB (l_dobj) inhibition/NN (l_prep) without/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) virus/NN (l_compound) immunodeficiency/NN -PUNC- Urd/NNP (r_appos) uridine/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) reported/VBN (l_xcomp) reduce/VB (l_dobj) inhibition/NN (l_prep) without/IN (l_pobj) impairment/NN (l_prep) of/IN (l_pobj) virus/NN (l_compound) immunodeficiency/NN
D015215_D001855 CID azidothymidine/RB (r_advmod) induced/VBN (r_amod) suppression/NN -PUNC- AZT/NNP (r_pobj) with/IN (r_prep) coadministered/VBN (r_advcl) reduced/VBD (l_dobj) toxicity/NN -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D015215_D000740 CID AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) leukopenic/JJ (r_conj) rendered/VBD (l_oprd) anemic/JJ -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) leukopenic/JJ (r_conj) rendered/VBD (r_acl) mice/NNS (r_pobj) In/IN (r_prep) reversed/VBD (l_dobj) anemia/NN -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_prep) In/IN (l_pobj) mice/NNS (l_acl) rendered/VBD (l_oprd) anemic/JJ -PUNC- AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) anemia/NN -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN (r_dobj) reversed/VBD (l_prep) In/IN (l_pobj) mice/NNS (l_acl) rendered/VBD (l_oprd) anemic/JJ -PUNC- AZT/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN
C034753_D007970 NONE benzylacyclouridine/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) assessed/VBN (l_nsubjpass) anemia/NN (l_conj) leukopenia/NN -PUNC- BAU/NNP (r_appos) benzylacyclouridine/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) assessed/VBN (l_nsubjpass) anemia/NN (l_conj) leukopenia/NN -PUNC- BAU/NNP (r_conj) AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_prep) In/IN (l_pobj) mice/NNS (l_acl) rendered/VBD (l_conj) leukopenic/JJ -PUNC- BAU/NNP (r_conj) AZT/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) anemia/NN (l_conj) leukopenia/NN
D014529_D064420 NONE Urd/NNP (r_compound) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicities/NNS -PUNC- Urd/NNP (r_compound) catabolism/NN (r_dobj) inhibits/VBZ (l_conj) increases/VBZ (l_prep) without/IN (l_pobj) toxicity/NN -PUNC- Urd/NNP (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) increases/VBZ (l_prep) without/IN (l_pobj) toxicity/NN -PUNC- Urd/NNP (r_npadvmod) related/VBN (r_amod) toxicity/NN
1286498
D005442_D010146 NONE flumazenil/JJ (r_compound) group/NN (l_conj) pain/NN
D005442_D009325 CID flumazenil/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) vomiting/VBG (r_conj) nausea/NN -PUNC- flumazenil/JJ (r_compound) group/NN (l_conj) pain/NN (l_nmod) nausea/NN
D005442_D014839 CID flumazenil/JJ (r_compound) group/NN (r_pobj) in/IN (r_prep) vomiting/VBG
8437969
D011899_D001145 NONE ranitidine/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) recur/VB (r_conj) disappeared/VBD (l_ccomp) related/VBN (l_nsubjpass) arrhythmias/NNS
D002927_D001145 NONE cimetidine/NN (r_compound) administration/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) arrhythmias/NNS
D002927_D054138 CID cimetidine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) arrest/NN -PUNC- cimetidine/NN (r_dobj) receiving/VBG (r_advcl) recurrent/JJ (l_appos) episodes/NNS (l_prep) of/IN (l_pobj) arrest/NN -PUNC- cimetidine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) arrest/NN
D002927_D006331 NONE cimetidine/NN (r_dobj) receiving/VBG (r_advcl) recurrent/JJ (r_appos) man/NN (l_conj) history/NN (l_prep) of/IN (l_pobj) disease/NN
D002927_D001919 CID cimetidine/NN (r_pobj) of/IN (r_prep) infusions/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) bradyarrhythmias/NNS
D002927_D007938 NONE cimetidine/NN (r_dobj) receiving/VBG (r_advcl) recurrent/JJ (r_appos) man/NN (l_prep) with/IN (l_pobj) leukemia/NN
11838826
D004298_D006966 NONE dopamine/NN (r_compound) agonist/NN (r_pobj) with/IN (r_prep) hyperprolactinemia/NN
D018967_D011605 NONE risperidone/NN (r_npadvmod) induced/VBN (r_amod) elevations/NNS (r_pobj) with/IN (r_prep) males/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) psychoses/NNS
C047047_D011605 NONE cabergoline/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) males/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) psychoses/NNS
C047047_D001523 NONE cabergoline/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) males/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_amod) Diagnostic/NNP (l_conj) Manual/NNP (l_prep) of/IN (l_pobj) Disorders/NNPS
D018967_D001714 NONE risperidone/NN (r_npadvmod) induced/VBN (r_amod) elevations/NNS (r_pobj) with/IN (r_prep) males/NNS (l_prep) with/IN (l_pobj) disorder/NN
C047047_D001714 NONE cabergoline/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) males/NNS (l_prep) with/IN (l_pobj) disorder/NN
D018967_D001523 NONE risperidone/NN (r_npadvmod) induced/VBN (r_amod) elevations/NNS (r_pobj) with/IN (r_prep) males/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_amod) Diagnostic/NNP (l_conj) Manual/NNP (l_prep) of/IN (l_pobj) Disorders/NNPS
D018967_D006966 CID risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN -PUNC- Risperidone/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) hyperprolactinemia/NN -PUNC- risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN -PUNC- risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN -PUNC- risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN
C047047_D006966 NONE cabergoline/NN (r_pobj) with/IN (r_prep) hyperprolactinemia/NN -PUNC- cabergoline/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) hyperprolactinemia/NN -PUNC- Cabergoline/NNP (r_nsubj) be/VB (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
19721134
D010862_D017180 NONE pilocarpine/NN (r_amod) onset/NN (r_dobj) showed/VBD (r_ccomp) decreased/VBD (l_dobj) course/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_conj) fibrillation/NN
D010862_D001145 NONE pilocarpine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) evaluate/VB (l_conj) explore/VB (l_conj) using/VBG (l_dobj) rat/NN (l_conj) models/NNS (l_compound) arrhythmia/NN -PUNC- pilocarpine/NN (r_amod) onset/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS -PUNC- pilocarpine/NN (r_amod) onset/NN (r_dobj) showed/VBD (r_ccomp) decreased/VBD (l_npadvmod) score/NN (l_compound) arrhythmia/NN -PUNC- pilocarpine/NN (r_amod) onset/NN (r_dobj) showed/VBD (r_ccomp) decreased/VBD (l_npadvmod) score/NN (l_conj) increased/VBD (l_dobj) time/NN (l_prep) of/IN (l_pobj) rats/NNS (l_amod) arrhythmic/JJ -PUNC- pilocarpine/NN (r_nsubj) produced/VBD (l_dobj) actions/NNS (l_prep) on/IN (l_pobj) models/NNS (l_nmod) rat/NN (l_amod) arrhythmic/JJ
D010042_D001145 CID ouabain/NN (r_npadvmod) induced/VBN (r_amod) models/NNS (l_compound) arrhythmia/NN -PUNC- ouabain/RB (r_conj) aconitine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) models/NNS (l_nmod) rat/NN (l_amod) arrhythmic/JJ
D002118_D001145 NONE Ca(2/NNP (r_pobj) of/IN (r_prep) improvement/NN (r_pobj) to/IN (r_prep) related/VBN (r_relcl) cardiac/JJ (r_dobj) stimulating/VBG (r_pcomp) via/IN (r_prep) ouabain/RB (r_conj) aconitine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) models/NNS (l_nmod) rat/NN (l_amod) arrhythmic/JJ
D000157_D001145 CID aconitine/NN (r_npadvmod) induced/VBN (r_amod) rat/NN (l_conj) models/NNS (l_compound) arrhythmia/NN -PUNC- aconitine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) models/NNS (l_nmod) rat/NN (l_amod) arrhythmic/JJ
D010862_D014693 NONE pilocarpine/NN (r_amod) onset/NN (r_dobj) showed/VBD (r_ccomp) decreased/VBD (l_dobj) course/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_conj) fibrillation/NN
2054792
D004317_D005334 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) Effect/NN (l_acl) combined/VBN (l_prep) with/IN (l_pobj) hyperthermia/NN -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) activity/NN (l_conj) toxicities/NNS (l_prep) by/IN (l_pobj) hyperthermia/NN -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) activity/NN (r_dobj) enhanced/VBD (l_nsubj) hyperthermia/NN -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) effect/NN (r_dobj) enhances/VBZ (l_nsubj) hyperthermia/NN
D004317_D009369 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) Effect/NN (l_acl) combined/VBN (l_prep) on/IN (l_pobj) tumor/NN
D004317_D064420 NONE Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) activity/NN (l_conj) toxicities/NNS -PUNC- Adriamycin/NNP (r_npadvmod) mediated/VBN (r_amod) effect/NN (r_dobj) enhances/VBZ (r_advcl) increased/VBN (l_nsubjpass) toxicity/NN
625456
D002119_D053040 CID ate/VBN (r_amod) sodium/NN (r_compound) powders/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_dobj) consumed/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) two/CD (l_prep) of/IN (l_pobj) nephrolithiasis/NN
D002119_D006934 CID ate/VBN (r_amod) sodium/NN (r_compound) powders/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_dobj) consumed/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) hypercalcaemia/NN
D017693_D006934 CID bicarbonate/NN (r_compound) powders/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_dobj) consumed/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) hypercalcaemia/NN
D017693_D053040 CID bicarbonate/NN (r_compound) powders/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_dobj) consumed/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) two/CD (l_prep) of/IN (l_pobj) nephrolithiasis/NN
7248170
D002251_D006529 NONE tetrachloride/NN (r_advmod) induced/VBN (r_amod) cirrhosis/NN (r_pobj) to/TO (r_prep) relationship/NN (r_appos) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- tetrachloride/NN (r_advmod) given/VBN (l_conj) increased/VBN (l_prep) by/IN (l_pcomp) giving/VBG (l_prep) at/IN (l_pobj) peak/NN (l_prep) of/IN (l_pobj) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (l_prep) at/IN (l_pobj) peak/NN (l_prep) of/IN (l_pobj) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN
D002251_D001284 NONE tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN
D010634_D005355 NONE Phenobarbitone/NNP (r_npadvmod) induced/VBN (r_amod) enlargement/NN (l_appos) relationship/NN (l_prep) to/TO (l_pobj) cirrhosis/NN
D010634_D008103 CID phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN
D002251_D001201 NONE tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ
D002251_D005355 NONE tetrachloride/NN (r_advmod) induced/VBN (r_amod) cirrhosis/NN
D010634_D013163 NONE phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ
D002251_D013163 NONE tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ
D010634_D001284 NONE phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_conj) albumin/NN (l_conj) splenomegaly/JJ (l_conj) atrophy/NN
D010634_D001201 NONE phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_nsubj) ascites/VBZ -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (r_pobj) of/IN (r_prep) peak/NN (r_pobj) at/IN (r_prep) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ
D002251_D008103 CID tetrachloride/NN (r_advmod) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- tetrachloride/NN (r_advmod) calibrating/VBG (r_dative) giving/VBG (r_pcomp) by/IN (r_prep) increased/VBN (r_conj) given/VBN (l_nsubj) ascites/VBZ (l_nsubj) yield/NN (l_prep) of/IN (l_pobj) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN
D010634_D006529 CID Phenobarbitone/NNP (r_npadvmod) induced/VBN (r_amod) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- phenobarbitone/NN (r_npadvmod) primed/VBN (r_amod) rat/NN (r_pobj) in/IN (r_prep) given/VBN (l_conj) increased/VBN (l_prep) by/IN (l_pcomp) giving/VBG (l_prep) at/IN (l_pobj) peak/NN (l_prep) of/IN (l_pobj) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- phenobarbitone/NN (r_npadvmod) induced/VBN (r_amod) enlargement/NN (l_prep) of/IN (l_pobj) liver/NN
2569282
D020927_D012021 NONE MED/NNP (r_compound) animals/NNS (r_nsubj) were/VBD (l_conj) lacked/VBD (l_dobj) response/NN (l_compound) startle/JJ
D015760_D009127 CID alfentanil/NN (r_compound) anesthesia/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) rigidity/NN -PUNC- alfentanil/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN
D020927_D009123 NONE dexmedetomidine/NN (r_nsubj) is/VBZ (l_acomp) capable/JJ (l_prep) of/IN (l_pcomp) inducing/VBG (l_dobj) flaccidity/NN -PUNC- MED/NNP (r_appos) dexmedetomidine/NN (r_nsubj) is/VBZ (l_acomp) capable/JJ (l_prep) of/IN (l_pcomp) inducing/VBG (l_dobj) flaccidity/NN
D020927_D018476 NONE MED/NNP (r_compound) animals/NNS (r_nsubj) were/VBD (l_acomp) flaccid/JJ (l_conj) akinetic/JJ
D020927_D009127 NONE Dexmedetomidine/NNP (r_nsubj) prevents/VBZ (l_dobj) rigidity/NN -PUNC- MED/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) prevents/VBZ (l_dobj) rigidity/NN -PUNC- MED/NNP (r_nsubj) prevented/VBD (l_dobj) rigidity/NN
12745515
D016642_D012892 NONE bupropion/NN (r_conj) deprivation/NN -PUNC- bupropion/NN (r_compound) use/NN (l_conj) deprivation/NN -PUNC- bupropion/NN (r_npadvmod) associated/VBN (r_amod) seizures/NNS (r_pobj) of/IN (r_prep) risk/NN (r_pobj) to/IN (r_prep) add/VB (l_nsubj) deprivation/NN
D016642_D012640 CID bupropion/NN (r_conj) deprivation/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Seizure/NN -PUNC- bupropion/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) seizure/NN -PUNC- bupropion/NN (r_compound) use/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) After/IN (r_prep) experienced/VBD (l_dobj) seizure/NN -PUNC- bupropion/NN (r_npadvmod) associated/VBN (r_amod) seizures/NNS
4038130
D008619_D009135 CID mepivacaine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) seen/VBN (l_prep) In/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) damage/NN
D008012_D009135 CID lidocaine/NN (r_conj) mepivacaine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) seen/VBN (l_prep) In/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) damage/NN
D004837_D009135 NONE epinephrine/NN (r_conj) mepivacaine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) seen/VBN (l_prep) In/IN (l_pobj) addition/NN (l_prep) to/IN (l_pobj) damage/NN
20103708
D010100_D051437 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) production/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_relcl) causes/NNS (l_prep) of/IN (l_pobj) failure/NN
D013311_D058186 NONE streptozotocin/RB (r_npadvmod) induced/VBN (r_amod) damage/NN
D013311_D003928 CID streptozotocin/JJ (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- streptozotocin/RB (r_npadvmod) induced/VBN (r_amod) model/NN (l_ccomp) explore/VBP (l_dobj) role/NN (l_prep) against/IN (l_pobj) nephropathy/NN -PUNC- streptozotocin/RB (r_npadvmod) induced/VBN (r_amod) model/NN (l_ccomp) explore/VBP (l_dobj) role/NN (l_prep) against/IN (l_pobj) nephropathy/NN (l_acl) using/VBG (l_prep) from/IN (l_pobj) patients/NNS (l_compound) nephropathy/NN -PUNC- streptozotocin/RB (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) nephropathy/NN
D010100_D003928 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) production/NN (r_pobj) by/IN (r_agent) accompanied/VBN (r_relcl) causes/NNS (r_pobj) of/IN (r_prep) one/CD (r_attr) is/VBZ (l_nsubj) nephropathy/NN
19473225
D018698_D020258 NONE glutamate/NN (r_nsubjpass) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN -PUNC- glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN
D000596_D020258 NONE acid/NN (r_compound) glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN
D000596_D010523 NONE acid/NN (r_compound) glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN
D017239_D020258 NONE paclitaxel/NN (r_pobj) with/IN (r_prep) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_advcl) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN -PUNC- PAC/NNP (r_appos) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_advcl) claimed/VBN (l_xcomp) ameliorate/VB (l_dobj) neurotoxicity/NN -PUNC- PAC/NNP (r_compound) neurotoxicity/NN
D018698_D010523 NONE glutamate/NN (r_compound) supplementation/NN (r_nsubj) failed/VBD (l_xcomp) protect/VB (l_prep) against/IN (l_pobj) neurotoxicity/NN -PUNC- glutamate/NN (r_nsubjpass) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN -PUNC- glutamine/NN (r_conj) glutamate/NN (r_nsubjpass) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN -PUNC- glutamate/NN (r_compound) supplementation/NN (l_prep) for/IN (l_pcomp) preventing/VBG (l_dobj) neuropathy/NN -PUNC- glutamate/NN (r_compound) supplementation/NN (r_nsubj) fails/VBZ (l_xcomp) protect/VB (l_prep) against/IN (l_pobj) neurotoxicity/NN
D017239_D010523 CID paclitaxel/NN (r_pobj) of/IN (r_prep) neurotoxicity/NN -PUNC- paclitaxel/NN (r_pobj) with/IN (r_prep) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_nsubj) neuropathy/NN -PUNC- PAC/NNP (r_appos) chemotherapy/NN (r_pobj) for/IN (r_prep) factor/NN (r_attr) is/VBZ (l_nsubj) neuropathy/NN -PUNC- PAC/NNP (r_compound) neurotoxicity/NN (r_dobj) ameliorate/VB (r_xcomp) claimed/VBN (r_advcl) is/VBZ (l_nsubj) neuropathy/NN -PUNC- PAC/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- PAC/NNP (r_pobj) of/IN (r_prep) neurotoxicity/NN
D017239_D010051 NONE PAC/NNP (r_npadvmod) containing/VBG (r_amod) regimen/NN (r_pobj) of/IN (r_prep) cycles/NNS (r_pobj) following/VBG (r_prep) analysis/NN (r_pobj) for/IN (r_prep) available/JJ (r_acomp) were/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN
D018698_D010051 NONE glutamate/NN (r_pobj) by/IN (r_agent) supplemented/VBN (l_ccomp) were/VBD (l_nsubj) patients/NNS (l_compound) cancer/NN
11135224
C056507_D064420 NONE gemcitabine/NN (r_compound) combination/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN
D002945_D002289 NONE cisplatin/NN (l_conj) chemotherapy/NN (l_prep) within/IN (l_pobj) approach/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- Cisplatin/NN (r_npadvmod) based/VBN (r_amod) combinations/NNS (r_nsubj) improve/VBP (l_dobj) quality/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- Cisplatin/NN (r_npadvmod) based/VBN (r_amod) combinations/NNS (r_nsubj) improve/VBP (l_dobj) quality/NN (l_prep) in/IN (l_pobj) carcinoma/NN (l_appos) NSCLC/NNP -PUNC- cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) rate/NN (r_conj) feasibility/NN (r_dobj) determine/VB (l_xcomp) treat/VB (l_dobj) NSCLC/NN -PUNC- cisplatin/NN (r_conj) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) tolerated/VBN (l_conj) shows/VBZ (l_prep) in/IN (l_pobj) NSCLC/NNP
C056507_D002289 NONE gemcitabine/NN (r_compound) combination/NN (r_compound) chemotherapy/NN (l_prep) within/IN (l_pobj) approach/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- gemcitabine/NN (r_compound) combination/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) rate/NN (r_conj) feasibility/NN (r_dobj) determine/VB (l_xcomp) treat/VB (l_dobj) NSCLC/NN -PUNC- gemcitabine/NN (r_conj) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- gemcitabine/NN (r_conj) combination/NN (r_nsubjpass) tolerated/VBN (l_conj) shows/VBZ (l_prep) in/IN (l_pobj) NSCLC/NNP
D002945_D064420 NONE cisplatin/NN (r_conj) paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN
D017239_D064420 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN
D017239_D002289 NONE Paclitaxel/NNP (l_conj) cisplatin/NN (l_conj) chemotherapy/NN (l_prep) within/IN (l_pobj) approach/NN (l_prep) in/IN (l_pobj) carcinoma/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) toxicity/NN (r_conj) rate/NN (r_conj) feasibility/NN (r_dobj) determine/VB (l_xcomp) treat/VB (l_dobj) NSCLC/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) tolerated/VBN (l_conj) shows/VBZ (l_prep) in/IN (l_pobj) NSCLC/NNP
6402369
D013438_D008175 NONE thiol/JJ (r_compound) sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D007069_D001745 CID ifosfamide/RB (r_advmod) induced/VBN (r_amod) toxicity/NN -PUNC- ifosfamide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) toxicity/NN -PUNC- IF/IN (r_mark) tested/VBN (l_nsubjpass) effect/NN (l_prep) against/IN (l_pobj) toxicity/NN -PUNC- IF/IN (r_mark) m2/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) cancer/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) in/IN (r_prep) tested/VBN (l_nsubjpass) effect/NN (l_prep) against/IN (l_pobj) toxicity/NN
D015080_D064420 NONE MESNA/NNP (r_compound) series/NN (l_conj) series/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) toxicity/NN
D007069_D008175 NONE ifosfamide/RB (r_advmod) induced/VBN (r_amod) toxicity/NN (r_pobj) of/IN (r_prep) Treatment/NN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- ifosfamide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) toxicity/NN (r_pobj) against/IN (r_prep) effect/NN (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- IF/IN (r_mark) tested/VBN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- IF/IN (r_mark) m2/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) cancer/NN
D013438_D001745 NONE thiol/JJ (r_compound) sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) against/IN (l_pobj) toxicity/NN
D015080_D001745 NONE sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) toxicity/NN -PUNC- MESNA/NNP (r_appos) sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) toxicity/NN -PUNC- sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) against/IN (l_pobj) toxicity/NN -PUNC- MESNA/NNP (r_appos) sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) against/IN (l_pobj) toxicity/NN
D015080_D008175 NONE sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) toxicity/NN (r_pobj) of/IN (r_prep) Treatment/NN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- MESNA/NNP (r_appos) sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_prep) toxicity/NN (r_pobj) of/IN (r_prep) Treatment/NN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- MESNA/NNP (r_appos) sulphonate/JJ (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
19884587
D009582_D008850 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anophthalmia/NN (l_conj) microphthalmos/NNS
D009582_D002972 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) AOR/NNP (l_conj) lip/NN (l_prep) with/IN (l_pobj) palate/NN
D009582_D000014 CID nitrofurantoins/NNS (r_conj) Sulfonamides/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D009582_D006344 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) AOR/NNP (l_appos) defects/NNS
D010406_D000014 NONE penicillins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D013449_D000014 CID Sulfonamides/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D013449_D018636 CID Sulfonamides/NNS (r_nsubjpass) associated/VBN (r_ccomp) interval/NN (l_appos) syndrome/NN
D002511_D000014 NONE cephalosporins/NNS (r_conj) erythromycins/NNS (r_conj) penicillins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
D013449_D000757 CID Sulfonamides/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) AOR/NNP (l_amod) anencephaly/NNS
D009582_D002971 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) AOR/NNP (l_conj) lip/NN
D009582_D018636 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_appos) AOR/NNP (l_appos) syndrome/NN
D009582_D000853 CID Nitrofurantoins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anophthalmia/NN
D004917_D000014 NONE erythromycins/NNS (r_conj) penicillins/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) defects/NNS
227508
-1_D006973 NONE nalozone/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) inhibited/VBN (r_conj) rats/NNS (l_amod) hypertensive/JJ -PUNC- 3H]-naloxone/CD (r_pobj) of/IN (r_prep) binding/NN (r_dobj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- 3H]-dihydroergocryptine/CD (r_nummod) nM/NNP (r_pobj) of/IN (r_prep) binding/NN (r_dobj) influence/VB (r_conj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D008750_D007022 CID methyldopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ
D009270_D007022 NONE naloxone/NN (r_pobj) by/IN (r_agent) reversed/VBN (l_nsubjpass) effect/NN (l_amod) hypotensive/JJ
D009270_D006973 NONE naloxone/NN (r_nsubj) influence/VB (r_conj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D003000_D006973 NONE clonidine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) pressure/NN (r_pobj) in/IN (r_prep) decrease/NN (r_dobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- clonidine/NN (r_preconj) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- clonidine/NN (r_npadvmod) suppressible/NN (r_amod) binding/NN (r_dobj) influence/VB (r_conj) influence/VB (l_prep) In/IN (l_pobj) membranes/NNS (l_prep) from/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
18186898
D016559_D005198 CID tacrolimus/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN
D016559_D009135 CID tacrolimus/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN (l_conj) myopathy/NNS
D019259_D028361 NONE lamivudine/NN (r_pobj) by/IN (r_agent) augmented/VBN (r_conj) triggered/VBN (r_relcl) dysfunction/NN
D020123_D000138 NONE sirolimus/NN (r_pobj) by/IN (r_agent) replaced/VBN (r_conj) suspected/VBN (l_xcomp) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) acidosis/NN -PUNC- sirolimus/NN (l_conj) acidosis/NN
D019259_D005198 CID lamivudine/NN (r_pobj) by/IN (r_agent) augmented/VBN (r_conj) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN
D016559_D000138 NONE tacrolimus/NN (r_nsubjpass) suspected/VBN (l_xcomp) be/VB (l_attr) cause/NN (l_prep) of/IN (l_pobj) acidosis/NN -PUNC- tacrolimus/NN (r_nsubjpass) suspected/VBN (l_conj) replaced/VBN (l_agent) by/IN (l_pobj) sirolimus/NN (l_conj) acidosis/NN
D019259_D009135 CID lamivudine/NN (r_pobj) by/IN (r_agent) augmented/VBN (r_conj) triggered/VBN (r_relcl) dysfunction/NN (r_pobj) from/IN (r_prep) resulted/VBN (l_nsubj) dysfunction/NN (l_conj) myopathy/NNS
D019259_D006509 NONE Lamivudine/NNP (r_nsubjpass) added/VBN (l_prep) because/IN (l_pobj) infection/NN
D016559_D028361 NONE tacrolimus/NN (r_pobj) by/IN (r_agent) triggered/VBN (r_relcl) dysfunction/NN
18752389
C532833_D056486 NONE acid/NN (r_pobj) of/IN (r_prep) glucuronidation/NN (r_dobj) inhibited/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) exposure/NN (l_conj) hepatotoxicity/NN
D019821_D056486 NONE simvastatin/NN (r_pobj) with/IN (r_prep) maintained/VBN (l_prep) for/IN (l_pobj) months/NNS (l_prep) before/IN (l_pobj) conversion/NN (l_prep) without/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- simvastatin/NN (r_amod) exposure/NN (l_conj) hepatotoxicity/NN -PUNC- simvastatin/NN (r_amod) exposure/NN (r_attr) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D015283_D003866 NONE escitalopram/NNP (r_conj) Simvastatinezetimibe/NNP (l_relcl) taking/VBG (l_prep) for/IN (l_pobj) depression/NN
C492458_D003866 NONE Simvastatinezetimibe/NNP (l_relcl) taking/VBG (l_prep) for/IN (l_pobj) depression/NN
C492458_D017093 NONE ezetimibe/NN (r_npadvmod) induced/VBN (r_amod) failure/NN -PUNC- ezetimibe/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
C108606_D056486 NONE ezetimibe/NN (r_pobj) with/IN (r_prep) published/VBN (l_nsubjpass) events/NNS (l_amod) hepatotoxic/JJ -PUNC- Ezetimibe/NNP (r_nsubj) undergoes/VBZ (l_conj) inhibited/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) exposure/NN (l_conj) hepatotoxicity/NN -PUNC- ezetimibe/NN (r_compound) inhibition/NN (r_pobj) by/IN (r_prep) exposure/NN (r_attr) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN
D014530_D056486 NONE diphosphate/NN (r_compound) glucoronosyltransferases/NNS (r_pobj) by/IN (r_prep) glucuronidation/NN (r_dobj) undergoes/VBZ (l_conj) inhibited/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) exposure/NN (l_conj) hepatotoxicity/NN
D019821_D017114 NONE simvastatin/NN (r_nmod) day/NN (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) after/IN (r_prep) necessitating/VBG (r_acl) failure/NN
D015283_D056486 NONE escitalopram/NNP (r_conj) Simvastatinezetimibe/NNP (r_nsubjpass) discontinued/VBN (l_conj) excluded/VBN (l_nsubjpass) causes/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN
C492458_D056486 CID ezetimibe/NN (r_appos) agent/NN (r_conj) ezetimibe/NN (r_pobj) with/IN (r_prep) published/VBN (l_nsubjpass) events/NNS (l_amod) hepatotoxic/JJ -PUNC- Simvastatinezetimibe/NNP (r_nsubjpass) discontinued/VBN (l_conj) excluded/VBN (l_nsubjpass) causes/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- simvastatinezetimibe/NN (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN -PUNC- ezetimibe/NN (r_pobj) with/IN (r_prep) hepatotoxicity/NN
C492458_D017114 CID mg/NN (r_nummod) day/NN (r_npadvmod) ezetimibe/NN (r_dobj) simvastatin/NN (r_advcl) necessitating/VBG (r_acl) failure/NN
17111419
C102006_D064420 NONE citrate/JJ (r_compound) toxicity/NN -PUNC- citrate/JJ (r_compound) toxicity/NN -PUNC- citrate/JJ (r_compound) toxicity/NN
C102006_D006996 CID citrate/NN (r_compound) anticoagulant/NN (r_pobj) by/IN (r_prep) reaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) hypocalcemia/NN -PUNC- citrate/JJ (r_compound) toxicity/NN (r_pobj) to/IN (r_pcomp) due/IN (r_amod) reactions/NNS (r_dobj) prevent/VB (r_xcomp) help/VB (r_xcomp) recommended/VBN (l_nsubjpass) screening/NN (l_prep) for/IN (l_pobj) medications/NNS (l_conj) conditions/NNS (l_acl) predisposing/VBG (l_prep) to/IN (l_pobj) hypocalcemia/NN
D049994_D006996 NONE diuretic/NN (r_amod) loop/NN (l_relcl) cause/VB (l_dobj) hypocalcemia/NN
D002118_D006996 NONE calcium/NN (r_compound) chelation/NN (r_pobj) to/IN (r_prep) reaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) hypocalcemia/NN
D002125_C536214 NONE gluconate/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubjpass) initiated/VBN (l_conj) subsided/VBD (l_nsubj) contractions/NNS
D002034_D006996 NONE bumetanide/NN (r_nsubj) is/VBZ (l_attr) loop/NN (l_relcl) cause/VB (l_dobj) hypocalcemia/NN
10520387
D015742_D017202 NONE propofol/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_acl) inducing/VBG (l_dobj) ischemia/NN
D004809_D017202 NONE ephedrine/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_acl) inducing/VBG (l_dobj) ischemia/NN
D015742_D013610 CID propofol/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tachycardia/NNS -PUNC- propofol/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN
D004809_D007022 NONE ephedrine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) adding/VBG (l_xcomp) propofol/NN (l_prep) in/IN (l_pobj) order/NN (l_acl) obtund/VB (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- ephedrine/NN (r_pobj) of/IN (r_prep) addition/NN (r_nsubj) appears/VBZ (l_xcomp) be/VB (l_attr) method/NN (l_prep) of/IN (l_pcomp) obtunding/VBG (l_dobj) response/NN (l_amod) hypotensive/JJ
D015742_D007022 CID propofol/NN (l_prep) in/IN (l_pobj) order/NN (l_acl) obtund/VB (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- propofol/NN (r_acl) addition/NN (r_nsubj) appears/VBZ (l_xcomp) be/VB (l_attr) method/NN (l_prep) of/IN (l_pcomp) obtunding/VBG (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- propofol/NN (r_advcl) obtunding/VBG (l_dobj) response/NN (l_amod) hypotensive/JJ
D004809_D013610 CID ephedrine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) tachycardia/NNS -PUNC- ephedrine/NN (r_nmod) mixtures/NNS (r_pobj) of/IN (r_prep) any/DT (r_pobj) of/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_dobj) recommend/VB (l_prep) Due/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) tachycardia/NN
7710775
D008315_D007511 NONE malondialdehyde/NN (r_nsubj) increased/VBD (l_prep) after/IN (l_pobj) min/NN (l_prep) of/IN (l_pobj) ischemia/NN -PUNC- malondialdehyde/NN (r_pobj) in/IN (r_prep) was/VBD (r_advcl) min/NN (l_prep) during/IN (l_pobj) ischemia/NN -PUNC- malondialdehyde/NN (r_pobj) of/IN (r_prep) determination/NN (r_nsubjpass) used/VBN (l_xcomp) monitor/VB (l_dobj) alterations/NNS (l_acl) occurring/VBG (l_prep) during/IN (l_pobj) phenomena/NNS (l_amod) ischemic/JJ
D009705_D007511 NONE nucleosides/NNS (r_conj) oxypurines/NNS (r_pobj) of/IN (r_prep) increase/NN (r_nsubjpass) observed/VBN (l_prep) During/IN (l_pobj) ischemia/NN -PUNC- nucleosides/NNS (r_conj) oxypurines/NNS (r_conj) malondialdehyde/NN (r_pobj) of/IN (r_prep) determination/NN (r_nsubjpass) used/VBN (l_xcomp) monitor/VB (l_dobj) alterations/NNS (l_acl) occurring/VBG (l_prep) during/IN (l_pobj) phenomena/NNS (l_amod) ischemic/JJ
D009705_D002545 NONE nucleosides/NNS (l_prep) during/IN (l_pobj) ischemia/NN
-1_D007511 NONE oxypurines/NNS (r_pobj) of/IN (r_prep) increase/NN (r_nsubjpass) observed/VBN (l_prep) During/IN (l_pobj) ischemia/NN -PUNC- oxypurines/NNS (r_conj) malondialdehyde/NN (r_pobj) of/IN (r_prep) determination/NN (r_nsubjpass) used/VBN (l_xcomp) monitor/VB (l_dobj) alterations/NNS (l_acl) occurring/VBG (l_prep) during/IN (l_pobj) phenomena/NNS (l_amod) ischemic/JJ
-1_D002545 NONE oxypurines/NNS (l_conj) nucleosides/NNS (l_prep) during/IN (l_pobj) ischemia/NN
D009599_D007511 NONE nitroprusside/NN (r_acl) drug/NN (r_pobj) of/IN (r_prep) min/NN (l_prep) during/IN (l_pobj) ischemia/NN
D009599_D007022 NONE nitroprusside/NN (r_acl) drug/NN (l_amod) hypotensive/JJ
D008315_D007022 NONE malondialdehyde/NN (r_pobj) in/IN (r_prep) was/VBD (r_advcl) min/NN (l_prep) of/IN (l_pobj) drug/NN (l_amod) hypotensive/JJ
D008315_D002545 CID malondialdehyde/NN (r_pobj) of/IN (r_prep) dependence/NN (r_nsubj) oxypurines/NNS (l_conj) nucleosides/NNS (l_prep) during/IN (l_pobj) ischemia/NN
D001241_D007511 NONE acetylsalicylate/VBP (l_prep) before/IN (l_pobj) ischemia/NN
15957009
D014236_D008569 NONE metrifonate/NN (r_conj) Ro4368554/NNP (r_nsubj) reversed/VBD (l_dobj) deficits/NNS
D014364_D008569 NONE TRP/NNP (r_compound) depletion/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) deficits/NNS
D012701_D008569 NONE 5-HT(6/CD (r_compound) antagonists/NNS (r_conj) involved/VBN (r_ccomp) suggesting/VBG (r_advcl) reversed/VBD (l_dobj) cholinergic/JJ (l_conj) deficit/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) deficits/NNS
C507242_D008569 NONE Ro4368554/NN (r_nsubj) restores/VBZ (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) deficiency/NN -PUNC- Ro4368554/NNP (r_nsubj) reversed/VBD (l_dobj) deficits/NNS -PUNC- Ro4368554/NN (r_nsubj) improve/VB (r_advcl) reversed/VBD (l_dobj) cholinergic/JJ (l_conj) deficit/NN -PUNC- Ro4368554/NN (r_pobj) by/IN (r_prep) facilitation/NN (r_pobj) in/IN (r_prep) involved/VBN (r_ccomp) suggesting/VBG (r_advcl) reversed/VBD (l_dobj) cholinergic/JJ (l_conj) deficit/NN
11467664
D008687_D041781 CID metformin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) jaundice/NN -PUNC- hydrochloride/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) jaundice/NN
D008687_D007565 NONE hydrochloride/NN (r_nsubjpass) discontinued/VBN (l_conj) resolved/VBN (l_nsubj) jaundice/NN -PUNC- metformin/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) onset/NN (l_prep) of/IN (l_pobj) jaundice/NN -PUNC- metformin/NN (r_npadvmod) associated/VBN (r_amod) hepatotoxicity/NN (r_pobj) of/IN (r_prep) example/NN (r_dobj) represents/VBZ (r_ccomp) believe/VBP (l_prep) Given/VBN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) jaundice/NN
D008687_D056486 NONE metformin/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) onset/NN (r_pobj) Given/VBN (r_prep) believe/VBP (l_ccomp) represents/VBZ (l_dobj) example/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- metformin/NN (r_npadvmod) associated/VBN (r_amod) hepatotoxicity/NN
2894766
D012460_D002305 CID sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) man/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) autoantibodies/NNS (r_conj) evidence/NN (l_prep) of/IN (l_pobj) tamponade/NN
D012460_D010996 CID sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) man/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) autoantibodies/NNS (r_conj) evidence/NN (r_appos) effusions/NNS
D012460_D015212 NONE sulfasalazine/NN (r_dobj) use/VBP (l_xcomp) treat/VB (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- sulfasalazine/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN (r_pobj) of/IN (r_prep) signs/NNS (r_pobj) of/IN (r_prep) aware/JJ (r_acomp) be/VB (l_nsubj) Physicians/NNS (l_relcl) use/VBP (l_xcomp) treat/VB (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D012460_D003093 NONE sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (l_prep) for/IN (l_pobj) colitis/NN
D012460_D012700 NONE sulfasalazine/RB (r_npadvmod) induced/VBN (r_amod) lupus/NN (l_relcl) manifested/VBD (l_prep) with/IN (l_pobj) serositis/NN
D012460_D011014 CID sulfasalazine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_relcl) man/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) autoantibodies/NNS (r_conj) evidence/NN (r_appos) effusions/NNS (l_dep) Pneumonitis/NNP
D012460_D008180 CID Sulfasalazine/NNP (r_npadvmod) induced/VBN (r_amod) erythematosus/NN -PUNC- sulfasalazine/RB (r_npadvmod) induced/VBN (r_amod) lupus/NN -PUNC- sulfasalazine/NN (r_dobj) use/VBP (r_relcl) Physicians/NNS (r_nsubj) be/VB (l_acomp) aware/JJ (l_prep) of/IN (l_pobj) signs/NNS (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- sulfasalazine/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN
7421734
D004967_D010049 NONE estrogens/NNS (r_dobj) received/VBD (r_conj) had/VBD (l_dobj) failure/NN -PUNC- estrogens/NNS (l_prep) for/IN (l_pobj) failure/NN
D004967_D006689 NONE estrogens/NNS (r_dobj) received/VBD (r_conj) had/VBD (l_dobj) failure/NN (l_prep) after/IN (l_pobj) irradiation/NN (l_prep) for/IN (l_pobj) disease/NN
D004967_D009369 NONE estrogens/NNS (r_pobj) on/IN (r_prep) women/NNS (r_nsubj) increased/VBN (l_nsubj) therapy/NN (l_compound) cancer/NN
D004967_D016889 CID estrogens/NNS (r_dobj) received/VBD (l_npadvmod) treatment/NN (l_acl) implicated/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- estrogens/NNS (r_pobj) on/IN (r_prep) women/NNS (r_nsubj) increased/VBN (l_dobj) risk/NN (l_prep) of/IN (l_pobj) carcinoma/NN
16298782
D009569_D006316 NONE oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN -PUNC- NO/NNP (r_intj) ester/NN (r_appos) oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN
D000617_D006319 NONE aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) loss/NN
D005839_D006311 NONE gentamicin/NN (r_compound) ototoxicity/NN
D019331_D034381 NONE NAME/NN (r_nsubj) reduced/VBN (l_dobj) loss/NN
D009569_D006311 NONE NO/DT (r_pobj) of/IN (r_prep) production/NN (r_dobj) involves/VBZ (r_conj) is/VBZ (l_nsubj) ototoxicity/NN -PUNC- NO/DT (r_pobj) of/IN (r_prep) production/NN (r_dobj) involves/VBZ (l_nsubj) mechanism/NN (l_compound) ototoxic/JJ -PUNC- NO/DT (r_det) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_nsubj) ototoxicity/NN -PUNC- NO/DT (r_det) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_conj) involves/VBZ (l_nsubj) mechanism/NN (l_compound) ototoxic/JJ
D000617_D006311 NONE aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) loss/NN (r_pobj) of/IN (r_prep) prevention/NN (r_pobj) for/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_nsubj) ototoxicity/NN -PUNC- aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) loss/NN (r_pobj) of/IN (r_prep) prevention/NN (r_pobj) for/IN (r_prep) use/NN (r_dobj) assess/VB (r_xcomp) need/VBP (l_ccomp) is/VBZ (l_conj) involves/VBZ (l_nsubj) mechanism/NN (l_compound) ototoxic/JJ
D019331_D006316 NONE ester/NN (r_appos) oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN -PUNC- NAME/NN (r_appos) ester/NN (r_appos) oxide/NN (r_nsubj) act/VB (l_prep) as/IN (l_pobj) otoprotectant/NN (l_prep) against/IN (l_pobj) loss/NN
D019331_D006311 NONE ester/NN (l_appos) protector/NN (l_prep) against/IN (l_pobj) ototoxicity/NN
D009569_D006319 NONE NO/DT (r_pobj) of/IN (r_prep) production/NN (r_dobj) involves/VBZ (r_conj) is/VBZ (r_ccomp) need/VBP (l_xcomp) assess/VB (l_dobj) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) loss/NN -PUNC- NO/DT (r_det) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) loss/NN
D005839_D034381 CID gentamicin/NN (r_npadvmod) induced/VBN (r_amod) loss/NN
D005839_D006316 NONE gentamicin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) loss/NN
10225068
D008012_D020258 NONE lignocaine/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) ranged/VBD (r_ccomp) caused/VBN (l_agent) by/IN (l_pobj) neurotoxicity/NN -PUNC- lignocaine/NN (r_pobj) of/IN (r_prep) neurotoxicity/NN
D008012_D011128 CID lignocaine/NN (r_pobj) with/IN (r_prep) anaesthesia/NN (r_pobj) after/IN (r_prep) syndrome/NN -PUNC- lignocaine/NN (r_pobj) with/IN (r_prep) anaesthesia/NN (r_pobj) after/IN (r_prep) syndrome/NN (l_appos) review/NN (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) syndrome/NN
6150641
D011899_D056486 NONE ranitidine/NN (r_conj) median/NN (r_conj) cimetidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- ranitidine/NN (r_compound) therapy/NN (r_nsubjpass) associated/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D003404_D056486 NONE creatinine/NN (r_compound) level/NN (r_pobj) with/IN (r_prep) associated/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D011899_D006402 NONE ranitidine/NN (r_conj) median/NN (r_conj) cimetidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- ranitidine/NN (r_compound) therapy/NN (r_nsubjpass) associated/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D003404_D006402 NONE creatinine/NN (r_compound) level/NN (r_pobj) with/IN (r_prep) associated/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D011899_D007172 NONE ranitidine/NN (r_pobj) by/IN (r_agent) replaced/VBN (r_advcl) disappeared/VBD (r_conj) taking/VBG (r_advcl) developed/VBD (l_dobj) changes/NNS (l_conj) impotence/NN
D002927_D056486 NONE cimetidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- cimetidine/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) seen/VBN (r_advcl) level/NN (r_pobj) with/IN (r_prep) associated/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D002927_D007172 CID cimetidine/NN (r_dobj) taking/VBG (r_advcl) developed/VBD (l_dobj) changes/NNS (l_conj) impotence/NN -PUNC- cimetidine/NN (r_nsubjpass) replaced/VBN (r_advcl) disappeared/VBD (r_conj) taking/VBG (r_advcl) developed/VBD (l_dobj) changes/NNS (l_conj) impotence/NN
D002927_D006402 NONE cimetidine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- cimetidine/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) seen/VBN (r_advcl) level/NN (r_pobj) with/IN (r_prep) associated/VBN (r_conj) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
16157917
C047781_C562694 NONE Lamotrigine/NNP (l_acl) associated/VBD (l_prep) with/IN (l_pobj) exacerbation/NN (l_prep) in/IN (l_pobj) epilepsies/NNS -PUNC- lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) epilepsies/NNS -PUNC- lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) epilepsies/NNS (l_appos) IGE/NNP -PUNC- LTG/NNP (r_appos) lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) epilepsies/NNS -PUNC- LTG/NNP (r_appos) lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) epilepsies/NNS (l_appos) IGE/NNP
C047781_D009207 CID Lamotrigine/NNP (l_acl) associated/VBD (l_prep) with/IN (l_pobj) exacerbation/NN (l_conj) myoclonus/NN -PUNC- lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) experienced/VBD (l_dobj) exacerbation/NN (l_conj) appearance/NN (l_prep) of/IN (l_pobj) jerks/NNS -PUNC- lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) experienced/VBD (l_dobj) exacerbation/NN (l_conj) appearance/NN (l_prep) of/IN (l_pobj) jerks/NNS (l_appos) MJ/NNP -PUNC- LTG/NNP (r_appos) lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) experienced/VBD (l_dobj) exacerbation/NN (l_conj) appearance/NN (l_prep) of/IN (l_pobj) jerks/NNS -PUNC- LTG/NNP (r_appos) lamotrigine/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) experienced/VBD (l_dobj) exacerbation/NN (l_conj) appearance/NN (l_prep) of/IN (l_pobj) jerks/NNS (l_appos) MJ/NNP -PUNC- LTG/NNP (r_nsubj) exacerbated/VBD (l_dobj) MJ/NNP -PUNC- LTG/NNP (r_compound) dose/NN (r_nsubjpass) decreased/VBN (r_advcl) disappeared/VBD (l_nsubj) MJ/NNP -PUNC- LTG/NNP (r_nsubj) exacerbated/VBD (l_dobj) MJ/NNP -PUNC- LTG/NNP (r_nsubj) exacerbated/VBD (l_prep) with/IN (l_pobj) status/NN -PUNC- LTG/NNP (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) ceased/VBD (r_relcl) status/NN (r_pobj) with/IN (r_prep) exacerbated/VBD (l_dobj) MJ/NNP -PUNC- LTG/NNP (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) ceased/VBD (r_relcl) status/NN
3934126
D000617_D013924 NONE aminoglycoside/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) confined/VBN (l_ccomp) occurred/VBD (l_nsubj) Thrombophlebitis/NNP
D014640_D006311 CID vancomycin/NNP (r_appos) aminoglycoside/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) confined/VBN (l_nsubjpass) nephrotoxicity/NN (l_conj) ototoxicity/NN
D014640_D013924 CID vancomycin/NNP (r_appos) aminoglycoside/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) confined/VBN (l_ccomp) occurred/VBD (l_nsubj) Thrombophlebitis/NNP
D014640_D007674 NONE vancomycin/NNP (r_appos) aminoglycoside/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) confined/VBN (l_nsubjpass) nephrotoxicity/NN
D000617_D006311 NONE aminoglycoside/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) confined/VBN (l_nsubjpass) nephrotoxicity/NN (l_conj) ototoxicity/NN
D000617_D007674 NONE aminoglycoside/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) to/IN (r_prep) confined/VBN (l_nsubjpass) nephrotoxicity/NN
D014640_D007239 NONE Vancomycin/NNP (r_nsubj) was/VBD (l_acomp) curative/JJ (l_prep) in/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infection/NN -PUNC- vancomycin/NNP (r_nsubj) constitutes/VBZ (l_dobj) therapy/NN (l_prep) for/IN (l_pobj) infections/NNS
7802851
D000525_D016584 NONE alprazolam/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) disorder/NN -PUNC- alprazolam/NN (r_xcomp) randomised/VBN (l_prep) In/IN (l_pobj) London/NNP (l_conj) patients/NNS (l_relcl) met/VBD (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) disorder/NN
D000525_D001523 NONE alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_prep) of/IN (l_pobj) depression/NN (l_conj) enuresis/NN (l_conj) disinhibition/NN (l_conj) aggression/NN -PUNC- alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN
D000525_D000379 NONE alprazolam/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) disorder/NN (l_prep) with/IN (l_pobj) agoraphobia/NNP -PUNC- alprazolam/NN (r_xcomp) randomised/VBN (l_prep) In/IN (l_pobj) London/NNP (l_conj) patients/NNS (l_relcl) met/VBD (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) disorder/NN (l_prep) with/IN (l_pobj) agoraphobia/NNP
D000525_D001259 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN (l_conj) memory/NN (l_conj) loss/NN (l_conj) ataxia/NN
D000525_D008569 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN (l_conj) memory/NN
D000525_D003866 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_prep) of/IN (l_pobj) depression/NN
D000525_D015431 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_conj) effects/NNS (l_appos) sedation/NN (l_conj) irritability/NN (l_conj) memory/NN (l_conj) loss/NN
D000525_D004775 CID alprazolam/NN (r_compound) patients/NNS (r_nsubj) developed/VBD (l_dobj) reactions/NNS (l_prep) of/IN (l_pobj) depression/NN (l_conj) enuresis/NN
7263204
D007213_D000741 CID indomethacin/NN (r_pobj) due/IN (r_amod) anemia/NN -PUNC- indomethacin/NN (r_nsubjpass) implicated/VBN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- indomethacin/NN (r_conj) allopurinol/NN (r_pobj) than/IN (r_prep) other/JJ (r_amod) drugs/NNS (r_nsubjpass) given/VBN (r_relcl) described/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- indomethacin/NN (r_pobj) with/IN (r_prep) test/NN (r_nsubj) substantiates/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pcomp) causing/VBG (l_dobj) anemia/NN
D000493_D000741 NONE allopurinol/NN (r_pobj) than/IN (r_prep) other/JJ (r_amod) drugs/NNS (r_nsubjpass) given/VBN (r_relcl) described/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) anemia/NN
2322844
C053876_D006930 NONE AH6809/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) effect/NN (l_amod) hyperalgesic/JJ -PUNC- AH6809/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) hyperalgesia/NN
D019342_D010146 NONE acid/NN (r_conj) plate/NN (r_dobj) using/VBG (r_pcomp) by/IN (r_prep) evaluated/VBN (l_nsubjpass) effects/NNS (l_prep) on/IN (l_pobj) responses/NNS (l_compound) pain/NN
D011453_D006930 NONE pg/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) at/IN (r_prep) effect/NN (l_amod) hyperalgesic/JJ
D011453_D010146 NONE prostaglandins/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) responses/NNS (l_compound) pain/NN
D015237_D010146 NONE alpha/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) responses/NNS (l_compound) pain/NN
D015230_D006930 CID D2/NN (r_nsubj) had/VBD (l_dobj) action/NN (l_amod) hyperalgesic/JJ -PUNC- D2/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) than/IN (r_prep) min/NN (r_dobj) lasted/VBD (r_conj) showed/VBD (l_dobj) effect/NN (l_amod) hyperalgesic/JJ -PUNC- D2/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hyperalgesic/JJ -PUNC- D2/NN (r_nsubj) exert/VBP (l_dobj) hyperalgesia/NN
D015232_D006930 CID E2/NNP (r_nsubj) showed/VBD (l_dobj) effect/NN (l_amod) hyperalgesic/JJ -PUNC- E2-induced/NNP (r_amod) hyperalgesia/NN -PUNC- E2/NNP (r_conj) D2/NN (r_nsubj) exert/VBP (l_dobj) hyperalgesia/NN
19803309
D013390_D014313 CID suxamethonium/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) following/VBG (r_prep) threatening/VBG (l_dobj) spasm/NN
D013390_D009224 NONE suxamethonium/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) following/VBG (r_prep) threatening/VBG (r_ccomp) developed/VBD (r_relcl) primigravida/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) congenita/NN
11860495
D013256_D000647 NONE Steroid/NN (r_compound) structure/NN (r_nsubj) determine/VBP (l_dobj) effects/NNS (l_amod) amnesic/JJ
C018370_D000647 NONE sulphate/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) amnesic/JJ -PUNC- PREGS/NNP (r_nsubj) is/VBZ (l_acomp) able/JJ (l_xcomp) reverse/VB (l_dobj) effects/NNS (l_amod) like/JJ (l_amod) amnesic/JJ -PUNC- PREGS/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) task/NN (l_acl) using/VBG (l_dobj) model/NN (l_prep) of/IN (l_pobj) amnesia/NN -PUNC- PREGS/NNP (r_pobj) of/IN (r_prep) ability/NN (l_acl) be/VB (l_attr) order/NN (l_amod) effective/JJ (l_prep) than/IN (l_pobj) enantiomer/NN (l_prep) in/IN (l_pcomp) reversing/VBG (l_dobj) amnesia/NN
D005680_D000647 NONE GABA(A)R/NNP (r_compound) ligands/NNS (r_conj) NMDAR/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_amod) like/JJ (l_amod) amnesic/JJ
D012601_D000647 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN
9698967
D008619_D006973 CID mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
D008619_D004387 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (l_prep) for/IN (l_pobj) correction/NN (l_prep) of/IN (l_pobj) contracture/NN
D004837_D006973 CID adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_prep) in/IN (l_pobj) pressure/NN
D008619_D001281 CID mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN
D004837_D011595 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN
D008619_D011595 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN
D004837_D001281 CID adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN
D008619_D019954 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS
D004837_D014474 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS (l_prep) of/IN (l_pobj) consciousness/NN
D004837_D004387 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (l_prep) for/IN (l_pobj) correction/NN (l_prep) of/IN (l_pobj) contracture/NN
D004837_D019954 NONE adrenaline/NN (r_dobj) containing/VBG (r_pcomp) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS
D008619_D014474 NONE mepivacaine/NN (r_amod) mg/NN (r_pobj) with/IN (r_prep) block/NN (r_pobj) of/IN (r_prep) performance/NN (r_pobj) after/IN (r_prep) min/NN (r_appos) group/NN (r_appos) observed/VBN (l_nsubjpass) increase/NN (l_acl) accompanied/VBN (l_agent) by/IN (l_pobj) fibrillation/NN (l_conj) agitation/NN (l_conj) shouts/NNS (l_prep) of/IN (l_pobj) consciousness/NN
16584858
D014810_D009203 NONE E/NN (r_conj) C/NN (r_conj) cerruloplasmin/NN (r_pobj) as/IN (r_prep) antioxidants/NNS (r_appos) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP
C013592_D009203 NONE mangiferin/NN (l_prep) on/IN (l_pobj) alterations/NNS (l_prep) in/IN (l_pobj) infarction/NN -PUNC- mangiferin/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) Upon/IN (r_prep) suspended/VBN (l_prep) given/VBN (l_prep) to/IN (l_pobj) rats/NNS (l_compound) MI/NNP -PUNC- mangiferin/JJ (r_compound) administration/NN (r_pobj) upon/IN (r_prep) rose/VBD (l_prep) compared/VBN (l_prep) to/IN (l_pobj) rats/NNS (l_compound) MI/NNP -PUNC- mangiferin/NN (r_nsubj) exerts/VBZ (l_dobj) effect/NN (l_prep) against/IN (l_pobj) MI/NNP
C013592_D017202 NONE mangiferin/NN (r_pobj) of/IN (r_prep) role/NN (r_nsubjpass) analyzed/VBN (l_agent) by/IN (l_pobj) test/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) assay/NN (l_prep) of/IN (l_pobj) myocardium/NN
D019344_D009202 NONE lactate/NN (r_compound) dehydrogenase/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) by/IN (r_agent) determined/VBN (r_relcl) heart/NN (r_pobj) in/IN (r_prep) damage/NN
D007501_D009202 NONE iron/NN (r_nmod) capacity/NN (r_conj) level/NN (r_dobj) increased/VBN (l_ccomp) caused/VBD (l_dobj) damage/NN
C009591_D017202 NONE chloride/NN (r_nmod) test/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) assay/NN (l_prep) of/IN (l_pobj) myocardium/NN -PUNC- TTC/NNP (r_nmod) test/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) assay/NN (l_prep) of/IN (l_pobj) myocardium/NN
D005978_D009203 NONE glutathione/NN (r_compound) peroxidase/NN (r_conj) catalase/NNP (r_conj) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP -PUNC- glutathione/NN (r_compound) transferase/NN (r_conj) peroxidase/NN (r_conj) catalase/NNP (r_conj) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP -PUNC- glutathione/NN (r_compound) reductase/NN (r_compound) activities/NNS (r_conj) transferase/NN (r_conj) peroxidase/NN (r_conj) catalase/NNP (r_conj) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP -PUNC- glutathione/NN (r_conj) E/NN (r_conj) C/NN (r_conj) cerruloplasmin/NN (r_pobj) as/IN (r_prep) antioxidants/NNS (r_appos) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP
D007545_D006331 NONE ISPH/NNP (r_npadvmod) induced/VBN (r_amod) MI/NNP (r_pobj) against/IN (r_prep) effect/NN (r_dobj) exerts/VBZ (l_prep) due/IN (l_pcomp) to/IN (l_pobj) potential/NN (l_relcl) regulated/VBD (l_prep) against/IN (l_pobj) damage/NN
D013481_D009203 NONE superoxide/JJ (r_amod) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP
C013592_D006331 NONE mangiferin/NN (r_nsubj) exerts/VBZ (l_prep) due/IN (l_pcomp) to/IN (l_pobj) potential/NN (l_relcl) regulated/VBD (l_prep) against/IN (l_pobj) damage/NN
D003401_D009202 NONE creatine/NN (r_conj) caused/VBD (l_dobj) damage/NN
D001205_D009203 NONE C/NN (r_conj) cerruloplasmin/NN (r_pobj) as/IN (r_prep) antioxidants/NNS (r_appos) dismutase/NN (r_pobj) as/IN (r_prep) enzymes/NNS (r_dobj) tissue/NN (r_nsubjpass) altered/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_compound) MI/NNP
D004121_D009203 NONE sulphoxide/RB (r_pobj) of/IN (r_prep) ml/NNS (r_pobj) in/IN (r_prep) suspended/VBN (l_prep) given/VBN (l_prep) to/IN (l_pobj) rats/NNS (l_compound) MI/NNP
D007545_D009202 NONE ISPH/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) caused/VBD (l_dobj) damage/NN
D014527_D009202 NONE acid/NN (r_compound) level/NN (r_dobj) increased/VBN (l_ccomp) caused/VBD (l_dobj) damage/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_pobj) on/IN (r_prep) infarction/NN -PUNC- isoproterenol/NN (r_pobj) on/IN (r_prep) infarction/NN (l_appos) MI/NNP -PUNC- ISPH)-induced/JJ (r_amod) infarction/NN -PUNC- ISPH)-induced/JJ (r_amod) infarction/NN (l_appos) MI/NNP -PUNC- ISPH/NNP (r_npadvmod) induced/VBN (r_amod) rats/NNS (l_compound) MI/NNP -PUNC- ISPH/NNP (r_npadvmod) induced/VBN (r_amod) MI/NNP
11195262
D014635_D002493 NONE VPA/NNP (r_pobj) of/IN (r_prep) administration/NN (r_conj) weakness/NN (l_prep) of/IN (l_pobj) system/NN
D014635_D004830 NONE VPA/NNP (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D014635_D007177 CID valproate/NN (l_prep) to/IN (l_pobj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN (l_prep) of/IN (l_pobj) hormone/NN -PUNC- valproate/NN (l_conj) developed/VBD (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN (l_prep) of/IN (l_pobj) hormone/NN -PUNC- valproate/NN (l_conj) developed/VBD (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN (l_prep) of/IN (l_pobj) hormone/NN (l_appos) SIADH/NNP -PUNC- VPA/NNP (r_npadvmod) valproate/NN (l_conj) developed/VBD (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN (l_prep) of/IN (l_pobj) hormone/NN -PUNC- VPA/NNP (r_npadvmod) valproate/NN (l_conj) developed/VBD (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN (l_prep) of/IN (l_pobj) hormone/NN (l_appos) SIADH/NNP -PUNC- VPA/NNP (r_pobj) of/IN (r_prep) administration/NN (r_conj) weakness/NN (r_pobj) including/VBG (r_prep) factors/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) be/VB (l_nsubj) episode/NN (l_prep) of/IN (l_pobj) SIADH/NNP
2598570
D007052_D006073 NONE ibuprofen/NNP (r_appos) agents/NNS (r_pobj) of/IN (r_prep) use/NN (r_appos) age/NN (l_conj) disease/NN (l_conj) history/NN (l_prep) of/IN (l_pobj) gout/NN
D000431_D006255 NONE alcohol/NN (r_dobj) use/VB (r_conj) participate/VB (l_ccomp) were/VBD (l_conj) suffer/VB (l_prep) from/IN (l_pobj) fever/NN
D000431_D001249 NONE alcohol/NN (r_dobj) use/VB (r_conj) participate/VB (l_ccomp) were/VBD (l_conj) suffer/VB (l_prep) from/IN (l_pobj) fever/NN (l_conj) asthma/NN
D007052_D007674 NONE ibuprofen/NNP (r_appos) agents/NNS (r_pobj) of/IN (r_prep) use/NN (r_appos) age/NN (l_conj) disease/NN
D007052_D007669 NONE ibuprofen/NNP (r_appos) agents/NNS (r_pobj) of/IN (r_prep) use/NN (r_appos) age/NN (l_conj) disease/NN (l_conj) history/NN (l_prep) of/IN (l_pobj) stones/NNS
D013496_D021501 CID suprofen/NN (r_pobj) from/IN (r_prep) epidemiology/NN (l_prep) of/IN (l_pobj) syndrome/NN (l_compound) pain/NN
354896
D008012_D006323 CID Lidocaine/NN (r_npadvmod) induced/VBN (r_amod) asystole/NN
D008012_D001919 NONE lidocaine/NN (r_pobj) to/IN (r_prep) idiosyncrasy/NN (r_dobj) represented/VBD (r_conj) had/VBD (l_dobj) conditions/NNS (l_relcl) predisposed/VBN (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) bradyarrhythmias/NNS
D008012_D003866 NONE lidocaine/NN (r_pobj) of/IN (r_prep) bolus/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) depression/NN
8665051
D013256_D013746 NONE steroid/NN (r_compound) groups/NNS (r_pobj) in/IN (r_prep) prolonged/VBN (l_conj) was/VBD (l_advcl) were/VBD (l_nsubj) tensions/NNS (l_compound) tetanic/JJ
D014221_D000855 CID triamcinolone/NN (r_conj) methylprednisolone/NN (r_appos) C/NNP (r_pobj) of/IN (r_prep) injection/NN (r_dobj) receive/VB (r_xcomp) assigned/VBN (l_conj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) intake/NN -PUNC- T/NNP (r_appos) triamcinolone/NN (r_conj) methylprednisolone/NN (r_appos) C/NNP (r_pobj) of/IN (r_prep) injection/NN (r_dobj) receive/VB (r_xcomp) assigned/VBN (l_conj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) intake/NN -PUNC- T/NNP (r_conj) M/NNP (r_pobj) in/IN (r_prep) %/NN (r_appos) groups/NNS (r_pobj) in/IN (r_prep) reduction/NN (l_prep) of/IN (l_pobj) intake/NN
D000305_D009135 NONE corticosteroids/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occur/VB (l_nsubj) myopathy/NN
D008775_D000855 CID methylprednisolone/NN (r_appos) C/NNP (r_pobj) of/IN (r_prep) injection/NN (r_dobj) receive/VB (r_xcomp) assigned/VBN (l_conj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) intake/NN -PUNC- M/NNP (r_appos) methylprednisolone/NN (r_appos) C/NNP (r_pobj) of/IN (r_prep) injection/NN (r_dobj) receive/VB (r_xcomp) assigned/VBN (l_conj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) intake/NN -PUNC- M/NNP (r_pobj) in/IN (r_prep) %/NN (r_appos) groups/NNS (r_pobj) in/IN (r_prep) reduction/NN (l_prep) of/IN (l_pobj) intake/NN
D014221_D009336 NONE T/NNP (r_pobj) with/IN (r_prep) atrophy/NN (r_conj) atrophy/NN (r_dobj) showed/VBD (l_advcl) revealed/VBD (l_dobj) pattern/NN (l_prep) with/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) necrosis/NN
D013256_D009336 NONE steroid/NN (r_compound) groups/NNS (r_pobj) in/IN (r_prep) atrophy/NN (r_dobj) showed/VBD (l_advcl) revealed/VBD (l_dobj) pattern/NN (l_prep) with/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) necrosis/NN -PUNC- steroids/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) induced/VBD (r_ccomp) conclude/VBP (r_ccomp) induced/VBD (r_ccomp) caused/VBD (l_dobj) necrosis/NN -PUNC- steroids/NNS (r_pobj) of/IN (r_prep) types/NNS (r_nsubj) induced/VBD (r_ccomp) caused/VBD (l_dobj) necrosis/NN -PUNC- steroid/NN (r_nsubj) caused/VBD (l_dobj) necrosis/NN
D013256_D000855 NONE steroid/NN (r_npadvmod) treated/VBN (r_amod) groups/NNS (r_pobj) in/IN (r_prep) reduction/NN (l_prep) of/IN (l_pobj) intake/NN
D014221_D009133 CID T/NNP (r_pobj) with/IN (r_prep) atrophy/NN (r_conj) atrophy/NN -PUNC- T/NNP (r_pobj) with/IN (r_prep) atrophy/NN -PUNC- T/NNP (r_conj) C/NNP (r_appos) rats/NNS (r_pobj) in/IN (r_prep) performed/VBN (r_acl) study/NN (r_nsubj) showed/VBD (l_ccomp) was/VBD (l_nsubj) atrophy/NN -PUNC- T/NNP (r_npadvmod) treated/VBN (r_amod) animals/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) pronounced/VBN (r_acomp) was/VBD (l_nsubj) atrophy/NN
D008775_D013746 NONE M/NNP (r_pobj) with/IN (r_prep) was/VBD (l_advcl) were/VBD (l_nsubj) tensions/NNS (l_compound) tetanic/JJ
D013256_D001284 NONE steroids/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) induced/VBD (r_ccomp) conclude/VBP (r_ccomp) induced/VBD (l_dobj) atrophy/NN -PUNC- steroids/NNS (r_pobj) of/IN (r_prep) types/NNS (r_nsubj) induced/VBD (l_dobj) atrophy/NN -PUNC- steroid/NN (r_nsubj) caused/VBD (l_ccomp) induced/VBD (l_dobj) atrophy/NN
D013256_D009133 NONE steroid/NN (r_compound) groups/NNS (r_pobj) in/IN (r_prep) atrophy/NN -PUNC- steroid/NN (r_compound) groups/NNS (r_pobj) in/IN (r_prep) atrophy/NN (l_conj) atrophy/NN -PUNC- steroids/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) induced/VBD (r_ccomp) conclude/VBP (r_ccomp) induced/VBD (r_ccomp) caused/VBD (r_ccomp) caused/VBN (l_nsubjpass) atrophy/NN -PUNC- steroids/NNS (r_pobj) of/IN (r_prep) types/NNS (r_nsubj) induced/VBD (r_ccomp) caused/VBD (r_ccomp) caused/VBN (l_nsubjpass) atrophy/NN -PUNC- steroid/NN (r_nsubj) caused/VBD (r_ccomp) caused/VBN (l_nsubjpass) atrophy/NN
11773892
D016572_D007674 CID cyclosporine/VBP (r_appos) inhibitors/NNS (r_nsubjpass) known/VBN (l_xcomp) be/VB (l_acomp) nephrotoxic/JJ
D003404_D007676 NONE creatinine/NN (r_conj) CRF/NNP (r_conj) Controls/NNS (l_conj) CRF/NNP -PUNC- creatinine/NN (r_conj) CRF/NNP (r_conj) Controls/NNS (l_conj) CRF/NNP (l_conj) ESRD/NNP -PUNC- creatinine/NN (r_conj) CRF/NNP -PUNC- creatinine/NN (r_conj) CRF/NNP (r_conj) Controls/NNS (r_appos) groups/NNS (l_conj) n=45/JJ (l_nmod) ESRD/NNS -PUNC- creatinine/NN (r_compound) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_nmod) CRF/NNP -PUNC- creatinine/NN (r_compound) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_compound) ESRD/NNP -PUNC- creatinine/NN (r_conj) requirement/NN (r_appos) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_nmod) CRF/NNP -PUNC- creatinine/NN (r_conj) requirement/NN (r_appos) levels/NNS (r_dobj) had/VBD (l_nsubj) patients/NNS (l_compound) ESRD/NNP -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) were/VBD (l_attr) factors/NNS (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) were/VBD (l_attr) factors/NNS (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP (l_conj) ESRD/NNP -PUNC- creatinine/NN (r_dobj) have/VBP (l_nsubj) Patients/NNS (l_relcl) develop/VBP (l_dobj) ESRD/NNS -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) is/VBZ (l_acomp) predictive/JJ (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP -PUNC- creatinine/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) is/VBZ (l_acomp) predictive/JJ (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) CRF/NNP (l_conj) ESRD/NNP
D003404_D006530 NONE creatinine/NN (r_compound) levels/NNS (l_appos) percentage/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- creatinine/NN (r_conj) requirement/NN (r_appos) levels/NNS (l_appos) percentage/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- creatinine/NN (r_dobj) have/VBP (l_conj) are/VBP (l_acomp) likely/JJ (l_xcomp) have/VB (l_dobj) syndrome/NN
D016559_D007674 CID tacrolimus/NN (r_conj) cyclosporine/VBP (r_appos) inhibitors/NNS (r_nsubjpass) known/VBN (l_xcomp) be/VB (l_acomp) nephrotoxic/JJ
16600756
D015237_D053201 CID PGF2alpha/NNP (r_conj) PGE2/NNP (r_conj) NGF/NNP (r_nsubjpass) increased/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) OAB/NNP -PUNC- PGF2alpha/NNP (r_appos) NGF/NNP (r_nsubj) correlate/VB (l_prep) with/IN (l_pobj) parameters/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) OAB/NNP
D011464_D053201 NONE PGI2/NNP (r_nsubj) was/VBD (l_acomp) different/JJ (l_prep) between/IN (l_pobj) controls/NNS (l_prep) with/IN (l_pobj) OAB/NNP -PUNC- PGI2/NNP (r_conj) PGF2alpha/NNP (r_appos) NGF/NNP (r_nsubj) correlate/VB (l_prep) with/IN (l_pobj) parameters/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) OAB/NNP
D015232_D053201 CID PGE2/NNP (r_conj) NGF/NNP (r_nsubjpass) increased/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) OAB/NNP -PUNC- PGE2/NNP (l_compound) OAB/NNP
D011453_D053201 NONE prostaglandins/NNS (r_conj) factor/NN (l_prep) in/IN (l_pobj) urine/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) bladder/NN -PUNC- PGs/NNS (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) OAB/NNP -PUNC- PG/NNP (r_conj) NGF/NNP (r_pobj) between/IN (r_prep) correlations/NNS (l_conj) parameters/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) OAB/NNP -PUNC- PGs/NNS (r_conj) NGF/NNP (r_nsubj) have/VBP (l_dobj) roles/NNS (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) symptoms/NNS (l_compound) OAB/NNP
8268147
D010396_D003882 NONE penicillamine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) one/CD (r_pobj) as/IN (r_prep) develop/VB (l_nsubj) dermatomyositis/NN -PUNC- penicillamine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) Patients/NNS (r_nsubjpass) followed/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) complications/NNS (l_prep) like/IN (l_pobj) dermatomyositis/NN
D010396_D012216 NONE penicillamine/NN (r_nsubjpass) used/VBN (l_prep) for/IN (l_pobj) diseases/NNS
D010396_D017285 CID penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cirrhosis/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) polymyositis/NN -PUNC- penicillamine/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) one/CD (r_pobj) as/IN (r_prep) develop/VB (l_nsubj) dermatomyositis/NN (l_nmod) Polymyositis/NNP -PUNC- penicillamine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) polymyositis/NN -PUNC- penicillamine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) Patients/NNS (r_nsubjpass) followed/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) complications/NNS (l_prep) like/IN (l_pobj) dermatomyositis/NN (l_nmod) polymyositis/NN
D010396_D008105 NONE penicillamine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cirrhosis/NN -PUNC- penicillamine/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (r_relcl) cirrhosis/NN
D010396_D064420 NONE penicillamine/NN (r_nsubjpass) used/VBN (r_advcl) limits/VBZ (l_nsubj) toxicity/NN
3187073
D005472_D013610 NONE 5-FU/CD (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) be/VB (l_conj) discontinued/VBN (l_advcl) observed/VBN (l_nsubjpass) pain/NN (l_conj) tachyarrhythmia/NN
D005472_D002637 CID 5-FU/CD (r_compound) treatment/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) be/VB (l_conj) discontinued/VBN (l_advcl) observed/VBN (l_nsubjpass) pain/NN
11569530
D020117_D016171 CID cisapride/NN (r_conj) terodiline/NN (r_conj) terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP -PUNC- cisapride/JJ (r_conj) terodiline/NN (r_conj) terfenadine/NN (r_appos) clinic/NN (r_pobj) in/IN (r_prep) shown/VBN (l_dobj) TDP/NNP
D016593_D016171 CID terfenadine/NN (r_appos) market/NN (r_pobj) from/IN (r_prep) withdrawal/NN (r_pobj) to/IN (r_prep) led/VBN (r_relcl) effect/NN (r_attr) is/VBZ (l_nsubj) TDP/NNP -PUNC- terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP -PUNC- terfenadine/NN (r_appos) clinic/NN (r_pobj) in/IN (r_prep) shown/VBN (l_dobj) TDP/NNP
C063968_D016171 NONE E4031/NNP (r_conj) cisapride/NN (r_conj) terodiline/NN (r_conj) terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP
C010637_D016171 CID terodiline/NN (r_conj) terfenadine/NN (r_appos) market/NN (r_pobj) from/IN (r_prep) withdrawal/NN (r_pobj) to/IN (r_prep) led/VBN (r_relcl) effect/NN (r_attr) is/VBZ (l_nsubj) TDP/NNP -PUNC- terodiline/NN (r_conj) terfenadine/NN (r_appos) investigated/VBN (l_nsubjpass) TDP/NNP -PUNC- terodiline/NN (r_conj) terfenadine/NN (r_appos) clinic/NN (r_pobj) in/IN (r_prep) shown/VBN (l_dobj) TDP/NNP
9523805
D008012_D009422 CID lidocaine/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) incidence/NN (r_appos) symptoms/NNS -PUNC- lidocaine/NN (r_amod) anesthesia/NN (r_dobj) follow/VBP (l_nsubj) symptoms/NNS -PUNC- lidocaine/NN (r_amod) anesthesia/NN (r_dobj) follow/VBP (l_nsubj) symptoms/NNS (l_appos) TNSs/NNS -PUNC- lidocaine/NN (l_conj) bupivacaine/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) action/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) TNSs/NNS -PUNC- lidocaine/NN (r_dobj) receiving/VBG (l_dobj) TNSs/NNS -PUNC- lidocaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_conj) had/VBD (l_dobj) TNSs/NNS -PUNC- lidocaine/NN (r_xcomp) preferable/JJ (r_acomp) be/VB (l_advcl) has/VBZ (l_dobj) duration/NN (l_conj) incidence/NN (l_prep) of/IN (l_pobj) TNSs/NNS
D002045_D009422 NONE bupivacaine/NN (r_conj) prilocaine/NN (r_pobj) with/IN (r_prep) incidence/NN (r_appos) symptoms/NNS -PUNC- bupivacaine/NN (r_pobj) with/IN (r_prep) infrequent/JJ (r_acomp) are/VBP (r_conj) follow/VBP (l_nsubj) symptoms/NNS -PUNC- bupivacaine/NN (r_pobj) with/IN (r_prep) infrequent/JJ (r_acomp) are/VBP (r_conj) follow/VBP (l_nsubj) symptoms/NNS (l_appos) TNSs/NNS -PUNC- bupivacaine/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) action/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) TNSs/NNS -PUNC- bupivacaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) none/NN (r_nsubj) had/VBD (r_conj) had/VBD (l_nsubj) patients/NNS (l_acl) receiving/VBG (l_dobj) TNSs/NNS -PUNC- bupivacaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) none/NN (r_nsubj) had/VBD (l_dobj) TNSs/NNS
D011318_D009422 CID prilocaine/NN (r_pobj) with/IN (r_prep) incidence/NN (r_appos) symptoms/NNS -PUNC- prilocaine/JJ (l_prep) with/IN (l_pobj) lidocaine/NN (l_conj) bupivacaine/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) duration/NN (l_prep) of/IN (l_pobj) action/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) TNSs/NNS -PUNC- prilocaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_nsubj) patients/NNS (l_acl) receiving/VBG (l_dobj) TNSs/NNS -PUNC- prilocaine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_conj) had/VBD (l_dobj) TNSs/NNS -PUNC- Prilocaine/NNP (r_nsubj) be/VB (l_advcl) has/VBZ (l_dobj) duration/NN (l_conj) incidence/NN (l_prep) of/IN (l_pobj) TNSs/NNS
7453952
D008094_D011141 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) polydipsia/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_compound) concentration/NN (r_pobj) on/IN (r_conj) on/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- lithium/NN (r_compound) levels/NNS (r_pobj) in/IN (r_prep) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN
D008094_D059606 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) polydipsia/NN -PUNC- lithium/NN (r_compound) concentration/NN (r_pobj) on/IN (r_conj) on/IN (l_pobj) polydipsia/NN -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN -PUNC- lithium/NN (r_compound) levels/NNS (r_pobj) in/IN (r_prep) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN
D008094_D003919 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- lithium/NN (r_compound) concentration/NN (r_pobj) between/IN (r_prep) ratio/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) accompanied/VBN (l_nsubjpass) attenuation/NN (l_prep) of/IN (l_pobj) syndrome/NN
D011188_D003919 NONE potassium/NN (r_compound) level/NN (r_pobj) in/IN (r_prep) elevation/NN (r_conj) concentration/NN (r_pobj) between/IN (r_prep) ratio/NN (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) accompanied/VBN (l_nsubjpass) attenuation/NN (l_prep) of/IN (l_pobj) syndrome/NN
D018021_D059606 NONE LiCl/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_conj) investigated/VBN (l_nsubjpass) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN
D000584_D003919 NONE amiloride/NN (r_pobj) by/IN (r_prep) syndrome/NN -PUNC- amiloride/NN (r_pobj) by/IN (r_prep) syndrome/NN
D000584_D059606 NONE amiloride/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN -PUNC- amiloride/NN (r_compound) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN -PUNC- amiloride/JJ (r_compound) supplementation/NN (r_nsubj) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN
D018021_D011141 NONE LiCl/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_conj) investigated/VBN (l_nsubjpass) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN
D000584_D011141 NONE amiloride/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- amiloride/NN (r_compound) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN -PUNC- amiloride/JJ (r_compound) supplementation/NN (r_nsubj) result/VB (r_conj) relieve/VB (l_nsubj) administration/NN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) polydipsia/NN (l_conj) polyuria/NN
16710500
D004977_D014786 CID Ethambutol/NNP (r_nsubjpass) used/VBN (l_conj) associated/VBN (l_prep) with/IN (l_pobj) loss/NN -PUNC- Ethambutol/NNP (r_compound) usage/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) loss/NN
D004977_D014376 NONE Ethambutol/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tuberculosis/NN
D004977_D009901 CID Ethambutol/NN (r_npadvmod) associated/VBN (r_amod) neuropathy/NN -PUNC- ethambutol/NN (r_npadvmod) associated/VBN (r_amod) neuropathy/NNS
8421099
D015282_D002764 NONE octreotide/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) formation/NN (l_prep) of/IN (l_pobj) sludge/NN (l_conj) gallstones/NNS (l_conj) cholecystitis/NN
D015282_D000172 NONE octreotide/NN (r_appos) analog/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) function/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) acromegalic/JJ -PUNC- octreotide/NN (r_appos) analog/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) acromegaly/NNS -PUNC- octreotide/NN (r_compound) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) acromegalic/JJ -PUNC- octreotide/NN (r_compound) therapy/NN (l_prep) of/IN (l_pobj) patients/NNS (l_compound) acromegalic/JJ
D015282_D042882 CID octreotide/NN (r_appos) analog/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) function/NN (l_conj) formation/NN (l_compound) gallstone/NN -PUNC- octreotide/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) During/IN (r_prep) developed/VBD (l_conj) had/VBD (l_dobj) gallstones/NNS -PUNC- octreotide/NN (r_pobj) of/IN (r_prep) withdrawal/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) gallstones/NNS -PUNC- octreotide/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) formation/NN (l_prep) of/IN (l_pobj) sludge/NN (l_conj) gallstones/NNS
D015282_D041881 CID octreotide/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) During/IN (r_prep) developed/VBD (l_conj) had/VBD (l_conj) developed/VBD (l_dobj) cholecystitis/NN
2887062
D001971_D015175 NONE bromocriptine/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) prolactinomas/NNS -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) clarify/VB (r_advcl) applied/VBN (l_prep) to/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) h/NN (r_conj) applied/VBN (l_advcl) clarify/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- bromocriptine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) after/IN (r_prep) h/NN (r_conj) applied/VBN (l_prep) to/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN
D004967_D015175 CID estrogen/NN (r_npadvmod) induced/VBN (r_amod) prolactinomas/NNS -PUNC- estrogen/NN (r_npadvmod) induced/VBN (r_amod) cells/NNS (r_pobj) to/IN (r_prep) applied/VBN (l_advcl) clarify/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) cells/NNS (l_compound) prolactinoma/NN -PUNC- estrogen/NN (r_npadvmod) induced/VBN (r_amod) cells/NNS (l_compound) prolactinoma/NN
D001971_D000236 NONE bromocriptine/JJ (r_amod) treatment/NN (l_prep) of/IN (l_pobj) cells/NNS (l_compound) adenoma/NN
3101906
D007654_D056486 CID ketoconazole/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) deaths/NNS (r_pobj) of/IN (r_prep) two/CD (r_pobj) In/IN (r_prep) continued/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) jaundice/NN (l_conj) symptoms/NNS (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ketoconazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) advised/VBN (l_nsubjpass) monitoring/NN (l_prep) for/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- ketoconazole/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) advised/VBN (l_advcl) prevent/VB (l_dobj) injury/NN
D007654_D007565 CID ketoconazole/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) deaths/NNS (r_pobj) of/IN (r_prep) two/CD (r_pobj) In/IN (r_prep) continued/VBN (l_prep) after/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) jaundice/NN
D007654_D003643 NONE ketoconazole/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) deaths/NNS
6699841
D009288_D001172 NONE naproxen/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) institution/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) man/NN (l_prep) with/IN (l_pobj) arthritis/NN
D013467_D007681 NONE sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN -PUNC- sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN (l_appos) RPN/NNP -PUNC- sulindac/NN (r_pobj) of/IN (r_prep) advantages/NNS (r_dobj) discuss/VB (r_conj) linking/VBG (l_dobj) RPN/NNP
D005279_D001172 NONE calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (l_prep) with/IN (l_pobj) arthritis/NN
D013467_D001172 NONE sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (l_prep) with/IN (l_pobj) arthritis/NN
D006046_D007681 NONE gold/NN (r_compound) salts/NNS (r_conj) salicylates/NNS (r_conj) calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN -PUNC- gold/NN (r_compound) salts/NNS (r_conj) salicylates/NNS (r_conj) calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN (l_appos) RPN/NNP
D013467_D007674 NONE sulindac/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) experienced/VBN (l_dobj) toxicity/NN
D005279_D007681 NONE calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN -PUNC- calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN (l_appos) RPN/NNP
D012459_D001172 NONE salicylates/NNS (r_conj) calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (l_prep) with/IN (l_pobj) arthritis/NN
D009288_D007681 CID naproxen/NN (r_pobj) due/IN (r_prep) necrosis/NN -PUNC- naproxen/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) institution/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) necrosis/NN -PUNC- naproxen/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) institution/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) necrosis/NN (l_appos) RPN/NNP
D012459_D007681 NONE salicylates/NNS (r_conj) calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN -PUNC- salicylates/NNS (r_conj) calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) necrosis/NN (l_appos) RPN/NNP
D006046_D001172 NONE gold/NN (r_compound) salts/NNS (r_conj) salicylates/NNS (r_conj) calcium/NN (r_conj) sulindac/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (l_prep) with/IN (l_pobj) arthritis/NN
6209318
D008801_D014202 CID mexiletine/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) frequent/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_appos) tremor/JJ
D008801_D009203 NONE mexiletine/NN (r_pobj) of/IN (r_prep) form/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- Perlongets/NNP (r_pobj) of/IN (r_prep) form/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) evaluated/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
D008801_D012817 CID mexiletine/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) frequent/JJ (r_acomp) were/VBD (l_nsubj) effects/NNS (l_appos) tremor/JJ (l_conj) problems/NNS
D008801_D003643 NONE mexiletine/NN (r_amod) group/NN (r_pobj) in/IN (r_prep) deaths/NNS
D008801_D001145 NONE mexiletine/NN (r_nmod) trial/NN (l_appos) Report/NNP (l_prep) on/IN (l_pobj) arrhythmia/NN
11379838
D008094_D001714 NONE lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- lithium/NN (r_appos) stabilizers/NNS (r_pobj) of/IN (r_prep) type/NN (r_conj) use/NN (r_conj) inhibitors/NNS (r_appos) episodes/NNS (l_amod) manic/JJ
D017367_D001714 CID inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- inhibitors/NNS (r_appos) episodes/NNS (l_amod) manic/JJ -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- SSRIs/NNPS (r_appos) inhibitors/NNS (r_appos) episodes/NNS (l_amod) manic/JJ -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (r_parataxis) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Switches/NNS (l_prep) to/IN (l_pobj) hypomania/NN -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (r_parataxis) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Switches/NNS (l_prep) to/IN (l_pobj) hypomania/NN (l_conj) mania/NN -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (l_dobj) episodes/NNS (l_amod) manic/JJ -PUNC- SSRIs/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) subgroup/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) experienced/JJ (r_parataxis) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_npadvmod) episodes/NNS (l_amod) hypomanic/JJ
D000928_D001714 CID Antidepressant/NNP (r_npadvmod) induced/VBN (r_amod) mania/NN -PUNC- Antidepressant/NNP (r_npadvmod) induced/VBN (r_amod) mania/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- antidepressants/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) mania/NN -PUNC- antidepressants/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) mania/NN (r_pobj) to/IN (r_prep) switching/VBG (r_pcomp) of/IN (r_prep) risks/NNS (r_pobj) about/IN (r_prep) Concerns/NNS (r_nsubj) continue/VBP (l_xcomp) interfere/VB (l_prep) with/IN (l_pobj) establishment/NN (l_prep) of/IN (l_pobj) paradigm/NN (l_prep) for/IN (l_pobj) depression/NN -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- antidepressant/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) type/NN (r_appos) episodes/NNS (l_amod) manic/JJ -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (r_pobj) with/IN (r_prep) compared/VBN (l_nsubjpass) Patients/NNS (l_relcl) experienced/VBD (l_dobj) switch/NN (l_amod) manic/JJ (l_conj) hypomanic/JJ -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (r_pobj) of/IN (r_prep) number/NN (r_appos) those/DT (l_relcl) did/VBD (l_prep) on/IN (l_pobj) variables/NNS (l_prep) including/VBG (l_pobj) age/NN (l_conj) sex/NN (l_conj) diagnosis/NN (l_appos) IV/NNP (l_appos) I/PRP (l_prep) vs./IN (l_pobj) II/NNP -PUNC- antidepressant/NN (r_amod) drugs/NNS (r_pobj) vs./IN (r_prep) therapy/NN (r_dobj) used/VBN (r_acl) episodes/NNS (l_amod) manic/JJ
4027862
D003891_D003693 CID Desipramine/NN (r_npadvmod) induced/VBN (r_amod) delirium/NN -PUNC- Desipramine/NNP (r_nsubj) developed/VBD (l_dobj) delirium/NN
8607407
D002110_D006973 CID caffeine/NN (r_pobj) with/IN (r_prep) elevations/NNS (l_prep) in/IN (l_pobj) men/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) actions/NNS (r_nsubjpass) enhanced/VBN (l_prep) in/IN (l_pobj) persons/NNS (l_amod) hypertensive/JJ -PUNC- caffeine/NN (r_compound) ingestion/NN (r_pobj) after/IN (r_prep) achieved/VBD (l_dobj) levels/NNS (l_amod) hypertensive/JJ -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) responses/NNS (r_nsubj) were/VBD (l_prep) in/IN (l_pobj) men/NNS (l_amod) hypertensive/JJ -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) responses/NNS (r_nsubj) were/VBD (l_advcl) replicated/VBN (l_conj) representative/NN (l_prep) of/IN (l_pobj) hypertensives/NNS
18201582
C084178_D006973 NONE telmisartan/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- telmisartan/NNP (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) evaluate/VB (l_conj) amlodipine/NN (l_prep) compared/VBN (l_prep) with/IN (l_pobj) amlodipine/NN (l_appos) monotherapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D017311_D006973 NONE amlodipine/NN (r_conj) telmisartan/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- amlodipine/NN (r_pobj) versus/IN (r_prep) telmisartan/NN (r_pobj) of/IN (r_prep) combination/NN (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- amlodipine/NN (l_prep) compared/VBN (l_prep) with/IN (l_pobj) amlodipine/NN (l_appos) monotherapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- amlodipine/NN (l_appos) monotherapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
9165568
D018967_D009459 CID risperidone/NN (r_pobj) with/IN (r_prep) syndrome/NN -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) monotherapy/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) syndrome/NN -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) observed/VBN (r_ccomp) appears/VBZ (l_conj) ensure/VB (l_dobj) protection/NN (l_prep) from/IN (l_pobj) syndrome/NN
D018967_D001480 NONE risperidone/NN (r_pobj) with/IN (r_prep) frequency/NN (l_prep) of/IN (l_pobj) symptoms/NNS
D004298_D009459 NONE dopamine/NN (r_compound) blockade/NN (r_pobj) of/IN (r_prep) result/NN (r_attr) be/VB (r_xcomp) thought/VBN (l_nsubjpass) syndrome/NN
1085609
D007538_D012640 CID isoniazid/NN (r_amod) therapy/NN (r_pobj) due/IN (r_amod) convulsions/NNS -PUNC- isoniazid/NN (r_pobj) on/IN (r_prep) infant/NN (r_nsubjpass) admitted/VBN (l_prep) after/IN (l_pobj) days/NNS (l_prep) of/IN (l_pobj) fits/NNS -PUNC- isoniazid/NN (r_relcl) aetiology/NN (r_dobj) suggesting/VBG (r_advcl) ceased/VBD (l_nsubj) fits/NNS
D011736_D012640 NONE pyridoxine/NN (r_nmod) convulsions/NNS -PUNC- pyridoxine/NN (r_dobj) administering/VBG (r_pcomp) of/IN (r_prep) hours/NNS (r_pobj) within/IN (r_prep) ceased/VBD (l_nsubj) fits/NNS -PUNC- pyridoxine/JJ (r_compound) deficiency/NN (r_pobj) of/IN (r_prep) aetiology/NN (r_dobj) suggesting/VBG (r_advcl) ceased/VBD (l_nsubj) fits/NNS
D007538_D014376 NONE isoniazid/NN (r_pobj) on/IN (r_prep) infant/NN (l_prep) because/IN (l_pobj) tuberculosis/NN
1130930
D002512_D009846 NONE sodium/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D002512_D007674 NONE cephalothin/NN (r_compound) gentamicin/NN (r_compound) regimen/NN (r_pobj) of/IN (r_prep) Nephrotoxicity/NN
D005839_D007674 NONE gentamicin/NN (r_compound) regimen/NN (r_pobj) of/IN (r_prep) Nephrotoxicity/NN
D005839_D009846 NONE sulfate/NN (r_compound) therapy/NN (r_dobj) gentamicin/NN (r_conj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D002512_D007683 CID sodium/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN
D005839_D051437 NONE sulfate/NN (r_compound) therapy/NN (r_dobj) gentamicin/NN (r_conj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D002512_D051437 NONE sodium/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) failure/NN
D005839_D007683 CID sulfate/NN (r_compound) therapy/NN (r_dobj) gentamicin/NN (r_conj) receiving/VBG (r_advcl) developed/VBD (l_dobj) necrosis/NN
18239197
D014282_D003221 NONE trihexyphenidyl/NN (l_prep) on/IN (l_pobj) measures/NNS (l_acl) reflecting/VBG (l_dobj) sedation/NN (l_conj) confusion/NN -PUNC- trihexyphenidyl/NN (r_npadvmod) induced/VBN (r_amod) effects/NNS (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) investigate/VB (r_conj) examine/VB (l_dobj) relationship/NN (l_conj) effects/NNS (l_prep) of/IN (l_pobj) trihexyphenidyl/NN (l_prep) on/IN (l_pobj) measures/NNS (l_acl) reflecting/VBG (l_dobj) sedation/NN (l_conj) confusion/NN
D014282_D003072 CID trihexyphenidyl/JJ (r_pcomp) after/IN (r_prep) associated/VBN (r_acl) slowing/NN -PUNC- trihexyphenidyl/JJ (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) ratings/NNS (l_prep) of/IN (l_pobj) slowness/NN -PUNC- trihexyphenidyl/JJ (r_pobj) between/IN (r_prep) scores/NNS (l_prep) on/IN (l_pobj) ratings/NNS (l_prep) of/IN (l_pobj) slowness/NN -PUNC- trihexyphenidyl/JJ (r_amod) challenge/NN (r_pobj) after/IN (r_prep) slowing/NN
15974569
D005557_D006930 NONE formalin/NN (r_npadvmod) induced/VBN (r_amod) licking/NN (r_pobj) of/IN (r_prep) reversal/NN (l_conj) hyperalgesia/NN -PUNC- formalin/NN (r_npadvmod) induced/VBN (r_amod) licking/NN (r_pobj) of/IN (r_prep) reversal/NN (l_conj) hyperalgesia/NN (l_conj) hyperalgesia/NN
D002211_D006930 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_conj) hyperalgesia/NN -PUNC- capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN
D005557_D010146 NONE formalin/NN (r_npadvmod) induced/VBN (r_amod) licking/NN (r_pobj) of/IN (r_prep) reversal/NN (r_appos) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D002351_D010146 NONE carrageenan/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_conj) reversal/NN (r_appos) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D007608_D010146 NONE kainate/NN (r_compound) antagonists/NNS (r_compound) actives/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D002211_D010146 NONE capsaicin/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (r_conj) hyperalgesia/NN (r_conj) reversal/NN (r_appos) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D002351_D006930 CID carrageenan/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN -PUNC- carrageenan/NN (r_npadvmod) induced/VBN (r_amod) hyperalgesia/NN (l_conj) hyperalgesia/NN
18589141
D006493_D001791 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) test/NN (l_compound) aggregation/NN
D006493_D013921 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) HIT/NNP -PUNC- heparin/NN (r_pobj) to/IN (r_prep) reaction/NN (r_attr) is/VBZ (l_nsubj) thrombocytopenia/NN -PUNC- heparin/NN (r_pobj) to/IN (r_prep) reaction/NN (r_attr) is/VBZ (l_nsubj) thrombocytopenia/NN (l_appos) HIT/NNP -PUNC- 4/heparin/NN (r_nummod) reactive/JJ (r_amod) antibody/NN (r_nmod) positivity/NN (r_conj) frequencies/NNS (l_prep) of/IN (l_pobj) HIT/NN -PUNC- 4/heparin/NN (r_nummod) reactive/JJ (r_amod) antibody/NN (r_nmod) positivity/NN (l_nmod) antibody/NN (l_nmod) HIT/NNP -PUNC- UFH/NN (r_npadvmod) related/VBN (r_amod) HIT/NN
D006493_D013927 NONE sodium/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) thrombosis/NN -PUNC- UFH/NNP (r_appos) sodium/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) thrombosis/NN
D006495_D013927 NONE heparin/NN (r_conj) sodium/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) thrombosis/NN
15531665
D001205_D020521 NONE C/NN (r_compound) intake/NN (r_pobj) between/IN (r_prep) relation/NN (r_dobj) studied/VBD (l_dep) disease/NN (l_conj) stroke/NN
D005492_D002318 NONE folate/NN (r_nmod) E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (r_conj) type/NN (r_appos) factors/NNS (l_compound) risk/NN (l_compound) disease/NN -PUNC- folate/NN (r_nmod) E/NN (l_conj) carotene/NN (l_appos) risks/NNS (l_prep) of/IN (l_pobj) mortality/NN (l_compound) disease/NN
D001205_D002318 CID C/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_compound) disease/NN -PUNC- C/NN (r_compound) intake/NN (l_prep) from/IN (l_pobj) disease/NN -PUNC- C/NN (r_compound) intake/NN (l_prep) from/IN (l_pobj) disease/NN -PUNC- C/NN (r_compound) intake/NN (r_pobj) of/IN (r_prep) quintiles/NNS (r_pobj) across/IN (r_prep) 1.0/CD (r_attr) were/VBD (l_nsubj) adjustment/NN (l_prep) for/IN (l_pobj) factors/NNS (l_compound) risk/NN (l_compound) disease/NN -PUNC- C/NN (r_compound) intake/NN (r_pobj) of/IN (r_prep) quintiles/NNS (r_pobj) across/IN (r_prep) 1.0/CD (r_attr) were/VBD (l_nsubj) adjustment/NN (l_prep) for/IN (l_pobj) factors/NNS (l_appos) type/NN (l_conj) duration/NN (l_conj) intakes/NNS (l_prep) of/IN (l_pobj) E/NN (l_conj) carotene/NN (l_appos) risks/NNS (l_prep) of/IN (l_pobj) mortality/NN (l_compound) disease/NN -PUNC- C/NN (r_compound) intake/NN (r_nsubj) was/VBD (l_acomp) unrelated/JJ (l_prep) to/IN (l_pobj) mortality/NN (l_prep) from/IN (l_pobj) disease/NN -PUNC- C/NN (r_compound) intake/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) mortality/NN (l_compound) disease/NN
D019207_D002318 NONE carotene/NN (r_conj) E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (r_conj) type/NN (r_appos) factors/NNS (l_compound) risk/NN (l_compound) disease/NN -PUNC- carotene/NN (l_appos) risks/NNS (l_prep) of/IN (l_pobj) mortality/NN (l_compound) disease/NN
D001205_D003920 NONE C/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- C/NN (r_pobj) of/IN (r_prep) intake/NN (l_prep) in/IN (l_pobj) persons/NNS (l_amod) diabetic/JJ -PUNC- C/NN (r_compound) intake/NN (r_pobj) between/IN (r_prep) relation/NN (r_dobj) studied/VBD (l_dep) disease/NN (l_conj) stroke/NN (l_prep) in/IN (l_pobj) women/NNS (l_relcl) reported/VBD (l_xcomp) being/VBG (l_acomp) diabetic/JJ -PUNC- C/NN (r_compound) intake/NN (r_pobj) of/IN (r_prep) quintiles/NNS (r_pobj) across/IN (r_prep) 1.0/CD (r_attr) were/VBD (l_nsubj) adjustment/NN (l_prep) for/IN (l_pobj) factors/NNS (l_appos) type/NN (l_prep) of/IN (l_pobj) medication/NN (l_compound) diabetes/NN -PUNC- C/NN (r_compound) intake/NN (r_pobj) of/IN (r_prep) quintiles/NNS (r_pobj) across/IN (r_prep) 1.0/CD (r_attr) were/VBD (l_nsubj) adjustment/NN (l_prep) for/IN (l_pobj) factors/NNS (l_appos) type/NN (l_conj) duration/NN (l_prep) of/IN (l_pobj) diabetes/NNS -PUNC- C/NN (r_compound) intake/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) mortality/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) diabetes/NNS
D019207_D003920 NONE carotene/NN (r_conj) E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (r_conj) type/NN (l_prep) of/IN (l_pobj) medication/NN (l_compound) diabetes/NN -PUNC- carotene/NN (r_conj) E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (l_prep) of/IN (l_pobj) diabetes/NNS
D001205_D003324 NONE C/NN (r_compound) intake/NN (r_pobj) between/IN (r_prep) relation/NN (r_dobj) studied/VBD (l_dep) disease/NN
D005492_D003920 NONE folate/NN (r_nmod) E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (r_conj) type/NN (l_prep) of/IN (l_pobj) medication/NN (l_compound) diabetes/NN -PUNC- folate/NN (r_nmod) E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (l_prep) of/IN (l_pobj) diabetes/NNS
D001205_D050197 NONE C/NN (r_pobj) of/IN (r_prep) intake/NN (r_nsubj) promote/VB (l_dobj) atherosclerosis/NN
D014810_D003920 NONE E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (r_conj) type/NN (l_prep) of/IN (l_pobj) medication/NN (l_compound) diabetes/NN -PUNC- E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (l_prep) of/IN (l_pobj) diabetes/NNS
D014810_D002318 NONE E/NN (r_pobj) of/IN (r_prep) intakes/NNS (r_conj) duration/NN (r_conj) type/NN (r_appos) factors/NNS (l_compound) risk/NN (l_compound) disease/NN -PUNC- E/NN (l_conj) carotene/NN (l_appos) risks/NNS (l_prep) of/IN (l_pobj) mortality/NN (l_compound) disease/NN
2894433
D004837_D001919 CID adrenaline/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) produced/VBN (l_nsubjpass) bradycardia/NN -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) effect/NN (r_pobj) in/IN (r_prep) change/NN (r_dobj) causing/VBG (r_advcl) pretreatment/NN (r_nsubj) enhance/VB (l_dobj) bradycardia/NN -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN -PUNC- adrenaline/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN
D002712_D001919 NONE chloride/NN (r_compound) channels/NNS (r_dobj) blocks/NNS (r_appos) picrotoxin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) antagonized/VBN (l_nsubjpass) enhancement/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- chloride/NN (r_compound) complex/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) sites/NNS (r_pobj) to/IN (r_prep) binding/VBG (r_pcomp) by/IN (r_prep) blocks/NNS (r_appos) picrotoxin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) antagonized/VBN (l_nsubjpass) enhancement/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- chloride/NN (r_compound) complex/NN (r_pobj) through/IN (r_prep) acts/VBZ (l_advcl) facilitate/VB (l_dobj) bradycardia/NN
D003975_D001919 CID Diazepam/NNP (r_nsubj) facilitates/VBZ (l_dobj) bradycardia/NN -PUNC- diazepam/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) enhance/VB (l_dobj) bradycardia/NN -PUNC- diazepam/NN (r_compound) enhancement/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- diazepam/NN (r_nsubj) acts/VBZ (l_advcl) facilitate/VB (l_dobj) bradycardia/NN
D001569_D001919 NONE benzodiazepine/JJ (r_amod) complex/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) sites/NNS (r_pobj) to/IN (r_prep) binding/VBG (r_pcomp) by/IN (r_prep) blocks/NNS (r_appos) picrotoxin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) antagonized/VBN (l_nsubjpass) enhancement/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- benzodiazepine/JJ (r_amod) complex/NN (r_pobj) through/IN (r_prep) acts/VBZ (l_advcl) facilitate/VB (l_dobj) bradycardia/NN
D010852_D001919 NONE picrotoxin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) antagonized/VBN (l_nsubjpass) enhancement/NN (l_prep) of/IN (l_pobj) bradycardia/NN
D005680_D001919 NONE GABA/NNP (r_compound) chloride/NN (r_compound) complex/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) sites/NNS (r_pobj) to/IN (r_prep) binding/VBG (r_pcomp) by/IN (r_prep) blocks/NNS (r_appos) picrotoxin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) antagonized/VBN (l_nsubjpass) enhancement/NN (l_prep) of/IN (l_pobj) bradycardia/NN -PUNC- GABA/NNP (r_compound) chloride/NN (r_compound) complex/NN (r_pobj) through/IN (r_prep) acts/VBZ (l_advcl) facilitate/VB (l_dobj) bradycardia/NN
3629586
D015790_D006402 NONE cefonicid/NN (r_pobj) of/IN (r_prep) effects/NNS (l_appos) model/NN (l_prep) of/IN (l_pobj) hematotoxicity/NN -PUNC- cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_attr) compromising/NN (l_prep) of/IN (l_pobj) cytopenias/NNS -PUNC- cefonicid/NN (r_amod) dogs/NNS (r_nsubj) showed/VBD (l_ccomp) reproduced/VBN (l_nsubjpass) syndrome/NN -PUNC- cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN -PUNC- cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) dyscrasias/NNS
C021341_D009503 CID cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN (l_conj) neutropenia/NN
D015790_D064420 NONE cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_prep) In/IN (l_pobj) studies/NNS (l_compound) toxicity/NN
C021341_D000740 CID cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_nsubj) anemia/NN
D015790_D000740 CID cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN -PUNC- cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_nsubj) anemia/NN
C021341_D013921 CID cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_ccomp) thrombocytopenia/NN
D002511_D006402 NONE cephalosporin/JJ (r_amod) hematotoxicity/NN -PUNC- Cephalosporin/JJ (r_amod) antibiotics/NNS (r_nsubj) cause/VBP (l_dobj) variety/NN (l_prep) of/IN (l_pobj) disturbances/NNS -PUNC- cephalosporin/NN (r_pobj) with/IN (r_prep) rechallenge/VB (r_pobj) Upon/IN (r_prep) reproduced/VBN (l_nsubjpass) syndrome/NN -PUNC- cephalosporin/NN (r_advmod) induced/VBN (r_amod) dyscrasias/NNS (r_pobj) to/IN (r_prep) similar/JJ (r_amod) hematotoxicity/NN -PUNC- cephalosporin/NN (r_advmod) induced/VBN (r_amod) dyscrasias/NNS
C021341_D064420 NONE cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_prep) In/IN (l_pobj) studies/NNS (l_compound) toxicity/NN
C021341_D006402 NONE cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) effects/NNS (l_appos) model/NN (l_prep) of/IN (l_pobj) hematotoxicity/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_dobj) receiving/VBG (r_acl) dogs/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) occurred/VBD (r_conj) was/VBD (l_attr) compromising/NN (l_prep) of/IN (l_pobj) cytopenias/NNS -PUNC- cefazedone)-treated/VBN (r_amod) dogs/NNS (r_nsubj) showed/VBD (l_ccomp) reproduced/VBN (l_nsubjpass) syndrome/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN -PUNC- cefazedone/NN (r_conj) cefonicid/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induce/VB (l_dobj) hematotoxicity/NN (l_amod) similar/JJ (l_prep) to/IN (l_pobj) dyscrasias/NNS
D015790_D009503 CID cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) anemia/NN (l_conj) neutropenia/NN
D015790_D013921 CID cefonicid/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) caused/VBD (l_ccomp) thrombocytopenia/NN
20588063
D011692_D009401 CID aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- aminonucleoside/JJ (r_amod) nephrosis/NN
8638876
D011374_D012640 NONE progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (l_dobj) hemiparesis/NN (l_conj) seizure/NN
D011374_D009325 NONE progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (r_conj) developed/VBD (l_dobj) headache/NN (l_conj) nausea/NN
D011374_D002341 CID progesterone/NN (r_conj) estradiol/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increased/VBD (l_dobj) thrombogenicity/NN (l_relcl) provided/VBD (l_dobj) denominator/NN (l_prep) for/IN (l_pobj) thrombosis/NN (l_prep) of/IN (l_pobj) ICA/NNP (l_conj) sinus/NN
D004958_D002341 CID estradiol/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increased/VBD (l_dobj) thrombogenicity/NN (l_relcl) provided/VBD (l_dobj) denominator/NN (l_prep) for/IN (l_pobj) thrombosis/NN (l_prep) of/IN (l_pobj) ICA/NNP (l_conj) sinus/NN
D011374_D012851 CID progesterone/NN (r_conj) estradiol/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increased/VBD (l_dobj) thrombogenicity/NN (l_relcl) provided/VBD (l_dobj) denominator/NN (l_prep) for/IN (l_pobj) thrombosis/NN (l_prep) of/IN (l_pobj) ICA/NNP (l_conj) sinus/NN
D011374_D003920 NONE progesterone/NN (r_conj) estradiol/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) DM/NNP
D004958_D003920 NONE estradiol/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) DM/NNP
D004958_D010291 NONE estradiol/NN (r_conj) progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (l_dobj) hemiparesis/NN
D004958_D012851 CID estradiol/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increased/VBD (l_dobj) thrombogenicity/NN (l_relcl) provided/VBD (l_dobj) denominator/NN (l_prep) for/IN (l_pobj) thrombosis/NN (l_prep) of/IN (l_pobj) ICA/NNP (l_conj) sinus/NN
D004958_D009325 NONE estradiol/NN (r_conj) progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (r_conj) developed/VBD (l_dobj) headache/NN (l_conj) nausea/NN
D011374_D010291 NONE progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (l_dobj) hemiparesis/NN
D004958_D012640 NONE estradiol/NN (r_conj) progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (l_dobj) hemiparesis/NN (l_conj) seizure/NN
D004958_D014839 NONE estradiol/NN (r_conj) progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (r_conj) developed/VBD (l_dobj) headache/NN (l_conj) nausea/NN (l_conj) vomiting/NN
D011374_D006261 NONE progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (r_conj) developed/VBD (l_dobj) headache/NN
D004958_D006261 NONE estradiol/NN (r_conj) progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (r_conj) developed/VBD (l_dobj) headache/NN
D011374_D014839 NONE progesterone/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) left/VBD (r_conj) developed/VBD (l_dobj) headache/NN (l_conj) nausea/NN (l_conj) vomiting/NN
12536034
D005680_D004832 NONE acid/NN (r_npadvmod) transmitted/VBN (r_amod) circuitry/NN (r_compound) accounts/VBZ (l_prep) for/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) neurophysiology/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D002220_D004832 CID carbamazepine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) present/VBP (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
D020888_D004832 CID vigabatrin/NN (r_conj) carbamazepine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) present/VBP (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
2709684
D005839_D058186 CID gentamicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN -PUNC- gentamicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN (l_appos) ARF/NNP -PUNC- gentamicin/NN (r_compound) ARF/NNP
D010695_D006029 NONE Phlorizin/NNP (r_npadvmod) induced/VBN (r_amod) glycosuria/NN -PUNC- P/NN (r_nmod) animals/NNS (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) degree/NN (r_pobj) in/IN (r_prep) similar/JJ (r_amod) glycosuria/NN -PUNC- P/NN (r_nsubj) induced/VBD (l_dobj) glycosuria/NN
D005839_D003920 NONE gentamicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN (r_pobj) to/IN (r_prep) resistance/NN (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_ccomp) suggested/VBN (l_advcl) have/VBP (l_nsubj) rats/NNS (l_prep) with/IN (l_pobj) mellitus/NN -PUNC- gentamicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN (r_pobj) to/IN (r_prep) resistance/NN (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_ccomp) suggested/VBN (l_advcl) have/VBP (l_nsubj) rats/NNS (l_prep) with/IN (l_pobj) mellitus/NN (l_appos) DM/NNP -PUNC- gentamicin/NN (r_amod) nephrotoxicity/NN (r_pobj) from/IN (r_prep) protection/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ -PUNC- gentamicin/NN (r_conj) P/NN (r_appos) II/NNP (l_conj) III/NNP (l_acl) gentamicin/NN (l_conj) IV/NNP (l_appos) DM/NNP -PUNC- gentamicin/NN (l_conj) IV/NNP (l_appos) DM/NNP -PUNC- gentamicin/NN (r_conj) DM/NNP
D005839_D007674 NONE gentamicin/NN (r_compound) nephrotoxicity/NN -PUNC- gentamicin/NN (r_amod) nephrotoxicity/NN -PUNC- gentamicin/NN (r_pobj) of/IN (r_prep) doses/NNS (l_amod) Nephrotoxic/JJ
D013311_D006029 NONE streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) mellitus/NN (r_pobj) with/IN (r_prep) rats/NNS (r_nsubj) have/VBP (l_dobj) diuresis/NN (l_appos) glycosuria/NN
D010695_D003920 NONE phlorizin/NN (r_pobj) with/IN (r_prep) reabsorption/NN (r_pobj) of/IN (r_prep) blockage/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) rats/NNS (l_amod) diabetic/JJ -PUNC- P/NN (r_appos) phlorizin/NN (r_pobj) with/IN (r_prep) reabsorption/NN (r_pobj) of/IN (r_prep) blockage/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) rats/NNS (l_amod) diabetic/JJ -PUNC- P/NN (r_nmod) animals/NNS (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) degree/NN (r_pobj) in/IN (r_prep) similar/JJ (r_amod) glycosuria/NN (r_pobj) with/IN (r_prep) rats/NNS (l_compound) DM/NNP -PUNC- P/NN (r_nsubj) received/VBD (l_conj) II/NNP (l_conj) III/NNP (l_acl) gentamicin/NN (l_conj) IV/NNP (l_appos) DM/NNP -PUNC- P/NN (r_dobj) received/VBD (l_conj) II/NNP (l_conj) III/NNP (l_acl) gentamicin/NN (l_conj) IV/NNP (l_appos) DM/NNP -PUNC- P/NN (r_appos) II/NNP (l_conj) III/NNP (l_acl) gentamicin/NN (l_conj) IV/NNP (l_appos) DM/NNP
D005947_D007674 NONE glucose/NN (r_compound) reabsorption/NN (r_pobj) of/IN (r_prep) blockage/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_nsubjpass) protection/NN (l_prep) from/IN (l_pobj) nephrotoxicity/NN
D005947_D003920 NONE glucose/NN (r_compound) reabsorption/NN (r_pobj) of/IN (r_prep) blockage/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) rats/NNS (l_amod) diabetic/JJ
D013311_D003920 CID streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) mellitus/NN -PUNC- streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) mellitus/NN (l_appos) DM/NNP
D010695_D007674 NONE Phlorizin/NNP (r_npadvmod) induced/VBN (r_amod) glycosuria/NN (r_nsubj) prevent/VB (l_dobj) nephrotoxicity/NN -PUNC- phlorizin/NN (r_pobj) with/IN (r_prep) reabsorption/NN (r_pobj) of/IN (r_prep) blockage/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_nsubjpass) protection/NN (l_prep) from/IN (l_pobj) nephrotoxicity/NN -PUNC- P/NN (r_appos) phlorizin/NN (r_pobj) with/IN (r_prep) reabsorption/NN (r_pobj) of/IN (r_prep) blockage/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_nsubjpass) protection/NN (l_prep) from/IN (l_pobj) nephrotoxicity/NN -PUNC- P/NN (r_nsubj) induced/VBD (l_conj) CCr/IN (l_nsubj) evidence/NN (l_prep) of/IN (l_pobj) dysfunction/NN
D005839_D006029 NONE gentamicin/NN (r_compound) nephrotoxicity/NN (r_dobj) prevent/VB (l_nsubj) glycosuria/NN -PUNC- gentamicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN (r_pobj) to/IN (r_prep) resistance/NN (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_ccomp) suggested/VBN (l_advcl) have/VBP (l_dobj) diuresis/NN (l_appos) glycosuria/NN
D013311_D058186 NONE streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) mellitus/NN (r_pobj) with/IN (r_prep) rats/NNS (r_nsubj) have/VBP (r_advcl) suggested/VBN (l_ccomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) resistance/NN (l_prep) to/IN (l_pobj) failure/NN -PUNC- streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) diabetes/NN (r_compound) mellitus/NN (r_pobj) with/IN (r_prep) rats/NNS (r_nsubj) have/VBP (r_advcl) suggested/VBN (l_ccomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) resistance/NN (l_prep) to/IN (l_pobj) failure/NN (l_appos) ARF/NNP
D010695_D009956 NONE P/NN (r_nsubj) induced/VBD (l_conj) CCr/IN (l_dobj) score/NN (l_compound) necrosis/NN -PUNC- P/NN (r_nsubj) prevent/VB (l_conj) day/NN (l_conj) score/NN (l_compound) necrosis/NN -PUNC- P/NN (r_appos) ARF/NNP (r_dobj) prevent/VB (l_conj) day/NN (l_conj) score/NN (l_compound) necrosis/NN
D005839_D009956 NONE gentamicin/NN (r_compound) ARF/NNP (r_dobj) prevent/VB (l_conj) day/NN (l_conj) score/NN (l_compound) necrosis/NN
D010695_D058186 NONE P/NN (r_nsubj) prevent/VB (l_dobj) ARF/NNP -PUNC- P/NN (r_appos) ARF/NNP
11271907
D003520_D006470 CID cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) secondary/JJ (l_amod) myocarditis/NN -PUNC- cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) myocarditis/NN
D003520_D009205 CID cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) secondary/JJ (l_amod) myocarditis/NN -PUNC- cyclophosphamide/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) myocarditis/NN
15811908
C012052_D006261 CID amisulpride/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) after/IN (r_prep) vomiting/NN (r_conj) developed/VBD (l_dobj) hypertension/NN (l_prep) with/IN (l_pobj) headache/NN
C037689_D010673 NONE benzamide/JJ (r_amod) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) symptoms/NNS (l_prep) of/IN (l_pobj) pheochromocytoma/NN
D063325_D006973 CID tiapride/NN (r_compound) therapy/NN (r_conj) amisulpride/NN (r_conj) crisis/NN (l_amod) hypertensive/JJ -PUNC- tiapride/NN (r_npadvmod) induced/VBN (r_amod) crisis/NN (l_amod) hypertensive/JJ
D063325_D010673 NONE tiapride/NN (r_conj) amisulpride/NN (r_pobj) by/IN (r_prep) unmasked/VBD (l_nsubj) Pheochromocytoma/NNP -PUNC- tiapride/NN (r_conj) amisulpride/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) unmasking/NN (l_prep) of/IN (l_pobj) pheochromocytoma/NN -PUNC- tiapride/NN (r_npadvmod) induced/VBN (r_amod) crisis/NN (r_conj) amisulpride-/JJ (r_pobj) of/IN (r_prep) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) pheochromocytoma/NN
C012052_D014839 CID amisulpride/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) after/IN (r_prep) vomiting/NN
C012052_D006973 CID amisulpride/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) after/IN (r_prep) vomiting/NN (r_conj) developed/VBD (l_dobj) hypertension/NN -PUNC- amisulpride/NN (r_conj) crisis/NN (l_amod) hypertensive/JJ -PUNC- amisulpride-/JJ (l_conj) crisis/NN (l_amod) hypertensive/JJ
C012052_D010673 NONE amisulpride/NN (r_pobj) by/IN (r_prep) unmasked/VBD (l_nsubj) Pheochromocytoma/NNP -PUNC- amisulpride/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) unmasking/NN (l_prep) of/IN (l_pobj) pheochromocytoma/NN -PUNC- amisulpride-/JJ (r_pobj) of/IN (r_prep) case/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) pheochromocytoma/NN
2790457
D002220_D012640 NONE carbamazepine/NN (r_nsubj) inhibits/VBZ (l_dobj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- carbamazepine/NN (l_appos) treatment/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- CBZ/NNP (r_nmod) treatment/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- CBZ/NNP (r_compound) administration/NN (r_pobj) of/IN (r_prep) methods/NNS (r_pobj) under/IN (r_conj) in/IN (r_prep) evaluated/VBN (l_nsubjpass) effects/NNS (l_prep) of/IN (l_pobj) carbamazepine/NN (l_appos) treatment/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- CBZ/NN (r_nsubj) inhibited/VBD (l_dobj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- CBZ/NN (r_nsubj) inhibited/VBD (l_conj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- CBZ/NN (r_nsubj) decreased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) mortality/NN (l_amod) related/VBN (l_npadvmod) seizure/NN -PUNC- CBZ/NN (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- CBZ/NNP (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) was/VBD (l_prep) without/IN (l_pobj) effect/NN (l_prep) on/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- CBZ/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) depending/VBG (l_prep) upon/IN (l_pobj) stage/NN (l_prep) of/IN (l_pobj) development/NN (l_compound) seizure/NN -PUNC- CBZ/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) suggest/VBP (l_ccomp) underlie/VBP (l_dobj) development/NN (l_prep) versus/IN (l_pobj) maintenance/NN (l_prep) of/IN (l_pobj) seizures/NNS
D003042_D012640 CID cocaine/NN (r_pobj) by/IN (r_agent) kindled/VBN (r_acl) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_conj) lidocaine-/NN (r_nmod) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_conj) lidocaine-/NN (r_nmod) seizures/NNS (r_pobj) of/IN (r_prep) development/NN (r_dobj) inhibited/VBD (l_conj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) injected/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) mortality/NN (l_amod) related/VBN (l_npadvmod) seizure/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) kindled/VBN (r_amod) seizures/NNS
D008012_D012640 CID lidocaine/NN (r_conj) cocaine/NN (r_pobj) by/IN (r_agent) kindled/VBN (r_acl) seizures/NNS -PUNC- lidocaine-/NN (r_nmod) seizures/NNS -PUNC- lidocaine-/NN (r_nmod) seizures/NNS (r_pobj) of/IN (r_prep) development/NN (r_dobj) inhibited/VBD (l_conj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- lidocaine/NN (r_npadvmod) kindled/VBN (r_amod) seizures/NNS -PUNC- lidocaine-/NN (r_nmod) seizures/NNS
8649546
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN
D011433_D004409 NONE propranolol/NN (r_pcomp) by/IN (r_prep) Improvement/NN (l_prep) of/IN (l_pobj) dyskinesia/NN -PUNC- propranolol/NN (r_dobj) received/VBN (l_nsubj) patients/NNS (l_acl) suffering/VBG (l_prep) with/IN (l_pobj) dyskinesia/NN
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_pobj) of/IN (r_prep) Improvement/NN (l_prep) by/IN (l_pcomp) propranolol/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_prep) in/IN (l_pobj) PD/NNP
D011433_D010300 NONE propranolol/NN (l_prep) in/IN (l_pobj) disease/NN -PUNC- propranolol/NN (r_dobj) received/VBN (l_nsubj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) disease/NN -PUNC- propranolol/NN (r_dobj) received/VBN (l_nsubj) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) disease/NN (l_appos) PD/NNP
12600698
D013307_D015837 CID streptomycin/NN (r_npadvmod) induced/VBN (r_amod) vestibulotoxicity/NN -PUNC- streptomycin/NNS (r_npadvmod) induced/VBN (r_amod) vestibulotoxicity/NN -PUNC- streptomycin/NN (r_npadvmod) induced/VBN (r_amod) vestibulotoxicity/NN
C005435_D015837 NONE edaravone/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) against/IN (l_pobj) vestibulotoxicity/NN -PUNC- edaravone/NN (r_pobj) by/IN (r_prep) alleviation/NN (l_prep) of/IN (l_pobj) vestibulotoxicity/NN -PUNC- edaravone/NN (r_nsubj) suppresses/VBZ (l_dobj) vestibulotoxicity/NN
C005435_D002544 NONE Edaravone/NNP (r_nsubj) has/VBZ (l_conj) used/VBN (l_xcomp) treat/VB (l_dobj) infarction/NN
1504402
D007741_D056486 CID dilevalol/NN (r_npadvmod) associated/VBN (r_amod) hepatitis/NN -PUNC- dilevalol/VB (l_conj) serum/VB (l_prep) in/IN (l_pobj) case/NN (l_prep) of/IN (l_pobj) injury/NN -PUNC- dilevalol/JJ (r_compound) antigens/NNS (r_dobj) containing/VBG (r_xcomp) serum/VB (l_prep) in/IN (l_pobj) case/NN (l_prep) of/IN (l_pobj) injury/NN -PUNC- dilevalol/NN (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- dilevalol/NN (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- dilevalol/JJ (r_compound) antigens/NNS (r_dobj) containing/VBG (r_acl) sera/NN (r_pobj) to/IN (r_prep) sensitization/NN (r_pobj) of/IN (r_prep) detection/NN (r_dobj) allowed/VBD (l_advcl) suggesting/VBG (l_dobj) involvement/NN (l_prep) of/IN (l_pobj) mechanism/NN (l_prep) in/IN (l_pobj) injury/NN -PUNC- dilevalol/NN (r_npadvmod) induced/VBN (r_amod) injury/NN
D007741_D004342 CID dilevalol/NN (r_npadvmod) associated/VBN (r_amod) hepatitis/NN (r_pobj) for/IN (r_prep) mechanism/NN (r_pobj) as/IN (r_prep) reaction/NN (l_nmod) Hypersensitivity/NN
15096016
D007980_D009127 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_dobj) improving/VBG (r_pcomp) in/IN (r_prep) be/VB (r_xcomp) seems/VBZ (l_ccomp) improves/VBZ (l_dobj) bradykinesia/JJ (l_conj) rigidity/NN
D007980_D018476 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_dobj) improving/VBG (r_pcomp) in/IN (r_prep) be/VB (r_xcomp) seems/VBZ (l_ccomp) improves/VBZ (l_dobj) bradykinesia/JJ
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
6634932
D010042_D017180 CID ouabain/RB (r_npadvmod) induced/VBN (r_amod) tachycardias/NNS
C002616_D017180 NONE UM-272/NNP (r_punct) dimethylpropranolol/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) tachycardias/NNS -PUNC- dimethylpropranolol/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) tachycardias/NNS -PUNC- UM-272/NNP (r_punct) converted/VBD (l_dobj) tachycardia/NN
6942642
D006852_C563897 NONE hydrochlorothiazide/NN (r_pobj) with/IN (r_prep) hypertension/NN -PUNC- HCTC/NNP (r_appos) hydrochlorothiazide/NN (r_pobj) with/IN (r_prep) hypertension/NN
D049971_D001145 NONE Thiazide/NNP (r_compound) diuretics/NNS (l_conj) hypokalemia/JJ (l_conj) arrhythmias/NNS
D011188_D007008 NONE potassium/NN (r_pobj) of/IN (r_prep) depletion/NN (r_conj) hypokalemia/NN
D049971_D007008 NONE Thiazide/NNP (r_compound) diuretics/NNS (l_conj) hypokalemia/JJ -PUNC- thiazide/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) consequence/NN (r_attr) is/VBZ (l_nsubj) Hypokalemia/NNP -PUNC- thiazide/JJ (r_csubj) cause/VBP (l_dobj) hypokalemia/NN
950631
D010396_D001172 NONE penicillamine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
D010396_D007674 CID penicillamine/NN (r_npadvmod) induced/VBN (r_amod) disease/NN
D010396_D011507 CID penicillamine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) months/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) proteinuria/NN
3970039
D001379_D008228 CID azathioprine/NN (r_conj) agents/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) lymphoma/NN
D001379_D009369 NONE azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (r_attr) been/VBN (l_conj) increased/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) most/JJS (l_prep) of/IN (l_pobj) cancers/NNS
D000477_D015470 CID agents/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) leukemia/NN -PUNC- agents/NNS (r_nsubjpass) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) leukemia/NN
D003520_D001172 NONE cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
D001379_D001172 NONE azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
D000477_D009369 NONE agents/NNS (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) reserved/VBN (r_conj) collected/VBN (l_nsubjpass) Data/NNS (l_prep) on/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) malignancy/NN
D003520_D001749 CID Cyclophosphamide/NNP (r_compound) therapy/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) bladder/NN
D000477_D008228 CID agents/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VBP (l_conj) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) lymphoma/NN -PUNC- agents/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) lymphoma/NN
D003520_D002277 CID Cyclophosphamide/NNP (r_compound) therapy/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) bladder/NN
D001379_D015470 NONE azathioprine/NN (r_conj) agents/NNS (r_nsubjpass) associated/VBN (r_conj) have/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) leukemia/NN
D000477_D001172 NONE agents/NNS (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) reserved/VBN (r_conj) collected/VBN (l_nsubjpass) Data/NNS (l_prep) on/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) malignancy/NN (l_prep) in/IN (l_pobj) arthritis/NN -PUNC- agents/NNS (r_appos) drugs/NNS (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) arthritis/NN
D003520_D009369 NONE cyclophosphamide/NN (r_conj) azathioprine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) studies/NNS (r_attr) been/VBN (l_conj) increased/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) most/JJS (l_prep) of/IN (l_pobj) cancers/NNS
16192988
D008694_D006948 NONE METH/NNP (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D008694_D001523 CID Methamphetamine/NN (r_nsubj) causes/VBZ (l_dobj) alterations/NNS (l_relcl) display/VBP (l_dobj) aggressiveness/NN -PUNC- methamphetamine/NN (r_pobj) in/IN (r_prep) common/JJ (r_acomp) are/VBP (r_conj) reported/VBN (l_nsubjpass) behaviors/NNS -PUNC- methamphetamine/NN (r_pobj) in/IN (r_prep) common/JJ (r_acomp) are/VBP (r_conj) reported/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) suffer/VBP (l_prep) from/IN (l_pobj) disorders/NNS -PUNC- METH/NN (r_nmod) abusers/NNS (r_appos) methamphetamine/NN (r_pobj) in/IN (r_prep) common/JJ (r_acomp) are/VBP (r_conj) reported/VBN (l_nsubjpass) behaviors/NNS -PUNC- METH/NN (r_nmod) abusers/NNS (r_appos) methamphetamine/NN (r_pobj) in/IN (r_prep) common/JJ (r_acomp) are/VBP (r_conj) reported/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) suffer/VBP (l_prep) from/IN (l_pobj) disorders/NNS -PUNC- METH/NNP (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) increased/VBD (l_dobj) aggressiveness/NN -PUNC- METH/NNP (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_acomp) was/VBD (l_nsubj) increase/NN (l_prep) in/IN (l_pobj) aggressiveness/NN
15278670
D004737_D012640 NONE enflurane/NN (r_conj) sevoflurane/NN (r_pobj) between/IN (r_prep) threshold/NN (l_amod) convulsive/JJ -PUNC- enflurane/NN (r_conj) sevoflurane/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) administered/VBN (l_conj) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS -PUNC- enflurane/NN (r_conj) %/NN (r_pobj) in/IN (r_conj) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS
D001030_D012640 NONE Apamin/NNP (r_nsubj) had/VBD (l_dobj) tendency/NN (l_acl) decrease/VB (l_dobj) threshold/NN (l_amod) convulsive/JJ
D008012_D012640 CID lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- lidocaine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- lidocaine/NN (r_compound) infusion/NN (r_pobj) with/IN (r_prep) was/VBD (l_nsubj) threshold/NN (l_amod) convulsive/JJ -PUNC- lidocaine/JJ (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) convulsive/JJ
D008012_D064420 NONE lidocaine/JJ (r_compound) toxicity/NN
C009250_D064420 NONE sevoflurane/NN (r_nsubj) reduces/VBZ (l_dobj) effect/NN (l_prep) of/IN (l_pobj) toxicity/NN
C009250_D012640 NONE sevoflurane/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) was/VBD (r_relcl) l(-1/NN (r_pobj) to/IN (r_prep) increasing/VBG (r_advcl) was/VBD (l_nsubj) threshold/NN (l_amod) convulsive/JJ -PUNC- sevoflurane/NN (r_pobj) between/IN (r_prep) threshold/NN (l_amod) convulsive/JJ -PUNC- sevoflurane/NN (r_pobj) of/IN (r_prep) concentrations/NNS (r_nsubjpass) administered/VBN (l_conj) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (r_pobj) in/IN (r_prep) decreased/VBD (l_nsubj) pressure/NN (l_prep) at/IN (l_pobj) convulsions/NNS -PUNC- sevoflurane/NN (r_nsubj) reduces/VBZ (l_dobj) effect/NN (l_amod) convulsive/JJ
D008012_D003866 NONE lidocaine/JJ (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reduces/VBZ (l_conj) carries/VBZ (l_prep) due/IN (l_pcomp) to/IN (l_pobj) depression/NN
C009250_D003866 NONE sevoflurane/NN (r_nsubj) reduces/VBZ (l_conj) carries/VBZ (l_prep) due/IN (l_pcomp) to/IN (l_pobj) depression/NN
2522601
D002220_D003873 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN (l_conj) eosinophilia/NN (l_conj) erythroderma/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) erythroderma/NN
D002220_D007955 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN
D002220_D007010 CID carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN (l_conj) eosinophilia/NN (l_conj) hyponatremia/NN
D002220_D004802 NONE carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN (l_conj) eosinophilia/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN (l_conj) eosinophilia/NN
D002220_D004342 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN
D002220_D051437 CID carbamazepine/NN (r_pobj) to/IN (r_prep) Hypersensitivity/NN (l_acl) presenting/VBG (l_prep) with/IN (l_pobj) reaction/NN (l_conj) failure/NN -PUNC- carbamazepine/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_nsubj) presented/VBN (r_relcl) patient/NN (l_conj) reaction/NN (l_conj) eosinophilia/NN (l_conj) hyponatremia/NN (l_conj) failure/NN
20466178
D016559_D003872 NONE tacrolimus/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dermatitis/NN -PUNC- tacrolimus/NN (r_compound) ointment/NN (r_dobj) using/VBG (r_advcl) developed/VBD (l_dobj) eruptions/NNS (l_compound) dermatitis/NN -PUNC- tacrolimus/NN (r_pobj) as/IN (r_prep) immunomodulators/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) regarded/VBN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) dermatitis/NN
D016559_D012393 NONE tacrolimus/NN (r_compound) ointment/NN (r_dobj) using/VBG (r_advcl) developed/VBD (l_dobj) eruptions/NNS (l_amod) like/JJ (l_npadvmod) rosacea/NN
D016559_D003875 NONE tacrolimus/NN (r_compound) ointment/NN (r_dobj) using/VBG (r_advcl) developed/VBD (l_dobj) eruptions/NNS
D016559_D005148 NONE tacrolimus/NN (r_compound) ointment/NN (r_dobj) using/VBG (l_prep) for/IN (l_pobj) dermatitis/NN
C117268_D003872 CID pimecrolimus/NN (r_conj) tacrolimus/NN (r_pobj) as/IN (r_prep) immunomodulators/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) regarded/VBN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) dermatitis/NN
7803371
D003915_D003072 CID dextromethorphan/NN (r_pobj) of/IN (r_prep) abuse/NN (r_pobj) from/IN (r_prep) deterioration/NN -PUNC- DM/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) deterioration/NN
28952
D002752_D007008 CID chlorthalidone/NN (r_compound) administration/NN (r_pobj) during/IN (r_prep) hypokalaemia/NN
D012964_D007008 NONE sodium/NN (r_compound) restriction/NN (r_pobj) of/IN (r_prep) influence/NN (r_appos) loss/NN (l_conj) hypokalaemia/NN
D011188_D007008 NONE potassium/NN (r_compound) loss/NN (l_conj) hypokalaemia/NN -PUNC- potassium/NN (r_compound) loss/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) hypokalaemia/NN -PUNC- potassium/NN (r_compound) loss/NN (r_dobj) investigate/VB (r_csubjpass) performed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN (l_relcl) shown/VBN (l_dobj) hypokalaemia/NN
D011188_D006973 NONE potassium/NN (r_compound) loss/NN (l_conj) hypokalaemia/NN (l_prep) during/IN (l_pobj) administration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- potassium/NN (r_compound) loss/NN (r_dobj) investigate/VB (r_csubjpass) performed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D002752_D006973 NONE chlorthalidone/NN (r_compound) administration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D012964_D006973 NONE sodium/NN (r_compound) restriction/NN (r_pobj) of/IN (r_prep) influence/NN (r_appos) loss/NN (l_conj) hypokalaemia/NN (l_prep) during/IN (l_pobj) administration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
9195768
D018170_D010292 CID sumatriptan/NN (r_pobj) of/IN (r_prep) use/NN (r_dobj) following/VBG (r_prep) sensations/NNS
3001299
D008094_D018500 NONE lithium/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) insipidus/NN
D008094_D007037 CID lithium/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) insipidus/NN (l_conj) hypothyroidism/NN -PUNC- lithium/NN (r_dobj) taking/VBG (r_advcl) developed/VBD (l_nsubj) Hypothyroidism/NN
6381653
D007980_D010302 NONE Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesia/NN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) Parkinsonism/NNP -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_pobj) of/IN (r_prep) Control/NN (l_prep) in/IN (l_pobj) course/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) Parkinsonism/NNP
D007980_D004409 CID Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesia/JJ -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesia/NN -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
D007980_D020821 NONE Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesia/NN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) Parkinsonism/NNP (l_relcl) was/VBD (l_attr) choreic/JJ (l_conj) ballistic/JJ (l_conj) dystonic/JJ
D007980_D013786 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_prep) by/IN (l_pobj) lesions/NNS
11694026
D000894_D000799 CID NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN (l_conj) angioedema/NN -PUNC- NSAIDs/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) angioedema/NNP -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) angioedema/NN
C012655_D014581 NONE nimesulide/NN (r_pobj) of/IN (r_prep) Tolerability/DT (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angioedema/NN (l_nmod) urticaria/NN -PUNC- nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) investigated/VBD (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN (l_nmod) urticaria/NN -PUNC- nimesulide/NN (r_pobj) with/IN (r_prep) procedure/NN (r_nsubjpass) applied/VBN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN (l_nmod) urticaria/NN -PUNC- nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) experienced/VBD (l_dobj) angioedema/NNP (l_nmod) urticaria/NN
D000082_D000799 CID paracetamol/NN (r_conj) nimesulide/NN (r_pobj) of/IN (r_prep) Tolerability/DT (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angioedema/NN -PUNC- paracetamol/NN (r_conj) nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) investigated/VBD (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN -PUNC- paracetamol/NNP (r_conj) nimesulide/NN (r_pobj) with/IN (r_prep) procedure/NN (r_nsubjpass) applied/VBN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN -PUNC- paracetamol/NN (r_conj) nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) experienced/VBD (l_dobj) angioedema/NNP
D000894_D014581 NONE NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) subjects/NNS (r_pobj) of/IN (r_prep) %/NN (r_conj) history/NN (l_prep) of/IN (l_pobj) urticaria/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) urticaria/NN (r_nmod) angioedema/NN (r_pobj) of/IN (r_prep) history/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) urticaria/NN -PUNC- NSAIDs/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) angioedema/NNP (l_nmod) urticaria/NN -PUNC- NSAID/NNP (r_npadvmod) induced/VBN (r_amod) angioedema/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) by/IN (r_prep) increased/VBN (l_agent) by/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) urticaria/NN
D000082_D014581 NONE paracetamol/NN (r_conj) nimesulide/NN (r_pobj) of/IN (r_prep) Tolerability/DT (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angioedema/NN (l_nmod) urticaria/NN -PUNC- paracetamol/NN (r_conj) nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) investigated/VBD (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN (l_nmod) urticaria/NN -PUNC- paracetamol/NNP (r_conj) nimesulide/NN (r_pobj) with/IN (r_prep) procedure/NN (r_nsubjpass) applied/VBN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN (l_nmod) urticaria/NN -PUNC- paracetamol/NN (r_conj) nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) experienced/VBD (l_dobj) angioedema/NNP (l_nmod) urticaria/NN
C012655_D000799 CID nimesulide/NN (r_pobj) of/IN (r_prep) Tolerability/DT (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angioedema/NN -PUNC- nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) investigated/VBD (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN -PUNC- nimesulide/NN (r_pobj) with/IN (r_prep) procedure/NN (r_nsubjpass) applied/VBN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) angioedema/NN -PUNC- nimesulide/NN (r_pobj) of/IN (r_prep) tolerability/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) experienced/VBD (l_dobj) angioedema/NNP
8953972
D004837_D013345 CID epinephrine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) bleeding/NN
D004837_D005076 NONE epinephrine/NN (r_dobj) administer/VB (r_xcomp) led/VBD (l_nsubj) onset/NN (l_prep) of/IN (l_pobj) distress/NN (l_conj) rash/JJ
D004837_D012128 NONE epinephrine/NN (r_dobj) administer/VB (r_xcomp) led/VBD (l_nsubj) onset/NN (l_prep) of/IN (l_pobj) distress/NN
D004837_D006323 CID Epinephrine/NN (r_nsubj) has/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) arrest/NN
D004837_D004342 NONE Epinephrine/NN (r_nsubj) has/VBZ (r_ccomp) use/NN (l_prep) by/IN (l_pobj) paramedics/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) reaction/NN
D004837_D006973 NONE Epinephrine/NN (r_nsubj) has/VBZ (r_ccomp) use/NN (l_prep) by/IN (l_pobj) paramedics/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) reaction/NN (l_conj) hypertension/NN
9587734
D013390_D004342 CID suxamethonium/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN
D013390_D006323 CID Suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) arrest/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) arrest/NN -PUNC- suxamethonium/NN (l_appos) arrest/NN
D013390_D003643 NONE Suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) arrest/NN (l_conj) death/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) arrest/NN (l_conj) death/NN -PUNC- suxamethonium/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) death/NN
D013390_D006947 CID suxamethonium/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) case/NN (l_prep) of/IN (l_pobj) arrest/NN (l_conj) death/NN (l_prep) as/IN (l_pobj) result/NN (l_prep) of/IN (l_pobj) hyperkalaemia/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) signs/NNS (l_prep) of/IN (l_conj) of/IN (l_pobj) any/DT (l_prep) of/IN (l_pobj) conditions/NNS (l_prep) for/IN (l_pobj) hyperkalaemia/NN
D013390_D001919 CID suxamethonium/NN (l_appos) arrest/NN (l_amod) bradycardia/NN
18791946
D002939_D013921 CID ciprofloxacin/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thrombocytopenia/JJ -PUNC- ciprofloxacin/NNS (r_nsubj) precipitate/VB (l_dobj) thrombocytopenia/JJ
D002939_D007565 CID ciprofloxacin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_prep) with/IN (l_pobj) pain/NN (l_conj) jaundice/NN
D002939_D000743 CID ciprofloxacin/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thrombocytopenia/JJ (l_conj) anaemia/NN -PUNC- ciprofloxacin/NNS (r_nsubj) precipitate/VB (l_dobj) thrombocytopenia/JJ (l_conj) anaemia/NN
D002939_D015746 CID ciprofloxacin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reported/VBN (l_prep) with/IN (l_pobj) pain/NN
D002939_D014552 NONE ciprofloxacin/NNS (r_pobj) of/IN (r_prep) administration/NN (l_prep) for/IN (l_pobj) suspect/NN (l_prep) of/IN (l_pobj) infection/NN
17344330
D003932_D008133 NONE heroin/NN (r_compound) dependence/NN (r_pobj) for/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) among/IN (r_prep) Syncope/NNP (l_conj) prolongation/NN -PUNC- heroin/NN (r_compound) addicts/NNS (r_pobj) of/IN (r_prep) population/NN (r_pobj) in/IN (r_prep) syncope/NN (r_pobj) of/IN (r_prep) reporting/NN (r_conj) prolongation/NN
D003932_D016171 NONE heroin/NN (r_compound) addicts/NNS (r_nsubj) faint/JJ (r_advcl) attribute/VB (l_conj) underestimate/VBP (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) TdP/NNP
D003932_D013575 NONE heroin/NN (r_compound) dependence/NN (r_pobj) for/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) among/IN (r_prep) Syncope/NNP -PUNC- heroin/NN (r_compound) addicts/NNS (r_nsubj) faint/JJ (r_advcl) attribute/VB (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) syncope/NN -PUNC- heroin/NN (r_compound) addicts/NNS (r_pobj) of/IN (r_prep) population/NN (r_pobj) in/IN (r_prep) syncope/NN
D008691_D016171 NONE methadone/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) Prolongation/NN (l_prep) of/IN (l_pobj) interval/NN (l_prep) in/IN (l_pobj) ECG/NNP (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pointes/FW -PUNC- methadone/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) Prolongation/NN (l_prep) of/IN (l_pobj) interval/NN (l_prep) in/IN (l_pobj) ECG/NNP (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pointes/FW (l_appos) TdP/NN -PUNC- methadone/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) by/IN (r_agent) caused/VBN (r_conj) attribute/VB (l_conj) underestimate/VBP (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) TdP/NNP
D008691_D008133 CID methadone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) among/IN (r_prep) Syncope/NNP (l_conj) prolongation/NN -PUNC- methadone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) subjects/NNS (r_pobj) Among/IN (r_prep) had/VBD (l_dobj) interval/NN -PUNC- Methadone/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) prolongation/NN
D008691_D013575 CID methadone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) among/IN (r_prep) Syncope/NNP -PUNC- methadone/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) by/IN (r_agent) caused/VBN (r_conj) attribute/VB (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) syncope/NN -PUNC- methadone/NN (r_compound) dose/NN (l_conj) reporting/NN (l_prep) of/IN (l_pobj) syncope/NN -PUNC- methadone/NN (r_compound) dose/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) CI/NNP (l_appos) odds/NNS (l_prep) for/IN (l_pobj) syncope/NN -PUNC- Methadone/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) prolongation/NN (l_conj) reporting/NN (l_prep) of/IN (l_pobj) syncope/NN
20722491
C110904_D003967 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN
C110904_D013280 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN (l_conj) vomiting/NN (l_conj) stomatitis/JJ
C110904_D060831 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN (l_conj) vomiting/NN (l_conj) stomatitis/JJ (l_conj) syndrome/NN
D005472_D009369 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS
D005472_D015179 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS (l_prep) including/VBG (l_pobj) colorectal/NN (l_conj) breast/NN (l_conj) cancers/NNS
C110904_D014839 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN (l_conj) vomiting/NN
D005472_D001943 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS (l_prep) including/VBG (l_pobj) colorectal/NN (l_conj) breast/NN (l_conj) cancers/NNS
C110904_D008107 NONE Capecitabine/NNP (r_nsubj) has/VBZ (l_conj) given/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) dysfunctions/NNS
C110904_D007674 NONE capecitabine/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) populations/NNS (l_prep) as/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Capecitabine/NNP (r_nsubj) has/VBZ (l_conj) given/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) dysfunctions/NNS
C110904_D009325 CID capecitabine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_attr) diarrhea/NN (l_appos) nausea/NN
D005472_D006258 NONE 5-FU/CD (r_nsubj) been/VBN (l_attr) mainstay/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) tumors/NNS (l_prep) including/VBG (l_pobj) colorectal/NN (l_conj) breast/NN (l_conj) cancers/NNS
11752998
D000241_D010146 NONE adenosine/NN (r_amod) doses/NNS (r_pobj) with/IN (r_prep) trial/NN (r_appos) trials/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) obtained/VBN (l_conj) determined/VBN (l_nsubjpass) ratings/NNS (l_compound) pain/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) trial/NN (r_conj) doses/NNS (r_pobj) with/IN (r_prep) trial/NN (r_appos) trials/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) obtained/VBN (l_conj) determined/VBN (l_nsubjpass) ratings/NNS (l_compound) pain/NN -PUNC- Adenosine/NNP (r_nsubj) produced/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) report/NN (l_compound) pain/NN
D002211_D006930 CID capsaicin/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) stimuli/NNS (l_conj) areas/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- capsaicin/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) stimuli/NNS (l_conj) areas/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- capsaicin/NN (r_compound) injection/NN (r_pobj) from/IN (r_prep) allodynia/NN (r_conj) hyperalgesia/NN -PUNC- capsaicin/NN (r_compound) injection/NN (r_pobj) from/IN (r_prep) allodynia/NN
D000241_D059350 NONE adenosine/NN (r_pobj) of/IN (r_prep) studies/NNS (r_nsubj) suggest/VBP (l_ccomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) formulation/NN (r_pobj) with/IN (r_prep) volunteers/NNS (r_pobj) in/IN (r_prep) studies/NNS (r_nsubj) suggests/VBZ (r_conj) suggest/VBP (l_ccomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN
D000241_D009437 NONE adenosine/NN (r_pobj) of/IN (r_prep) residence/NN (r_pobj) due/JJ (r_acomp) is/VBZ (r_conj) is/VBZ (l_acomp) consistent/JJ (l_prep) with/IN (l_pcomp) observed/VBN (l_prep) in/IN (l_pobj) reports/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pain/NN
D000241_D059787 NONE adenosine/NN (r_pobj) of/IN (r_prep) studies/NNS (r_nsubj) suggest/VBP (l_ccomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) formulation/NN (r_pobj) with/IN (r_prep) volunteers/NNS (r_pobj) in/IN (r_prep) studies/NNS (r_nsubj) suggests/VBZ (r_conj) suggest/VBP (l_ccomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pain/NN
D002211_D010146 NONE capsaicin/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) stimuli/NNS (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) ratings/NNS (l_compound) pain/NN -PUNC- capsaicin/NN (r_compound) injection/NN (r_pobj) from/IN (r_prep) allodynia/NN (r_conj) hyperalgesia/NN (r_conj) stimulation/NN (r_pobj) to/IN (r_prep) produced/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) report/NN (l_compound) pain/NN
D000241_D004342 NONE adenosine/NN (r_pobj) of/IN (r_prep) studies/NNS (r_nsubj) suggest/VBP (l_conj) suggests/VBZ (l_ccomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) states/NNS (l_compound) hypersensitivity/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) formulation/NN (r_pobj) with/IN (r_prep) volunteers/NNS (r_pobj) in/IN (r_prep) studies/NNS (r_nsubj) suggests/VBZ (l_ccomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) states/NNS (l_compound) hypersensitivity/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) formulation/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) for/IN (r_prep) screen/VB (l_advcl) using/VBG (l_dobj) stimulation/NN (l_conj) hypersensitivity/NN -PUNC- adenosine/NN (l_prep) of/IN (l_pobj) hypersensitivity/NN
D002211_D004342 NONE capsaicin/NN (r_npadvmod) evoked/VBN (r_amod) hypersensitivity/NN -PUNC- capsaicin/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) reflect/VB (r_xcomp) presumed/VBN (r_advcl) show/VBP (l_dobj) inhibition/NN (l_prep) by/IN (l_pobj) adenosine/NN (l_prep) of/IN (l_pobj) hypersensitivity/NN
D000241_D006930 NONE adenosine/NN (r_amod) doses/NNS (r_pobj) with/IN (r_prep) trial/NN (r_appos) trials/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) obtained/VBN (l_conj) determined/VBN (l_nsubjpass) ratings/NNS (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) stimuli/NNS (l_conj) areas/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- adenosine/NN (r_amod) doses/NNS (r_pobj) with/IN (r_prep) trial/NN (r_appos) trials/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) obtained/VBN (l_conj) determined/VBN (l_nsubjpass) ratings/NNS (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) stimuli/NNS (l_conj) areas/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) trial/NN (r_conj) doses/NNS (r_pobj) with/IN (r_prep) trial/NN (r_appos) trials/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) obtained/VBN (l_conj) determined/VBN (l_nsubjpass) ratings/NNS (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) stimuli/NNS (l_conj) areas/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- adenosine/NN (r_pobj) of/IN (r_prep) trial/NN (r_conj) doses/NNS (r_pobj) with/IN (r_prep) trial/NN (r_appos) trials/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) obtained/VBN (l_conj) determined/VBN (l_nsubjpass) ratings/NNS (l_prep) in/IN (l_pobj) response/NN (l_prep) to/IN (l_pobj) stimuli/NNS (l_conj) areas/NNS (l_prep) of/IN (l_pobj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- Adenosine/NNP (r_nsubj) produced/VBD (l_prep) to/IN (l_pobj) stimulation/NN (l_conj) hyperalgesia/NN -PUNC- Adenosine/NNP (r_nsubj) produced/VBD (l_prep) to/IN (l_pobj) stimulation/NN (l_conj) hyperalgesia/NN (l_conj) allodynia/NN
12615818
D004997_D054556 CID estradiol/NN (r_appos) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D003276_D054556 NONE contraceptives/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) demonstrated/VBN (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- contraceptives/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) demonstrated/VBN (l_dobj) risk/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP
D017373_D000152 NONE acetate/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN
D004997_D011085 NONE estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP
D017373_D006628 NONE acetate/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN
D017373_D011085 NONE acetate/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- acetate/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_conj) is/VBZ (l_attr) option/NN (l_prep) for/IN (l_pobj) syndrome/NN (l_appos) PCOS/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN (l_conj) PCOS/NNP
D004997_D000152 NONE estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN
D017373_D054556 CID acetate/NN (r_oprd) prescribed/VBD (r_acl) women/NNS (r_pobj) in/IN (r_prep) thromboembolism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN (l_appos) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP -PUNC- CPA/NNP (r_nmod) EE/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D004997_D006628 NONE estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- EE/NNP (r_appos) estradiol/NN (r_nsubjpass) licensed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- EE/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) VTE/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) estimate/VB (r_advcl) conducted/VBD (l_npadvmod) years/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN -PUNC- EE/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) acne/NN (l_conj) hirsutism/NN
9228650
D012601_D000647 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN
C049860_D000647 CID NIK-247/NNP (l_prep) on/IN (l_pobj) cholinesterase/NN (l_conj) amnesia/NN -PUNC- NIK-247/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_nsubjpass) amnesia/NN -PUNC- NIK-247/NNP (r_nsubj) improves/VBZ (l_dobj) amnesia/NN
C076946_D000647 CID E-2020/NNS (r_conj) tacrine/NN (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) examined/VBN (l_nsubjpass) amnesia/NN
C049860_D000544 NONE NIK-247/NNP (r_nsubj) be/VB (l_attr) drug/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN
D013619_D000647 CID tacrine/NN (r_appos) inhibitors/NNS (r_pobj) of/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) examined/VBN (l_nsubjpass) amnesia/NN
11245434
D003520_D064420 NONE cyclophosphamide/NN (r_compound) cytotoxicity/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN
D016190_D012509 NONE carboplatin/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) implanted/VBN (l_nsubjpass) tumors/NNS (l_appos) sarcoma/NN
D016190_D000740 CID carboplatin/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) using/VBG (r_xcomp) induced/VBN (l_nsubjpass) Anemia/NN -PUNC- carboplatin/NN (r_amod) application/NN (r_pobj) before/IN (r_prep) days/NNS (r_dobj) starting/VBG (r_advcl) administered/VBN (r_conj) prevented/VBN (l_nsubjpass) development/NN (l_prep) of/IN (l_pobj) anemia/NN
D003520_D000740 NONE cyclophosphamide/NN (r_compound) cytotoxicity/NN (r_pobj) in/IN (r_prep) reduction/NN (l_amod) induced/VBN (l_npadvmod) anemia/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN (r_pobj) on/IN (r_prep) treatment/NN (r_pobj) by/IN (r_prep) impact/NN (l_prep) of/IN (l_pobj) prevention/NN (l_compound) anemia/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN (r_dobj) reduces/VBZ (l_nsubj) anemia/NN -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN (r_dobj) reduces/VBZ (l_advcl) increases/VBZ (l_nsubj) correction/NN (l_prep) of/IN (l_pobj) anemia/NN
D016190_D009369 NONE carboplatin/NN (r_amod) treatment/NN (r_pobj) after/IN (r_prep) implanted/VBN (l_nsubjpass) tumors/NNS -PUNC- carboplatin/NN (l_conj) influenced/VBN (l_dobj) rate/NN (l_compound) tumor/NN
D003520_D009369 NONE cyclophosphamide/NN (r_compound) cytotoxicity/NN (l_prep) in/IN (l_pobj) tumors/NNS -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN (l_prep) in/IN (l_pobj) tumors/NNS -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) tumors/NNS -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) observed/VBN (l_nsubjpass) delay/NN (l_prep) with/IN (l_pobj) regrowth/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN (l_prep) in/IN (l_pobj) tumors/NNS -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) cytotoxicity/NN (r_dobj) reduces/VBZ (l_advcl) increases/VBZ (l_prep) as/IN (l_pobj) result/NN (l_prep) of/IN (l_pobj) supply/NN (l_prep) to/IN (l_pobj) tissue/NN (l_compound) tumor/NN
D010100_D064420 NONE oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) increases/VBZ (r_advcl) reduces/VBZ (l_dobj) cytotoxicity/NN
D010100_D000740 NONE oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) increases/VBZ (r_advcl) reduces/VBZ (l_nsubj) anemia/NN -PUNC- oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) increases/VBZ (l_nsubj) correction/NN (l_prep) of/IN (l_pobj) anemia/NN
D010100_D009369 NONE oxygen/NN (r_compound) supply/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) increases/VBZ (r_advcl) reduces/VBZ (l_dobj) cytotoxicity/NN (l_prep) in/IN (l_pobj) tumors/NNS -PUNC- oxygen/NN (r_compound) supply/NN (l_prep) to/IN (l_pobj) tissue/NN (l_compound) tumor/NN
3973521
8492347
D008274_D007008 NONE magnesium/NN (r_compound) depletion/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) noted/VBN (r_conj) observed/VBN (r_conj) reported/VBN (l_nsubjpass) hypokalemia/NN
D002118_D013035 NONE calcium/NN (r_conj) potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_prep) with/IN (l_pobj) spasms/NNS
D002118_D018908 NONE calcium/NN (r_conj) potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_advcl) cause/VB (l_dobj) weakness/NN
D008274_D012206 NONE magnesium/NN (r_compound) supplementation/NN (r_pobj) of/IN (r_prep) importance/NN (r_appos) Tetany/NNP (l_conj) rhabdomyolysis/NN
D005665_D012206 CID furosemide/NN (r_pobj) due/JJ (r_prep) Tetany/NNP (l_conj) rhabdomyolysis/NN
D002118_D007008 NONE calcium/NN (r_conj) potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_advcl) cause/VB (l_nsubj) hypokalemia/NN
D005665_D013746 CID furosemide/NN (r_pobj) due/JJ (r_prep) Tetany/NNP
D011188_D013746 NONE potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_prep) with/IN (l_pobj) spasms/NNS (l_conj) tetany/NN
D011188_D013035 NONE potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_prep) with/IN (l_pobj) spasms/NNS
D011188_D018908 NONE potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_advcl) cause/VB (l_dobj) weakness/NN
D002118_C537153 NONE calcium/NN (r_conj) potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_nsubjpass) hypomagnesemia/NN
D002118_D013746 NONE calcium/NN (r_conj) potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_prep) with/IN (l_pobj) spasms/NNS (l_conj) tetany/NN
D011188_D007008 NONE potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_advcl) cause/VB (l_nsubj) hypokalemia/NN
D011188_C537153 NONE potassium/NN (r_nmod) supplementation/NN (r_pobj) by/IN (r_agent) corrected/VBN (r_ccomp) associated/VBN (l_nsubjpass) hypomagnesemia/NN
D008274_D006996 NONE magnesium/NN (r_compound) depletion/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) noted/VBN (r_conj) observed/VBN (l_prep) in/IN (l_pobj) hypocalcemia/NN
D008274_D013746 NONE magnesium/NN (r_compound) supplementation/NN (r_pobj) of/IN (r_prep) importance/NN (r_appos) Tetany/NNP
10743694
19761039
D010936_D004409 NONE sinensis/NN (r_pobj) of/IN (r_prep) extract/NN (r_pobj) of/IN (r_prep) Effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) dyskinesia/JJ -PUNC- sinensis/NN (r_nsubj) had/VBD (l_dobj) role/NN (l_prep) against/IN (l_pobj) dyskinesia/JJ
D012110_D004409 CID reserpine/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/JJ -PUNC- reserpine/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/JJ
9672273
D013629_D015228 CID tamoxifen/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) events/NNS (l_conj) hypertriglyceridaemia/NN
D013629_D016889 NONE Tamoxifen/NNP (r_nsubj) is/VBZ (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cancer/NN
D013629_D001943 NONE tamoxifen/NN (r_pobj) with/IN (r_prep) Prevention/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- Tamoxifen/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) of/IN (r_prep) trial/NN (l_relcl) have/VB (l_dobj) cancer/NN -PUNC- tamoxifen/NN (r_nmod) arms/NNS (r_conj) placebo/NN (r_pobj) between/IN (r_prep) frequency/NN (l_compound) cancer/NN -PUNC- tamoxifen/NN (r_dobj) receiving/VBG (r_acl) women/NNS (r_pobj) among/IN (r_prep) reduction/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_dobj) receiving/VBG (r_acl) women/NNS (r_pobj) among/IN (r_prep) reduction/NN (r_attr) is/VBZ (r_ccomp) found/VBD (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) to/IN (r_prep) allocated/VBN (r_acl) women/NNS (r_pobj) among/IN (r_prep) case/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) found/VBD (l_ccomp) is/VBZ (l_attr) reduction/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) to/IN (r_prep) allocated/VBN (r_acl) women/NNS (r_pobj) among/IN (r_prep) case/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) found/VBD (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) cancer/NN -PUNC- tamoxifen/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) are/VBP (l_prep) in/IN (l_prep) at/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) cancer/NN
D013629_D014652 CID tamoxifen/NN (r_pobj) on/IN (r_prep) women/NNS (r_pobj) among/IN (r_prep) events/NNS
18442015
D004872_D006471 CID D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN
D014700_D014456 NONE verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) ulcers/NNS -PUNC- verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) model/NN (l_compound) ulcer/NN -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_acomp) were/VBD (l_nsubj) ulcer/NN -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_relcl) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN
D002118_D050197 NONE calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (l_amod) atherosclerotic/JJ -PUNC- calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (r_nsubjpass) obtained/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ
D004872_D014456 CID D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_conj) ulcer/NN
D014700_D006471 NONE verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) ulcers/NNS (l_amod) hemorrhagic/JJ -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_acomp) were/VBD (l_nsubj) ulcer/NN (l_amod) hemorrhagic/JJ -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_relcl) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN (l_amod) hemorrhagic/JJ
D006632_D014456 NONE histamine/NN (r_compound) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_conj) ulcer/NN -PUNC- histamine/NN (r_compound) concentration/NN (l_conj) permeability/NN (l_conj) content/NN (l_conj) areas/NNS (l_compound) ulcer/NN -PUNC- histamine/NN (r_compound) release/NN (r_conj) diffusion/NN (r_pobj) including/VBG (r_prep) factors/NNS (r_pobj) with/IN (r_prep) accompanied/VBN (l_nsubj) ulcers/NNS -PUNC- histamine/NN (r_pobj) of/IN (r_prep) correlation/NN (l_prep) to/IN (l_conj) to/IN (l_pobj) ulcer/NN -PUNC- histamine/NN (r_compound) release/NN (r_conj) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN
D002784_D014456 CID cholesterol/NN (r_conj) D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_conj) ulcer/NN
D006632_D050197 NONE histamine/NN (r_compound) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- histamine/NN (r_pobj) of/IN (r_prep) correlation/NN (r_nsubjpass) found/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ -PUNC- histamine/NN (r_compound) release/NN (r_conj) generation/NN (l_ccomp) produce/VB (l_nsubj) Atherosclerosis/NN
D004872_D050197 CID D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- D2/NN (r_dobj) containing/VBG (l_advcl) induce/VB (l_dobj) atherosclerosis/NN
D002784_D006471 CID cholesterol/NN (r_conj) D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN
D006632_D006471 NONE histamine/NN (r_compound) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN -PUNC- histamine/NN (r_pobj) of/IN (r_prep) correlation/NN (l_prep) to/IN (l_pobj) hemorrhage/NN -PUNC- histamine/NN (r_compound) release/NN (r_conj) generation/NN (l_ccomp) produce/VB (l_dobj) ulcer/NN (l_amod) hemorrhagic/JJ
D014700_D050197 NONE verapamil/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) ulcers/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ -PUNC- verapamil/NN (r_pobj) by/IN (r_agent) ameliorated/VBN (r_relcl) generation/NN (l_ccomp) produce/VB (l_nsubj) Atherosclerosis/NN
D010634_D014456 NONE luminal/JJ (r_amod) content/NN (l_conj) areas/NNS (l_compound) ulcer/NN -PUNC- luminal/JJ (r_amod) content/NN (r_conj) generation/NN (r_conj) release/NN (r_conj) diffusion/NN (r_pobj) including/VBG (r_prep) factors/NNS (r_pobj) with/IN (r_prep) accompanied/VBN (l_nsubj) ulcers/NNS
D002784_D050197 CID cholesterol/NN (r_conj) D2/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) release/NN (l_conj) peroxide/NN (l_appos) permeability/NN (l_prep) in/IN (l_pcomp) modulating/VBG (l_dobj) hemorrhage/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) atherosclerosis/NN -PUNC- cholesterol/NN (r_conj) D2/NN (r_dobj) containing/VBG (l_advcl) induce/VB (l_dobj) atherosclerosis/NN -PUNC- cholesterol/NN (r_conj) calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (l_amod) atherosclerotic/JJ -PUNC- cholesterol/NN (r_conj) calcium/NN (r_pobj) as/IN (r_prep) parameters/NNS (r_nsubjpass) obtained/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) atherosclerotic/JJ
8955532
D003911_D006973 NONE dextran/NN (r_pobj) of/IN (r_prep) clearance/NN (l_prep) before/IN (l_conj) during/IN (l_pobj) hypertension/NN
D001920_D006973 NONE bradykinin/NN (l_prep) in/IN (l_pobj) disruption/NN (l_prep) during/IN (l_pobj) hypertension/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) release/NN (r_pobj) of/IN (r_prep) role/NN (r_dobj) determine/VB (l_xcomp) activate/VB (l_prep) in/IN (l_pobj) disruption/NN (l_prep) during/IN (l_pobj) hypertension/NN -PUNC- bradykinin/NN (r_pobj) of/IN (r_prep) release/NN (r_pobj) to/IN (r_prep) related/VBN (l_auxpass) is/VBZ (l_nsubj) disruption/NN (l_prep) during/IN (l_pobj) hypertension/NN
D010656_D006973 CID phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
C065679_D006973 NONE Hoe-140/NNP (r_conj) vehicle/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) hypertension/NN
3115150
D002707_D009127 NONE Chlordiazepoxide/VB (r_nsubj) failed/VBD (l_xcomp) influence/VB (l_dobj) rigidity/NN
D012701_D012131 NONE serotonin/NN (r_compound) antagonists/NNS (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) be/VB (l_advcl) be/VB (l_xcomp) assess/VB (l_dobj) interaction/NN (l_prep) of/IN (l_pobj) CNS/NNP (l_conj) cardiovascular/JJ (l_conj) depression/NN
D012701_D002318 NONE serotonin/NN (r_compound) antagonists/NNS (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) be/VB (l_advcl) be/VB (l_xcomp) assess/VB (l_dobj) interaction/NN (l_prep) of/IN (l_pobj) CNS/NNP (l_conj) cardiovascular/JJ (l_conj) depression/NN
D012701_D009127 NONE serotonin/NN (r_compound) antagonist/NN (r_appos) pretreatment/NN (r_nsubj) attenuated/VBD (l_dobj) rigidity/NN -PUNC- serotonin/NN (r_compound) antagonists/NNS (r_pobj) with/IN (r_prep) Pretreatment/NN (r_nsubj) be/VB (l_acomp) useful/JJ (l_prep) in/IN (l_pcomp) attenuating/VBG (l_dobj) rigidity/NN
D015760_D009127 CID alfentanil/NN (r_npadvmod) induced/VBN (r_amod) rigidity/NN -PUNC- alfentanil/NN (r_advcl) attenuated/VBD (l_dobj) rigidity/NN -PUNC- alfentanil/NNS (r_pobj) by/IN (r_agent) produced/VBN (r_acl) rigidity/NN -PUNC- alfentanil/NNS (r_pobj) by/IN (r_agent) followed/VBN (l_prep) Despite/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) rigidity/NN -PUNC- alfentanil/NN (r_advmod) receiving/VBG (r_acl) animals/NNS (r_nsubj) were/VBD (r_advcl) responsive/JJ (r_conj) flaccid/JJ (r_conj) motionless/JJ (r_acomp) were/VBD (l_csubj) followed/VBN (l_prep) Despite/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) rigidity/NN
D007650_D009127 NONE Ketanserin/JJ (r_compound) pretreatment/NN (r_nsubj) reverses/VBZ (l_dobj) rigidity/NN -PUNC- ketanserin/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) attenuated/VBD (l_dobj) rigidity/NN -PUNC- ketanserin/JJ (r_dobj) received/VBD (r_relcl) animals/NNS (r_nsubj) followed/VBN (l_prep) Despite/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) rigidity/NN
19356307
C032208_D003704 NONE alcohol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) dementia/NN
C032208_D008569 NONE alcohol/NN (r_nsubj) relieved/VBD (l_ccomp) showed/VBD (l_dobj) ability/NN (l_acl) improve/VB (l_dobj) memory/NN (l_amod) impaired/VBN -PUNC- alcohol/NN (r_nsubj) relieved/VBD (l_dobj) deficit/NN (l_prep) of/IN (l_pobj) memory/NN
D012601_D003704 NONE scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Components/NNS (l_prep) of/IN (l_pobj) dementia/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) impaired/VBN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) impaired/VBN (r_amod) memory/NN (r_dobj) improve/VB (r_acl) ability/NN (r_dobj) showed/VBD (r_ccomp) relieved/VBD (l_dobj) deficit/NN (l_prep) of/IN (l_pobj) memory/NN
C008281_D003704 NONE limonene/NN (r_nmod) alcohol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_compound) dementia/NN
1687392
D004298_D002375 NONE dopamine/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) Blockade/NN (r_nsubj) induce/VB (l_dobj) catalepsy/NN -PUNC- dopamine/NN (r_compound) antagonists/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- dopamine/NN (r_compound) antagonists/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN (r_nsubjpass) tested/VBN (l_conj) determined/VBN (l_nsubjpass) subtypes/NNS (l_acl) involved/VBN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- dopamine/NN (r_compound) subtypes/NNS (r_nsubjpass) determined/VBN (r_conj) tested/VBN (l_nsubjpass) catalepsy/NN -PUNC- dopamine/NN (r_compound) subtypes/NNS (l_acl) involved/VBN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- Dopamine/NN (r_compound) fluphenazine/NN (r_nsubj) induced/VBD (l_dobj) catalepsy/NN -PUNC- dopamine/NN (r_compound) antagonists/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effect/NN (l_prep) on/IN (l_pobj) catalepsy/NN
C534628_D002375 CID 23390/CD (r_nummod) SCH/NNP (r_appos) fluphenazine/NN (r_nsubj) induced/VBD (l_dobj) catalepsy/NN -PUNC- 23390/CD (r_nummod) SCH/NNP (r_pobj) of/IN (r_prep) Combination/NN (r_nsubj) induce/VB (l_dobj) potentiation/NN (l_compound) catalepsy/NN -PUNC- 23390/CD (r_nummod) SCH/NNP (r_appos) fluphenazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D013469_D002375 CID sulpiride/NN (r_npadvmod) induced/VBD (l_dobj) catalepsy/NN -PUNC- sulpiride/NN (r_pobj) with/IN (r_prep) Combination/NN (r_nsubj) induce/VB (l_dobj) potentiation/NN (l_compound) catalepsy/NN -PUNC- sulpiride/NN (r_conj) SCH/NNP (r_appos) fluphenazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D005476_D002375 CID fluphenazine/NN (r_nsubj) induced/VBD (l_dobj) catalepsy/NN -PUNC- fluphenazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D019257_D002375 NONE quinpirole/NN (r_nsubj) decreased/VBD (l_dobj) catalepsy/NN -PUNC- quinpirole/NN (r_pobj) with/IN (r_prep) Combination/NN (r_nsubj) cause/VB (l_ccomp) potentiated/VBN (l_dobj) effect/NN (l_prep) on/IN (l_pobj) catalepsy/NN
D015647_D002375 NONE 38393/CD (r_nummod) SKF/NNP (r_nmod) quinpirole/NN (r_nsubj) decreased/VBD (l_dobj) catalepsy/NN -PUNC- 38393/CD (r_nummod) SKF/NNP (r_pobj) of/IN (r_prep) Combination/NN (r_nsubj) cause/VB (l_ccomp) potentiated/VBN (l_dobj) effect/NN (l_prep) on/IN (l_pobj) catalepsy/NN
15276120
D014859_D006470 CID warfarin/RB (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN -PUNC- warfarin/RB (r_npadvmod) related/VBN (r_amod) bleeding/NN
16403073
D007654_D008133 CID ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (r_conj) developed/VBD (l_dobj) interval/NN -PUNC- ketoconazole/JJ (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) factors/NNS (l_prep) for/IN (l_pobj) syndrome/NN
D007654_D003324 NONE ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (r_conj) developed/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) disease/NN
D007654_D009181 NONE ketoconazole/RB (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) infection/NN
D007654_D016171 CID Ketoconazole/NNP (r_nsubj) induced/VBD (l_dobj) pointes/FW -PUNC- ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (l_dobj) pointes/FW -PUNC- ketoconazole/RB (r_dobj) taking/VBG (r_pcomp) after/IN (r_prep) torsades/NNS (l_dobj) pointes/FW (l_appos) TdP/NN -PUNC- ketoconazole/RB (r_nsubj) prolong/VB (l_conj) induce/VB (l_dobj) TdP./NN
8586822
D002216_D006973 NONE captopril/FW (r_npadvmod) treated/VBN (l_dobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- captopril/FW (r_npadvmod) treated/VBN (l_dobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- captopril/FW (r_npadvmod) treated/VBN (r_relcl) hypothesis/NN (r_dobj) test/VB (r_advcl) contributes/VBZ (l_prep) to/IN (l_pobj) effect/NN (l_amod) hypertensive/JJ
D017673_D006973 CID chloride/NN (r_compound) supplementation/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) to/IN (r_prep) contributes/VBZ (l_advcl) test/VB (l_dobj) hypothesis/NN (l_relcl) treated/VBN (l_dobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- chloride/NN (r_compound) supplementation/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypertensive/JJ -PUNC- chloride/NN (r_npadvmod) induced/VBN (r_amod) increase/NN (l_prep) in/IN (l_pobj) MAP/NNP
D018738_D006973 NONE hexamethonium/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) decline/NN (l_relcl) eliminated/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) MAP/NNP
12921865
D011280_D012640 NONE Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnan-20-one/NNP (r_advmod) 3alpha/CD (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnan-20-one/NNP (r_parataxis) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- allopregnanolone/NN (r_pobj) of/IN (r_prep) derivative/NN (r_appos) ganaxolone/NN (r_conj) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- allopregnanolone/NN (r_nsubj) inhibited/VBD (r_advcl) suppressed/VBD (l_dobj) expression/NN (l_prep) of/IN (l_pobj) seizures/NNS
D013256_D009422 NONE steroids/NNS (r_nsubj) demonstrate/VBP (l_dobj) actions/NNS (l_relcl) have/VBP (l_dobj) relevance/NN (l_prep) for/IN (l_pobj) host/NN (l_prep) of/IN (l_pobj) disorders/NNS
D013256_D001523 NONE steroids/NNS (r_nsubj) demonstrate/VBP (l_dobj) actions/NNS (l_relcl) have/VBP (l_dobj) relevance/NN (l_prep) for/IN (l_pobj) host/NN (l_prep) of/IN (l_pobj) disorders/NNS
D005680_D012640 NONE acid/NN (l_appos) receptor/NN (l_prep) against/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- GABA(A/NNP (r_appos) acid/NN (l_appos) receptor/NN (l_prep) against/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- GABA(A/NN (r_nmod) modulators/NNS (r_pobj) of/IN (r_prep) All/DT (r_nsubj) suppressed/VBD (l_dobj) expression/NN (l_prep) of/IN (l_pobj) seizures/NNS
D013256_D012640 NONE steroids/NNS (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- steroid/NN (l_relcl) modulate/VBP (l_dobj) acid/NN (l_appos) receptor/NN (l_prep) against/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_prep) to/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN
D003042_D012640 CID cocaine/NN (r_compound) seizures/NNS -PUNC- cocaine/NN (l_acl) engendered/VBN (l_agent) by/IN (l_pobj) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- cocaine/NN (r_compound) administration/NN (l_appos) kindling/NN (l_compound) seizure/NN -PUNC- cocaine/NN (r_npadvmod) kindled/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (l_csubjpass) Kindled/VBN (l_dobj) seizures/NNS
C105051_D012640 NONE ganaxolone/NN (r_conj) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pregnan-20-one/NNP (r_appos) 3alpha/CD (r_appos) allopregnanolone/NN (r_pobj) of/IN (r_prep) derivative/NN (r_appos) ganaxolone/NN (r_conj) pregnanolone/NN (r_appos) Allopregnanolone/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) ability/NN (l_acl) suppress/VB (l_dobj) expression/NN (l_appos) effect/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- ganaxolone/NN (r_conj) allopregnanolone/NN (r_nsubj) inhibited/VBD (r_advcl) suppressed/VBD (l_dobj) expression/NN (l_prep) of/IN (l_pobj) seizures/NNS
7102237
D012601_D001049 NONE scopolamine/NN (r_pobj) with/IN (r_prep) premedicated/VBN (r_acl) patients/NNS (r_pobj) In/IN (r_prep) was/VBD (l_advcl) occurred/VBD (l_nsubj) apnoea/NN
D009567_D001049 NONE nitrazepam/NN (r_amod) mg/IN (r_conj) scopolamine/NN (r_pobj) with/IN (r_prep) premedicated/VBN (r_acl) patients/NNS (r_pobj) In/IN (r_prep) was/VBD (l_advcl) occurred/VBD (l_nsubj) apnoea/NN
D009020_D001049 NONE morphine/NN (r_conj) scopolamine/NN (r_pobj) with/IN (r_prep) premedicated/VBN (r_acl) patients/NNS (r_pobj) In/IN (r_prep) was/VBD (l_advcl) occurred/VBD (l_nsubj) apnoea/NN
D008874_D001049 CID midazolam/JJ (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) was/VBD (l_advcl) occurred/VBD (l_nsubj) apnoea/NN -PUNC- midazolam/JJ (r_amod) group/NN (r_pobj) in/IN (r_prep) found/VBN (r_conj) was/VBD (l_advcl) occurred/VBD (l_nsubj) apnoea/NN -PUNC- midazolam/JJ (r_amod) group/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) apnoea/NN
D013874_D001049 CID thiopentone/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) than/IN (r_prep) onset/NN (r_pobj) in/IN (r_prep) slower/JJR (r_acomp) was/VBD (l_advcl) occurred/VBD (l_nsubj) apnoea/NN
11928786
D016642_D020258 NONE Zyban/NNP (r_nsubj) caused/VBD (l_dobj) toxicity/NN
D000241_D012640 NONE adenosine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) treated/VBN (l_nsubjpass) seizures/NNS
D016642_D064420 NONE Bupropion/NNP (r_nmod) toxicity/NN -PUNC- Zyban/NNP (r_nmod) toxicity/NN
D000241_D013610 NONE adenosine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) treated/VBN (l_prep) with/IN (l_pobj) diazepam/NN (l_conj) tachycardia/NN
D016642_D002318 NONE Zyban/NNP (r_nsubj) caused/VBD (l_dobj) toxicity/NN
D003975_D012640 NONE diazepam/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) seizures/NNS
D016642_D062787 NONE Zyban/NNP (r_nsubj) caused/VBD (l_dobj) toxicity/NN (l_prep) in/IN (l_pobj) overdose/NN
D003975_D013610 NONE diazepam/NN (l_conj) tachycardia/NN
16174948
D003042_D013345 CID cocaine/NN (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN (l_appos) SAH/NNP -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) after/IN (r_prep) underwent/VBD (r_relcl) hemorrhage/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) after/IN (r_prep) underwent/VBD (r_relcl) hemorrhage/NN (l_appos) SAH/NNP -PUNC- cocaine/NN (r_pobj) for/IN (r_prep) toxicology/NN (r_pobj) with/IN (r_prep) those/DT (r_dobj) identified/VBD (r_conj) screened/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) SAH/NNP -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) SAH/NNP
D003042_D014657 NONE Cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) complications/NNS (l_prep) including/VBG (l_pobj) vasoconstriction/NN (l_conj) vasculitis/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) SAH/NNP (r_pobj) after/IN (r_prep) underwent/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) evidence/NN (l_prep) for/IN (l_pobj) narrowing/VBG (l_prep) of/IN (l_pobj) arteries/NNS (l_conj) evidence/NN (l_prep) for/IN (l_pobj) narrowing/NN (l_conj) vasculitis/NN
D003042_D017542 CID cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) SAH/NNP (l_amod) aneurysmal/NN
D003042_D013901 NONE Cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) complications/NNS
804391
D012293_D014376 NONE rifampin/NN (r_advmod) treated/VBN (r_amod) patients/NNS (l_prep) with/IN (l_pobj) tuberculosis/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_compound) tuberculosis/NN
D012293_D011507 CID rifampin/NN (r_advmod) treated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) proteinuria/NN -PUNC- rifampin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) found/VBN (l_nsubjpass) proteinuria/NN
17975693
D002939_D001008 CID ciprofloxacin-/JJ (r_nmod) rats/NNS (r_nsubj) showed/VBD (l_dobj) behaviour/NN
D009643_D001008 CID norfloxacin/NNS (r_npadvmod) treated/VBN (r_conj) ciprofloxacin-/JJ (r_nmod) rats/NNS (r_nsubj) showed/VBD (l_dobj) behaviour/NN
11897407
D007545_D007238 NONE isoproterenol/NN (r_pobj) with/IN (r_prep) obtained/VBN (r_conj) implies/VBZ (l_nsubj) model/NN (l_acl) used/VBN (l_xcomp) produce/VB (l_dobj) infarction/NN -PUNC- isoproterenol/JJ (r_compound) administration/NN (r_pobj) after/IN (r_prep) h/NN (r_npadvmod) developed/VBD (l_dobj) infarct/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
D005937_D007238 NONE acid/NN (r_pobj) on/IN (r_prep) based/VBN (r_acl) radiopharmaceutical/NN (l_amod) avid/JJ (l_npadvmod) infarct/NN
C067171_D009203 NONE glucarate/NN (l_prep) for/IN (l_pobj) detection/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- glucarate/NN (r_nsubj) was/VBD (l_conj) used/VBN (l_xcomp) study/VB (l_dobj) biodistribution/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) infarction/NN
7628595
D002955_D064420 NONE acid/NN (r_compound) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) toxicity/NN
D014805_D001855 NONE B12/NN (l_conj) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) suppression/NN -PUNC- B12/NN (l_conj) levels/NNS (l_conj) development/NN (l_prep) of/IN (l_pobj) myelosuppression/NN -PUNC- B12/NN (r_nsubj) seem/VB (l_oprd) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_conj) reducing/VBG (l_dobj) myelotoxicity/NN
D015215_D064420 NONE zidovudine/NN (r_pobj) of/IN (r_prep) toxicity/NN
D015215_D015658 NONE ZDV/NNP (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) virus/NN (l_appos) patients/NNS (l_amod) HIV)-infected/VBN
D014805_D064420 NONE B12/NN (l_conj) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) toxicity/NN
D002955_D001855 NONE acid/NN (r_compound) supplementation/NN (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) suppression/NN -PUNC- acid/NN (r_compound) supplementation/NN (r_conj) B12/NN (r_nsubj) seem/VB (l_oprd) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_conj) reducing/VBG (l_dobj) myelotoxicity/NN
D015215_D001855 CID zidovudine/NNP (r_nmod) suppression/NN -PUNC- ZDV)-induced/VBN (r_amod) suppression/NN -PUNC- ZDV/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) supplementation/NN (r_conj) B12/NN (r_nsubj) seem/VB (l_oprd) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_conj) reducing/VBG (l_dobj) myelotoxicity/NN -PUNC- ZDV/NNP (r_npadvmod) induced/VBN (r_amod) myelotoxicity/NN
D005492_D001855 NONE folate/JJ (r_compound) levels/NNS (l_conj) development/NN (l_prep) of/IN (l_pobj) myelosuppression/NN
2008831
D008755_D013035 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) use/VBP (r_relcl) tests/NNS (l_compound) spasm/NN
D008755_D000787 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) studied/VBN (l_prep) without/IN (l_pobj) angina/NN (l_appos) pectoris/NN
D008755_D000788 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_conj) without/IN (l_pobj) angina/NN -PUNC- methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN -PUNC- methylergonovine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) use/VBP (r_relcl) tests/NNS (r_nsubj) have/VBP (l_dobj) sensitivity/NN (l_prep) in/IN (l_pobj) angina/NN
D008755_D002637 NONE methylergonovine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angina/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) pain/NN
9334596
D013739_D007172 NONE testosterone/NN (r_pobj) of/IN (r_prep) results/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_acl) referred/VBD (l_prep) because/IN (l_pobj) dysfunction/NN -PUNC- testosterone/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) Most/JJS (r_nsubj) seemed/VBD (l_xcomp) result/VB (l_prep) because/IN (l_conj) have/VB (l_dobj) role/NN (l_prep) in/IN (l_pobj) dysfunction/NN -PUNC- testosterone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) dysfunction/NN
D013739_D006177 NONE testosterone/NN (r_pobj) for/IN (r_prep) screened/VBN (l_conj) screened/VBN (l_prep) on/IN (l_pobj) basis/NN (l_prep) of/IN (l_pobj) desire/NN (l_conj) gynecomastia/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN
D013739_D010911 NONE testosterone/NN (r_compound) determination/NN (r_pobj) after/IN (r_prep) discovered/VBN (l_nsubjpass) tumors/NNS
D013739_D007027 NONE testosterone/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) Most/JJS (r_nsubj) seemed/VBD (l_xcomp) result/VB (l_prep) from/IN (l_pobj) dysfunction/NN
C004648_D007006 NONE heptylate/NN (l_conj) gonadotropin/NN (l_prep) for/IN (l_pobj) hypogonadism/NN
D001971_D007006 NONE bromocriptine/NN (r_conj) hypogonadism/NN
C004648_D006966 NONE heptylate/NN (l_conj) gonadotropin/NN (l_prep) for/IN (l_pobj) hypogonadism/NN (l_conj) bromocriptine/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN
D013739_D020018 CID testosterone/NN (r_pobj) for/IN (r_prep) screened/VBN (l_conj) screened/VBN (l_prep) on/IN (l_pobj) basis/NN (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN (r_conj) desire/NN -PUNC- testosterone/NN (r_dobj) Determining/VBG (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_pobj) with/IN (r_prep) cases/NNS (r_pobj) of/IN (r_prep) %/NN (r_dobj) missed/VBN (l_csubj) Determining/VBG (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_nsubjpass) determined/VBN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) desire/NN -PUNC- testosterone/NN (r_conj) gynecomastia/NN (r_conj) desire/NN
D001971_D006966 NONE bromocriptine/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN
8888541
D014191_D020230 CID tranylcypromine/NN (r_compound) interaction/NN (r_pobj) from/IN (r_prep) syndrome/NN -PUNC- tranylcypromine/NN (r_dobj) taking/VBG (r_relcl) male/NN (r_pobj) in/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) syndrome/NN
D014191_D003866 NONE tranylcypromine/NN (l_prep) for/IN (l_pobj) depression/NN
D012701_D003221 NONE serotonin/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) stimulation/NN (r_nsubj) causes/VBZ (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN (l_conj) confusion/NN -PUNC- serotonin/NN (r_compound) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN (l_conj) confusion/NN
C047426_D003866 NONE venlafaxine/NNP (r_compound) MAOI/NNP (r_compound) interaction/NN (l_relcl) resulted/VBD (l_prep) in/IN (l_pobj) male/NN (l_relcl) taking/VBG (l_dobj) tranylcypromine/NN (l_prep) for/IN (l_pobj) depression/NN
D012701_D011595 NONE serotonin/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) stimulation/NN (r_nsubj) causes/VBZ (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN (l_conj) confusion/NN (l_conj) agitation/NN -PUNC- serotonin/NN (r_compound) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN (l_conj) confusion/NN (l_conj) agitation/NN
C047426_D020230 CID venlafaxine/NNP (r_compound) tranylcypromine/NN (r_compound) interaction/NN (r_pobj) from/IN (r_prep) syndrome/NN -PUNC- venlafaxine/NNP (r_compound) MAOI/NNP (r_compound) interaction/NN (l_relcl) resulted/VBD (l_prep) in/IN (l_pobj) syndrome/NN
D012701_D012798 NONE serotonin/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) stimulation/NN (r_nsubj) causes/VBZ (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN -PUNC- serotonin/NN (r_compound) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN
D012701_D009127 NONE serotonin/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) stimulation/NN (r_nsubj) causes/VBZ (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN -PUNC- serotonin/NN (r_compound) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN
D012701_D005334 NONE serotonin/NN (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) stimulation/NN (r_nsubj) causes/VBZ (l_dobj) syndrome/NN (l_prep) of/IN (l_pobj) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN (l_conj) confusion/NN (l_conj) agitation/NN (l_conj) hyperthermia/NN -PUNC- serotonin/NN (r_compound) excess/NN (l_relcl) consists/VBZ (l_prep) of/IN (l_pcomp) shivering/VBG (l_conj) rigidity/NN (l_conj) salivation/NN (l_conj) confusion/NN (l_conj) agitation/NN (l_conj) hyperthermia/NN
D003975_D009127 NONE diazepam/NN (r_pobj) of/IN (r_prep) mg/NN (r_pobj) After/IN (r_prep) remained/VBD (l_acomp) tremulous/JJ (l_prep) with/IN (l_pobj) rigidity/NN
7449470
D004317_D066126 NONE doxorubicin/NN (r_compound) cardiotoxicity/NN -PUNC- adriamycin/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) limits/VBZ (r_relcl) complication/NN (r_attr) is/VBZ (l_nsubj) toxicity/NN
16418614
D011441_D006111 NONE PTU/NNP (r_npadvmod) associated/VBN (r_amod) vasculitis/NN (l_prep) in/IN (l_pobj) girl/NN (l_prep) with/IN (l_pobj) Syndrome/NNP (l_conj) disease/NN
D011441_D014657 CID PTU/NNP (r_npadvmod) associated/VBN (r_amod) vasculitis/NN -PUNC- propylthiouracil/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_nsubjpass) made/VBN (l_nsubjpass) vasculitis/NN -PUNC- PTU)-associated/VBN (r_amod) vasculitis/NN -PUNC- PTU/NNP (r_pobj) of/IN (r_prep) withdrawal/NN (r_dobj) following/VBG (r_acl) resolution/NN (r_conj) detection/NN (r_appos) made/VBN (l_nsubjpass) vasculitis/NN
D011441_D014424 NONE PTU/NNP (r_npadvmod) associated/VBN (r_amod) vasculitis/NN (l_prep) in/IN (l_pobj) girl/NN (l_prep) with/IN (l_pobj) Syndrome/NNP
18541230
D011692_D009401 CID aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- aminonucleoside/RB (r_advmod) induced/VBN (r_amod) nephrosis/NN
D011692_D006402 NONE aminonucleoside/NN (r_advmod) induced/VBN (r_amod) abnormalities/NNS
D011692_D006949 NONE aminonucleoside/RB (r_advmod) induced/VBN (r_amod) dysfunction/NN (l_conj) hyperlipidemia/NN
D011692_D009404 NONE aminonucleoside/RB (r_advmod) induced/VBN (r_amod) nephrosis/NN (l_relcl) is/VBZ (l_attr) model/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- aminonucleoside/RB (r_advmod) induced/VBN (r_amod) syndrome/NN
D011692_D007674 NONE aminonucleoside/RB (r_advmod) induced/VBN (r_amod) dysfunction/NN
8599504
D004329_D014060 NONE droperidol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) minutes/NNS (r_pobj) within/IN (r_prep) developed/VBN (l_nsubj) angioedema/NN (l_prep) with/IN (l_pobj) swelling/NN
D004329_D004487 NONE droperidol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) minutes/NNS (r_pobj) within/IN (r_prep) developed/VBN (l_nsubj) angioedema/NN (l_prep) with/IN (l_pobj) swelling/NN
D004329_D000799 CID droperidol/NN (r_compound) administration/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) Angioedema/NNP -PUNC- droperidol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) minutes/NNS (r_pobj) within/IN (r_prep) developed/VBN (l_nsubj) angioedema/NN
D004329_D004342 NONE droperidol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) minutes/NNS (r_pobj) within/IN (r_prep) developed/VBN (r_relcl) allergies/NNS
20304337
D003042_-1 NONE cocaine/NN (r_pobj) to/IN (r_prep) exposed/VBN (l_nsubj) dysgenesis/NN
2266990
D008454_D012817 CID mazindol/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBN (l_dobj) appetite/NN (l_appos) change/NN (l_conj) symptoms/NNS -PUNC- mazindol/NN (r_amod) dosage/NN (r_nsubjpass) reduced/VBN (l_ccomp) included/VBN (l_dobj) appetite/NN (l_appos) change/NN (l_conj) symptoms/NNS
D008454_D001068 CID mazindol/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBN (l_dobj) appetite/NN -PUNC- mazindol/NN (r_amod) dosage/NN (r_nsubjpass) reduced/VBN (l_ccomp) included/VBN (l_dobj) appetite/NN
D008454_D020388 NONE mazindol/NN (l_prep) in/IN (l_pobj) dystrophy/NN -PUNC- mazindol/NN (r_pobj) of/IN (r_prep) trial/NN (r_dobj) conducted/VBD (l_prep) in/IN (l_pobj) boys/NNS (l_prep) with/IN (l_pobj) dystrophy/NN -PUNC- Mazindol/JJ (r_compound) doses/NNS (r_nsubj) slow/VBP (l_dobj) progression/NN (l_prep) of/IN (l_pobj) weakness/NN (l_prep) in/IN (l_pobj) dystrophy/NN
D008454_D014987 CID mazindol/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBN (l_dobj) appetite/NN (l_appos) mouth/NN -PUNC- mazindol/NN (r_amod) dosage/NN (r_nsubjpass) reduced/VBN (l_ccomp) included/VBN (l_dobj) appetite/NN (l_appos) mouth/NN
D008454_D018908 NONE Mazindol/JJ (r_compound) doses/NNS (r_nsubj) slow/VBP (l_dobj) progression/NN (l_prep) of/IN (l_pobj) weakness/NN
15985056
D008874_D006606 NONE midazolam/NN (r_appos) benzodiazepines/NNS (r_appos) Corticosteroids/NNS (r_nsubj) been/VBN (l_attr) agents/NNS (l_acl) mentioned/VBD (l_prep) as/IN (l_pcomp) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hiccups/NNS
D017963_D006606 CID azithromycin/RB (r_advmod) associated/VBN (r_amod) hiccups/NNS -PUNC- azithromycin/CD (r_amod) therapy/NN (r_pobj) by/IN (r_agent) associated/VBN (r_acl) hiccups/NNS -PUNC- azithromycin/RB (r_advmod) beginning/VBG (r_pcomp) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) hiccups/NNS -PUNC- azithromycin/NNP (r_pobj) of/IN (r_prep) Discontinuation/NN (r_nsubj) resolved/VBD (l_dobj) hiccups/NNS -PUNC- azithromycin/WP (r_pobj) by/IN (r_agent) mediated/VBN (r_acl) mechanism/NN (r_nsubj) be/VB (l_attr) pathogenesis/NN (l_prep) of/IN (l_pobj) hiccups/NNS
D003907_D006606 NONE dexamethasone/NN (r_appos) Corticosteroids/NNS (r_nsubj) been/VBN (l_attr) agents/NNS (l_acl) mentioned/VBD (l_prep) as/IN (l_pcomp) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hiccups/NNS
D018942_D006606 NONE macrolide/NN (r_amod) antimicrobials/NNS (r_pobj) to/IN (r_prep) related/VBN (r_oprd) reported/VBN (l_nsubjpass) cases/NNS (l_prep) of/IN (l_pobj) hiccups/NNS -PUNC- macrolides/NNS (r_pobj) with/IN (r_prep) reaction/NN (l_conj) absence/NN (l_prep) of/IN (l_pobj) explanation/NN (l_prep) for/IN (l_pobj) hiccups/NNS -PUNC- macrolide/NN (r_amod) antimicrobials/NNS (r_nsubjpass) reported/VBN (l_xcomp) associated/VBN (l_prep) with/IN (l_pobj) mechanism/NN (l_nmod) hiccups/NNS
D008775_D006606 NONE methylprednisolone/NN (r_conj) dexamethasone/NN (r_appos) Corticosteroids/NNS (r_nsubj) been/VBN (l_attr) agents/NNS (l_acl) mentioned/VBD (l_prep) as/IN (l_pcomp) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hiccups/NNS
D017963_D010612 NONE azithromycin/RB (r_advmod) beginning/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) pharyngitis/NN
D001418_D006606 CID baclofen/NN (r_pobj) with/IN (r_prep) therapy/NN (r_conj) Discontinuation/NN (r_nsubj) resolved/VBD (l_dobj) hiccups/NNS
D001569_D006606 NONE benzodiazepines/NNS (r_appos) Corticosteroids/NNS (r_nsubj) been/VBN (l_attr) agents/NNS (l_acl) mentioned/VBD (l_prep) as/IN (l_pcomp) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hiccups/NNS
9636837
D016190_D020258 NONE carboplatin/NN (r_poss) advantages/NNS (r_pobj) of/IN (r_prep) striking/JJ (r_nsubj) is/VBZ (l_attr) rate/NN (l_prep) of/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- CBDCA/NNP (r_appos) advantages/NNS (r_pobj) of/IN (r_prep) striking/JJ (r_nsubj) is/VBZ (l_attr) rate/NN (l_prep) of/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- CBDCA/NNP (r_nmod) schedules/NNS (l_conj) association/NN (l_prep) with/IN (l_pobj) drugs/NNS (l_amod) neurotoxic/JJ -PUNC- CBDCA/NNP (r_nsubj) is/VBZ (l_acomp) neurotoxic/JJ -PUNC- CBDCA/NNP (r_nsubj) is/VBZ (l_conj) are/VBP (l_ccomp) is/VBZ (l_ccomp) induced/VBN (l_nsubjpass) neurotoxicity/NN
D016190_D010523 CID CBDCA/NNP (r_nmod) schedules/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubj) cause/VB (l_dobj) concern/NN (l_prep) about/IN (l_pobj) safety/NN (l_prep) with/IN (l_pobj) respect/NN (l_prep) to/IN (l_pobj) damage/NN -PUNC- CBDCA/JJ (r_compound) administration/NN (r_nsubj) induced/VBD (l_dobj) neurotoxicity/NN
D002945_D020258 NONE cisplatin/NN (r_nmod) CDDP/NNP (r_pobj) over/IN (r_prep) striking/JJ (r_nsubj) is/VBZ (l_attr) rate/NN (l_prep) of/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- CDDP/NNP (r_pobj) over/IN (r_prep) striking/JJ (r_nsubj) is/VBZ (l_attr) rate/NN (l_prep) of/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- CDDP/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) those/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) are/VBP (r_conj) is/VBZ (l_acomp) neurotoxic/JJ -PUNC- CDDP/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) those/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) are/VBP (l_ccomp) is/VBZ (l_ccomp) induced/VBN (l_nsubjpass) neurotoxicity/NN
18023325
D004221_D010523 CID disulfiram/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neuropathy/NN
D004221_D011115 NONE disulfiram/NN (r_compound) intoxication/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) polyneuropathy/NN
D004221_D010243 NONE disulfiram/NN (r_compound) intoxication/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) polyneuropathy/NN (r_dobj) superimposed/VBN (r_conj) was/VBD (l_attr) case/NN (l_prep) of/IN (l_pobj) palsy/JJ
D004221_D014826 CID disulfiram/NN (r_compound) intoxication/NN (r_pobj) after/IN (r_prep) palsy/JJ -PUNC- disulfiram/NN (r_compound) overdose/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neuropathy/NN (r_nsubj) is/VBZ (l_conj) is/VBZ (l_attr) report/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) palsy/JJ
D004221_D062787 NONE disulfiram/NN (r_compound) overdose/NN
7596955
D000242_D001791 NONE cAMP/NNS (r_pobj) of/IN (r_prep) determination/NN (r_conj) aggregation/NN
C045645_D009325 CID CLZ/NNP (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) accompanying/VBG (l_dobj) flush/NN (l_prep) in/IN (l_pobj) one/CD (l_conj) nausea/NN
C045645_D005483 CID CLZ/NNP (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) accompanying/VBG (l_dobj) flush/NN
C045645_D006261 CID CLZ/NNP (r_pobj) of/IN (r_prep) ingestion/NN (r_pobj) after/IN (r_prep) accompanying/VBG (r_acl) duration/NN (r_pobj) of/IN (r_prep) headache/NN
15673851
D018698_D020336 NONE glutamate/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) with/IN (r_prep) induces/VBZ (l_dobj) paraparesis/NN
D016202_D020336 NONE NMDA/NNP (r_compound) activation/NN (r_pobj) in/IN (r_prep) involved/VBN (r_relcl) glutamate/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) with/IN (r_prep) induces/VBZ (l_dobj) paraparesis/NN
D009020_D001157 NONE morphine/NN (r_pobj) after/IN (r_prep) degeneration/NN (l_prep) following/VBG (l_pobj) interval/NN (l_prep) of/IN (l_pobj) occlusion/NN
D016291_D020336 NONE MK-801/NNP (r_punct) (/-LRB- (r_punct) mug/NN (l_prep) on/IN (l_pobj) changes/NNS (l_prep) after/IN (l_pobj) paraparesis/NN -PUNC- MK-801/NNP (r_punct) reduced/VBD (l_prep) after/IN (l_pobj) paraparesis/NN
D016202_D020258 NONE NMDA/NNP (r_compound) activation/NN (r_pobj) via/IN (r_prep) ischemia/NN (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) be/VB (l_acomp) neurotoxic/JJ
D009020_D020336 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) paraparesis/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) paraparesis/NN -PUNC- morphine/NN (r_nsubj) induces/VBZ (l_dobj) paraparesis/NN
D016202_D020760 NONE aspartate/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) activation/NN (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) degeneration/NN (l_acl) induced/VBN (l_prep) after/IN (l_pobj) interval/NN (l_prep) of/IN (l_pobj) ischemia/NN -PUNC- NMDA/NNP (r_compound) activation/NN (r_pobj) via/IN (r_prep) ischemia/NN
D009020_D020760 NONE morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_prep) after/IN (l_pobj) interval/NN (l_prep) of/IN (l_pobj) ischemia/NN
D016202_D001157 NONE aspartate/NNP (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) activation/NN (r_conj) neurons/NNS (r_pobj) of/IN (r_prep) degeneration/NN (l_prep) following/VBG (l_pobj) interval/NN (l_prep) of/IN (l_pobj) occlusion/NN -PUNC- NMDA/NNP (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) activation/NN (r_conj) neurons/NNS (r_pobj) of/IN (r_prep) degeneration/NN (l_prep) following/VBG (l_pobj) interval/NN (l_prep) of/IN (l_pobj) occlusion/NN
11282081
D009020_D001281 NONE morphine/NN (r_npadvmod) chloralose/NN (r_amod) dogs/NNS (r_pobj) to/IN (r_prep) administered/VBD (l_advcl) evaluate/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) promotion/NN (l_compound) AF/NNP
D002118_D001281 NONE Ca(2/NNP (r_dobj) decreases/VBZ (r_conj) promotes/VBZ (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) fibrillation/NN -PUNC- Ca(2/NNP (r_dobj) decreases/VBZ (r_conj) promotes/VBZ (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) fibrillation/NN (l_appos) AF/NNP -PUNC- Ca(2/NN (r_nmod) channel/NN (r_compound) blockade/NN (r_nsubj) promote/VB (l_dobj) AF/NNP -PUNC- Ca(2/NN (r_nmod) channel/NN (r_compound) blockade/NN (r_nsubj) promote/VB (l_advcl) consistent/JJ (l_prep) with/IN (l_pobj) effect/NN (l_compound) AF/NNP -PUNC- Ca(2/NNP (r_nmod) inhibition/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) with/IN (r_prep) consistent/JJ (r_advcl) promote/VB (l_dobj) AF/NNP -PUNC- Ca(2/NNP (r_nmod) inhibition/NN (r_pobj) of/IN (r_prep) effect/NN (l_compound) AF/NNP -PUNC- Ca(2/NNP (r_nmod) blockers/NNS (r_pobj) by/IN (r_prep) promotion/NN (l_compound) AF/NNP
D002118_D013617 NONE Ca(2/NNP (r_dobj) decreases/VBZ (r_conj) promotes/VBZ (l_nsubj) tachycardia/NN
D014700_D001281 CID verapamil/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) fibrillation/NN -PUNC- verapamil/NN (r_dobj) administered/VBD (l_advcl) evaluate/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) promotion/NN (l_compound) AF/NNP -PUNC- Verapamil/NNP (r_nsubj) caused/VBD (l_dobj) promotion/NN (l_compound) AF/NNP -PUNC- Verapamil/NNP (r_nsubj) caused/VBD (l_advcl) increasing/VBG (l_dobj) duration/NN (l_prep) of/IN (l_pobj) AF/NNP -PUNC- verapamil/NN (r_nsubj) shortened/VBN (l_conj) accelerated/VBN (l_conj) decreased/VBD (l_dobj) length/NN (l_prep) of/IN (l_pobj) 94+/-4/CD (l_nmod) AF/NNP -PUNC- verapamil/NNP (r_nmod) n=5/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_amod) acceleration/NN (r_dobj) produced/VBD (r_conj) affect/VB (l_dobj) ERP/NNP (l_conj) length/NN (l_compound) AF/NNP -PUNC- verapamil/NNP (r_nmod) n=5/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_amod) acceleration/NN (r_dobj) produced/VBD (r_conj) affect/VB (l_dobj) ERP/NNP (l_conj) length/NN (l_conj) duration/NN (l_compound) AF/NNP -PUNC- verapamil/NN (r_nsubj) failed/VBD (l_xcomp) promote/VB (l_dobj) AF/NNP -PUNC- verapamil/NN (r_nsubj) promoted/VBD (l_dobj) AF/NNP -PUNC- Verapamil/NNP (r_nsubj) promotes/VBZ (l_dobj) AF/NNP
D002698_D001281 NONE chloralose/NN (r_amod) dogs/NNS (r_pobj) to/IN (r_prep) administered/VBD (l_advcl) evaluate/VB (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) promotion/NN (l_compound) AF/NNP
D004110_D001281 NONE Diltiazem/NNP (r_nsubj) affect/VB (l_dobj) ERP/NNP (l_conj) length/NN (l_compound) AF/NNP -PUNC- Diltiazem/NNP (r_nsubj) affect/VB (l_dobj) ERP/NNP (l_conj) length/NN (l_conj) duration/NN (l_compound) AF/NNP -PUNC- diltiazem/NN (r_pobj) by/IN (r_agent) shared/VBN (r_conj) effect/NN (r_dobj) promotes/VBZ (l_dobj) AF/NNP
3962737
D000638_D056486 CID amiodarone/NN (r_pobj) of/IN (r_prep) Hepatotoxicity/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_appos) patient/NN (l_prep) with/IN (l_pobj) hepatitis/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_appos) patient/NN (r_nsubjpass) presented/VBN (l_conj) given/VBN (l_nsubjpass) review/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) hepatotoxicity/NN (r_pobj) of/IN (r_prep) review/NN (r_nsubjpass) given/VBN (r_conj) presented/VBN (l_nsubjpass) patient/NN (l_prep) with/IN (l_pobj) hepatitis/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) hepatotoxicity/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) exists/VBZ (l_prep) of/IN (l_pobj) injury/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (l_pobj) alterations/NNS (l_acl) resembling/VBG (l_dobj) hepatitis/NN (l_appos) cirrhosis/NN (l_nmod) hepatitis/NN
D000638_D005234 CID amiodarone/NN (r_compound) treatment/NN (l_prep) including/VBG (l_pobj) steatosis/NN
D000638_D002779 CID amiodarone/NN (r_compound) treatment/NN (r_appos) patient/NN (l_prep) with/IN (l_pobj) hepatitis/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) hepatotoxicity/NN (r_pobj) of/IN (r_prep) review/NN (r_nsubjpass) given/VBN (r_conj) presented/VBN (l_nsubjpass) patient/NN (l_prep) with/IN (l_pobj) hepatitis/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (l_pobj) alterations/NNS (l_acl) resembling/VBG (l_dobj) hepatitis/NN (l_appos) cirrhosis/NN (l_nmod) hepatitis/NN
D000638_D013610 NONE Amiodarone/NNP (r_nsubj) proved/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tachyarrhythmias/NNS
D000638_D006519 NONE amiodarone/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (l_pobj) alterations/NNS (l_acl) resembling/VBG (l_dobj) hepatitis/NN
D000638_D008103 CID amiodarone/NN (r_compound) treatment/NN (r_pobj) to/IN (r_pcomp) due/IN (l_pobj) alterations/NNS (l_acl) resembling/VBG (l_dobj) hepatitis/NN (l_appos) cirrhosis/NN (l_prep) of/IN (l_pobj) liver/NN
17042910
D003907_D006973 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- Dexamethasone/NNP (l_parataxis) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- Dex)-induced/JJ (r_amod) hypertension/NN
D013481_D006973 NONE superoxide/NN (r_advmod) increased/VBN (r_conj) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- O2-/NNPS (r_nmod) production/NN (r_appos) Dexamethasone/NNP (l_parataxis) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- O2-/JJ (r_compound) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
D009569_D006973 NONE oxide/NN (r_nmod) deficiency/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dysfunction/NN (r_pobj) by/IN (r_agent) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- NO/NNP (r_intj) deficiency/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) dysfunction/NN (r_pobj) by/IN (r_agent) characterized/VBN (l_nsubjpass) hypertension/NN -PUNC- NO/DT (r_amod) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
C065179_D006973 NONE atorvastatin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- Atorvastatin/NNP (r_nsubj) possesses/VBZ (l_dobj) properties/NNS (l_relcl) reported/VBN (l_xcomp) improve/VB (l_prep) through/IN (l_pobj) availability/NN (l_prep) of/IN (l_pobj) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- Ato/NNP (r_appos) Atorvastatin/NNP (r_nsubj) possesses/VBZ (l_dobj) properties/NNS (l_relcl) reported/VBN (l_xcomp) improve/VB (l_prep) through/IN (l_pobj) availability/NN (l_prep) of/IN (l_pobj) production/NN (l_prep) in/IN (l_pobj) forms/NNS (l_prep) of/IN (l_pobj) hypertension/NN
6540303
D002395_D002389 NONE catecholamines/NNS (r_pobj) of/IN (r_prep) role/NN (l_prep) on/IN (l_pobj) catatonia/NN
D007649_D002389 CID ketamine/NN (r_compound) catatonia/NN -PUNC- ketamine/NN (r_npadvmod) induced/VBN (r_amod) catatonia/NN -PUNC- ketamine/NN (r_pobj) after/IN (r_prep) increased/VBD (l_dobj) duration/NN (l_prep) of/IN (l_pobj) catatonia/NNP -PUNC- ketamine/NN (r_compound) catatonia/NNP
D000588_D002389 NONE amine/NN (r_compound) pretreatment/NN (l_prep) on/IN (l_pobj) catatonia/NN
D004298_D002389 CID dopamine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) increased/VBD (l_dobj) duration/NN (l_prep) of/IN (l_pobj) catatonia/NNP -PUNC- dopamine/NN (r_nsubj) appeared/VBD (l_xcomp) act/VB (l_prep) on/IN (l_pobj) systems/NNS (l_acl) involved/JJ (l_prep) with/IN (l_pobj) induction/NN (l_prep) of/IN (l_pobj) catatonia/NNP
D009638_D002389 NONE norepinephrine/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) did/VBD (r_conj) increased/VBD (l_dobj) duration/NN (l_prep) of/IN (l_pobj) catatonia/NNP
9855119
D016559_D005355 NONE FK506/NNP (r_compound) nephropathy/NN (r_nsubj) consisted/VBD (r_ccomp) angiodegeneration/NN (l_appos) biopsies/NNS (l_conj) glomerulosclerosis/NN (l_conj) form/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D016559_D005923 CID FK506/NNP (r_compound) nephropathy/NN (r_nsubj) consisted/VBD (r_ccomp) angiodegeneration/NN (l_appos) biopsies/NNS (l_conj) glomerulosclerosis/NN
D003404_D007674 NONE creatinine/NN (r_compound) levels/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN -PUNC- creatinine/NN (r_compound) levels/NNS (r_nsubj) were/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) those/DT (l_prep) in/IN (l_pobj) group/NN (l_compound) FK506-nephropathy/NNP
D016559_D005922 NONE FK506/NN (r_compound) nephropathy/NN (r_conj) findings/NNS (r_conj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_conj) nephropathy/NN (r_conj) findings/NNS (r_conj) nephropathy/NN
D016559_D007674 NONE FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (l_conj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_conj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NNP (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_pobj) of/IN (r_prep) levels/NNS (r_nsubj) were/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) those/DT (l_prep) in/IN (l_pobj) group/NN (l_compound) FK506-nephropathy/NNP -PUNC- FK506-nephropathy/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) higher/JJR (r_acomp) were/VBD (l_nsubj) levels/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_prep) in/IN (l_pobj) group/NN (l_compound) nephropathy/NN -PUNC- FK506-nephropathy/NNP -PUNC- FK506/NNP (r_compound) nephropathy/NN -PUNC- FK506/NNP (r_compound) nephropathy/NN (r_nsubj) consists/VBZ (r_ccomp) demonstrates/VBZ (l_conj) suggests/VBZ (l_ccomp) is/VBZ (l_nsubj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN (r_nsubj) is/VBZ (r_ccomp) suggests/VBZ (r_conj) demonstrates/VBZ (l_ccomp) consists/VBZ (l_nsubj) nephropathy/NN -PUNC- FK506/NN (r_compound) nephropathy/NN
6387529
D003975_D008569 CID diazepam/NN (r_pobj) for/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_conj) impaired/VBD (l_dobj) recall/NN
D011433_D008569 CID propranolol/NN (r_advcl) diazepam/NN (r_pobj) for/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_conj) impaired/VBD (l_dobj) recall/NN
D003975_D000379 NONE diazepam/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) agoraphobia/NNP -PUNC- diazepam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS (l_conj) agoraphobia/NNP
D011433_D016584 NONE propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
D011433_D000379 NONE propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) agoraphobia/NNP -PUNC- propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS (l_conj) agoraphobia/NNP
D003975_D016584 NONE diazepam/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) propranolol/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- diazepam/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) propranolol/NN (r_advcl) investigated/VBN (l_nsubjpass) dose/NN (l_prep) on/IN (l_pobj) performance/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
9199746
D000583_D013290 NONE amikacin/JJ (r_prep) presumed/VBN (l_prep) following/VBG (l_pobj) treatment/NN (l_prep) with/IN (l_pobj) amikacin/JJ (l_conj) vancomycin/NNP (l_prep) for/IN (l_pobj) endophthalmitis/NN -PUNC- amikacin/JJ (l_conj) vancomycin/NNP (l_prep) for/IN (l_pobj) endophthalmitis/NN
D014640_D012164 NONE vancomycin/NNP (r_conj) amikacin/JJ (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) presumed/VBN (l_prep) amikacin/JJ (l_pobj) toxicity/NN
D000617_D007238 NONE aminoglycosides/NNS (r_nsubj) improved/VBN (r_advcl) impair/VB (l_nsubj) infarction/NN
D000617_D009877 NONE aminoglycosides/NNS (r_nsubj) improved/VBN (l_dobj) prognosis/NN (l_prep) in/IN (l_pobj) endophthalmitis/NN
D000583_D012164 CID amikacin/JJ (l_pobj) toxicity/NN -PUNC- amikacin/JJ (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) following/VBG (r_prep) presumed/VBN (l_prep) amikacin/JJ (l_pobj) toxicity/NN
D014640_D013290 NONE vancomycin/NNP (l_prep) for/IN (l_pobj) endophthalmitis/NN
D019793_D013684 NONE fluorescein/NN (r_amod) angiography/NN (r_nsubj) confirmed/VBD (l_dobj) closure/NN (l_conj) telangiectasis/NN
D000583_D064420 NONE amikacin/RB (l_nsubj) toxicity/NN
6794356
D008094_D006331 NONE lithium/NN (r_compound) compounds/NNS (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) infants/NNS (r_pobj) among/IN (r_prep) disease/NN
D008094_D006333 NONE lithium/NN (r_compound) level/NN (r_conj) failure/NN
D016651_D064420 NONE carbonate/NN (r_compound) toxicity/NN
D016651_D006331 NONE carbonate/NN (r_nsubj) be/VB (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) disease/NN
D008094_D001282 NONE lithium/NN (r_compound) level/NN (r_conj) failure/NN (r_conj) flutter/JJ -PUNC- lithium/NN (r_compound) compounds/NNS (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) infants/NNS (r_pobj) among/IN (r_prep) disease/NN (r_pobj) with/IN (r_prep) patient/NN (r_dobj) described/VBN (r_conj) is/VBZ (l_attr) patient/NN (l_relcl) manifest/VB (l_dobj) regurgitation/NN (l_conj) flutter/NN
D008094_D014262 NONE lithium/NN (r_compound) level/NN (r_conj) failure/NN (r_conj) flutter/JJ (r_conj) regurgitation/NN -PUNC- lithium/NN (r_compound) compounds/NNS (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) infants/NNS (r_pobj) among/IN (r_prep) disease/NN (r_pobj) with/IN (r_prep) patient/NN (r_dobj) described/VBN (r_conj) is/VBZ (l_attr) patient/NN (l_relcl) manifest/VB (l_dobj) regurgitation/NN
D016651_D014262 NONE carbonate/NN (r_compound) toxicity/NN (r_conj) regurgitation/NN
3411101
D011802_D056486 NONE Quinidine/NN (r_nsubj) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) hepatitis/NN
C033457_D056486 CID phenylethylbarbiturate/NN (r_npadvmod) induced/VBN (l_dobj) hepatitis/NN -PUNC- phenylethylbarbiturate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) affected/VBN (l_agent) by/IN (l_pobj) hepatitis/NN -PUNC- phenylethylbarbiturate/NN (r_conj) Quinidine/NN (r_nsubj) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) hepatitis/NN
17919553
C106791_D064420 NONE telithromycin/NNS (r_nsubj) was/VBD (l_prep) Based/VBN (l_prep) on/IN (l_pobj) score/NN (l_prep) on/IN (l_pobj) scale/NN (l_compound) probability/NN (l_compound) reaction/NN
C106791_D056486 CID telithromycin/NNS (r_relcl) exposure/NN (r_pobj) after/IN (r_prep) attack/NN (l_compound) hepatitis/NNP -PUNC- telithromycin/NNS (r_compound) usage/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_ccomp) suffered/VBN (l_dobj) episode/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- telithromycin/NNS (r_nsubj) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) hepatitis/NN -PUNC- telithromycin/NNS (r_nsubj) was/VBD (l_conj) suggested/VBD (l_dobj) hepatitis/NN -PUNC- telithromycin/NNS (r_dobj) prescribed/VBD (r_relcl) physician/NN (r_pobj) to/IN (r_prep) communicated/VBN (r_advcl) avoided/VBN (l_nsubjpass) Recurrence/NN (l_prep) of/IN (l_pobj) attack/NN (l_compound) hepatitis/NN -PUNC- telithromycin/NNS (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) hepatitis/NN
1992636
D009853_D004417 CID omeprazole/NN (r_pobj) with/IN (r_prep) starting/VBG (r_pcomp) after/IN (r_prep) weakness/NN (l_conj) lethargy/NN (l_conj) shortness/NN (l_prep) of/IN (l_pobj) breath/NN
D009853_D053609 CID omeprazole/NN (r_pobj) with/IN (r_prep) starting/VBG (r_pcomp) after/IN (r_prep) weakness/NN (l_conj) lethargy/NN
D009853_D000743 CID omeprazole/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) anemia/NN -PUNC- omeprazole/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) reaction/NN (r_pobj) of/IN (r_prep) case/NN (l_appos) anemia/NN -PUNC- omeprazole/NN (r_nsubj) caused/VBD (l_ccomp) is/VBZ (l_nsubj) anemia/NN
8752018
D014635_D001714 NONE sodium/NN (r_dobj) divalproex/NN (r_advcl) switching/VBG (l_dobj) patients/NNS (l_amod) bipolar/JJ -PUNC- sodium/NN (r_pobj) with/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_acl) attributed/VBN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ
D008094_D003072 CID Lithium/NN (r_npadvmod) associated/VBN (r_amod) deficits/NNS -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) management/NN (r_pobj) about/IN (r_prep) written/VBN (r_advcl) remain/VBP (l_nsubj) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) management/NN (r_pobj) about/IN (r_prep) written/VBN (r_advcl) remain/VBP (l_nsubj) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) of/IN (r_prep) management/NN (r_pobj) about/IN (r_prep) written/VBN (r_advcl) remain/VBP (l_nsubj) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_conj) impairments/NNS -PUNC- lithium/NN (r_compound) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS -PUNC- lithium/NN (r_compound) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- lithium/NN (r_compound) effects/NNS (l_prep) as/IN (l_pobj) deficits/NNS (l_conj) loss/NN (l_conj) impairments/NNS -PUNC- lithium/NN (r_pobj) from/IN (r_prep) switching/VBG (l_advcl) divalproex/NN (l_xcomp) alleviate/VB (l_dobj) impairments/NNS -PUNC- lithium/NN (r_pobj) of/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_conj) motivational/JJ (l_conj) deficits/NNS -PUNC- lithium/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_acl) cognitive/JJ (l_conj) motivational/JJ (l_conj) deficits/NNS -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN (l_conj) impairments/NNS
D008094_D011141 NONE lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN -PUNC- lithium/NN (r_compound) effects/NNS (r_nsubj) remain/VBP (l_advcl) written/VBN (l_prep) about/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN
D008094_D001714 NONE Lithium/NN (r_nsubj) remains/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disorder/NN -PUNC- lithium/NN (r_pobj) from/IN (r_prep) switching/VBG (l_dobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (r_pobj) of/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_acl) attributed/VBN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ
D008094_D014202 NONE lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN (l_conj) tremor/NN -PUNC- lithium/NN (r_compound) effects/NNS (r_nsubj) remain/VBP (l_advcl) written/VBN (l_prep) about/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) as/IN (l_pobj) polyuria/NN (l_conj) tremor/NN
D014635_D003072 NONE sodium/NN (r_dobj) divalproex/NN (r_advcl) reduced/VBN (r_acl) deficits/NNS -PUNC- sodium/NN (r_dobj) divalproex/NN (l_xcomp) alleviate/VB (l_dobj) impairments/NNS -PUNC- sodium/NN (r_pobj) with/IN (r_prep) substitution/NN (r_nsubj) was/VBD (l_acomp) helpful/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) cognitive/JJ (l_conj) motivational/JJ (l_conj) deficits/NNS -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN -PUNC- sodium/NN (r_nsubj) was/VBD (l_attr) alternative/NN (l_prep) to/IN (l_pobj) lithium/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) experiencing/VBG (l_dobj) deficits/NNS (l_conj) loss/NN (l_prep) of/IN (l_pobj) creativity/NN (l_conj) impairments/NNS
17511042
C417083_D019698 NONE alpha-2b/NN (r_pobj) during/IN (r_prep) parasitosis/NN (l_prep) in/IN (l_pobj) patient/NN (l_compound) C/NN
D012254_D019698 NONE ribavirin/JJ (r_compound) treatment/NN (r_conj) alpha-2b/NN (r_pobj) during/IN (r_prep) parasitosis/NN (l_prep) in/IN (l_pobj) patient/NN (l_compound) C/NN -PUNC- ribavirin/RB (r_conj) interferon/NN (r_pobj) with/IN (r_prep) patients/NNS (l_compound) C/NNP
D012254_D063726 CID ribavirin/JJ (r_compound) treatment/NN (r_conj) alpha-2b/NN (r_pobj) during/IN (r_prep) parasitosis/NN -PUNC- ribavirin/RB (r_conj) weekly/RB (r_amod) alpha-2b/CD (r_prep) present/VBP (l_dobj) woman/NN (l_relcl) developed/VBD (l_dobj) parasitosis/NN
C417083_D063726 CID alpha-2b/NN (r_pobj) during/IN (r_prep) parasitosis/NN -PUNC- alpha-2b/CD (r_prep) present/VBP (l_dobj) woman/NN (l_relcl) developed/VBD (l_dobj) parasitosis/NN
9522152
D002045_D009461 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_dobj) following/VBG (r_acl) deficit/NN -PUNC- bupivacaine/NN (r_pobj) with/IN (r_prep) anaesthesia/NN (r_pobj) after/IN (r_prep) occurred/VBD (r_relcl) deficit/NN
17194457
D012701_D001523 NONE 5-HT/CD (r_pobj) with/IN (r_prep) users/NNS (r_nsubj) be/VB (l_acomp) prone/JJ (l_xcomp) exhibit/VB (l_dobj) behavior/NN
D013739_D001523 CID T/NNP (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) locomotion/NN (l_conj) irritability/NN -PUNC- T/NNP (r_nsubj) had/VBD (l_conj) preference/NN (l_conj) aggression/NN
-1_D001523 NONE PCPA/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) decreased/VBD (l_conj) increased/VBN (l_dobj) irritability/NN -PUNC- PCPA/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) decreased/VBD (l_conj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) behavior/NN (l_conj) preference/NN (l_conj) aggression/NN
17437408
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
9061311
D009240_D017114 NONE phenylalanine/NN (r_nmod) fMLP/NN (r_pobj) with/IN (r_prep) stimulated/VBN (l_prep) from/IN (l_pobj) patients/NNS (l_compound) ALF/NNP -PUNC- fMLP/NN (r_pobj) with/IN (r_prep) stimulated/VBN (l_prep) from/IN (l_pobj) patients/NNS (l_compound) ALF/NNP
D000082_D017114 CID paracetamol/JJ (r_compound) overdose/NN (r_pobj) due/IN (r_amod) production/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) ALF/NNP -PUNC- paracetamol/JJ (r_compound) overdose/NN (r_pobj) due/IN (r_prep) demonstrate/VBP (l_dobj) defect/NN (l_prep) in/IN (l_pobj) ALF/NNP
D006861_D017114 NONE peroxide/NN (r_conj) superoxide/NN (r_nmod) production/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- peroxide/NN (r_compound) production/NN (r_pobj) in/IN (r_prep) Defects/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- peroxide/NN (r_compound) production/NN (r_pobj) in/IN (r_prep) Defects/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_appos) ALF/NNP -PUNC- peroxide/NN (r_compound) production/NN (r_conj) Superoxide/NN (l_prep) by/IN (l_pobj) neutrophils/NNS (l_compound) ALF/NNP -PUNC- peroxide/NN (r_compound) production/NN (r_conj) Superoxide/NN (r_nsubj) stimulated/VBN (l_dobj) opsonized/VBN (l_prep) with/IN (l_pobj) serum/NN (l_compound) ALF/NNP -PUNC- peroxide/NN (r_compound) production/NN (r_conj) Superoxide/NN (l_prep) in/IN (l_pobj) neutrophils/NNS (l_acl) stimulated/VBN (l_prep) from/IN (l_pobj) patients/NNS (l_compound) ALF/NNP
D010100_D017114 NONE oxygen/NN (r_nmod) production/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) ALF/NNP
D006861_D001424 NONE peroxide/NN (r_compound) production/NN (r_pobj) in/IN (r_prep) Defects/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infections/NNS
D013481_D001424 NONE superoxide/NN (r_amod) production/NN (r_pobj) in/IN (r_prep) Defects/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infections/NNS
D000082_D062787 NONE paracetamol/JJ (r_compound) overdose/NN -PUNC- paracetamol/JJ (r_compound) overdose/NN
D013481_D017114 NONE superoxide/NN (r_nmod) production/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- superoxide/NN (r_amod) production/NN (r_pobj) in/IN (r_prep) Defects/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- superoxide/NN (r_amod) production/NN (r_pobj) in/IN (r_prep) Defects/NNS (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_appos) ALF/NNP -PUNC- Superoxide/NN (l_prep) by/IN (l_pobj) neutrophils/NNS (l_compound) ALF/NNP -PUNC- Superoxide/NN (r_nsubj) stimulated/VBN (l_dobj) opsonized/VBN (l_prep) with/IN (l_pobj) serum/NN (l_compound) ALF/NNP -PUNC- Superoxide/NN (l_prep) in/IN (l_pobj) neutrophils/NNS (l_acl) stimulated/VBN (l_prep) from/IN (l_pobj) patients/NNS (l_compound) ALF/NNP
D010100_D062787 NONE oxygen/NN (r_nmod) production/NN (l_amod) due/IN (l_pobj) overdose/NN
2334618
D009020_D020182 CID morphine/NN (r_compound) infusion/NN (r_dobj) had/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) obstructive/JJ (l_appos) P/NN (l_conj) apnoea/NN
D002045_D001049 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_conj) patients/NNS (r_pobj) between/IN (r_prep) compared/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) apnoea/NN
D009020_D013610 NONE morphine/NN (r_compound) infusion/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) beats/NNS (r_conj) tachyarrhythmias/NNS
D009020_D020181 CID morphine/NN (r_compound) infusion/NN (r_dobj) had/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) obstructive/JJ (l_appos) P/NN (l_conj) apnoea/NN
D009020_D001049 NONE morphine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) between/IN (r_prep) compared/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) apnoea/NN
D009020_D018879 CID morphine/NN (r_compound) infusion/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) beats/NNS
8996652
D005665_D006311 NONE furosemide/NN (r_conj) aminoglycosides/NNS (r_appos) administration/NN (r_pobj) to/IN (r_prep) related/JJ (r_oprd) appeared/VBD (l_nsubj) Ototoxicity/NN -PUNC- furosemide/NN (r_conj) aminoglycosides/NNS (r_appos) administration/NN (l_conj) dose/NN (l_prep) of/IN (l_pobj) drugs/NNS (l_compound) ototoxic/JJ
D000617_D006311 NONE aminoglycosides/NNS (r_appos) administration/NN (r_pobj) to/IN (r_prep) related/JJ (r_oprd) appeared/VBD (l_nsubj) Ototoxicity/NN -PUNC- aminoglycosides/NNS (r_appos) administration/NN (l_conj) dose/NN (l_prep) of/IN (l_pobj) drugs/NNS (l_compound) ototoxic/JJ
3750012
D010396_D009157 CID penicillamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) gravis/NN -PUNC- penicillamine/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) gravis/NN
D010396_D001172 NONE penicillamine/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN -PUNC- penicillamine/NN (l_conj) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN
D002738_D009157 CID chloroquine/NN (r_amod) therapy/NN (r_conj) penicillamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) gravis/NN -PUNC- chloroquine/NN (r_compound) therapy/NN (r_conj) penicillamine/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) gravis/NN
D002738_D001172 NONE chloroquine/NN (r_amod) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN -PUNC- chloroquine/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) arthritis/NN
19944736
D013619_D004827 NONE tacrine/NN (r_npadvmod) loaded/VBN (r_amod) nanoparticles/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) showed/VBD (l_dobj) outcome/NN (l_prep) of/IN (l_pobj) symptoms/NNS (l_appos) onset/NN (l_amod) epileptic/JJ -PUNC- tacrine/NN (r_compound) lithium/NN (r_compound) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D018021_D001930 CID LiCl/NNP (r_pobj) in/IN (r_prep) administered/VBN (r_acl) Tacrine/NNP (r_nsubj) induces/VBZ (l_conj) delayed/VBD (l_dobj) damage/NN
D008094_D004827 NONE lithium/NN (r_compound) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D013619_D012640 CID Tacrine/NNP (r_nsubj) induces/VBZ (l_dobj) seizures/NNS
D018021_D012640 CID LiCl/NNP (r_pobj) in/IN (r_prep) administered/VBN (r_acl) Tacrine/NNP (r_nsubj) induces/VBZ (l_dobj) seizures/NNS
D013619_D001930 CID Tacrine/NNP (r_nsubj) induces/VBZ (l_conj) delayed/VBD (l_dobj) damage/NN -PUNC- tacrine/NN (r_npadvmod) loaded/VBN (r_amod) administration/NN (r_nsubj) induced/VBD (l_dobj) damage/NN (l_prep) of/IN (l_pobj) cells/NNS -PUNC- tacrine/NN (r_pobj) of/IN (r_prep) solution/NN (r_advcl) induced/VBD (l_dobj) damage/NN (l_prep) of/IN (l_pobj) cells/NNS
8251368
D009543_D013684 CID nifedipine/RB (r_advmod) induced/VBN (r_amod) telangiectasia/NN -PUNC- nifedipine/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) telangiectasia/NN -PUNC- Adalat/NNP (r_oprd) starting/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) telangiectasia/NN
D017311_D013684 CID amlodipine/NN (r_dobj) commenced/VBD (l_prep) with/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) telangiectasia/NN
9201797
D004298_D009069 NONE dopamine/NN (r_nmod) signs/NNS (l_prep) as/IN (l_pobj) stereotypy/NN (l_conj) hyperlocomotion/NN
D004298_D017109 NONE dopamine/NN (r_nmod) receptor/NN (r_nmod) activity/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) attenuating/VBG (r_pcomp) without/IN (r_prep) treatment/NN (l_prep) of/IN (l_pobj) akathisia/NN
D002354_D017109 NONE carteolol/NN (r_nsubj) improves/VBZ (l_conj) expected/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) akathisia/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
D011433_D002375 NONE propranolol/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) studied/VBN (l_nsubjpass) effects/NNS (l_appos) antagonist/NN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- propranolol/NN (l_conj) inhibited/VBD (l_dobj) catalepsy/NN
D001712_D002375 NONE biperiden/VBN (r_conj) propranolol/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_conj) studied/VBN (l_nsubjpass) effects/NNS (l_appos) antagonist/NN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- biperiden/RB (r_conj) propranolol/NN (l_conj) inhibited/VBD (l_dobj) catalepsy/NN
D002354_D002375 NONE hydrochloride/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- carteolol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_appos) antagonist/NN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- Carteolol/NNP (l_conj) propranolol/NN (l_conj) inhibited/VBD (l_dobj) catalepsy/NN -PUNC- carteolol/NN (r_nsubj) improves/VBZ (l_dobj) catalepsy/NN
D002354_D009069 NONE Carteolol/NNP (r_nsubj) evoke/VB (l_dobj) signs/NNS (l_prep) as/IN (l_pobj) stereotypy/NN (l_conj) hyperlocomotion/NN
D004298_D002375 NONE dopamine/NN (r_nmod) receptor/NN (r_nmod) activity/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) attenuating/VBG (r_pcomp) without/IN (r_prep) treatment/NN (r_pobj) in/IN (r_prep) effective/JJ (r_acomp) be/VB (r_xcomp) expected/VBN (r_conj) improves/VBZ (l_dobj) catalepsy/NN
D006220_D017109 NONE haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN (r_dobj) improves/VBZ (l_conj) expected/VBN (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) akathisia/NN
15266362
D004280_D004342 CID dobutamine/NN (r_xcomp) related/VBN (l_nsubjpass) hypersensitivity/NN
D004280_D004802 CID dobutamine/NN (r_xcomp) related/VBN (l_nsubjpass) hypersensitivity/NN (l_amod) eosinophilic/JJ
D004280_D009205 CID dobutamine/NN (r_xcomp) related/VBN (l_nsubjpass) hypersensitivity/NN (l_amod) myocarditis/NN
D004280_D018754 NONE dobutamine/NN (r_compound) infusion/NN (r_pobj) with/IN (r_prep) managed/VBD (r_conj) admitted/VBN (l_prep) with/IN (l_pobj) failure/NN
D004280_D002312 NONE dobutamine/NN (r_compound) infusion/NN (r_pobj) with/IN (r_prep) managed/VBD (r_conj) admitted/VBN (l_nsubjpass) patient/NN (l_acl) known/VBN (l_xcomp) have/VB (l_dobj) cardiomyopathy/NN
16858720
D014859_D006470 NONE warfarin/JJ (r_compound) drug/NN (r_compound) interaction/NN (r_nsubj) contributed/VBN (l_prep) to/IN (l_pobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) drug/NN (r_compound) interaction/NN (r_nsubj) contributed/VBN (l_conj) considered/VBN (l_nsubjpass) complication/NN (l_amod) bleeding/VBG -PUNC- warfarin/JJ (r_compound) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) contributed/VBN (l_prep) to/IN (l_pobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) contributed/VBN (l_conj) considered/VBN (l_nsubjpass) complication/NN (l_amod) bleeding/VBG
D014859_D002543 CID warfarin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) haemorrhage/NN -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) haemorrhages/NNS -PUNC- warfarin/JJ (r_pobj) due/IN (r_prep) evaluate/VB (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) haemorrhages/NNS -PUNC- warfarin/JJ (r_compound) drug/NN (r_compound) interactions/NNS (r_conj) warfarin/JJ (r_pobj) due/IN (r_prep) evaluate/VB (l_dobj) frequency/NN (l_prep) of/IN (l_pobj) haemorrhages/NNS -PUNC- warfarin/JJ (r_nmod) interactions/NNS (r_nsubj) caused/VBN (l_dobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) drug/NN (r_conj) warfarin/JJ (r_nmod) interactions/NNS (r_nsubj) caused/VBN (l_dobj) haemorrhage/NN -PUNC- warfarin/JJ (r_compound) treatment/NN (r_pobj) to/IN (r_prep) related/VBN (r_amod) as/IN (r_prep) assessed/VBN (l_prep) Among/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) haemorrhage/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) haemorrhages/NNS -PUNC- warfarin/RB (r_npadvmod) related/VBN (r_amod) haemorrhages/NNS -PUNC- warfarin/NN (r_pobj) with/IN (r_prep) interact/VB (r_xcomp) known/VBN (r_acl) drugs/NNS (r_dobj) prescribing/VBG (r_advcl) taken/VBN (r_advcl) prevented/VBN (l_nsubjpass) proportion/NN (l_prep) of/IN (l_pobj) haemorrhages/NNS
15145918
D008750_D007022 CID methyldopa/NN (r_conj) rilmenidine/NN (r_amod) rats/NNS (r_pobj) In/IN (r_prep) elicited/VBD (l_dobj) hypotension/NN -PUNC- methyldopa/NN (r_pobj) to/IN (r_prep) response/NN (l_amod) hypotensive/JJ -PUNC- methyldopa/NN (r_pobj) to/IN (r_prep) response/NN (r_dobj) enhanced/VBD (l_prep) in/IN (l_pobj) contrast/NN (l_prep) to/IN (l_pobj) effect/NN (l_prep) on/IN (l_pobj) hypotension/NN -PUNC- methyldopa/NN (r_compound) hypotension/NN -PUNC- methyldopa/NN (r_compound) estrogen/NN (r_compound) interaction/NN (r_pobj) in/IN (r_prep) control/NN (r_pobj) for/IN (r_prep) role/NN (r_dobj) highlight/VB (r_conj) downregulates/VBZ (l_conj) hypotension/NN
D048288_D007022 NONE I1-imidazoline/NNP (r_punct) mediated/VBN (r_conj) alpha2-adrenergic/JJ (r_amod) hypotension/NN
C032302_D007022 CID rilmenidine/NN (r_amod) rats/NNS (r_pobj) In/IN (r_prep) elicited/VBD (l_dobj) hypotension/NN -PUNC- rilmenidine/JJ (r_amod) hypotension/NN (r_pobj) on/IN (r_prep) effect/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) in/IN (r_prep) enhanced/VBD (l_dobj) response/NN (l_amod) hypotensive/JJ -PUNC- rilmenidine/JJ (r_amod) hypotension/NN
D004967_D007022 NONE estrogen/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- estrogen/NN (r_nsubj) modulates/VBZ (l_dobj) effect/NN (l_amod) hypotensive/JJ -PUNC- estrogen/NN (r_nsubj) downregulates/VBZ (l_conj) hypotension/NN -PUNC- estrogen/NN (r_compound) interaction/NN (r_pobj) in/IN (r_prep) control/NN (r_pobj) for/IN (r_prep) role/NN (r_dobj) highlight/VB (r_conj) downregulates/VBZ (l_conj) hypotension/NN
D003000_D007022 NONE clonidine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ
D008750_D001523 NONE methyldopa/NN (r_compound) hypotension/NN (r_nsubjpass) paralleled/VBN (l_prep) with/IN (l_pobj) reduction/NN (l_conj) activity/NN
6496797
D014196_D006327 CID trazodone/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) following/VBG (r_prep) block/NN -PUNC- trazodone/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) receiving/VBG (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) block/NN
12695819
D016559_D009422 NONE tacrolimus/NNS (l_relcl) developed/VBD (l_dobj) complications/NNS
D016559_D020258 NONE tacrolimus/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN -PUNC- tacrolimus/NN (r_npadvmod) induced/VBN (r_amod) neurotoxicity/NN
14745746
2385256
D008274_D020511 NONE magnesium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) are/VBP (r_relcl) Patients/NNS (r_nsubjpass) suspected/VBN (l_prep) of/IN (l_pcomp) having/VBG (l_dobj) disorder/NN (l_prep) of/IN (l_pobj) transmission/NN
D008274_D009157 CID magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) weakness/NN (r_pobj) as/IN (r_prep) presenting/VBG (r_acl) gravis/NN -PUNC- magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) paralysis/NN (r_nsubjpass) described/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) gravis/NN
D008274_D009468 NONE magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) became/VBD (r_relcl) disease/NN
D008274_D010243 NONE magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) paralysis/NN
D008274_D011225 NONE magnesium/NN (r_compound) administration/NN (l_prep) for/IN (l_pobj) preeclampsia/NN
D008274_D011782 NONE magnesium/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) became/VBD (l_acomp) quadriplegic/JJ
3703509
D011241_D011141 NONE prednisone/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) Following/VBG (r_prep) developed/VBD (l_advcl) increasing/VBG (l_dobj) somnolence/NN (l_conj) polydipsia/NN (l_conj) polyphagia/NN (l_conj) polyuria/NN
D011241_D053609 NONE prednisone/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) Following/VBG (r_prep) developed/VBD (l_dobj) lethargy/NN
D019344_D007662 NONE lactate/NN (r_compound) level/NN (r_pobj) without/IN (r_prep) present/JJ (l_prep) in/IN (l_pobj) one/CD (l_conj) ketosis/NN
D011241_D006970 NONE prednisone/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) Following/VBG (r_prep) developed/VBD (l_advcl) increasing/VBG (l_dobj) somnolence/NN
D011241_D059606 NONE prednisone/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) Following/VBG (r_prep) developed/VBD (l_advcl) increasing/VBG (l_dobj) somnolence/NN (l_conj) polydipsia/NN
D019344_D000140 NONE lactate/NN (r_compound) level/NN (r_pobj) without/IN (r_prep) present/JJ (r_acomp) was/VBD (l_nsubj) acidosis/NN
D011241_D006963 NONE prednisone/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) Following/VBG (r_prep) developed/VBD (l_advcl) increasing/VBG (l_dobj) somnolence/NN (l_conj) polydipsia/NN (l_conj) polyphagia/NN
11058428
D008775_D009135 CID methylprednisolone/NN (r_nsubj) cause/VB (r_acl) possibility/NN (l_prep) myopathy/NNS -PUNC- methylprednisolone/NN (r_relcl) protection/NN (r_pobj) of/IN (r_cc) recording/NN (r_attr) be/VB (r_conj) recovers/VBZ (l_nsubj) myopathy/NN -PUNC- methylprednisolone/NN (r_relcl) protection/NN (r_pobj) of/IN (r_cc) recording/NN (l_prep) of/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) myopathy/NNS -PUNC- methylprednisolone/NN (r_nsubj) cause/VB (l_ccomp) myopathy/NNS
D013256_D013119 NONE steroid/NN (r_compound) myopathy/NN (r_nsubj) recovers/VBZ (l_conj) be/VB (l_attr) recording/NN (l_cc) of/IN (l_pobj) protection/NN (l_relcl) methylprednisolone/NN (l_dobj) offers/VBZ (l_prep) to/IN (l_pobj) injury/NN -PUNC- steroid/NN (r_compound) myopathy/NNS (r_pobj) from/IN (r_prep) recovery/NN (r_pobj) of/IN (r_prep) recording/NN (l_cc) of/IN (l_pobj) protection/NN (l_relcl) methylprednisolone/NN (l_dobj) offers/VBZ (l_prep) to/IN (l_pobj) injury/NN
D008775_D013119 NONE methylprednisolone/NN (r_nsubj) do/VB (l_dobj) harm/NN (l_prep) for/IN (l_pobj) injury/NN -PUNC- methylprednisolone/NN (r_nsubj) became/VBD (l_prep) Because/IN (l_pobj) Studies/NNP (l_compound) Injury/NNP -PUNC- methylprednisolone/NN (r_nsubj) became/VBD (l_attr) standard/NN (l_prep) for/IN (l_pobj) injury/NN -PUNC- methylprednisolone/NN (l_dobj) offers/VBZ (l_prep) to/IN (l_pobj) injury/NN
D000305_D009135 NONE corticosteroid/NN (r_pobj) of/IN (r_prep) possibility/NN (l_prep) myopathy/NNS -PUNC- corticosteroid/NN (r_nsubj) myopathy/NNS
D013256_D009135 NONE steroid/NN (r_compound) myopathy/NN -PUNC- steroid/NN (r_compound) myopathy/NN (r_nsubj) recovers/VBZ (l_conj) be/VB (l_attr) recording/NN (l_prep) of/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) myopathy/NNS -PUNC- steroid/NN (r_compound) myopathy/NNS (r_pobj) from/IN (r_prep) recovery/NN (r_pobj) of/IN (r_prep) recording/NN (r_attr) be/VB (r_conj) recovers/VBZ (l_nsubj) myopathy/NN -PUNC- steroid/NN (r_compound) myopathy/NNS
12907924
D008774_D000544 NONE methylphenidate/NN (r_pobj) on/IN (r_prep) started/VBN (l_nsubjpass) man/NN (l_prep) with/IN (l_pobj) depression/NN (l_conj) disease/NN
D008774_D061218 NONE methylphenidate/NN (r_pobj) on/IN (r_prep) started/VBN (l_nsubjpass) man/NN (l_prep) with/IN (l_pobj) depression/NN
D008774_D009771 CID Methylphenidate/NNP (r_npadvmod) induced/VBN (r_amod) symptoms/NNS -PUNC- methylphenidate/NN (r_nsubjpass) replaced/VBN (r_advcl) diminished/VBN (r_conj) ensued/VBD (l_nsubj) behavior/NN
D016666_D009771 NONE fluvoxamine/NN (r_pobj) by/IN (r_agent) replaced/VBN (r_advcl) diminished/VBN (r_conj) ensued/VBD (l_nsubj) behavior/NN
3780697
D005283_D012131 NONE fentanyl/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) received/VBD (r_relcl) patient/NN (r_pobj) in/IN (r_prep) period/NN (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) rigidity/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) failure/NN
D005283_D009127 CID fentanyl/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) rigidity/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) received/VBD (r_relcl) patient/NN (r_pobj) in/IN (r_prep) period/NN (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) case/NN (l_prep) of/IN (l_pobj) rigidity/NN
19105845
D016642_D012640 CID hydrochloride/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- bupropion/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- HCl/NNP (r_pobj) of/IN (r_prep) rates/NNS (r_dobj) varying/VBG (r_pcomp) of/IN (r_prep) effect/NN (l_appos) CD50/NNP (l_amod) convulsive/JJ -PUNC- HCl/NNP (r_pobj) of/IN (r_prep) rates/NNS (r_dobj) varying/VBG (r_pcomp) of/IN (r_prep) effect/NN (r_dobj) investigated/VBD (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- bupropion/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS (r_pobj) of/IN (r_prep) incidence/NN (r_pobj) on/IN (r_prep) investigated/VBD (l_dobj) effect/NN (l_appos) CD50/NNP (l_amod) convulsive/JJ -PUNC- bupropion/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- HCl/NNP (r_ccomp) showed/VBD (l_advcl) induced/VBD (l_dobj) convulsions/NNS -PUNC- HCl/NNP (r_pobj) of/IN (r_prep) time/NN (r_dobj) increasing/VBG (r_conj) ratio/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) odds/NNS (l_prep) of/IN (l_pobj) convulsions/NNS -PUNC- bupropion/NN (r_pobj) of/IN (r_prep) dose/NN (l_amod) fixed/JJ (l_conj) convulsive/JJ -PUNC- bupropion/NN (r_pobj) of/IN (r_prep) dose/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) convulsions/NNS
20633755
D009943_D001049 CID poisons/NNS (r_pobj) by/IN (r_agent) deactivated/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) apnea/NN -PUNC- compound/NN (r_pobj) by/IN (r_prep) attempt/NN (r_pobj) about/IN (r_prep) information/NN (r_nsubjpass) concealed/VBN (r_advcl) ensued/VBD (l_nsubj) apnea/NN
D013390_D001049 CID Suxamethonium/NNS (r_nsubj) induced/VBD (l_dobj) apnea/NN -PUNC- Suxamethonium/JJ (r_nsubj) causes/VBZ (l_dobj) apnea/NN
11704023
D013999_D009798 NONE timolol/NN (r_compound) solution/NN (r_conj) crossed/VBN (r_conj) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) glaucoma/NN (l_conj) hypertension/NN -PUNC- timolol/NN (r_compound) gellan/NN (r_conj) solution/NN (r_conj) crossed/VBN (r_conj) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) glaucoma/NN (l_conj) hypertension/NN
D013999_D005902 NONE timolol/NN (r_compound) solution/NN (r_conj) crossed/VBN (r_conj) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) glaucoma/NN -PUNC- timolol/NN (r_compound) gellan/NN (r_conj) solution/NN (r_conj) crossed/VBN (r_conj) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) glaucoma/NN
D013999_D005901 NONE timolol/NN (l_prep) on/IN (l_pobj) response/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) on/IN (l_pobj) treatment/NN (l_prep) for/IN (l_pobj) glaucoma/NN -PUNC- timolol/NN (l_conj) suspension/NN (l_relcl) forms/VBZ (l_prep) on/IN (l_pobj) application/NN (l_prep) on/IN (l_pobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treated/VBN (l_prep) for/IN (l_pobj) glaucoma/NN -PUNC- timolol/NN (r_compound) solution/NN (r_appos) timolol/NN (l_conj) suspension/NN (l_relcl) forms/VBZ (l_prep) on/IN (l_pobj) application/NN (l_prep) on/IN (l_pobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treated/VBN (l_prep) for/IN (l_pobj) glaucoma/NN -PUNC- timolol/NN (r_compound) suspension/NN (l_relcl) forms/VBZ (l_prep) on/IN (l_pobj) application/NN (l_prep) on/IN (l_pobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treated/VBN (l_prep) for/IN (l_pobj) glaucoma/NN -PUNC- timolol/NN (r_compound) gellan/NN (r_appos) conjunctiva/NN (r_pobj) to/IN (r_prep) application/NN (l_prep) on/IN (l_pobj) rate/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treated/VBN (l_prep) for/IN (l_pobj) glaucoma/NN
18996674
D003042_D011317 CID cocaine/NN (r_compound) user/NN (r_appos) man/NN (r_nsubj) presented/VBN (l_prep) on/IN (l_pobj) occasions/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) priapism/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) after/IN (r_prep) history/NN (l_prep) of/IN (l_pobj) priapism/NN
D004837_D011317 NONE epinephrine/NN (l_appos) treatment/NN (l_prep) for/IN (l_pobj) priapism/NN
11230490
D003520_D064420 NONE cyclophosphamide/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) receive/VB (l_npadvmod) weeks/NNS (l_prep) until/IN (l_pobj) progression/NN (l_conj) toxicity/NN
D004317_D001943 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_conj) cardiotoxicity/NN (l_prep) compared/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) compared/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- Myocet/NNP (r_nmod) doxorubicin/NN (r_dobj) determine/VB (r_advcl) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- Myocet/NNP (r_nmod) doxorubicin/NN (r_dobj) determine/VB (r_advcl) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN (l_appos) MBC/NNP -PUNC- doxorubicin/NN (r_dobj) determine/VB (r_advcl) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_dobj) determine/VB (r_advcl) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN (l_appos) MBC/NNP -PUNC- doxorubicin/NN (r_compound) cardiotoxicity/NN (r_dobj) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_compound) cardiotoxicity/NN (r_dobj) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN (l_appos) MBC/NNP -PUNC- Myocet/NNP (r_nmod) M/NNP (r_pobj) of/IN (r_prep) m(2/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) MBC/NNP -PUNC- doxorubicin/NN (r_dobj) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) MBC/NNP -PUNC- Myocet/NNP (r_nsubj) improves/VBZ (l_conj) provides/VBZ (l_advcl) used/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) MBC/NNP -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) index/NN (r_dobj) improves/VBZ (l_conj) provides/VBZ (l_advcl) used/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) MBC/NNP
D004317_D009503 CID Myocet/NNP (r_nsubj) improves/VBZ (l_dobj) neutropenia/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) index/NN (r_dobj) improves/VBZ (l_dobj) neutropenia/NN
D003520_D001943 NONE cyclophosphamide/NN (r_conj) doxorubicin/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_conj) cardiotoxicity/NN (l_prep) compared/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_conj) doxorubicin/NN (r_pobj) with/IN (r_prep) compared/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) Company/NNP (r_nsubj) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) Company/NNP (r_nsubj) reduces/VBZ (l_advcl) providing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN (l_appos) MBC/NNP -PUNC- cyclophosphamide/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) receive/VB (r_xcomp) randomized/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) MBC/NNP -PUNC- cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) used/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) MBC/NNP
D004317_D064420 NONE Myocet/NNP (r_nmod) M/NNP (r_pobj) of/IN (r_prep) m(2/NN (r_dobj) receive/VB (l_npadvmod) weeks/NNS (l_prep) until/IN (l_pobj) progression/NN (l_conj) toxicity/NN -PUNC- doxorubicin/NN (r_dobj) receive/VB (l_npadvmod) weeks/NNS (l_prep) until/IN (l_pobj) progression/NN (l_conj) toxicity/NN
D004317_D066126 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_conj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) cardiotoxicity/NN -PUNC- Myocet/NNP (r_nmod) doxorubicin/NN (r_dobj) determine/VB (r_advcl) reduces/VBZ (l_dobj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_dobj) determine/VB (r_advcl) reduces/VBZ (l_dobj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_compound) cardiotoxicity/NN -PUNC- Myocet/NNP (r_nsubj) improves/VBZ (l_prep) by/IN (l_pcomp) reducing/VBG (l_dobj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) index/NN (r_dobj) improves/VBZ (l_prep) by/IN (l_pcomp) reducing/VBG (l_dobj) cardiotoxicity/NN
D003520_D009503 CID cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) used/VBN (r_advcl) provides/VBZ (r_conj) improves/VBZ (l_dobj) neutropenia/NN
D003520_D066126 NONE cyclophosphamide/NN (r_conj) doxorubicin/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_conj) cardiotoxicity/NN -PUNC- cyclophosphamide/NN (r_conj) doxorubicin/NN (r_pobj) with/IN (r_prep) compared/VBN (r_prep) cardiotoxicity/NN -PUNC- cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) Company/NNP (r_nsubj) reduces/VBZ (l_dobj) cardiotoxicity/NN -PUNC- cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) used/VBN (r_advcl) provides/VBZ (r_conj) improves/VBZ (l_prep) by/IN (l_pcomp) reducing/VBG (l_dobj) cardiotoxicity/NN
3496378
D014217_D004802 CID troleandomycin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_conj) associated/VBN (l_prep) with/IN (l_pobj) hypereosinophilia/NNS
D014217_D002779 CID troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_pobj) after/IN (r_prep) cholestasis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_relcl) patient/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) report/VBP (l_ccomp) followed/VBN (l_agent) by/IN (l_pobj) cholestasis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN (r_dobj) follow/VB (l_nsubj) cholestasis/NN
D014217_D056486 CID troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_relcl) patient/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) report/VBP (l_ccomp) followed/VBN (l_nsubjpass) hepatitis/NN -PUNC- troleandomycin/NN (r_npadvmod) induced/VBN (r_amod) hepatitis/NN
D014217_D007565 CID troleandomycin/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) Jaundice/NN
2559236
D004656_D009401 NONE enalapril/NN (r_appos) inhibitor/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) assessed/VBN (l_prep) with/IN (l_pobj) nephrosis/NN -PUNC- enalapril/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) injury/NN (l_prep) in/IN (l_pobj) nephrosis/NN
D004656_D007674 NONE enalapril/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) injury/NN
D004656_D000419 NONE enalapril/DT (r_nsubj) reduced/JJ (l_prep) vs./IN (l_pobj) Hg/NNP (l_conj) pressure/NN (l_appos) +/-/SYM (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) albuminuria/NN -PUNC- enalapril/NN (r_compound) treatment/NN (r_nsubj) reduced/VBN (r_amod) pressure/NN (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) albuminuria/NN
D004317_D000419 CID adriamycin/NNS (r_pobj) of/IN (r_prep) dose/NN (r_dobj) given/VBN (l_advcl) divided/VBD (l_prep) into/IN (l_pobj) groups/NNS (l_acl) matched/VBN (l_prep) for/IN (l_pobj) albuminuria/NN
D004317_D009401 CID adriamycin/NNS (r_amod) nephrosis/NN -PUNC- adriamycin/JJ (r_amod) nephrosis/NN
D004317_D007674 NONE adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- adriamycin/JJ (r_amod) nephrosis/NN (r_pobj) in/IN (r_prep) injury/NN
12653683
D012964_D009404 NONE sodium/NN (r_compound) channel/NN (l_appos) subunit/NN (l_appos) mRNA/NN (l_conj) expression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- sodium/NN (r_compound) excretion/NN (r_nsubjpass) decreased/VBN (l_prep) In/IN (l_pobj) syndrome/NN
D000450_D011507 NONE aldosterone/NN (r_compound) concentration/NN (l_conj) proteinuria/NN
D011692_D011507 CID PAN/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_nsubjpass) courses/NNS (l_prep) of/IN (l_pobj) excretion/NN (l_conj) concentration/NN (l_conj) proteinuria/NN
D011692_D009404 CID aminonucleoside/RB (r_advmod) induced/VBN (r_amod) syndrome/NN -PUNC- aminonucleoside/NN (l_pobj) syndrome/NN -PUNC- PAN)-induced/VBN (r_amod) syndrome/NN -PUNC- PAN/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN
D012964_D011507 NONE sodium/NN (r_compound) excretion/NN (l_conj) concentration/NN (l_conj) proteinuria/NN -PUNC- sodium/NN (r_compound) excretion/NN (r_pobj) of/IN (r_prep) kinetics/NNS (l_conj) appearance/NN (l_prep) of/IN (l_pobj) proteinuria/NN
D000450_D009404 NONE aldosterone/NN (r_pobj) by/IN (r_prep) regulation/NN (r_pobj) from/IN (r_prep) escape/VB (r_xcomp) appears/VBZ (r_conj) increased/VBN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) syndrome/NN
2320800
D007069_D001002 CID ifosfamide/JJ (r_compound) chemotherapy/NN (r_dobj) complicating/VBG (l_nsubj) anuria/NN -PUNC- ifosfamide/NN (r_pobj) after/IN (r_prep) day/NN (r_npadvmod) developed/VBD (l_dobj) failure/NN (l_prep) with/IN (l_pobj) anuria/NN -PUNC- ifosfamide/NN (r_xcomp) due/JJ (r_acomp) was/VBD (l_nsubj) anuria/NN
D007069_D001943 NONE ifosfamide/JJ (r_compound) chemotherapy/NN (r_dobj) complicating/VBG (l_prep) in/IN (l_pobj) patient/NN (l_compound) cancer/NN -PUNC- ifosfamide/NN (r_pobj) after/IN (r_prep) day/NN (r_npadvmod) developed/VBD (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) cancer/NN
D007069_D007674 CID ifosfamide/JJ (r_compound) chemotherapy/NN (r_dobj) complicating/VBG (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) function/NN -PUNC- Ifosfamide/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_amod) nephrotoxic/JJ -PUNC- Ifosfamide/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_prep) with/IN (l_pobj) tubulopathies/NNS -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) pretreated/VBN (l_prep) with/IN (l_pobj) chemotherapy/NN (l_amod) nephrotoxic/JJ
D002945_D001943 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) woman/NN (l_prep) with/IN (l_pobj) cancer/NN
D002945_D007022 NONE cisplatin/NN (r_amod) chemotherapy/NN (r_dobj) received/VBN (l_prep) with/IN (l_pobj) perfusion/NN (l_prep) due/IN (l_pcomp) to/IN (l_pobj) hypotension/NN
D002945_D051437 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) woman/NN (r_nsubj) developed/VBD (l_dobj) failure/NN
D002945_D001002 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) woman/NN (r_nsubj) developed/VBD (l_dobj) failure/NN (l_prep) with/IN (l_pobj) anuria/NN -PUNC- cisplatin/NN (r_amod) chemotherapy/NN (r_dobj) received/VBN (r_advcl) occurring/VBG (r_advcl) was/VBD (l_nsubj) anuria/NN
D007069_D007022 NONE ifosfamide/NN (r_xcomp) due/JJ (r_acomp) was/VBD (l_advcl) occurring/VBG (l_advcl) received/VBN (l_prep) with/IN (l_pobj) perfusion/NN (l_prep) due/IN (l_pcomp) to/IN (l_pobj) hypotension/NN
D007069_D051437 NONE ifosfamide/NN (r_pobj) after/IN (r_prep) day/NN (r_npadvmod) developed/VBD (l_dobj) failure/NN
8686832
D008012_D001416 CID lignocaine/NN (r_dobj) involving/VBG (r_acl) anaesthesia/NN (r_pobj) after/IN (r_prep) pain/NN -PUNC- lignocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) Leg/NNP (l_conj) pain/NN
D000431_D010146 NONE alcohol/NN (r_compound) intake/NN (r_pobj) to/IN (r_prep) admitted/VBD (r_acl) pain/NN (r_pobj) without/IN (r_prep) pain/NN -PUNC- alcohol/NN (r_compound) intake/NN (r_pobj) to/IN (r_prep) admitted/VBD (r_acl) pain/NN
21294084
D010406_D004827 NONE penicillin/NN (r_npadvmod) induced/VBN (r_amod) model/NN (r_pobj) in/IN (r_prep) discharges/NNS (l_amod) epileptic/JJ -PUNC- penicillin/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) epilepsy/NN -PUNC- penicillin/NN (r_npadvmod) induced/VBN (r_amod) model/NN (r_pobj) in/IN (r_prep) activity/NN (l_amod) epileptic/JJ -PUNC- penicillin/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) epilepsy/NN -PUNC- penicillin/NN (r_npadvmod) induced/VBN (r_amod) activity/NN (l_amod) epileptic/JJ
16634859
D000431_D006130 CID alcohol/NN (r_npadvmod) related/VBN (r_amod) impairment/NN -PUNC- alcohol/NN (r_compound) consumption/NN (r_compound) recognition/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) growth/NN -PUNC- alcohol/NN (r_compound) consumption/NN (r_compound) recognition/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) growth/NN (l_conj) cranial/JJ (l_acl) body/NN (l_dobj) growth/NN
7053705
D013866_D006504 CID 6-thioguanine/CD (r_pobj) by/IN (r_agent) caused/VBN (r_acl) disease/NN -PUNC- 6-thioguanine/CD (r_punct) ./. (r_punct) disease/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- 6-thioguanine/CD (r_pobj) to/IN (r_prep) related/VBN (r_pobj) of/IN (r_prep) case/NN (r_attr) be/VB (r_conj) presented/VBD (l_dobj) opportunity/NN (l_acl) observe/VB (l_dobj) features/NNS (l_prep) of/IN (l_pobj) disease/NN
D013866_D054198 NONE 6-thioguanine/CD (r_punct) ./. (r_punct) disease/NN (l_prep) of/IN (l_pobj) liver/NN (l_acl) developed/VBN (l_prep) in/IN (l_pobj) man/NN (l_prep) with/IN (l_pobj) leukemia/NN
20683499
D013311_D007859 NONE STZ/NNP (r_npadvmod) injected/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) impairment/NN
C029036_D000544 NONE crocin/NNS (l_prep) on/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- crocins/NNS (l_prep) on/IN (l_pobj) disease/NN -PUNC- crocin/NNS (r_pobj) of/IN (r_prep) effectiveness/NN (l_prep) in/IN (l_pcomp) antagonizing/VBG (l_dobj) deficits/NNS (l_acl) caused/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_conj) potential/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) diseases/NNS (l_prep) as/IN (l_pobj) disease/NN
C029036_D008569 NONE crocin/NNS (l_prep) in/IN (l_pobj) impairment/NN
D013311_D003072 CID STZ/NNP (r_compound) icv/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) deficits/NNS
C029036_D007859 NONE crocin/NNS (l_prep) in/IN (l_pobj) impairment/NN
D013311_D019636 NONE STZ/NNP (r_compound) icv/NN (r_pobj) by/IN (r_agent) caused/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_conj) potential/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) diseases/NNS
C029036_D019636 NONE crocin/NNS (r_pobj) of/IN (r_prep) effectiveness/NN (l_prep) in/IN (l_pcomp) antagonizing/VBG (l_dobj) deficits/NNS (l_acl) caused/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_conj) potential/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) diseases/NNS
C029036_D003072 NONE crocin/NNS (r_pobj) of/IN (r_prep) effectiveness/NN (l_prep) in/IN (l_pcomp) antagonizing/VBG (l_dobj) deficits/NNS
D013311_D008569 NONE STZ/NNP (r_npadvmod) injected/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) impairment/NN
D013311_D000544 CID streptozocin/NNS (r_npadvmod) induced/VBN (r_amod) model/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- streptozocin/NNP (r_appos) effect/NN (l_prep) of/IN (l_pobj) crocins/NNS (l_prep) on/IN (l_pobj) disease/NN -PUNC- STZ/NNP (r_appos) streptozocin/NNP (r_appos) effect/NN (l_prep) of/IN (l_pobj) crocins/NNS (l_prep) on/IN (l_pobj) disease/NN -PUNC- STZ/NNP (r_compound) icv/NN (r_pobj) with/IN (r_prep) injected/VBN (l_prep) In/IN (l_pobj) groups/NNS (l_compound) disease/NN -PUNC- STZ/NNP (r_compound) icv/NN (r_compound) application/NN (r_nsubjpass) repeated/VBN (l_ccomp) injected/VBN (l_prep) In/IN (l_pobj) groups/NNS (l_compound) disease/NN -PUNC- STZ/NNP (r_compound) icv/NN (r_pobj) by/IN (r_agent) caused/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_conj) potential/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) diseases/NNS (l_prep) as/IN (l_pobj) disease/NN
17562951
D000111_D003920 NONE acetylcysteine/NN (r_pobj) of/IN (r_prep) use/NN (r_appos) volume/NN (l_appos) presence/NN (l_prep) of/IN (l_pobj) mellitus/NN
D007479_D007674 CID iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D007479_D003920 NONE iopamidol/NN (r_pobj) with/IN (r_prep) were/VBD (r_conj) increases/VBZ (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_prep) with/IN (l_conj) without/IN (l_pobj) mellitus/NN
C044834_D051436 NONE iodixanol/NN (r_conj) iopamidol/NN (r_pobj) of/IN (r_prep) comparison/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
C044834_D003920 NONE iodixanol/NN (r_pobj) with/IN (r_prep) with/IN (r_prep) were/VBD (r_conj) increases/VBZ (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- iodixanol/NN (r_conj) iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_prep) with/IN (l_conj) without/IN (l_pobj) mellitus/NN
D007479_D051436 NONE iopamidol/NN (r_pobj) of/IN (r_prep) comparison/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
C044834_D007674 CID iodixanol/NN (r_conj) iopamidol/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) is/VBZ (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) nephropathy/NN
1969772
D009599_D007022 CID nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN (r_pobj) during/IN (r_prep) decreased/VBD (r_conj) increased/VBD (l_prep) during/IN (l_pobj) hypotension/NN -PUNC- nitroprusside/RB (r_advmod) induced/VBN (r_amod) hypotension/NN -PUNC- nitroprusside/NN (r_nsubj) is/VBZ (l_attr) vasodilator/NN (l_relcl) produce/VB (l_prep) during/IN (l_pobj) hypotension/NN
D018818_D007022 CID fenoldopam/NN (r_pobj) with/IN (r_prep) induced/VBN (l_nsubj) Preservation/NN (l_prep) during/IN (l_pobj) hypotension/NN -PUNC- fenoldopam/NN (r_relcl) hypothesis/NN (r_nsubjpass) used/VBN (l_xcomp) induce/VB (l_dobj) hypotension/NN -PUNC- fenoldopam/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- fenoldopam/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_pobj) during/IN (r_prep) increased/VBD (l_conj) decreased/VBD (l_prep) during/IN (l_pobj) hypotension/NN
D012964_D007022 NONE sodium/NN (r_amod) hypotension/NN (r_pobj) during/IN (r_prep) decreased/VBD (r_conj) increased/VBD (l_prep) during/IN (l_pobj) hypotension/NN -PUNC- sodium/NN (r_amod) hypotension/NN
D004298_D007022 NONE dopamine-1/NNS (r_punct) agonist/NN (l_relcl) causes/VBZ (l_conj) preserves/VBZ (l_prep) during/IN (l_pobj) hypotension/NN
15075188
D012964_D009404 NONE sodium/NN (r_compound) retention/NN (r_pobj) by/IN (r_agent) accompanied/VBN (l_nsubjpass) syndrome/NN -PUNC- sodium/NN (r_compound) retention/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) syndrome/NN
D011692_D011507 CID PAN/NNP (r_compound) treatment/NN (r_nsubj) induced/VBD (l_dobj) proteinuria/NN
D011692_D009404 CID aminonucleoside/RB (r_advmod) induced/VBN (r_amod) syndrome/NN -PUNC- PAN/NNP (r_npadvmod) induced/VBN (r_amod) syndrome/NN
D012964_D001201 NONE sodium/NN (r_compound) excretion/NN (l_conj) ascites/NNS
D012964_D004487 NONE sodium/NN (r_compound) retention/NN (l_conj) edema/NN
D012964_D011507 NONE sodium/NN (r_compound) excretion/NN (r_dobj) decreased/VBD (l_advcl) induced/VBD (l_dobj) proteinuria/NN
D012964_D034141 NONE sodium/NN (r_compound) excretion/NN (r_dobj) decreased/VBD (l_advcl) induced/VBD (l_dobj) proteinuria/NN (l_appos) hypoalbuminemia/NN
D011692_D001201 CID PAN/NNP (r_compound) treatment/NN (r_nsubj) induced/VBD (r_advcl) decreased/VBD (l_dobj) excretion/NN (l_conj) ascites/NNS
D011692_D034141 CID PAN/NNP (r_compound) treatment/NN (r_nsubj) induced/VBD (l_dobj) proteinuria/NN (l_appos) hypoalbuminemia/NN
9305828
D010862_D004833 CID pilocarpine/NN (r_amod) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN -PUNC- PILO/NNP (r_amod) model/NN (l_prep) of/IN (l_pobj) TLE/NNP
D010862_D004827 NONE pilocarpine/NN (r_nsubjpass) characterized/VBN (l_nsubjpass) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN -PUNC- PILO/NNP (r_nmod) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D001930 NONE pilocarpine/NN (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) period/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) seizures/NNS (l_conj) damage/NN -PUNC- PILO/NNP (r_nmod) model/NN (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) period/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) seizures/NNS (l_conj) damage/NN
D010862_D012640 NONE pilocarpine/NN (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) period/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) seizures/NNS -PUNC- PILO/NNP (r_nmod) model/NN (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) period/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) seizures/NNS
D010862_D013226 NONE pilocarpine/NN (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) period/NN (l_prep) of/IN (l_pobj) epilepticus/NN -PUNC- PILO/NNP (r_nmod) model/NN (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) period/NN (l_prep) of/IN (l_pobj) epilepticus/NN
16755009
D012601_D000647 CID scopolamine-/NN (r_nmod) amnesia/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D010936_D000647 NONE DCE/NNP (r_nsubj) reversed/VBD (l_dobj) amnesia/NN
D002784_D003072 NONE cholesterol/NN (r_nsubj) lowering/VBG (r_conj) property/NN (r_dobj) improving/VBG (r_acl) remedy/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) dysfunctions/NNS
D003975_D000647 CID Diazepam-/NN (l_appos) amnesia/NN -PUNC- diazepam/NN (r_conj) scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D010936_D003072 NONE DCE/NNP (r_nsubj) prove/VB (l_xcomp) be/VB (l_attr) remedy/NN (l_prep) for/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) dysfunctions/NNS
18483878
D003520_D001745 NONE CYP/NNP (r_pobj) with/IN (r_prep) WT/NNP (r_pobj) in/IN (r_prep) observed/VBD (r_advcl) increased/VBN (l_advcl) mice/NNS (l_prep) with/IN (l_pobj) inflammation/NN
D003520_D003556 CID cyclophosphamide/NN (r_pobj) with/IN (r_prep) mice/NNS (r_appos) knockout/NN (l_appos) cystitis/NN -PUNC- CYP)-induced/VBN (r_compound) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) after/IN (r_prep) altered/JJ (l_dobj) cystitis/NN -PUNC- CYP)-induced/VBN (r_amod) cystitis/NN -PUNC- CYP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN
11022397
D010862_D008569 NONE pilocarpine/NN (r_conj) tropicamide/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) size/NN (r_ccomp) impairment/NN (l_prep) in/IN (l_pobj) recall/NN
D012601_D008569 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) impairment/NN (l_prep) in/IN (l_pobj) recall/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) impairment/NN (r_dobj) had/VBD (l_dobj) recall/NN
D014331_D008569 NONE tropicamide/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) size/NN (r_ccomp) impairment/NN (l_prep) in/IN (l_pobj) recall/NN
18086064
D020927_D009203 NONE Dexmedetomidine/NNP (r_nsubjpass) associated/VBN (r_ccomp) mortality/NN (l_appos) infarction/NN
8384253
D014750_D008228 NONE vincristine/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) Lymphoma/NNP -PUNC- vincristine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) evaluate/VB (r_acl) order/NN (r_pobj) in/IN (r_prep) investigated/VBN (r_parataxis) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) Lymphoma/NNP
D014750_D009422 NONE vincristine/NN (r_pobj) with/IN (r_prep) are/VBP (l_nsubj) signs/NNS (l_conj) symptoms/NNS (l_prep) of/IN (l_pobj) neuropathy/NN -PUNC- vincristine/NN (r_compound) neuropathy/NN
19319147
D014859_D006470 NONE warfarin/RB (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) reduces/VBZ (l_dobj) volume/NN (l_compound) hemorrhage/NN
C025667_D002543 NONE PCC/NNP (r_nsubj) be/VB (l_attr) treatment/NN (l_prep) for/IN (l_pobj) ICH/NNP
D014859_D002543 CID warfarin/RB (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN -PUNC- Warfarin/NNP (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN -PUNC- Warfarin/NNP (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN (l_appos) ICH/NNP
D014859_D020521 NONE Warfarin/NNP (r_npadvmod) associated/VBN (r_amod) hemorrhage/NN (r_nsubj) is/VBZ (l_attr) type/NN (l_prep) of/IN (l_pobj) stroke/NN
3413271
D004837_D000787 NONE epinephrine/NN (r_nsubj) produced/VBD (l_advcl) evidenced/VBN (l_agent) by/IN (l_pobj) depression/NN (l_conj) angina/NN
D004837_D007511 NONE epinephrine/NN (l_appos) comparison/NN (l_prep) with/IN (l_pobj) ischemia/NN -PUNC- epinephrine/NN (r_amod) infusion/NN (r_pobj) during/IN (r_prep) compared/VBN (l_nsubjpass) signs/NNS (l_prep) of/IN (l_pobj) ischemia/NN -PUNC- epinephrine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- epinephrine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) ischemia/NN
D004837_D003324 NONE epinephrine/NN (r_pobj) of/IN (r_prep) role/NN (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D010100_D007511 NONE oxygen/NN (r_compound) consumption/NN (r_nsubjpass) compared/VBN (l_nsubjpass) signs/NNS (l_prep) of/IN (l_pobj) ischemia/NN
D004837_D017202 CID epinephrine/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Mechanisms/NNS (l_prep) of/IN (l_pobj) ischemia/NN -PUNC- epinephrine/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pcomp) eliciting/VBG (l_dobj) ischemia/NN -PUNC- epinephrine/NN (r_nsubj) produced/VBD (l_dobj) ischemia/NN -PUNC- epinephrine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) mechanisms/NNS (l_prep) of/IN (l_pobj) ischemia/NN -PUNC- epinephrine/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN (r_nsubjpass) characterized/VBN (r_advcl) marked/VBN (l_nsubjpass) ischemia/NN
D004837_D003866 NONE epinephrine/NN (r_nsubj) produced/VBD (l_advcl) evidenced/VBN (l_agent) by/IN (l_pobj) depression/NN
10669626
D014807_D002114 NONE D/JJ (r_conj) growth/NN (r_nmod) treatment/NN (r_nsubj) enhance/VB (l_prep) given/VBN (l_advcl) inhibit/VB (l_dobj) carboxylation/NN (l_prep) of/IN (l_pobj) protein/NN (l_appos) inhibitor/NN (l_compound) calcification/NN -PUNC- D/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) of/IN (r_prep) media/NNS (r_pobj) in/IN (r_prep) calcification/NN -PUNC- D/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- D/NN (r_pobj) between/IN (r_prep) synergy/NN (r_appos) D/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN
D014859_D061205 CID Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) given/VBN (r_prep) enhance/VB (l_dobj) extent/NN (l_prep) of/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) calcification/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) caused/VBD (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- Warfarin/NNP (r_compound) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) detected/VBN (l_nsubjpass) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) groups/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) groups/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_nsubj) produced/VBD (l_dobj) calcification/NN (l_conj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN (r_pobj) to/IN (r_prep) resistant/JJ (r_acomp) was/VBD (r_relcl) groups/NNS (r_pobj) of/IN (r_prep) either/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) rats/NNS (r_appos) relationship/NN (r_attr) was/VBD (l_advcl) determined/VBN (l_nsubjpass) explanation/NN (l_prep) for/IN (l_pobj) association/NN (l_prep) between/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN (r_pobj) to/IN (r_prep) resistant/JJ (r_acomp) was/VBD (r_relcl) groups/NNS (r_pobj) of/IN (r_prep) either/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) rats/NNS (r_appos) relationship/NN (l_prep) between/IN (l_pobj) phosphate/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_npadvmod) induced/VBN (r_amod) calcification/NN -PUNC- Warfarin/NNP (r_conj) D/NN (r_pobj) between/IN (r_prep) synergy/NN (l_prep) in/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_nsubjpass) known/VBN (l_xcomp) cause/VB (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- Warfarin/NNP (r_conj) D/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) calcification/NN
D014859_D002114 NONE Warfarin/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) given/VBN (l_advcl) inhibit/VB (l_dobj) carboxylation/NN (l_prep) of/IN (l_pobj) protein/NN (l_appos) inhibitor/NN (l_compound) calcification/NN -PUNC- Warfarin/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) caused/VBD (l_dobj) calcification/NN (l_conj) calcification/NN -PUNC- Warfarin/NNP (r_compound) administration/NN (r_nsubj) increased/VBD (l_dobj) extent/NN (l_prep) of/IN (l_pobj) calcification/NN -PUNC- Warfarin/NNP (r_compound) treatment/NN (r_nsubj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- Warfarin/NNP (r_nmod) D/NN (r_pobj) between/IN (r_prep) synergy/NN (r_appos) D/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- Warfarin/NNP (r_nsubj) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN
D015055_D002114 NONE carboxyglutamate/NN (r_compound) residues/NNS (r_nsubjpass) required/VBN (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN -PUNC- carboxyglutamate/NN (r_compound) residues/NNS (r_nsubjpass) required/VBN (r_advcl) required/VBN (l_prep) for/IN (l_pobj) accumulation/NN (l_prep) at/IN (l_pobj) sites/NNS (l_compound) calcification/NN
D002118_D002114 NONE calcium/NN (r_pobj) in/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) effect/NN (r_dobj) had/VBD (r_advcl) explained/VBN (l_agent) by/IN (l_pobj) hypothesis/NN (l_acl) inhibits/VBZ (l_prep) as/IN (l_pobj) inhibitor/NN (l_compound) calcification/NN
D015055_D061205 NONE carboxylated/JJ (r_acomp) was/VBD (r_ccomp) showed/VBD (r_conj) found/VBN (l_prep) at/IN (l_pobj) sites/NNS (l_prep) of/IN (l_pobj) calcification/NN
D014807_D061205 NONE D./NNP (r_conj) growth/NN (r_pobj) by/IN (r_agent) accelerated/VBN (l_nsubjpass) calcification/NN -PUNC- D/JJ (r_conj) growth/NN (r_nmod) treatment/NN (r_nsubj) enhance/VB (l_dobj) extent/NN (l_prep) of/IN (l_pobj) calcification/NN -PUNC- D/NN (r_pobj) between/IN (r_prep) synergy/NN (l_prep) in/IN (l_pobj) calcification/NN -PUNC- D/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubjpass) known/VBN (l_xcomp) cause/VB (l_dobj) calcification/NN (l_prep) of/IN (l_pobj) media/NNS (l_compound) artery/NN -PUNC- D/NN (r_compound) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- D/NN (r_compound) dose/NN (r_pobj) of/IN (r_prep) effect/NN (l_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) elevation/NN (l_relcl) suggests/VBZ (l_ccomp) induce/VB (l_dobj) calcification/NN -PUNC- D/NNP (r_compound) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- D/NNP (r_compound) dose/NN (l_prep) on/IN (l_pobj) elevation/NN (l_relcl) suggests/VBZ (l_ccomp) induce/VB (l_dobj) calcification/NN -PUNC- D/NN (r_nsubj) induce/VB (r_ccomp) suggests/VBZ (r_relcl) elevation/NN (r_pobj) on/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- D/NN (r_nsubj) induce/VB (l_dobj) calcification/NN -PUNC- D/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) calcification/NN
D010710_D061205 NONE phosphate/NN (r_pobj) between/IN (r_prep) relationship/NN (r_attr) was/VBD (l_advcl) determined/VBN (l_nsubjpass) explanation/NN (l_prep) for/IN (l_pobj) association/NN (l_prep) between/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) between/IN (r_prep) relationship/NN (l_appos) rats/NNS (l_prep) compared/VBN (l_prep) with/IN (l_pobj) either/DT (l_prep) of/IN (l_pobj) groups/NNS (l_relcl) was/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) with/IN (r_prep) relationship/NN (r_attr) was/VBD (l_advcl) determined/VBN (l_nsubjpass) explanation/NN (l_prep) for/IN (l_pobj) association/NN (l_prep) between/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) with/IN (r_prep) relationship/NN (l_prep) between/IN (l_pobj) phosphate/NN (l_conj) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) with/IN (r_prep) relationship/NN (l_appos) rats/NNS (l_prep) compared/VBN (l_prep) with/IN (l_pobj) either/DT (l_prep) of/IN (l_pobj) groups/NNS (l_relcl) was/VBD (l_acomp) resistant/JJ (l_prep) to/IN (l_pobj) calcification/NN -PUNC- phosphate/NN (r_compound) levels/NNS (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) susceptibility/NN (l_prep) to/IN (l_pobj) calcification/NN
D002118_D061205 NONE calcium/NN (r_pobj) of/IN (r_prep) elevation/NN (r_pobj) on/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- calcium/NN (r_pobj) of/IN (r_prep) elevation/NN (l_relcl) suggests/VBZ (l_ccomp) induce/VB (l_dobj) calcification/NN -PUNC- calcium/NN (r_pobj) on/IN (r_prep) effect/NN (r_pobj) through/IN (r_prep) induce/VB (r_ccomp) suggests/VBZ (r_relcl) elevation/NN (r_pobj) on/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) effect/NN (r_conj) effect/NN (l_prep) of/IN (l_pobj) dose/NN (l_prep) on/IN (l_pobj) calcification/NN -PUNC- calcium/NN (r_pobj) on/IN (r_prep) effect/NN (r_pobj) through/IN (r_prep) induce/VB (l_dobj) calcification/NN
17074608
D014635_D008607 NONE valproate/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) presentation/NN (r_pobj) following/VBG (r_prep) found/VBN (r_relcl) delay/NN (l_conj) retardation/NN
D014635_D002819 CID Valproate/NNP (r_npadvmod) induced/VBN (r_amod) chorea/NN -PUNC- valproate/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) presentation/NN (l_prep) with/IN (l_pobj) encephalopathy/NN (l_conj) chorea/NN
D014635_D020158 NONE Valproate/NNP (r_npadvmod) induced/VBN (r_amod) chorea/NN (l_conj) encephalopathy/JJ (l_prep) in/IN (l_pobj) hyperglycinemia/NN -PUNC- valproate/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) presentation/NN (r_pobj) following/VBG (r_prep) found/VBN (l_xcomp) have/VB (l_dobj) hyperglycinemia/NN
D005998_D000592 NONE glycine/NN (r_compound) system/NN (r_pobj) in/IN (r_prep) defect/NN (r_nsubj) leads/VBZ (r_relcl) metabolism/NN -PUNC- glycine/NN (r_pobj) of/IN (r_prep) accumulation/NN (r_pobj) to/IN (r_prep) leads/VBZ (r_relcl) metabolism/NN
D014635_D007805 NONE valproate/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) presentation/NN (r_pobj) following/VBG (r_prep) found/VBN (r_relcl) delay/NN
D014635_D001927 CID Valproate/NNP (r_npadvmod) induced/VBN (r_amod) chorea/NN (l_conj) encephalopathy/JJ -PUNC- valproate/NN (r_amod) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) presentation/NN (l_prep) with/IN (l_pobj) encephalopathy/NN
D005998_D020158 NONE glycine/NN (r_compound) system/NN (r_pobj) in/IN (r_prep) defect/NN (r_nsubj) leads/VBZ (r_relcl) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (r_attr) is/VBZ (l_nsubj) hyperglycinemia/NN -PUNC- glycine/NN (r_pobj) of/IN (r_prep) accumulation/NN (r_pobj) to/IN (r_prep) leads/VBZ (r_relcl) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (r_attr) is/VBZ (l_nsubj) hyperglycinemia/NN
20164825
D008687_D014652 NONE metformin/NN (r_nsubj) diminish/VB (l_conj) prevent/VB (l_dobj) dysfunction/NN
D005839_D064420 NONE gentamicin/NN (r_amod) toxicity/NN
D008687_D058186 NONE Metformin/NNP (r_compound) treatment/NN (r_nsubj) blocked/VBD (l_dobj) failure/NN
D005839_D007674 NONE gentamicin/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- gentamicin/NN (r_amod) nephrotoxicity/NN
D008687_D007674 NONE Metformin/NNP (r_nsubj) prevents/VBZ (l_dobj) nephropathy/NN -PUNC- metformin/NN (r_pobj) by/IN (r_prep) correction/NN (r_conj) markers/NNS (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- metformin/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) lessen/VB (l_dobj) nephrotoxicity/NN
D005839_D058186 CID gentamicin/NN (r_npadvmod) mediated/VBN (r_amod) failure/NN
20528871
C104457_D006402 CID AraG/NNP (r_pobj) than/IN (r_prep) combination/NN (r_pobj) for/IN (r_prep) greater/JJR (r_acomp) was/VBD (l_nsubj) toxicity/NN
D003520_D015458 NONE cyclophosphamide/NN (r_conj) etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- cyclophosphamide/NN (r_conj) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- CPM/NNP (r_appos) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
C104457_D015458 NONE nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
D003520_D016399 NONE cyclophosphamide/NN (r_conj) etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- cyclophosphamide/NN (r_conj) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- CPM/NNP (r_appos) VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
D005047_D016399 NONE etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- etoposide/NN (r_pobj) of/IN (r_prep) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
C104457_D009422 CID AraG/NNP (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBD (l_dobj) neuropathy/NN -PUNC- AraG/NN (r_dobj) giving/VBG (r_pcomp) of/IN (r_prep) safety/NN (r_dobj) supports/VBZ (l_advcl) monitored/VBN (l_nsubjpass) toxicity/NN
D005047_D015458 NONE etoposide/RB (r_conj) nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- etoposide/NN (r_pobj) of/IN (r_prep) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- VP/NNP (r_appos) d/SYM (r_pobj) with/IN (r_prep) AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
D003520_D009422 NONE cyclophosphamide/NN (r_conj) etoposide/NN (r_pobj) with/IN (r_prep) synchrony/NN (r_pobj) in/IN (r_prep) therapy/NN (r_pobj) as/IN (r_prep) giving/VBG (r_pcomp) of/IN (r_prep) safety/NN (r_dobj) supports/VBZ (l_advcl) monitored/VBN (l_nsubjpass) toxicity/NN
C104457_D016399 NONE nelarabine/NN (l_prep) in/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN -PUNC- AraG/NNP (r_appos) nelarabine/JJ (r_pobj) of/IN (r_prep) d/SYM (r_pobj) of/IN (r_prep) combination/NN (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukaemia/NN (l_conj) lymphoma/NN
C104457_D059352 CID AraG/NNP (r_pobj) to/IN (r_prep) attributable/JJ (r_amod) effects/NNS (r_nsubj) included/VBD (l_dobj) neuropathy/NN (l_conj) pain/NN
D005047_D009422 NONE etoposide/NN (r_pobj) with/IN (r_prep) synchrony/NN (r_pobj) in/IN (r_prep) therapy/NN (r_pobj) as/IN (r_prep) giving/VBG (r_pcomp) of/IN (r_prep) safety/NN (r_dobj) supports/VBZ (l_advcl) monitored/VBN (l_nsubjpass) toxicity/NN
10692744
D000086_D003221 NONE acetazolamide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) confusion/NN
D000086_D005862 CID Acetazolamide/RB (r_npadvmod) induced/VBN (r_amod) syndrome/NN -PUNC- acetazolamide/NN (r_npadvmod) induced/VBN (r_amod) syndrome/NN
D000086_D007674 NONE acetazolamide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) confusion/NN (r_nsubj) is/VBZ (l_attr) reaction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) impairment/NN
2355241
D009638_D010300 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- noradrenaline/NN (r_amod) levels/NNS (l_prep) in/IN (l_pobj) brain/NN (l_amod) parkinsonian/JJ
D009638_D003643 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) death/NN
D007980_D003643 NONE levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) death/NN
D007980_D010300 NONE levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_conj) mechanism/NN (l_amod) due/IN (l_pobj) levels/NNS (l_prep) in/IN (l_pobj) brain/NN (l_amod) parkinsonian/JJ
D009638_D007022 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (l_amod) hypotensive/JJ -PUNC- noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (l_amod) hypotensive/JJ
D007980_D002543 NONE levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) haemorrhage/NN
D007980_D007022 CID levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_conj) mechanism/NN (l_amod) hypotensive/JJ
D009638_D002543 NONE noradrenaline/NN (r_amod) levels/NNS (r_pobj) due/IN (r_amod) mechanism/NN (r_conj) effect/NN (r_dobj) reflect/VB (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) haemorrhage/NN
16574713
D018817_D008569 CID MDMA/NNP (r_compound) users/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) evidence/NN (l_prep) of/IN (l_pobj) impairment/NN -PUNC- MDMA/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) quantities/NNS (l_relcl) considered/VBN (l_oprd) associated/VBN (l_prep) with/IN (l_pobj) functioning/VBG -PUNC- MDMA/NNP (r_pobj) of/IN (r_prep) use/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) impairments/NNS -PUNC- MDMA/NNP (r_compound) use/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) lead/VB (l_nsubj) use/NN (l_prep) in/IN (l_pobj) quantities/NNS (l_relcl) considered/VBN (l_oprd) associated/VBN (l_prep) with/IN (l_pobj) functioning/VBG -PUNC- MDMA/NNP (r_compound) use/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) impairments/NNS
D012701_D020258 NONE serotonin/NN (r_dobj) damage/VB (r_xcomp) shown/VBN (r_advcl) known/VBN (l_prep) about/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) lesions/NNS -PUNC- 5-HT/CD (r_nmod) neurons/NNS (r_appos) serotonin/NN (r_dobj) damage/VB (r_xcomp) shown/VBN (r_advcl) known/VBN (l_prep) about/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) lesions/NNS -PUNC- 5-HT/CD (r_nummod) lesions/NNS -PUNC- 5-HT/CD (r_nsubjpass) involved/VBN (r_relcl) functions/NNS (r_pobj) on/IN (r_prep) lesions/NNS
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine/CD (r_nsubjpass) shown/VBN (r_advcl) known/VBN (l_prep) about/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) lesions/NNS -PUNC- MDMA/NNP (r_nsubjpass) shown/VBN (r_advcl) known/VBN (l_prep) about/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) lesions/NNS -PUNC- ecstasy/NN (r_conj) MDMA/NNP (r_nsubjpass) shown/VBN (r_advcl) known/VBN (l_prep) about/IN (l_pobj) consequences/NNS (l_prep) of/IN (l_pobj) lesions/NNS -PUNC- MDMA/NNP (r_npadvmod) induced/VBN (r_amod) lesions/NNS
11642480
D015283_D003865 NONE citalopram/NN (r_pobj) with/IN (r_prep) treatment/NN (l_prep) by/IN (l_pobj) boy/NN (l_prep) with/IN (l_pobj) depression/NN
D015283_D003866 NONE citalopram/NN (r_pobj) on/IN (r_prep) adolescent/NN (l_amod) depressed/JJ
D015283_D004409 CID citalopram/NN (r_pobj) on/IN (r_prep) adolescent/NN (r_pobj) in/IN (r_prep) twitching/VBG -PUNC- citalopram/NN (r_pobj) with/IN (r_prep) treatment/NN (l_prep) by/IN (l_pobj) boy/NN (l_prep) with/IN (l_pobj) depression/NN (l_relcl) exhibited/VBD (l_dobj) twitching/NN
18544179
C009250_D001919 NONE sevoflurane/NN (r_npadvmod) sparing/VBG (r_amod) effect/NN (r_dobj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN (l_conj) bradycardia/NN
D003907_D020250 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (r_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- Dexamethasone/NNP (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN
D003907_D009325 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN
C009250_D014839 NONE sevoflurane/NN (r_pobj) after/IN (r_prep) reduces/VBZ (l_dobj) nausea/NN (l_conj) vomiting/NN
D005283_D001919 CID Fentanyl/NNP (r_nsubj) reduce/VB (l_conj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN (l_conj) bradycardia/NN
C009250_D020250 NONE sevoflurane/NN (r_pobj) with/IN (r_prep) advantages/NNS (r_pobj) Despite/IN (r_prep) occurs/VBZ (l_nsubj) nausea/NN (l_conj) vomiting/NN -PUNC- sevoflurane/NN (r_compound) anaesthesia/NN (r_pobj) after/IN (r_prep) h/NN (r_pobj) in/IN (r_prep) examined/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- sevoflurane/NN (r_relcl) supplement/NN (r_attr) be/VB (r_xcomp) appears/VBZ (l_advcl) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG
C009250_D007022 NONE sevoflurane/NN (r_npadvmod) sparing/VBG (r_amod) effect/NN (r_dobj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN
D005283_D012131 CID Fentanyl/NNP (r_nsubj) reduce/VB (l_conj) had/VBD (l_conj) depression/NN
D005283_D020250 CID fentanyl/NN (r_pobj) of/IN (r_prep) Omission/NN (r_nsubj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_nmod) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (r_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_compound) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (r_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_compound) groups/NNS (r_dobj) Combining/VBG (r_csubj) revealed/VBD (l_advcl) reducing/VBG (l_dobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_nsubj) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG
C009250_D010149 NONE sevoflurane/NN (r_relcl) supplement/NN (r_attr) be/VB (r_xcomp) appears/VBZ (l_advcl) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG (l_prep) without/IN (l_pobj) improvement/NN (l_prep) in/IN (l_pobj) pain/NN
D005283_D010149 NONE fentanyl/NN (r_nsubj) exacerbated/VBD (l_dobj) nausea/NN (l_conj) vomiting/VBG (l_prep) without/IN (l_pobj) improvement/NN (l_prep) in/IN (l_pobj) pain/NN
C009250_D010146 NONE sevoflurane/NN (r_pobj) after/IN (r_prep) reduces/VBZ (l_prep) without/IN (l_pcomp) increasing/VBG (l_dobj) pain/NN -PUNC- sevoflurane/NN (r_compound) anaesthesia/NN (r_pobj) after/IN (r_prep) h/NN (r_pobj) in/IN (r_prep) examined/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) pain/NN
C009250_D012131 NONE sevoflurane/NN (r_npadvmod) sparing/VBG (r_amod) effect/NN (r_dobj) had/VBD (l_conj) depression/NN
D003907_D014839 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN
D005283_D014839 NONE fentanyl/NN (r_dobj) Omitting/VBG (r_csubj) reduces/VBZ (l_dobj) nausea/NN (l_conj) vomiting/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) Omission/NN (r_nsubj) reduce/VB (l_conj) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN -PUNC- fentanyl/NN (r_nmod) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN -PUNC- fentanyl/NN (r_compound) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) vomiting/NN
D005283_D010146 NONE fentanyl/NN (r_dobj) Omitting/VBG (r_csubj) reduces/VBZ (l_prep) without/IN (l_pcomp) increasing/VBG (l_dobj) pain/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) omission/NN (r_pobj) by/IN (r_prep) unaffected/JJ (r_acomp) were/VBD (l_nsubj) severity/NN (l_compound) Pain/NN
C009250_D009325 NONE sevoflurane/NN (r_pobj) after/IN (r_prep) reduces/VBZ (l_dobj) nausea/NN
D005283_D007022 CID Fentanyl/NNP (r_nsubj) reduce/VB (l_conj) had/VBD (l_conj) depression/NN (l_conj) hypotension/NN
D005283_D009325 NONE fentanyl/NN (r_dobj) Omitting/VBG (r_csubj) reduces/VBZ (l_dobj) nausea/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) Omission/NN (r_nsubj) reduce/VB (l_conj) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN -PUNC- fentanyl/NN (r_nmod) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN -PUNC- fentanyl/NN (r_compound) dexamethasone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) %/NN (r_pobj) from/IN (r_prep) discharge/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) reduce/VB (l_conj) moderate/JJ (l_prep) to/TO (l_pobj) nausea/NN -PUNC- fentanyl/NN (r_compound) groups/NNS (r_dobj) Combining/VBG (r_csubj) revealed/VBD (l_advcl) reducing/VBG (l_dobj) nausea/NN (l_conj) vomiting/NN (l_conj) nausea/NN -PUNC- fentanyl/NN (r_compound) groups/NNS (r_dobj) Combining/VBG (r_csubj) revealed/VBD (l_advcl) decreased/VBN (l_nsubjpass) nausea/NN
9848575
C055866_D009202 NONE SM-5887/NNP (r_appos) derivative/JJ (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) heart/NN (l_conj) cardiomyopathy/NN -PUNC- SM-5887/NNP (r_compound) administration/NN (r_nsubj) show/VB (r_advcl) demonstrated/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) pressure/NN (l_conj) cardiomyopathy/NN -PUNC- SM-5887/NNP (r_nmod) cardiomyopathy/NN -PUNC- SM-5887/NNP (r_compound) treatment/NN (r_nsubj) progress/VB (l_dobj) grade/NN (l_prep) of/IN (l_pobj) cardiomyopathy/NN
D004317_D066126 NONE doxorubicin/NN (r_appos) potential/NN (l_amod) cardiotoxic/JJ -PUNC- doxorubicin/NN (r_appos) potential/NN (l_conj) effect/NN (l_prep) on/IN (l_pobj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) courses/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_csubjpass) examine/VB (l_dobj) effect/NN (l_amod) cardiotoxic/JJ -PUNC- doxorubicin/NN (r_compound) treatment/NN (r_pobj) by/IN (r_agent) enhanced/VBN (l_nsubjpass) changes/NNS (l_amod) cardiotoxic/JJ -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_pobj) on/IN (r_prep) effect/NN (r_conj) cardiotoxicity/NN -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
D004317_D009202 CID doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) courses/NNS (r_dobj) received/VBD (r_relcl) Animals/NNS (r_nsubj) demonstrated/VBD (l_dobj) decrease/NN (l_prep) of/IN (l_pobj) pressure/NN (l_conj) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) courses/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_csubjpass) examine/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) cardiomyopathy/NN
C055866_D066126 NONE SM-5887/NNP (r_pobj) of/IN (r_prep) potential/NN (l_amod) cardiotoxic/JJ -PUNC- SM-5887/NNP (r_pobj) of/IN (r_prep) potential/NN (l_conj) effect/NN (l_prep) on/IN (l_pobj) cardiotoxicity/NN -PUNC- SM-5887/NNP (r_pobj) of/IN (r_prep) effect/NN (r_conj) potential/NN (l_amod) cardiotoxic/JJ -PUNC- SM-5887/NNP (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) cardiotoxicity/NN -PUNC- SM-5887/NNP (r_nmod) cardiomyopathy/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) cardiotoxic/JJ -PUNC- SM-5887/NNP (r_nsubj) have/VB (l_dobj) potential/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- SM-5887/NNP (r_nsubj) have/VB (l_dobj) potential/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN (l_conj) effect/NN (l_prep) on/IN (l_pobj) cardiotoxicity/NN
D018943_D009202 NONE anthracycline/NN (r_amod) derivative/JJ (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) heart/NN (l_conj) cardiomyopathy/NN
1867351
D015767_D008288 NONE mefloquine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_conj) prophylaxis/NN (l_compound) malaria/NN
6415512
D002220_D012640 NONE carbamazepine/NN (r_nsubjpass) discontinued/VBN (r_advcl) returned/VBD (r_ccomp) had/VBD (l_ccomp) resolve/VBP (l_nsubj) seizures/NNS -PUNC- carbamazepine/NN (r_nsubjpass) discontinued/VBN (r_advcl) returned/VBD (r_ccomp) had/VBD (l_conj) had/VBD (l_ccomp) persist/VB (l_nsubj) seizures/NNS
D002220_D004831 CID carbamazepine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) institution/NN (r_dobj) following/VBG (r_prep) seizures/NNS -PUNC- carbamazepine/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) had/VBD (l_dobj) reaction/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) absence/NN (l_conj) seizures/NNS
D002220_D004827 NONE carbamazepine/NN (l_prep) for/IN (l_pobj) epilepsy/NN
D002220_D004832 CID carbamazepine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) institution/NN (r_dobj) following/VBG (r_prep) seizures/NNS -PUNC- carbamazepine/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) had/VBD (l_dobj) reaction/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) absence/NN (l_conj) seizures/NNS
3560096
D013467_D006947 CID sulindac/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Hyperkalemia/NNP -PUNC- sulindac/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) within/IN (r_prep) developed/VBD (l_nsubj) hyperkalemia/VBD -PUNC- sulindac/NN (l_conj) hyperkalemia/NN
D011188_D006947 NONE potassium/NN (r_dobj) effect/NN (r_xcomp) known/VBN (r_acl) medications/NNS (r_nsubjpass) given/VBN (r_advcl) is/VBZ (l_acomp) suggestive/JJ (l_prep) of/IN (l_pobj) relationship/NN (l_prep) between/IN (l_pobj) sulindac/NN (l_conj) hyperkalemia/NN
D007213_D006947 CID indomethacin/NN (r_pobj) as/IN (r_prep) NSAID/NNP (r_appos) agents/NNS (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) recognized/VBN (l_nsubjpass) Hyperkalemia/NNP
10728962
D014667_D007022 CID Vasopressin/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) restored/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_prep) with/IN (l_pobj) hypotension/NN
D020105_D007022 CID milrinone/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- milrinone/NN (r_pobj) as/IN (r_prep) inhibitors/NNS (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) restricted/VBN (l_advcl) cause/VBP (l_dobj) vasodilation/NN (l_conj) hypotension/NN -PUNC- milrinone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) hypotension/NN -PUNC- milrinone/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) inhibiting/VBG (r_pcomp) without/IN (r_prep) restored/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_prep) with/IN (l_pobj) hypotension/NN
D014667_D006333 NONE Vasopressin/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypotension/NN (l_prep) in/IN (l_pobj) failure/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) restored/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D020105_D006333 NONE milrinone/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_prep) in/IN (l_pobj) failure/NN -PUNC- milrinone/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- milrinone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) hypotension/NN (r_pobj) with/IN (r_prep) failure/NN -PUNC- milrinone/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) inhibiting/VBG (r_pcomp) without/IN (r_prep) restored/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
18162529
D004967_D006966 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) surge/NN (r_conj) secretion/NN (r_appos) parameters/NNS (r_dobj) inhibited/VBD (l_nsubj) hyperprolactinemia/NN
D004298_D006966 NONE dopamine/NN (r_compound) antagonist/NN (r_compound) sulpiride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperprolactinemia/NN
D013469_D006966 CID sulpiride/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperprolactinemia/NN
D013256_D006966 NONE steroid/NN (r_npadvmod) dependent/JJ (r_amod) manner/NN (r_pobj) in/IN (r_prep) inhibited/VBN (l_agent) by/IN (l_pobj) hyperprolactinemia/NN
D004958_D006966 NONE estradiol/NN (r_pobj) on/IN (r_prep) dependent/JJ (r_acomp) are/VBP (l_nsubj) levels/NNS (l_conj) signaling/NN (l_conj) inhibition/NN (l_amod) hyperprolactinemic/JJ -PUNC- estradiol/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_conj) caused/VBD (l_nsubj) hyperprolactinemia/NN
D012313_D006966 NONE acid/NN (r_compound) levels/NNS (l_conj) signaling/NN (l_conj) inhibition/NN (l_amod) hyperprolactinemic/JJ
